{
 "cells": [
  {
   "cell_type": "code",
   "id": "initial_id",
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2026-01-19T13:04:05.553500Z",
     "start_time": "2026-01-19T13:01:22.381217Z"
    }
   },
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import re\n",
    "from difflib import SequenceMatcher\n",
    "from pathlib import Path\n",
    "import itertools\n",
    "\n",
    "from networkx.algorithms.traversal import dfs_edges\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "from rapidfuzz import fuzz\n",
    "from sympy import sequence\n",
    "\n",
    "from matplotlib import pyplot as plt\n",
    "\n"
   ],
   "outputs": [],
   "execution_count": 91
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T10:09:13.373677Z",
     "start_time": "2026-01-19T10:09:13.360218Z"
    }
   },
   "cell_type": "code",
   "source": [
    "METHODS = [\"agent\", \"mrr\", \"sc\", \"default\", \"cot\", \"cot2\"]\n",
    "RUN_IDS = [1, 2, 3]\n",
    "\n",
    "THRESH_REGEX = np.arange(100,1000,200)\n",
    "THRESH_LCS_mc = np.arange(0.5,0.9,0.1)\n",
    "THRESH_LCS_oemc = np.arange(0.02,0.1,0.02)\n",
    "THRESH_FUZZY = np.arange(0.9,0.9,0.0)\n",
    "\n",
    "PARAM_GRID_outer = list(itertools.product(THRESH_REGEX,THRESH_LCS_mc ,THRESH_LCS_oemc, THRESH_FUZZY))\n",
    "PARAM_GRID = list(itertools.product(METHODS,RUN_IDS))\n"
   ],
   "id": "40a0b954ed6b42df",
   "outputs": [
    {
     "ename": "ZeroDivisionError",
     "evalue": "float division by zero",
     "output_type": "error",
     "traceback": [
      "\u001B[31m---------------------------------------------------------------------------\u001B[39m",
      "\u001B[31mZeroDivisionError\u001B[39m                         Traceback (most recent call last)",
      "\u001B[36mCell\u001B[39m\u001B[36m \u001B[39m\u001B[32mIn[75]\u001B[39m\u001B[32m, line 7\u001B[39m\n\u001B[32m      5\u001B[39m THRESH_LCS_mc = np.arange(\u001B[32m0.5\u001B[39m,\u001B[32m0.9\u001B[39m,\u001B[32m0.1\u001B[39m)\n\u001B[32m      6\u001B[39m THRESH_LCS_oemc = np.arange(\u001B[32m0.02\u001B[39m,\u001B[32m0.1\u001B[39m,\u001B[32m0.02\u001B[39m)\n\u001B[32m----> \u001B[39m\u001B[32m7\u001B[39m THRESH_FUZZY = \u001B[43mnp\u001B[49m\u001B[43m.\u001B[49m\u001B[43marange\u001B[49m\u001B[43m(\u001B[49m\u001B[32;43m0.9\u001B[39;49m\u001B[43m,\u001B[49m\u001B[32;43m0.9\u001B[39;49m\u001B[43m,\u001B[49m\u001B[32;43m0.0\u001B[39;49m\u001B[43m)\u001B[49m\n\u001B[32m      9\u001B[39m PARAM_GRID_outer = \u001B[38;5;28mlist\u001B[39m(itertools.product(THRESH_REGEX,THRESH_LCS_mc ,THRESH_LCS_oemc, THRESH_FUZZY))\n\u001B[32m     10\u001B[39m PARAM_GRID = \u001B[38;5;28mlist\u001B[39m(itertools.product(METHODS,RUN_IDS))\n",
      "\u001B[31mZeroDivisionError\u001B[39m: float division by zero"
     ]
    }
   ],
   "execution_count": 75
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T11:10:25.456490Z",
     "start_time": "2026-01-19T11:10:25.429947Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#define \n",
    "questions = pd.read_json('data/curebench_valset_pharse1.jsonl',lines=True) \n",
    "\n",
    "def _norm(s: str) -> str:\n",
    "    s = \"\" if s is None else str(s)\n",
    "    s = s.lower().strip()\n",
    "    s = re.sub(r\"\\s+\", \" \", s)\n",
    "    return s\n",
    "\n",
    "def best_option_by_fuzzy(prediction: str, options_dict: dict) -> tuple[str, float]:\n",
    "    pred = _norm(prediction)\n",
    "    scores = {}\n",
    "    for k, opt in options_dict.items():\n",
    "        optn = _norm(opt)\n",
    "\n",
    "        # Primary: robust to extra words + reordering\n",
    "        s1 = fuzz.token_set_ratio(pred, optn) / 100.0\n",
    "\n",
    "        # Secondary: robust if pred includes a copied snippet of the option\n",
    "        s2 = fuzz.partial_ratio(pred, optn) / 100.0\n",
    "\n",
    "        # Blend (tweak weights if you want)\n",
    "        score = 0.7 * s1 + 0.3 * s2\n",
    "        scores[k] = score\n",
    "\n",
    "    best = max(scores, key=scores.get)\n",
    "    return best, float(scores[best])\n",
    "\n",
    "def run(METHOD , RUN_ID,THRESH_REGEX, THRESH_LCS_mc,THRESH_LCS_oemc, THRESH_FUZZY,always_fuzzy=False ):\n",
    "    #Read data\n",
    "    path = Path(\"competition_results\",METHOD,str(RUN_ID),\"submission.csv\")\n",
    "    answers = pd.read_csv(path)\n",
    "    \n",
    "    ###### GENERAL CHANGE OF REGEX PREDICTION WHERE 'prediction' TOO LONG\n",
    "    answers = answers.copy()\n",
    "    for i,row in answers.iterrows():\n",
    "        if len(row['prediction']) >=THRESH_REGEX:\n",
    "            row['choice']= 'NOTAVALUE'\n",
    "    \n",
    "    #SPLITTING DATA INTO MC, OPEN-ENDED MC, and OPEN QUESTIONS\n",
    "    data = questions.merge(answers,on=\"id\",how=\"right\")\n",
    "    colnames = data.columns\n",
    "    \n",
    "    \n",
    "    data_mc = data[data[\"question_type\"]==\"multi_choice\"]\n",
    "    data_open_mc = data[data[\"question_type\"]==\"open_ended_multi_choice\"]\n",
    "    data_open = data[data[\"question_type\"]==\"open_ended\"]\n",
    "    \n",
    "    if always_fuzzy:\n",
    "        data_mc = data_mc.copy()\n",
    "        \n",
    "        fuzz_results = data_mc.apply(\n",
    "            lambda r: best_option_by_fuzzy(r[\"prediction\"], dict(r[\"options\"])),\n",
    "            axis=1\n",
    "        )\n",
    "        data_mc[\"pred_LCS\"] = fuzz_results.map(lambda x: x[0])\n",
    "        data_mc[\"LCS_similarity\"] = fuzz_results.map(lambda x: x[1])\n",
    "        \n",
    "        data_mc[\"final_choice\"] = np.where(\n",
    "            data_mc[\"LCS_similarity\"] >= THRESH_LCS_mc,\n",
    "            data_mc[\"pred_LCS\"],\n",
    "            data_mc[\"choice\"])\n",
    "    else:\n",
    "        #####ANALYZE MC DATA #######\n",
    "        data_mc = data_mc.copy()\n",
    "        \n",
    "        for i,row in data_mc.iterrows():\n",
    "            prediction = row[\"prediction\"]\n",
    "            options = dict(row[\"options\"])\n",
    "            LCSratios = {}\n",
    "            for key in options.keys():\n",
    "                option = options[key]\n",
    "                LCSratios[key] = SequenceMatcher(None, prediction, option).ratio()\n",
    "            \n",
    "            best_pred = max(LCSratios, key=LCSratios.get)\n",
    "            data_mc.loc[i,\"pred_LCS\"] = best_pred\n",
    "            data_mc.loc[i,\"LCS_similarity\"]=LCSratios[best_pred]\n",
    "        \n",
    "        data_mc['final_choice'] = np.where(\n",
    "            data_mc['LCS_similarity'] > THRESH_LCS_mc,\n",
    "            data_mc['pred_LCS'],\n",
    "            data_mc['choice']    \n",
    "        )\n",
    "    \n",
    "    data_mc[\"is_correct\"] = data_mc['final_choice'] == data_mc[\"correct_answer\"]     \n",
    "    NaN_mc = len(data_mc[data_mc[\"final_choice\"] == 'NOTAVALUE'])\n",
    "    valid_mc = len(data_mc) - NaN_mc\n",
    "    ACC_mc = data_mc[\"is_correct\"].sum() / valid_mc\n",
    "    \n",
    "    #ANALYZE OPEN MC DATA - ALTERNATIVE APPROACH\n",
    "    if always_fuzzy:\n",
    "        data_open_mc = data_open_mc.copy()\n",
    "        \n",
    "        fuzz_results = data_open_mc.apply(\n",
    "            lambda r: best_option_by_fuzzy(r[\"prediction\"], dict(r[\"options\"])),\n",
    "            axis=1\n",
    "        )\n",
    "        data_open_mc[\"pred_LCS\"] = fuzz_results.map(lambda x: x[0])\n",
    "        data_open_mc[\"LCS_similarity\"] = fuzz_results.map(lambda x: x[1])\n",
    "        \n",
    "        data_open_mc[\"final_choice\"] = np.where(\n",
    "            data_open_mc[\"LCS_similarity\"] >= THRESH_LCS_mc,\n",
    "            data_open_mc[\"pred_LCS\"],\n",
    "            data_open_mc[\"choice\"])\n",
    "    else:\n",
    "        #ANALYZE OPEN MC DATA\n",
    "        data_open_mc = data_open_mc.copy()\n",
    "    \n",
    "        for i,row in data_open_mc.iterrows():\n",
    "            prediction = row[\"prediction\"]\n",
    "            options = dict(row[\"options\"])\n",
    "            LCSratios = {}\n",
    "            for key in options.keys():\n",
    "                option = options[key]\n",
    "                LCSratios[key] = SequenceMatcher(None, prediction, option).ratio()\n",
    "            \n",
    "            best_pred = max(LCSratios, key=LCSratios.get)\n",
    "            data_open_mc.loc[i,\"pred_LCS\"] = best_pred\n",
    "            data_open_mc.loc[i,\"LCS_similarity\"] = LCSratios[best_pred]\n",
    "            \n",
    "        data_open_mc['final_choice'] = np.where(\n",
    "            data_open_mc['prediction'].str.len() > THRESH_REGEX,\n",
    "            np.where(\n",
    "                data_open_mc['LCS_similarity'] > THRESH_LCS_oemc,\n",
    "                data_open_mc['pred_LCS'],\n",
    "                data_open_mc['choice']\n",
    "            ),\n",
    "            np.where(\n",
    "                data_open_mc['LCS_similarity'] > THRESH_LCS_mc,\n",
    "                data_open_mc['pred_LCS'],\n",
    "                data_open_mc['choice']\n",
    "            )\n",
    "        )\n",
    "    \n",
    "    data_open_mc['is_correct'] = data_open_mc[\"final_choice\"] == data_open_mc[\"correct_answer\"]    \n",
    "    NaN_open_mc = len(data_open_mc[data_open_mc[\"final_choice\"] == 'NOTAVALUE'])\n",
    "    valid_open_mc = len(data_open_mc) - NaN_open_mc\n",
    "    ACC_open_mc = data_open_mc[\"is_correct\"].sum() / valid_open_mc\n",
    "\n",
    "    #TOTAL ACCURACY (excl. open questions)\n",
    "    ACC_total = ((ACC_mc*valid_mc + \n",
    "             ACC_open_mc*valid_open_mc) / \n",
    "             (valid_open_mc + valid_mc))\n",
    "\n",
    "    #ANALYZE OPEN QUESTIONS\n",
    "    data_open = data_open.copy()\n",
    "    \n",
    "    fuzz_results = data_open.apply(\n",
    "        lambda r: best_option_by_fuzzy(r[\"prediction\"], dict(r[\"options\"])),\n",
    "        axis=1\n",
    "    )\n",
    "    data_open[\"pred_LCS\"] = fuzz_results.map(lambda x: x[0])\n",
    "    data_open[\"LCS_similarity\"] = fuzz_results.map(lambda x: x[1])\n",
    "    \n",
    "    \n",
    "    data_open[\"final_choice\"] = np.where(\n",
    "        data_open[\"LCS_similarity\"] >= THRESH_FUZZY,\n",
    "        data_open[\"pred_LCS\"],\n",
    "        data_open[\"choice\"])\n",
    "    \n",
    "    data_open[\"is_correct\"] = data_open[\"final_choice\"] == data_open[\"correct_answer\"]\n",
    "    \n",
    "    NaN_open = len(data_open[data_open[\"final_choice\"] == 'NOTAVALUE'])\n",
    "    valid_open = len(data_open) - NaN_open\n",
    "    ACC_open = data_open[\"is_correct\"].sum() / valid_open\n",
    "    \n",
    "    #COMBINE DATA INTO DATAFRAMES:\n",
    "    # det: detailed predictions, \n",
    "    # acc: summuary statistics\n",
    "    det = pd.concat(\n",
    "        [data_mc,\n",
    "        data_open_mc,\n",
    "        data_open],\n",
    "        axis=0\n",
    "    )\n",
    "    det['method']=METHOD\n",
    "    det['run_id']=RUN_ID\n",
    "    det.rename(columns={'pred_LCS':'pred_SIM',\n",
    "                        'LCS_similarity':'SIM_score',\n",
    "                        'id':'question_id'},\n",
    "               inplace=True)\n",
    "    det = det[\n",
    "        ['method','run_id','question_type','question_id','question',\n",
    "         'correct_answer','options','prediction','choice','reasoning','pred_SIM',\n",
    "         'SIM_score','final_choice','is_correct']\n",
    "    ]\n",
    "    \n",
    "    \n",
    "    acc = pd.DataFrame(\n",
    "        {'method':[METHOD]*4,\n",
    "         'run_id':[RUN_ID]*4,\n",
    "         'question_type':['multi_choice','open_ended_multi_choice','open_ended','total'],\n",
    "         })\n",
    "    acc['accuracy'] = [ACC_mc,ACC_open_mc,ACC_open,ACC_total]\n",
    "    acc['valid_answers'] = [valid_mc,valid_open_mc,valid_open,valid_mc+valid_open_mc]\n",
    "    acc['invalid_answers'] = [NaN_mc,NaN_open_mc,NaN_open,NaN_mc+NaN_open_mc]\n",
    "    acc['prop_valid'] = acc['valid_answers'] / (acc['valid_answers']+acc['invalid_answers'])\n",
    "    acc['similarity_threshold'] = [THRESH_LCS_mc,THRESH_LCS_oemc,THRESH_FUZZY,THRESH_REGEX]\n",
    "    \n",
    "    return acc, det\n",
    "    \n"
   ],
   "id": "b55242424e42e40b",
   "outputs": [],
   "execution_count": 80
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "### gogo sanchez ski shoes\n",
    "ACC = pd.DataFrame(\n",
    "    columns=['thresh_regex','thresh_sim_high','thresh_sim_low','thresh_oe',\n",
    "             'method','run_id','question_type','accuracy','valid_answers','invalid_answers','prop_valid','similarity_threshold']\n",
    ")\n",
    "DET = pd.DataFrame(\n",
    "    columns = ['thresh_regex','thresh_sim_high','thresh_sim_low','thresh_oe',\n",
    "               'method','run_id','question_type','question_id','question',\n",
    "         'correct_answer','options','prediction','choice','reasoning','pred_SIM',\n",
    "         'SIM_score','final_choice','is_correct']\n",
    ")\n",
    "\n",
    "for THRESH_REGEX,THRESH_LCS_mc,THRESH_LCS_oemc,THRESH_FUZZY in PARAM_GRID_outer:\n",
    "    print(\"\\nðŸ’ªðŸ» Next Iteration.\\n\")\n",
    "    for METHOD, RUN_ID in PARAM_GRID:\n",
    "        acc,det = run(METHOD=METHOD,\n",
    "            RUN_ID=RUN_ID,\n",
    "            THRESH_REGEX=THRESH_REGEX,\n",
    "            THRESH_LCS_mc=THRESH_LCS_mc,\n",
    "            THRESH_LCS_oemc=THRESH_LCS_oemc,\n",
    "            THRESH_FUZZY=THRESH_FUZZY,\n",
    "            always_fuzzy=True)\n",
    "        \n",
    "        acc['thresh_regex'] = THRESH_REGEX\n",
    "        acc['thresh_sim_high'] = THRESH_LCS_mc\n",
    "        acc['thresh_sim_low'] = THRESH_LCS_oemc\n",
    "        acc['thresh_oe'] = THRESH_FUZZY\n",
    "        \n",
    "        det['thresh_regex'] = THRESH_REGEX\n",
    "        det['thresh_sim_high'] = THRESH_LCS_mc\n",
    "        det['thresh_sim_low'] = THRESH_LCS_oemc\n",
    "        det['thresh_oe'] = THRESH_FUZZY\n",
    "        \n",
    "        ACC = pd.concat([ACC,acc],axis=0)\n",
    "        DET = pd.concat([DET,det],axis=0)\n",
    "\n",
    "\n",
    "    "
   ],
   "id": "e22f30ffb6f608f4",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T15:14:48.143801Z",
     "start_time": "2026-01-19T15:14:48.105318Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#calculate tradeoff between valid entries and accuracy\n",
    "ACC['tradeoff'] = ACC['prop_valid'] *ACC['accuracy']"
   ],
   "id": "d95a5a6426d632bc",
   "outputs": [],
   "execution_count": 118
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": "",
   "id": "d13b1395564e4df1"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T16:07:41.440971Z",
     "start_time": "2026-01-19T16:07:41.418771Z"
    }
   },
   "cell_type": "code",
   "source": [
    "DET_f = DET[DET['question_type']!='open_ended']\n",
    "\n",
    "ACC_f = ACC[(ACC['question_type']!='open_ended') &\n",
    "            (ACC['prop_valid']>0.5)]  \n",
    "ACC_f = ACC_f.sort_values(by=['question_type','accuracy'],ascending=False)"
   ],
   "id": "8547d79e37080de0",
   "outputs": [],
   "execution_count": 131
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T16:22:29.099596Z",
     "start_time": "2026-01-19T16:22:29.094535Z"
    }
   },
   "cell_type": "code",
   "source": "df = ACC_f[ACC_f['question_type']=='total'].sort_values(by='tradeoff',ascending=False).groupby('method').head(1)\n",
   "id": "55fcbdad0e3874a2",
   "outputs": [],
   "execution_count": 139
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": [
    "#Save results\n",
    "ACC.to_csv('accuracy_summary.csv',index=False)\n",
    "ACC_f.to_csv('accuracy_summary_excl_open.csv',index=False)\n",
    "DET.to_csv('detailed_results.csv',index=False)\n",
    "DET_f.to_csv('detailed_results_excl_open.csv',index=False)"
   ],
   "id": "881914dd711682c7"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T16:55:53.048535Z",
     "start_time": "2026-01-19T16:55:52.802324Z"
    }
   },
   "cell_type": "code",
   "source": [
    "item_summary = DET_f.groupby(['question_id']).agg(\n",
    "    n = ('is_correct', 'size'),\n",
    "    n_correct = ('is_correct', 'sum'),\n",
    ").reset_index()\n",
    "item_summary['prop_correct'] = item_summary['n_correct']/item_summary['n']\n",
    "\n",
    "item_summary = item_summary.sort_values(by=['n_correct'])\n",
    "\n",
    "unsolveable_questions = item_summary[item_summary['prop_correct']==0]['question_id']\n",
    "\n",
    "hardest_questions = item_summary[\n",
    "(item_summary['prop_correct']>0.0) &\n",
    "(item_summary['prop_correct']<0.05)]['question_id']\n",
    "\n",
    "item_summary_by_method = DET_f.groupby(['question_id','method']).agg(\n",
    "    n = ('is_correct', 'size'),\n",
    "    n_correct = ('is_correct', 'sum'),\n",
    ").reset_index()\n",
    "item_summary_by_method['prop_correct'] = item_summary_by_method['n_correct']/item_summary_by_method['n']\n",
    "\n"
   ],
   "id": "1e51824250a7b22b",
   "outputs": [],
   "execution_count": 147
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T17:17:48.545025Z",
     "start_time": "2026-01-19T17:17:48.539189Z"
    }
   },
   "cell_type": "code",
   "source": [
    "hard_question_solvers = item_summary_by_method[\n",
    "    (item_summary_by_method['question_id'].isin(hardest_questions))&\n",
    "    (item_summary_by_method['prop_correct']>0.0)\n",
    "].groupby(['question_id','method']).head(1).reset_index()\n",
    "\n",
    "hard_question_solvers = hard_question_solvers.groupby('method').agg(\n",
    "    n = ('method', 'size'),\n",
    "    \n",
    ")\n",
    "\n",
    "print(\"Number of unsolveable questions:\", len(unsolveable_questions))\n",
    "print(\"Number hard questions: \", len(hardest_questions))\n",
    "\n",
    "\n"
   ],
   "id": "65cb61e898c6261e",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of unsolveable questions: 15\n",
      "Number hard questions:  12\n"
     ]
    }
   ],
   "execution_count": 155
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": "item_summary = item_summary.sort_values(by=['question_id'])",
   "id": "479190a9c828ac32"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T16:44:24.990165Z",
     "start_time": "2026-01-19T16:44:24.942323Z"
    }
   },
   "cell_type": "code",
   "source": [
    "plt.hist(item_summary['prop_correct'],bins=20)\n",
    "plt.xlabel(\"Proportion of correct answers\")\n",
    "plt.ylabel(\"Number of Questions\")\n",
    "plt.show()\n",
    "\n"
   ],
   "id": "c07e4ee5ec08fd15",
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ],
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "execution_count": 141
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T13:29:21.185980Z",
     "start_time": "2026-01-19T13:29:21.113097Z"
    }
   },
   "cell_type": "code",
   "source": [
    "df = [\n",
    "    g['prop_correct'].values\n",
    "    for _, g in item_summary.groupby('method')\n",
    "]\n",
    "\n",
    "labels = item_summary['method'].unique()\n",
    "\n",
    "plt.hist(\n",
    "    df,\n",
    "    bins=20,\n",
    "    stacked=True,\n",
    "    label=labels\n",
    ")\n",
    "\n",
    "plt.legend(title='method')\n",
    "plt.show()\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ],
   "id": "e90eb7def870f2af",
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ],
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "execution_count": 114
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T14:13:10.421659Z",
     "start_time": "2026-01-19T14:13:06.642802Z"
    }
   },
   "cell_type": "code",
   "source": "DET_f = DET_f.sort_values(by=['question','method','run_id'])\n",
   "id": "ee7df7794d088ccd",
   "outputs": [],
   "execution_count": 117
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T10:46:12.853448Z",
     "start_time": "2026-01-19T10:45:32.968957Z"
    }
   },
   "cell_type": "code",
   "source": "",
   "id": "cffcd74d99a5be5b",
   "outputs": [],
   "execution_count": 78
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-17T13:30:33.271407Z",
     "start_time": "2026-01-17T13:30:33.267124Z"
    }
   },
   "cell_type": "code",
   "source": [
    "\n",
    "qus = questions[questions['question'].str.contains('What should patients using Tri Femynor do if they are concurrently taking enzyme-inducing drugs?')]['options']\n",
    "\n",
    "for q in qus:\n",
    "    print(q)\n",
    "\n"
   ],
   "id": "916f8b2062dbdf32",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'A': 'Stop taking Tri Femynor immediately.', 'B': 'Use a back-up or alternative method of contraception.', 'C': 'Increase the dose of Tri Femynor.', 'D': 'Take Tri Femynor with food to reduce interactions.'}\n"
     ]
    }
   ],
   "execution_count": 24
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T08:46:22.071677Z",
     "start_time": "2026-01-19T08:46:21.282001Z"
    }
   },
   "cell_type": "code",
   "source": [
    "\n",
    "unq = np.unique(DET[\n",
    "                    (DET['is_correct']==False) &\n",
    "                    (DET['question_type']!='open_ended')\n",
    "                ]['prediction'])\n",
    "for q in unq:\n",
    "    x = DET[DET['prediction']==q][['method','SIM_score','prediction','pred_SIM','choice','correct_answer','options']]\n",
    "    print('method: ',x['method'].to_string(index=False)   )\n",
    "    print('SIM_score: ',x['SIM_score'].to_string(index=False))\n",
    "    print('prediction: ',x['prediction'].iloc[0])\n",
    "    print('pred_SIM: ',x['pred_SIM'].to_string(index=False))\n",
    "    print('choice: ',x['choice'].to_string(index=False))\n",
    "    print('correct_answer: ',x['correct_answer'].to_string(index=False))\n",
    "    print('correct answer:', x['options'].iloc[0][x['correct_answer'].iloc[0]])\n",
    "    print('\\n-------------------------\\n')\n"
   ],
   "id": "9275b53335e12dff",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "method:  cot2\n",
      "SIM_score:  0.010624\n",
      "prediction:  'Meijer Stomach Relief Regular Strength' typically contains the active ingredient loperamide, which is primarily used to treat diarrhea. However, it may also be indicated for other gastrointestinal conditions. Hereâ€™s a step-by-step breakdown of its uses:\n",
      "\n",
      "1. **Understanding Loperamide**: Loperamide is an opioid-receptor agonist that works by slowing down gut movement, which decreases the number of bowel movements and makes the stool less watery.\n",
      "\n",
      "2. **Primary Indication**: The primary indication for loperamide is the treatment of acute diarrhea, including diarrhea caused by gastroenteritis or food-related issues.\n",
      "\n",
      "3. **Chronic Diarrhea**: In addition to acute diarrhea, loperamide can also be used to manage chronic diarrhea associated with conditions such as inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. It helps to control symptoms and improve the quality of life for patients with these conditions.\n",
      "\n",
      "4. **Traveler's Diarrhea**: Loperamide is often recommended for the symptomatic relief of traveler's diarrhea, which can occur due to changes in diet or exposure to unfamiliar bacteria while traveling.\n",
      "\n",
      "5. **Post-Surgical Use**: In some cases, loperamide may be used post-operatively to manage diarrhea that can occur after certain types of gastrointestinal surgery.\n",
      "\n",
      "6. **Irritable Bowel Syndrome (IBS)**: While not a primary treatment, loperamide may be used in some patients with IBS who experience diarrhea as a predominant symptom.\n",
      "\n",
      "7. **Dosage and Administration**: It is important to follow the recommended dosage and not to exceed the maximum daily limit, as overuse can lead to constipation or more serious complications.\n",
      "\n",
      "8. **Consultation with Healthcare Provider**: Patients should consult with a healthcare provider before using loperamide for conditions other than diarrhea, especially if they have underlying health issues or are taking other medications.\n",
      "\n",
      "In summary, in addition to diarrhea, 'Meijer Stomach Relief Regular Strength' (loperamide) may also be indicated for chronic diarrhea associated with conditions like IBD, traveler's diarrhea, and potentially for managing symptoms in IBS. Always consult a healthcare professional for personalized advice and treatment options.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.010628\n",
      "prediction:  'Meijer Stomach Relief Regular Strength' typically contains the active ingredient loperamide, which is primarily used to treat diarrhea. However, it may also be indicated for other gastrointestinal conditions. Hereâ€™s a step-by-step breakdown of its uses:\n",
      "\n",
      "1. **Understanding Loperamide**: Loperamide is an opioid-receptor agonist that works by slowing down gut movement, which decreases the number of bowel movements and makes the stool less watery.\n",
      "\n",
      "2. **Primary Indication**: The primary indication for loperamide is to treat acute diarrhea, including diarrhea caused by gastroenteritis or food-related issues.\n",
      "\n",
      "3. **Chronic Diarrhea**: Loperamide can also be used for chronic diarrhea, particularly in conditions like irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), where diarrhea is a prominent symptom.\n",
      "\n",
      "4. **Traveler's Diarrhea**: It is often recommended for managing symptoms of traveler's diarrhea, which can occur due to consuming contaminated food or water while traveling.\n",
      "\n",
      "5. **Post-Surgical Use**: In some cases, loperamide may be used post-operatively to manage diarrhea that can occur after certain types of surgery, particularly gastrointestinal surgery.\n",
      "\n",
      "6. **Non-Diarrheal Uses**: While loperamide is primarily indicated for diarrhea, it may also provide symptomatic relief for conditions that cause increased bowel motility, although this is not its primary use.\n",
      "\n",
      "7. **Consultation with Healthcare Provider**: It is important to consult with a healthcare provider before using loperamide for any condition other than diarrhea, as it may not be appropriate for all gastrointestinal issues, especially those involving bacterial infections or certain types of colitis.\n",
      "\n",
      "In summary, in addition to diarrhea, 'Meijer Stomach Relief Regular Strength' (loperamide) may be indicated for chronic diarrhea, traveler's diarrhea, and potentially for managing symptoms related to increased bowel motility in certain gastrointestinal conditions. Always consult a healthcare professional for personalized advice and treatment options.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.010747\n",
      "prediction:  'Meijer Stomach Relief Regular Strength' typically contains the active ingredient loperamide, which is primarily used to treat diarrhea. However, it may also be indicated for other gastrointestinal conditions. Hereâ€™s a step-by-step breakdown of its uses:\n",
      "\n",
      "1. **Understanding Loperamide**: Loperamide is an opioid-receptor agonist that works by slowing down gut movement, which decreases the number of bowel movements and makes the stool less watery.\n",
      "\n",
      "2. **Primary Indication**: The primary indication for loperamide is to treat acute diarrhea, including diarrhea caused by gastroenteritis or food-related issues.\n",
      "\n",
      "3. **Chronic Diarrhea**: Loperamide can also be used for chronic diarrhea, such as that associated with conditions like irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), where diarrhea is a persistent symptom.\n",
      "\n",
      "4. **Traveler's Diarrhea**: It is often used to manage symptoms of traveler's diarrhea, which can occur due to consuming contaminated food or water while traveling.\n",
      "\n",
      "5. **Post-Surgical Use**: In some cases, loperamide may be used post-operatively to manage diarrhea that can occur after certain types of gastrointestinal surgery.\n",
      "\n",
      "6. **Non-Diarrheal Uses**: While loperamide is primarily indicated for diarrhea, it may also provide symptomatic relief for conditions that cause increased bowel motility, leading to discomfort or urgency, although this is not its primary use.\n",
      "\n",
      "7. **Consultation with Healthcare Provider**: It is important to consult with a healthcare provider before using loperamide for any condition other than diarrhea, as it may not be appropriate for all gastrointestinal issues, especially those involving bacterial infections or certain types of colitis.\n",
      "\n",
      "In summary, in addition to diarrhea, 'Meijer Stomach Relief Regular Strength' (loperamide) may be indicated for chronic diarrhea, traveler's diarrhea, and potentially for managing symptoms related to increased bowel motility. Always consult a healthcare professional for personalized advice and treatment options.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.016517\n",
      "prediction:  'Up & Up' ibuprofen, like many over-the-counter medications, should be stored properly to maintain its efficacy and safety. The maximum temperature for storing ibuprofen, including 'Up & Up' brand, is typically recommended to be below 25Â°C (77Â°F). \n",
      "\n",
      "In general, ibuprofen should be kept in a cool, dry place away from direct sunlight and moisture. Extreme temperatures can affect the stability of the medication, potentially leading to reduced effectiveness or degradation of the active ingredients. \n",
      "\n",
      "For best practices, it is advisable to:\n",
      "\n",
      "1. **Store in Original Packaging**: Keep ibuprofen in its original container with the label intact to ensure you have access to important information, including expiration dates and storage instructions.\n",
      "\n",
      "2. **Avoid Humidity**: Bathrooms are often not ideal for storage due to humidity. A bedroom or a kitchen cabinet away from heat sources is preferable.\n",
      "\n",
      "3. **Check Expiration Dates**: Always check the expiration date on the packaging and dispose of any expired medications properly.\n",
      "\n",
      "4. **Follow Specific Instructions**: If the packaging provides specific storage instructions, those should be followed closely.\n",
      "\n",
      "If you have any concerns about the storage conditions or the integrity of the medication, it is best to consult a pharmacist or healthcare provider for guidance.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020333\n",
      "prediction:  'Up & Up' ibuprofen, like other over-the-counter medications, should be stored according to the guidelines provided on the packaging or in the accompanying patient information leaflet. Generally, ibuprofen should be stored at room temperature, which is typically defined as between 20Â°C to 25Â°C (68Â°F to 77Â°F). \n",
      "\n",
      "However, it is important to note that ibuprofen can be exposed to temperatures up to 30Â°C (86Â°F) for short periods without significant degradation. Prolonged exposure to temperatures above this range can lead to a decrease in the medication's effectiveness and stability. \n",
      "\n",
      "In addition to temperature, ibuprofen should be kept in a dry place, away from moisture and direct sunlight, as these factors can also affect the integrity of the medication. It is advisable to keep the medication in its original container, tightly closed, and out of reach of children.\n",
      "\n",
      "If you have specific concerns about the storage conditions of 'Up & Up' ibuprofen or any other medication, it is always best to consult a pharmacist or healthcare provider for personalized advice.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021934\n",
      "prediction:  'Up & Up' ibuprofen, like other over-the-counter medications, should be stored according to the guidelines provided on the packaging or in the accompanying patient information leaflet. Generally, ibuprofen should be stored at room temperature, which is typically defined as between 20Â°C to 25Â°C (68Â°F to 77Â°F). \n",
      "\n",
      "However, it is important to note that ibuprofen should not be exposed to temperatures above 30Â°C (86Â°F) for extended periods, as higher temperatures can potentially degrade the medication and affect its efficacy. \n",
      "\n",
      "In addition to temperature, ibuprofen should be kept in a cool, dry place away from direct sunlight and moisture. It is also advisable to keep it in its original container, tightly closed, to protect it from environmental factors that could compromise its stability.\n",
      "\n",
      "If you have specific concerns about the storage conditions of 'up & up' ibuprofen or any other medication, it is always best to consult a pharmacist or healthcare provider for personalized advice.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.054878\n",
      "prediction:  **Answer:**\n",
      "\n",
      "RETHYMIC (thymoglobulin), an immunosuppressive agent derived from rabbit serum, has a specific contraindication profile, particularly for patients with a known hypersensitivity to rabbit proteins or any other component of the product. Its usage requires careful monitoring in patients with a history of malignancies, as it may increase the risk of post-transplant lymphoproliferative disorder (PTLD) and other infections due to its immunosuppressive effects.\n",
      "\n",
      "When comparing RETHYMIC's contraindication profile to other drugs with specific contraindications, several factors come into play. For instance, other immunosuppressants like cyclosporine and tacrolimus have contraindications related to renal dysfunction or specific allergies, while biologics might have contraindications regarding active infections or live vaccinations. RETHYMIC's unique characteristic lies in the strong possibility of severe hypersensitive reactions, which may necessitate pre-treatment screening, and its specific application in the context of organ transplantation.\n",
      "\n",
      "Studies comparing the contraindications of medications reveal varying degrees of overlap in patient populations at risk for adverse reactions. For example, systemic corticosteroids can also lead to increased susceptibility to infections, similar to RETHYMIC. However, the mechanisms of action and typical patient scenarios differ significantly based on underlying conditions and treatment goals.\n",
      "\n",
      "In summary, while RETHYMIC shares some common contraindications with other immunosuppressive therapies, its unique association with hypersensitivity to animal proteins and the implications for transplant patients set it apart from those drugs that may have broader contraindications related to other health conditions or drug interactions. This highlights the importance of individualized patient assessment when considering immunosuppressive therapies.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.037946\n",
      "prediction:  **Answer:**\n",
      "\n",
      "The contraindication profile of RETHYMIC, a recombinant form of the human thymosin alpha-1 used to enhance immune function, can be compared to other medications with known contraindications in various ways. RETHYMIC is generally well-tolerated, but it does have specific contraindications and precautions that should be considered in comparison with other immunomodulatory drugs.\n",
      "\n",
      "1. **Allergic Reactions**: Similar to many biological medications, RETHYMIC may be contraindicated in patients with known hypersensitivity to its components or other immunotherapeutics. This is akin to other drugs in immunotherapy that can provoke allergic responses, such as monoclonal antibodies.\n",
      "\n",
      "2. **Infection Risks**: As RETHYMIC impacts immune modulation, it is contraindicated in patients with active infections or severe immune deficiencies. This mirrors other immunosuppressants like corticosteroids or biologics, where the risk of opportunistic infections is significantly increased.\n",
      "\n",
      "3. **Co-administration**: RETHYMIC may have contraindications when used with certain drugs that further suppress the immune system or are nephrotoxic. This is comparable to other therapies, such as methotrexate, which may have limited use in combination therapies due to increased toxicity profiles.\n",
      "\n",
      "4. **Specific Populations**: The contraindication profile may also expand based on the patient's age, comorbid conditions, and concurrent therapies. For instance, certain immunotherapies are cautioned against in geriatric populations or patients with specific organ dysfunction. RETHYMIC's use needs careful monitoring in such patients, similar to how chemotherapy drugs are approached.\n",
      "\n",
      "5. **Comparative Analysis**: Drugs with well-established contraindications, such as Etoposide in patients with a history of hypersensitivity reactions or Azathioprine in individuals with a history of liver issues, can provide a clearer framework for understanding the safety profile of RETHYMIC. The severity and nature of contraindications may vary based on the specific drug class and mechanism of action.\n",
      "\n",
      "In conclusion, understanding the contraindication profile of RETHYMIC in comparison with other drugs requires an assessment of its mechanisms, the conditions it is intended to treat, and the broader implications for patient safety in the context of immune modulation and potential interactions with other therapies. The careful selection of patients based on their health status and comorbidities is essential for optimizing the therapeutic benefits while minimizing risks, much like in the use of other medications with specific contraindications.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.030189\n",
      "prediction:  **Answer:** In addition to treating diarrhea, the \"Meijer Stomach Relief Regular Strength\" is indicated for the relief of upset stomach, nausea, and indigestion. This product contains **bismuth subsalicylate** as its active ingredient, which is known for its effectiveness in managing symptoms associated with gastrointestinal discomfort, such as those caused by overindulgence in food or drink. Specifically, it can help alleviate symptoms related to gastritis and is sometimes recommended for the treatment of travelers' diarrhea, a condition that results from consuming contaminated food or water while traveling (Food and Drug Administration, 2004).\n",
      "\n",
      "Sources:\n",
      "1. FDA indication for bismuth subsalicylate.\n",
      "2. General uses of bismuth subsalicylate in gastrointestinal conditions.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "sc\n",
      "SIM_score:  0.076628\n",
      "0.076628\n",
      "prediction:  - 'Meijer stomach relief regular strength' is indicated to treat upset stomach.\n",
      "- It contains active ingredients that help alleviate symptoms associated with indigestion.\n",
      "- The formulation is designed to provide relief from gas and bloating as well.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.053286\n",
      "prediction:  - 'Up and Up Nighttime Cold and Flu' should not be stored at temperatures above 25Â°C (77Â°F), as excessive heat can degrade the active ingredients.\n",
      "- It is incorrect to store 'Up and Up Nighttime Cold and Flu' in a bathroom, as humidity can affect the stability of the medication.\n",
      "- The product should not be exposed to direct sunlight, which can also compromise its effectiveness.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3333333333333333, 'B': 0.25, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.052265\n",
      "prediction:  - 'Up and Up Nighttime Cold and Flu' should not be stored at temperatures above 25Â°C (77Â°F), as excessive heat can degrade the active ingredients.\n",
      "- It is incorrect to store 'Up and Up Nighttime Cold and Flu' in a bathroom, as humidity can negatively affect the stability of the medication.\n",
      "- The product should not be exposed to direct sunlight, which can also compromise its effectiveness.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3333333333333333, 'B': 0.25, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.051635\n",
      "prediction:  - 'Up and Up Nighttime Cold and Flu' should not be stored at temperatures above 25Â°C (77Â°F), as excessive heat can degrade the active ingredients.\n",
      "- It is incorrect to store 'Up and Up Nighttime Cold and Flu' in a bathroom, where humidity can affect the stability of the medication.\n",
      "- The product should not be exposed to direct sunlight, as UV light can compromise the efficacy of the formulation.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3333333333333333, 'B': 0.25, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.045643\n",
      "0.045643\n",
      "0.045643\n",
      "prediction:  - 'Up and Up ibuprofen' should be stored at a maximum temperature of 25Â°C (77Â°F).\n",
      "- It is important to keep 'up and up ibuprofen' away from excessive heat and moisture to maintain its efficacy.\n",
      "- The product should not be frozen, as extreme temperatures can affect the stability of the ibuprofen formulation.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.076655\n",
      "prediction:  - 'Up and Up ibuprofen' should be stored at a maximum temperature of 25Â°C (77Â°F).\n",
      "- It is important to keep the medication away from excessive heat and moisture to maintain its efficacy.\n",
      "- Always check the packaging for specific storage instructions to ensure proper handling.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.075862\n",
      "prediction:  - 'Up and Up ibuprofen' should be stored at a maximum temperature of 25Â°C (77Â°F).\n",
      "- It is important to keep the medication away from excessive heat and moisture to maintain its efficacy.\n",
      "- Always refer to the specific storage instructions on the packaging for optimal conditions.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.07309\n",
      "0.07309\n",
      "0.07309\n",
      "prediction:  - 'Up and Up ibuprofen' should be stored at a maximum temperature of 25Â°C (77Â°F).\n",
      "- It is important to keep the medication away from excessive heat and moisture to maintain its efficacy.\n",
      "- Proper storage conditions help prevent degradation of the active ingredient in 'up and up ibuprofen'.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.076125\n",
      "prediction:  - 'Up and Up ibuprofen' should be stored at a maximum temperature of 25Â°C (77Â°F).\n",
      "- It is important to keep the medication away from excessive heat and moisture to maintain its efficacy.\n",
      "- Storing 'up and up ibuprofen' in a cool, dry place is recommended to prevent degradation.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.026217\n",
      "prediction:  - A minimum of 14 days should elapse after stopping venlafaxine before initiating treatment with an MAOI, such as phenelzine or tranylcypromine, to avoid the risk of serotonin syndrome.\n",
      "- This waiting period is crucial to ensure that venlafaxine is fully cleared from the system, as it has a half-life that can affect the timing of MAOI initiation.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.4444444444444444, 'B': 0.38888888888888884, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.026975\n",
      "prediction:  - A minimum of 14 days should elapse after stopping venlafaxine before initiating treatment with an MAOI, such as phenelzine or tranylcypromine, to avoid the risk of serotonin syndrome.\n",
      "- This washout period is crucial to ensure that venlafaxine is fully cleared from the system, as it has a half-life that can affect the timing of starting an MAOI.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.029536\n",
      "prediction:  - A minimum of 14 days should elapse after stopping venlafaxine before initiating treatment with an MAOI, such as phenelzine or tranylcypromine.\n",
      "- This waiting period is crucial to avoid the risk of serotonin syndrome, which can occur due to the interaction between venlafaxine and MAOIs.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.4444444444444444, 'B': 0.38888888888888884, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.113426\n",
      "prediction:  - ARIKAYCE contains amikacin liposome inhalation suspension, which is designed for targeted delivery to the lungs, minimizing systemic absorption and reducing the risk of accumulation.\n",
      "- The dosing regimen for ARIKAYCE typically involves once-daily administration, which helps maintain lower plasma levels of amikacin compared to traditional intravenous formulations, even in patients with renal impairment.\n",
      "- Clinical studies have shown that the pharmacokinetics of amikacin from ARIKAYCE do not lead to significant systemic exposure, thus reducing the likelihood of clinically relevant accumulation in patients with compromised renal function.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.3333333333333333, 'B': 0.5, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: ARIKAYCE has low systemic exposure following inhalation.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.109966\n",
      "prediction:  - ARIKAYCE is administered via inhalation, which allows for localized delivery of amikacin to the lungs, minimizing systemic absorption and reducing the risk of accumulation in patients with renal impairment.\n",
      "- The dosing regimen for ARIKAYCE is designed to achieve therapeutic levels in the lungs while limiting systemic exposure, thus decreasing the likelihood of clinically relevant accumulation in patients with compromised renal function.\n",
      "- Unlike intravenous amikacin, which can lead to higher systemic levels and potential toxicity in renal impairment, ARIKAYCE's route of administration and pharmacokinetics help prevent significant accumulation.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.3333333333333333, 'B': 0.5, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: ARIKAYCE has low systemic exposure following inhalation.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.106464\n",
      "prediction:  - ARIKAYCE is administered via inhalation, which results in localized delivery to the lungs and minimizes systemic absorption, reducing the risk of accumulation in patients with renal impairment.\n",
      "- The dosing regimen for ARIKAYCE typically involves a lower total daily dose compared to systemic amikacin, further decreasing the likelihood of clinically relevant accumulation.\n",
      "- In patients with renal impairment, the pharmacokinetics of inhaled amikacin differ significantly from intravenous formulations, leading to reduced systemic exposure and lower risk of toxicity.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.3333333333333333, 'B': 0.5, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: ARIKAYCE has low systemic exposure following inhalation.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.055249\n",
      "prediction:  - Accutane (isotretinoin) is specifically indicated for the treatment of severe acne that has not responded to other therapies.\n",
      "- Differin (adapalene) is a topical retinoid indicated for the treatment of acne vulgaris.\n",
      "- Benzaclin (benzoyl peroxide and clindamycin) is a combination topical medication indicated for the treatment of acne.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.27777777777777773, 'C': 1.0, 'D': 0.3055555555555555}; rankings=[['C', 'A', 'D', 'B'], ['C', 'A', 'B', 'D'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.055249\n",
      "prediction:  - Accutane (isotretinoin) is specifically indicated for the treatment of severe acne that has not responded to other therapies.\n",
      "- Differin (adapalene) is a topical retinoid indicated for the treatment of acne vulgaris.\n",
      "- Benzaclin (benzoyl peroxide and clindamycin) is a combination topical medication indicated for the treatment of acne.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3055555555555555, 'C': 1.0, 'D': 0.27777777777777773}; rankings=[['C', 'A', 'D', 'B'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.056818\n",
      "prediction:  - Accutane (isotretinoin) is specifically indicated for the treatment of severe acne that has not responded to other therapies.\n",
      "- Differin (adapalene) is a topical retinoid indicated for the treatment of acne vulgaris.\n",
      "- Benzaclin (benzoyl peroxide and clindamycin) is a combination topical medication indicated for the treatment of acne.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.275862\n",
      "prediction:  - Administer Verkazia first, followed by a wait of at least 5 minutes before using any other eye drops.\n",
      "- If using an ointment, apply Verkazia and then wait at least 10 minutes before applying the ointment.\n",
      "- Ensure that any other eye drops are administered after the waiting period to avoid dilution or interference with Verkazia's effectiveness.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "sc\n",
      "SIM_score:  0.193353\n",
      "0.193353\n",
      "prediction:  - Administer appropriate antiarrhythmic medications to stabilize the patient's heart rhythm.\n",
      "- Consider the use of intravenous fluids and electrolyte management to support cardiac function.\n",
      "- Monitor the patient closely for any signs of further complications or recurrence of arrhythmias.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Discontinue Sumatriptan injection immediately\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.013274\n",
      "prediction:  - After 8 weeks of treatment with pantoprazole sodium delayed-release tablets, 80% of patients achieved endoscopically proven healing of esophageal lesions.\n",
      "- The study specifically evaluated the efficacy of pantoprazole sodium compared to a placebo in patients with esophageal lesions.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.012712\n",
      "prediction:  - After 8 weeks of treatment with pantoprazole sodium delayed-release tablets, 80% of patients achieved endoscopically proven healing of esophageal lesions.\n",
      "- The study specifically measured the effectiveness of pantoprazole sodium compared to a placebo in patients with esophageal lesions.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.38888888888888884, 'B': 0.4444444444444444, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.013158\n",
      "prediction:  - After 8 weeks of treatment with pantoprazole sodium delayed-release tablets, 80% of patients achieved endoscopically proven healing of esophageal lesions.\n",
      "- The study specifically measured the effectiveness of pantoprazole sodium compared to a placebo in patients with esophageal lesions.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.034749\n",
      "prediction:  - Albuterol sulfate demonstrated no evidence of impaired fertility in rats at an oral dose of 100 mg/kg/day.\n",
      "- The study indicated that this dose did not adversely affect reproductive parameters in the test subjects.\n",
      "- Comparatively, lower doses did not show significant effects, reinforcing the safety profile of albuterol sulfate at this level.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.046729\n",
      "prediction:  - Albuterol sulfate demonstrated no evidence of tumorigenicity in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study involved long-term exposure to albuterol sulfate in the diet, confirming its safety profile in this specific animal model.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.052758\n",
      "prediction:  - Albuterol sulfate showed no evidence of tumorigenicity in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study involved long-term exposure to albuterol sulfate in the diet without any observed tumor formation in the tested rats.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.052632\n",
      "prediction:  - Albuterol sulfate showed no evidence of tumorigenicity in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study involved long-term exposure to albuterol sulfate in the diet without any observed tumor formation in the treated rats.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.033272\n",
      "prediction:  - Albuterol sulfate was administered at an oral dose of 100 mg/kg/day in rats without showing evidence of impaired fertility.\n",
      "- The study indicated that doses up to 100 mg/kg/day did not adversely affect reproductive parameters in the test subjects.\n",
      "- No fertility impairment was observed at the highest tested dose of albuterol sulfate in the evaluated rat population.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.031469\n",
      "prediction:  - Albuterol sulfate was administered at an oral dose of 100 mg/kg/day in rats without showing evidence of impaired fertility.\n",
      "- The study indicated that doses up to 100 mg/kg/day did not adversely affect reproductive parameters in the test subjects.\n",
      "- No fertility impairment was observed at the highest tested dose of albuterol sulfate, which was significantly higher than typical therapeutic doses.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.065455\n",
      "prediction:  - Albuterol sulfate was administered at doses up to 100 mg/kg/day in rats.\n",
      "- No evidence of impaired fertility was observed at this dosage level.\n",
      "- The study indicated that albuterol sulfate did not adversely affect reproductive performance in the tested population.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.072\n",
      "0.072\n",
      "0.072\n",
      "0.072\n",
      "prediction:  - Albuterol sulfate was administered at doses up to 100 mg/kg/day in rats.\n",
      "- No evidence of impaired fertility was observed at this high dose.\n",
      "- The study indicated that reproductive performance remained unaffected at this level of exposure.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.070866\n",
      "prediction:  - Albuterol sulfate was administered at doses up to 100 mg/kg/day in rats.\n",
      "- No evidence of impaired fertility was observed at this high oral dose.\n",
      "- The study indicated that reproductive parameters remained unaffected at this level of exposure.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.076125\n",
      "0.076125\n",
      "prediction:  - Albuterol sulfate was tested in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study indicated no evidence of tumorigenicity in this specific animal model.\n",
      "- The findings suggest a lack of carcinogenic potential for albuterol sulfate in rats at the tested dosage.\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.075862\n",
      "prediction:  - Albuterol sulfate was tested in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study indicated no evidence of tumorigenicity in this specific animal model.\n",
      "- The findings suggest that albuterol sulfate does not promote tumor formation in rats at the tested dosage.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.075862\n",
      "0.075862\n",
      "0.075862\n",
      "prediction:  - Albuterol sulfate was tested in a rat model at dietary doses up to 500 mg/kg.\n",
      "- The study indicated no evidence of tumorigenicity in this specific animal model.\n",
      "- This finding suggests a lack of carcinogenic potential for albuterol sulfate in rats at the tested dosage.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.110414\n",
      "prediction:  - Animal studies have shown that pantoprazole sodium, a proton pump inhibitor, can lead to decreased bone mineral density in offspring when administered to pregnant animals.\n",
      "- The studies indicated that exposure to pantoprazole sodium during gestation resulted in altered bone development and potential long-term skeletal issues in the offspring.\n",
      "- In comparison to control groups receiving a placebo, the offspring of animals treated with pantoprazole sodium exhibited significant differences in bone growth parameters.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 0.8333333333333334, 'B': 0.6666666666666666, 'C': 0.3055555555555555, 'D': 0.27777777777777773}; rankings=[['B', 'A', 'C', 'D'], ['A', 'B', 'D', 'C'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to changes in bone parameters that are partially reversible.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.065292\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Staphylococcus or Streptococcus species.\n",
      "- Conditions like viral infections, such as influenza or HIV, are also not treated by antifungal medications.\n",
      "- Antifungal treatments, such as fluconazole or itraconazole, specifically target fungal infections like candidiasis or aspergillosis, not non-fungal conditions.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.064957\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Staphylococcus or Streptococcus species.\n",
      "- Conditions like viral infections, such as influenza or herpes, are also not treated by antifungal medications.\n",
      "- Antifungal treatments, such as fluconazole or itraconazole, specifically target fungal infections like candidiasis or aspergillosis, not non-fungal conditions.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.092457\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Streptococcus or Staphylococcus species.\n",
      "- Conditions like athlete's foot or ringworm are treated with antifungal medications, but not viral infections like influenza.\n",
      "- Antifungal treatments are ineffective against parasitic infections, such as those caused by Plasmodium species, which lead to malaria.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.096203\n",
      "0.096203\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Streptococcus or Staphylococcus species.\n",
      "- Conditions like athlete's foot or ringworm are treated with antifungal medications, but not viral infections like influenza.\n",
      "- Antifungal treatments, such as fluconazole or itraconazole, are ineffective against parasitic infections like malaria.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.088167\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Streptococcus or Staphylococcus species.\n",
      "- Conditions like athlete's foot or ringworm are treated with antifungal medications, while viral infections like influenza are not.\n",
      "- Antifungal treatments, such as fluconazole or itraconazole, are ineffective against conditions like tuberculosis, which is treated with antibiotics.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.094763\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Streptococcus or Staphylococcus species.\n",
      "- Conditions like athlete's foot or ringworm are treated with antifungal medications, while viral infections like influenza are not.\n",
      "- Antifungal treatments, such as fluconazole or itraconazole, are ineffective against parasitic infections like malaria.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.092683\n",
      "prediction:  - Antifungal drugs are not used to treat bacterial infections, such as those caused by Streptococcus or Staphylococcus species.\n",
      "- Conditions like athlete's foot or ringworm are treated with antifungals, while viral infections like influenza are not.\n",
      "- Antifungal medications, such as fluconazole or itraconazole, specifically target fungal pathogens and do not affect non-fungal conditions.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.053371\n",
      "prediction:  - Antifungal drugs, such as fluconazole and itraconazole, are primarily used to treat fungal infections like candidiasis and aspergillosis.\n",
      "- Conditions like bacterial infections or viral infections, such as those treated with antibiotics (e.g., amoxicillin) or antivirals (e.g., acyclovir), are NOT treated by antifungal medications.\n",
      "- Antifungal treatments do not address conditions like athlete's foot or ringworm, which are specifically fungal infections, but they do not treat non-fungal conditions like bacterial pneumonia.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.041379\n",
      "prediction:  - Apply a sufficient amount of hydrocort shampoo to cover the affected area of the scalp thoroughly, typically around 1 to 2 ounces.\n",
      "- Massage the hydrocort shampoo into the scalp gently and leave it on for 5 to 10 minutes before rinsing.\n",
      "- Use the hydrocort shampoo as directed, usually 2 to 3 times a week, depending on the severity of the condition being treated.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 0.8333333333333334, 'B': 0.6666666666666666, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['B', 'A', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.121348\n",
      "0.121348\n",
      "prediction:  - Assess the patient's current medications to avoid potential interactions, particularly with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs.\n",
      "- Evaluate the patient's history of hypertension, as venlafaxine can increase blood pressure, especially at higher doses.\n",
      "- Consider the patient's mental health history, particularly any history of bipolar disorder, to prevent the risk of manic episodes.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.118162\n",
      "prediction:  - Assess the patient's current medications to avoid potential interactions, particularly with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs.\n",
      "- Evaluate the patient's history of hypertension, as venlafaxine can increase blood pressure, especially at higher doses.\n",
      "- Screen for any history of bipolar disorder to prevent the risk of inducing a manic episode when initiating treatment with venlafaxine.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.12529\n",
      "prediction:  - Assess the patient's current medications to avoid potential interactions, particularly with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs.\n",
      "- Evaluate the patient's history of hypertension, as venlafaxine can increase blood pressure, especially at higher doses.\n",
      "- Screen for any history of bipolar disorder to prevent the risk of inducing a manic episode with venlafaxine.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.186528\n",
      "prediction:  - Assess the patient's history of hypertension, as venlafaxine can increase blood pressure, especially at higher doses.\n",
      "- Evaluate for any history of serotonin syndrome, particularly if the patient is taking other serotonergic medications.\n",
      "- Consider the patient's renal function, as dose adjustments may be necessary in cases of renal impairment.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.186528\n",
      "prediction:  - Assess the patient's history of hypertension, as venlafaxine can increase blood pressure, particularly at higher doses.\n",
      "- Evaluate for any history of serotonin syndrome, especially if the patient is taking other serotonergic medications.\n",
      "- Consider the patient's renal function, as dose adjustments may be necessary in cases of renal impairment.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.050909\n",
      "0.050909\n",
      "prediction:  - At least 14 days should elapse after stopping venlafaxine before starting an MAOI.\n",
      "- This precaution is necessary to avoid the risk of serotonin syndrome.\n",
      "- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that can interact dangerously with MAOIs.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.052239\n",
      "prediction:  - At least 14 days should elapse after stopping venlafaxine before starting an MAOI.\n",
      "- This precaution is necessary to avoid the risk of serotonin syndrome.\n",
      "- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that requires this washout period.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.056\n",
      "prediction:  - At least 14 days should elapse after stopping venlafaxine before starting an MAOI.\n",
      "- This precaution is necessary to avoid the risk of serotonin syndrome.\n",
      "- Venlafaxine is an SNRI that can affect serotonin levels, which MAOIs also influence.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.056225\n",
      "prediction:  - At least 14 days should elapse after stopping venlafaxine before starting an MAOI.\n",
      "- This precaution is necessary to avoid the risk of serotonin syndrome.\n",
      "- Venlafaxine is an SNRI, and MAOIs include drugs like phenelzine or tranylcypromine.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.055777\n",
      "prediction:  - At least 14 days should elapse after stopping venlafaxine before starting an MAOI.\n",
      "- This precaution is necessary to prevent the risk of serotonin syndrome.\n",
      "- Venlafaxine is an SNRI, and MAOIs include drugs like phenelzine or tranylcypromine.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.241379\n",
      "0.241379\n",
      "0.241379\n",
      "0.241379\n",
      "0.241379\n",
      "prediction:  - Avoid using WL-AAB-Z-W-1350 while wearing contact lenses to prevent potential irritation or discomfort.\n",
      "- If contact lenses must be worn, ensure they are removed before applying WL-AAB-Z-W-1350 to minimize the risk of adverse effects.\n",
      "- Consult with an eye care professional for specific recommendations regarding the use of WL-AAB-Z-W-1350 and contact lenses.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Contact lenses should be removed prior to instillation and reinserted 15 minutes after administration.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.248927\n",
      "prediction:  - Avoid using WL-AAB-Z-W-1350 while wearing contact lenses to prevent potential irritation or discomfort.\n",
      "- If contact lenses must be worn, ensure they are removed before applying WL-AAB-Z-W-1350 to minimize the risk of adverse reactions.\n",
      "- Consult with an eye care professional for specific recommendations regarding the use of WL-AAB-Z-W-1350 and contact lenses.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Contact lenses should be removed prior to instillation and reinserted 15 minutes after administration.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.045767\n",
      "prediction:  - Avoid using clindamycin due to the patient's history of hypersensitivity to this antibiotic.\n",
      "- Consider alternatives such as doxycycline or minocycline, which are not related to clindamycin and may be safer options for the patient.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3611111111111111, 'B': 0.27777777777777773, 'C': 1.0, 'D': 0.4444444444444444}; rankings=[['C', 'A', 'D', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.068966\n",
      "0.068966\n",
      "prediction:  - Avoid using clindamycin due to the patient's hypersensitivity history.\n",
      "- Consider alternatives that do not belong to the lincosamide class, such as macrolides or tetracyclines.\n",
      "- Monitor for any cross-reactivity with other antibiotics if necessary.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.139466\n",
      "prediction:  - BRILINTA (ticagrelor) is not recommended for patients with end-stage renal disease (ESRD) on dialysis due to limited clinical data supporting its safety and efficacy in this population.\n",
      "- In patients with ESRD, alternative antiplatelet therapies, such as clopidogrel, may be considered instead of BRILINTA.\n",
      "- Close monitoring and individualized treatment plans are essential for managing antiplatelet therapy in patients with ESRD on dialysis.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.142636\n",
      "prediction:  - BRILINTA (ticagrelor) is not recommended for patients with end-stage renal disease (ESRD) on dialysis due to limited data on its safety and efficacy in this population.\n",
      "- In patients with ESRD, alternative antiplatelet therapies, such as clopidogrel, may be considered instead of BRILINTA.\n",
      "- Close monitoring and individualized treatment plans are essential for patients with ESRD who require antiplatelet therapy.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.197753\n",
      "0.197753\n",
      "prediction:  - BRILINTA (ticagrelor) is not recommended for patients with end-stage renal disease (ESRD) on dialysis due to limited safety and efficacy data.\n",
      "- Alternative antiplatelet therapies, such as clopidogrel, may be considered for these patients instead of BRILINTA.\n",
      "- Close monitoring and individualized treatment plans are essential for managing antiplatelet therapy in patients with ESRD on dialysis.\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.128843\n",
      "prediction:  - BRILINTA (ticagrelor) is not recommended for use in patients with end-stage renal disease (ESRD) on dialysis due to limited clinical data and potential for increased bleeding risk.\n",
      "- In patients with ESRD, alternative antiplatelet therapies, such as clopidogrel, may be considered as they have more established safety profiles in this population.\n",
      "- Close monitoring and individualized treatment plans are essential for patients with ESRD who require antiplatelet therapy.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.174797\n",
      "prediction:  - BRILINTA (ticagrelor) should be used with caution in patients with end-stage renal disease (ESRD) on dialysis due to potential accumulation and increased risk of bleeding.\n",
      "- The recommended dose of BRILINTA in patients with ESRD is typically reduced to 60 mg twice daily after an initial loading dose, if applicable.\n",
      "- Close monitoring for adverse effects and bleeding complications is essential in this patient population when using BRILINTA.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.166667\n",
      "prediction:  - BRILINTA (ticagrelor) should be used with caution in patients with end-stage renal disease (ESRD) on dialysis due to potential accumulation and increased risk of bleeding.\n",
      "- The recommended dose of BRILINTA in patients with ESRD is typically reduced, and careful monitoring is advised.\n",
      "- It is important to consider alternative antiplatelet therapies or consult a specialist when managing patients with ESRD on dialysis who require antiplatelet treatment.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.183369\n",
      "prediction:  - BRILINTA (ticagrelor) should be used with caution in patients with end-stage renal disease (ESRD) on dialysis due to potential accumulation and increased risk of bleeding.\n",
      "- The recommended dose of BRILINTA in patients with ESRD is typically reduced, and careful monitoring is advised.\n",
      "- It is important to consider alternative antiplatelet therapies or consult a specialist when managing patients with ESRD on dialysis.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.166234\n",
      "prediction:  - Breastfeeding is generally considered safe for mothers treated with FOSAPREPITANT, as it is not expected to harm a nursing infant.\n",
      "- FOSAPREPITANT is a neurokinin-1 receptor antagonist used for the prevention of nausea and vomiting associated with chemotherapy, and its excretion in breast milk is minimal.\n",
      "- It is advisable for mothers to consult with their healthcare provider for personalized recommendations while on FOSAPREPITANT.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.3333333333333333, 'B': 1.0, 'C': 0.5, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for FOSAPREPITANT and potential adverse effects on the infant.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.047945\n",
      "prediction:  - Clindamycin phosphate is present in Clindamycin topical lotion at a concentration of 1%.\n",
      "- This formulation is specifically designed for topical application to treat acne.\n",
      "- Clindamycin phosphate is a prodrug that is converted to clindamycin upon application to the skin.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 10 mg per milliliter\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.045902\n",
      "prediction:  - Clindamycin phosphate is present in Clindamycin topical lotion at a concentration of 1%.\n",
      "- This formulation is specifically designed for topical application to treat acne.\n",
      "- Clindamycin phosphate is a prodrug that is converted to clindamycin, which is the active antibiotic component.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 10 mg per milliliter\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.058608\n",
      "prediction:  - Clindamycin phosphate is present in Clindamycin topical lotion at a concentration of 1%.\n",
      "- This formulation is used primarily for the treatment of acne vulgaris.\n",
      "- Clindamycin phosphate acts as an antibiotic to reduce acne-causing bacteria on the skin.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 10 mg per milliliter\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.055363\n",
      "prediction:  - Clindamycin phosphate is present in Clindamycin topical lotion at a concentration of 1%.\n",
      "- This formulation is used primarily for the treatment of acne vulgaris.\n",
      "- Clindamycin phosphate is a prodrug that is converted to clindamycin, which has antibacterial properties.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 10 mg per milliliter\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.056738\n",
      "0.056738\n",
      "prediction:  - Clindamycin phosphate is present in the topical lotion at a concentration of 1%.\n",
      "- The formulation is designed for application on the skin to treat acne vulgaris.\n",
      "- Clindamycin phosphate acts as an antibiotic to reduce bacteria and inflammation in acne lesions.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 10 mg per milliliter\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.167813\n",
      "prediction:  - Conducting a thorough review of the patient's current medications to identify potential drug interactions, as Paxlovid (nirmatrelvir/ritonavir) can interact with many common drugs.\n",
      "- Assessing the patient's renal function, since dosage adjustments may be necessary for those with renal impairment before prescribing Paxlovid.\n",
      "- Evaluating the patient's history for any contraindications to the use of ritonavir, which is a component of Paxlovid, to ensure safe prescribing practices.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Ignoring potential drug-drug interactions due to Paxlovid's safety profile.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.17305\n",
      "prediction:  - Conducting a thorough review of the patient's current medications to identify potential drug interactions, as Paxlovid (nirmatrelvir/ritonavir) can interact with many common medications.\n",
      "- Assessing the patient's renal function, since dosage adjustments may be necessary for those with renal impairment before prescribing Paxlovid.\n",
      "- Evaluating the patient's history of hypersensitivity reactions to components of Paxlovid, as this could contraindicate its use.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Ignoring potential drug-drug interactions due to Paxlovid's safety profile.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.164642\n",
      "prediction:  - Conducting a thorough review of the patient's current medications to identify potential drug interactions, as Paxlovid (nirmatrelvir/ritonavir) can interact with many common medications.\n",
      "- Assessing the patient's renal function, since dosage adjustments may be necessary for those with renal impairment before prescribing Paxlovid.\n",
      "- Evaluating the patient's history of hypersensitivity reactions to components of Paxlovid, ensuring there are no contraindications before prescribing the treatment.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Ignoring potential drug-drug interactions due to Paxlovid's safety profile.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.184953\n",
      "prediction:  - Consider dose reduction or interruption of MONJUVI (tafasitamab-cxix) if the patient's platelet count falls to 50,000/mcL or less.\n",
      "- Monitor the patient's platelet levels closely and evaluate for potential causes of thrombocytopenia while on MONJUVI therapy.\n",
      "- If the platelet count does not improve or worsens, consult with a hematologist for further management options.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Withhold MONJUVI and lenalidomide and monitor CBC weekly until platelet count is 50,000/mcL or higher.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.175857\n",
      "prediction:  - Consider dose reduction or interruption of MONJUVI (tafasitamab-cxix) if the patient's platelet count falls to 50,000/mcL or less.\n",
      "- Monitor the patient's platelet levels closely and evaluate for potential causes of thrombocytopenia while on MONJUVI therapy.\n",
      "- If the platelet count does not improve or worsens, further management may include consultation with a hematologist for potential interventions.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Withhold MONJUVI and lenalidomide and monitor CBC weekly until platelet count is 50,000/mcL or higher.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.152975\n",
      "prediction:  - Consider dose reduction or interruption of MONJUVI (tafasitamab-cxix) if the platelet count falls to 50,000/mcL or less.\n",
      "- Monitor the patient's platelet levels closely and evaluate for potential causes of thrombocytopenia while on MONJUVI therapy.\n",
      "- If the platelet count does not improve or worsens, further management may include consultation with a hematologist for potential interventions.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.27777777777777773, 'B': 0.6666666666666666, 'C': 0.3055555555555555, 'D': 0.8333333333333334}; rankings=[['D', 'B', 'C', 'A'], ['B', 'D', 'A', 'C'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Withhold MONJUVI and lenalidomide and monitor CBC weekly until platelet count is 50,000/mcL or higher.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.150579\n",
      "0.150579\n",
      "0.150579\n",
      "0.150579\n",
      "prediction:  - Consider using Nivolumab, an immune checkpoint inhibitor, as it has shown efficacy in patients with recurrent metastatic non-squamous NSCLC after chemotherapy.\n",
      "- A combination of Atezolizumab with chemotherapy may also be appropriate, particularly if the patient has not previously received immunotherapy.\n",
      "- Evaluate the potential use of Docetaxel as a second-line chemotherapy option for patients who have progressed after Pemetrexed treatment.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "choice:  E\n",
      "E\n",
      "E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.149712\n",
      "0.149712\n",
      "prediction:  - Consider using Nivolumab, an immune checkpoint inhibitor, as it has shown efficacy in patients with recurrent metastatic non-squamous NSCLC after chemotherapy.\n",
      "- A combination of Atezolizumab with chemotherapy may also be appropriate, particularly if the patient has not previously received immunotherapy.\n",
      "- Evaluate the potential use of Docetaxel as a second-line treatment option, especially if the patient has previously responded to Pemetrexed.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.151515\n",
      "prediction:  - Dialysis may be beneficial in managing AIRSUPRA overdosage due to its ability to remove the active components of the drug from the bloodstream.\n",
      "- In cases of severe toxicity, hemodialysis can help reduce the plasma concentration of AIRSUPRA, potentially alleviating symptoms associated with overdose.\n",
      "- Monitoring and supportive care are essential, but dialysis can be a critical intervention for patients with significant AIRSUPRA overdosage.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: There is insufficient evidence to determine its benefit.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.131298\n",
      "prediction:  - Diclofenac Sodium extended-release formulation may not be bioequivalent to Diclofenac Potassium tablets, despite having the same milligram strength, due to differences in release mechanisms and absorption rates.\n",
      "- Topical Diclofenac formulations, such as Diclofenac gel or patch, are also not necessarily bioequivalent to Diclofenac Potassium tablets, as they deliver the drug through the skin and may have different pharmacokinetics.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Both A and B\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.127031\n",
      "prediction:  - Diclofenac Sodium extended-release formulation may not be bioequivalent to Diclofenac Potassium tablets, despite having the same milligram strength.\n",
      "- The different salt forms (sodium vs. potassium) can lead to variations in absorption and onset of action, affecting bioequivalence.\n",
      "- Diclofenac topical formulations, such as gels or patches, are also not bioequivalent to oral Diclofenac Potassium tablets, even if they contain the same active ingredient.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Both A and B\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.129323\n",
      "prediction:  - Diclofenac Sodium extended-release formulation may not be bioequivalent to Diclofenac Potassium tablets, despite having the same milligram strength.\n",
      "- The pharmacokinetics of Diclofenac Sodium and Diclofenac Potassium differ, affecting their absorption and onset of action.\n",
      "- Diclofenac topical formulations, such as gels or patches, are also not bioequivalent to Diclofenac Potassium tablets, as they deliver the drug through different routes.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Both A and B\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.150485\n",
      "prediction:  - Dopamine HCl can cause hemolysis when mixed with blood products, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if blood is contaminated, increasing the risk of infection.\n",
      "- Administering Dopamine HCl with blood can alter the effectiveness of the medication, potentially affecting hemodynamic stability.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.153846\n",
      "0.153846\n",
      "0.153846\n",
      "prediction:  - Dopamine HCl can cause hemolysis when mixed with blood, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if blood is contaminated, increasing the risk of infection.\n",
      "- Administering Dopamine HCl with blood can alter the effectiveness of the medication, potentially affecting hemodynamic stability.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.149398\n",
      "prediction:  - Dopamine HCl can cause hemolysis when mixed with blood, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if blood is contaminated, increasing the risk of infection.\n",
      "- Administering Dopamine HCl with blood can alter the pH and osmolarity of the blood product, potentially compromising its efficacy and safety.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.153086\n",
      "prediction:  - Dopamine HCl can cause hemolysis when mixed with blood, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if blood is contaminated, increasing the risk of infection.\n",
      "- Administering dopamine with blood can alter the effectiveness of the drug, potentially affecting hemodynamic stability in patients.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.101639\n",
      "prediction:  - Dopamine HCl in Dextrose Injection can cause hemolysis when mixed with blood, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if blood products are contaminated, increasing the risk of infection.\n",
      "- Administering Dopamine HCl with blood can alter the pH and osmolarity of the blood product, potentially compromising its efficacy and safety.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.100486\n",
      "0.100486\n",
      "prediction:  - Dopamine HCl in Dextrose Injection can cause hemolysis when mixed with blood, leading to the destruction of red blood cells.\n",
      "- The presence of dextrose in the injection may promote bacterial growth if mixed with blood, increasing the risk of infection.\n",
      "- Administering Dopamine HCl in Dextrose Injection with blood can alter the pH and osmolarity of the blood product, potentially compromising its efficacy and safety.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.117326\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed for migraine management.\n",
      "- Consider the addition of a blood pressure-lowering medication, such as a calcium channel blocker or ACE inhibitor, if the patient is experiencing persistent hypertension despite NURTEC ODT use.\n",
      "- Assess for potential drug interactions or side effects from NURTEC ODT that may contribute to elevated blood pressure, and review the patient's overall medication profile.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.14939\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed for migraine management.\n",
      "- Consider the addition of an antihypertensive medication if the patient has persistent hypertension despite the use of NURTEC ODT.\n",
      "- Assess for potential drug interactions or side effects from NURTEC ODT that may contribute to elevated blood pressure, and discuss alternative treatments if necessary.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A'], ['D', 'B', 'C', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.149618\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed for migraine management.\n",
      "- Consider the addition of an antihypertensive medication, as NURTEC ODT is primarily used for migraine treatment and may not address underlying hypertension.\n",
      "- Assess for potential drug interactions or side effects that could be contributing to inadequate blood pressure control while on NURTEC ODT.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.3333333333333333, 'B': 0.5, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C'], ['D', 'B', 'A', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.17803\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed.\n",
      "- Consider the addition of a different antihypertensive medication if the current treatment is insufficient, as NURTEC ODT is primarily used for migraine treatment and may not address blood pressure control.\n",
      "- Assess for potential drug interactions or underlying conditions that may be contributing to the inadequate blood pressure control while on NURTEC ODT.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.213808\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed.\n",
      "- Consider the potential need for additional antihypertensive medications if NURTEC ODT is not sufficiently controlling blood pressure.\n",
      "- Assess for any underlying conditions or lifestyle factors that may be contributing to inadequate blood pressure control despite NURTEC ODT use.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.218679\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed.\n",
      "- Consider the potential need for additional antihypertensive medications if blood pressure remains high despite NURTEC ODT use.\n",
      "- Assess for any underlying conditions or lifestyle factors that may be contributing to inadequate blood pressure control while on NURTEC ODT.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.22069\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed.\n",
      "- Consider the potential need for additional antihypertensive medications if blood pressure remains high despite NURTEC ODT.\n",
      "- Assess for any underlying conditions or lifestyle factors that may be contributing to inadequate blood pressure control while on NURTEC ODT.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.215247\n",
      "0.215247\n",
      "prediction:  - Evaluate the patient's adherence to the NURTEC ODT regimen, ensuring they are taking the medication as prescribed.\n",
      "- Consider the potential need for additional antihypertensive medications if blood pressure remains high despite the use of NURTEC ODT.\n",
      "- Assess for any underlying conditions or lifestyle factors that may be contributing to inadequate blood pressure control while on NURTEC ODT.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.125984\n",
      "prediction:  - Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat depression and anxiety, which may not be associated with traditional patterns of misuse seen with controlled substances.\n",
      "- The long half-life of Fluoxetine and its active metabolite norfluoxetine can lead to prolonged effects, making it difficult to gauge immediate misuse potential compared to shorter-acting medications.\n",
      "- Variability in individual responses to Fluoxetine, including differences in metabolism and psychological factors, complicates predictions about misuse or abuse patterns in the general population.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.3333333333333333, 'B': 0.6666666666666666, 'C': 0.25, 'D': 0.8333333333333334}; rankings=[['D', 'B', 'A', 'C'], ['B', 'D', 'A', 'C'], ['D', 'B', 'A', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Because premarketing clinical studies were not systematic in evaluating drug-seeking behavior.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.149533\n",
      "prediction:  - Fluoxetine, when combined with Olanzapine, has been shown to be effective in reducing depressive symptoms in patients with Bipolar I Disorder.\n",
      "- This combination therapy can help stabilize mood and may reduce the risk of manic episodes compared to using Fluoxetine alone.\n",
      "- Clinical studies indicate that the combination can improve overall functioning and quality of life for patients experiencing depressive episodes in the context of Bipolar I Disorder.\n",
      "pred_SIM:  B\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.175589\n",
      "0.175589\n",
      "prediction:  - Fluoxetine, when combined with Olanzapine, has been shown to be effective in reducing depressive symptoms in patients with Bipolar I Disorder.\n",
      "- This combination therapy can help stabilize mood and reduce the frequency of depressive episodes compared to monotherapy.\n",
      "- Clinical studies indicate that the combination may improve overall functioning and quality of life for patients experiencing depressive episodes.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.15534\n",
      "prediction:  - Fluoxetine, when combined with Olanzapine, has been shown to be effective in reducing depressive symptoms in patients with Bipolar I Disorder.\n",
      "- This combination therapy can help stabilize mood and reduce the frequency of depressive episodes compared to using Olanzapine alone.\n",
      "- Clinical studies indicate that the combination may improve overall functioning and quality of life for patients experiencing depressive episodes in the context of Bipolar I Disorder.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.175926\n",
      "prediction:  - Fluoxetine, when combined with Olanzapine, has been shown to improve depressive symptoms in patients with Bipolar I Disorder.\n",
      "- This combination can help stabilize mood and reduce the frequency of depressive episodes.\n",
      "- Clinical studies indicate that the combination may be more effective than using either medication alone for this specific indication.\n",
      "pred_SIM:  B\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.193237\n",
      "prediction:  - Fluoxetine, when combined with Olanzapine, has been shown to improve depressive symptoms in patients with Bipolar I Disorder.\n",
      "- This combination therapy can help stabilize mood and reduce the frequency of depressive episodes.\n",
      "- Clinical studies indicate that the combination may be more effective than using either medication alone for this specific indication.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.160959\n",
      "prediction:  - GOPRELTO contains the active ingredient ketorolac, which can increase the risk of gastrointestinal bleeding, a concern for patients on disulfiram due to potential alcohol-related interactions.\n",
      "- Disulfiram can cause severe reactions when alcohol is consumed, and ketorolac may not be safe for patients who might inadvertently consume alcohol while on disulfiram.\n",
      "- The combination of ketorolac and disulfiram may lead to increased side effects or complications, making it advisable to avoid using GOPRELTO in these patients.\n",
      "pred_SIM:  C\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: Disulfiram increases plasma cocaine exposure significantly.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.034483\n",
      "prediction:  - Gadobutrol is known for its low retention of gadolinium in the body due to its high relaxivity and low dose.\n",
      "- Compared to other agents, gadobutrol has a higher clearance rate, leading to minimal gadolinium accumulation.\n",
      "- Studies indicate that gadobutrol has a favorable safety profile with reduced risk of nephrogenic systemic fibrosis.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: Gadavist\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.033613\n",
      "prediction:  - Gadobutrol is known for its low retention of gadolinium in the body due to its high relaxivity and low dose.\n",
      "- Compared to other agents, gadobutrol has a higher stability which contributes to reduced gadolinium deposition in tissues.\n",
      "- Studies indicate that gadobutrol has a favorable safety profile with minimal long-term gadolinium accumulation.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: Gadavist\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.033898\n",
      "0.033898\n",
      "prediction:  - Gadobutrol is known for its low retention of gadolinium in the body due to its high relaxivity and stability.\n",
      "- Compared to other agents, gadobutrol has a higher molecular weight, which contributes to its lower tissue deposition.\n",
      "- Studies indicate that gadobutrol has a favorable safety profile with minimal gadolinium accumulation in tissues.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: Gadavist\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.037736\n",
      "prediction:  - Gadobutrol is known for its low retention of gadolinium in the body due to its high relaxivity and stability.\n",
      "- Compared to other agents, gadobutrol has a lower risk of gadolinium deposition in tissues.\n",
      "- Clinical studies indicate that gadobutrol is associated with minimal long-term gadolinium accumulation.\n",
      "pred_SIM:  C\n",
      "choice:  E\n",
      "correct_answer:  C\n",
      "correct answer: Gadavist\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.037855\n",
      "prediction:  - Gadobutrol is known for its low retention of gadolinium in the body due to its high stability.\n",
      "- Compared to other agents, gadobutrol has a lower risk of gadolinium accumulation in tissues.\n",
      "- Clinical studies indicate that gadobutrol is associated with a reduced likelihood of nephrogenic systemic fibrosis.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: Gadavist\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.315186\n",
      "prediction:  - HIMARK should be stored at a temperature between 2Â°C to 8Â°C to maintain its efficacy.\n",
      "- It must be protected from light to prevent degradation of the active ingredients.\n",
      "- The product should be kept in its original packaging until use to ensure stability and prevent contamination.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: HIMARK should be stored at room temperature for optimal stability.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.060837\n",
      "prediction:  - Head & Shoulders is a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff.\n",
      "- Selsun Blue is another brand name product that targets dandruff symptoms, specifically flaking and itching.\n",
      "- Nizoral A-D is a brand name antifungal shampoo that helps prevent dandruff-related flaking and itching.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.25, 'B': 1.0, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.05959\n",
      "prediction:  - Head & Shoulders is a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff.\n",
      "- Selsun Blue is another brand that targets dandruff symptoms, specifically formulated to reduce flaking and itching.\n",
      "- Neutrogena T/Gel is also indicated for dandruff prevention, utilizing coal tar to help alleviate symptoms.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.25, 'B': 1.0, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.049307\n",
      "prediction:  - Head & Shoulders is a brand name product that contains active ingredients like pyrithione zinc, which is indicated for preventing the recurrence of flaking and itching associated with dandruff.\n",
      "- Nizoral A-D is another brand that contains ketoconazole, an antifungal agent effective in treating dandruff and preventing its recurrence.\n",
      "- Selsun Blue, which contains selenium sulfide, is also indicated for the prevention of flaking and itching associated with dandruff.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.25, 'B': 1.0, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.090247\n",
      "prediction:  - If a CYP3A4 inhibitor is discontinued, it is recommended to monitor the patient closely for increased effects of RoxyBond, as the metabolism of this medication may be altered.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression after the CYP3A4 inhibitor is stopped.\n",
      "- Educate the patient about potential changes in the efficacy and side effects of RoxyBond following the discontinuation of the CYP3A4 inhibitor.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.27777777777777773, 'D': 0.3055555555555555}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'C', 'D'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.087447\n",
      "prediction:  - If a CYP3A4 inhibitor is discontinued, it is recommended to monitor the patient closely for increased effects of RoxyBond, as the metabolism of this medication may be altered.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression after the CYP3A4 inhibitor is stopped.\n",
      "- Educate the patient about the potential for increased side effects from RoxyBond due to the change in CYP3A4 activity following the discontinuation of the inhibitor.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3055555555555555, 'D': 0.27777777777777773}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.090909\n",
      "prediction:  - If a CYP3A4 inhibitor is discontinued, it is recommended to monitor the patient closely for increased effects of RoxyBond, as the metabolism of this medication may be altered.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression after the CYP3A4 inhibitor is stopped.\n",
      "- It may be necessary to switch to a different pain management regimen if the patient cannot tolerate the effects of RoxyBond without the CYP3A4 inhibitor.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.108291\n",
      "0.108291\n",
      "0.108291\n",
      "prediction:  - If a patient misses a dose of RoxyBond, they should take the missed dose as soon as they remember, unless it is almost time for the next scheduled dose.\n",
      "- If it is close to the time for the next dose of RoxyBond, the patient should skip the missed dose and resume their regular dosing schedule.\n",
      "- Patients should not take two doses of RoxyBond at the same time to make up for a missed dose.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: Take the next dose at the usual time\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.085873\n",
      "0.085873\n",
      "0.085873\n",
      "prediction:  - In clinical studies, the mortality rate for patients treated with NUZYRA (sarecycline) for Community-Acquired Bacterial Pneumonia (CABP) was observed to be lower than that of patients treated with moxifloxacin.\n",
      "- Specifically, the mortality rate in the NUZYRA group was reported to be approximately 2.5%, while the moxifloxacin group had a higher mortality rate of around 4.5%.\n",
      "- These findings suggest that NUZYRA may offer a more favorable outcome in terms of mortality compared to moxifloxacin in the treatment of CABP.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.137931\n",
      "0.137931\n",
      "0.137931\n",
      "0.137931\n",
      "0.137931\n",
      "prediction:  - In vitro studies have been conducted to assess the mutagenicity of Hydrocort using bacterial reverse mutation assays.\n",
      "- Animal studies have been performed to evaluate the potential mutagenic effects of Hydrocort in vivo, particularly focusing on chromosomal aberrations.\n",
      "- Clinical trials have monitored long-term exposure to Hydrocort for any genotoxic effects in patients receiving the drug for chronic conditions.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.165919\n",
      "prediction:  - In vitro studies have been conducted to assess the mutagenicity of Hydrocort using bacterial reverse mutation assays.\n",
      "- Animal studies have been performed to evaluate the potential mutagenic effects of Hydrocort in vivo, particularly focusing on chromosomal aberrations.\n",
      "- Clinical trials have monitored long-term exposure to Hydrocort to observe any potential mutagenic outcomes in human subjects.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.101341\n",
      "prediction:  - Individuals who become pregnant while on Tybost coadministered with darunavir should continue the therapy, as it is considered safe during pregnancy.\n",
      "- For those on Tybost with atazanavir, it is also recommended to continue the regimen, but close monitoring of the mother and fetus is advised.\n",
      "- It is important to consult with a healthcare provider for personalized management and to ensure the health of both the mother and the developing fetus.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.27777777777777773, 'C': 0.5, 'D': 0.3055555555555555}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'B', 'D'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Switch to an alternative regimen\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.10625\n",
      "prediction:  - Individuals who become pregnant while on Tybost coadministered with darunavir should continue the therapy, as it is generally considered safe during pregnancy.\n",
      "- For those on Tybost with atazanavir, it is also recommended to continue the regimen, but close monitoring of the mother and fetus is advised.\n",
      "- Consultation with a healthcare provider is essential to assess the risks and benefits of continuing therapy during pregnancy.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Switch to an alternative regimen\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.103817\n",
      "prediction:  - Individuals who become pregnant while on Tybost coadministered with darunavir should continue the therapy, as it is generally considered safe during pregnancy.\n",
      "- For those on Tybost with atazanavir, it is also recommended to continue the regimen, but close monitoring of the mother and fetus is advised.\n",
      "- It is important to consult with a healthcare provider for personalized management and potential adjustments to the therapy during pregnancy.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Switch to an alternative regimen\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.118012\n",
      "prediction:  - JAYPIRCA (pazopanib) is known to inhibit CYP3A4, which can lead to increased plasma concentrations of CYP3A substrates when co-administered.\n",
      "- Patients taking CYP3A substrates should be monitored closely for potential toxicity when receiving JAYPIRCA, as the drug may enhance the effects of these substrates.\n",
      "- The use of strong CYP3A inducers alongside JAYPIRCA may decrease the efficacy of CYP3A substrates due to increased metabolism.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.116208\n",
      "prediction:  - JAYPIRCA (pazopanib) is known to inhibit CYP3A4, which can lead to increased plasma concentrations of CYP3A substrates when co-administered.\n",
      "- Patients taking CYP3A substrates should be monitored closely for potential toxicity when starting JAYPIRCA, as the drug may enhance the effects of these substrates.\n",
      "- It is recommended to avoid concomitant use of JAYPIRCA with strong CYP3A inducers or inhibitors to prevent significant drug interactions.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.113264\n",
      "prediction:  - JAYPIRCA (pazopanib) is known to inhibit CYP3A4, which can lead to increased plasma concentrations of CYP3A substrates when co-administered.\n",
      "- Patients taking CYP3A substrates, such as midazolam, may require dose adjustments when starting treatment with JAYPIRCA to avoid potential toxicity.\n",
      "- The use of JAYPIRCA alongside active CYP3A substrates necessitates careful monitoring for adverse effects due to the drug's inhibitory effects on the CYP3A enzyme system.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.189055\n",
      "0.189055\n",
      "prediction:  - JAYPIRCA (pazopanib) is known to inhibit CYP3A4, which can lead to increased plasma concentrations of CYP3A substrates.\n",
      "- Co-administration of JAYPIRCA with drugs metabolized by CYP3A may require dose adjustments to avoid toxicity.\n",
      "- Patients taking CYP3A substrates should be monitored closely for adverse effects when starting or stopping JAYPIRCA therapy.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.176744\n",
      "0.176744\n",
      "prediction:  - JAYPIRCA is known to inhibit CYP3A4, which can lead to increased plasma concentrations of drugs metabolized by this enzyme.\n",
      "- Co-administration of JAYPIRCA with CYP3A substrates may require dose adjustments of those substrates to avoid potential toxicity.\n",
      "- Patients taking JAYPIRCA should be monitored closely if they are also on medications that are primarily metabolized by CYP3A4.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.185819\n",
      "0.185819\n",
      "prediction:  - JAYPIRCA is known to inhibit CYP3A4, which can lead to increased plasma concentrations of drugs metabolized by this enzyme.\n",
      "- Co-administration of JAYPIRCA with CYP3A substrates may require dose adjustments to avoid potential toxicity.\n",
      "- Patients taking medications that are CYP3A substrates should be monitored closely when starting or stopping JAYPIRCA therapy.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.202279\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive containing ethinyl estradiol and norethindrone, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the typical failure rate for the contraceptive implant (e.g., Nexplanon) is less than 1%, making it significantly more effective than Junel 21 Day.\n",
      "- Barrier methods, such as male condoms, have a typical failure rate of about 18%, which is higher than that of Junel 21 Day.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.38888888888888884, 'B': 0.25, 'C': 1.0, 'D': 0.4444444444444444}; rankings=[['C', 'A', 'D', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.2\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive containing ethinyl estradiol and norethindrone, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the typical failure rate for the contraceptive implant (e.g., Nexplanon) is less than 1%, making it significantly more effective than Junel 21 Day.\n",
      "- Barrier methods, such as male condoms, have a typical failure rate of approximately 18%, which is higher than that of Junel 21 Day.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.4444444444444444, 'B': 0.25, 'C': 1.0, 'D': 0.38888888888888884}; rankings=[['C', 'A', 'D', 'B'], ['C', 'D', 'A', 'B'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.2\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive containing ethinyl estradiol and norethindrone, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the typical failure rate for the contraceptive implant (e.g., Nexplanon) is less than 1%, making it significantly more effective than Junel 21 Day.\n",
      "- Barrier methods, such as male condoms, have a typical failure rate of approximately 18%, which is higher than that of Junel 21 Day.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.4444444444444444, 'B': 0.25, 'C': 1.0, 'D': 0.38888888888888884}; rankings=[['C', 'D', 'A', 'B'], ['C', 'A', 'D', 'B'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.312634\n",
      "0.312634\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive pill, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the failure rate for the contraceptive implant (e.g., Nexplanon) is less than 1%, making it significantly more effective.\n",
      "- Barrier methods, such as condoms, have a typical failure rate of about 13% with typical use, which is higher than that of Junel 21 Day.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  B\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.324444\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive pill, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the failure rate for the contraceptive implant (e.g., Nexplanon) is less than 1%, making it significantly more effective.\n",
      "- Barrier methods, such as condoms, have a typical failure rate of about 13%, which is higher than that of Junel 21 Day.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.324444\n",
      "0.324444\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive pill, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the failure rate for the contraceptive implant (like Nexplanon) is less than 1%, making it significantly more effective.\n",
      "- Barrier methods, such as condoms, have a typical failure rate of around 13%, which is higher than that of Junel 21 Day.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.317181\n",
      "prediction:  - Junel 21 Day, a combination oral contraceptive pill, has a typical failure rate of about 7% with typical use.\n",
      "- In comparison, the failure rate for the contraceptive implant (like Nexplanon) is less than 1%, making it significantly more effective.\n",
      "- Barrier methods, such as male condoms, have a typical failure rate of about 18%, which is higher than that of Junel 21 Day.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.037333\n",
      "prediction:  - Monitor for increased suicidal thoughts or behaviors, particularly during the initial treatment phase or when doses are adjusted, as venlafaxine is an antidepressant that can elevate these risks in younger populations.\n",
      "- Assess for changes in mood, anxiety levels, and any emergence of agitation or irritability, as these can indicate adverse reactions to venlafaxine therapy.\n",
      "- Regularly evaluate for signs of serotonin syndrome, especially if venlafaxine is used in conjunction with other serotonergic medications, due to the potential for this serious side effect.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.075881\n",
      "0.075881\n",
      "0.075881\n",
      "0.075881\n",
      "0.075881\n",
      "0.075881\n",
      "prediction:  - Monitor for increased suicidal thoughts or behaviors, particularly during the initial treatment phase or when doses are adjusted.\n",
      "- Assess for changes in mood, anxiety levels, and any emergence of agitation or irritability.\n",
      "- Regularly evaluate for side effects such as increased blood pressure, as venlafaxine can cause dose-dependent hypertension.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.039548\n",
      "prediction:  - Monitor for increased suicidal thoughts or behaviors, particularly during the initial treatment phase with venlafaxine, as this risk is heightened in children and adolescents.\n",
      "- Assess for changes in mood, anxiety levels, and any signs of agitation or irritability while on venlafaxine, as these can indicate adverse reactions to the medication.\n",
      "- Regularly evaluate for any cardiovascular side effects, such as elevated blood pressure or heart rate, which can occur with venlafaxine use in younger populations.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3055555555555555, 'D': 0.27777777777777773}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.042169\n",
      "prediction:  - Monitor for increased suicidal thoughts or behaviors, particularly during the initial treatment phase with venlafaxine, as this risk is heightened in children and adolescents.\n",
      "- Assess for changes in mood, anxiety levels, and any signs of agitation or irritability while on venlafaxine, as these can indicate adverse reactions.\n",
      "- Regularly evaluate for potential side effects such as increased blood pressure, as venlafaxine can cause dose-dependent hypertension in this population.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.15873\n",
      "prediction:  - Monitor for reduced efficacy of JAIMIESS due to increased metabolism when co-administered with enzyme inducers like rifampin or carbamazepine.\n",
      "- Consider dose adjustment of JAIMIESS to maintain therapeutic levels in patients taking enzyme inducers.\n",
      "- Educate patients about potential interactions and the importance of reporting any changes in their condition while on enzyme inducers.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use a backup or alternative method of contraception\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.158371\n",
      "0.158371\n",
      "prediction:  - Monitor for reduced efficacy of JAIMIESS due to increased metabolism when co-administered with enzyme inducers like rifampin or carbamazepine.\n",
      "- Consider dose adjustments of JAIMIESS to maintain therapeutic levels in patients taking enzyme inducers.\n",
      "- Educate patients about potential interactions and the importance of reporting any changes in their condition while on enzyme inducers.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Use a backup or alternative method of contraception\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.155902\n",
      "0.155902\n",
      "prediction:  - Monitor for reduced efficacy of JAIMIESS due to increased metabolism when co-administered with enzyme inducers like rifampin or carbamazepine.\n",
      "- Consider dose adjustments of JAIMIESS to maintain therapeutic levels in patients taking strong enzyme inducers.\n",
      "- Educate patients about potential interactions and the importance of reporting any changes in their condition while on enzyme inducers.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Use a backup or alternative method of contraception\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.151515\n",
      "prediction:  - Monitor for reduced efficacy of JAIMIESS due to increased metabolism when co-administered with enzyme inducers like rifampin or carbamazepine.\n",
      "- Consider dose adjustments of JAIMIESS to maintain therapeutic levels in patients taking strong enzyme inducers.\n",
      "- Educate patients about potential interactions and the importance of reporting any changes in their health status while on this combination therapy.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use a backup or alternative method of contraception\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.281081\n",
      "0.281081\n",
      "0.281081\n",
      "prediction:  - Monitor lipid levels regularly to assess the impact of Tri Femynor on dyslipidemia.\n",
      "- Consider lifestyle modifications alongside the use of Tri Femynor to improve lipid profiles.\n",
      "- Evaluate the potential need for additional lipid-lowering medications if dyslipidemia remains uncontrolled while on Tri Femynor.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: Switch to an alternative contraceptive method.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.27154\n",
      "0.27154\n",
      "prediction:  - Monitor lipid levels regularly to assess the impact of Tri Femynor on dyslipidemia.\n",
      "- Consider lifestyle modifications, such as diet and exercise, to complement the effects of Tri Femynor.\n",
      "- Evaluate the potential need for additional lipid-lowering medications if dyslipidemia remains uncontrolled despite Tri Femynor use.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Switch to an alternative contraceptive method.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.273684\n",
      "prediction:  - Monitor lipid levels regularly to assess the impact of Tri Femynor on dyslipidemia.\n",
      "- Consider lifestyle modifications, such as diet and exercise, to complement the effects of Tri Femynor.\n",
      "- Evaluate the potential need for additional lipid-lowering medications if dyslipidemia remains uncontrolled while on Tri Femynor.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Switch to an alternative contraceptive method.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.146341\n",
      "0.146341\n",
      "prediction:  - Monitor lipid levels regularly, as Tri Femynor contains ethinyl estradiol and norgestimate, which may impact lipid metabolism.\n",
      "- Consider alternative contraceptive options if the patient has a history of thromboembolic events, as Tri Femynor can increase the risk in women with dyslipidemia.\n",
      "- Educate the patient on lifestyle modifications, including diet and exercise, to help manage dyslipidemia alongside the use of Tri Femynor.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Switch to an alternative contraceptive method.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.11437\n",
      "prediction:  - Monitor lipid levels regularly, as Tri Femynor contains ethinyl estradiol and norgestimate, which may impact lipid metabolism.\n",
      "- Consider alternative contraceptive options if the patient has a history of thromboembolic events, as Tri Femynor can increase the risk in women with dyslipidemia.\n",
      "- Evaluate the patient's overall cardiovascular risk profile, as Tri Femynor may not be suitable for women with significant dyslipidemia or other cardiovascular risk factors.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Switch to an alternative contraceptive method.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.144928\n",
      "0.144928\n",
      "0.144928\n",
      "prediction:  - Monitor the patient for increased effects of RoxyBond due to potential changes in metabolism after discontinuation of the CYP3A4 inhibitor.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression.\n",
      "- Educate the patient about the signs of opioid toxicity, as the risk may increase with the removal of the CYP3A4 inhibitor.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.146341\n",
      "prediction:  - Monitor the patient for increased effects of RoxyBond due to reduced metabolism after discontinuation of the CYP3A4 inhibitor.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression.\n",
      "- Educate the patient about potential changes in pain control and side effects following the discontinuation of the CYP3A4 inhibitor.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.123457\n",
      "prediction:  - Monitor the patient for increased effects or side effects of RoxyBond due to potential changes in metabolism after discontinuation of the CYP3A4 inhibitor.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences increased sedation or respiratory depression following the cessation of the CYP3A4 inhibitor.\n",
      "- Educate the patient about the signs of opioid toxicity, as the metabolism of RoxyBond may be altered without the CYP3A4 inhibitor.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.121704\n",
      "prediction:  - Monitor the patient for increased effects or side effects of RoxyBond due to the potential for increased plasma levels after discontinuation of the CYP3A4 inhibitor.\n",
      "- Consider adjusting the dosage of RoxyBond if the patient experiences heightened analgesic effects or adverse reactions following the cessation of the CYP3A4 inhibitor.\n",
      "- Educate the patient about the signs of opioid toxicity, as the risk may increase with the removal of the CYP3A4 inhibitor.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.048077\n",
      "prediction:  - Nighttime Severe Cold and Flu contains diphenhydramine, an antihistamine that helps relieve symptoms like nasal congestion, allowing for easier breathing during sleep.\n",
      "- The formulation also includes phenylephrine, which can reduce sinus pressure and discomfort, contributing to improved sleep quality.\n",
      "- By alleviating cough and sore throat symptoms, Nighttime Severe Cold and Flu helps minimize nighttime disturbances, promoting better rest.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.048701\n",
      "prediction:  - Nighttime Severe Cold and Flu contains diphenhydramine, an antihistamine that helps relieve symptoms like nasal congestion, allowing for easier breathing during sleep.\n",
      "- The formulation includes phenylephrine, which reduces sinus pressure and can alleviate headaches, contributing to improved sleep quality.\n",
      "- The product also addresses cough symptoms, which can disrupt sleep, helping users to rest more comfortably through the night.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.046368\n",
      "prediction:  - Nighttime Severe Cold and Flu contains diphenhydramine, an antihistamine that helps relieve symptoms like nasal congestion, which can improve sleep quality.\n",
      "- The formulation also includes phenylephrine, a decongestant that alleviates sinus pressure, contributing to better breathing during sleep.\n",
      "- By addressing symptoms such as cough and runny nose, Nighttime Severe Cold and Flu aids in reducing nighttime disturbances, leading to improved overall sleep quality.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "sc\n",
      "SIM_score:  0.079268\n",
      "0.079268\n",
      "prediction:  - Nighttime severe cold and flu can relieve nasal congestion, allowing for easier breathing during sleep.\n",
      "- It may reduce coughing, which can disrupt sleep and lead to better rest.\n",
      "- The formulation often includes ingredients that alleviate body aches, contributing to overall comfort and improved sleep quality.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.074928\n",
      "prediction:  - Nighttime severe cold and flu helps relieve nasal congestion, allowing for easier breathing during sleep.\n",
      "- It alleviates cough symptoms, reducing nighttime disturbances and promoting uninterrupted rest.\n",
      "- The formulation may include ingredients that reduce body aches, contributing to overall comfort and improved sleep quality.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.195918\n",
      "prediction:  - Ondansetron may enhance the analgesic effect of Tramadol by reducing nausea and vomiting associated with opioid use.\n",
      "- The combination could potentially lead to increased risk of serotonin syndrome, especially if Tramadol is used at higher doses or in patients taking other serotonergic medications.\n",
      "- Monitoring for side effects such as dizziness or sedation is advised, as both Ondansetron and Tramadol can contribute to these effects.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.22179\n",
      "prediction:  - Ondansetron may enhance the analgesic effect of Tramadol by reducing nausea and vomiting, potentially leading to improved pain management.\n",
      "- The combination could increase the risk of serotonin syndrome, especially if Tramadol is used at higher doses or in patients taking other serotonergic medications.\n",
      "- Patients should be monitored for increased sedation or respiratory depression, as both Ondansetron and Tramadol can have sedative effects.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.217195\n",
      "prediction:  - Ondansetron may enhance the analgesic effects of Tramadol, potentially leading to improved pain relief.\n",
      "- The combination could increase the risk of serotonin syndrome, especially if Tramadol is used at higher doses or in patients taking other serotonergic medications.\n",
      "- Ondansetron's antiemetic properties may help mitigate nausea associated with Tramadol use, improving patient comfort.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.217918\n",
      "prediction:  - Ondansetron may enhance the analgesic effects of Tramadol, potentially leading to improved pain relief.\n",
      "- The combination could increase the risk of serotonin syndrome, especially if Tramadol is used at higher doses.\n",
      "- Patients should be monitored for increased sedation or gastrointestinal side effects due to the interaction between Ondansetron and Tramadol.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.173432\n",
      "prediction:  - Ondansetron, a 5-HT3 receptor antagonist, may enhance the analgesic effects of Tramadol, which acts on the opioid receptors and inhibits the reuptake of serotonin and norepinephrine.\n",
      "- The combination could potentially lead to increased risk of serotonin syndrome due to the serotonergic effects of both Ondansetron and Tramadol.\n",
      "- Patients may experience improved nausea control from Ondansetron while receiving pain relief from Tramadol, leading to better overall management of symptoms.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.180361\n",
      "prediction:  - Ondansetron, an antiemetic, may enhance the analgesic effects of Tramadol, potentially leading to improved pain control.\n",
      "- The combination could increase the risk of serotonin syndrome due to Tramadol's serotonergic properties, especially in patients on other serotonergic medications.\n",
      "- Patients may experience increased sedation or drowsiness when Ondansetron is used alongside Tramadol, necessitating caution in activities requiring alertness.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.153203\n",
      "prediction:  - Overdosage of TAKHZYRO (lanadelumab) may lead to increased risk of adverse effects, particularly injection site reactions and hypersensitivity.\n",
      "- In clinical studies, no specific antidote for TAKHZYRO has been established, and management of overdose primarily involves supportive care.\n",
      "- The maximum tolerated dose of TAKHZYRO has not been defined, but doses significantly higher than the recommended regimen of 300 mg every two weeks could exacerbate side effects.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.5555555555555555, 'C': 0.5, 'D': 0.7777777777777777}; rankings=[['D', 'C', 'B', 'A'], ['B', 'C', 'D', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: There is no available clinical data on overdosage of TAKHZYRO.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.237136\n",
      "prediction:  - Overdosage of TAKHZYRO (lanadelumab) may lead to increased risk of adverse effects, particularly injection site reactions.\n",
      "- In clinical studies, doses exceeding the recommended regimen of 300 mg every two weeks did not show additional therapeutic benefit.\n",
      "- Monitoring for symptoms of hypersensitivity or other severe reactions is advised in cases of TAKHZYRO overdosage.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: There is no available clinical data on overdosage of TAKHZYRO.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.010772\n",
      "prediction:  - Patients treated with lamotrigine experienced a median percent reduction in primary generalized tonic-clonic seizures (PGTC) of approximately 50%.\n",
      "- The clinical trial specifically evaluated the efficacy of lamotrigine as an active treatment compared to a placebo group.\n",
      "- The results indicated that lamotrigine significantly reduced the frequency of PGTC seizures in the treatment cohort.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.009631\n",
      "prediction:  - Patients treated with lamotrigine experienced a median percent reduction in primary generalized tonic-clonic seizures (PGTC) of approximately 50%.\n",
      "- The clinical trial specifically evaluated the efficacy of lamotrigine compared to a placebo group, highlighting the significant impact of the active treatment.\n",
      "- The results indicated that lamotrigine was effective in reducing seizure frequency in patients with PGTC, demonstrating its therapeutic benefit.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.010017\n",
      "prediction:  - Patients treated with lamotrigine experienced a median percent reduction in primary generalized tonic-clonic seizures (PGTC) of approximately 50%.\n",
      "- The clinical trial specifically evaluated the efficacy of lamotrigine compared to a placebo group, highlighting the significant impact of the active treatment.\n",
      "- The results indicated that lamotrigine was effective in reducing the frequency of PGTC seizures in the study population.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.004796\n",
      "prediction:  - Patients treated with pantoprazole sodium delayed-release tablets showed a significant percentage of endoscopically proven healing of esophageal lesions after 8 weeks.\n",
      "- The specific percentage of patients achieving this healing was reported in clinical studies evaluating the efficacy of pantoprazole.\n",
      "- This treatment is commonly used for conditions like gastroesophageal reflux disease (GERD) and esophagitis.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.01626\n",
      "0.01626\n",
      "0.01626\n",
      "prediction:  - Patients treated with pantoprazole sodium delayed-release tablets showed a significant percentage of endoscopically proven healing of esophageal lesions after 8 weeks.\n",
      "- The specific percentage of patients achieving this healing was reported to be 80%.\n",
      "- This outcome highlights the effectiveness of pantoprazole in managing esophageal lesions compared to placebo.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.015957\n",
      "prediction:  - Patients treated with pantoprazole sodium delayed-release tablets showed a significant percentage of endoscopically proven healing of esophageal lesions after 8 weeks.\n",
      "- The specific percentage of patients achieving this healing was reported to be around 80%.\n",
      "- This outcome highlights the effectiveness of pantoprazole in managing esophageal lesions compared to placebo.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.01676\n",
      "prediction:  - Patients treated with pantoprazole sodium delayed-release tablets showed a significant percentage of endoscopically proven healing of esophageal lesions after 8 weeks.\n",
      "- The specific percentage reported for healing in these patients was 80%.\n",
      "- This outcome highlights the effectiveness of pantoprazole in managing esophageal lesions compared to placebo.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.130612\n",
      "prediction:  - Patients with a history of substance use disorder, particularly those who have previously abused opioids or other controlled substances, are at higher risk of abusing RoxyBond.\n",
      "- Individuals with chronic pain conditions who are prescribed RoxyBond for pain management may develop a psychological dependence on the medication, increasing the risk of abuse.\n",
      "- Young adults and adolescents, especially those with access to RoxyBond through prescriptions or illicit means, are also at a heightened risk of misuse and abuse.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.12549\n",
      "prediction:  - Patients with a history of substance use disorder, particularly those who have previously abused opioids or other controlled substances, are at higher risk of abusing RoxyBond.\n",
      "- Individuals with chronic pain conditions who are prescribed RoxyBond for pain management may develop a psychological dependence on the medication, increasing the risk of abuse.\n",
      "- Young adults and adolescents, especially those with access to RoxyBond through prescriptions or illicit means, are also at a heightened risk of misuse and abuse.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.6666666666666666, 'B': 0.8333333333333334, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.129555\n",
      "prediction:  - Patients with a history of substance use disorder, particularly those who have previously abused opioids or other controlled substances, are at higher risk of abusing RoxyBond.\n",
      "- Individuals with chronic pain conditions who have been prescribed RoxyBond for pain management may develop a psychological dependence on the medication, increasing the risk of abuse.\n",
      "- Young adults and adolescents, especially those with access to RoxyBond through prescriptions or illicit means, are also at a heightened risk of misuse and abuse.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.287611\n",
      "0.287611\n",
      "0.287611\n",
      "0.287611\n",
      "prediction:  - Patients with hepatic impairment should be closely monitored for liver function tests before and during Zynteglo treatment.\n",
      "- Dose adjustments may be necessary for patients with moderate to severe hepatic impairment when considering Zynteglo.\n",
      "- It is recommended to avoid Zynteglo in patients with severe hepatic impairment due to potential increased risk of adverse effects.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Hepatic function should be assessed to ensure hematopoietic stem cell transplantation is appropriate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.306604\n",
      "prediction:  - Patients with hepatic impairment should be closely monitored for liver function tests before and during Zynteglo treatment.\n",
      "- Dose adjustments may be necessary for patients with moderate to severe hepatic impairment when considering Zynteglo.\n",
      "- It is recommended to avoid Zynteglo in patients with severe hepatic impairment due to potential risks.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Hepatic function should be assessed to ensure hematopoietic stem cell transplantation is appropriate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.103343\n",
      "prediction:  - Physicians should assess the patient's history of hypertension, as venlafaxine can increase blood pressure, particularly at higher doses.\n",
      "- It is important to evaluate any current medications the patient is taking to avoid potential drug interactions, especially with other serotonergic agents or MAO inhibitors.\n",
      "- Physicians should consider the patient's history of bipolar disorder, as venlafaxine may trigger manic episodes in susceptible individuals.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.25, 'C': 1.0, 'D': 0.3333333333333333}; rankings=[['C', 'A', 'D', 'B'], ['C', 'A', 'D', 'B'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.100147\n",
      "0.100147\n",
      "prediction:  - Physicians should assess the patient's history of hypertension, as venlafaxine can increase blood pressure, particularly at higher doses.\n",
      "- It is important to evaluate any current medications the patient is taking to avoid potential drug interactions, especially with other serotonergic agents or monoamine oxidase inhibitors (MAOIs).\n",
      "- Physicians should consider the patient's history of bipolar disorder, as venlafaxine may induce manic episodes in susceptible individuals.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.25, 'C': 1.0, 'D': 0.3333333333333333}; rankings=[['C', 'A', 'D', 'B'], ['C', 'A', 'D', 'B'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.107296\n",
      "prediction:  - RETHYMIC has specific contraindications for patients with active infections or those who have a history of hypersensitivity to its components, which is similar to other immunosuppressive agents like azathioprine that also contraindicate use in patients with active infections.\n",
      "- Unlike RETHYMIC, which is contraindicated in patients with a history of malignancies, some other drugs like corticosteroids may not have such strict contraindications, allowing their use in certain cancer patients under careful monitoring.\n",
      "- RETHYMIC's contraindications include severe hepatic impairment, contrasting with drugs like mycophenolate mofetil, which may have different liver-related safety profiles and contraindications.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.123153\n",
      "prediction:  - RETHYMIC has specific contraindications for patients with active infections, which is a common concern in immunosuppressive therapies like those seen with drugs such as azathioprine.\n",
      "- Unlike RETHYMIC, which is contraindicated in patients with a history of hypersensitivity to its components, drugs like methotrexate may have broader contraindications related to liver disease.\n",
      "- RETHYMIC's contraindications also include caution in patients with a history of malignancies, similar to the contraindications seen with other immunosuppressants like cyclophosphamide.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3055555555555555, 'B': 0.4444444444444444, 'C': 1.0, 'D': 0.3333333333333333}; rankings=[['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.124031\n",
      "prediction:  - RETHYMIC has specific contraindications for patients with active infections, which is a common concern in immunosuppressive therapies like those seen with drugs such as azathioprine.\n",
      "- Unlike RETHYMIC, which may have contraindications related to hypersensitivity reactions, drugs like methotrexate also have contraindications for patients with liver disease.\n",
      "- RETHYMIC's contraindications include a history of malignancy, contrasting with other immunosuppressants like mycophenolate mofetil, which may have different risk profiles regarding cancer history.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.161491\n",
      "0.161491\n",
      "0.161491\n",
      "prediction:  - RETHYMIC is contraindicated in patients with a history of hypersensitivity to any of its components, similar to how certain drugs like penicillin are contraindicated in individuals with a known allergy to penicillin.\n",
      "- Unlike some immunosuppressants that may have contraindications related to active infections, RETHYMIC does not have specific contraindications for active infections but should be used cautiously in such cases.\n",
      "- RETHYMIC's contraindications also include severe hepatic impairment, which is a common concern for drugs like methotrexate that are metabolized in the liver.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.155922\n",
      "prediction:  - RETHYMIC is contraindicated in patients with a history of hypersensitivity to any of its components, similar to how certain drugs like penicillin are contraindicated in individuals with a known allergy to penicillin.\n",
      "- Unlike some immunosuppressants that may have contraindications related to active infections, RETHYMIC's contraindications specifically include active infections due to its immunosuppressive effects.\n",
      "- RETHYMIC should not be used in patients with severe hepatic impairment, which is a common contraindication seen in drugs like methotrexate that also require careful liver function monitoring.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.145049\n",
      "prediction:  - RETHYMIC is contraindicated in patients with known hypersensitivity to any of its components, similar to other immunosuppressants like azathioprine, which also has specific contraindications related to hypersensitivity.\n",
      "- Unlike some drugs that may have contraindications based on organ function, RETHYMIC does not have specific contraindications related to renal or hepatic impairment, which is a consideration for drugs like methotrexate.\n",
      "- RETHYMIC's contraindications include active infections, paralleling the profile of biologics such as infliximab, which also cannot be used in patients with active infections due to increased risk of serious infections.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.145863\n",
      "prediction:  - RETHYMIC is contraindicated in patients with known hypersensitivity to its components, similar to how certain drugs like penicillin are contraindicated in individuals with a history of allergic reactions to beta-lactams.\n",
      "- Unlike some immunosuppressants that may have contraindications related to active infections, RETHYMIC's profile specifically highlights contraindications in patients with severe heart failure or those receiving certain cardiac medications.\n",
      "- RETHYMIC's contraindications also extend to patients with a history of malignancies, paralleling the contraindication of drugs like methotrexate in patients with active or recent malignancies.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.113043\n",
      "0.113043\n",
      "0.113043\n",
      "prediction:  - Reduces nasal congestion, allowing for easier breathing during sleep.\n",
      "- Alleviates body aches, which can disrupt restful sleep.\n",
      "- Mitigates cough, preventing nighttime awakenings and promoting uninterrupted rest.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.124314\n",
      "prediction:  - Remove the spray nozzle from the dg health nasal spray bottle and rinse it under warm running water for about 30 seconds.\n",
      "- Allow the nozzle to air dry completely before reattaching it to the bottle to prevent contamination.\n",
      "- Avoid using any cleaning agents or solvents, as they may damage the nozzle or affect the medication.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.3333333333333333, 'B': 1.0, 'C': 0.5, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.120438\n",
      "prediction:  - Remove the spray nozzle from the dg health nasal spray bottle and rinse it under warm running water for about 30 seconds.\n",
      "- Allow the nozzle to air dry completely before reattaching it to the dg health nasal spray bottle.\n",
      "- Avoid using any cleaning agents or detergents on the nozzle to prevent contamination of the nasal spray.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.3333333333333333, 'B': 1.0, 'C': 0.5, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.117021\n",
      "prediction:  - Remove the spray nozzle from the dg health nasal spray bottle and rinse it under warm running water for about 30 seconds.\n",
      "- Allow the nozzle to air dry completely before reattaching it to the dg health nasal spray bottle.\n",
      "- Avoid using any cleaning agents or detergents on the nozzle to prevent contamination of the nasal spray.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.38888888888888884, 'B': 1.0, 'C': 0.4444444444444444, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.232365\n",
      "0.232365\n",
      "0.232365\n",
      "0.232365\n",
      "0.232365\n",
      "0.232365\n",
      "prediction:  - Remove the spray nozzle from the dg health nasal spray bottle.\n",
      "- Rinse the nozzle under warm running water to remove any residue.\n",
      "- Allow the nozzle to air dry completely before reattaching it to the bottle.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "choice:  C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.014109\n",
      "prediction:  - Sumatriptan succinate is a salt form of sumatriptan, and it typically contains approximately 85% of the active drug; therefore, 8.4 mg of sumatriptan succinate is equivalent to about 7.14 mg of sumatriptan.\n",
      "- In the context of the injection, each 0.5 mL of Sumatriptan injection, USP contains 8.4 mg of sumatriptan succinate, which translates to approximately 7.14 mg of sumatriptan.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.27777777777777773, 'D': 0.3055555555555555}; rankings=[['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: 6 mg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.020704\n",
      "prediction:  - Sumatriptan succinate is a salt form of sumatriptan, and it typically has a molecular weight that is approximately 1.2 times that of the free base sumatriptan.\n",
      "- Therefore, 8.4 mg of sumatriptan succinate is approximately equivalent to 7 mg of sumatriptan (free base) in each 0.5 mL of Sumatriptan injection, USP.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: 6 mg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.026738\n",
      "prediction:  - Sumatriptan succinate is the salt form of sumatriptan, and it has a molecular weight that is approximately 1.2 times that of sumatriptan.\n",
      "- To convert 8.4 mg of sumatriptan succinate to sumatriptan, divide by the conversion factor: 8.4 mg / 1.2 = 7 mg of sumatriptan.\n",
      "- Therefore, 8.4 mg of sumatriptan succinate is equivalent to 7 mg of sumatriptan in the injection.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 6 mg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.154622\n",
      "prediction:  - TAKHZYRO (lanadelumab) is a monoclonal antibody used for the prevention of hereditary angioedema attacks, and overdosage may lead to increased risk of adverse effects.\n",
      "- In clinical studies, doses higher than the recommended 300 mg every two weeks did not show a significant increase in efficacy, indicating that higher doses may not provide additional benefits.\n",
      "- Symptoms of overdosage may include injection site reactions, headache, and gastrointestinal symptoms, which are consistent with the known side effects of TAKHZYRO.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: There is no available clinical data on overdosage of TAKHZYRO.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.169312\n",
      "0.169312\n",
      "0.169312\n",
      "0.169312\n",
      "prediction:  - TAKHZYRO (lanadelumab) is a monoclonal antibody used for the prevention of hereditary angioedema attacks, and overdosage may lead to increased risk of adverse effects.\n",
      "- In clinical studies, doses higher than the recommended 300 mg every two weeks have not been extensively evaluated, indicating potential unknown risks with overdosage.\n",
      "- Symptoms of overdosage may include increased incidence of injection site reactions or other immune-related effects due to the drug's mechanism of action.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: There is no available clinical data on overdosage of TAKHZYRO.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.193548\n",
      "0.193548\n",
      "0.193548\n",
      "0.193548\n",
      "0.193548\n",
      "0.193548\n",
      "prediction:  - Take the missed dose of RoxyBond as soon as remembered, unless it is almost time for the next scheduled dose.\n",
      "- If it is close to the time for the next dose, skip the missed dose and resume the regular dosing schedule.\n",
      "- Do not take two doses of RoxyBond at the same time to make up for the missed dose.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct answer: Take the next dose at the usual time\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.127243\n",
      "0.127243\n",
      "prediction:  - Terbinafine should not be prescribed to patients with a history of liver disease, as it can cause hepatotoxicity.\n",
      "- Patients with a known hypersensitivity to terbinafine or any of its components should avoid this medication to prevent allergic reactions.\n",
      "- Caution is advised when prescribing terbinafine to individuals with active or chronic renal impairment, as dosage adjustments may be necessary.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  D\n",
      "D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.121685\n",
      "prediction:  - Terbinafine should not be prescribed to patients with a history of liver disease, as it can cause hepatotoxicity.\n",
      "- Patients with a known hypersensitivity to terbinafine or any of its components should avoid this medication to prevent allergic reactions.\n",
      "- Caution is advised when prescribing terbinafine to individuals with renal impairment, as dosage adjustments may be necessary due to altered drug clearance.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.4444444444444444, 'B': 1.0, 'C': 0.38888888888888884, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.207627\n",
      "0.207627\n",
      "0.207627\n",
      "0.207627\n",
      "prediction:  - The American Academy of Pediatrics provides evidence-based recommendations for the safe and effective use of D-109 in pediatric populations.\n",
      "- They emphasize the importance of monitoring for potential side effects associated with D-109, particularly in children with pre-existing conditions.\n",
      "- The guidelines include dosage adjustments for D-109 based on age and weight to ensure optimal therapeutic outcomes.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  E\n",
      "E\n",
      "E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.186613\n",
      "0.186613\n",
      "prediction:  - The American Academy of Pediatrics provides evidence-based recommendations for the safe and effective use of D-109 in pediatric populations.\n",
      "- They evaluate clinical studies and data to establish guidelines that ensure appropriate dosing and administration of D-109 in children.\n",
      "- The organization also emphasizes the importance of monitoring for potential side effects and interactions when using D-109 in pediatric patients.\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.144781\n",
      "prediction:  - The Ames test demonstrated that Fluoxetine and its metabolite Norfluoxetine do not induce mutations in bacterial DNA.\n",
      "- The micronucleus assay showed no evidence of genotoxicity for Fluoxetine and Norfluoxetine in mammalian cells.\n",
      "- In vitro chromosomal aberration tests indicated that neither Fluoxetine nor Norfluoxetine caused structural chromosomal damage.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.10989\n",
      "0.10989\n",
      "prediction:  - The Ames test demonstrated that Fluoxetine and its metabolite Norfluoxetine do not induce mutations in bacterial strains, indicating no genotoxic effects.\n",
      "- In vitro assays using human lymphocytes showed that neither Fluoxetine nor Norfluoxetine caused chromosomal damage or increased the frequency of micronuclei.\n",
      "- The Comet assay results indicated that Fluoxetine and Norfluoxetine did not lead to DNA strand breaks in cultured mammalian cells, further supporting their lack of genotoxicity.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.198704\n",
      "prediction:  - The Ames test was used to assess the genotoxicity of Fluoxetine and Norfluoxetine, showing no mutagenic effects.\n",
      "- In vitro assays, including the micronucleus test, indicated that neither Fluoxetine nor its metabolite Norfluoxetine caused chromosomal damage.\n",
      "- The results from the Comet assay confirmed that Fluoxetine and Norfluoxetine did not induce DNA strand breaks in human lymphocytes.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "sc\n",
      "SIM_score:  0.201373\n",
      "0.201373\n",
      "prediction:  - The Ames test was used to evaluate the genotoxicity of Fluoxetine and Norfluoxetine, showing no mutagenic effects.\n",
      "- In vitro assays, including the micronucleus test, indicated that neither Fluoxetine nor Norfluoxetine caused chromosomal damage.\n",
      "- The Comet assay demonstrated that Fluoxetine and its metabolite did not induce DNA strand breaks in human lymphocytes.\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.190698\n",
      "0.190698\n",
      "0.190698\n",
      "prediction:  - The Ames test was used to evaluate the genotoxicity of Fluoxetine and Norfluoxetine, showing no mutagenic effects.\n",
      "- In vitro assays, including the micronucleus test, indicated that neither Fluoxetine nor Norfluoxetine caused chromosomal damage.\n",
      "- The results from the Comet assay confirmed that Fluoxetine and its metabolite did not induce DNA strand breaks.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.081967\n",
      "0.081967\n",
      "prediction:  - The age group of 18 to 24 years showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts and behaviors in young adults aged 18 to 24 when compared to the placebo group.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.3333333333333333, 'B': 1.0, 'C': 0.5, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  D\n",
      "D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.059211\n",
      "prediction:  - The age group of 18 to 24 years showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts and behaviors in young adults aged 18 to 24.\n",
      "- The findings indicated that venlafaxine was more effective than placebo in lowering the risk of suicidality in this specific age demographic.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.3055555555555555, 'B': 1.0, 'C': 0.5, 'D': 0.27777777777777773}; rankings=[['B', 'C', 'D', 'A'], ['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.098925\n",
      "prediction:  - The age group of adolescents (ages 12-17) showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts among younger patients compared to those receiving a placebo.\n",
      "- The efficacy of venlafaxine in reducing suicidality was particularly noted in the treatment of major depressive disorder in this age demographic.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.108235\n",
      "prediction:  - The age group of adolescents (ages 12-17) showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts among younger patients.\n",
      "- The efficacy of venlafaxine in reducing suicidality was specifically noted in the context of major depressive disorder in this age demographic.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.109785\n",
      "0.109785\n",
      "prediction:  - The age group of adolescents (ages 12-17) showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts among younger patients.\n",
      "- The efficacy of venlafaxine in reducing suicidality was specifically noted in the context of major depressive disorder in this age group.\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  D\n",
      "D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.105023\n",
      "0.105023\n",
      "prediction:  - The age group of adolescents (ages 12-17) showed a reduction in suicidality risk with venlafaxine tablets compared to placebo.\n",
      "- In clinical studies, venlafaxine was associated with a significant decrease in suicidal thoughts among younger patients.\n",
      "- The findings suggest that venlafaxine may be beneficial for treating depression in adolescents while reducing the risk of suicidality compared to a placebo.\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  D\n",
      "D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.027397\n",
      "prediction:  - The antifungal brand-name drug Lamisil (terbinafine) should be used daily for 1 week to treat athlete's foot.\n",
      "- Lotrimin (clotrimazole) is typically applied twice daily for 2 to 4 weeks for effective treatment of athlete's foot.\n",
      "- Tinactin (tolnaftate) is recommended for daily use for 2 to 4 weeks to alleviate symptoms of athlete's foot.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.025316\n",
      "prediction:  - The antifungal brand-name drug Lamisil (terbinafine) should be used daily for 1 week to treat athlete's foot.\n",
      "- Lotrimin (clotrimazole) is typically applied twice daily for 2 to 4 weeks for effective treatment of athlete's foot.\n",
      "- Tinactin (tolnaftate) is recommended to be used twice daily for 2 to 4 weeks to ensure complete resolution of athlete's foot symptoms.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.025271\n",
      "prediction:  - The antifungal brand-name drug Lamisil (terbinafine) should be used daily for a duration of 1 week to effectively treat athlete's foot.\n",
      "- Lotrimin (clotrimazole) is typically applied twice daily for 2 to 4 weeks for the treatment of athlete's foot.\n",
      "- Tinactin (tolnaftate) is recommended to be used twice daily for 2 to 4 weeks to achieve optimal results in treating athlete's foot.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.037333\n",
      "prediction:  - The antifungal brand-name drug should be used daily for at least 2 weeks to effectively treat athlete's foot.\n",
      "- It is important to continue the treatment for a few days after symptoms resolve to prevent recurrence.\n",
      "- Follow the specific instructions provided with the antifungal product, as some may recommend longer durations based on the severity of the infection.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.118421\n",
      "0.118421\n",
      "0.118421\n",
      "0.118421\n",
      "0.118421\n",
      "0.118421\n",
      "prediction:  - The brand name drug Accutane is specifically indicated for the treatment of severe acne.\n",
      "- Another option is Differin, which is a topical retinoid used for acne treatment.\n",
      "- Additionally, the brand name drug Epiduo combines adapalene and benzoyl peroxide for acne management.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.015504\n",
      "prediction:  - The brand name of the drug used for general body cleansing processes is \"Miralax.\"\n",
      "- Miralax is commonly used to treat constipation by drawing water into the colon.\n",
      "- It is an osmotic laxative that helps to increase the frequency of bowel movements.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.016327\n",
      "prediction:  - The brand name of the drug used for general body cleansing processes is \"Miralax.\"\n",
      "- Miralax is commonly used to treat constipation by drawing water into the intestines.\n",
      "- It is an osmotic laxative that helps facilitate bowel movements.\n",
      "pred_SIM:  C\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.015564\n",
      "0.015564\n",
      "0.015564\n",
      "0.015564\n",
      "prediction:  - The brand name of the drug used for general body cleansing processes is \"Miralax.\"\n",
      "- Miralax is commonly used to treat constipation by drawing water into the intestines.\n",
      "- It is an osmotic laxative that helps to promote bowel movements effectively.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "choice:          E\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.013129\n",
      "prediction:  - The brand name of the drug used for general body cleansing processes is GoLYTELY.\n",
      "- GoLYTELY is commonly used as a bowel preparation solution prior to colonoscopy procedures.\n",
      "- It contains polyethylene glycol and electrolytes to help cleanse the gastrointestinal tract.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.75}; rankings=[['A', 'B', 'C', 'D'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.013129\n",
      "prediction:  - The brand name of the drug used for general body cleansing processes is GoLYTELY.\n",
      "- GoLYTELY is commonly used as a bowel preparation solution prior to colonoscopy procedures.\n",
      "- It contains polyethylene glycol and electrolytes to help cleanse the gastrointestinal tract.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.75}; rankings=[['D', 'C', 'B', 'A'], ['A', 'B', 'C', 'D'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.073227\n",
      "prediction:  - The brand name product that is indicated for preventing the recurrence of flaking and itching associated with dandruff is Head & Shoulders, which contains active ingredients like pyrithione zinc.\n",
      "- Another option is Nizoral, which contains ketoconazole as its active ingredient, effective in treating dandruff.\n",
      "- Selsun Blue is also indicated for dandruff prevention, utilizing selenium sulfide as its active component.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.074592\n",
      "0.074592\n",
      "0.074592\n",
      "prediction:  - The brand name product that is indicated for preventing the recurrence of flaking and itching associated with dandruff is Head & Shoulders, which contains zinc pyrithione as an active ingredient.\n",
      "- Another option is Nizoral, which contains ketoconazole, an antifungal agent effective against dandruff.\n",
      "- Selsun Blue is also indicated for dandruff prevention, containing selenium sulfide as its active component.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.074766\n",
      "prediction:  - The brand name product that is indicated for preventing the recurrence of flaking and itching associated with dandruff is Head & Shoulders, which contains zinc pyrithione as an active ingredient.\n",
      "- Another option is Nizoral, which contains ketoconazole, an antifungal agent effective against dandruff.\n",
      "- Selsun Blue is also indicated for dandruff prevention, utilizing selenium sulfide as its active component.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.073903\n",
      "prediction:  - The brand name product that is indicated for preventing the recurrence of flaking and itching associated with dandruff is Head & Shoulders, which contains zinc pyrithione as an active ingredient.\n",
      "- Another option is Nizoral, which contains ketoconazole, an antifungal agent effective in treating dandruff.\n",
      "- Selsun Blue is also indicated for dandruff prevention, containing selenium sulfide as its active component.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.129801\n",
      "0.129801\n",
      "prediction:  - The combination of Ondansetron, a 5-HT3 receptor antagonist, with Tramadol, an opioid analgesic, may increase the risk of serotonin syndrome due to Tramadol's serotonergic properties.\n",
      "- Ondansetron may enhance the analgesic effects of Tramadol, potentially leading to improved pain management in patients experiencing nausea and pain simultaneously.\n",
      "- Caution should be exercised when using Ondansetron with Tramadol, as both drugs can affect the central nervous system, potentially leading to increased sedation or respiratory depression.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3333333333333333, 'B': 0.25, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.127108\n",
      "prediction:  - The combination of Ondansetron, a 5-HT3 receptor antagonist, with Tramadol, an opioid analgesic, may increase the risk of serotonin syndrome due to Tramadol's serotonergic properties.\n",
      "- Ondansetron may enhance the analgesic effects of Tramadol, potentially leading to improved pain management in patients experiencing nausea and pain simultaneously.\n",
      "- Caution should be exercised when using Ondansetron with Tramadol, as both drugs can affect the central nervous system, potentially leading to increased sedation or respiratory depression.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.38888888888888884, 'B': 0.25, 'C': 1.0, 'D': 0.4444444444444444}; rankings=[['C', 'A', 'D', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.081191\n",
      "0.081191\n",
      "0.081191\n",
      "prediction:  - The daytime formulation of 'nighttime severe cold and flu' typically contains a non-drowsy antihistamine, allowing users to alleviate cold symptoms without experiencing sedation during the day.\n",
      "- It often includes a combination of pain relievers and decongestants, providing effective symptom relief while enabling individuals to maintain their daily activities.\n",
      "- Unlike the nighttime version, which may contain ingredients like diphenhydramine that promote sleep, the daytime formulation is designed to keep users alert and functional.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.105437\n",
      "prediction:  - The daytime formulation of 'nighttime severe cold and flu' typically contains non-drowsy ingredients, allowing individuals to manage their cold symptoms without experiencing sedation.\n",
      "- It often includes a combination of pain relievers and decongestants, such as acetaminophen and phenylephrine, to alleviate symptoms like headache and nasal congestion during the day.\n",
      "- The formulation is designed to provide relief from cold and flu symptoms while enabling users to maintain their daily activities without the sedative effects associated with nighttime formulations.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.162637\n",
      "prediction:  - The daytime formulation typically contains ingredients like phenylephrine for nasal congestion relief, allowing for symptom management without drowsiness.\n",
      "- It often includes acetaminophen for pain and fever reduction, helping to maintain productivity during the day.\n",
      "- The absence of sedating antihistamines in the daytime version helps users avoid the grogginess associated with nighttime formulations.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.120536\n",
      "prediction:  - The daytime formulation typically contains ingredients like phenylephrine for nasal congestion relief, allowing for symptom management without drowsiness.\n",
      "- It often includes acetaminophen for pain relief and fever reduction, helping individuals maintain productivity during the day.\n",
      "- The absence of sedating antihistamines in the daytime version helps prevent sleepiness, making it suitable for daytime use.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.123348\n",
      "0.123348\n",
      "0.123348\n",
      "prediction:  - The daytime formulation typically contains non-drowsy ingredients, allowing individuals to manage cold and flu symptoms without sedation.\n",
      "- It often includes a combination of pain relievers like acetaminophen and decongestants to alleviate symptoms while maintaining alertness.\n",
      "- The formulation is designed to provide relief from symptoms such as nasal congestion and headache, enabling continued daily activities.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "SIM_score:  0.12731\n",
      "0.12731\n",
      "0.12731\n",
      "prediction:  - The dg health nasal spray may influence growth rates in children aged 4 to 11 years by potentially affecting hormonal levels related to growth.\n",
      "- If the nasal spray contains active ingredients that impact metabolism or appetite, it could lead to changes in growth patterns in this age group.\n",
      "- Long-term use of the nasal spray should be monitored for any adverse effects on growth, particularly if it alters nutritional intake or hormonal balance.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.053908\n",
      "prediction:  - The drug brand name relevant for the indication is Lipitor, which is used for lowering cholesterol levels.\n",
      "- Another relevant drug brand name is Lantus, indicated for long-acting insulin therapy in diabetes management.\n",
      "- Additionally, Advair is a brand name relevant for the indication of asthma and chronic obstructive pulmonary disease (COPD) treatment.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.045584\n",
      "0.045584\n",
      "prediction:  - The drug brand name relevant for the indication is Lipitor, which is used to lower cholesterol levels.\n",
      "- Another relevant drug brand name is Lantus, indicated for managing diabetes by providing long-acting insulin.\n",
      "- Additionally, Advair is relevant for the indication of asthma and chronic obstructive pulmonary disease (COPD) management.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.05988\n",
      "prediction:  - The drug brand name relevant for the indication is Lipitor, which is used to lower cholesterol levels.\n",
      "- Another relevant drug brand name is Lantus, indicated for managing diabetes by providing long-acting insulin.\n",
      "- For treating hypertension, the brand name Norvasc is commonly prescribed to help relax blood vessels.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.07717\n",
      "0.07717\n",
      "prediction:  - The drug brand name that is explicitly stated as not being a controlled substance is \"Zyrtec.\"\n",
      "- Zyrtec is an antihistamine used for allergy relief and is available over-the-counter.\n",
      "- Unlike controlled substances, Zyrtec does not have restrictions on its prescription or dispensing.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.087432\n",
      "prediction:  - The drug brand name that is explicitly stated as not being a controlled substance is Claritin.\n",
      "- Claritin is an antihistamine used to relieve allergy symptoms without the potential for abuse associated with controlled substances.\n",
      "- Unlike other allergy medications, Claritin does not have restrictions under the Controlled Substances Act.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.08\n",
      "prediction:  - The drug brand name that is explicitly stated as not being a controlled substance is Claritin.\n",
      "- Claritin is an antihistamine used to treat allergy symptoms and is available over-the-counter.\n",
      "- Unlike controlled substances, Claritin does not have restrictions on its prescription or distribution due to its safety profile.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.079772\n",
      "prediction:  - The drug brand name that is explicitly stated as not being a controlled substance is Claritin.\n",
      "- Claritin is an antihistamine used to treat allergy symptoms and is available over-the-counter.\n",
      "- Unlike controlled substances, Claritin does not have restrictions on its prescription or distribution due to potential for abuse.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.07717\n",
      "prediction:  - The drug brand name that is explicitly stated as not being a controlled substance is Zyrtec.\n",
      "- Zyrtec is an antihistamine used for allergy relief and is available over-the-counter.\n",
      "- Unlike controlled substances, Zyrtec does not have restrictions on its prescription or distribution.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.05848\n",
      "prediction:  - The drug brand name that is relevant for the indication is commonly used in clinical practice for treating the specified condition.\n",
      "- It has been shown to have significant efficacy in clinical trials compared to placebo.\n",
      "- The drug is often prescribed as part of a standard treatment regimen for patients with this indication.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.049875\n",
      "prediction:  - The drug brand name that is relevant for the indication is commonly used in the treatment of specific conditions, such as hypertension or diabetes.\n",
      "- This brand name is often prescribed in a regimen that may include lifestyle modifications alongside pharmacotherapy.\n",
      "- Clinical trials have demonstrated the efficacy of this drug compared to placebo in managing the indicated condition.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.076782\n",
      "prediction:  - The drug branded as 70% is primarily used as a topical antiseptic for skin disinfection, particularly in surgical settings.\n",
      "- It contains 70% isopropyl alcohol, which is effective in killing bacteria and preventing infection.\n",
      "- This formulation is commonly used in hospitals and clinics for pre-operative skin preparation and cleaning of medical instruments.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.076923\n",
      "prediction:  - The drug branded as 70% is primarily used as a topical antiseptic for skin disinfection, particularly in surgical settings.\n",
      "- It contains 70% isopropyl alcohol, which is effective in killing bacteria and preventing infection.\n",
      "- This formulation is commonly used in hospitals and clinics for preoperative skin preparation and cleaning of medical instruments.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.069421\n",
      "prediction:  - The drug branded as 70% is primarily used as a topical antiseptic for skin disinfection, particularly in the form of isopropyl alcohol.\n",
      "- It is commonly utilized in medical settings for sanitizing hands and surfaces to reduce the risk of infection.\n",
      "- The 70% concentration is effective because it strikes a balance between water and alcohol, enhancing its ability to penetrate cell walls of bacteria.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.4444444444444444, 'D': 0.38888888888888884}; rankings=[['A', 'C', 'D', 'B'], ['A', 'D', 'C', 'B'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.121037\n",
      "prediction:  - The drug branded as 70% is primarily used as a topical antiseptic for skin disinfection.\n",
      "- It is commonly utilized in healthcare settings for cleaning skin before injections or surgical procedures.\n",
      "- The formulation typically contains 70% isopropyl alcohol, which is effective in killing bacteria and viruses on the skin.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.12987\n",
      "0.12987\n",
      "0.12987\n",
      "prediction:  - The drug branded as 70% is primarily used as an antiseptic for skin disinfection.\n",
      "- It is commonly utilized in healthcare settings for sterilizing surfaces and equipment.\n",
      "- The formulation typically contains 70% isopropyl alcohol, which is effective in killing bacteria and viruses.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.131148\n",
      "0.131148\n",
      "prediction:  - The drug branded as 70% is primarily used as an antiseptic for skin disinfection.\n",
      "- It is commonly utilized in medical settings for sterilizing surfaces and equipment.\n",
      "- The formulation typically contains 70% isopropyl alcohol, which is effective in killing bacteria and viruses.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.066914\n",
      "prediction:  - The drug indicated for the treatment of hypertension is lisinopril, an ACE inhibitor.\n",
      "- Metformin is specifically used for managing type 2 diabetes mellitus.\n",
      "- Atorvastatin is prescribed for lowering cholesterol levels and preventing cardiovascular disease.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.068182\n",
      "0.068182\n",
      "0.068182\n",
      "0.068182\n",
      "0.068182\n",
      "prediction:  - The drug indicated for the treatment of hypertension is lisinopril, an ACE inhibitor.\n",
      "- Metformin is specifically used for managing type 2 diabetes mellitus.\n",
      "- Atorvastatin is prescribed for lowering cholesterol levels and reducing cardiovascular risk.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  E\n",
      "E\n",
      "E\n",
      "E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.040712\n",
      "prediction:  - The drug that blocked the tumorigenic effect of albuterol sulfate in Sprague-Dawley rats is a specific beta-blocker.\n",
      "- In the study, the administration of the beta-blocker was compared against a control group receiving only albuterol sulfate.\n",
      "- The results indicated a significant reduction in tumor formation in the group treated with the beta-blocker alongside albuterol sulfate.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Propranolol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.059016\n",
      "0.059016\n",
      "0.059016\n",
      "prediction:  - The highest dietary dose of albuterol sulfate tested in Golden hamsters was 1,000 mg/kg/day.\n",
      "- At this dosage, there was no evidence of tumorigenicity observed in the study.\n",
      "- The study specifically evaluated the long-term effects of albuterol sulfate on tumor development in this animal model.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  E\n",
      "E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.061644\n",
      "0.061644\n",
      "prediction:  - The highest dietary dose of albuterol sulfate tested in Golden hamsters was 1,000 mg/kg/day.\n",
      "- At this dosage, there was no evidence of tumorigenicity observed in the study.\n",
      "- The study specifically focused on the long-term effects of albuterol sulfate in the diet of the hamsters.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.0625\n",
      "prediction:  - The highest dietary dose of albuterol sulfate tested in Golden hamsters was 1,000 mg/kg/day.\n",
      "- At this dosage, there was no evidence of tumorigenicity observed in the study.\n",
      "- This finding suggests that albuterol sulfate may be safe at high dietary levels in this animal model.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.357798\n",
      "0.357798\n",
      "0.357798\n",
      "0.357798\n",
      "0.357798\n",
      "0.357798\n",
      "prediction:  - The highest dose of fluoxetine administered to adult rats was 40 mg/kg.\n",
      "- This dose is approximately 2.5 times the maximum recommended human dose (MRHD) on a mg/mÂ² basis.\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "choice:  E\n",
      "E\n",
      "E\n",
      "E\n",
      "E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.204724\n",
      "0.204724\n",
      "0.204724\n",
      "prediction:  - The highest dose of fluoxetine administered to adult rats was 40 mg/kg.\n",
      "- This dose is approximately 2.5 times the maximum recommended human dose (MRHD) on a mg/mÂ² basis.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.179872\n",
      "prediction:  - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg.\n",
      "- The maximum recommended human dose (MRHD) for fluoxetine is 80 mg/day, which translates to approximately 1.1 mg/mÂ² based on average body surface area.\n",
      "- When comparing the doses, the rat dose of 60 mg/kg is significantly higher than the MRHD on a mg/mÂ² basis, indicating a much greater exposure in the animal study.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.20438\n",
      "prediction:  - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg.\n",
      "- The maximum recommended human dose (MRHD) for fluoxetine is 80 mg/day, which translates to approximately 1.1 mg/mÂ² based on average body surface area.\n",
      "- When comparing the doses, the rat dose of 60 mg/kg is significantly higher than the MRHD on a mg/mÂ² basis.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.180258\n",
      "prediction:  - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg.\n",
      "- The maximum recommended human dose (MRHD) of fluoxetine is 80 mg/day, which translates to approximately 1.1 mg/mÂ² based on average body surface area.\n",
      "- When comparing the doses, the rat dose of 60 mg/kg is significantly higher than the MRHD on a mg/mÂ² basis, indicating a much greater exposure in the animal study.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.204878\n",
      "0.204878\n",
      "prediction:  - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg.\n",
      "- The maximum recommended human dose (MRHD) of fluoxetine is 80 mg/day, which translates to approximately 1.1 mg/mÂ² based on average body surface area.\n",
      "- When comparing the doses, the rat dose of 60 mg/kg is significantly higher than the MRHD on a mg/mÂ² basis.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.2\n",
      "prediction:  - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg/day.\n",
      "- The maximum recommended human dose (MRHD) for fluoxetine is 60 mg/day for adults, which translates to approximately 1.2 mg/mÂ² based on average body surface area.\n",
      "- When comparing the doses, the rat dose of 60 mg/kg/day is significantly higher than the MRHD on a mg/mÂ² basis.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.09607\n",
      "prediction:  - The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was 60 mg/kg/day.\n",
      "- When converted to a human equivalent dose based on body surface area, this dose is significantly higher than the maximum recommended human dose (MRHD) of fluoxetine, which is typically around 60 mg/day for adults.\n",
      "- On a mg/mÂ² basis, the rat dose exceeds the MRHD, indicating a potential difference in sensitivity to fluoxetine between rats and humans.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.75}; rankings=[['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.036474\n",
      "prediction:  - The initial treatment duration with pantoprazole sodium for injection was 7 days.\n",
      "- After the initial treatment, patients were switched to oral pantoprazole sodium delayed-release tablets.\n",
      "- This regimen aimed to effectively manage acute reflux esophagitis symptoms during the transition from intravenous to oral therapy.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.043321\n",
      "0.043321\n",
      "prediction:  - The initial treatment duration with pantoprazole sodium for injection was 7 days.\n",
      "- After the initial treatment, patients were switched to oral pantoprazole sodium delayed-release tablets.\n",
      "- This regimen aimed to effectively manage symptoms of acute reflux esophagitis.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.041812\n",
      "prediction:  - The initial treatment duration with pantoprazole sodium for injection was 7 days.\n",
      "- After the initial treatment, patients were switched to oral pantoprazole sodium delayed-release tablets.\n",
      "- This transition aimed to maintain acid suppression and promote healing of the esophagus.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.036254\n",
      "prediction:  - The initial treatment with pantoprazole sodium for injection lasted for 3 days.\n",
      "- After the initial treatment, patients were switched to oral pantoprazole sodium delayed-release tablets for continued management.\n",
      "- This regimen aimed to provide rapid symptom relief followed by maintenance therapy with the oral formulation.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.027972\n",
      "0.027972\n",
      "prediction:  - The initial treatment with pantoprazole sodium for injection was administered for a duration of 7 days.\n",
      "- After the 7-day period, patients were switched to oral pantoprazole sodium delayed-release tablets for continued management of acute reflux esophagitis.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.046693\n",
      "prediction:  - The initial treatment with pantoprazole sodium for injection was administered for a duration of 7 days.\n",
      "- After the 7-day period, patients were switched to oral pantoprazole sodium delayed-release tablets for continued management of their condition.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.03\n",
      "prediction:  - The initial treatment with pantoprazole sodium for injection was administered for a duration of 7 days.\n",
      "- After the 7-day period, patients were switched to oral pantoprazole sodium delayed-release tablets for continued treatment.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.079121\n",
      "prediction:  - The maximum dose of ondansetron administered to rats in carcinogenicity studies is significantly higher than the maximum recommended human oral dose.\n",
      "- In these studies, doses of ondansetron were often in the range of 10 mg/kg or higher, while the maximum recommended human oral dose is typically 16 mg per day.\n",
      "- This comparison highlights the differences in dosing between animal studies and human clinical recommendations.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Approximately 4 times higher\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.066055\n",
      "prediction:  - The maximum dose of ondansetron administered to rats in carcinogenicity studies is significantly higher than the maximum recommended human oral dose.\n",
      "- In these studies, doses of ondansetron were often in the range of 10 mg/kg or more, while the maximum recommended human oral dose is typically 16 mg per day.\n",
      "- This comparison highlights the differences in dosing between animal studies and human clinical recommendations, emphasizing the need for careful interpretation of animal data in relation to human safety.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Approximately 4 times higher\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.087805\n",
      "0.087805\n",
      "prediction:  - The maximum dose of ondansetron administered to rats in carcinogenicity studies is significantly higher than the maximum recommended human oral dose.\n",
      "- In these studies, rats received doses that were several times greater than the typical human dose of 8 mg per day.\n",
      "- This comparison highlights the differences in dosing between animal studies and human clinical recommendations.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Approximately 4 times higher\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.115632\n",
      "prediction:  - The maximum dose of ondansetron administered to rats in carcinogenicity studies is significantly higher than the maximum recommended human oral dose.\n",
      "- In these studies, rats received doses up to 100 mg/kg/day, while the maximum recommended human oral dose is typically 16 mg/day.\n",
      "- This indicates a substantial difference in dosing, with the animal studies using doses that are approximately 6250 times higher than the human equivalent.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Approximately 4 times higher\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.060811\n",
      "prediction:  - The maximum number of nicotine lozenges that can be used in a single day is 24.\n",
      "- This dosage is typically recommended for individuals who are heavily dependent on nicotine.\n",
      "- It is important to follow the guidelines provided on the product packaging to avoid potential side effects.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: 20 lozenges\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.050279\n",
      "prediction:  - The maximum number of nicotine lozenges that can be used in a single day is 24.\n",
      "- This dosage is typically recommended for individuals who are using the lozenges as part of a smoking cessation program.\n",
      "- It is important to follow the guidelines provided by healthcare professionals to avoid potential side effects from excessive nicotine intake.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: 20 lozenges\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.072\n",
      "prediction:  - The maximum number of nicotine lozenges that can be used in a single day is 24.\n",
      "- This limit applies to both the 2 mg and 4 mg nicotine lozenges.\n",
      "- Users should space the lozenges at least 1 hour apart to avoid exceeding the daily limit.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: 20 lozenges\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.05625\n",
      "0.05625\n",
      "prediction:  - The maximum number of nicotine lozenges that can be used in a single day is 24.\n",
      "- This recommendation is based on the standard dosing guidelines for over-the-counter nicotine replacement therapy.\n",
      "- Users should not exceed this limit to avoid potential side effects associated with excessive nicotine intake.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: 20 lozenges\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.065574\n",
      "0.065574\n",
      "0.065574\n",
      "0.065574\n",
      "0.065574\n",
      "0.065574\n",
      "prediction:  - The maximum oral dose of ondansetron administered to rats in carcinogenicity studies was 80 mg/kg/day.\n",
      "- This dose was given for a duration of 2 years to assess potential carcinogenic effects.\n",
      "- The studies aimed to evaluate the long-term safety profile of ondansetron in a rodent model.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "        E\n",
      "        E\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.08982\n",
      "0.08982\n",
      "0.08982\n",
      "0.08982\n",
      "0.08982\n",
      "prediction:  - The maximum oral dose of ondansetron administered to rats in the carcinogenicity studies was 16 mg/kg per day.\n",
      "- This dose was part of a long-term study to evaluate the potential carcinogenic effects of ondansetron.\n",
      "- The study aimed to assess the safety profile of ondansetron at high doses over an extended period.\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.08982\n",
      "prediction:  - The maximum oral dose of ondansetron administered to rats in the carcinogenicity studies was 80 mg/kg per day.\n",
      "- This dose was part of a long-term study to evaluate the potential carcinogenic effects of ondansetron.\n",
      "- The study aimed to assess the safety profile of ondansetron at high doses over an extended period.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.014388\n",
      "prediction:  - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was 50%.\n",
      "- This reduction was observed in a clinical trial specifically assessing the efficacy of lamotrigine as an antiepileptic medication.\n",
      "- Patients receiving lamotrigine showed significant improvement compared to those on placebo, highlighting its effectiveness in managing PGTC seizures.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.015267\n",
      "prediction:  - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was 50%.\n",
      "- This reduction was observed in a clinical trial specifically assessing the efficacy of lamotrigine as an antiepileptic medication.\n",
      "- The results indicated a significant improvement in seizure control compared to baseline measurements in the study population.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.014851\n",
      "prediction:  - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was 50%.\n",
      "- This reduction was observed in a clinical trial specifically assessing the efficacy of lamotrigine as an antiepileptic medication.\n",
      "- The results indicated that lamotrigine significantly improved seizure control compared to baseline measurements in the study population.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.015345\n",
      "prediction:  - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was approximately 50%.\n",
      "- In the clinical trial, patients receiving lamotrigine showed a significant improvement compared to the placebo group.\n",
      "- The results indicated that lamotrigine was effective in reducing the frequency of PGTC seizures in the studied population.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.014599\n",
      "prediction:  - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was reported to be 50%.\n",
      "- In the clinical trial, lamotrigine was compared to a placebo, demonstrating a significant reduction in seizure frequency.\n",
      "- Patients receiving lamotrigine experienced a notable improvement in seizure control, highlighting its efficacy in managing PGTC seizures.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.01432\n",
      "prediction:  - The median percent reduction in primary generalized tonic-clonic seizures (PGTC) for patients treated with lamotrigine was reported to be 50%.\n",
      "- This reduction was observed in a clinical trial specifically assessing the efficacy of lamotrigine as an antiepileptic medication.\n",
      "- The results indicated that lamotrigine significantly improved seizure control compared to baseline measurements in the study population.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.010909\n",
      "prediction:  - The median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine was 50% compared to placebo.\n",
      "- In the trial, patients receiving lamotrigine experienced a significant improvement in seizure control compared to those on placebo.\n",
      "- The results indicated that lamotrigine at 400 mg/day was effective as an adjunctive therapy for adults with partial-onset seizures.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 0.5, 'D': 1.0}; rankings=[['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.009662\n",
      "prediction:  - The median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine was significantly greater than that of the placebo group.\n",
      "- Patients receiving lamotrigine at 400 mg/day experienced a median reduction of approximately 50% in seizure frequency compared to those on placebo.\n",
      "- The trial demonstrated that lamotrigine at this dosage effectively reduced the frequency of partial-onset seizures in adults when used as adjunctive therapy.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 0.5, 'D': 1.0}; rankings=[['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.009317\n",
      "prediction:  - The median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine was significantly greater than that of the placebo group.\n",
      "- Specifically, patients receiving lamotrigine at 400 mg/day experienced a median reduction of approximately 50% in seizure frequency compared to those on placebo.\n",
      "- This indicates that lamotrigine at this dosage provides a meaningful therapeutic benefit over placebo in managing partial-onset seizures.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.4166666666666667, 'B': 0.3333333333333333, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'C', 'B', 'A'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.014218\n",
      "0.014218\n",
      "prediction:  - The median seizure frequency reduction with a 400 mg/day dose of lamotrigine was significantly greater than that observed with placebo.\n",
      "- In the trial, patients receiving lamotrigine experienced a median reduction of approximately 50% in seizure frequency compared to those on placebo.\n",
      "- The results indicated that lamotrigine at this dosage provided a meaningful adjunctive effect in managing partial-onset seizures.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.014963\n",
      "0.014963\n",
      "0.014963\n",
      "prediction:  - The median seizure frequency reduction with a 400 mg/day dose of lamotrigine was significantly greater than that observed with placebo.\n",
      "- In the trial, patients receiving lamotrigine experienced a median reduction of approximately 50% in seizure frequency.\n",
      "- The placebo group showed a much lower median seizure frequency reduction, highlighting the efficacy of lamotrigine as adjunctive therapy.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.015666\n",
      "prediction:  - The median seizure frequency reduction with a 400 mg/day dose of lamotrigine was significantly greater than that observed with placebo.\n",
      "- In the trial, patients receiving lamotrigine experienced a median reduction of approximately 50% in seizure frequency.\n",
      "- The results indicated that lamotrigine at this dosage provided a meaningful therapeutic benefit over the placebo group.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.125261\n",
      "0.125261\n",
      "prediction:  - The mortality rate in patients treated with NUZYRA (omadacycline) for CABP was observed to be lower than that in patients treated with moxifloxacin.\n",
      "- In clinical trials, the mortality rate for NUZYRA was reported to be approximately 5.5%, while moxifloxacin had a higher mortality rate of around 7.5%.\n",
      "- The data suggests that NUZYRA may offer a more favorable outcome in terms of mortality compared to moxifloxacin in the treatment of CABP.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.175953\n",
      "prediction:  - The mortality rate in patients treated with NUZYRA for CABP was 3.5%.\n",
      "- In comparison, the mortality rate for patients treated with moxifloxacin was 3.1%.\n",
      "- The difference in mortality rates indicates that NUZYRA has a slightly higher observed mortality rate than moxifloxacin in this patient population.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.131291\n",
      "prediction:  - The mortality rate in patients treated with NUZYRA for CABP was observed to be lower than that in patients treated with moxifloxacin.\n",
      "- In clinical trials, NUZYRA demonstrated a mortality rate of approximately 2.5% compared to a higher rate of around 4.5% in the moxifloxacin group.\n",
      "- The data suggests that NUZYRA may offer a more favorable outcome in terms of mortality for patients with CABP compared to moxifloxacin.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.156863\n",
      "prediction:  - The mortality rate in patients treated with NUZYRA for CABP was observed to be lower than that in patients treated with moxifloxacin.\n",
      "- In clinical trials, NUZYRA demonstrated a statistically significant reduction in mortality compared to moxifloxacin.\n",
      "- The specific mortality rates reported for NUZYRA were 2.5% versus 4.0% for moxifloxacin in the studied population.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.154567\n",
      "prediction:  - The mortality rate in patients treated with NUZYRA for CABP was observed to be lower than that in patients treated with moxifloxacin.\n",
      "- In clinical trials, NUZYRA demonstrated a statistically significant reduction in mortality compared to moxifloxacin.\n",
      "- The specific mortality rates reported for NUZYRA were approximately 2.5% compared to 4.5% for moxifloxacin in the studied population.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.05425\n",
      "prediction:  - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves insomnia associated with cold and flu symptoms due to its sedative ingredients.\n",
      "- It helps alleviate symptoms such as cough and nasal congestion, allowing for better sleep during the night.\n",
      "- The formulation is designed to provide relief from body aches and fever, which can disrupt sleep.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.25, 'D': 0.5}; rankings=[['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.049917\n",
      "prediction:  - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves insomnia associated with cold and flu symptoms due to its sedative ingredients.\n",
      "- It helps alleviate symptoms such as cough and nasal congestion, allowing for better sleep during the night.\n",
      "- The formulation typically contains diphenhydramine, which is known for its effectiveness in reducing nighttime cough and promoting restful sleep.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.047468\n",
      "prediction:  - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves insomnia associated with cold symptoms, allowing for better sleep.\n",
      "- It contains diphenhydramine, an antihistamine that helps alleviate symptoms like runny nose and sneezing while promoting drowsiness.\n",
      "- The active ingredients in the nighttime formulation are designed to provide relief from cough and congestion, which can disrupt sleep.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 0.8333333333333334, 'B': 0.611111111111111, 'C': 0.25, 'D': 0.38888888888888884}; rankings=[['A', 'D', 'B', 'C'], ['B', 'A', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.046753\n",
      "0.046753\n",
      "0.046753\n",
      "0.046753\n",
      "prediction:  - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves symptoms such as cough, allowing for better sleep.\n",
      "- It often contains diphenhydramine, an antihistamine that helps reduce nighttime sneezing and runny nose.\n",
      "- The formulation may also include a pain reliever like acetaminophen to alleviate body aches associated with cold and flu symptoms.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.046154\n",
      "prediction:  - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves symptoms such as cough, allowing for better sleep.\n",
      "- It often contains diphenhydramine, an antihistamine that helps reduce nighttime sneezing and runny nose.\n",
      "- The formulation may also include a pain reliever like acetaminophen, which alleviates body aches associated with cold and flu symptoms.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.062893\n",
      "prediction:  - The nighttime formulation of 'nighttime severe cold and flu' specifically relieves symptoms such as insomnia due to its sedative component, often containing diphenhydramine.\n",
      "- It also alleviates cough and nasal congestion, providing relief from these symptoms to help improve sleep quality.\n",
      "- The formulation is designed to address multiple cold and flu symptoms, but its unique benefit is the reduction of nighttime coughing, allowing for uninterrupted rest.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.066298\n",
      "prediction:  - The recommended amount of hydrocort shampoo to use is typically a quarter-sized amount for each application.\n",
      "- It is advised to apply the shampoo to the affected areas of the scalp and massage gently for optimal absorption.\n",
      "- The shampoo should be left on the scalp for about 5-10 minutes before rinsing thoroughly to ensure effectiveness.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.064516\n",
      "prediction:  - The recommended amount of hydrocort shampoo to use is typically a quarter-sized amount for each application.\n",
      "- It should be applied to the affected area of the scalp and left on for about 5-10 minutes before rinsing.\n",
      "- For optimal results, this application should be done 1-2 times per week, depending on the severity of the condition being treated.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.092664\n",
      "prediction:  - The recommended amount of hydrocort shampoo to use is typically a quarter-sized amount.\n",
      "- It should be applied to the affected area of the scalp and massaged gently.\n",
      "- Allow the shampoo to sit for 5-10 minutes before rinsing thoroughly.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.029654\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of polyethylene glycol 3350, which is commonly used as a laxative.\n",
      "- It is important to ensure that the polyethylene glycol 3350 is administered with adequate fluids to enhance its effectiveness.\n",
      "- This dosage is typically part of a regimen that may include dietary adjustments and increased fluid intake to promote bowel regularity.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 0.5, 'D': 1.0}; rankings=[['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.029654\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of polyethylene glycol 3350, which is commonly used as a laxative.\n",
      "- It is important to ensure that the polyethylene glycol 3350 is administered with adequate fluids to enhance its effectiveness.\n",
      "- This dosage is typically part of a regimen that may include dietary adjustments and increased water intake to promote bowel regularity.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 0.5, 'D': 1.0}; rankings=[['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.028302\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of polyethylene glycol 3350, which is commonly used as a laxative.\n",
      "- It is important to ensure that the polyethylene glycol 3350 is administered with adequate fluids to enhance its effectiveness.\n",
      "- This dosage is typically part of a regimen that may include dietary adjustments and increased water intake to promote bowel regularity.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.4166666666666667, 'B': 0.3333333333333333, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.110553\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of the laxative for women, taken once daily.\n",
      "- It is important to ensure that the laxative is appropriate for pediatric use and to consult a healthcare provider if unsure.\n",
      "- Dosage may vary based on individual needs, so monitoring the child's response to the laxative is essential.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.117021\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of the laxative for women, taken once daily.\n",
      "- It is important to ensure that the laxative is mixed with sufficient water to aid in its effectiveness.\n",
      "- Monitoring for any adverse effects is crucial, especially if the child has not previously used a laxative.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.109785\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of the laxative for women, taken once daily.\n",
      "- It is important to ensure that the laxative is suitable for pediatric use and to follow the specific product guidelines.\n",
      "- Always consult a healthcare professional before administering any laxative to children to confirm the appropriate dosage and safety.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.14791\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is 5 to 10 grams of the laxative for women.\n",
      "- This dosage should be taken once daily, preferably in the evening.\n",
      "- It is important to ensure adequate fluid intake while using the laxative to prevent dehydration.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.102326\n",
      "0.102326\n",
      "prediction:  - The recommended dosage for children aged 6 to under 12 years is typically 5 to 10 grams of the laxative for women, taken once daily.\n",
      "- It is important to ensure that the laxative is appropriate for pediatric use and to consult a healthcare provider for specific recommendations.\n",
      "- Dosage may vary based on the specific formulation of the laxative, so checking the product label is essential.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.206731\n",
      "prediction:  - The recommended dosage of Belladona for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose.\n",
      "- It is important to administer Belladona in a controlled environment due to its potency and potential side effects.\n",
      "- Dosage may vary based on the specific formulation and the condition being treated, so consulting a healthcare provider is essential.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.209756\n",
      "prediction:  - The recommended dosage of Belladona for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose.\n",
      "- It is important to administer Belladona in a controlled environment, as it can have potent effects and potential side effects.\n",
      "- Always consult a healthcare professional before starting any regimen involving Belladona, especially for children.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.219388\n",
      "prediction:  - The recommended dosage of Belladona for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose.\n",
      "- It is important to administer Belladona in a controlled environment, as it can have potent effects.\n",
      "- Always consult a healthcare professional before starting any regimen involving Belladona, especially in pediatric patients.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.204762\n",
      "0.204762\n",
      "prediction:  - The recommended dosage of Belladona for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose.\n",
      "- It is important to administer Belladona in a controlled manner, often in a tincture form, to avoid potential toxicity.\n",
      "- Dosage may vary based on the specific formulation and the condition being treated, so consulting a healthcare provider is essential.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.195455\n",
      "prediction:  - The recommended dosage of Belladona for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose.\n",
      "- It is important to administer Belladona in a controlled manner, often in a tincture form, with careful monitoring of the child's response.\n",
      "- Dosage may vary based on the specific formulation and the condition being treated, so consulting a healthcare provider is essential.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.130303\n",
      "prediction:  - The recommended dosage of Belladonna for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose, administered every 4 to 6 hours as needed.\n",
      "- It is important to note that Belladonna should be used with caution and under medical supervision due to potential side effects and toxicity.\n",
      "- Always consult a healthcare professional before administering Belladonna to ensure appropriate dosing and safety for the child.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3055555555555555, 'B': 0.27777777777777773, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.133333\n",
      "prediction:  - The recommended dosage of Belladonna for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose, administered every 4 to 6 hours as needed.\n",
      "- It is important to note that Belladonna should be used with caution and under medical supervision due to potential side effects and toxicity.\n",
      "- Always consult a healthcare professional before administering Belladonna to ensure appropriate dosing and safety for the child.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3333333333333333, 'B': 0.25, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.126844\n",
      "prediction:  - The recommended dosage of Belladonna for children aged 2 to 12 years is typically 0.5 to 1.0 mg per dose, administered every 4 to 6 hours as needed.\n",
      "- It is important to note that Belladonna should be used with caution and under medical supervision due to potential side effects and toxicity.\n",
      "- Always consult a healthcare professional before administering Belladonna to ensure safety and appropriateness for the child's specific condition.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3055555555555555, 'B': 0.27777777777777773, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.175758\n",
      "prediction:  - The recommended dosage of vaginal essential oil is typically 2-3 drops applied to the vaginal area.\n",
      "- Essential oils should be diluted with a carrier oil before application to avoid irritation.\n",
      "- It is advised to use this regimen during menstruation to help prevent repeated cross-infection.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.145349\n",
      "prediction:  - The recommended dosage of vaginal essential oil is typically 2-3 drops applied to the vaginal area.\n",
      "- Essential oils such as tea tree oil or lavender oil are commonly used for their antimicrobial properties.\n",
      "- It is advised to use this regimen during menstruation to help prevent repeated cross-infection.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.161725\n",
      "prediction:  - The recommended dosage of vaginal essential oil is typically 2-3 drops applied topically to the vaginal area.\n",
      "- Essential oils should be diluted with a carrier oil, such as coconut or almond oil, before application to avoid irritation.\n",
      "- It is advised to use this regimen during the menstrual period to help prevent cross-infection.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.135747\n",
      "prediction:  - The recommended dosage of vaginal essential oil is typically 2-3 drops of tea tree oil diluted in a carrier oil, applied externally.\n",
      "- For internal use, a common regimen is 1-2 drops of lavender essential oil mixed with a carrier oil, used during menstruation.\n",
      "- It is important to ensure that the essential oil is of high quality and suitable for vaginal use to prevent irritation or adverse reactions.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.147541\n",
      "prediction:  - The recommended dosage of vaginal essential oil is typically around 2-3 drops applied externally to the vaginal area.\n",
      "- Essential oils such as tea tree oil or lavender oil are commonly used for their antimicrobial properties.\n",
      "- It is important to dilute essential oils with a carrier oil before application to avoid irritation.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.035461\n",
      "prediction:  - The recommended storage temperature range for the drug 'sterile' is between 36Â°F and 46Â°F.\n",
      "- It is important to keep the drug away from extreme temperatures to maintain its efficacy.\n",
      "- Storing the drug outside of this range may compromise its sterility and effectiveness.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 59 - 86Â°F\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.034722\n",
      "0.034722\n",
      "0.034722\n",
      "0.034722\n",
      "0.034722\n",
      "prediction:  - The recommended storage temperature range for the drug 'sterile' is between 36Â°F and 46Â°F.\n",
      "- It is important to keep the drug within this range to maintain its efficacy and safety.\n",
      "- Storing the drug outside of this temperature range may lead to degradation or loss of potency.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: 59 - 86Â°F\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.021552\n",
      "0.021552\n",
      "prediction:  - The recommended storage temperature range for the drug 'sterile' is between 36Â°F to 46Â°F.\n",
      "- It is important to keep the drug 'sterile' within this temperature range to maintain its efficacy and safety.\n",
      "- Storing the drug outside of this range may compromise its sterility and effectiveness.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.25, 'D': 0.5}; rankings=[['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 59 - 86Â°F\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.021097\n",
      "prediction:  - The recommended storage temperature range for the drug 'sterile' is typically between 36Â°F to 46Â°F.\n",
      "- It is important to keep the drug 'sterile' within this temperature range to maintain its efficacy and safety.\n",
      "- Storing the drug outside of this range may compromise its sterility and effectiveness.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.25, 'D': 0.5}; rankings=[['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 59 - 86Â°F\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.089122\n",
      "prediction:  - The study indicates that dg health nasal spray, when administered as an active treatment, may lead to a statistically significant increase in the growth rate of children aged 4 to 11 years compared to a placebo.\n",
      "- Children receiving the active dg health nasal spray showed improved height velocity measurements over a specified treatment period, suggesting a positive impact on growth.\n",
      "- In contrast, the placebo group did not exhibit any notable changes in growth rate, highlighting the potential efficacy of the active nasal spray formulation.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.27777777777777773, 'C': 0.3055555555555555, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.087516\n",
      "prediction:  - The study indicates that dg health nasal spray, when administered as an active treatment, may lead to a statistically significant increase in the growth rate of children aged 4 to 11 years compared to a placebo.\n",
      "- Children receiving the active dg health nasal spray showed improved height velocity measurements over a specified treatment period, suggesting a positive impact on growth.\n",
      "- In contrast, the placebo group did not exhibit any notable changes in growth rate, highlighting the potential efficacy of the active nasal spray formulation.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3055555555555555, 'C': 0.3333333333333333, 'D': 0.4444444444444444}; rankings=[['A', 'D', 'B', 'C'], ['A', 'C', 'D', 'B'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.090909\n",
      "prediction:  - The study indicates that dg health nasal spray, when administered as an active treatment, may lead to a statistically significant increase in the growth rate of children aged 4 to 11 years compared to a placebo.\n",
      "- Children receiving the active dg health nasal spray showed improved height velocity measurements over a specified treatment period, suggesting a positive impact on growth.\n",
      "- In contrast, the placebo group did not exhibit any notable changes in growth rate, highlighting the potential efficacy of the active nasal spray formulation.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.25, 'D': 0.5}; rankings=[['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.072555\n",
      "prediction:  - The suggested water temperature for a sitz bath is typically around 37-40 degrees Celsius (98.6-104 degrees Fahrenheit), which is comfortable and soothing for vaginal use.\n",
      "- When using vaginal essential oils, ensure that the water is not too hot to avoid irritation or burns, maintaining a safe temperature range.\n",
      "- Essential oils should be diluted properly in the sitz bath to enhance the therapeutic effects while ensuring safety and comfort.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.070015\n",
      "prediction:  - The suggested water temperature for a sitz bath is typically around 37-40 degrees Celsius (98.6-104 degrees Fahrenheit), which is comfortable and soothing for vaginal use.\n",
      "- When using vaginal essential oils, ensure the water is not too hot to avoid irritation, maintaining a warm temperature that promotes relaxation and healing.\n",
      "- Essential oils should be diluted properly in the sitz bath to prevent any adverse reactions, ensuring a safe and effective experience.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.068452\n",
      "prediction:  - The suggested water temperature for a sitz bath is typically around 37-40 degrees Celsius (98.6-104 degrees Fahrenheit), which is warm but not hot to avoid irritation.\n",
      "- When using vaginal essential oils, ensure the water is comfortable to the touch, as essential oils can enhance relaxation and soothing effects in warm water.\n",
      "- It is important to use a clean, non-irritating essential oil specifically formulated for vaginal use, ensuring it is diluted properly in the warm water.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.033582\n",
      "prediction:  - The symptom of \"sore throat\" is not mentioned as being relieved by the 'nighttime severe cold and flu' medication.\n",
      "- The relief of \"fever\" is specifically noted, while \"sore throat\" is absent from the list of alleviated symptoms.\n",
      "- The active ingredients in 'nighttime severe cold and flu' do not include any that target sore throat relief.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.5, 'B': 0.75, 'C': 0.5277777777777778, 'D': 0.3055555555555555}; rankings=[['B', 'A', 'D', 'C'], ['B', 'A', 'C', 'D'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.032653\n",
      "0.032653\n",
      "prediction:  - The target basal acid secretion level for patients with Zollinger-Ellison Syndrome without prior gastric surgery was less than 10 mEq/hour during treatment with pantoprazole sodium for injection.\n",
      "- Pantoprazole sodium for injection was administered to achieve this target level effectively in managing acid secretion.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 10 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.030948\n",
      "prediction:  - The target basal acid secretion level for patients with Zollinger-Ellison Syndrome without prior gastric surgery was less than 10 mEq/hour during treatment with pantoprazole sodium for injection.\n",
      "- Pantoprazole sodium for injection was used to achieve this target level in managing excessive gastric acid secretion associated with the syndrome.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 10 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.091778\n",
      "0.091778\n",
      "prediction:  - Use the nicotine lozenge (2 mg or 4 mg) as needed to manage cravings, typically 1 lozenge every 1-2 hours during Weeks 7 to 9.\n",
      "- Gradually reduce the number of lozenges used per day, aiming for a maximum of 6-8 lozenges daily during this period.\n",
      "- Continue to avoid using the lozenge more than 20 times per day to prevent overuse.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.1\n",
      "prediction:  - Use the nicotine lozenge (2 mg or 4 mg) as needed to manage cravings, typically aiming for 1 lozenge every 1-2 hours during Weeks 7 to 9.\n",
      "- Gradually reduce the number of lozenges used as you approach the end of the 12-week schedule, focusing on tapering down from the initial frequency.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.162791\n",
      "prediction:  - Use the nicotine lozenge 1 to 2 times per hour during Weeks 7 to 9.\n",
      "- Do not exceed 5 lozenges in a 6-hour period during this phase.\n",
      "- Gradually reduce the number of lozenges used as you approach the end of the 12-week schedule.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.166008\n",
      "prediction:  - Use the nicotine lozenge 1 to 2 times per hour during Weeks 7 to 9.\n",
      "- Do not exceed a maximum of 5 lozenges in a 6-hour period.\n",
      "- Gradually reduce the number of lozenges used as you approach the end of the 12-week schedule.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.135714\n",
      "prediction:  - Use the nicotine lozenge 1 to 2 times per week during Weeks 7 to 9.\n",
      "- Gradually reduce the frequency of use as you approach the end of the 12-week schedule.\n",
      "- Ensure not to exceed the maximum recommended dosage of lozenges per day during this period.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.135231\n",
      "prediction:  - Use the nicotine lozenge 1 to 2 times per week during Weeks 7 to 9.\n",
      "- Gradually reduce the frequency of use as you approach the end of the 12-week schedule.\n",
      "- Ensure not to exceed the maximum recommended dosage of nicotine lozenges during this period.\n",
      "pred_SIM:  A\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.187692\n",
      "prediction:  - Users of WL-AAB-Z-W-1350 should avoid wearing contact lenses while using the medication, as it may cause dryness or irritation in the eyes.\n",
      "- It is recommended to switch to glasses during the treatment period with WL-AAB-Z-W-1350 to prevent discomfort and potential complications.\n",
      "- If contact lens use is necessary, consult with an eye care professional for appropriate recommendations and possible alternatives.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D'], ['C', 'A', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Contact lenses should be removed prior to instillation and reinserted 15 minutes after administration.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.162311\n",
      "prediction:  - Users of WL-AAB-Z-W-1350 should avoid wearing contact lenses while using the medication, as it may cause eye irritation or discomfort.\n",
      "- It is recommended to wait at least 15 minutes after applying WL-AAB-Z-W-1350 before inserting contact lenses to minimize potential adverse effects.\n",
      "- If experiencing any eye discomfort or changes in vision while using WL-AAB-Z-W-1350, users should consult their healthcare provider before continuing to wear contact lenses.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.3333333333333333, 'B': 0.5, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Contact lenses should be removed prior to instillation and reinserted 15 minutes after administration.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.087805\n",
      "prediction:  - Venlafaxine did not show a significant increase in the incidence of seizures compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher rate of psychotic symptoms associated with venlafaxine compared to the active treatment group.\n",
      "- Clinical trials did not report an increase in the risk of severe allergic reactions with venlafaxine compared to placebo.\n",
      "\n",
      "MRRV(meta) winner=B; scores={'A': 0.4166666666666667, 'B': 0.7777777777777777, 'C': 0.3611111111111111, 'D': 0.5277777777777778}; rankings=[['D', 'A', 'B', 'C'], ['B', 'C', 'D', 'A'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.091993\n",
      "prediction:  - Venlafaxine did not show a significant increase in the incidence of seizures compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher rate of psychotic symptoms associated with venlafaxine compared to the active treatment group.\n",
      "- Clinical trials did not report an increase in the risk of severe allergic reactions with venlafaxine compared to placebo.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.5555555555555555, 'C': 0.27777777777777773, 'D': 0.75}; rankings=[['B', 'A', 'C', 'D'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.130751\n",
      "0.130751\n",
      "prediction:  - Venlafaxine did not show a significant increase in the incidence of seizures compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher rate of psychotic symptoms associated with venlafaxine use compared to active treatment groups.\n",
      "- Clinical trials did not report an increase in the risk of developing tardive dyskinesia in patients treated with venlafaxine.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  E\n",
      "E\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.103044\n",
      "prediction:  - Venlafaxine did not show a significant increase in the incidence of seizures compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher rate of psychotic symptoms associated with venlafaxine use compared to active treatment groups.\n",
      "- Clinical trials did not report an increase in the risk of developing tardive dyskinesia with venlafaxine compared to other antidepressants.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.137592\n",
      "0.137592\n",
      "0.137592\n",
      "prediction:  - Venlafaxine did not show a significant increase in the incidence of seizures compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher rate of psychotic symptoms associated with venlafaxine use in the studied populations.\n",
      "- Clinical trials did not report an increased risk of severe allergic reactions linked to venlafaxine compared to active controls.\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.090177\n",
      "prediction:  - Venlafaxine did not show a significant increase in the incidence of severe weight gain compared to placebo in clinical trials.\n",
      "- There was no evidence of a higher risk of developing tardive dyskinesia associated with venlafaxine compared to active treatments like SSRIs.\n",
      "- Clinical trials did not report a notable increase in the frequency of seizures in patients taking venlafaxine compared to those receiving a placebo.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.201044\n",
      "prediction:  - Venlafaxine is approximately 27% bound to plasma proteins, which may lead to displacement interactions with drugs that are highly protein-bound, potentially increasing the free concentration of the displaced drug.\n",
      "- When venlafaxine is co-administered with highly protein-bound drugs like warfarin or phenytoin, careful monitoring is necessary due to the risk of altered pharmacokinetics and increased effects or side effects of the displaced drug.\n",
      "- The interaction may not be clinically significant for all patients, but individual variability in protein binding and metabolism can affect the overall therapeutic outcomes when venlafaxine is used alongside other medications.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.232628\n",
      "prediction:  - Venlafaxine is approximately 27% bound to plasma proteins, which may lead to displacement interactions with drugs that are highly protein-bound, potentially increasing the free concentration of the displaced drug.\n",
      "- When venlafaxine is co-administered with highly protein-bound drugs like warfarin or phenytoin, careful monitoring is necessary to avoid increased effects or toxicity of the displaced drug.\n",
      "- The interaction may not significantly alter the pharmacokinetics of venlafaxine itself, but it can affect the therapeutic outcomes of the other medications involved.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.227618\n",
      "0.227618\n",
      "prediction:  - Venlafaxine is approximately 27% bound to plasma proteins, which may lead to displacement interactions with other drugs that are highly protein-bound, potentially increasing their free concentrations.\n",
      "- When venlafaxine is administered alongside drugs like warfarin or phenytoin, which are highly protein-bound, there may be an increased risk of adverse effects due to elevated free drug levels.\n",
      "- Clinicians should monitor patients for signs of toxicity or altered therapeutic effects when venlafaxine is used in combination with other highly protein-bound medications.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.28164\n",
      "prediction:  - Venlafaxine is approximately 27% bound to plasma proteins, which may lead to increased free concentrations of other highly protein-bound drugs when co-administered.\n",
      "- When venlafaxine is taken with drugs like warfarin or phenytoin, the displacement of these drugs from plasma proteins could enhance their effects or toxicity.\n",
      "- Clinicians should monitor patients for increased effects of anticoagulants or anticonvulsants when venlafaxine is introduced into their regimen.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.28164\n",
      "prediction:  - Venlafaxine is approximately 27% bound to plasma proteins, which may lead to increased free concentrations of other highly protein-bound drugs when co-administered.\n",
      "- When venlafaxine is taken with drugs like warfarin or phenytoin, the displacement of these drugs from plasma proteins could enhance their effects or toxicity.\n",
      "- Clinicians should monitor patients for increased effects of anticoagulants or anticonvulsants when venlafaxine is part of the treatment regimen.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.180571\n",
      "prediction:  - Venlafaxine is known to be approximately 27% bound to plasma proteins, which may lead to increased free concentrations of other highly protein-bound drugs, such as warfarin, potentially enhancing their effects or side effects.\n",
      "- When venlafaxine is administered alongside drugs like phenytoin, which is highly protein-bound, there may be a displacement effect, resulting in altered pharmacokinetics and increased toxicity of phenytoin.\n",
      "- The interaction between venlafaxine and other highly protein-bound medications necessitates careful monitoring to avoid adverse effects due to changes in drug levels in the bloodstream.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.168955\n",
      "prediction:  - Venlafaxine is known to be approximately 27% bound to plasma proteins, which may lead to potential interactions with other drugs that are highly bound to plasma proteins, such as warfarin or phenytoin, potentially increasing the free concentration of these drugs.\n",
      "- When venlafaxine is administered alongside highly protein-bound medications, it may displace these drugs from their binding sites, leading to an increased risk of side effects or toxicity due to elevated free drug levels.\n",
      "- Clinicians should monitor patients closely for signs of increased effects or adverse reactions when venlafaxine is used in combination with other highly protein-bound drugs, adjusting dosages as necessary.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.176724\n",
      "prediction:  - Venlafaxine is known to be approximately 27% bound to plasma proteins, which means it has a relatively low binding affinity compared to drugs that are highly bound, potentially leading to increased free concentrations of those drugs.\n",
      "- When venlafaxine is administered alongside highly protein-bound drugs, such as warfarin or phenytoin, it may displace these drugs from their binding sites, resulting in elevated levels of the active drug in circulation.\n",
      "- The interaction can lead to an increased risk of side effects or toxicity from the highly bound drugs, necessitating careful monitoring and possible dosage adjustments when venlafaxine is co-prescribed.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.106294\n",
      "prediction:  - Venlafaxine, at doses of 10 and 30 mg/kg, produced significant drug-appropriate responding in primate studies, indicating a potential for abuse.\n",
      "- The drug's effects were compared to the active control, amphetamine, which also elicited similar drug-appropriate responses, suggesting a moderate abuse liability for venlafaxine.\n",
      "- In contrast, the placebo condition resulted in minimal drug-appropriate responding, highlighting the specific effects of venlafaxine compared to non-active substances.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: No significant stimulant or depressant abuse liability\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.111601\n",
      "0.111601\n",
      "prediction:  - Venlafaxine, at doses of 10 and 30 mg/kg, produced significant drug-appropriate responding in primates, indicating a potential for abuse.\n",
      "- The study showed that venlafaxine's effects were comparable to those of the active control, amphetamine, suggesting a moderate level of abuse liability.\n",
      "- In contrast, the placebo condition resulted in minimal drug-appropriate responding, highlighting the specific effects of venlafaxine compared to non-active substances.\n",
      "\n",
      "MRRV(meta) winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  C\n",
      "C\n",
      "correct answer: No significant stimulant or depressant abuse liability\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.201653\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication for use in patients with severe renal impairment, similar to drugs like Metformin, which is also contraindicated in this population.\n",
      "- Unlike many NSAIDs, WL-AAB-Z-W-982 does not have a contraindication for patients with a history of gastrointestinal bleeding, making it potentially safer for this group compared to drugs like Ibuprofen.\n",
      "- WL-AAB-Z-W-982 is contraindicated in pregnant women, aligning it with other medications such as ACE inhibitors, which are also not recommended during pregnancy.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "cot\n",
      "SIM_score:  0.200345\n",
      "0.200345\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication for use in patients with severe renal impairment, similar to drugs like Metformin, which is also contraindicated in this population.\n",
      "- Unlike many NSAIDs, WL-AAB-Z-W-982 does not have a contraindication for patients with a history of gastrointestinal bleeding, making it potentially safer for those individuals.\n",
      "- WL-AAB-Z-W-982 is contraindicated in pregnant women, aligning it with other medications such as ACE inhibitors, which are also not recommended during pregnancy.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.13831\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication profile that includes severe hypersensitivity reactions, which is similar to other biologics like omalizumab, known for its risk of anaphylaxis.\n",
      "- Unlike many traditional medications, WL-AAB-Z-W-982 may have specific contraindications related to concurrent use with immunosuppressants, similar to drugs like rituximab, which also has restrictions when used with other immunosuppressive therapies.\n",
      "- The contraindications for WL-AAB-Z-W-982 may also include a history of certain autoimmune disorders, paralleling the profile of drugs like adalimumab, which is contraindicated in patients with active infections or certain autoimmune conditions.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.25, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'A', 'C', 'B'], ['D', 'A', 'C', 'B'], ['D', 'A', 'C', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.141097\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication profile that includes severe hypersensitivity reactions, which is similar to other biologics like omalizumab, known for its risk of anaphylaxis.\n",
      "- Unlike many traditional medications, WL-AAB-Z-W-982 may have specific contraindications related to concurrent use with immunosuppressants, similar to drugs like rituximab, which also has restrictions when used with other immunosuppressive therapies.\n",
      "- The contraindications for WL-AAB-Z-W-982 may also include pregnancy and lactation, paralleling the safety profiles of drugs like methotrexate, which is contraindicated in these populations due to potential teratogenic effects.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.25, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'A', 'C', 'B'], ['D', 'A', 'C', 'B'], ['D', 'A', 'C', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.146853\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication profile that includes severe hypersensitivity reactions, which is similar to other biologics like omalizumab, known for its risk of anaphylaxis.\n",
      "- Unlike many traditional medications, WL-AAB-Z-W-982 may have specific contraindications related to concurrent use with immunosuppressants, similar to drugs like rituximab, which also requires caution in patients on other immunosuppressive therapies.\n",
      "- The contraindications for WL-AAB-Z-W-982 may also include specific organ dysfunctions, akin to the profile of drugs like methotrexate, which is contraindicated in patients with liver disease.\n",
      "\n",
      "MRRV(meta) winner=D; scores={'A': 0.5, 'B': 0.25, 'C': 0.3333333333333333, 'D': 1.0}; rankings=[['D', 'A', 'C', 'B'], ['D', 'A', 'C', 'B'], ['D', 'A', 'C', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.167916\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication profile that includes severe renal impairment, similar to drugs like Metformin, which is also contraindicated in patients with significant renal dysfunction.\n",
      "- Unlike some other medications, WL-AAB-Z-W-982 may have specific contraindications related to concurrent use with certain anticoagulants, similar to the profile of Warfarin, which has known interactions with various drugs.\n",
      "- The contraindications for WL-AAB-Z-W-982 may also extend to patients with a history of hypersensitivity reactions, akin to the contraindications seen with Penicillin antibiotics.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "sc\n",
      "SIM_score:  0.198319\n",
      "0.198319\n",
      "prediction:  - WL-AAB-Z-W-982 has a contraindication profile that includes severe renal impairment, similar to drugs like lisinopril, which is contraindicated in patients with a history of angioedema.\n",
      "- Unlike metformin, which is contraindicated in patients with significant renal dysfunction, WL-AAB-Z-W-982 may have additional contraindications related to hepatic impairment.\n",
      "- The contraindications for WL-AAB-Z-W-982 also extend to patients with a known hypersensitivity to its components, paralleling the profile of drugs like penicillin.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.209106\n",
      "prediction:  - Zynteglo is contraindicated in patients with active infections, which is a specific concern not typically highlighted for many other gene therapies.\n",
      "- Unlike some immunosuppressive drugs, Zynteglo does not have contraindications related to live vaccines, allowing for broader vaccination options post-treatment.\n",
      "- Zynteglo's contraindications also include hypersensitivity reactions, which may not be as prominently featured in the contraindication profiles of traditional hematopoietic stem cell therapies.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      "cot\n",
      "SIM_score:  0.207513\n",
      "0.207513\n",
      "prediction:  - Zynteglo is contraindicated in patients with active infections, which is a specific concern not typically highlighted for many other gene therapies.\n",
      "- Unlike some immunosuppressive drugs, Zynteglo does not have contraindications related to live vaccines, allowing for broader vaccination options post-treatment.\n",
      "- Zynteglo's contraindications also include hypersensitivity reactions, which may not be as prominently featured in the profiles of other gene therapies or biologics.\n",
      "pred_SIM:  A\n",
      "A\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot\n",
      "SIM_score:  0.199678\n",
      "prediction:  - Zynteglo is contraindicated in patients with active infections, which is a specific concern not universally applicable to all gene therapies.\n",
      "- Unlike some drugs that may have contraindications related to organ function (e.g., liver or kidney impairment), Zynteglo's contraindications focus more on the patient's overall immune status.\n",
      "- Zynteglo may also have specific contraindications related to hypersensitivity reactions, which can differ from traditional medications that may have broader contraindications based on age or pregnancy status.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.134091\n",
      "prediction:  - Zynteglo is contraindicated in patients with active or uncontrolled infections, which is a specific concern not typically highlighted for many conventional therapies.\n",
      "- Unlike some gene therapies, Zynteglo requires pre-treatment with chemotherapy (such as busulfan) to create space for the new gene-modified cells, which adds a layer of contraindications related to the pre-treatment regimen.\n",
      "- Zynteglo's contraindications also include hypersensitivity to any of its components, which is a common concern but may differ in severity compared to other drugs that have broader contraindications related to organ function or specific disease states.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.200608\n",
      "prediction:  - Zynteglo is contraindicated in patients with active or uncontrolled infections, which is a specific concern not typically highlighted for many other gene therapies.\n",
      "- Unlike some drugs that may have contraindications related to organ function (e.g., liver or kidney), Zynteglo's contraindications focus more on the patient's immune status and history of hypersensitivity.\n",
      "- Zynteglo requires careful consideration in patients with a history of malignancies, which may not be a common contraindication for other therapies like monoclonal antibodies or traditional chemotherapy agents.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  sc\n",
      "SIM_score:  0.194305\n",
      "prediction:  - Zynteglo is contraindicated in patients with active or uncontrolled infections, which is a specific concern not typically highlighted for many other gene therapies.\n",
      "- Unlike some immunosuppressive drugs, Zynteglo does not have contraindications related to live vaccines, allowing for broader vaccination options post-treatment.\n",
      "- The contraindication for Zynteglo includes hypersensitivity to any of its components, which is a common concern but may vary in specificity compared to other biologics or gene therapies.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.145125\n",
      "prediction:  - Zynteglo is contraindicated in patients with active or uncontrolled infections, which is a specific concern not typically highlighted in the contraindications of many conventional therapies.\n",
      "- Unlike some gene therapies, Zynteglo requires careful monitoring for hematologic malignancies, a consideration that may not be present in the contraindication profiles of standard immunosuppressive drugs.\n",
      "- The use of Zynteglo is also contraindicated in individuals with hypersensitivity to any of its components, which is a more specific requirement compared to broader contraindications seen in other treatments like traditional chemotherapy agents.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.137643\n",
      "prediction:  - Zynteglo, which is a gene therapy for beta-thalassemia, has specific contraindications related to hypersensitivity reactions and the presence of active infections, unlike traditional drugs that may have contraindications based on organ function or drug interactions.\n",
      "- Unlike many conventional therapies, Zynteglo's contraindications also include a history of certain malignancies, reflecting its unique mechanism of action and the potential for long-term effects on the patient's immune system.\n",
      "- In contrast to drugs like hydroxyurea, which may have contraindications related to pregnancy and bone marrow suppression, Zynteglo's contraindications focus more on genetic predispositions and prior treatment history.\n",
      "\n",
      "MRRV(meta) winner=C; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:    agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "SIM_score:  0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.086957\n",
      "0.019231\n",
      "0.105263\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.086957\n",
      "0.019231\n",
      "0.068966\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.019231\n",
      "0.000000\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.475000\n",
      "1.000000\n",
      "0.329787\n",
      "0.000000\n",
      "0.360870\n",
      "1.000000\n",
      "1.000000\n",
      "0.345161\n",
      "0.351852\n",
      "1.000000\n",
      "0.455556\n",
      "1.000000\n",
      "0.348276\n",
      "0.416667\n",
      "1.000000\n",
      "0.356000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.373684\n",
      "0.335897\n",
      "0.348276\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.000000\n",
      "0.323333\n",
      "1.000000\n",
      "0.326415\n",
      "0.416667\n",
      "0.337838\n",
      "1.000000\n",
      "0.346667\n",
      "0.346667\n",
      "0.346667\n",
      "0.322951\n",
      "0.343750\n",
      "0.338889\n",
      "1.000000\n",
      "0.321538\n",
      "0.416667\n",
      "0.475000\n",
      "1.000000\n",
      "0.329787\n",
      "0.000000\n",
      "0.360870\n",
      "1.000000\n",
      "1.000000\n",
      "0.345161\n",
      "0.351852\n",
      "1.000000\n",
      "0.455556\n",
      "1.000000\n",
      "0.348276\n",
      "0.416667\n",
      "1.000000\n",
      "0.356000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.373684\n",
      "0.335897\n",
      "0.348276\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.000000\n",
      "0.323333\n",
      "1.000000\n",
      "0.326415\n",
      "0.416667\n",
      "0.337838\n",
      "1.000000\n",
      "0.346667\n",
      "0.346667\n",
      "0.346667\n",
      "0.322951\n",
      "0.343750\n",
      "0.338889\n",
      "1.000000\n",
      "0.321538\n",
      "0.416667\n",
      "0.475000\n",
      "1.000000\n",
      "0.329787\n",
      "0.000000\n",
      "0.360870\n",
      "1.000000\n",
      "1.000000\n",
      "0.345161\n",
      "0.351852\n",
      "1.000000\n",
      "0.455556\n",
      "1.000000\n",
      "0.348276\n",
      "0.416667\n",
      "1.000000\n",
      "0.356000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.373684\n",
      "0.335897\n",
      "0.348276\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.000000\n",
      "0.323333\n",
      "1.000000\n",
      "0.326415\n",
      "0.416667\n",
      "0.337838\n",
      "1.000000\n",
      "0.346667\n",
      "0.346667\n",
      "0.346667\n",
      "0.322951\n",
      "0.343750\n",
      "0.338889\n",
      "1.000000\n",
      "0.321538\n",
      "0.416667\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.000000\n",
      "0.019231\n",
      "0.000000\n",
      "0.105263\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.000000\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.000000\n",
      "0.019231\n",
      "0.000000\n",
      "0.105263\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.000000\n",
      "0.019231\n",
      "0.000000\n",
      "0.105263\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.475000\n",
      "1.000000\n",
      "0.329787\n",
      "0.000000\n",
      "0.360870\n",
      "1.000000\n",
      "1.000000\n",
      "0.345161\n",
      "0.351852\n",
      "1.000000\n",
      "0.455556\n",
      "1.000000\n",
      "0.348276\n",
      "0.416667\n",
      "1.000000\n",
      "0.356000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.373684\n",
      "0.335897\n",
      "0.348276\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.000000\n",
      "0.323333\n",
      "1.000000\n",
      "0.326415\n",
      "0.416667\n",
      "0.337838\n",
      "1.000000\n",
      "0.346667\n",
      "0.346667\n",
      "0.346667\n",
      "0.322951\n",
      "0.343750\n",
      "0.338889\n",
      "1.000000\n",
      "0.321538\n",
      "0.416667\n",
      "0.475000\n",
      "1.000000\n",
      "0.329787\n",
      "0.000000\n",
      "0.360870\n",
      "1.000000\n",
      "1.000000\n",
      "0.345161\n",
      "0.351852\n",
      "1.000000\n",
      "0.455556\n",
      "1.000000\n",
      "0.348276\n",
      "0.416667\n",
      "1.000000\n",
      "0.356000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.373684\n",
      "0.335897\n",
      "0.348276\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.000000\n",
      "0.323333\n",
      "1.000000\n",
      "0.326415\n",
      "0.416667\n",
      "0.337838\n",
      "1.000000\n",
      "0.346667\n",
      "0.346667\n",
      "0.346667\n",
      "0.322951\n",
      "0.343750\n",
      "0.338889\n",
      "1.000000\n",
      "0.321538\n",
      "0.416667\n",
      "0.475000\n",
      "1.000000\n",
      "0.329787\n",
      "0.000000\n",
      "0.360870\n",
      "1.000000\n",
      "1.000000\n",
      "0.345161\n",
      "0.351852\n",
      "1.000000\n",
      "0.455556\n",
      "1.000000\n",
      "0.348276\n",
      "0.416667\n",
      "1.000000\n",
      "0.356000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.373684\n",
      "0.335897\n",
      "0.348276\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "1.000000\n",
      "0.000000\n",
      "0.323333\n",
      "1.000000\n",
      "0.326415\n",
      "0.416667\n",
      "0.337838\n",
      "1.000000\n",
      "0.346667\n",
      "0.346667\n",
      "0.346667\n",
      "0.322951\n",
      "0.343750\n",
      "0.338889\n",
      "1.000000\n",
      "0.321538\n",
      "0.416667\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.019231\n",
      "0.000000\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.019231\n",
      "0.000000\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "0.133333\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.105263\n",
      "0.066667\n",
      "0.071429\n",
      "0.200000\n",
      "0.117647\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.100000\n",
      "0.068966\n",
      "0.045455\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.200000\n",
      "0.000000\n",
      "0.086957\n",
      "0.019231\n",
      "0.000000\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.046512\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.071429\n",
      "0.038462\n",
      "0.000000\n",
      "0.000000\n",
      "0.043478\n",
      "0.054054\n",
      "0.000000\n",
      "0.000000\n",
      "0.060606\n",
      "0.000000\n",
      "0.066667\n",
      "0.039216\n",
      "prediction:  A\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "C\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "C\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "choice:          A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "        A\n",
      "correct_answer:  C\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Treatment of chronic pain conditions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.047619\n",
      "prediction:  A brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff is **Nizoral**, which contains the antifungal agent Ketoconazole. Additionally, **Head & Shoulders** is another popular brand that offers specialized formulas aimed at reducing and preventing dandruff symptoms. Both brands are well-regarded in the treatment of scalp conditions related to dandruff and provide effective relief from associated itching and flaking. \n",
      "\n",
      "Other noteworthy options include **Selsun Blue** and **Photonic Anti-Dandruff Shampoo**, both of which are formulated to control and prevent recurrence of dandruff symptoms as well.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.027004\n",
      "prediction:  A prominent brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff is **Selsun Blue**, which contains selenium sulfide. Another effective option is **Head & Shoulders**, known for its active ingredient, pyrithione zinc. These products have been clinically shown to reduce dandruff symptoms and can help maintain scalp health by targeting the fungi associated with this condition.\n",
      "\n",
      "In addition to these specific products, formulations containing **ketoconazole** and **salicylic acid** are often recommended for more severe cases of dandruff, as they provide antifungal and exfoliating properties that help alleviate symptoms. \n",
      "\n",
      "The efficacy of these active ingredients has been supported by various studies, which highlight their mechanisms in combating the underlying causes of dandruff, such as the overgrowth of specific fungal organisms like *Malassezia*.\n",
      "\n",
      "For additional context, dandruff is primarily caused by a combination of factors including increased skin cell turnover, fungal infections, and scalp irritation. Regular use of these medicated shampoos can help manage and reduce the frequency of flare-ups.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017151\n",
      "prediction:  A sitz bath is a therapeutic bath in which a person sits in warm water to relieve discomfort in the lower part of the body, particularly the genital and anal areas. When incorporating vaginal essential oils into a sitz bath, it is important to consider both the temperature of the water and the safety of the essential oils used.\n",
      "\n",
      "### Step 1: Suggested Water Temperature\n",
      "\n",
      "The recommended water temperature for a sitz bath is typically between **92Â°F to 100Â°F (33Â°C to 38Â°C)**. This range is warm enough to promote relaxation and improve blood circulation without being so hot that it causes discomfort or burns. \n",
      "\n",
      "### Step 2: Safety Considerations\n",
      "\n",
      "1. **Test the Temperature**: Before sitting in the bath, itâ€™s crucial to test the water temperature with your hand or a thermometer to ensure it is comfortable and safe.\n",
      "  \n",
      "2. **Avoid Hot Water**: Water that is too hot (above 100Â°F or 38Â°C) can lead to burns or irritation, especially in sensitive areas. It can also exacerbate certain conditions, such as inflammation or infections.\n",
      "\n",
      "### Step 3: Incorporating Essential Oils\n",
      "\n",
      "1. **Dilution**: Essential oils should always be diluted before use, especially in sensitive areas. A common practice is to add a few drops (typically 3-5 drops) of essential oil to a carrier oil (like coconut oil or almond oil) before adding it to the bathwater. This helps to prevent irritation.\n",
      "\n",
      "2. **Choosing Essential Oils**: Some essential oils that are often used for vaginal health include:\n",
      "   - **Lavender**: Known for its calming properties.\n",
      "   - **Tea Tree Oil**: Has antifungal and antibacterial properties.\n",
      "   - **Chamomile**: Soothing and anti-inflammatory.\n",
      "\n",
      "3. **Patch Test**: Before using any essential oil, itâ€™s advisable to perform a patch test on a small area of skin to check for any allergic reactions.\n",
      "\n",
      "### Step 4: Duration of the Bath\n",
      "\n",
      "A sitz bath typically lasts about **15 to 20 minutes**. This duration allows for the therapeutic effects of the warm water and essential oils to take place without causing excessive dryness or irritation.\n",
      "\n",
      "### Step 5: Post-Bath Care\n",
      "\n",
      "After the sitz bath, itâ€™s important to gently pat the area dry with a clean towel. Avoid vigorous rubbing, as this can cause irritation. If any irritation occurs, discontinue use of the essential oils and consult a healthcare provider.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the suggested water temperature for a sitz bath using vaginal essential oil is between **92Â°F to 100Â°F (33Â°C to 38Â°C)**. Always ensure that essential oils are properly diluted and perform a patch test to avoid irritation. Following these guidelines can help maximize the benefits of a sitz bath while minimizing risks.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.016559\n",
      "prediction:  A sitz bath is a therapeutic bath in which a person sits in warm water to relieve discomfort in the lower part of the body, particularly the genital and anal areas. When incorporating vaginal essential oils into a sitz bath, it is important to consider both the temperature of the water and the safety of the essential oils used.\n",
      "\n",
      "### Step 1: Suggested Water Temperature\n",
      "\n",
      "The recommended water temperature for a sitz bath is typically between **92Â°F to 100Â°F (33Â°C to 38Â°C)**. This range is warm enough to promote relaxation and improve blood circulation without being so hot that it causes discomfort or burns. \n",
      "\n",
      "### Step 2: Safety Considerations\n",
      "\n",
      "1. **Test the Temperature**: Before sitting in the bath, itâ€™s crucial to test the water temperature with your hand or a thermometer to ensure it is comfortable and safe. \n",
      "\n",
      "2. **Avoid Extreme Temperatures**: Water that is too hot (above 104Â°F or 40Â°C) can lead to burns or overheating, especially in sensitive areas. Conversely, water that is too cold may not provide the desired therapeutic effects.\n",
      "\n",
      "### Step 3: Incorporating Essential Oils\n",
      "\n",
      "When using essential oils in a sitz bath, itâ€™s important to follow these guidelines:\n",
      "\n",
      "1. **Dilution**: Essential oils should always be diluted before use. A common practice is to mix a few drops (usually 3-5 drops) of essential oil with a carrier oil (like coconut oil, almond oil, or olive oil) before adding it to the bathwater. This helps to prevent skin irritation.\n",
      "\n",
      "2. **Choosing Safe Oils**: Not all essential oils are safe for vaginal use. Some commonly recommended essential oils for sitz baths include:\n",
      "   - **Lavender**: Known for its calming properties.\n",
      "   - **Tea Tree Oil**: Has antifungal and antibacterial properties.\n",
      "   - **Chamomile**: Soothing and anti-inflammatory.\n",
      "\n",
      "3. **Patch Test**: Before using a new essential oil, perform a patch test on a small area of skin to check for any allergic reactions.\n",
      "\n",
      "### Step 4: Duration of the Bath\n",
      "\n",
      "The duration of a sitz bath is typically around **15 to 20 minutes**. This allows enough time for the warm water and essential oils to provide relief without causing skin irritation or discomfort.\n",
      "\n",
      "### Step 5: Post-Bath Care\n",
      "\n",
      "After the sitz bath, gently pat the area dry with a clean towel. Avoid vigorous rubbing, as the area may be sensitive. If any irritation occurs, discontinue use of the essential oils and consult a healthcare provider.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the suggested water temperature for a sitz bath using vaginal essential oil is between **92Â°F to 100Â°F (33Â°C to 38Â°C)**. Always ensure proper dilution of essential oils, choose safe options, and monitor for any adverse reactions. This approach can help maximize the therapeutic benefits of the sitz bath while minimizing risks.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.019295\n",
      "prediction:  A sitz bath is a therapeutic bath in which a person sits in warm water to relieve discomfort in the lower part of the body, particularly the genital and anal areas. When incorporating vaginal essential oils into a sitz bath, it is important to consider both the temperature of the water and the safety of the essential oils used.\n",
      "\n",
      "### Step 1: Suggested Water Temperature\n",
      "The recommended water temperature for a sitz bath is typically between **92Â°F to 100Â°F (33Â°C to 38Â°C)**. This range is warm enough to promote relaxation and improve blood circulation without being so hot that it causes discomfort or burns. \n",
      "\n",
      "### Step 2: Safety Considerations\n",
      "1. **Test the Temperature**: Before sitting in the bath, itâ€™s advisable to test the water temperature with your wrist or elbow to ensure it feels comfortable and not too hot.\n",
      "2. **Avoid Extreme Temperatures**: Water that is too hot (above 104Â°F or 40Â°C) can lead to burns or overheating, especially in sensitive areas.\n",
      "\n",
      "### Step 3: Incorporating Essential Oils\n",
      "When using essential oils in a sitz bath, itâ€™s crucial to dilute them properly to avoid irritation. Here are some guidelines:\n",
      "\n",
      "1. **Dilution**: Essential oils should be diluted in a carrier oil (like coconut oil, almond oil, or olive oil) before being added to the bath. A common dilution ratio is about **5-10 drops of essential oil per tablespoon of carrier oil**.\n",
      "2. **Choose Safe Oils**: Not all essential oils are safe for vaginal use. Some commonly recommended oils for sitz baths include:\n",
      "   - **Lavender**: Known for its calming properties.\n",
      "   - **Tea Tree Oil**: Has antifungal and antibacterial properties.\n",
      "   - **Chamomile**: Soothing and anti-inflammatory.\n",
      "   - **Frankincense**: Known for its healing properties.\n",
      "\n",
      "### Step 4: Preparing the Sitz Bath\n",
      "1. **Fill the Bath**: Fill a basin or bathtub with warm water at the recommended temperature.\n",
      "2. **Add Essential Oils**: Mix the diluted essential oil into the water. Stir gently to ensure even distribution.\n",
      "3. **Soak**: Sit in the bath for about **15-20 minutes** to allow the warm water and essential oils to provide relief.\n",
      "\n",
      "### Step 5: Post-Bath Care\n",
      "After the sitz bath, itâ€™s important to gently pat the area dry with a clean towel. Avoid vigorous rubbing, as this can cause irritation. \n",
      "\n",
      "### Conclusion\n",
      "In summary, the suggested water temperature for a sitz bath using vaginal essential oil is between **92Â°F to 100Â°F (33Â°C to 38Â°C)**. Always ensure that essential oils are properly diluted and that you choose safe oils for use in sensitive areas. Following these guidelines can help maximize the therapeutic benefits of a sitz bath while minimizing the risk of irritation or discomfort.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.023235\n",
      "prediction:  A sitz bath is a therapeutic bath in which a person sits in warm water to relieve discomfort in the lower part of the body, particularly the genital and anal areas. When incorporating vaginal essential oils into a sitz bath, it is important to consider both the water temperature and the safety of the essential oils used.\n",
      "\n",
      "**Suggested Water Temperature:**\n",
      "The recommended water temperature for a sitz bath is typically between 92Â°F to 100Â°F (33Â°C to 38Â°C). This range is warm enough to promote relaxation and improve blood circulation without being so hot that it causes discomfort or burns. \n",
      "\n",
      "**Considerations for Essential Oils:**\n",
      "1. **Dilution:** Essential oils should always be diluted before being added to a sitz bath. A common dilution ratio is to mix a few drops (usually 3-5) of essential oil with a carrier oil (like coconut oil, almond oil, or olive oil) before adding it to the bathwater. This helps to prevent skin irritation.\n",
      "\n",
      "2. **Skin Sensitivity:** Individuals may have varying sensitivities to essential oils. It is advisable to perform a patch test on a small area of skin before using a new essential oil in a sitz bath.\n",
      "\n",
      "3. **Choosing Essential Oils:** Some essential oils that are often recommended for vaginal health include tea tree oil (known for its antifungal properties), lavender (for its calming effects), and chamomile (for its soothing properties). However, it is crucial to ensure that the essential oils used are safe for vaginal use.\n",
      "\n",
      "4. **Consultation with Healthcare Provider:** Before using essential oils in a sitz bath, especially for therapeutic purposes, it is wise to consult with a healthcare provider. This is particularly important for individuals with existing health conditions, pregnant women, or those who are breastfeeding.\n",
      "\n",
      "5. **Duration of the Bath:** A sitz bath typically lasts about 15 to 20 minutes. It is important to stay hydrated and to listen to your body during the bath.\n",
      "\n",
      "In summary, the ideal water temperature for a sitz bath with vaginal essential oils is between 92Â°F to 100Â°F (33Â°C to 38Â°C). Always ensure proper dilution of essential oils, consider individual sensitivities, and consult with a healthcare provider for personalized advice.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021355\n",
      "prediction:  A sitz bath is a therapeutic bath in which an individual sits in warm water to relieve discomfort in the lower part of the body, particularly the genital and anal areas. When incorporating vaginal essential oils into a sitz bath, it is important to consider both the temperature of the water and the safety of the essential oils used.\n",
      "\n",
      "**Suggested Water Temperature:**\n",
      "The recommended water temperature for a sitz bath is typically between 92Â°F to 100Â°F (33Â°C to 38Â°C). This range is warm enough to promote relaxation and improve blood circulation without being so hot that it causes discomfort or burns. \n",
      "\n",
      "**Considerations for Temperature:**\n",
      "1. **Personal Comfort:** Individual tolerance to heat can vary, so itâ€™s essential to ensure that the water feels comfortable. It should be warm but not scalding.\n",
      "2. **Safety Precautions:** Always test the water temperature with your hand or a thermometer before entering the bath. If you have any conditions that affect your sensitivity to heat (such as diabetes or certain skin conditions), consult a healthcare provider for personalized advice.\n",
      "\n",
      "**Using Essential Oils:**\n",
      "When adding vaginal essential oils to a sitz bath, itâ€™s crucial to use them safely:\n",
      "1. **Dilution:** Essential oils should be diluted properly before use. A common recommendation is to mix a few drops of essential oil with a carrier oil (like coconut oil or almond oil) before adding it to the bathwater. This helps prevent irritation.\n",
      "2. **Choosing Oils:** Not all essential oils are suitable for vaginal use. Safe options may include lavender, tea tree, or chamomile, but itâ€™s best to consult with a healthcare professional to ensure the oils are appropriate for your specific needs.\n",
      "3. **Allergies and Sensitivities:** Be aware of any allergies or sensitivities to essential oils. Conduct a patch test on a small area of skin before using them in a sitz bath.\n",
      "\n",
      "**Duration of the Bath:**\n",
      "Typically, a sitz bath lasts about 15 to 20 minutes. This duration allows for adequate relief while minimizing the risk of skin irritation or discomfort.\n",
      "\n",
      "**Conclusion:**\n",
      "In summary, the ideal water temperature for a sitz bath with vaginal essential oils is between 92Â°F to 100Â°F (33Â°C to 38Â°C). Always prioritize comfort and safety by testing the water temperature, diluting essential oils properly, and consulting with a healthcare provider if you have any concerns or specific health conditions.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020627\n",
      "prediction:  A sitz bath is a therapeutic bath in which an individual sits in warm water to relieve discomfort in the lower part of the body, particularly the genital and anal areas. When incorporating vaginal essential oils into a sitz bath, it is important to consider both the temperature of the water and the safety of the essential oils used.\n",
      "\n",
      "**Suggested Water Temperature:**\n",
      "The recommended water temperature for a sitz bath typically ranges from 92Â°F to 100Â°F (approximately 33Â°C to 38Â°C). This temperature range is warm enough to promote relaxation and improve blood circulation without causing discomfort or burns. It is crucial to ensure that the water is not too hot, as excessive heat can lead to skin irritation or exacerbate certain conditions.\n",
      "\n",
      "**Preparation and Use:**\n",
      "1. **Fill the Bath:** Start by filling a clean basin or bathtub with warm water, ensuring that the temperature is comfortable to the touch. You can use a thermometer to check the temperature if needed.\n",
      "   \n",
      "2. **Add Essential Oils:** If you choose to add vaginal essential oils, select those that are safe for topical use and specifically formulated for sensitive areas. Common essential oils that may be used include lavender, tea tree, or chamomile, known for their soothing and anti-inflammatory properties. Always dilute essential oils in a carrier oil (like coconut or almond oil) before adding them to the bath to prevent irritation.\n",
      "\n",
      "3. **Duration:** Sit in the bath for about 15 to 20 minutes, allowing the warm water and essential oils to provide relief. \n",
      "\n",
      "4. **Post-Bath Care:** After the sitz bath, gently pat the area dry with a clean towel. Avoid vigorous rubbing, as this can cause irritation.\n",
      "\n",
      "**Safety Considerations:**\n",
      "- **Consult a Healthcare Provider:** Before using essential oils, especially for sensitive areas, consult with a healthcare provider to ensure they are appropriate for your specific condition.\n",
      "- **Patch Test:** If you are using a new essential oil, perform a patch test on a small area of skin to check for any allergic reactions before using it in a sitz bath.\n",
      "- **Avoid Irritants:** Be cautious with the use of essential oils if you have any existing skin conditions, infections, or sensitivities.\n",
      "\n",
      "In summary, the ideal water temperature for a sitz bath with vaginal essential oils is between 92Â°F and 100Â°F. Always prioritize safety and comfort, and consult with a healthcare professional if you have any concerns or questions regarding the use of essential oils in this context.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.030067\n",
      "prediction:  A sitz bath is a therapeutic bath in which only the hips and buttocks are submerged in warm water, often recommended for various medical conditions, including postpartum healing and hemorrhoid relief. When using vaginal essential oils in a sitz bath, it is important to consider the water temperature for maximum effectiveness and comfort.\n",
      "\n",
      "**Recommended Water Temperature:**\n",
      "The generally suggested water temperature for a sitz bath is warm, typically around 37-40 degrees Celsius (98.6-104 degrees Fahrenheit). This warm temperature helps to soothe and relax the pelvic region and can aid in alleviating symptoms associated with discomfort or inflammation.\n",
      "\n",
      "**Essential Oil Use:**\n",
      "When incorporating essential oils into the sitz bath, it is advised to add about 3-5 drops of your chosen essential oil to the warm water and stir well to ensure proper distribution. Common essential oils for this purpose include tea tree oil, lavender, or chamomile, known for their soothing properties. \n",
      "\n",
      "**Duration of the Bath:**\n",
      "It is usually recommended to sit in the warm water for 10-15 minutes to allow for effective absorption of the beneficial properties of the essential oils while enjoying the soothing effect of the warm water.\n",
      "\n",
      "**Cautions:**\n",
      "Always ensure that the water is not too hot to avoid burns or discomfort, especially for sensitive areas. It is also wise to consult with a healthcare professional if you are unsure about specific essential oils, particularly if you have underlying conditions or are postpartum.\n",
      "\n",
      "For more detailed guidance, a resource discussing the preparation of a sitz bath can be found [here](https://www.ilterozer.com/en/blog/warm-sitz-bath), which provides practical tips on achieving the right temperature and incorporating oils safely.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.044568\n",
      "prediction:  A sitz bath is a therapeutic bath that focuses on the pelvic region, providing relief for various ailments. When using vaginal essential oils in a sitz bath, the suggested water temperature typically ranges from 95 to 105 degrees Fahrenheit (approximately 35 to 41 degrees Celsius). \n",
      "\n",
      "This temperature range is warm enough to promote relaxation and stimulate blood circulation without being uncomfortably hot. It is also important to ensure that the water level is not higher than the navel to create an effective sitz bath experience. Additionally, it is advisable to add the essential oils only after the bath has been filled, as introducing oils to hot water can cause them to evaporate quickly, reducing their therapeutic effects.\n",
      "\n",
      "For specific oils, tea tree oil is often recommended for its antiseptic properties, while other oils may be chosen based on their intended therapeutic effects. Make sure to consult with a healthcare professional if you have any medical concerns or specific conditions before using essential oils in a sitz bath.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.044099\n",
      "prediction:  A widely recognized brand name drug specifically indicated for the treatment of acne is **Accutane**, which is the brand name for **isotretinoin**. Isotretinoin is a powerful retinoid that is primarily used for severe cases of acne that do not respond to other treatments. It works by decreasing the amount of oil released by oil glands in the skin and helping the skin renew itself more quickly.\n",
      "\n",
      "Other brand name options include **AvÃ¨ne Cleanance** and **Differin**, which contains adapalene, a topical retinoid effective in treating acne. \n",
      "\n",
      "Itâ€™s important to note that while these medications are effective, they also come with potential side effects and risks, which should be discussed with a healthcare provider before starting treatment.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.096091\n",
      "prediction:  AIRSUPRA, a combination of albuterol sulfate and budesonide, is primarily used for asthma management. However, the effect of renal impairment on its pharmacokinetics is not well-documented in the literature. \n",
      "\n",
      "According to the labeling for AIRSUPRA, there are no specific clinical studies addressing its use in patients with renal impairment. A related examination on the pharmacokinetics of albuterol, one of its components, was conducted involving patients with varying levels of renal function (creatinine clearance of 7 to 53 mL/min). In this study, the results from these patients were compared to those from healthy volunteers. However, detailed pharmacokinetic changes due to renal impairment in AIRSUPRA specifically were not provided.\n",
      "\n",
      "Given the lack of direct studies, clinicians are advised to proceed with caution when prescribing AIRSUPRA to patients with renal impairment and consider monitoring for potential accumulation and adverse effects. Further research may be needed to elucidate the implications fully. For current patients, it's essential to tailor dosing and monitor response carefully, particularly in cases of significant renal compromise.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: No formal pharmacokinetic studies have been conducted.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.260870\n",
      "0.100000\n",
      "0.047619\n",
      "0.048193\n",
      "0.133333\n",
      "0.148148\n",
      "0.098361\n",
      "0.111111\n",
      "0.095238\n",
      "0.037736\n",
      "0.000000\n",
      "0.121212\n",
      "0.111111\n",
      "0.078947\n",
      "0.074074\n",
      "0.090909\n",
      "0.157895\n",
      "0.111111\n",
      "0.160000\n",
      "0.160000\n",
      "0.133333\n",
      "0.000000\n",
      "0.100000\n",
      "0.105263\n",
      "0.111111\n",
      "0.083333\n",
      "0.142857\n",
      "0.162162\n",
      "0.076923\n",
      "0.083333\n",
      "0.166667\n",
      "0.160000\n",
      "0.070175\n",
      "0.044444\n",
      "0.093023\n",
      "0.222222\n",
      "0.120000\n",
      "0.129032\n",
      "0.060606\n",
      "0.051282\n",
      "0.054054\n",
      "0.057143\n",
      "0.181818\n",
      "0.114286\n",
      "0.042553\n",
      "0.083333\n",
      "0.160000\n",
      "0.102564\n",
      "0.148148\n",
      "0.166667\n",
      "0.066667\n",
      "0.173913\n",
      "0.033333\n",
      "0.080000\n",
      "0.074074\n",
      "0.105263\n",
      "0.095238\n",
      "0.048780\n",
      "0.146341\n",
      "0.064516\n",
      "0.150000\n",
      "0.101695\n",
      "0.260870\n",
      "0.100000\n",
      "0.047619\n",
      "0.048193\n",
      "0.133333\n",
      "0.148148\n",
      "0.098361\n",
      "0.111111\n",
      "0.095238\n",
      "0.037736\n",
      "0.000000\n",
      "0.121212\n",
      "0.111111\n",
      "0.078947\n",
      "0.074074\n",
      "0.090909\n",
      "0.157895\n",
      "0.111111\n",
      "0.160000\n",
      "0.160000\n",
      "0.133333\n",
      "0.000000\n",
      "0.100000\n",
      "0.111111\n",
      "0.068966\n",
      "0.083333\n",
      "0.142857\n",
      "0.162162\n",
      "0.076923\n",
      "0.083333\n",
      "0.166667\n",
      "0.160000\n",
      "0.070175\n",
      "0.044444\n",
      "0.093023\n",
      "0.222222\n",
      "0.120000\n",
      "0.129032\n",
      "0.086957\n",
      "0.060606\n",
      "0.051282\n",
      "0.054054\n",
      "0.057143\n",
      "0.181818\n",
      "0.114286\n",
      "0.042553\n",
      "0.083333\n",
      "0.160000\n",
      "0.102564\n",
      "0.148148\n",
      "0.166667\n",
      "0.066667\n",
      "0.173913\n",
      "0.033333\n",
      "0.080000\n",
      "0.074074\n",
      "0.105263\n",
      "0.095238\n",
      "0.048780\n",
      "0.146341\n",
      "0.064516\n",
      "0.150000\n",
      "0.101695\n",
      "0.260870\n",
      "0.100000\n",
      "0.047619\n",
      "0.048193\n",
      "0.133333\n",
      "0.148148\n",
      "0.098361\n",
      "0.111111\n",
      "0.095238\n",
      "0.037736\n",
      "0.000000\n",
      "0.121212\n",
      "0.111111\n",
      "0.078947\n",
      "0.074074\n",
      "0.090909\n",
      "0.157895\n",
      "0.111111\n",
      "0.160000\n",
      "0.160000\n",
      "0.133333\n",
      "0.000000\n",
      "0.100000\n",
      "0.111111\n",
      "0.083333\n",
      "0.142857\n",
      "0.162162\n",
      "0.076923\n",
      "0.083333\n",
      "0.166667\n",
      "0.160000\n",
      "0.070175\n",
      "0.044444\n",
      "0.093023\n",
      "0.222222\n",
      "0.120000\n",
      "0.129032\n",
      "0.060606\n",
      "0.051282\n",
      "0.054054\n",
      "0.057143\n",
      "0.181818\n",
      "0.114286\n",
      "0.042553\n",
      "0.083333\n",
      "0.160000\n",
      "0.102564\n",
      "0.148148\n",
      "0.166667\n",
      "0.066667\n",
      "0.173913\n",
      "0.033333\n",
      "0.080000\n",
      "0.074074\n",
      "0.105263\n",
      "0.095238\n",
      "0.048780\n",
      "0.146341\n",
      "0.064516\n",
      "0.150000\n",
      "0.101695\n",
      "0.260870\n",
      "0.100000\n",
      "0.047619\n",
      "0.048193\n",
      "0.133333\n",
      "0.148148\n",
      "0.098361\n",
      "0.111111\n",
      "0.095238\n",
      "0.037736\n",
      "0.000000\n",
      "0.121212\n",
      "0.111111\n",
      "0.078947\n",
      "0.074074\n",
      "0.090909\n",
      "0.157895\n",
      "0.111111\n",
      "0.160000\n",
      "0.160000\n",
      "0.133333\n",
      "0.000000\n",
      "0.100000\n",
      "0.111111\n",
      "0.083333\n",
      "0.142857\n",
      "0.162162\n",
      "0.076923\n",
      "0.083333\n",
      "0.166667\n",
      "0.160000\n",
      "0.070175\n",
      "0.044444\n",
      "0.093023\n",
      "0.222222\n",
      "0.120000\n",
      "0.129032\n",
      "0.060606\n",
      "0.051282\n",
      "0.054054\n",
      "0.181818\n",
      "0.114286\n",
      "0.042553\n",
      "0.083333\n",
      "0.160000\n",
      "0.102564\n",
      "0.148148\n",
      "0.166667\n",
      "0.066667\n",
      "0.173913\n",
      "0.033333\n",
      "0.080000\n",
      "0.074074\n",
      "0.105263\n",
      "0.095238\n",
      "0.048780\n",
      "0.146341\n",
      "0.064516\n",
      "0.150000\n",
      "0.101695\n",
      "0.260870\n",
      "0.100000\n",
      "0.047619\n",
      "0.048193\n",
      "0.133333\n",
      "0.148148\n",
      "0.098361\n",
      "0.111111\n",
      "0.095238\n",
      "0.037736\n",
      "0.000000\n",
      "0.121212\n",
      "0.111111\n",
      "0.078947\n",
      "0.074074\n",
      "0.090909\n",
      "0.157895\n",
      "0.111111\n",
      "0.160000\n",
      "0.160000\n",
      "0.133333\n",
      "0.000000\n",
      "0.100000\n",
      "0.111111\n",
      "0.083333\n",
      "0.142857\n",
      "0.162162\n",
      "0.076923\n",
      "0.083333\n",
      "0.166667\n",
      "0.160000\n",
      "0.070175\n",
      "0.044444\n",
      "0.093023\n",
      "0.222222\n",
      "0.120000\n",
      "0.129032\n",
      "0.060606\n",
      "0.051282\n",
      "0.054054\n",
      "0.057143\n",
      "0.181818\n",
      "0.114286\n",
      "0.042553\n",
      "0.083333\n",
      "0.160000\n",
      "0.102564\n",
      "0.148148\n",
      "0.166667\n",
      "0.066667\n",
      "0.173913\n",
      "0.033333\n",
      "0.080000\n",
      "0.074074\n",
      "0.105263\n",
      "0.095238\n",
      "0.048780\n",
      "0.146341\n",
      "0.064516\n",
      "0.150000\n",
      "0.101695\n",
      "0.260870\n",
      "0.100000\n",
      "0.047619\n",
      "0.048193\n",
      "0.133333\n",
      "0.148148\n",
      "0.098361\n",
      "0.111111\n",
      "0.095238\n",
      "0.037736\n",
      "0.000000\n",
      "0.121212\n",
      "0.111111\n",
      "0.078947\n",
      "0.074074\n",
      "0.090909\n",
      "0.157895\n",
      "0.111111\n",
      "0.160000\n",
      "0.160000\n",
      "0.133333\n",
      "0.000000\n",
      "0.100000\n",
      "0.111111\n",
      "0.083333\n",
      "0.142857\n",
      "0.162162\n",
      "0.076923\n",
      "0.083333\n",
      "0.166667\n",
      "0.160000\n",
      "0.070175\n",
      "0.044444\n",
      "0.093023\n",
      "0.222222\n",
      "0.120000\n",
      "0.129032\n",
      "0.060606\n",
      "0.051282\n",
      "0.054054\n",
      "0.057143\n",
      "0.181818\n",
      "0.114286\n",
      "0.042553\n",
      "0.083333\n",
      "0.160000\n",
      "0.102564\n",
      "0.148148\n",
      "0.166667\n",
      "0.066667\n",
      "0.173913\n",
      "0.033333\n",
      "0.080000\n",
      "0.074074\n",
      "0.105263\n",
      "0.095238\n",
      "0.048780\n",
      "0.146341\n",
      "0.064516\n",
      "0.150000\n",
      "0.101695\n",
      "prediction:  ANSWER: A\n",
      "pred_SIM:  A\n",
      "B\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Salicylic Acid\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.042553\n",
      "0.066667\n",
      "0.206897\n",
      "0.088889\n",
      "0.100000\n",
      "0.193548\n",
      "0.114286\n",
      "0.100000\n",
      "0.044444\n",
      "0.133333\n",
      "0.160000\n",
      "0.042553\n",
      "0.173913\n",
      "0.054054\n",
      "0.045455\n",
      "0.054795\n",
      "0.083333\n",
      "0.153846\n",
      "0.075472\n",
      "0.057971\n",
      "0.142857\n",
      "0.081633\n",
      "0.057143\n",
      "0.052632\n",
      "0.071429\n",
      "0.061538\n",
      "0.045455\n",
      "0.051282\n",
      "0.030303\n",
      "0.072727\n",
      "0.095238\n",
      "0.114286\n",
      "0.030303\n",
      "0.125000\n",
      "0.054795\n",
      "0.068966\n",
      "0.048780\n",
      "0.114286\n",
      "0.125000\n",
      "0.133333\n",
      "0.065574\n",
      "0.054795\n",
      "0.133333\n",
      "0.125000\n",
      "0.117647\n",
      "0.102564\n",
      "0.111111\n",
      "0.142857\n",
      "0.067797\n",
      "0.153846\n",
      "0.117647\n",
      "0.146341\n",
      "0.080000\n",
      "0.153846\n",
      "0.097561\n",
      "0.045455\n",
      "0.153846\n",
      "0.153846\n",
      "0.036364\n",
      "0.080000\n",
      "0.073171\n",
      "0.083333\n",
      "0.000000\n",
      "0.093023\n",
      "0.105263\n",
      "0.086957\n",
      "0.074074\n",
      "0.076923\n",
      "0.102564\n",
      "0.071429\n",
      "0.058824\n",
      "0.102564\n",
      "0.113208\n",
      "0.148148\n",
      "0.065574\n",
      "0.102564\n",
      "0.108108\n",
      "0.045455\n",
      "0.077922\n",
      "0.200000\n",
      "0.075472\n",
      "0.102564\n",
      "0.080000\n",
      "0.035088\n",
      "0.083333\n",
      "0.071429\n",
      "0.029851\n",
      "0.038462\n",
      "0.042553\n",
      "0.066667\n",
      "0.206897\n",
      "0.088889\n",
      "0.100000\n",
      "0.193548\n",
      "0.114286\n",
      "0.100000\n",
      "0.044444\n",
      "0.133333\n",
      "0.160000\n",
      "0.042553\n",
      "0.173913\n",
      "0.054054\n",
      "0.045455\n",
      "0.054795\n",
      "0.083333\n",
      "0.153846\n",
      "0.075472\n",
      "0.057971\n",
      "0.142857\n",
      "0.081633\n",
      "0.057143\n",
      "0.052632\n",
      "0.071429\n",
      "0.061538\n",
      "0.045455\n",
      "0.051282\n",
      "0.030303\n",
      "0.072727\n",
      "0.095238\n",
      "0.114286\n",
      "0.030303\n",
      "0.125000\n",
      "0.105263\n",
      "0.054795\n",
      "0.048780\n",
      "0.114286\n",
      "0.125000\n",
      "0.133333\n",
      "0.065574\n",
      "0.054795\n",
      "0.133333\n",
      "0.125000\n",
      "0.117647\n",
      "0.102564\n",
      "0.111111\n",
      "0.142857\n",
      "0.067797\n",
      "0.153846\n",
      "0.117647\n",
      "0.146341\n",
      "0.080000\n",
      "0.153846\n",
      "0.097561\n",
      "0.045455\n",
      "0.153846\n",
      "0.153846\n",
      "0.036364\n",
      "0.080000\n",
      "0.073171\n",
      "0.083333\n",
      "0.000000\n",
      "0.093023\n",
      "0.105263\n",
      "0.086957\n",
      "0.074074\n",
      "0.076923\n",
      "0.102564\n",
      "0.071429\n",
      "0.058824\n",
      "0.102564\n",
      "0.113208\n",
      "0.148148\n",
      "0.065574\n",
      "0.102564\n",
      "0.108108\n",
      "0.045455\n",
      "0.077922\n",
      "0.200000\n",
      "0.075472\n",
      "0.102564\n",
      "0.080000\n",
      "0.035088\n",
      "0.083333\n",
      "0.071429\n",
      "0.029851\n",
      "0.043478\n",
      "0.038462\n",
      "0.042553\n",
      "0.066667\n",
      "0.206897\n",
      "0.088889\n",
      "0.100000\n",
      "0.193548\n",
      "0.114286\n",
      "0.100000\n",
      "0.044444\n",
      "0.133333\n",
      "0.160000\n",
      "0.042553\n",
      "0.173913\n",
      "0.054054\n",
      "0.045455\n",
      "0.054795\n",
      "0.083333\n",
      "0.153846\n",
      "0.075472\n",
      "0.057971\n",
      "0.142857\n",
      "0.081633\n",
      "0.057143\n",
      "0.052632\n",
      "0.071429\n",
      "0.061538\n",
      "0.045455\n",
      "0.051282\n",
      "0.030303\n",
      "0.072727\n",
      "0.095238\n",
      "0.114286\n",
      "0.030303\n",
      "0.125000\n",
      "0.105263\n",
      "0.054795\n",
      "0.068966\n",
      "0.048780\n",
      "0.114286\n",
      "0.125000\n",
      "0.133333\n",
      "0.065574\n",
      "0.054795\n",
      "0.133333\n",
      "0.125000\n",
      "0.117647\n",
      "0.102564\n",
      "0.111111\n",
      "0.142857\n",
      "0.067797\n",
      "0.153846\n",
      "0.117647\n",
      "0.146341\n",
      "0.080000\n",
      "0.153846\n",
      "0.097561\n",
      "0.045455\n",
      "0.153846\n",
      "0.153846\n",
      "0.036364\n",
      "0.080000\n",
      "0.073171\n",
      "0.083333\n",
      "0.000000\n",
      "0.093023\n",
      "0.105263\n",
      "0.086957\n",
      "0.074074\n",
      "0.076923\n",
      "0.102564\n",
      "0.071429\n",
      "0.058824\n",
      "0.102564\n",
      "0.113208\n",
      "0.148148\n",
      "0.065574\n",
      "0.102564\n",
      "0.108108\n",
      "0.045455\n",
      "0.077922\n",
      "0.200000\n",
      "0.075472\n",
      "0.102564\n",
      "0.080000\n",
      "0.035088\n",
      "0.083333\n",
      "0.071429\n",
      "0.029851\n",
      "0.038462\n",
      "0.042553\n",
      "0.066667\n",
      "0.206897\n",
      "0.088889\n",
      "0.100000\n",
      "0.193548\n",
      "0.114286\n",
      "0.100000\n",
      "0.044444\n",
      "0.133333\n",
      "0.160000\n",
      "0.042553\n",
      "0.173913\n",
      "0.054054\n",
      "0.045455\n",
      "0.054795\n",
      "0.083333\n",
      "0.153846\n",
      "0.075472\n",
      "0.057971\n",
      "0.142857\n",
      "0.081633\n",
      "0.057143\n",
      "0.052632\n",
      "0.071429\n",
      "0.061538\n",
      "0.045455\n",
      "0.051282\n",
      "0.030303\n",
      "0.072727\n",
      "0.095238\n",
      "0.114286\n",
      "0.030303\n",
      "0.125000\n",
      "0.105263\n",
      "0.054795\n",
      "0.068966\n",
      "0.048780\n",
      "0.114286\n",
      "0.125000\n",
      "0.133333\n",
      "0.065574\n",
      "0.054795\n",
      "0.133333\n",
      "0.125000\n",
      "0.117647\n",
      "0.102564\n",
      "0.111111\n",
      "0.142857\n",
      "0.067797\n",
      "0.153846\n",
      "0.117647\n",
      "0.146341\n",
      "0.080000\n",
      "0.153846\n",
      "0.097561\n",
      "0.057143\n",
      "0.045455\n",
      "0.153846\n",
      "0.153846\n",
      "0.036364\n",
      "0.080000\n",
      "0.073171\n",
      "0.083333\n",
      "0.000000\n",
      "0.093023\n",
      "0.105263\n",
      "0.086957\n",
      "0.074074\n",
      "0.076923\n",
      "0.102564\n",
      "0.071429\n",
      "0.058824\n",
      "0.102564\n",
      "0.113208\n",
      "0.148148\n",
      "0.065574\n",
      "0.102564\n",
      "0.108108\n",
      "0.045455\n",
      "0.077922\n",
      "0.200000\n",
      "0.075472\n",
      "0.102564\n",
      "0.080000\n",
      "0.035088\n",
      "0.083333\n",
      "0.071429\n",
      "0.029851\n",
      "0.038462\n",
      "0.042553\n",
      "0.066667\n",
      "0.206897\n",
      "0.088889\n",
      "0.100000\n",
      "0.193548\n",
      "0.114286\n",
      "0.100000\n",
      "0.044444\n",
      "0.133333\n",
      "0.160000\n",
      "0.042553\n",
      "0.173913\n",
      "0.054054\n",
      "0.045455\n",
      "0.054795\n",
      "0.083333\n",
      "0.153846\n",
      "0.075472\n",
      "0.057971\n",
      "0.142857\n",
      "0.081633\n",
      "0.057143\n",
      "0.052632\n",
      "0.071429\n",
      "0.061538\n",
      "0.045455\n",
      "0.051282\n",
      "0.030303\n",
      "0.072727\n",
      "0.095238\n",
      "0.114286\n",
      "0.030303\n",
      "0.125000\n",
      "0.105263\n",
      "0.054795\n",
      "0.068966\n",
      "0.048780\n",
      "0.114286\n",
      "0.125000\n",
      "0.133333\n",
      "0.065574\n",
      "0.054795\n",
      "0.133333\n",
      "0.125000\n",
      "0.117647\n",
      "0.102564\n",
      "0.111111\n",
      "0.142857\n",
      "0.067797\n",
      "0.153846\n",
      "0.117647\n",
      "0.146341\n",
      "0.080000\n",
      "0.153846\n",
      "0.097561\n",
      "0.045455\n",
      "0.153846\n",
      "0.153846\n",
      "0.036364\n",
      "0.080000\n",
      "0.073171\n",
      "0.083333\n",
      "0.000000\n",
      "0.093023\n",
      "0.105263\n",
      "0.086957\n",
      "0.074074\n",
      "0.076923\n",
      "0.102564\n",
      "0.071429\n",
      "0.058824\n",
      "0.102564\n",
      "0.113208\n",
      "0.148148\n",
      "0.065574\n",
      "0.102564\n",
      "0.108108\n",
      "0.045455\n",
      "0.077922\n",
      "0.200000\n",
      "0.075472\n",
      "0.102564\n",
      "0.080000\n",
      "0.035088\n",
      "0.083333\n",
      "0.071429\n",
      "0.029851\n",
      "0.043478\n",
      "0.038462\n",
      "0.042553\n",
      "0.066667\n",
      "0.206897\n",
      "0.088889\n",
      "0.100000\n",
      "0.193548\n",
      "0.114286\n",
      "0.100000\n",
      "0.044444\n",
      "0.133333\n",
      "0.160000\n",
      "0.042553\n",
      "0.173913\n",
      "0.054054\n",
      "0.045455\n",
      "0.054795\n",
      "0.083333\n",
      "0.153846\n",
      "0.075472\n",
      "0.057971\n",
      "0.142857\n",
      "0.057143\n",
      "0.052632\n",
      "0.071429\n",
      "0.061538\n",
      "0.045455\n",
      "0.051282\n",
      "0.030303\n",
      "0.072727\n",
      "0.095238\n",
      "0.114286\n",
      "0.030303\n",
      "0.125000\n",
      "0.105263\n",
      "0.054795\n",
      "0.068966\n",
      "0.048780\n",
      "0.114286\n",
      "0.125000\n",
      "0.133333\n",
      "0.065574\n",
      "0.054795\n",
      "0.133333\n",
      "0.125000\n",
      "0.117647\n",
      "0.102564\n",
      "0.111111\n",
      "0.142857\n",
      "0.067797\n",
      "0.153846\n",
      "0.117647\n",
      "0.146341\n",
      "0.080000\n",
      "0.153846\n",
      "0.097561\n",
      "0.045455\n",
      "0.153846\n",
      "0.153846\n",
      "0.036364\n",
      "0.080000\n",
      "0.073171\n",
      "0.083333\n",
      "0.000000\n",
      "0.093023\n",
      "0.105263\n",
      "0.086957\n",
      "0.074074\n",
      "0.076923\n",
      "0.102564\n",
      "0.071429\n",
      "0.058824\n",
      "0.102564\n",
      "0.113208\n",
      "0.148148\n",
      "0.065574\n",
      "0.102564\n",
      "0.108108\n",
      "0.045455\n",
      "0.077922\n",
      "0.200000\n",
      "0.075472\n",
      "0.102564\n",
      "0.080000\n",
      "0.035088\n",
      "0.083333\n",
      "0.071429\n",
      "0.029851\n",
      "0.043478\n",
      "0.038462\n",
      "prediction:  ANSWER: B\n",
      "pred_SIM:  D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "A\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Plasma levels of albuterol are low, and effects on breastfed children are likely minimal.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.000000\n",
      "0.071429\n",
      "0.095238\n",
      "0.046512\n",
      "0.040000\n",
      "0.080000\n",
      "0.210526\n",
      "0.031250\n",
      "0.052632\n",
      "0.074074\n",
      "0.000000\n",
      "0.102564\n",
      "0.088889\n",
      "0.072727\n",
      "0.148148\n",
      "0.111111\n",
      "0.041667\n",
      "0.095238\n",
      "0.129032\n",
      "0.096774\n",
      "0.100000\n",
      "0.095238\n",
      "0.074074\n",
      "0.024691\n",
      "0.000000\n",
      "0.071429\n",
      "0.095238\n",
      "0.046512\n",
      "0.040000\n",
      "0.080000\n",
      "0.210526\n",
      "0.031250\n",
      "0.052632\n",
      "0.074074\n",
      "0.000000\n",
      "0.102564\n",
      "0.088889\n",
      "0.072727\n",
      "0.148148\n",
      "0.111111\n",
      "0.041667\n",
      "0.095238\n",
      "0.129032\n",
      "0.096774\n",
      "0.100000\n",
      "0.095238\n",
      "0.074074\n",
      "0.024691\n",
      "0.000000\n",
      "0.071429\n",
      "0.095238\n",
      "0.046512\n",
      "0.040000\n",
      "0.080000\n",
      "0.210526\n",
      "0.031250\n",
      "0.052632\n",
      "0.074074\n",
      "0.000000\n",
      "0.102564\n",
      "0.088889\n",
      "0.072727\n",
      "0.148148\n",
      "0.111111\n",
      "0.041667\n",
      "0.095238\n",
      "0.129032\n",
      "0.096774\n",
      "0.100000\n",
      "0.095238\n",
      "0.074074\n",
      "0.024691\n",
      "0.000000\n",
      "0.071429\n",
      "0.095238\n",
      "0.046512\n",
      "0.036364\n",
      "0.040000\n",
      "0.080000\n",
      "0.210526\n",
      "0.031250\n",
      "0.052632\n",
      "0.074074\n",
      "0.000000\n",
      "0.102564\n",
      "0.088889\n",
      "0.072727\n",
      "0.148148\n",
      "0.111111\n",
      "0.041667\n",
      "0.095238\n",
      "0.129032\n",
      "0.096774\n",
      "0.100000\n",
      "0.095238\n",
      "0.074074\n",
      "0.024691\n",
      "0.000000\n",
      "0.071429\n",
      "0.095238\n",
      "0.046512\n",
      "0.040000\n",
      "0.080000\n",
      "0.210526\n",
      "0.031250\n",
      "0.052632\n",
      "0.074074\n",
      "0.000000\n",
      "0.102564\n",
      "0.088889\n",
      "0.072727\n",
      "0.148148\n",
      "0.111111\n",
      "0.041667\n",
      "0.095238\n",
      "0.129032\n",
      "0.096774\n",
      "0.100000\n",
      "0.095238\n",
      "0.074074\n",
      "0.024691\n",
      "0.000000\n",
      "0.071429\n",
      "0.095238\n",
      "0.046512\n",
      "0.081633\n",
      "0.040000\n",
      "0.080000\n",
      "0.210526\n",
      "0.031250\n",
      "0.052632\n",
      "0.074074\n",
      "0.000000\n",
      "0.102564\n",
      "0.088889\n",
      "0.072727\n",
      "0.148148\n",
      "0.111111\n",
      "0.041667\n",
      "0.095238\n",
      "0.129032\n",
      "0.096774\n",
      "0.100000\n",
      "0.095238\n",
      "0.074074\n",
      "0.024691\n",
      "prediction:  ANSWER: C\n",
      "pred_SIM:  A\n",
      "A\n",
      "C\n",
      "C\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "D\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "correct answer: 15\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:   sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      " sc\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "cot\n",
      "SIM_score:  0.160000\n",
      "0.068966\n",
      "0.102564\n",
      "0.090909\n",
      "0.222222\n",
      "0.086957\n",
      "0.121212\n",
      "0.043478\n",
      "0.160000\n",
      "0.068966\n",
      "0.102564\n",
      "0.090909\n",
      "0.222222\n",
      "0.121212\n",
      "0.160000\n",
      "0.068966\n",
      "0.102564\n",
      "0.090909\n",
      "0.222222\n",
      "0.086957\n",
      "0.121212\n",
      "0.043478\n",
      "0.160000\n",
      "0.068966\n",
      "0.102564\n",
      "0.090909\n",
      "0.222222\n",
      "0.086957\n",
      "0.121212\n",
      "0.043478\n",
      "0.160000\n",
      "0.068966\n",
      "0.102564\n",
      "0.090909\n",
      "0.222222\n",
      "0.086957\n",
      "0.121212\n",
      "0.160000\n",
      "0.068966\n",
      "0.102564\n",
      "0.090909\n",
      "0.222222\n",
      "0.086957\n",
      "0.121212\n",
      "prediction:  ANSWER: D\n",
      "pred_SIM:  D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "correct_answer:  D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.014508\n",
      "prediction:  After stopping venlafaxine, it is generally recommended to wait at least **14 days** before initiating treatment with a monoamine oxidase inhibitor (MAOI). This is to avoid the risk of serotonin syndrome, a potentially life-threatening condition that can occur when combining medications that affect serotonin levels.\n",
      "\n",
      "Venlafaxine is an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs) and is utilized for various psychiatric disorders, including major depressive disorder and anxiety disorders. MAOIs, on the other hand, work by inhibiting the enzymes responsible for the breakdown of monoamines (neurotransmitters) such as serotonin and dopamine, also used to treat certain psychiatric disorders.\n",
      "\n",
      "It is essential to consult healthcare professionals for personalized guidance, as individual cases may vary, and specific protocols may differ based on the medical history and current health status of the patient.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.167665\n",
      "prediction:  Albuterol sulfate showed no evidence of tumorigenicity in a study involving golden hamsters, where it was administered at dietary doses up to 500 mg/kg.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020364\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used in the treatment of asthma and other respiratory conditions, has been studied for its safety and potential side effects, including tumorigenicity. In preclinical studies, albuterol sulfate was evaluated in various animal models to assess its safety profile.\n",
      "\n",
      "The specific animal model in which albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is the **rat model**, particularly the **F344 rat** (Fischer 344 rat). In studies conducted to evaluate the long-term effects of albuterol sulfate, including its potential carcinogenic effects, F344 rats were administered the drug at various doses, including the high dose of 500 mg/kg. The results indicated that there was no significant increase in tumor formation or other malignancies associated with the administration of albuterol sulfate at this dosage.\n",
      "\n",
      "These findings are important for understanding the safety of albuterol sulfate in both clinical and long-term use, as they suggest that, at the tested doses, the drug does not pose a significant risk of inducing tumors in this specific animal model. However, it is essential to note that results in animal models do not always directly translate to humans, and ongoing monitoring and research are necessary to fully understand the long-term safety of any medication.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.018592\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used in the treatment of asthma and other respiratory conditions, has been studied for its safety and potential side effects, including tumorigenicity. In the context of animal studies, albuterol sulfate has been evaluated in various models to assess its long-term effects.\n",
      "\n",
      "The specific animal model in which albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is the **rat model**, particularly the **F344 rat** (Fischer 344 rat). In studies conducted to evaluate the carcinogenic potential of albuterol sulfate, these rats were administered the drug at high doses over extended periods, and the results indicated that there was no significant increase in tumor formation compared to control groups.\n",
      "\n",
      "These findings are important for understanding the safety profile of albuterol sulfate, especially in the context of long-term use in humans. The absence of tumorigenicity in the F344 rat model suggests that, at the tested doses, albuterol sulfate does not pose a significant cancer risk, which is a critical consideration for both regulatory approval and clinical use. \n",
      "\n",
      "It's worth noting that while animal studies provide valuable insights, the results may not always directly translate to humans due to differences in metabolism, physiology, and other factors. Therefore, ongoing research and monitoring in human populations remain essential to fully understand the long-term safety of albuterol sulfate.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.024889\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used in the treatment of asthma and other respiratory conditions, has been studied for its safety and potential side effects, including tumorigenicity. In the context of animal studies, albuterol sulfate has been evaluated in various models to assess its long-term effects.\n",
      "\n",
      "The specific animal model in which albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is the **rat model**, particularly the Fischer 344 rat. In studies conducted to evaluate the carcinogenic potential of albuterol sulfate, these rats were administered the drug at high doses over extended periods. The results indicated that there was no significant increase in tumor formation compared to control groups, suggesting that albuterol sulfate does not pose a carcinogenic risk at the tested dietary levels.\n",
      "\n",
      "It's important to note that while these findings are promising, further research and long-term studies in different models and species are essential to fully understand the safety profile of albuterol sulfate and its implications for human health.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011799\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used in the treatment of asthma and other respiratory conditions, has been studied for its safety and potential side effects, including tumorigenicity. In the context of animal studies, the specific model in which albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is the **rat model**.\n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Tumorigenicity**: Tumorigenicity refers to the ability of a substance to induce tumor formation. Assessing the tumorigenic potential of drugs is a critical part of preclinical safety evaluations.\n",
      "\n",
      "2. **Animal Models in Research**: Various animal models are used in toxicology studies, including mice, rats, and other species. Rats are commonly used due to their well-characterized biology and the availability of extensive historical data.\n",
      "\n",
      "3. **Study Design**: In studies assessing the safety of albuterol sulfate, researchers typically administer the drug at various doses to groups of rats over a specified period. The highest dose mentioned in your question is 500 mg/kg, which is a significant amount for dietary studies.\n",
      "\n",
      "4. **Findings**: In the specific studies conducted on rats, researchers observed that even at the high dietary dose of 500 mg/kg, there was no evidence of tumor formation. This suggests that albuterol sulfate does not have carcinogenic properties in this animal model.\n",
      "\n",
      "5. **Regulatory Implications**: The findings from such studies are crucial for regulatory submissions to agencies like the FDA or EMA, as they help establish the safety profile of the drug for human use.\n",
      "\n",
      "6. **Conclusion**: Therefore, the answer to your question is that **albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg in rat models**. This information is vital for understanding the safety of albuterol sulfate in clinical use and contributes to the overall assessment of its risk-benefit profile in patients. \n",
      "\n",
      "### Additional Considerations:\n",
      "- It is important to note that while results in animal models are informative, they do not always directly translate to humans due to differences in metabolism, physiology, and other factors.\n",
      "- Ongoing monitoring and post-marketing surveillance are essential to ensure the continued safety of medications like albuterol sulfate in the general population.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013766\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used in the treatment of asthma and other respiratory conditions, has been studied for its safety and potential side effects, including tumorigenicity. In the context of animal studies, the specific model in which albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is the **rat model**.\n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Tumorigenicity**: Tumorigenicity refers to the ability of a substance to induce tumor formation. Assessing the tumorigenic potential of drugs is a critical part of preclinical safety evaluations.\n",
      "\n",
      "2. **Animal Models in Research**: Various animal models are used in toxicology studies, including mice, rats, and rabbits. Rats are commonly used for long-term studies due to their well-characterized biology and the availability of historical data.\n",
      "\n",
      "3. **Study Design**: In studies assessing the safety of albuterol sulfate, researchers typically administer the drug at various doses to groups of rats over an extended period. The doses can vary widely, and in this case, doses up to 500 mg/kg were tested.\n",
      "\n",
      "4. **Findings**: The studies indicated that at the specified dietary doses, there was no evidence of tumor formation in the rats. This suggests that albuterol sulfate does not have carcinogenic properties at the tested levels in this particular animal model.\n",
      "\n",
      "5. **Regulatory Implications**: The absence of tumorigenicity in rat studies is an important finding for regulatory agencies, as it supports the safety profile of albuterol sulfate for human use, particularly in long-term treatment scenarios.\n",
      "\n",
      "6. **Conclusion**: In summary, albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg in **rats**, which is a significant finding in the context of its safety evaluation for therapeutic use.\n",
      "\n",
      "This comprehensive understanding of the study's context, methodology, and implications helps clarify the safety profile of albuterol sulfate in preclinical research.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013692\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used in the treatment of asthma and other respiratory conditions, has been studied for its safety and potential side effects, including tumorigenicity. In the context of animal studies, the specific model in which albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is typically the **rat model**, particularly the **F344 rat** (Fischer 344 rat).\n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Tumorigenicity**: Tumorigenicity refers to the ability of a substance to induce tumor formation. In preclinical studies, it is crucial to assess whether a drug has the potential to cause cancer, especially when it is intended for long-term use in humans.\n",
      "\n",
      "2. **Animal Models in Research**: Various animal models are used in toxicology and pharmacology studies to evaluate the safety of drugs. Rats, particularly the Fischer 344 strain, are commonly used due to their well-characterized genetics and physiology, which make them suitable for long-term studies.\n",
      "\n",
      "3. **Study Design**: In studies assessing the tumorigenic potential of albuterol sulfate, researchers typically administer the drug at various doses to groups of rats over an extended period. The highest dose in this context was 500 mg/kg, which is considered a high dietary dose.\n",
      "\n",
      "4. **Results**: The studies indicated that at this high dose, there was no significant evidence of tumor formation in the treated rats. This finding suggests that albuterol sulfate does not have tumorigenic properties at the tested doses in this specific animal model.\n",
      "\n",
      "5. **Regulatory Implications**: The absence of tumorigenicity in animal models is an important factor in the regulatory approval process for new drugs. It provides reassurance regarding the long-term safety of the drug for human use.\n",
      "\n",
      "6. **Conclusion**: Therefore, the answer to the question is that albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg in the **F344 rat model**.\n",
      "\n",
      "This comprehensive understanding of the study's context, methodology, and implications helps clarify the safety profile of albuterol sulfate in preclinical research.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.014718\n",
      "prediction:  Albuterol sulfate, a bronchodilator commonly used to treat asthma and other respiratory conditions, has been studied for its effects on fertility in animal models, including rats. In studies assessing the potential reproductive toxicity of albuterol sulfate, it was found that at certain doses, there was no evidence of impaired fertility.\n",
      "\n",
      "Specifically, in a study where albuterol sulfate was administered to rats, the no-observed-adverse-effect level (NOAEL) for fertility was determined to be 100 mg/kg/day. At this dose, there were no significant effects on mating performance, fertility, or reproductive outcomes in the treated rats compared to the control group. \n",
      "\n",
      "It is important to note that while this information is derived from animal studies, the relevance of these findings to human fertility is not directly translatable. Factors such as species differences, pharmacokinetics, and the context of use in humans must be considered when interpreting these results.\n",
      "\n",
      "In summary, albuterol sulfate demonstrated no evidence of impaired fertility in rats at an oral dose of 100 mg/kg/day. However, further research and clinical studies are necessary to fully understand the implications for human fertility.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.012579\n",
      "prediction:  Albuterol sulfate, a commonly used bronchodilator for the treatment of asthma and other respiratory conditions, has been studied for its effects on fertility in animal models, including rats. In studies assessing the potential reproductive toxicity of albuterol sulfate, it was found that at an oral dose of 100 mg/kg/day, there was no evidence of impaired fertility in rats. \n",
      "\n",
      "This finding indicates that at this specific dosage, albuterol sulfate did not adversely affect reproductive parameters such as mating performance, fertility rates, or the health of offspring. It is important to note that the assessment of reproductive toxicity typically involves evaluating various factors, including the effects on both male and female reproductive systems, as well as the development of the offspring.\n",
      "\n",
      "When interpreting these results, it is crucial to consider the context of the study, including the species used, the duration of exposure, and the relevance of animal data to human health. While the findings in rats suggest that albuterol sulfate may not impair fertility at the specified dose, further research and clinical data are necessary to fully understand its implications for human fertility.\n",
      "\n",
      "In summary, albuterol sulfate demonstrated no evidence of impaired fertility in rats at an oral dose of 100 mg/kg/day, highlighting the importance of evaluating the safety profile of medications in reproductive health.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.01473\n",
      "prediction:  Albuterol sulfate, a medication commonly used as a bronchodilator for conditions such as asthma and chronic obstructive pulmonary disease (COPD), has been studied for its effects on fertility in animal models, including rats. In studies assessing the potential reproductive toxicity of albuterol sulfate, it was found that at certain doses, there was no evidence of impaired fertility.\n",
      "\n",
      "Specifically, in a study where albuterol sulfate was administered to rats, doses up to 100 mg/kg/day did not show any adverse effects on fertility parameters. This means that at this oral dose, the reproductive capabilities of the rats were not negatively impacted, indicating that albuterol sulfate is unlikely to cause fertility issues at this level of exposure.\n",
      "\n",
      "It is important to note that while these findings are relevant for understanding the safety profile of albuterol sulfate in animal models, the implications for human fertility may not be directly translatable. Further research and clinical studies are necessary to fully understand the effects of albuterol sulfate on human fertility.\n",
      "\n",
      "In summary, albuterol sulfate demonstrated no evidence of impaired fertility in rats at an oral dose of up to 100 mg/kg/day.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.011696\n",
      "prediction:  Albuterol sulfate, a medication commonly used as a bronchodilator for conditions such as asthma and chronic obstructive pulmonary disease (COPD), has been studied for its safety and potential side effects, including any carcinogenic effects. In research involving Golden hamsters, various dietary doses of albuterol sulfate have been tested to assess its long-term safety profile.\n",
      "\n",
      "The highest dietary dose of albuterol sulfate tested in Golden hamsters that showed no evidence of tumorigenicity was 1,000 mg/kg/day. In studies, this dose was administered over an extended period, typically spanning several months to years, to evaluate any potential carcinogenic effects. The results indicated that at this dosage, there were no significant increases in tumor formation compared to control groups, suggesting that albuterol sulfate does not pose a carcinogenic risk at this level in Golden hamsters.\n",
      "\n",
      "It is important to note that while these findings are significant, they are specific to the animal model used and may not directly translate to humans. Further research and clinical studies are necessary to fully understand the implications of long-term albuterol use in humans, including any potential risks associated with high doses. Additionally, the safety profile of medications can vary based on individual patient factors, including underlying health conditions and concurrent medications. Therefore, it is always essential for patients to use albuterol and other medications as prescribed by their healthcare providers.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "default\n",
      "SIM_score:  0.01391\n",
      "0.01391\n",
      "prediction:  Albuterol sulfate, a medication commonly used as a bronchodilator for conditions such as asthma and chronic obstructive pulmonary disease (COPD), has been studied for its safety and potential side effects, including any carcinogenic effects. In research involving Golden hamsters, various doses of albuterol sulfate were tested to evaluate its long-term safety profile, particularly concerning tumorigenicity.\n",
      "\n",
      "The highest dietary dose of albuterol sulfate tested in Golden hamsters that showed no evidence of tumorigenicity was 1,000 mg/kg/day. This dose was part of a comprehensive study designed to assess the potential carcinogenic effects of albuterol when administered over an extended period. The findings indicated that at this level, there were no significant increases in tumor formation compared to control groups, suggesting that albuterol sulfate does not pose a carcinogenic risk at this dosage in the tested animal model.\n",
      "\n",
      "It is important to note that while these findings are significant, they are specific to the conditions of the study and the species tested. Further research, including studies in other animal models and human clinical trials, is essential to fully understand the long-term safety profile of albuterol sulfate and its implications for human health.\n",
      "pred_SIM:  D\n",
      "D\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.03672\n",
      "prediction:  An example of a drug brand name that is explicitly stated as not being a controlled substance is **Cyclobenzaprine**, which is commonly known under the brand names **Flexeril** and **Amrix**. These medications are muscle relaxants and do not fall under the Controlled Substances Act (CSA) as they are not classified as controlled substances by the Drug Enforcement Administration (DEA).\n",
      "\n",
      "In general, non-controlled substances include many over-the-counter (OTC) medications and common prescription drugs used for chronic conditions, such as blood pressure medications, cholesterol medications, diabetes medications including insulin, and various types of antimicrobials. These drugs are widely prescribed and used without the same regulatory restrictions that apply to controlled substances.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "agent\n",
      "agent\n",
      "SIM_score:  0.166667\n",
      "0.111111\n",
      "0.000000\n",
      "prediction:  Answer: B\n",
      "pred_SIM:  D\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "correct answer: For preparation of the skin prior to injection\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.0\n",
      "prediction:  Answer: C\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 75-85%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.029526\n",
      "prediction:  Antifungal drugs are specifically designed to treat infections caused by fungi, including conditions such as athlete's foot, ringworm, candidiasis (thrush), and systemic fungal infections like aspergillosis and cryptococcosis. However, there are several conditions that are NOT treated by antifungal medications. \n",
      "\n",
      "One prominent example is **bacterial infections**. Conditions such as strep throat, bacterial pneumonia, and urinary tract infections are caused by bacteria, not fungi, and therefore require antibiotics for treatment. Antibiotics are specifically formulated to target bacterial pathogens and are ineffective against fungal infections.\n",
      "\n",
      "Another example is **viral infections**. Conditions like the flu, common cold, and COVID-19 are caused by viruses. Antifungal medications do not have any effect on viral pathogens, and antiviral drugs are required to treat these types of infections.\n",
      "\n",
      "Additionally, **parasitic infections** such as malaria or giardiasis are caused by parasites and are treated with antiparasitic medications, not antifungals. \n",
      "\n",
      "In summary, conditions such as bacterial infections, viral infections, and parasitic infections are NOT treated by antifungal drugs, as these medications are specifically targeted towards fungal pathogens.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.026407\n",
      "prediction:  Antifungal drugs are specifically designed to treat infections caused by fungi, including conditions such as athlete's foot, ringworm, candidiasis (thrush), and systemic fungal infections like cryptococcosis and aspergillosis. However, there are several conditions that are NOT treated by antifungal medications. \n",
      "\n",
      "One prominent example is **bacterial infections**. Conditions such as strep throat, bacterial pneumonia, and urinary tract infections caused by bacteria are treated with antibiotics, not antifungals. Antibiotics target bacterial cell walls or protein synthesis, which are mechanisms that antifungals do not affect, as they are designed to target fungal cell membranes or cell wall synthesis.\n",
      "\n",
      "Another example is **viral infections**. Conditions like the flu, COVID-19, and herpes are caused by viruses and are treated with antiviral medications. Antifungal drugs have no effect on viruses, as their mechanisms of action are specific to fungi.\n",
      "\n",
      "Additionally, **non-infectious conditions** such as autoimmune diseases (like lupus or rheumatoid arthritis), allergies, and chronic inflammatory conditions are also not treated with antifungal medications. These conditions require different classes of drugs, such as immunosuppressants, corticosteroids, or antihistamines.\n",
      "\n",
      "In summary, conditions such as bacterial infections, viral infections, and non-infectious diseases are NOT treated by antifungal drugs.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.023647\n",
      "prediction:  Antifungal drugs are specifically designed to treat infections caused by fungi, including conditions such as athlete's foot, ringworm, candidiasis (thrush), and systemic fungal infections like cryptococcosis. However, there are several conditions that are NOT treated by antifungal medications. \n",
      "\n",
      "One prominent example is **bacterial infections**. Conditions such as strep throat, bacterial pneumonia, and urinary tract infections caused by bacteria are treated with antibiotics, not antifungals. Antibiotics target bacterial cell wall synthesis, protein synthesis, or other bacterial-specific processes, which are fundamentally different from the mechanisms targeted by antifungal agents.\n",
      "\n",
      "Additionally, antifungal drugs are ineffective against **viral infections**. Conditions such as influenza, HIV/AIDS, and COVID-19 are caused by viruses and require antiviral medications for treatment. Antivirals work by inhibiting viral replication or preventing the virus from entering host cells, which is a different approach than that used for fungal infections.\n",
      "\n",
      "Furthermore, antifungal medications do not treat **parasitic infections**. Conditions caused by parasites, such as malaria (caused by Plasmodium species) or giardiasis (caused by Giardia lamblia), require antiparasitic drugs, which are specifically formulated to target the biology of parasites.\n",
      "\n",
      "In summary, conditions such as bacterial infections, viral infections, and parasitic infections are NOT treated by antifungal drugs, as these conditions require different classes of medications tailored to their specific pathogens.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.028429\n",
      "prediction:  Antifungal drugs are specifically designed to treat infections caused by fungi, such as candidiasis, aspergillosis, and other fungal infections. However, there are multiple conditions that are **NOT** treated with antifungal medications. \n",
      "\n",
      "Based on the evidence from the reviewed literature, antifungal drugs do not treat:\n",
      "\n",
      "1. **Viral Infections** - Conditions caused by viruses, such as the common cold, influenza, or HIV/AIDS, require antivirals that target viral replication and assembly, not antifungals.\n",
      "\n",
      "2. **Bacterial Infections** - Antibiotics are needed for bacterial infections, such as strep throat or urinary tract infections, which are not responsive to antifungal treatments.\n",
      "\n",
      "3. **Parasitic Infections** - Diseases caused by parasites, such as malaria or giardiasis, require antiparasitic medications rather than antifungals.\n",
      "\n",
      "4. **Inflammatory Conditions** - Certain autoimmune or inflammatory disorders (like rheumatoid arthritis or lupus) are treated with immunosuppressants or anti-inflammatory drugs, not antifungals.\n",
      "\n",
      "5. **Neoplastic Conditions** - Certain cancers and tumors are treated with chemotherapy, radiation, or surgical interventions, which do not involve antifungal medications.\n",
      "\n",
      "In summary, antifungal drugs are ineffective against viral, bacterial, and parasitic infections, as well as non-infectious conditions such as inflammatory diseases and cancer.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.028107\n",
      "prediction:  Antifungal medications are primarily used to treat fungal infections, which can affect various parts of the body, including the skin, lungs, and bloodstream. Common fungal conditions treated with antifungals include:\n",
      "\n",
      "1. **Candidiasis**: Often caused by the fungus Candida, this can occur in various forms such as oral thrush, vaginal yeast infections, and invasive candidiasis.\n",
      "2. **Aspergillosis**: This infection is caused by the Aspergillus species and primarily affects the lungs, but can also disseminate to other parts of the body in immunocompromised individuals.\n",
      "3. **Cryptococcosis**: Caused by Cryptococcus neoformans, it is a serious infection that often affects the lungs and can spread to the brain, particularly in immunocompromised patients.\n",
      "4. **Dermatophytosis**: Infections of the skin, hair, or nails by dermatophytes, such as tinea pedis (athlete's foot) or tinea corporis (ringworm).\n",
      "\n",
      "In contrast, antifungal agents are **not effective** against bacterial infections, viral infections, or conditions caused by parasites. For instance, conditions like **bacterial pneumonia, viral infections like influenza, or amoebic dysentery** are not treated with antifungal drugs. \n",
      "\n",
      "Thus, the condition that is NOT treated by the drug 'antifungal' includes any type of **bacterial infection**, such as bacterial pneumonia.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.039448\n",
      "prediction:  Antifungal medications are primarily used to treat fungal infections, which can affect various parts of the body, leading to conditions such as:\n",
      "\n",
      "1. **Invasive Fungal Infections (IFIs)**: Commonly seen in immunocompromised patients, such as those with hematological malignancies.\n",
      "2. **Superficial Fungal Infections**: These include conditions like athlete's foot, ringworm, and yeast infections.\n",
      "\n",
      "However, there are conditions that are **not treated** by antifungal medications, such as:\n",
      "\n",
      "- **Bacterial infections**: Antifungals do not treat infections caused by bacteria, such as strep throat or pneumonia.\n",
      "- **Viral infections**: Conditions like influenza or herpes simplex are not affected by antifungal drugs.\n",
      "- **Parasitic infections**: Diseases caused by parasites, such as malaria or giardiasis, are also unrelated to antifungal treatment.\n",
      "\n",
      "In summary, while antifungal medications are effective against fungal infections, they **do not** treat bacterial, viral, or parasitic infections.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:    agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "SIM_score:  0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.028571\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.028571\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.095238\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.095238\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.095238\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.095238\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.111111\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.040816\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.041667\n",
      "prediction:  B\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Plasma levels of albuterol are low, and effects on breastfed children are likely minimal.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.066826\n",
      "prediction:  Based on my research, I could not find specific information regarding the maximum oral dose of ondansetron used in carcinogenicity studies in mice. However, the usual doses administered in animal studies appear to range around 15 mg/kg and some references implied the effects being observed at these doses.\n",
      "\n",
      "Thus, with this information in hand, the most plausible answer from the provided options is:\n",
      "\n",
      "B\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 30 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.477612\n",
      "prediction:  Based on the available information, XENOVIEW has no contraindications. Therefore, the correct answer to the question is:\n",
      "\n",
      "A\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: XENOVIEW has no contraindications, unlike drugs with common contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.073491\n",
      "prediction:  Based on the information gathered, 'nighttime severe cold and flu' relief products typically mention the following symptoms as being alleviated: cough, nasal congestion, fever, sore throat, headache, and body aches. \n",
      "\n",
      "However, a symptom that is generally **NOT** mentioned in the context of being relieved by nighttime severe cold and flu medication is **fatigue**.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.032424\n",
      "prediction:  Based on the literature reviewed, venlafaxine, an antidepressant commonly used to treat major depressive disorder, appears to show a reduction in suicidality risk, specifically among adolescents and young adults. \n",
      "\n",
      "A systematic review and meta-analysis involving randomized controlled trials focused on adults demonstrated that venlafaxine reduced the occurrence of suicides or suicide attempts compared to placebo. Although the review primarily centered on adult populations, it included trials that reported outcomes for younger subjects. The evidence suggests that adolescents treated with venlafaxine exhibited a statistically significant reduction in suicidality risk compared to those receiving a placebo.\n",
      "\n",
      "The details from studies indicate that while adults show clear benefits, the emphasis on adolescents emphasizes the importance of monitoring and managing suicidality risk during treatment with venlafaxine. Notably, the younger demographic tends to react differently to antidepressants, hence the need for tailored approaches when prescribing this medication.\n",
      "\n",
      "In conclusion, it is primarily the adolescent age group that showed a reduction in suicidality risk with venlafaxine treatment compared to placebo, highlighting the critical need for careful consideration of treatment options in this vulnerable population.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.088004\n",
      "prediction:  Before administering Gadavist (gadobuterol), a gadolinium-based contrast agent used in magnetic resonance imaging (MRI), it is imperative to take specific precautions for patients with a history of allergic disorders. These precautions are crucial to mitigate the risk of potential allergic reactions, which may occur in sensitive individuals. The following are important considerations:\n",
      "\n",
      "1. **Patient History Assessment**:\n",
      "   - Thoroughly evaluate the patient's history of allergies, particularly previous reactions to contrast media or other drugs. A detailed account can inform the risk assessment related to Gadavist administration.\n",
      "\n",
      "2. **Use of Pre-medication**:\n",
      "   - For patients with a known history of allergic reactions to contrast media, pre-treatment with corticosteroids and antihistamines may be considered. Studies indicate that corticosteroids can potentially reduce the incidence and severity of allergic-like reactions to contrast agents, although the efficacy for all patients may vary (Timberlake et al., 2026).\n",
      "\n",
      "3. **Skin Testing**:\n",
      "   - If the patient's allergy history is particularly concerning, consider consultation with an allergist. Skin testing for gadolinium-based agents might be recommended to identify potential reactivity.\n",
      "\n",
      "4. **Monitoring**:\n",
      "   - Patients should be monitored closely during the infusion of Gadavist. Emergency protocols should be in place in case of an unexpected allergic reaction. This includes having antihistamines, corticosteroids, and emergency medications available.\n",
      "\n",
      "5. **Informed Consent**:\n",
      "   - Discuss the risks and benefits of the contrast agent with the patient, ensuring they provide informed consent, understanding the potential for allergic reactions.\n",
      "\n",
      "In conclusion, a careful assessment of the patient's allergy history, potential pre-medication protocols, and vigilant monitoring can greatly enhance the safety of administering Gadavist to patients with a history of allergic disorders. Always tailor the approach based on individual risk factors and clinical guidance.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Assess the patientâ€™s history of reactions to contrast media and ensure trained personnel are available for resuscitation\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.109756\n",
      "prediction:  Before prescribing Paxlovid (nirmatrelvir and ritonavir), there are several recommended actions that healthcare providers should take. However, one action that is NOT recommended is:\n",
      "\n",
      "**Not checking the patient's renal function.**\n",
      "\n",
      "Paxlovid can cause complications in patients with renal impairment, and it's essential to assess renal function before prescribing. Other key recommended actions include:\n",
      "\n",
      "1. **Assessing for drug interactions:** Paxlovid has the potential to interact with many medications due to the presence of ritonavir, which can affect the metabolism of various drugs.\n",
      "\n",
      "2. **Confirming COVID-19 positivity:** Before initiating treatment, it is crucial to confirm that the patient has a positive SARS-CoV-2 viral test.\n",
      "\n",
      "3. **Initiating treatment promptly:** Treatment with Paxlovid should ideally begin within 5 days of symptom onset for maximum efficacy.\n",
      "\n",
      "In conclusion, neglecting to check renal function is a critical oversight that may lead to adverse effects, making it a notable action that should NOT be overlooked before prescribing Paxlovid.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Ignoring potential drug-drug interactions due to Paxlovid's safety profile.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.018239\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should conduct a thorough evaluation that encompasses several key areas to ensure the medication is appropriate and safe for the patient. Hereâ€™s a step-by-step breakdown of the evaluation process:\n",
      "\n",
      "### 1. **Patient History**\n",
      "   - **Medical History**: Assess the patient's overall medical history, including any history of psychiatric disorders, cardiovascular issues, liver or kidney disease, and any other chronic conditions.\n",
      "   - **Psychiatric History**: Evaluate for any previous episodes of depression, anxiety disorders, or other mental health conditions. Inquire about past treatments and their effectiveness.\n",
      "   - **Substance Use**: Screen for any history of substance abuse, including alcohol and recreational drugs, as these can interact with venlafaxine.\n",
      "\n",
      "### 2. **Current Medications**\n",
      "   - **Drug Interactions**: Review the patientâ€™s current medications to identify potential drug interactions. Venlafaxine can interact with other antidepressants (especially MAO inhibitors), certain pain medications, and medications that affect serotonin levels.\n",
      "   - **Over-the-Counter and Herbal Supplements**: Inquire about any over-the-counter medications or herbal supplements the patient may be taking, as these can also interact with venlafaxine.\n",
      "\n",
      "### 3. **Contraindications**\n",
      "   - **Allergies**: Check for any known allergies to venlafaxine or its components.\n",
      "   - **Contraindicated Conditions**: Identify any contraindications, such as uncontrolled hypertension, seizure disorders, or a history of serotonin syndrome.\n",
      "\n",
      "### 4. **Risk Assessment**\n",
      "   - **Suicidal Ideation**: Assess for any current or past suicidal thoughts or behaviors, as venlafaxine, like other antidepressants, carries a risk of increased suicidal ideation, especially in younger populations.\n",
      "   - **Cardiovascular Risk**: Evaluate the patientâ€™s cardiovascular health, as venlafaxine can increase blood pressure, particularly at higher doses.\n",
      "\n",
      "### 5. **Patientâ€™s Age and Demographics**\n",
      "   - **Age Considerations**: Consider the patientâ€™s age, as the response to venlafaxine can vary between children, adolescents, adults, and the elderly. Special caution is warranted in these populations.\n",
      "   - **Pregnancy and Lactation**: Assess if the patient is pregnant, planning to become pregnant, or breastfeeding, as venlafaxine can have implications for fetal and neonatal health.\n",
      "\n",
      "### 6. **Baseline Assessments**\n",
      "   - **Vital Signs**: Obtain baseline vital signs, particularly blood pressure and heart rate, to monitor for any changes after starting the medication.\n",
      "   - **Laboratory Tests**: Depending on the patientâ€™s medical history, consider ordering laboratory tests (e.g., liver function tests, renal function tests) to establish a baseline for monitoring.\n",
      "\n",
      "### 7. **Patient Education**\n",
      "   - **Informed Consent**: Discuss the potential benefits and risks of venlafaxine, including common side effects (e.g., nausea, dizziness, insomnia) and serious side effects (e.g., increased blood pressure, serotonin syndrome).\n",
      "   - **Treatment Expectations**: Set realistic expectations regarding the timeline for therapeutic effects and the importance of adherence to the prescribed regimen.\n",
      "\n",
      "### 8. **Follow-Up Plan**\n",
      "   - **Monitoring**: Establish a follow-up plan to monitor the patientâ€™s response to the medication, side effects, and any necessary adjustments to the dosage.\n",
      "   - **Crisis Plan**: Develop a plan for the patient to follow in case of worsening symptoms or side effects, including emergency contacts and resources.\n",
      "\n",
      "By conducting this comprehensive evaluation, physicians can make informed decisions about prescribing venlafaxine, ensuring that it is the right choice for the patientâ€™s specific situation while minimizing risks and maximizing therapeutic benefits.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.01908\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should conduct a thorough evaluation that encompasses several key areas to ensure the safety and efficacy of the treatment for the patient. Here are the critical factors to consider:\n",
      "\n",
      "1. **Patient History**:\n",
      "   - **Medical History**: Assess for any history of psychiatric disorders, particularly bipolar disorder, as venlafaxine can induce mania in susceptible individuals. Evaluate for any history of depression, anxiety disorders, or other mental health conditions.\n",
      "   - **Medication History**: Review current and past medications, including over-the-counter drugs and supplements, to identify potential drug interactions. Venlafaxine can interact with monoamine oxidase inhibitors (MAOIs), SSRIs, SNRIs, and other medications that affect serotonin levels.\n",
      "\n",
      "2. **Current Medications**:\n",
      "   - Evaluate for the use of other medications that may increase the risk of serotonin syndrome, such as other antidepressants, certain pain medications (like tramadol), and herbal supplements (like St. Johnâ€™s Wort).\n",
      "   - Consider the patient's use of anticoagulants or antiplatelet agents, as venlafaxine can affect platelet function and increase bleeding risk.\n",
      "\n",
      "3. **Contraindications**:\n",
      "   - Identify any contraindications to venlafaxine, such as hypersensitivity to the drug or its components, and a history of severe renal impairment, as dosage adjustments may be necessary.\n",
      "   - Assess for a history of uncontrolled hypertension, as venlafaxine can increase blood pressure, particularly at higher doses.\n",
      "\n",
      "4. **Psychiatric Evaluation**:\n",
      "   - Conduct a comprehensive psychiatric assessment to determine the severity of the patient's symptoms and the appropriateness of venlafaxine as a treatment option. This includes evaluating suicidal ideation or behavior, as antidepressants can increase the risk of suicidal thoughts in some patients, particularly in younger populations.\n",
      "\n",
      "5. **Physical Examination**:\n",
      "   - Perform a physical examination to assess overall health and identify any conditions that may affect treatment, such as cardiovascular issues or metabolic disorders.\n",
      "\n",
      "6. **Laboratory Tests**:\n",
      "   - Consider ordering baseline laboratory tests, such as renal function tests, liver function tests, and a complete blood count (CBC) if there are concerns about blood disorders or if the patient has a history of liver disease.\n",
      "\n",
      "7. **Patient Education**:\n",
      "   - Discuss the potential benefits and risks of venlafaxine, including common side effects (e.g., nausea, dizziness, insomnia, increased blood pressure) and the importance of adherence to the prescribed regimen.\n",
      "   - Educate the patient about the gradual onset of therapeutic effects and the importance of not abruptly discontinuing the medication to avoid withdrawal symptoms.\n",
      "\n",
      "8. **Monitoring Plan**:\n",
      "   - Establish a monitoring plan to assess the patient's response to treatment, including regular follow-up appointments to evaluate efficacy, side effects, and any emerging concerns, particularly regarding blood pressure and mood changes.\n",
      "\n",
      "9. **Special Populations**:\n",
      "   - Consider special populations, such as pregnant or breastfeeding women, elderly patients, and those with comorbid conditions, as these groups may require additional considerations regarding the use of venlafaxine.\n",
      "\n",
      "By carefully evaluating these factors, physicians can make informed decisions about prescribing venlafaxine, tailoring the treatment to the individual needs of the patient while minimizing risks and maximizing therapeutic outcomes.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.019871\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should conduct a thorough evaluation that encompasses several key areas to ensure the safety and efficacy of the treatment for the patient. Here are the critical factors to consider:\n",
      "\n",
      "1. **Patient History**:\n",
      "   - **Medical History**: Assess for any history of psychiatric disorders, particularly bipolar disorder, as venlafaxine can induce mania in susceptible individuals. Evaluate for any history of depression, anxiety disorders, or other mental health conditions.\n",
      "   - **Medication History**: Review current and past medications, including over-the-counter drugs and supplements, to identify potential drug interactions. Venlafaxine can interact with other medications, particularly monoamine oxidase inhibitors (MAOIs), SSRIs, and other serotonergic agents.\n",
      "\n",
      "2. **Current Medications**:\n",
      "   - Evaluate for the use of other medications that may increase the risk of serotonin syndrome, such as triptans, tramadol, or St. Johnâ€™s Wort. Assess for anticoagulants or antiplatelet agents, as venlafaxine can affect platelet function.\n",
      "\n",
      "3. **Contraindications**:\n",
      "   - Identify any contraindications to venlafaxine, such as hypersensitivity to the drug or its components, and a history of narrow-angle glaucoma, as venlafaxine can increase intraocular pressure.\n",
      "\n",
      "4. **Cardiovascular Health**:\n",
      "   - Assess cardiovascular health, including blood pressure and heart rate, as venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Patients with uncontrolled hypertension or significant cardiovascular disease may require careful monitoring or alternative treatments.\n",
      "\n",
      "5. **Renal and Hepatic Function**:\n",
      "   - Evaluate renal and hepatic function, as venlafaxine is primarily metabolized by the liver and excreted by the kidneys. Dose adjustments may be necessary for patients with renal impairment or liver disease.\n",
      "\n",
      "6. **Pregnancy and Lactation**:\n",
      "   - Discuss the patient's pregnancy status or plans for pregnancy, as venlafaxine is classified as a Category C medication. The risks and benefits should be carefully weighed. Additionally, consider the implications for breastfeeding, as venlafaxine is excreted in breast milk.\n",
      "\n",
      "7. **Substance Use**:\n",
      "   - Screen for substance use disorders, including alcohol and illicit drugs, as these can affect treatment outcomes and increase the risk of adverse effects.\n",
      "\n",
      "8. **Psychosocial Factors**:\n",
      "   - Evaluate psychosocial factors, including support systems, stressors, and the patient's understanding of their condition and treatment plan. This can help tailor the approach to the patient's needs and improve adherence.\n",
      "\n",
      "9. **Patient Education**:\n",
      "   - Discuss the potential side effects of venlafaxine, including nausea, dizziness, insomnia, and sexual dysfunction. Educate the patient about the importance of adherence to the prescribed regimen and the need for regular follow-up appointments to monitor progress and side effects.\n",
      "\n",
      "10. **Monitoring Plan**:\n",
      "    - Establish a monitoring plan to assess the patient's response to treatment, including regular follow-ups to evaluate efficacy, side effects, and any emerging concerns.\n",
      "\n",
      "By conducting a comprehensive evaluation that includes these factors, physicians can make informed decisions about prescribing venlafaxine, ensuring that it is appropriate for the individual patient's needs and circumstances.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.019346\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should conduct a thorough evaluation that encompasses several key areas to ensure the safety and efficacy of the treatment for the patient. Here are the critical factors to consider:\n",
      "\n",
      "1. **Patient History**:\n",
      "   - **Medical History**: Assess for any history of psychiatric disorders, particularly bipolar disorder, as venlafaxine can induce mania in susceptible individuals. Evaluate for any history of seizures, as venlafaxine can lower the seizure threshold.\n",
      "   - **Medication History**: Review current and past medications to identify any potential drug interactions, especially with other antidepressants (e.g., SSRIs, SNRIs, MAOIs), as well as medications that affect serotonin levels.\n",
      "   - **Substance Use**: Inquire about the use of alcohol, recreational drugs, or other substances that may interact with venlafaxine or exacerbate side effects.\n",
      "\n",
      "2. **Current Symptoms and Diagnosis**:\n",
      "   - **Indication for Use**: Confirm the diagnosis for which venlafaxine is being considered, such as major depressive disorder, generalized anxiety disorder, social anxiety disorder, or panic disorder.\n",
      "   - **Severity of Symptoms**: Evaluate the severity and duration of symptoms to determine if venlafaxine is an appropriate choice compared to other treatment options.\n",
      "\n",
      "3. **Risk Factors**:\n",
      "   - **Cardiovascular Health**: Assess for any history of hypertension or cardiovascular disease, as venlafaxine can increase blood pressure, particularly at higher doses.\n",
      "   - **Liver and Kidney Function**: Evaluate liver and renal function, as impaired function may necessitate dosage adjustments or alternative treatments.\n",
      "   - **Glaucoma**: Consider any history of narrow-angle glaucoma, as venlafaxine may exacerbate this condition.\n",
      "\n",
      "4. **Pregnancy and Lactation**:\n",
      "   - **Pregnancy Status**: Discuss the patient's pregnancy status or plans for pregnancy, as venlafaxine is classified as a Category C medication, meaning risk cannot be ruled out. The potential benefits and risks should be carefully weighed.\n",
      "   - **Breastfeeding**: Evaluate whether the patient is breastfeeding, as venlafaxine can be excreted in breast milk.\n",
      "\n",
      "5. **Patient Preferences and Understanding**:\n",
      "   - **Informed Consent**: Ensure that the patient understands the purpose of the medication, potential side effects, and the importance of adherence to the prescribed regimen.\n",
      "   - **Patient Preferences**: Discuss the patient's preferences regarding treatment options, including their willingness to try venlafaxine versus other therapies.\n",
      "\n",
      "6. **Monitoring Plan**:\n",
      "   - **Follow-Up**: Establish a plan for regular follow-up appointments to monitor the patient's response to the medication, side effects, and any necessary adjustments in dosage.\n",
      "   - **Assessment of Side Effects**: Educate the patient about potential side effects, including nausea, dizziness, insomnia, and increased blood pressure, and encourage them to report any concerning symptoms.\n",
      "\n",
      "7. **Contraindications**:\n",
      "   - **Known Allergies**: Check for any known allergies to venlafaxine or its components.\n",
      "   - **Concurrent Medications**: Identify any contraindicated medications, such as monoamine oxidase inhibitors (MAOIs), which can lead to serious interactions.\n",
      "\n",
      "By carefully evaluating these factors, physicians can make informed decisions about prescribing venlafaxine, tailoring treatment to the individual needs of the patient while minimizing risks and maximizing therapeutic benefits.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.023121\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should conduct a thorough evaluation that includes the following steps:\n",
      "\n",
      "### 1. **Patient History**\n",
      "   - **Medical History**: Assess the patient's overall health, including any history of cardiovascular disease, liver or kidney issues, seizures, or bipolar disorder. Venlafaxine can increase blood pressure and may not be suitable for patients with certain conditions.\n",
      "   - **Psychiatric History**: Evaluate the patient's history of mental health disorders, including depression, anxiety, and any previous treatments. Understanding past responses to medications can guide treatment decisions.\n",
      "   - **Substance Use**: Inquire about the use of alcohol, recreational drugs, or other medications that may interact with venlafaxine.\n",
      "\n",
      "### 2. **Current Medications**\n",
      "   - **Drug Interactions**: Review the patient's current medications to identify potential interactions. Venlafaxine can interact with other antidepressants, particularly monoamine oxidase inhibitors (MAOIs), and certain medications that affect serotonin levels, increasing the risk of serotonin syndrome.\n",
      "   - **Over-the-Counter and Herbal Supplements**: Ask about any OTC medications or herbal supplements the patient may be taking, as these can also interact with venlafaxine.\n",
      "\n",
      "### 3. **Physical Examination**\n",
      "   - Conduct a physical examination to assess the patient's general health and identify any contraindications to venlafaxine use, such as hypertension or other cardiovascular issues.\n",
      "\n",
      "### 4. **Baseline Assessments**\n",
      "   - **Blood Pressure**: Measure baseline blood pressure, as venlafaxine can cause dose-dependent increases in blood pressure.\n",
      "   - **Weight and BMI**: Consider the patient's weight and body mass index (BMI), as venlafaxine can lead to weight changes in some individuals.\n",
      "\n",
      "### 5. **Risk Assessment**\n",
      "   - **Suicidal Ideation**: Evaluate for any current or past suicidal thoughts or behaviors, especially in younger patients, as antidepressants can increase the risk of suicidal thoughts in this demographic.\n",
      "   - **Pregnancy and Lactation**: Assess whether the patient is pregnant, planning to become pregnant, or breastfeeding, as venlafaxine can have implications for fetal development and nursing infants.\n",
      "\n",
      "### 6. **Patient Education**\n",
      "   - Discuss the purpose of venlafaxine, how it works, and the expected timeline for therapeutic effects. Educate the patient about potential side effects, including nausea, dizziness, insomnia, and sexual dysfunction.\n",
      "   - Explain the importance of adherence to the prescribed regimen and the need for regular follow-up appointments to monitor progress and side effects.\n",
      "\n",
      "### 7. **Monitoring Plan**\n",
      "   - Establish a plan for regular follow-up visits to monitor the patient's response to the medication, side effects, and any necessary adjustments to the dosage.\n",
      "\n",
      "### 8. **Informed Consent**\n",
      "   - Ensure that the patient understands the treatment plan and consents to the use of venlafaxine, including discussing alternative treatment options if applicable.\n",
      "\n",
      "By conducting this comprehensive evaluation, physicians can make informed decisions about prescribing venlafaxine, ensuring it is appropriate for the patient's specific situation and minimizing potential risks.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017529\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should conduct a thorough evaluation that includes the following steps:\n",
      "\n",
      "### 1. **Patient History:**\n",
      "   - **Medical History:** Assess the patient's overall health, including any history of cardiovascular disease, liver or kidney dysfunction, seizures, or bipolar disorder. Venlafaxine can increase blood pressure and may not be suitable for patients with certain conditions.\n",
      "   - **Psychiatric History:** Evaluate the patient's psychiatric history, including any previous episodes of depression, anxiety disorders, or other mental health conditions. It's important to determine if the patient has a history of suicidal thoughts or behaviors.\n",
      "   - **Medication History:** Review the patient's current and past medications, including over-the-counter drugs and supplements, to identify potential drug interactions. Venlafaxine can interact with other medications, particularly monoamine oxidase inhibitors (MAOIs), SSRIs, and other serotonergic agents.\n",
      "\n",
      "### 2. **Current Symptoms:**\n",
      "   - **Assessment of Symptoms:** Conduct a detailed assessment of the patient's current symptoms, including the severity and duration of depressive or anxiety symptoms. This helps in determining the appropriateness of venlafaxine as a treatment option.\n",
      "   - **Functional Impairment:** Evaluate how the symptoms are affecting the patient's daily life, work, and relationships. This can guide the urgency and type of treatment needed.\n",
      "\n",
      "### 3. **Risk Factors:**\n",
      "   - **Suicidal Risk:** Assess the risk of suicide or self-harm, especially in younger patients or those with a history of suicidal ideation. This may involve using standardized screening tools.\n",
      "   - **Substance Use:** Inquire about any history of substance abuse, as this can complicate treatment and increase the risk of adverse effects.\n",
      "\n",
      "### 4. **Physical Examination:**\n",
      "   - Conduct a physical examination to rule out any underlying medical conditions that may contribute to the patient's symptoms or affect the safety of venlafaxine.\n",
      "\n",
      "### 5. **Laboratory Tests:**\n",
      "   - **Baseline Tests:** Depending on the patient's history and physical examination, consider ordering baseline laboratory tests, such as liver function tests, renal function tests, and a complete blood count (CBC) to monitor for potential side effects.\n",
      "   - **Blood Pressure Monitoring:** Since venlafaxine can increase blood pressure, it may be prudent to check the patient's blood pressure before starting treatment.\n",
      "\n",
      "### 6. **Patient Education:**\n",
      "   - Discuss the potential benefits and risks of venlafaxine, including common side effects (e.g., nausea, dizziness, insomnia) and serious risks (e.g., increased blood pressure, serotonin syndrome).\n",
      "   - Inform the patient about the importance of adherence to the prescribed regimen and the need for regular follow-up appointments to monitor progress and side effects.\n",
      "\n",
      "### 7. **Consideration of Alternatives:**\n",
      "   - Evaluate other treatment options, including psychotherapy, lifestyle modifications, or alternative medications, especially if the patient has contraindications to venlafaxine or prefers non-pharmacological approaches.\n",
      "\n",
      "### 8. **Follow-Up Plan:**\n",
      "   - Establish a follow-up plan to monitor the patient's response to treatment, side effects, and any necessary adjustments to the medication regimen.\n",
      "\n",
      "By conducting this comprehensive evaluation, physicians can make informed decisions about prescribing venlafaxine, ensuring it is appropriate and safe for the individual patient.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.02838\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should evaluate several important factors related to the patient's health status and potential risks. These considerations include:\n",
      "\n",
      "1. **Indications for Use**: Venlafaxine is primarily indicated for treating major depressive disorder, generalized anxiety disorder, and social anxiety disorder. Physicians should determine if the patient fits these criteria and understand their treatment goals.\n",
      "\n",
      "2. **Contraindications**: \n",
      "   - Physicians need to evaluate any history of hypersensitivity to venlafaxine or its components.\n",
      "   - Patients with uncontrolled narrow-angle glaucoma or a history of severe liver or kidney impairment may be at an increased risk of adverse effects (PubMed PMID: 40378325, 41505652).\n",
      "\n",
      "3. **Drug Interactions**: Venlafaxine exhibits potential interactions with various medications, including:\n",
      "   - Monoamine oxidase inhibitors (MAOIs): These should not be used concurrently or within 14 days of stopping an MAOI due to the risk of serotonin syndrome.\n",
      "   - Other serotonergic drugs: Combining venlafaxine with other serotonergic agents may increase the risk of serotonin syndrome (PubMed PMID: 41505652).\n",
      "\n",
      "4. **Medical History**: \n",
      "   - Evaluate a patient's history of cardiovascular diseases, seizures, or bipolar disorder, as venlafaxine can increase blood pressure and potentially induce mania in those with bipolar disorder.\n",
      "   - A mental health assessment should be performed to check for any history of suicidality or bipolar disorder (PubMed PMID: 40378325).\n",
      "\n",
      "5. **Pregnancy and Lactation**: Itâ€™s essential to assess whether the patient is pregnant, planning to become pregnant, or breastfeeding, as venlafaxine's effects on the fetus or nursing infant are still being studied. Some studies suggest it may be associated with certain risks during pregnancy (PubMed PMID: 41426913).\n",
      "\n",
      "6. **Adverse Effects**: Common side effects include nausea, dry mouth, dizziness, and insomnia. Understanding a patient's tolerance for these effects is crucial when deciding on treatment (PubMed PMID: 39059108).\n",
      "\n",
      "7. **Patient Education**: Physicians should inform patients about the potential risks and benefits of venlafaxine therapy, including the importance of adherence to treatment and what symptoms should prompt immediate medical attention (PubMed PMID: 39693465).\n",
      "\n",
      "By thoroughly evaluating these aspects, physicians can ensure a safer approach to prescribing venlafaxine, optimizing therapeutic outcomes while minimizing risks.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.026306\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should evaluate several important factors to ensure safe and effective treatment for their patients:\n",
      "\n",
      "1. **Medical History**: Assess for any history of psychiatric disorders, particularly bipolar disorder, as venlafaxine can elevate the risk of mania or hypomania. History of depression, anxiety, or suicidal thoughts is critical, as venlafaxine is an antidepressant, which carries a risk of increased suicidal ideation, especially in younger populations.\n",
      "\n",
      "2. **Current Medications**: Evaluate all current medications for potential drug-drug interactions. Venlafaxine is metabolized primarily by the liver enzyme CYP2D6, so consider factors affecting this enzyme. Caution is advised if the patient is taking medications that inhibit CYP2D6 or if the patient is a known poor metabolizer of this enzyme.\n",
      "\n",
      "3. **Cardiovascular Health**: Due to the potential of venlafaxine to increase blood pressure, obtain a baseline blood pressure reading and monitor it regularly, especially in patients with pre-existing hypertension or cardiovascular conditions.\n",
      "\n",
      "4. **Kidney and Liver Function**: Assess renal and hepatic function before prescribing venlafaxine, as dose adjustments may be necessary in patients with impairments in these organs.\n",
      "\n",
      "5. **Allergies and Contraindications**: Review any history of allergies to venlafaxine or related compounds. The presence of severe renal or hepatic impairment, as well as use of monoamine oxidase inhibitors (MAOIs) within the past 14 days, would contraindicate the use of venlafaxine.\n",
      "\n",
      "6. **Concurrent Medical Conditions**: Take into account any concurrent medical conditions that could complicate treatment, such as seizure disorders or those that predispose to serotonin syndrome (e.g., concurrent use of serotonergic drugs).\n",
      "\n",
      "7. **Pregnancy and Lactation**: Consider the implications for pregnant or breastfeeding patients, as the safety of venlafaxine in these populations should be carefully assessed against the potential benefits.\n",
      "\n",
      "8. **Patient Counseling**: Ensure the patient is fully informed about potential side effects, including but not limited to nausea, dizziness, insomnia, and increased sweating, as well as the importance of adherence to the prescribed regimen and any necessary follow-up.\n",
      "\n",
      "For comprehensive and up-to-date information, healthcare professionals can refer to the prescribing information provided by reliable sources such as the FDA or clinical guidelines.\n",
      "\n",
      "Further information on venlafaxine can also be obtained from resources like the [Drugs.com package insert](https://www.drugs.com/pro/venlafaxine.html) and [MedlinePlus](https://medlineplus.gov/druginfo/meds/a694020.html).\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.029647\n",
      "prediction:  Before prescribing venlafaxine tablets, physicians should evaluate several important factors to ensure safe and effective treatment. Here are the key considerations:\n",
      "\n",
      "1. **Patient History and Background**:\n",
      "   - **Psychiatric History**: Assess the patient's history of mental health disorders, including depression, anxiety, or other mood disorders, as venlafaxine is primarily used to treat major depressive disorder and anxiety disorders.\n",
      "   - **Family History**: Evaluate if there is a family history of psychotropic medication responses or adverse effects.\n",
      "\n",
      "2. **Contraindications and Precautions**:\n",
      "   - **Cardiovascular Health**: Examine the patientâ€™s cardiovascular health, as venlafaxine can increase blood pressure, particularly at higher doses. Patients with hypertension or heart conditions need close monitoring.\n",
      "   - **Liver and Kidney Function**: Investigate renal and hepatic function as venlafaxine is metabolized in the liver and excreted via the kidneys. Dose adjustments may be necessary for patients with impaired function.\n",
      "\n",
      "3. **Potential Drug Interactions**:\n",
      "   - Review the patient's current medication list to identify potential interactions. Venlafaxine can interact with several medications, including monoamine oxidase inhibitors (MAOIs) and other antidepressants, increasing the risk of serotonin syndrome.\n",
      "\n",
      "4. **Pregnancy and Lactation**:\n",
      "   - If the patient is pregnant, planning to become pregnant, or breastfeeding, assess the risks versus benefits, as venlafaxine has been associated with congenital anomalies in newborns when taken during pregnancy. \n",
      "\n",
      "5. **Side Effects and Withdrawal Symptoms**:\n",
      "   - Discuss the potential side effects, including nausea, dizziness, dry mouth, and sexual dysfunction. Also, inform the patient about possible withdrawal symptoms if the medication is abruptly discontinued.\n",
      "\n",
      "6. **Monitoring Plan**:\n",
      "   - Establish a monitoring plan for effects and side effects throughout the treatment. This includes regular follow-up visits to assess the therapeutic response and any adverse reactions.\n",
      "\n",
      "7. **Patientâ€™s Commitment to Treatment**:\n",
      "   - Evaluate the patient's understanding of the treatment plan and their commitment to adhere to the prescribed regimen, including any necessary lifestyle modifications.\n",
      "\n",
      "In summary, careful assessment of the patient's comprehensive medical history, potential contraindications, medication interactions, and ongoing monitoring is essential for the safe prescription of venlafaxine. This ensures not only effective management of the condition but also minimizes the risks associated with its use.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Patient's history of drug abuse\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.046976\n",
      "prediction:  Belladonna, also known as Atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family that contains toxic alkaloids including atropine, scopolamine, and hyoscyamine. These compounds can have serious effects on the body, particularly on the nervous system. Due to its toxicity, the use of belladonna in children requires careful consideration.\n",
      "\n",
      "In homeopathic and herbal medicine, belladonna is sometimes used for treating conditions such as fever, headaches, and muscle spasms. However, there isn't a standardized dosage for children aged 2 to 12 years. Because of the potential for toxicity and the varying ways in which children may respond to substances, it is essential that any use of belladonna in children is done under the supervision of a qualified healthcare professional.\n",
      "\n",
      "General recommendations suggest that if belladonna is to be used, it should be in a highly diluted form and closely monitored for adverse effects such as drowsiness, hallucinations, or other neurological symptoms. Caution is particularly warranted given that even small amounts can be harmful. \n",
      "\n",
      "As of now, insufficient clinical evidence is available to define a specific dosage range for belladonna in children aged 2 to 12 years. Parents are advised to err on the side of caution and consult healthcare providers regarding safe practices and potential alternatives before administering belladonna or any homeopathic treatments.\n",
      "\n",
      "For any form of medical intervention, especially in children, always consult with a healthcare professional who can provide guidance tailored to the individual's health needs and circumstances.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.041042\n",
      "prediction:  Belladonna, also known as deadly nightshade, is a plant that contains tropane alkaloids, including atropine, scopolamine, and hyoscyamine. It has been used historically in various medicinal applications, but its use, especially in children, is highly controversial and can be dangerous due to its toxicity.\n",
      "\n",
      "### Step 1: Understanding Belladonna\n",
      "- **Active Compounds**: The primary active compounds in Belladonna are atropine and scopolamine, which have anticholinergic properties.\n",
      "- **Uses**: Historically, Belladonna has been used for conditions such as muscle spasms, motion sickness, and as a sedative. However, its use is limited due to the potential for serious side effects.\n",
      "\n",
      "### Step 2: Safety and Efficacy\n",
      "- **Toxicity**: Belladonna is considered toxic, especially in children. The margin between a therapeutic dose and a toxic dose is narrow.\n",
      "- **Regulatory Status**: In many countries, the use of Belladonna in children is not recommended or is restricted. The American Academy of Pediatrics advises against the use of Belladonna in children due to safety concerns.\n",
      "\n",
      "### Step 3: Recommended Dosage\n",
      "- **Lack of Standardization**: There is no universally accepted dosage for Belladonna in children aged 2 to 12 years. The lack of standardization in herbal preparations and the variability in individual responses make it difficult to provide a safe dosage.\n",
      "- **Consultation with Healthcare Providers**: If Belladonna is being considered for a specific medical condition, it is crucial to consult a healthcare provider. They can provide guidance based on the child's specific health needs and the potential risks involved.\n",
      "\n",
      "### Step 4: Alternatives and Recommendations\n",
      "- **Safer Alternatives**: For conditions that Belladonna might be used for, there are often safer and more effective alternatives available. For example, for muscle spasms, other medications or therapies may be recommended.\n",
      "- **Monitoring and Education**: If Belladonna is used in any form, it should be done under strict medical supervision, with careful monitoring for any adverse effects.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the use of Belladonna in children aged 2 to 12 years is not recommended due to its toxicity and the potential for serious side effects. There is no established safe dosage for this age group, and it is essential to consult a healthcare provider for appropriate treatment options. Always prioritize safety and evidence-based practices when considering herbal remedies for children.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.069753\n",
      "prediction:  Belladonna, also known as deadly nightshade, is a plant that contains tropane alkaloids, including atropine, scopolamine, and hyoscyamine. It has been used historically in various medicinal applications, but its use, especially in children, is highly controversial and generally not recommended due to its potential toxicity and the narrow therapeutic window of its active compounds.\n",
      "\n",
      "In modern medicine, the use of belladonna in children is limited, and it is not commonly prescribed. The dosages can vary significantly based on the formulation (e.g., tinctures, extracts, or homeopathic preparations) and the specific condition being treated. However, due to the risks associated with belladonna, including severe side effects such as hallucinations, tachycardia, and respiratory distress, it is crucial to approach its use with caution.\n",
      "\n",
      "For any herbal or botanical product, including belladonna, it is essential to consult a healthcare professional before administration, especially in children. The healthcare provider can assess the child's specific health needs, consider any potential interactions with other medications, and determine the safest and most effective treatment options.\n",
      "\n",
      "In summary, there is no standardized or universally recommended dosage of belladonna for children aged 2 to 12 years due to safety concerns. Parents and caregivers should avoid administering belladonna without professional guidance and should seek alternative treatments that are proven to be safe and effective for children.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.035746\n",
      "prediction:  Belladonna, also known as deadly nightshade, is a plant that contains tropane alkaloids, including atropine, scopolamine, and hyoscyamine. It has been used historically in various medicinal applications, but its use, especially in children, is highly controversial and generally not recommended due to its potential toxicity and the risk of serious side effects.\n",
      "\n",
      "In modern medicine, the use of belladonna is limited, and it is primarily found in specific formulations for certain conditions, such as colicky pain or as an antispasmodic. However, the dosages can vary significantly based on the formulation and the specific condition being treated. \n",
      "\n",
      "For children aged 2 to 12 years, there is no universally accepted or recommended dosage of belladonna due to the following reasons:\n",
      "\n",
      "1. **Safety Concerns**: Belladonna is considered toxic, and its use in children can lead to severe side effects, including hallucinations, seizures, respiratory distress, and even death in cases of overdose.\n",
      "\n",
      "2. **Lack of Standardization**: The concentration of active ingredients in belladonna preparations can vary widely, making it difficult to establish a safe and effective dosage.\n",
      "\n",
      "3. **Regulatory Guidelines**: Many health organizations, including the American Academy of Pediatrics, advise against the use of belladonna in children due to the risks involved.\n",
      "\n",
      "4. **Alternative Treatments**: There are safer and more effective alternatives available for treating conditions that belladonna might be used for, such as gastrointestinal issues or muscle spasms.\n",
      "\n",
      "If belladonna is being considered for a specific medical condition in a child, it is crucial to consult a healthcare professional. They can provide guidance based on the child's individual health needs and the latest medical evidence. In general, it is advisable to avoid using belladonna in children unless under strict medical supervision and in a controlled setting. \n",
      "\n",
      "In summary, there is no recommended dosage of belladonna for children aged 2 to 12 years due to safety concerns, variability in formulations, and the availability of safer alternatives. Always consult a healthcare provider for appropriate treatment options.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.03435\n",
      "prediction:  Belladonna, also known as deadly nightshade, is a plant that contains tropane alkaloids, including atropine, scopolamine, and hyoscyamine. It has been used historically in various medicinal applications, but its use, especially in children, is highly controversial and generally not recommended due to its potential toxicity and the risk of serious side effects.\n",
      "\n",
      "In modern medicine, the use of belladonna is limited, and it is primarily found in specific formulations for certain conditions, such as colicky pain or as an antispasmodic. However, the dosages can vary significantly based on the formulation and the specific condition being treated. \n",
      "\n",
      "For children aged 2 to 12 years, there is no universally accepted or recommended dosage of belladonna due to the following reasons:\n",
      "\n",
      "1. **Safety Concerns**: Belladonna is considered toxic, and its use in children can lead to severe side effects, including hallucinations, seizures, respiratory distress, and even death. The therapeutic window is narrow, meaning the difference between a therapeutic dose and a toxic dose is small.\n",
      "\n",
      "2. **Lack of Standardization**: The concentration of active ingredients in belladonna preparations can vary widely, making it difficult to establish a safe and effective dosage.\n",
      "\n",
      "3. **Regulatory Guidelines**: Many health organizations, including the American Academy of Pediatrics, advise against the use of belladonna in children due to the risks involved. \n",
      "\n",
      "4. **Alternative Treatments**: There are safer and more effective alternatives available for treating conditions that belladonna might be used for, such as gastrointestinal issues or muscle spasms.\n",
      "\n",
      "If belladonna is being considered for a specific medical condition in a child, it is crucial to consult a healthcare professional. They can provide guidance based on the child's individual health needs and the latest medical evidence. In general, it is advisable to avoid using belladonna in children unless under strict medical supervision and in a controlled setting. \n",
      "\n",
      "In summary, there is no recommended dosage of belladonna for children aged 2 to 12 years due to safety concerns, variability in formulations, and the availability of safer alternatives. Always consult a healthcare provider for appropriate treatment options.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.037696\n",
      "prediction:  Belladonna, also known as deadly nightshade, is a plant that contains tropane alkaloids, including atropine, scopolamine, and hyoscyamine. It has been used historically in various medicinal applications, but its use, especially in children, is highly controversial and potentially dangerous due to its toxicity and the narrow therapeutic window of its active compounds.\n",
      "\n",
      "### Step 1: Understanding Belladonna\n",
      "\n",
      "1. **Active Compounds**: The primary active compounds in Belladonna are atropine, scopolamine, and hyoscyamine. These compounds can affect the nervous system and have anticholinergic properties.\n",
      "  \n",
      "2. **Uses**: Belladonna has been used for various conditions, including muscle spasms, motion sickness, and as a sedative. However, its use in children is limited and often discouraged due to safety concerns.\n",
      "\n",
      "### Step 2: Safety and Efficacy\n",
      "\n",
      "1. **Toxicity**: Belladonna is considered toxic, and the ingestion of even small amounts can lead to serious side effects, including hallucinations, seizures, and respiratory failure. The risk is particularly high in children, who may be more sensitive to its effects.\n",
      "\n",
      "2. **Regulatory Status**: In many countries, the use of Belladonna in children is not recommended or is restricted. The American Academy of Pediatrics and other health organizations generally advise against the use of Belladonna in pediatric populations.\n",
      "\n",
      "### Step 3: Dosage Considerations\n",
      "\n",
      "1. **Lack of Standardization**: There is no universally accepted dosage for Belladonna in children, particularly because of the variability in the concentration of active compounds in herbal preparations. \n",
      "\n",
      "2. **Consultation with Healthcare Providers**: If Belladonna is considered for use, it should only be done under the guidance of a qualified healthcare provider who can assess the risks and benefits based on the individual child's health status and needs.\n",
      "\n",
      "### Step 4: Alternatives and Recommendations\n",
      "\n",
      "1. **Alternative Treatments**: For conditions that Belladonna might be used for, there are often safer and more effective alternatives available. For example, for muscle spasms, other medications or therapies may be recommended.\n",
      "\n",
      "2. **Education and Awareness**: Parents and caregivers should be educated about the potential dangers of using Belladonna and should be encouraged to seek safer, evidence-based treatments for their children.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, there is no recommended dosage of Belladonna for children aged 2 to 12 years due to its toxicity and the lack of evidence supporting its safety and efficacy in this age group. It is crucial to consult with a healthcare professional before considering any use of Belladonna or similar substances in children. The focus should be on safer, more effective alternatives for managing health conditions in pediatric patients.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.036222\n",
      "prediction:  Belladonna, also known as deadly nightshade, is a plant that contains tropane alkaloids, including atropine, scopolamine, and hyoscyamine. It has been used historically in various medicinal applications, but its use, especially in children, is highly controversial and potentially dangerous due to its toxicity.\n",
      "\n",
      "### Step 1: Understanding Belladonna\n",
      "\n",
      "- **Active Compounds**: The primary active compounds in Belladonna are atropine, scopolamine, and hyoscyamine. These compounds can affect the nervous system and have anticholinergic properties.\n",
      "- **Uses**: Belladonna has been used for various conditions, including muscle spasms, motion sickness, and as a sedative. However, its use in children is limited and often discouraged due to safety concerns.\n",
      "\n",
      "### Step 2: Safety and Efficacy\n",
      "\n",
      "- **Toxicity**: Belladonna is considered toxic, and the margin between a therapeutic dose and a toxic dose is narrow. Symptoms of toxicity can include dilated pupils, sensitivity to light, tachycardia, hallucinations, and seizures.\n",
      "- **Regulatory Stance**: Many health organizations, including the American Academy of Pediatrics, advise against the use of Belladonna in children due to the risks associated with its toxicity and the availability of safer alternatives.\n",
      "\n",
      "### Step 3: Dosage Recommendations\n",
      "\n",
      "- **Lack of Standardization**: There is no universally accepted dosage for Belladonna in children, particularly for those aged 2 to 12 years. The lack of standardization in herbal preparations and the variability in individual responses make it difficult to recommend a safe dosage.\n",
      "- **Consultation with Healthcare Providers**: If Belladonna is being considered for a specific medical condition, it is crucial to consult a healthcare provider. They can provide guidance based on the child's specific health needs and the potential risks involved.\n",
      "\n",
      "### Step 4: Alternatives and Considerations\n",
      "\n",
      "- **Safer Alternatives**: For conditions that Belladonna might be used for, there are often safer and more effective alternatives available. For example, for muscle spasms, other medications or therapies may be recommended.\n",
      "- **Monitoring and Supervision**: If a healthcare provider does recommend Belladonna for a specific reason, it should be done under strict medical supervision, with careful monitoring for any adverse effects.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the use of Belladonna in children aged 2 to 12 years is not recommended due to its toxicity and the availability of safer alternatives. There is no established dosage for this age group, and any consideration of its use should be done with caution and under the guidance of a qualified healthcare professional. Always prioritize safety and consult with a healthcare provider for appropriate treatment options.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.059375\n",
      "prediction:  Belladonna, derived from the plant Atropa belladonna, contains alkaloids that have both therapeutic and toxic effects. Its use, particularly in children, is controversial and generally approached with caution due to potential adverse effects. \n",
      "\n",
      "1. **Dosage Considerations:** There is a lack of standardized dosing guidelines for children aged 2 to 12 years. Many medical resources and experts caution against using belladonna in young children, primarily due to the risks of toxicity. Available information suggests that belladonna should only be used under strict medical supervision.\n",
      "\n",
      "2. **Medical Advice:** The general guideline is that belladonna preparations, especially those that are not pharmaceuticals approved for pediatric use, should be avoided in young children. When prescribed for specific conditions, the dosage must be determined by a healthcare professional who will consider the child's weight, medical history, and specific health conditions.\n",
      "\n",
      "3. **Forms of Belladonna:** Belladonna is available in several preparations, including tinctures, extracts, and homeopathic formulations. For conditions like muscle spasms or certain types of colic, some practitioners might consider using it, but again, under medical supervision.\n",
      "\n",
      "4. **Safety Considerations:** The safety profile of belladonna in children is not well-established. Reports indicate potential side effects such as hallucinations, increased heart rate, and other anticholinergic symptoms, which can be particularly harmful in children.\n",
      "\n",
      "Given these considerations, it is crucial for caregivers to consult with a pediatrician or a healthcare provider before administering belladonna or any preparation containing it to children aged 2 to 12 years. Self-medication is strongly discouraged, and health professionals are best equipped to assess the risks and benefits of such treatments.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:    agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "     sc\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "    cot\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "SIM_score:  0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.580000\n",
      "0.329787\n",
      "0.427273\n",
      "0.580000\n",
      "0.329787\n",
      "0.427273\n",
      "0.580000\n",
      "0.329787\n",
      "0.427273\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.580000\n",
      "0.329787\n",
      "0.427273\n",
      "0.580000\n",
      "0.329787\n",
      "0.427273\n",
      "0.580000\n",
      "0.329787\n",
      "0.427273\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.057143\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.029412\n",
      "0.000000\n",
      "0.000000\n",
      "0.031250\n",
      "0.000000\n",
      "0.028986\n",
      "0.068966\n",
      "0.000000\n",
      "0.000000\n",
      "0.027027\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "prediction:  C\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:          C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "        C\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "D\n",
      "D\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "correct answer: 15\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.027703\n",
      "prediction:  Cleaning the spray nozzle of a nasal spray, such as DG Health nasal spray, is important to ensure proper hygiene and to maintain the effectiveness of the medication. Hereâ€™s a comprehensive procedure for cleaning the spray nozzle:\n",
      "\n",
      "### Materials Needed:\n",
      "- Clean, warm water\n",
      "- Mild soap (optional)\n",
      "- Clean cloth or paper towel\n",
      "- Alcohol wipes or cotton balls soaked in rubbing alcohol (optional)\n",
      "\n",
      "### Procedure:\n",
      "\n",
      "1. **Wash Your Hands**: \n",
      "   - Begin by thoroughly washing your hands with soap and water for at least 20 seconds. This helps prevent the introduction of bacteria or other contaminants to the nasal spray.\n",
      "\n",
      "2. **Remove the Spray Nozzle**: \n",
      "   - Carefully remove the spray nozzle from the bottle. This is usually done by gently twisting or pulling it off, depending on the design of the spray.\n",
      "\n",
      "3. **Rinse the Nozzle**: \n",
      "   - Rinse the nozzle under warm running water. Make sure to direct the water into the opening of the nozzle to help flush out any residual medication or debris.\n",
      "\n",
      "4. **Clean with Soap (if necessary)**: \n",
      "   - If the nozzle appears particularly dirty or if you want to ensure a thorough clean, you can use a mild soap. Apply a small amount of soap to your fingers or a soft cloth and gently scrub the nozzle, paying special attention to the opening.\n",
      "\n",
      "5. **Rinse Again**: \n",
      "   - After cleaning with soap, rinse the nozzle thoroughly under warm running water to remove all soap residue. Itâ€™s important that no soap remains, as it can irritate the nasal passages.\n",
      "\n",
      "6. **Disinfect (optional)**: \n",
      "   - If you want to further disinfect the nozzle, you can wipe it with an alcohol wipe or a cotton ball soaked in rubbing alcohol. This step is particularly useful if the spray has been shared or if you are concerned about germs.\n",
      "\n",
      "7. **Dry the Nozzle**: \n",
      "   - Use a clean cloth or paper towel to gently dry the nozzle. Ensure that it is completely dry before reattaching it to the bottle to prevent moisture from entering the medication.\n",
      "\n",
      "8. **Reattach the Nozzle**: \n",
      "   - Once the nozzle is clean and dry, carefully reattach it to the nasal spray bottle. Make sure it is securely in place.\n",
      "\n",
      "9. **Store Properly**: \n",
      "   - Store the nasal spray in a cool, dry place, away from direct sunlight. Ensure that the cap is on to protect the nozzle from dust and contaminants.\n",
      "\n",
      "### Additional Tips:\n",
      "- **Frequency of Cleaning**: It is advisable to clean the nozzle regularly, especially if you use the spray frequently or if it has been a while since the last cleaning.\n",
      "- **Avoid Sharing**: To minimize the risk of contamination, avoid sharing nasal sprays with others.\n",
      "- **Check for Damage**: While cleaning, inspect the nozzle for any signs of damage or wear. If the nozzle is damaged, it may need to be replaced to ensure proper function.\n",
      "\n",
      "By following these steps, you can help maintain the cleanliness of your DG Health nasal spray nozzle, ensuring that it remains effective and safe for use.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.030862\n",
      "prediction:  Cleaning the spray nozzle of a nasal spray, such as DG Health nasal spray, is important to ensure that the device functions properly and to prevent contamination. Hereâ€™s a step-by-step guide on how to clean the spray nozzle effectively:\n",
      "\n",
      "### Step 1: Gather Supplies\n",
      "Before you begin, gather the following supplies:\n",
      "- Warm water\n",
      "- Mild soap (optional)\n",
      "- Clean cloth or paper towel\n",
      "- A small bowl or cup (optional)\n",
      "\n",
      "### Step 2: Prepare the Nasal Spray\n",
      "1. **Remove the Cap**: Take off the protective cap from the nasal spray nozzle. This will expose the spray nozzle for cleaning.\n",
      "2. **Check for Residue**: Inspect the nozzle for any visible residue or blockage. This may include dried medication or other debris.\n",
      "\n",
      "### Step 3: Clean the Nozzle\n",
      "1. **Rinse with Warm Water**: Hold the nasal spray upright and rinse the nozzle under warm running water for about 30 seconds. This helps to loosen any dried medication.\n",
      "2. **Use Mild Soap (if necessary)**: If there is significant buildup, you can use a small amount of mild soap. Apply the soap to a clean cloth or your fingers and gently scrub the nozzle. Be careful not to apply too much pressure, as this could damage the nozzle.\n",
      "3. **Rinse Again**: After cleaning with soap, rinse the nozzle thoroughly under warm running water to remove any soap residue.\n",
      "\n",
      "### Step 4: Dry the Nozzle\n",
      "1. **Shake Off Excess Water**: Gently shake the nasal spray to remove excess water from the nozzle.\n",
      "2. **Pat Dry**: Use a clean cloth or paper towel to pat the nozzle dry. Ensure that it is completely dry before reattaching the cap.\n",
      "\n",
      "### Step 5: Reassemble the Nasal Spray\n",
      "1. **Replace the Cap**: Once the nozzle is dry, replace the protective cap to keep the nozzle clean and prevent contamination.\n",
      "2. **Store Properly**: Store the nasal spray in a cool, dry place, away from direct sunlight and heat.\n",
      "\n",
      "### Step 6: Regular Maintenance\n",
      "- **Frequency of Cleaning**: It is advisable to clean the nozzle regularly, especially if you notice any blockage or after each use if the spray is used frequently.\n",
      "- **Follow Manufacturer Instructions**: Always refer to the specific instructions provided by the manufacturer of the nasal spray, as some products may have unique cleaning requirements.\n",
      "\n",
      "### Additional Tips\n",
      "- **Avoid Submerging**: Do not submerge the entire nasal spray bottle in water, as this can damage the internal mechanism.\n",
      "- **Check Expiration Dates**: Regularly check the expiration date of the nasal spray and dispose of it properly if it is expired.\n",
      "\n",
      "By following these steps, you can ensure that your DG Health nasal spray remains clean and effective for use.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.075802\n",
      "prediction:  Currently, there is limited specific literature regarding recommendations for patients with hepatic impairment being considered for Zynteglo treatment, especially in PubMed or clinical trial registries. However, an overview of related information suggests the following:\n",
      "\n",
      "1. **Zynteglo Overview**: Zynteglo is a gene therapy designed for patients with beta-thalassemia who require regular blood transfusions. Its safety and effectiveness in patients with hepatic impairment are critical due to the potential impact on metabolic processes and drug clearance.\n",
      "\n",
      "2. **General Recommendation**: In general, medicinal products and therapies may require dose adjustments for patients with hepatic impairment based on the class and mechanism of action of the drug. For instance, treatments might be contraindicated or require careful monitoring for any adverse effects in patients with significant liver damage.\n",
      "\n",
      "3. **Specific Resources**: Drug manufacturers and medical guidelines often provide specific recommendations based on the child's classification of hepatic function (e.g., Child-Pugh score).\n",
      "\n",
      "In practical terms, it is recommended that a healthcare professional carefully evaluate the risks versus benefits of Zynteglo in patients with hepatic impairment and monitor the patient closely if treatment is considered. Consulting the prescribing information or product monograph for Zynteglo would be advisable for the most accurate and specific guidelines.\n",
      "\n",
      "For detailed and personalized recommendations, a consultation with a healthcare provider specializing in gene therapies or hematologic disorders is prudent.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Hepatic function should be assessed to ensure hematopoietic stem cell transplantation is appropriate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:    agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "  agent\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "default\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "   cot2\n",
      "SIM_score:  0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.037037\n",
      "0.000000\n",
      "0.051282\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.051282\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "0.000000\n",
      "prediction:  D\n",
      "pred_SIM:  A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "correct_answer:  D\n",
      "C\n",
      "D\n",
      "D\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "B\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.019446\n",
      "prediction:  Dopamine HCl in Dextrose Injection is a medication commonly used in critical care settings to manage conditions such as shock, heart failure, and certain types of cardiac arrest. However, it is crucial to understand why this medication should not be administered with blood products. Hereâ€™s a comprehensive breakdown of the reasons:\n",
      "\n",
      "### 1. **Chemical Compatibility**\n",
      "   - **Potential for Precipitation**: Dopamine can interact with certain components in blood products, leading to precipitation. This can occur due to the formation of complexes between dopamine and proteins or other substances in the blood, which can compromise the integrity of the blood product and reduce its efficacy.\n",
      "   - **pH Changes**: The pH of the dextrose solution may differ from that of blood products. Such differences can lead to instability of the blood components, particularly red blood cells, which may be sensitive to changes in pH.\n",
      "\n",
      "### 2. **Adverse Reactions**\n",
      "   - **Hemolysis Risk**: The combination of dopamine and blood products may increase the risk of hemolysis (destruction of red blood cells). This can occur due to the oxidative stress induced by dopamine, which can damage the red blood cell membranes.\n",
      "   - **Allergic Reactions**: Administering dopamine with blood products may increase the risk of allergic reactions or transfusion reactions, as the interaction could provoke an immune response.\n",
      "\n",
      "### 3. **Pharmacological Considerations**\n",
      "   - **Vasopressor Effects**: Dopamine is a vasopressor that can affect blood pressure and circulation. When administered with blood, it may alter the expected hemodynamic response to the transfusion, complicating the management of the patientâ€™s condition.\n",
      "   - **Dilution Effects**: The presence of dextrose in the solution may dilute the concentration of blood components, potentially affecting the therapeutic effects of the transfusion.\n",
      "\n",
      "### 4. **Clinical Guidelines and Best Practices**\n",
      "   - **Standard Protocols**: Most clinical guidelines and protocols recommend administering medications and blood products separately to avoid complications. This practice is based on extensive clinical experience and research that highlights the risks associated with co-administration.\n",
      "   - **Monitoring and Safety**: Administering dopamine separately allows for better monitoring of the patientâ€™s response to both the medication and the blood transfusion, ensuring that any adverse effects can be promptly addressed.\n",
      "\n",
      "### 5. **Administration Recommendations**\n",
      "   - **Separate Infusion Lines**: If both dopamine and blood products are needed, they should be administered through separate intravenous lines or at different times to prevent any potential interactions.\n",
      "   - **Flush Protocols**: If a common line is used, it is essential to flush the line thoroughly with saline before and after administering either the medication or the blood product to prevent any residual interaction.\n",
      "\n",
      "### Conclusion\n",
      "In summary, Dopamine HCl in Dextrose Injection should not be administered with blood due to concerns about chemical compatibility, the risk of adverse reactions, pharmacological interactions, adherence to clinical guidelines, and the importance of patient safety. By following these recommendations, healthcare providers can ensure optimal outcomes for patients requiring both medications and blood transfusions.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.022084\n",
      "prediction:  Dopamine HCl in Dextrose Injection is a medication commonly used in critical care settings to manage conditions such as shock, heart failure, and certain types of hypotension. However, it is crucial to avoid administering this medication concurrently with blood products for several reasons:\n",
      "\n",
      "1. **Chemical Interaction**: Dopamine is a catecholamine that can potentially interact with components of blood products. The presence of dopamine in the blood can lead to the formation of precipitates or other chemical reactions that may compromise the integrity of the blood product. This can result in the formation of aggregates that could obstruct blood flow or cause adverse reactions in the patient.\n",
      "\n",
      "2. **pH and Stability**: Dopamine is sensitive to changes in pH and can degrade when exposed to alkaline conditions. Blood products, particularly packed red blood cells, have a specific pH range that is optimal for their stability and function. Mixing dopamine with blood could alter the pH and lead to the degradation of both the dopamine and the blood components, reducing their efficacy.\n",
      "\n",
      "3. **Risk of Hemolysis**: The infusion of dopamine alongside blood products may increase the risk of hemolysis (the breakdown of red blood cells). This can occur due to the potential for increased oxidative stress or other biochemical interactions that may arise when these substances are mixed.\n",
      "\n",
      "4. **Infusion Compatibility**: Blood products are typically administered through specific blood administration sets that are designed to filter and manage the flow of blood. Dopamine, on the other hand, is usually administered through a separate intravenous line. Mixing these two therapies in the same line can lead to complications such as clotting or blockage of the IV line, which can compromise the delivery of both the medication and the blood product.\n",
      "\n",
      "5. **Monitoring and Safety**: Administering dopamine and blood products separately allows for better monitoring of the patientâ€™s response to each treatment. It is essential to observe for any adverse reactions to either the blood transfusion or the dopamine infusion. If they are administered together, it may be challenging to determine the cause of any adverse effects that arise.\n",
      "\n",
      "6. **Guidelines and Best Practices**: Medical guidelines and best practices typically recommend administering blood products and medications through separate lines or at different times to minimize the risk of complications. This is a standard precaution in clinical practice to ensure patient safety.\n",
      "\n",
      "In summary, Dopamine HCl in Dextrose Injection should not be administered with blood due to the potential for chemical interactions, changes in pH, risk of hemolysis, compatibility issues, and the need for careful monitoring. It is essential to follow established protocols to ensure the safety and efficacy of both treatments.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.023818\n",
      "prediction:  Dopamine HCl in Dextrose Injection is a medication commonly used in critical care settings to manage conditions such as shock, heart failure, and certain types of hypotension. However, it is crucial to avoid administering this medication concurrently with blood products for several reasons:\n",
      "\n",
      "1. **Chemical Interaction**: Dopamine is a catecholamine that can potentially interact with components of blood products. The presence of dopamine in the blood can lead to the formation of precipitates or other chemical reactions that may compromise the integrity of the blood product. This can result in the formation of aggregates that could obstruct blood flow or cause adverse reactions in the patient.\n",
      "\n",
      "2. **pH and Stability**: Dopamine is sensitive to changes in pH and can degrade when exposed to alkaline conditions. Blood products, particularly red blood cells, have specific pH requirements for storage and administration. Mixing dopamine with blood could alter the pH balance, leading to the degradation of dopamine and reducing its efficacy.\n",
      "\n",
      "3. **Risk of Hemolysis**: The infusion of dopamine alongside blood products may increase the risk of hemolysis (the breakdown of red blood cells). This is particularly concerning in patients who are already at risk for hemolytic reactions due to underlying conditions or previous transfusions. Hemolysis can lead to serious complications, including acute kidney injury and disseminated intravascular coagulation (DIC).\n",
      "\n",
      "4. **Vascular Effects**: Dopamine has vasodilatory effects at certain doses, which can alter blood flow dynamics. When administered with blood, these effects could lead to unpredictable changes in hemodynamics, potentially complicating the management of the patientâ€™s condition.\n",
      "\n",
      "5. **Guidelines and Best Practices**: Medical guidelines and best practices typically recommend administering medications and blood products separately to avoid complications. This is particularly emphasized in critical care settings where the stability and efficacy of both the medication and the blood product are paramount.\n",
      "\n",
      "6. **Monitoring and Safety**: Administering dopamine and blood products separately allows for better monitoring of the patientâ€™s response to each treatment. It ensures that any adverse reactions can be promptly identified and managed without the confounding effects of simultaneous administration.\n",
      "\n",
      "In summary, the administration of Dopamine HCl in Dextrose Injection with blood products is contraindicated due to potential chemical interactions, stability issues, increased risk of hemolysis, and the need for careful monitoring of patient responses. It is essential to follow established protocols to ensure patient safety and the effectiveness of treatment.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.025191\n",
      "prediction:  Dopamine HCl in Dextrose Injection is a medication commonly used in critical care settings to manage conditions such as shock, heart failure, and certain types of hypotension. However, it is crucial to avoid administering this medication concurrently with blood products for several reasons:\n",
      "\n",
      "1. **Chemical Interaction**: Dopamine is a catecholamine that can potentially interact with the components of blood products. The presence of dopamine in the blood can lead to the formation of precipitates or other chemical reactions that may compromise the integrity of the blood product. This can result in the formation of aggregates that could obstruct blood flow or cause adverse reactions in the patient.\n",
      "\n",
      "2. **pH and Stability**: Dopamine is sensitive to changes in pH and can degrade when exposed to alkaline conditions. Blood products, particularly packed red blood cells, have a specific pH range that is optimal for their storage and function. Mixing dopamine with blood could alter the pH and lead to the degradation of dopamine, reducing its efficacy and potentially leading to the release of harmful byproducts.\n",
      "\n",
      "3. **Risk of Hemolysis**: The infusion of dopamine alongside blood products may increase the risk of hemolysis (destruction of red blood cells). This is particularly concerning if the blood product is not properly matched or if there are underlying conditions that predispose the patient to hemolytic reactions. The presence of dopamine could exacerbate this risk.\n",
      "\n",
      "4. **Vascular Effects**: Dopamine has vasodilatory and vasoconstrictive properties depending on the dose. When administered with blood, there is a potential for unpredictable vascular responses, which could complicate the management of the patientâ€™s hemodynamics. This is particularly critical in patients who are already hemodynamically unstable.\n",
      "\n",
      "5. **Infusion Compatibility**: Blood products are typically administered through specific blood administration sets that are designed to filter and manage the flow of blood. Dopamine, on the other hand, is usually administered through different infusion systems. Mixing the two could lead to complications in flow rates, pressure, and overall delivery of the medications and blood products.\n",
      "\n",
      "6. **Clinical Guidelines**: Most clinical guidelines and protocols explicitly recommend against the co-administration of dopamine and blood products. This is based on the cumulative evidence of potential adverse effects and the importance of maintaining the integrity and efficacy of both the medication and the blood product.\n",
      "\n",
      "In summary, the administration of Dopamine HCl in Dextrose Injection with blood products is contraindicated due to the risk of chemical interactions, changes in pH, potential hemolysis, unpredictable vascular effects, infusion compatibility issues, and adherence to clinical guidelines. It is essential for healthcare providers to follow established protocols to ensure patient safety and optimal therapeutic outcomes.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It leads to pseudoagglutination of red cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.052675\n",
      "prediction:  Elderly patients using Zithromax (azithromycin) require careful consideration due to several safety factors:\n",
      "\n",
      "1. **Pharmacokinetics and Pharmacodynamics**: Elderly patients often experience altered pharmacokinetics, including changes in drug absorption, distribution, metabolism, and excretion. Age-related decline in renal function can affect the clearance of azithromycin, especially in those with compromised kidney function. This necessitates careful monitoring of dosing and an awareness of potential toxicity.\n",
      "\n",
      "2. **Adverse Effects**: Elderly individuals are at higher risk for adverse drug events due to polypharmacy (the concurrent use of multiple medications), which can lead to drug interactions. Common side effects of azithromycin include gastrointestinal issues like diarrhea and nausea, which can be particularly problematic for older patients, possibly leading to dehydration and exacerbation of existing health conditions.\n",
      "\n",
      "3. **Cardiovascular Risk**: Azithromycin has been associated with a risk of QT prolongation, which can lead to serious cardiac arrhythmias. Elderly patients, especially those with pre-existing cardiovascular conditions or those taking other QT-prolonging drugs, are at increased risk. Monitoring ECG changes and cardiovascular status is recommended during therapy.\n",
      "\n",
      "4. **Efficacy Considerations**: The effectiveness of azithromycin can also be influenced by the presence of co-morbidities commonly found in older adults, such as chronic obstructive pulmonary disease (COPD) or heart failure, necessitating individualized treatment plans that consider both efficacy and safety.\n",
      "\n",
      "5. **Infection Considerations**: Elderly patients are more susceptible to infections and may require treatment with antibiotics. However, clinicians must weigh the benefits of empirical antibiotic therapy against the risks of adverse effects, especially for medications like azithromycin that can carry significant side effect profiles.\n",
      "\n",
      "In summary, the safety considerations for elderly patients using Zithromax include careful monitoring of renal and cardiovascular function, vigilance for drug interactions, and a tailored approach to dosing and treatment duration to balance efficacy and safety. Regular review of medication regimens is prudent to minimize risks associated with polypharmacy and adverse drug reactions.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Elderly patients may be more susceptible to torsades de pointes arrhythmias.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "agent\n",
      "SIM_score:  0.193548\n",
      "0.235294\n",
      "0.177778\n",
      "0.115385\n",
      "0.125000\n",
      "0.100000\n",
      "0.333333\n",
      "0.193548\n",
      "0.235294\n",
      "0.137931\n",
      "0.113208\n",
      "0.142857\n",
      "0.200000\n",
      "0.181818\n",
      "0.289697\n",
      "0.401053\n",
      "prediction:  Error\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "B\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "choice:  NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "NOTAVALUE\n",
      "correct_answer:  A\n",
      "A\n",
      "C\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "A\n",
      "correct answer: Treatment of nicotine addiction by reducing withdrawal symptoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.109685\n",
      "prediction:  Fluoxetine and its metabolite Norfluoxetine have been assessed for genotoxic effects using various assays, and the findings indicate that they do not exhibit such effects. Specifically, studies have utilized assays like the bacterial mutation assay to evaluate mutagenicity, confirming that neither Fluoxetine nor Norfluoxetine demonstrate genotoxic properties.\n",
      "\n",
      "For further in-depth information, you can refer to the following sources that detail these findings:\n",
      "\n",
      "1. [Fluoxetine - wikidoc](https://www.wikidoc.org/index.php/Fluoxetine) \n",
      "2. Various articles that highlight the lack of observed genotoxic effects of Fluoxetine and Norfluoxetine based on multiple assays.\n",
      "\n",
      "These assessments are important for understanding the safety profile of these medications during pharmacological use.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.065901\n",
      "prediction:  Fluoxetine combined with Olanzapine is recommended in the treatment of depressive episodes associated with Bipolar I Disorder (BD-I), according to several studies. \n",
      "\n",
      "1. **Combination Therapy**: The combination of Olanzapine (an atypical antipsychotic) and Fluoxetine (an SSRI) has been indicated as a viable option for the treatment of bipolar depression. One significant study recommends this combination as effective and emphasizes that the therapeutic management of bipolar disorder may benefit from using both medications concurrently to tackle depressive symptoms.\n",
      "\n",
      "2. **Efficacy**: Evidence from clinical practice guidelines alongside consensus statements from organizations like the International Society for Bipolar Disorders suggests that this combination should be considered particularly when standard mono therapies are inadequate or when patients show treatment resistance. In trials, this combination demonstrated a more robust response than olanzapine monotherapy.\n",
      "\n",
      "3. **Dosage and Administration**: The effective dosages typically range with Olanzapine at 6-12 mg per day and Fluoxetine at 25-75 mg per day, administered for at least eight weeks, which is essential for ensuring adequate therapeutic response.\n",
      "\n",
      "4. **Considerations for Treatment-Resistant Depression**: In patients experiencing treatment-resistant bipolar depression (after failing at least two other treatments), the combination of Olanzapine and Fluoxetine remains one of the recommended strategies, marking its importance in guiding clinical decision-making.\n",
      "\n",
      "In summary, the use of Fluoxetine in combination with Olanzapine for treating depressive episodes in Bipolar I Disorder is supported by clinical evidence suggesting improved efficacy, especially in cases of treatment resistance. As with all pharmacological interventions, individual patient factors and potential side effects must be considered in tailoring the treatment approach.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.042373\n",
      "prediction:  Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and Olanzapine, an atypical antipsychotic, are sometimes used in combination to treat depressive episodes associated with Bipolar I Disorder. This combination is particularly relevant in the context of managing bipolar depression, which can be challenging due to the risk of inducing manic episodes when treating with antidepressants alone.\n",
      "\n",
      "Here are several key points regarding the use of Fluoxetine in combination with Olanzapine for this purpose:\n",
      "\n",
      "1. **Efficacy**: The combination of Fluoxetine and Olanzapine has been studied and is known to be effective in treating depressive episodes in patients with Bipolar I Disorder. The combination can help alleviate depressive symptoms while minimizing the risk of triggering mania, which is a significant concern when using antidepressants in bipolar patients.\n",
      "\n",
      "2. **FDA Approval**: The combination of Fluoxetine and Olanzapine is approved by the FDA for the treatment of depressive episodes associated with Bipolar I Disorder. This approval is based on clinical trials that demonstrated the efficacy of this combination in reducing depressive symptoms.\n",
      "\n",
      "3. **Mechanism of Action**: Fluoxetine works by increasing serotonin levels in the brain, which can help improve mood and alleviate depressive symptoms. Olanzapine, on the other hand, has a broader mechanism of action, affecting various neurotransmitter systems, including dopamine and serotonin. This dual action can provide a more balanced approach to treating bipolar depression.\n",
      "\n",
      "4. **Side Effects**: While the combination can be effective, it is also associated with potential side effects. Common side effects of Fluoxetine include nausea, insomnia, and sexual dysfunction, while Olanzapine can cause weight gain, sedation, and metabolic changes. Clinicians must monitor patients for these side effects and adjust treatment as necessary.\n",
      "\n",
      "5. **Risk of Manic Switch**: One of the primary concerns when using antidepressants in bipolar disorder is the risk of a manic switch, where a patient may transition from a depressive episode to a manic episode. The addition of Olanzapine can help mitigate this risk due to its mood-stabilizing properties.\n",
      "\n",
      "6. **Individualized Treatment**: The decision to use Fluoxetine in combination with Olanzapine should be individualized based on the patient's history, symptom profile, and response to previous treatments. It is essential for healthcare providers to conduct a thorough assessment and monitor the patient closely throughout the treatment process.\n",
      "\n",
      "7. **Long-term Management**: While this combination can be effective for acute depressive episodes, long-term management of Bipolar I Disorder often requires a comprehensive treatment plan that may include mood stabilizers, psychotherapy, and lifestyle modifications in addition to pharmacotherapy.\n",
      "\n",
      "In summary, the combination of Fluoxetine and Olanzapine can be an effective treatment option for depressive episodes associated with Bipolar I Disorder, with the potential to improve symptoms while minimizing the risk of manic episodes. However, careful monitoring and individualized treatment plans are essential to optimize outcomes and manage side effects.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.041506\n",
      "prediction:  Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and Olanzapine, an atypical antipsychotic, are sometimes used in combination to treat depressive episodes associated with Bipolar I Disorder. This combination is particularly relevant in the context of managing bipolar depression, which can be challenging due to the risk of inducing manic episodes when treating with antidepressants alone.\n",
      "\n",
      "Here are several key points regarding the use of Fluoxetine in combination with Olanzapine for this purpose:\n",
      "\n",
      "1. **Efficacy**: The combination of Fluoxetine and Olanzapine has been studied and is known to be effective in treating depressive episodes in patients with Bipolar I Disorder. The combination can help alleviate depressive symptoms while minimizing the risk of triggering mania, which is a significant concern when using antidepressants in bipolar patients.\n",
      "\n",
      "2. **FDA Approval**: The combination of Fluoxetine and Olanzapine is approved by the FDA for the treatment of depressive episodes associated with Bipolar I Disorder. This approval is based on clinical trials that demonstrated the efficacy of this combination in reducing depressive symptoms.\n",
      "\n",
      "3. **Mechanism of Action**: Fluoxetine works by increasing serotonin levels in the brain, which can help improve mood and alleviate depressive symptoms. Olanzapine, on the other hand, has a broader mechanism of action, affecting various neurotransmitter systems, including dopamine and serotonin. This dual action can provide a more balanced approach to treating bipolar depression.\n",
      "\n",
      "4. **Side Effects**: While the combination can be effective, it is also associated with potential side effects. Common side effects of Fluoxetine include nausea, insomnia, and sexual dysfunction, while Olanzapine can cause weight gain, sedation, and metabolic syndrome. Clinicians must monitor patients for these side effects and adjust treatment as necessary.\n",
      "\n",
      "5. **Risk of Manic Switch**: One of the primary concerns when using antidepressants in bipolar disorder is the risk of a manic switch, where a patient may transition from a depressive episode to a manic episode. The addition of Olanzapine can help mitigate this risk due to its mood-stabilizing properties.\n",
      "\n",
      "6. **Individualized Treatment**: Treatment for Bipolar I Disorder should be individualized. While the combination of Fluoxetine and Olanzapine can be effective for some patients, others may respond better to different medications or combinations. Clinicians should consider the patient's history, symptom profile, and any previous treatment responses when prescribing.\n",
      "\n",
      "7. **Long-term Management**: The management of Bipolar I Disorder often requires a long-term treatment strategy. While the combination of Fluoxetine and Olanzapine may be effective in the short term for depressive episodes, ongoing assessment and adjustment of the treatment plan are essential to ensure sustained stability and prevent relapse.\n",
      "\n",
      "In summary, the combination of Fluoxetine and Olanzapine can be an effective treatment option for depressive episodes associated with Bipolar I Disorder, with the potential to improve symptoms while minimizing the risk of manic episodes. However, careful monitoring for side effects and individualization of treatment are crucial for optimal patient outcomes.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.056921\n",
      "prediction:  Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and Olanzapine, an atypical antipsychotic, are utilized in combination for treating depressive episodes associated with Bipolar I Disorder. The combination therapy has been investigated due to its potential to address the complex symptoms of bipolar depression.\n",
      "\n",
      "### Key Findings:\n",
      "\n",
      "1. **Efficacy in Bipolar Depression**:\n",
      "   - Combination therapy with Olanzapine and Fluoxetine has been shown to be effective in managing bipolar depressive episodes. Studies indicate that this combination can improve depressive symptoms more significantly than monotherapy (using either medication alone) (PMID: 41124583).\n",
      "\n",
      "2. **Recommendations for Treatment**:\n",
      "   - Clinical guidelines suggest that for treating depressive episodes in bipolar disorder, olanzapine plus fluoxetine is an acceptable option. This is particularly relevant for children and adolescents, where treatment efficacy and safety profiles differ from adults (PMID: 41124583).\n",
      "\n",
      "3. **Clinical Trials**:\n",
      "   - Various clinical trials have explored the effectiveness of this combination (e.g., NCT00485771: \"Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression\"). These trials contribute to understanding the safety and efficacy of the Olanzapine-Fluoxetine combination compared to other treatments.\n",
      "\n",
      "4. **Long-term Management**:\n",
      "   - Long-term management of Bipolar I Disorder commonly includes a combination of mood stabilizers and atypical antipsychotics. The combination of Olanzapine and Fluoxetine may also aid in reducing the recurrence of depressive episodes (PMID: 39500601).\n",
      "\n",
      "5. **Considerations**:\n",
      "   - While the combination can be effective, it is crucial to monitor for potential side effects associated with both medications, such as toxicity or metabolic syndrome aspects associated with Olanzapine.\n",
      "\n",
      "### Conclusion:\n",
      "The use of Fluoxetine in combination with Olanzapine is a valid therapeutic strategy for depressive episodes in Bipolar I Disorder, offering enhanced efficacy compared to monotherapy. This approach is supported by clinical guidelines and research evidence but requires careful consideration of the individual patient's context and monitoring for side effects.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.05017\n",
      "prediction:  Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is sometimes used in combination with olanzapine, an atypical antipsychotic, in the treatment of depressive episodes associated with Bipolar I Disorder. Below are key points regarding this combination therapy:\n",
      "\n",
      "1. **Efficacy**: Studies have shown that the combination of fluoxetine and olanzapine may be effective in treating depressive episodes in patients with bipolar disorder. The combination is believed to leverage the mood-stabilizing properties of olanzapine with the antidepressant effects of fluoxetine.\n",
      "\n",
      "2. **Clinical Trials**: Several clinical trials have assessed this combination. For example, one trial (NCT00485771) specifically evaluated olanzapine/fluoxetine combinations against other treatments in bipolar I depression and has shown promising results in managing depressive symptoms effectively.\n",
      "\n",
      "3. **Recommendations for Use**: According to expert guidelines, particularly those concerning children and adolescents, the olanzapine and fluoxetine combination is recommended as an option for managing depressive episodes in bipolar disorder. This reflects a broader acceptance in clinical practice due to the observed benefits in mood stabilization and overall symptom management.\n",
      "\n",
      "4. **Safety & Considerations**: While the combination can be effective, clinicians should closely monitor for potential side effects. Olanzapine, in particular, has a risk profile that includes weight gain, metabolic changes, and sedation, which necessitates careful consideration in the treatment plan.\n",
      "\n",
      "5. **Long-term Management**: Bipolar disorder is characterized by recurrent episodes of depression and mania, and long-term treatment often includes mood stabilizers along with symptomatic treatments like SSRIs and atypical antipsychotics. The combination of fluoxetine and olanzapine may play a role in the overall strategy to minimize recurrence and manage acute episodes effectively.\n",
      "\n",
      "Overall, while the combination of fluoxetine and olanzapine can be beneficial in treating depressive episodes within Bipolar I Disorder, it is essential for healthcare providers to evaluate individual patient needs, potential risks, and the efficacy of this approach within the context of a comprehensive treatment plan.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: The combination is initiated with 20 mg of Fluoxetine and 5 mg of Olanzapine.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.021964\n",
      "prediction:  For a smoker who uses nicotine lozenges and smokes their first cigarette within 30 minutes of waking up, it is generally recommended to use a higher dose of nicotine replacement therapy. According to various guidelines and studies, including evidence from recent literature, smokers who have their first cigarette very early in the morning (e.g., within 30 minutes of waking) and have a higher level of nicotine dependence should consider starting with a higher dosage of nicotine lozenges, which is often 4 mg.\n",
      "\n",
      "The choice of dosage is based on the understanding that those who smoke soon after waking tend to have a higher degree of physical dependence on nicotine and may benefit from additional nicotine to manage withdrawal symptoms effectively. The standard lozenge strengths available are typically 2 mg and 4 mg, with the 4 mg strength being recommended for individuals who smoke within 30 minutes of waking ([PubMed ID: 37119945](https://pubmed.ncbi.nlm.nih.gov/37119945), [PubMed ID: 40106803](https://pubmed.ncbi.nlm.nih.gov/40106803)).\n",
      "\n",
      "It is also important to use the lozenge according to the manufacturer's instructions for maximum benefit, which usually entails allowing it to dissolve slowly in the mouth rather than chewing or swallowing it. Additionally, it might be beneficial for the smoker to seek professional advice or participate in a smoking cessation program, which can provide tailored guidance and support for their quitting journey ([PubMed ID: 32619725](https://pubmed.ncbi.nlm.nih.gov/32619725)).\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 mg Nicotine lozenge\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.086957\n",
      "prediction:  For patients with moderate renal impairment (eGFR â‰¥30 to <60 mL/min), the recommended dosage adjustment for Paxlovid (nirmatrelvir and ritonavir) is as follows:\n",
      "\n",
      "- **Dosage**: 150 mg nirmatrelvir (one 150 mg tablet) combined with 100 mg ritonavir (one 100 mg tablet), both taken together **twice daily** for a total duration of **5 days**.\n",
      "\n",
      "This adjustment is aimed at reducing the potential for drug accumulation and adverse effects in patients with compromised renal function. It is important for healthcare providers to consider these recommendations while prescribing Paxlovid to ensure safe and effective treatment in individuals with renal impairment.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Reduce the Paxlovid dosage.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.047305\n",
      "prediction:  For patients with recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy including Pemetrexed, several treatment options are available, depending on individual patient factors and previous treatments.\n",
      "\n",
      "1. **Nintedanib plus Pemetrexed**: A significant trial, LUME-Lung 2, has demonstrated the efficacy of combining Nintedanib, an oral tyrosine kinase inhibitor, with Pemetrexed in patients who had previously received chemotherapy. Although the trial faced a stop due to a futility analysis, it highlighted the potential for this combination in enhancing progression-free survival (PFS) compared to chemotherapy alone.\n",
      "\n",
      "2. **Immunotherapy**: Depending on the expression of PD-L1 and the patient's overall health status, immunotherapy agents such as Pembrolizumab or Nivolumab could be considered. These agents are effective in managing NSCLC, particularly in patients with high PD-L1 expression.\n",
      "\n",
      "3. **Docetaxel**: This is another option that has been used as a second-line treatment in patients who have previously undergone chemotherapy with Pemetrexed.\n",
      "\n",
      "4. **Combination of Chemotherapy and Targeted Therapy**: Depending on the mutation status (for example, EGFR mutations or ALK rearrangements), certain targeted therapies may be appropriate.\n",
      "\n",
      "5. **Clinical Trials**: Enrolling in clinical trials for novel agents or combinations could provide access to cutting-edge therapies specifically designed for recurrent metastatic NSCLC patients.\n",
      "\n",
      "The choice of treatment should take into account the individual patientâ€™s tumor characteristics, previous treatments, performance status, and any biomarkers present. A multidisciplinary team approach is often beneficial in determining the most appropriate therapy.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.030055\n",
      "prediction:  For patients with recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received chemotherapy with Pemetrexed, the treatment options can vary based on several factors, including the patient's overall health, the presence of specific genetic mutations, and prior treatment responses. Here are some potential treatment options:\n",
      "\n",
      "1. **Targeted Therapy**:\n",
      "   - **EGFR Inhibitors**: If the tumor has an EGFR mutation, targeted therapies such as Osimertinib (Tagrisso) may be appropriate. This is particularly relevant for patients with activating mutations in the EGFR gene.\n",
      "   - **ALK Inhibitors**: For patients with ALK rearrangements, options like Alectinib, Crizotinib, or Brigatinib can be considered.\n",
      "   - **ROS1 Inhibitors**: If the tumor is ROS1-positive, drugs like Crizotinib or Entrectinib may be effective.\n",
      "\n",
      "2. **Immunotherapy**:\n",
      "   - **Checkpoint Inhibitors**: Agents such as Pembrolizumab (Keytruda) or Nivolumab (Opdivo) can be used, especially if the tumor expresses PD-L1. These drugs can be effective in patients with high PD-L1 expression and can be used as monotherapy or in combination with chemotherapy.\n",
      "   - **Combination Therapy**: Nivolumab can also be combined with Ipilimumab (Yervoy) for certain patients, particularly those with high tumor mutational burden.\n",
      "\n",
      "3. **Chemotherapy**:\n",
      "   - If the patient has not received a combination of chemotherapy agents, re-challenging with a different chemotherapy regimen may be considered. Options may include Docetaxel or Gemcitabine, depending on the patient's previous treatment history and tolerance.\n",
      "\n",
      "4. **Clinical Trials**:\n",
      "   - Participation in clinical trials can be an excellent option for patients with recurrent metastatic NSCLC. Trials may offer access to novel therapies, including new targeted agents, immunotherapies, or combination therapies that are not yet widely available.\n",
      "\n",
      "5. **Supportive Care**:\n",
      "   - In addition to active treatment, supportive care measures should be considered to manage symptoms and improve quality of life. This may include palliative care, pain management, and psychosocial support.\n",
      "\n",
      "6. **Re-evaluation of Treatment**:\n",
      "   - It is essential to re-evaluate the tumor characteristics, including potential biomarkers and genetic testing, to guide treatment decisions effectively. This may involve re-biopsy or liquid biopsy to assess for new mutations or changes in tumor biology.\n",
      "\n",
      "In summary, the choice of treatment for recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed should be individualized based on the patient's specific clinical scenario, including molecular profiling of the tumor, previous treatment responses, and overall health status. Consulting with a multidisciplinary team, including oncologists specializing in lung cancer, is crucial for optimizing treatment strategies.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.058226\n",
      "prediction:  For patients with recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously undergone chemotherapy with Pemetrexed, several treatment options are available based on recent clinical evidence and guidelines.\n",
      "\n",
      "One promising approach involves combining chemotherapy with targeted therapy. Specifically, a study reported on the efficacy of **Adavosertib**, a Wee1 inhibitor when combined with either **Docetaxel** or **Carboplatin plus Pemetrexed**. In this research, patients received Docetaxel (75 mg/mÂ²) alongside Adavosertib (225 mg twice daily for the first three days of each cycle). This combination demonstrated improved outcomes as compared to Docetaxel alone, showing enhanced sensitivity in tumor response rates. \n",
      "\n",
      "Alternatively, **Immunotherapy** options could also be considered, such as **Nivolumab** or **Pembrolizumab**, which are PD-1 inhibitors that have shown effectiveness in treating NSCLC even after prior chemotherapy regimens. These agents can be beneficial, especially in patients with specific biomarkers such as high PD-L1 expression.\n",
      "\n",
      "In summary, after prior treatment with Pemetrexed, a combination of chemotherapy (like Docetaxel) with a targeted agent (such as Adavosertib) or moving to immunotherapy options are both viable treatments. An individual patient's overall health, disease progression, and molecular tumor characteristics should guide the final treatment choice.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.053763\n",
      "prediction:  For the treatment of recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy with Pemetrexed, recent studies suggest several emerging options:\n",
      "\n",
      "1. **Adavosertib in Combination with Docetaxel**: Recent clinical trials (specifically, two Phase II studies) have evaluated the efficacy of combining Adavosertib, a selective Wee1 inhibitor, with Docetaxel for recurrent NSCLC. Adavosertib works by sensitizing tumor cells to chemotherapy, potentially increasing the effectiveness of Docetaxel, which is a standard treatment option for recurrent NSCLC (PMID: 41212474). \n",
      "\n",
      "2. **Re-evaluation of Targeted Therapies**: For patients with specific genetic mutations or alterations, targeted therapy might be appropriate. For instance, if the tumor shows an alteration in the epidermal growth factor receptor (EGFR) or an anaplastic lymphoma kinase (ALK) gene rearrangement, drugs like erlotinib or crizotinib could be considered, even after progression on prior therapies.\n",
      "\n",
      "3. **Immunotherapy**: Checkpoint inhibitors (such as Pembrolizumab or Nivolumab) may also be effective in later lines of treatment for NSCLC. Their use is sometimes based on the tumor's PD-L1 expression levels. If patients were not previously treated with these agents, they could be an option now.\n",
      "\n",
      "4. **Clinical Trials**: Participating in clinical trials could provide access to novel therapies not widely available yet. The ongoing research often brings forth new treatment modalities that can be more effective for patients who experienced progression after standard therapies.\n",
      "\n",
      "Ultimately, treatment decisions should be tailored to individual patient characteristics, including the patient's performance status, previous treatment responses, and the presence of specific molecular characteristics of the tumor. Consulting with an oncologist specialized in lung cancer can also provide specific recommendations based on the latest evidence and available clinical trials.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.056986\n",
      "prediction:  For women taking Jaimiess (which contains levonorgestrel and ethinyl estradiol) who are scheduled for major surgery, the following actions are generally recommended:\n",
      "\n",
      "1. **Consultation with Healthcare Provider**: It's crucial for women to inform their healthcare provider or surgeon that they are taking Jaimiess. This is important for assessing any potential risks associated with surgery and anesthesia.\n",
      "\n",
      "2. **Consideration of Thromboembolic Risks**: Hormonal contraceptives like Jaimiess can increase the risk of venous thromboembolism (VTE), particularly during periods of immobility, such as after major surgery. Providers may evaluate individual risk factors such as personal or family history of VTE, obesity, smoking, and older age.\n",
      "\n",
      "3. **Possible Suspension of Medication**: Some healthcare professionals may recommend pausing the use of Jaimiess for a period before and after surgery, depending on the type of surgery and the patientâ€™s risk factors. This may vary from stopping the medication a few weeks prior to surgery to resuming it only after a specified recovery period post-surgery.\n",
      "\n",
      "4. **Monitoring After Surgery**: After surgery, continuous monitoring for signs of thrombosis is crucial. Women resuming hormonal contraceptives should be made aware of the symptoms that require immediate medical attention, such as leg swelling, chest pain, or difficulty breathing.\n",
      "\n",
      "5. **Alternative Contraceptive Methods**: Depending on the timing relative to the surgery, another contraceptive method may be considered to ensure effective ovulation suppression without the increased risk of thrombosis.\n",
      "\n",
      "Women should follow their healthcare provider's specific guidance tailored to their individual health needs and the nature of the surgical procedure.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Stop taking Jaimiess at least 4 weeks before surgery\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015361\n",
      "prediction:  Fosaprepitant for injection is a prodrug that is converted in the body to its active form, which is **aprepitant**. Aprepitant is a selective antagonist of the neurokinin-1 (NK1) receptor, which plays a significant role in the emetic (vomiting) response. \n",
      "\n",
      "### Step-by-Step Breakdown:\n",
      "\n",
      "1. **Understanding Fosaprepitant**: \n",
      "   - Fosaprepitant is an injectable formulation used primarily for the prevention of nausea and vomiting associated with chemotherapy. It is designed to be administered intravenously.\n",
      "\n",
      "2. **Prodrug Concept**: \n",
      "   - A prodrug is a medication that is administered in an inactive (or less active) form and is converted into an active form within the body. In the case of fosaprepitant, it is converted to aprepitant after administration.\n",
      "\n",
      "3. **Mechanism of Action**: \n",
      "   - Aprepitant works by blocking the NK1 receptors in the brain, which are involved in the vomiting reflex. By inhibiting these receptors, aprepitant helps to prevent nausea and vomiting that can occur after chemotherapy.\n",
      "\n",
      "4. **Clinical Use**: \n",
      "   - Fosaprepitant is often used in combination with other antiemetic agents to provide a more comprehensive approach to managing chemotherapy-induced nausea and vomiting (CINV). It is particularly effective for delayed nausea and vomiting, which can occur days after chemotherapy treatment.\n",
      "\n",
      "5. **Dosage and Administration**: \n",
      "   - Fosaprepitant is typically administered as a single intravenous dose before chemotherapy. The specific dosage may vary based on the chemotherapy regimen and the patient's individual needs.\n",
      "\n",
      "6. **Side Effects**: \n",
      "   - Common side effects of fosaprepitant and aprepitant may include fatigue, dizziness, diarrhea, and potential interactions with other medications due to its effects on liver enzymes.\n",
      "\n",
      "In summary, the active ingredient in fosaprepitant for injection is **aprepitant**, which is responsible for its antiemetic effects through the blockade of NK1 receptors.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Fosaprepitant.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014714\n",
      "prediction:  Fosaprepitant for injection is a prodrug that is converted in the body to its active form, which is **aprepitant**. Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist that is primarily used to prevent nausea and vomiting associated with chemotherapy and surgery. \n",
      "\n",
      "### Step-by-Step Breakdown:\n",
      "\n",
      "1. **Understanding Fosaprepitant**: \n",
      "   - Fosaprepitant is an injectable formulation that is administered intravenously. It is designed to enhance the bioavailability of aprepitant, allowing for effective management of nausea and vomiting.\n",
      "\n",
      "2. **Mechanism of Action**:\n",
      "   - Aprepitant works by blocking the action of substance P, a neuropeptide that binds to NK1 receptors in the brain. By inhibiting this pathway, aprepitant helps to reduce the signals that trigger nausea and vomiting.\n",
      "\n",
      "3. **Clinical Use**:\n",
      "   - Fosaprepitant is often used in combination with other antiemetic agents to provide a comprehensive approach to preventing chemotherapy-induced nausea and vomiting (CINV). It is particularly effective against delayed nausea and vomiting, which can occur days after chemotherapy.\n",
      "\n",
      "4. **Conversion Process**:\n",
      "   - Once administered, fosaprepitant is rapidly converted to aprepitant in the body, which is the active form that exerts the therapeutic effects.\n",
      "\n",
      "5. **Dosage and Administration**:\n",
      "   - Fosaprepitant is typically given as a single intravenous dose before chemotherapy, and the dosage may vary based on the specific chemotherapy regimen and patient factors.\n",
      "\n",
      "6. **Side Effects**:\n",
      "   - Common side effects of fosaprepitant and aprepitant may include fatigue, dizziness, diarrhea, and potential interactions with other medications due to its effects on liver enzymes.\n",
      "\n",
      "In summary, the active ingredient in fosaprepitant for injection is **aprepitant**, which plays a crucial role in managing nausea and vomiting in patients undergoing chemotherapy or surgery.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Fosaprepitant.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014545\n",
      "prediction:  Fosaprepitant for injection is a prodrug that is converted in the body to its active form, which is **aprepitant**. Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist that is primarily used to prevent nausea and vomiting associated with chemotherapy and surgery. \n",
      "\n",
      "### Step-by-Step Breakdown:\n",
      "\n",
      "1. **Understanding Fosaprepitant**: \n",
      "   - Fosaprepitant is an injectable formulation that serves as a precursor to aprepitant. It is designed to enhance the bioavailability and efficacy of aprepitant when administered intravenously.\n",
      "\n",
      "2. **Mechanism of Action**:\n",
      "   - Aprepitant works by blocking the action of substance P, a neuropeptide that binds to NK1 receptors in the brain. By inhibiting this pathway, aprepitant helps to reduce the signals that trigger nausea and vomiting.\n",
      "\n",
      "3. **Clinical Use**:\n",
      "   - Fosaprepitant is typically used in combination with other antiemetic agents to provide a more comprehensive approach to managing chemotherapy-induced nausea and vomiting (CINV). It is particularly effective against delayed nausea and vomiting, which can occur several days after chemotherapy.\n",
      "\n",
      "4. **Conversion Process**:\n",
      "   - Once fosaprepitant is administered, it is rapidly converted to aprepitant in the body, allowing for the therapeutic effects of aprepitant to take place.\n",
      "\n",
      "5. **Dosage and Administration**:\n",
      "   - Fosaprepitant is usually given as a single intravenous dose prior to chemotherapy, and the dosage may vary based on the specific chemotherapy regimen and patient factors.\n",
      "\n",
      "6. **Side Effects**:\n",
      "   - Common side effects of fosaprepitant (and aprepitant) may include fatigue, dizziness, diarrhea, and potential interactions with other medications due to its effects on liver enzymes.\n",
      "\n",
      "In summary, the active ingredient in fosaprepitant for injection is **aprepitant**, which plays a crucial role in preventing nausea and vomiting in patients undergoing chemotherapy or surgery.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Fosaprepitant.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.069463\n",
      "prediction:  GOPRELTO (combination of lidocaine and phenylephrine) is often administered during medical procedures, including procedures involving the nasal and airway areas. When considering the implications of breastfeeding immediately after its administration, a few key points must be addressed based on available research and expert recommendations.\n",
      "\n",
      "1. **Absorption and Excretion**: Medications taken by the mother, such as GOPRELTO, have the potential to enter breast milk. Components like lidocaine and phenylephrine can be present in low concentrations; however, the clinical significance of this transfer is often considered to be minimal, especially in acute, short-term applications such as those used during office procedures.\n",
      "\n",
      "2. **Potential Risks**: Immediate breastfeeding after insertion of GOPRELTO may pose some risk if the medication is still being transferred into the milk. Lidocaine, while generally regarded as safe during lactation, can cause respiratory depression in high doses. Phenylephrine's potential effects on infants, particularly concerning blood pressure and heart rate, may also be a concern, emphasizing the need for caution.\n",
      "\n",
      "3. **Recommendations**: Although the general consensus suggests that breastfeeding can continue after breastfeeding, it may be prudent to wait for a short period (usually a couple of hours) post-administration before breastfeeding. This time allows the body to metabolize and clear substantial amounts of the drug from the system; however, the exact duration can depend on the specific context of the drug administration and individual maternal factors.\n",
      "\n",
      "4. **Clinical Guidance**: It is critical for nursing mothers to consult healthcare providers regarding their specific circumstances. Personalized medical advice is essential, particularly if there is a history of health conditions or if other medications are involved.\n",
      "\n",
      "In summary, while the risk of significant harm may be low, mothers should exercise caution and seek guidance from healthcare professionals to ensure the health and safety of their breastfeeding infant when GOPRELTO is administered.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Infant plasma concentrations may reach half the maternal plasma concentrations, leading to adverse reactions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.032345\n",
      "prediction:  GOPRELTO is a medication containing phenylephrine, which is typically used as a nasal decongestant. In patients with a history of myocardial infarction (MI), caution is warranted when administering medications that can affect cardiovascular function, including those that may increase blood pressure and heart rate.\n",
      "\n",
      "Here are the recommended actions if GOPRELTO is administered to a patient with a history of myocardial infarction:\n",
      "\n",
      "1. **Medical Evaluation**: Prior to administration, a thorough medical evaluation is crucial. Assess the patient's cardiovascular health and history of myocardial infarction, as well as any complications that may have arisen from it.\n",
      "\n",
      "2. **Monitoring**: If GOPRELTO is to be administered, the patient's vital signs should be closely monitored, specifically heart rate and blood pressure. This monitoring is essential to promptly identify any adverse cardiovascular effects.\n",
      "\n",
      "3. **Consider Alternatives**: If the patient has significant cardiovascular disease or uncontrolled hypertension, considering alternative therapies that are safer for cardiovascular health may be prudent. \n",
      "\n",
      "4. **Patient Education**: Patients should be informed about the potential risks associated with using GOPRELTO, especially those with a history of myocardial infarction. They should be advised to report any unusual symptoms, such as chest pain or significant changes in blood pressure.\n",
      "\n",
      "5. **Consultation with a Specialist**: In cases of uncertainty, it may be beneficial to consult a cardiologist or a specialist in relevant fields to determine the best course of action.\n",
      "\n",
      "In conclusion, while there may not be absolute contraindications for administering GOPRELTO to patients with a history of MI, careful consideration, monitoring, and possible alternatives should be prioritized to ensure patient safety.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Monitor vital signs and ECG closely\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.033845\n",
      "prediction:  GOPRELTO, a drug recently approved for use, raises specific concerns when administered to patients with a history of myocardial infarction. Patients with a history of myocardial infarction are at an increased risk for cardiovascular events, and the use of new medications should be carefully evaluated to avoid exacerbating their condition.\n",
      "\n",
      "### Recommended Actions:\n",
      "\n",
      "1. **Risk Assessment**: Prior to administration, conduct a thorough risk assessment. This includes evaluating the patient's overall cardiovascular health, history of arrhythmias, and other pertinent risk factors.\n",
      "\n",
      "2. **Monitoring**: After administration of GOPRELTO, it is crucial to monitor the patient closely for any signs of cardiovascular distress. This includes watching for changes in heart rate, blood pressure, and other vital signs that could indicate stress on the heart.\n",
      "\n",
      "3. **Consultation with a Specialist**: It may be advisable to consult with a cardiologist or a medical specialist familiar with the patient's history and the pharmacodynamics of GOPRELTO, especially any associated cardiovascular risks.\n",
      "\n",
      "4. **Patient Education**: Inform the patient about the importance of reporting any unusual symptoms, like chest pain, shortness of breath, or palpitations, throughout the course of the treatment.\n",
      "\n",
      "5. **Review of Concurrent Medications**: Consider any other medications the patient might be taking that could interact adversely with GOPRELTO, particularly those affecting cardiovascular functions.\n",
      "\n",
      "### Conclusion:\n",
      "\n",
      "Given the potential for serious complications in patients with a history of myocardial infarction, the administration of GOPRELTO requires careful consideration and active management strategies to minimize risks. Engaging with the patient in shared decision-making and ensuring robust follow-up care can enhance the safety and effectiveness of therapy.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Monitor vital signs and ECG closely\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.098544\n",
      "prediction:  Guanfacine extended-release tablets are primarily indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. The primary mechanism of action involves the stimulation of alpha2-adrenergic receptors in the prefrontal cortex, which enhances attention and reduces impulsivity and hyperactivity.\n",
      "\n",
      "Key points regarding Guanfacine extended-release tablets include:\n",
      "\n",
      "1. **Efficacy**: Clinical trials have shown that Guanfacine extended-release is effective in treating ADHD, particularly in patients who may not respond optimally to stimulants. It can be beneficial as either monotherapy or in combination with stimulant medications.\n",
      "\n",
      "2. **Safety**: The extended-release formulation has been associated with improved tolerability compared to the immediate-release forms. This is particularly relevant for managing side effects, which are common with ADHD medications. \n",
      "\n",
      "3. **Side Effects**: While many patients tolerate Guanfacine well, potential side effects can include sedation, fatigue, and hypotension. The risk of side effects is generally lower with the extended-release formulation compared to immediate-release forms.\n",
      "\n",
      "4. **Combination Therapy**: Guanfacine can be used in conjunction with stimulant medications to address complex cases where patients exhibit symptoms resistant to monotherapy. This combination approach takes advantage of the complementary mechanisms of action of the drugs involved.\n",
      "\n",
      "Overall, Guanfacine extended-release tablets represent a valuable option in the management of ADHD, particularly for patients with comorbid conditions or those who do not respond to traditional stimulant therapies.\n",
      "pred_SIM:  C\n",
      "choice:  E\n",
      "correct_answer:  C\n",
      "correct answer: Guanfacine extended-release tablets are not a controlled substance and have no known potential for abuse or dependence.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.104628\n",
      "prediction:  Guanfacine extended-release tablets are primarily used for the treatment of attention-deficit hyperactivity disorder (ADHD) and exhibit several important characteristics:\n",
      "\n",
      "1. **Mechanism of Action**: Guanfacine is a selective Î±2A-adrenoreceptor agonist. It works by modulating noradrenergic transmission in the prefrontal cortex, which is thought to improve symptoms of ADHD by enhancing attention and reducing impulsivity and hyperactivity.\n",
      "\n",
      "2. **Indications**: It is indicated for both children and adolescents aged 6 to 17 years, either as a monotherapy or as an adjunctive treatment to stimulant medications.\n",
      "\n",
      "3. **Side Effects**: Common side effects can include drowsiness, fatigue, mood changes, and gastrointestinal disturbances. In cases of overdose, guanfacine can lead to serious complications such as hypotension (low blood pressure) and QT prolongation, which is a measure of delayed heart repolarization that can lead to abnormal heart rhythms.\n",
      "\n",
      "4. **Clinical Concerns**: A reported case illustrated the potential dangers of overdose. A 17-year-old individual ingested an excessive amount of guanfacine, resulting in pulmonary edema and significant reductions in cardiac function, which persisted even after serum levels of the drug had declined. This highlights the critical need for caution in dosing and monitoring for side effects, especially in vulnerable populations.\n",
      "\n",
      "5. **Therapeutic Monitoring**: Because of potential severe side effects like cardiac issues, monitoring will often be necessary, especially in patients with a history of cardiovascular problems or those who may be at increased risk of medication interactions.\n",
      "\n",
      "In summary, guanfacine extended-release is a valuable treatment for ADHD, particularly in the pediatric population, but its use must be carefully managed to avoid serious adverse effects, especially in cases of overdose.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Guanfacine extended-release tablets are not a controlled substance and have no known potential for abuse or dependence.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011785\n",
      "prediction:  Hydrocort shampoo, which typically contains hydrocortisone, is often used to treat various scalp conditions such as psoriasis, seborrheic dermatitis, or eczema. The recommended amount of hydrocort shampoo to use can vary based on the specific product formulation and the condition being treated. However, here is a step-by-step guide to help you understand the general application process and recommended amount:\n",
      "\n",
      "### Step 1: Read the Instructions\n",
      "- **Check the Label**: Always start by reading the product label or the patient information leaflet that comes with the shampoo. Different brands may have different concentrations and recommendations.\n",
      "\n",
      "### Step 2: Determine the Amount\n",
      "- **General Recommendation**: A common recommendation for hydrocort shampoo is to use about 1 to 2 tablespoons (15 to 30 mL) of shampoo. This amount is usually sufficient to cover the scalp adequately.\n",
      "- **Adjust Based on Hair Length**: If you have longer or thicker hair, you may need to adjust the amount slightly to ensure full coverage of the scalp.\n",
      "\n",
      "### Step 3: Application Process\n",
      "1. **Wet the Hair**: Start by thoroughly wetting your hair and scalp with warm water. This helps the shampoo to lather better and penetrate the scalp.\n",
      "2. **Apply the Shampoo**: Pour the recommended amount of hydrocort shampoo into your palm. \n",
      "3. **Massage into Scalp**: Apply the shampoo directly to the scalp, using your fingertips to gently massage it in. Focus on areas that are particularly affected by the condition.\n",
      "4. **Lather**: Work the shampoo into a lather, ensuring that it covers the entire scalp. You can add a little water if needed to help with lathering.\n",
      "5. **Leave it On**: Follow the instructions regarding how long to leave the shampoo on your scalp. This is often around 5 to 10 minutes, but it can vary based on the product.\n",
      "6. **Rinse Thoroughly**: After the recommended time, rinse your hair and scalp thoroughly with warm water to remove all the shampoo.\n",
      "\n",
      "### Step 4: Frequency of Use\n",
      "- **Follow Recommendations**: The frequency of use can also vary. Some may be advised to use it daily, while others may use it a few times a week. Always follow your healthcare provider's or the product's instructions.\n",
      "\n",
      "### Step 5: Monitor for Side Effects\n",
      "- **Watch for Reactions**: After using hydrocort shampoo, monitor your scalp for any adverse reactions, such as increased irritation or allergic reactions. If you experience any concerning symptoms, consult a healthcare professional.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the recommended amount of hydrocort shampoo is generally about 1 to 2 tablespoons, but it is essential to follow the specific instructions provided with the product. Proper application and adherence to the recommended frequency are crucial for effective treatment. If you have any doubts or specific conditions, consulting a healthcare provider is always advisable.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.012418\n",
      "prediction:  Hydrocort shampoo, which typically contains hydrocortisone, is often used to treat various scalp conditions such as psoriasis, seborrheic dermatitis, or eczema. The recommended amount of hydrocort shampoo to use can vary based on the specific product formulation and the condition being treated. However, here is a step-by-step guide to help you understand the general application process and recommended amount:\n",
      "\n",
      "### Step 1: Read the Instructions\n",
      "- **Check the Label**: Always start by reading the product label or the patient information leaflet that comes with the shampoo. Different brands may have different concentrations and recommendations.\n",
      "\n",
      "### Step 2: Determine the Amount\n",
      "- **General Recommendation**: A common recommendation for hydrocort shampoo is to use about 1 to 2 tablespoons (15 to 30 mL) of shampoo. This amount is usually sufficient to cover the scalp adequately.\n",
      "- **Adjust Based on Hair Length**: If you have longer or thicker hair, you may need to adjust the amount slightly to ensure full coverage of the scalp.\n",
      "\n",
      "### Step 3: Application Process\n",
      "1. **Wet the Hair**: Start by thoroughly wetting your hair and scalp with warm water. This helps the shampoo to spread more easily.\n",
      "2. **Apply the Shampoo**: Pour the recommended amount of hydrocort shampoo into your palm. \n",
      "3. **Massage into Scalp**: Apply the shampoo directly to the scalp, using your fingertips to gently massage it in. Focus on areas that are particularly affected by the condition.\n",
      "4. **Leave it On**: Follow the instructions regarding how long to leave the shampoo on your scalp. This is often around 5 to 10 minutes, but it can vary based on the product.\n",
      "5. **Rinse Thoroughly**: After the recommended time, rinse your hair and scalp thoroughly with water to remove all the shampoo.\n",
      "\n",
      "### Step 4: Frequency of Use\n",
      "- **Follow Recommendations**: The frequency of use can also vary. Some products may recommend using the shampoo daily, while others may suggest using it a few times a week. Always adhere to the specific instructions provided with the product.\n",
      "\n",
      "### Step 5: Monitor Your Condition\n",
      "- **Observe Effects**: After using the shampoo, monitor your scalp condition. If you notice any adverse effects or if the condition does not improve, consult a healthcare professional for further advice.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the recommended amount of hydrocort shampoo is generally about 1 to 2 tablespoons, but it is essential to follow the specific instructions provided with the product. Proper application and adherence to the recommended frequency are crucial for effective treatment. If you have any concerns or questions about using hydrocort shampoo, it is best to consult with a healthcare provider or dermatologist.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.015444\n",
      "prediction:  Hydrocortisone shampoo is typically used to treat various scalp conditions, such as seborrheic dermatitis, psoriasis, or eczema. The recommended amount of hydrocort shampoo to use can vary based on the specific product formulation and the severity of the condition being treated. However, general guidelines can be provided.\n",
      "\n",
      "1. **Amount to Use**: Generally, a quarter-sized amount of hydrocort shampoo is recommended for application. This amount can be adjusted based on the length and thickness of the hair. For individuals with longer or thicker hair, a slightly larger amount may be necessary to ensure even coverage of the scalp.\n",
      "\n",
      "2. **Application Method**:\n",
      "   - **Wet Hair**: Start by thoroughly wetting the hair and scalp with warm water.\n",
      "   - **Apply Shampoo**: Dispense the recommended amount of hydrocort shampoo into your palm and apply it directly to the scalp. Focus on areas that are particularly affected by the condition.\n",
      "   - **Massage**: Gently massage the shampoo into the scalp using your fingertips. This helps to ensure that the medication is evenly distributed and can penetrate the skin effectively.\n",
      "   - **Leave In**: After massaging, it is often recommended to leave the shampoo on the scalp for a specified period, usually around 5 to 10 minutes, to allow the active ingredients to work effectively.\n",
      "   - **Rinse**: Rinse the hair and scalp thoroughly with warm water to remove the shampoo.\n",
      "\n",
      "3. **Frequency of Use**: The frequency of application can vary based on the specific condition and the advice of a healthcare provider. Typically, hydrocort shampoo may be used once or twice a week, but it is essential to follow the instructions provided by a healthcare professional or the product label.\n",
      "\n",
      "4. **Consultation with Healthcare Provider**: It is crucial to consult with a healthcare provider or dermatologist before starting treatment with hydrocort shampoo. They can provide personalized recommendations based on the individual's specific condition, severity, and any other medications or treatments being used.\n",
      "\n",
      "5. **Monitoring and Adjustments**: After starting treatment, it is important to monitor the scalp's response. If there is no improvement or if the condition worsens, it is advisable to return to the healthcare provider for further evaluation and possible adjustment of the treatment plan.\n",
      "\n",
      "In summary, while a quarter-sized amount of hydrocort shampoo is a general guideline, individual needs may vary, and it is essential to follow specific instructions from a healthcare provider or the product label for optimal results.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.013605\n",
      "prediction:  Hydrocortisone shampoo is typically used to treat various scalp conditions, such as seborrheic dermatitis, psoriasis, or eczema. The recommended amount of hydrocort shampoo to use can vary based on the specific product formulation and the severity of the condition being treated. However, general guidelines can be provided.\n",
      "\n",
      "1. **Amount to Use**: Most manufacturers recommend using a small amount of hydrocort shampoo, usually about 1 to 2 tablespoons (15 to 30 mL), depending on the length and thickness of your hair. It's important to ensure that the shampoo adequately covers the affected areas of the scalp.\n",
      "\n",
      "2. **Application Method**:\n",
      "   - **Wet Hair**: Start by thoroughly wetting your hair and scalp with warm water.\n",
      "   - **Apply Shampoo**: Dispense the recommended amount of hydrocort shampoo into your hands and apply it directly to the scalp. Focus on the areas that are most affected by the condition.\n",
      "   - **Massage**: Gently massage the shampoo into the scalp for several minutes to ensure it penetrates the skin and is evenly distributed.\n",
      "   - **Leave In**: Follow the instructions on the product label regarding how long to leave the shampoo on the scalp. This is often around 5 to 10 minutes, allowing the medication to take effect.\n",
      "\n",
      "3. **Rinsing**: After the recommended time, rinse the shampoo thoroughly from your hair and scalp with warm water. Make sure no residue remains, as this can lead to irritation.\n",
      "\n",
      "4. **Frequency of Use**: The frequency of application can vary. Some products may recommend using the shampoo once or twice a week, while others may suggest more frequent use during flare-ups. Always follow the specific instructions provided by your healthcare provider or the product label.\n",
      "\n",
      "5. **Consultation**: It is essential to consult with a healthcare professional before starting treatment with hydrocort shampoo, especially if you have underlying health conditions or are taking other medications. They can provide personalized recommendations based on your specific situation.\n",
      "\n",
      "6. **Monitoring**: After starting treatment, monitor your scalp condition for improvement or any adverse reactions. If symptoms persist or worsen, contact your healthcare provider for further evaluation and management.\n",
      "\n",
      "In summary, while the general recommendation is to use about 1 to 2 tablespoons of hydrocort shampoo, it is crucial to follow the specific instructions provided with the product and consult with a healthcare professional for tailored advice.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.012308\n",
      "prediction:  Hydrocortisone shampoo is typically used to treat various scalp conditions, such as seborrheic dermatitis, psoriasis, or eczema. The recommended amount of hydrocortisone shampoo to use can vary based on the specific product formulation and the severity of the condition being treated. However, general guidelines can be provided.\n",
      "\n",
      "1. **Amount to Use**: Most manufacturers recommend using a small amount of hydrocortisone shampoo, usually about 1 to 2 tablespoons (15 to 30 mL), depending on the length and thickness of the hair and the affected area of the scalp. It's important to ensure that the shampoo adequately covers the affected areas.\n",
      "\n",
      "2. **Application Method**:\n",
      "   - **Wet Hair**: Start by thoroughly wetting your hair and scalp with warm water.\n",
      "   - **Apply Shampoo**: Dispense the recommended amount of hydrocortisone shampoo into your hands and apply it directly to the scalp. Focus on the areas that are inflamed or affected.\n",
      "   - **Massage**: Gently massage the shampoo into the scalp for several minutes to ensure it penetrates the skin and is evenly distributed.\n",
      "   - **Leave In**: Follow the instructions on the product label regarding how long to leave the shampoo on the scalp. This is often around 5 to 10 minutes, but it can vary by product.\n",
      "   - **Rinse**: Rinse thoroughly with warm water to remove the shampoo.\n",
      "\n",
      "3. **Frequency of Use**: The frequency of application can also vary. Some products may recommend using the shampoo once or twice a week, while others may suggest more frequent use during flare-ups. Always follow the specific instructions provided with the product or those given by your healthcare provider.\n",
      "\n",
      "4. **Consultation with Healthcare Provider**: It is essential to consult with a healthcare provider or dermatologist before starting treatment with hydrocortisone shampoo, especially if you have underlying health conditions or are using other medications. They can provide personalized recommendations based on your specific condition and needs.\n",
      "\n",
      "5. **Monitoring for Side Effects**: While hydrocortisone is generally safe for topical use, it is important to monitor for any side effects, such as increased irritation, burning, or allergic reactions. If any adverse effects occur, discontinue use and consult a healthcare professional.\n",
      "\n",
      "In summary, the recommended amount of hydrocortisone shampoo typically ranges from 1 to 2 tablespoons, applied to the scalp, massaged in, and left for a specified duration before rinsing. Always refer to the specific product instructions and consult with a healthcare provider for tailored advice.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.024221\n",
      "prediction:  Hydrocortisone, commonly referred to as Hydrocort, is a corticosteroid medication used to treat various conditions, including inflammation, allergies, and autoimmune disorders. When assessing the mutagenicity of a compound like Hydrocort, researchers typically conduct several categories of studies. These studies are designed to evaluate whether the substance can cause genetic mutations, which may lead to cancer or other genetic disorders.\n",
      "\n",
      "1. **In Vitro Studies**: These studies are conducted in a controlled laboratory environment using cell cultures. Common tests include:\n",
      "   - **Ames Test**: This is a widely used method that assesses the mutagenic potential of a compound by measuring its ability to induce mutations in specific strains of bacteria (usually Salmonella typhimurium). If Hydrocort shows a significant increase in mutation rates compared to a control, it may be considered mutagenic.\n",
      "   - **Mammalian Cell Mutation Assays**: These tests involve exposing mammalian cell lines (such as Chinese hamster ovary cells) to Hydrocort to observe any mutations in the cells' DNA.\n",
      "\n",
      "2. **In Vivo Studies**: These studies are conducted in living organisms, typically rodents, to assess the mutagenic effects of Hydrocort in a more complex biological system. Common approaches include:\n",
      "   - **Micronucleus Test**: This test evaluates the formation of micronuclei in the bone marrow of animals after exposure to Hydrocort. The presence of micronuclei indicates that the drug may have caused chromosomal damage or mutations.\n",
      "   - **Comet Assay**: This assay measures DNA strand breaks in individual cells. If Hydrocort induces significant DNA damage, it may suggest mutagenic potential.\n",
      "\n",
      "3. **Long-term Carcinogenicity Studies**: While primarily focused on cancer risk, these studies can provide insights into mutagenicity. Animals are exposed to Hydrocort over an extended period, and researchers monitor for tumor development and any associated genetic changes.\n",
      "\n",
      "4. **Genotoxicity Studies**: These studies specifically aim to determine whether a substance can damage genetic material. They often include a combination of in vitro and in vivo tests to provide a comprehensive assessment of mutagenic potential.\n",
      "\n",
      "5. **Regulatory Assessments**: Regulatory agencies, such as the FDA or EMA, may require specific mutagenicity studies as part of the drug approval process. These assessments ensure that the drug is safe for human use and does not pose a significant risk of causing genetic mutations.\n",
      "\n",
      "In summary, the determination of mutagenicity for Hydrocort involves a combination of in vitro and in vivo studies, including the Ames test, mammalian cell assays, micronucleus tests, and long-term carcinogenicity studies. The results from these studies help to establish the safety profile of Hydrocort and inform its use in clinical practice.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.024441\n",
      "prediction:  Hydrocortisone, commonly referred to as Hydrocort, is a corticosteroid used to treat various inflammatory and autoimmune conditions. When assessing the mutagenicity of a compound like Hydrocort, researchers typically conduct several categories of studies. These studies are designed to evaluate whether a substance can cause genetic mutations, which may lead to cancer or other genetic disorders.\n",
      "\n",
      "1. **In Vitro Studies**: These are laboratory studies conducted on cells or biological molecules outside of a living organism. Common tests include:\n",
      "   - **Ames Test**: This test uses bacteria (usually Salmonella) to assess whether a substance can cause mutations in the DNA of the bacteria. If the bacteria show increased mutation rates in the presence of Hydrocort, it may indicate mutagenic potential.\n",
      "   - **Mammalian Cell Mutation Assays**: These tests involve exposing mammalian cells (like Chinese hamster ovary cells) to Hydrocort to observe any mutations that occur in the cells' DNA.\n",
      "\n",
      "2. **In Vivo Studies**: These studies are conducted in living organisms, typically rodents, to assess the mutagenic effects of Hydrocort in a more complex biological system. Common approaches include:\n",
      "   - **Micronucleus Test**: This test evaluates the formation of micronuclei in the bone marrow of animals after exposure to Hydrocort. The presence of micronuclei indicates that the substance may have caused chromosomal damage or mutations.\n",
      "   - **Comet Assay**: This assay measures DNA strand breaks in individual cells, providing insight into the genotoxic effects of Hydrocort.\n",
      "\n",
      "3. **Long-term Carcinogenicity Studies**: While not exclusively focused on mutagenicity, these studies assess the potential of a substance to cause cancer over an extended period. They can provide indirect evidence of mutagenic effects if tumors develop due to genetic mutations.\n",
      "\n",
      "4. **Epidemiological Studies**: These studies look at populations exposed to Hydrocort to identify any correlations between exposure and increased rates of genetic mutations or cancer. While these studies are less controlled than laboratory studies, they can provide valuable real-world data on the mutagenic potential of a substance.\n",
      "\n",
      "5. **Regulatory Review and Meta-analyses**: Regulatory agencies like the FDA or EMA review existing studies and data on Hydrocort to assess its safety profile, including mutagenicity. Meta-analyses can also be conducted to synthesize findings from multiple studies to draw more robust conclusions.\n",
      "\n",
      "In summary, the determination of mutagenicity for Hydrocort involves a combination of in vitro and in vivo studies, long-term carcinogenicity assessments, and epidemiological research. The results from these studies help inform regulatory decisions and clinical guidelines regarding the safe use of Hydrocort in medical practice.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.024156\n",
      "prediction:  Hydrocortisone, commonly referred to as Hydrocort, is a corticosteroid used to treat various inflammatory and autoimmune conditions. When assessing the mutagenicity of a compound like Hydrocort, researchers typically conduct several categories of studies. These studies are designed to evaluate whether the substance can cause genetic mutations, which could potentially lead to cancer or other genetic disorders.\n",
      "\n",
      "1. **In Vitro Studies**: These are laboratory studies conducted on cells or biological molecules outside of a living organism. Common tests include:\n",
      "   - **Ames Test**: This test uses bacteria (usually Salmonella) to assess whether a substance can cause mutations in the DNA of the bacteria. If the bacteria show increased mutation rates in the presence of Hydrocort, it suggests potential mutagenicity.\n",
      "   - **Mammalian Cell Mutation Assays**: These tests involve exposing mammalian cells (like Chinese hamster ovary cells) to Hydrocort to observe any mutations that occur in the cells' DNA.\n",
      "\n",
      "2. **In Vivo Studies**: These studies are conducted in living organisms, typically rodents, to assess the mutagenic potential of Hydrocort in a more complex biological system. Common approaches include:\n",
      "   - **Micronucleus Test**: This test evaluates the formation of micronuclei in the bone marrow of animals after exposure to Hydrocort, indicating chromosomal damage or mutations.\n",
      "   - **Comet Assay**: This assay measures DNA strand breaks in individual cells, providing insight into the genotoxic effects of Hydrocort.\n",
      "\n",
      "3. **Long-term Carcinogenicity Studies**: While primarily focused on cancer risk, these studies can provide indirect evidence of mutagenicity. If Hydrocort is found to increase tumor incidence in long-term studies, it may suggest that the compound has mutagenic properties.\n",
      "\n",
      "4. **Genotoxicity Panels**: These are comprehensive assessments that may include a battery of tests designed to evaluate various aspects of genetic damage, including chromosomal aberrations, DNA repair mechanisms, and other indicators of mutagenicity.\n",
      "\n",
      "5. **Regulatory Guidelines**: Studies conducted to assess the mutagenicity of Hydrocort would typically follow guidelines set by regulatory agencies such as the International Conference on Harmonisation (ICH) or the U.S. Environmental Protection Agency (EPA). These guidelines outline the necessary tests and methodologies to ensure that the data generated is reliable and valid.\n",
      "\n",
      "In summary, the determination of mutagenicity for Hydrocort involves a combination of in vitro and in vivo studies, including bacterial mutation tests, mammalian cell assays, and long-term carcinogenicity studies. The results from these studies help to assess the safety profile of Hydrocort and inform its use in clinical settings.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.11127\n",
      "prediction:  I could not find specific data on the percentage of patients reporting headaches in the Phase 3 clinical study comparing GOPRELTO 4% solution, Cocaine Hydrochloride 8% solution, and placebo. The search returned generic information about the study, but not detailed results regarding headache occurrences.\n",
      "\n",
      "Based on the options provided and the context of clinical studies, the correct answer would likely lean towards one of the treatment groups. However, without specific data from the studies, I cannot definitively select an answer. Please consult specific study results for detailed information.\n",
      "\n",
      "If forced to choose without specific data, I would select:\n",
      "\n",
      "D\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: GOPRELTO 4% solution group\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.024691\n",
      "prediction:  I could not find specific information regarding the mean basal acid output (BAO) for patients treated with intravenous placebo on Day 7 from studies about pantoprazole sodium. Therefore, I am unable to answer the question accurately.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: 4.14 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.043103\n",
      "prediction:  I could not find specific information regarding the mean basal acid output for patients treated with pantoprazole sodium for injection on Day 7. Therefore, I cannot answer the question based on the provided resources.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 0.4 Â± 0.5 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.158845\n",
      "prediction:  I couldn't find relevant information specific to G-62's solubility and absorption. However, based on the common characteristics of pharmacological compounds:\n",
      "\n",
      "- A with high solubility often leads to rapid absorption.\n",
      "- B with low solubility would typically result in slow absorption.\n",
      "- C with moderate solubility is likely to lead to moderate absorption.\n",
      "- D regarding unpredictability could apply to some formulations.\n",
      "\n",
      "If I had to choose, based on general pharmacokinetic principles, my answer would be:\n",
      "\n",
      "A\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: G-62 has low solubility and slow absorption.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.006098\n",
      "prediction:  I couldn't find specific studies or data on the percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets. However, pantoprazole is commonly used for the treatment of erosive esophagitis and is indicated for a treatment period of up to 8 weeks for healing and symptomatic relief in such cases.\n",
      "\n",
      "Generally, clinical studies have indicated that proton pump inhibitors like pantoprazole can achieve significant healing rates in erosive esophagitis, often reported to be around 80% or higher at the end of an 8-week treatment course, though this can vary based on specific study designs and patient populations.\n",
      "\n",
      "For precise data, consulting a specific clinical trial result or systematic review regarding this treatment regimen would be advisable. If you're looking for hard numbers, I would recommend accessing clinical trial databases or comprehensive reviews focused on this therapy.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.242009\n",
      "prediction:  I couldn't find the specific information regarding systemic beta-adrenergic adverse effects of Levalbuterol compared to racemic Albuterol sulfate in clinical studies from the available resources. Therefore, I cannot provide a confident answer to the multiple-choice question.\n",
      "\n",
      "Please consult a medical professional or relevant clinical literature for detailed insights.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Levalbuterol had a slightly higher rate of systemic beta-adrenergic adverse effects.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.027165\n",
      "prediction:  I was unable to find specific information on a drug that blocks the tumorigenic effect of albuterol sulfate in Sprague-Dawley rats from both PubMed and internet sources. This could be due to either a lack of published research on this specific topic or limited visibility of relevant studies. \n",
      "\n",
      "For accurate information regarding drug interactions, effects, and specific experimental studies, it might be useful to consult primary research papers or specialized biomedical literature. If you have any further questions or need assistance with a different query, feel free to ask!\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Propranolol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.010204\n",
      "prediction:  I was unable to find specific information regarding the percentage of lamotrigine removed during a 4-hour hemodialysis session in renal failure patients. Given this context, I cannot provide the precise answer to your question. If you have access to relevant medical literature or databases, I encourage you to consult them for the most accurate information.\n",
      "\n",
      "Based on general knowledge regarding similar scenarios, a common finding in cases with certain drugs in hemodialysis could be around 30%. Therefore, if forced to choose based on existing clinical knowledge, I would answer:\n",
      "\n",
      "C\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 20%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.031088\n",
      "prediction:  I was unable to find specific studies detailing the maximum oral dose of ondansetron administered to rats in carcinogenicity studies. However, general research and pharmacokinetic studies indicate that some doses used in toxicological assessments range significantly.\n",
      "\n",
      "In some studies, typical oral doses for toxicity evaluation conducted on rats were observed to be highâ€”often at multiples of those administered to humans. Specifically, one study suggested doses around 30 to 100 times those utilized in clinical settings for humans, but exact figures vary between studies.\n",
      "\n",
      "If you are looking for official figures regarding a particular study or more detailed specifics, consulting comprehensive toxicology and pharmacology texts or databases dedicated to toxicity evaluations might provide the most accurate answers. Additionally, regulatory filings or official scientific literature could have the exact figures delineated in controlled studies.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.051643\n",
      "prediction:  I was unable to find specific studies in PubMed or reliable sources directly addressing which drug blocks the tumorigenic effect of albuterol sulfate in Sprague-Dawley rats. The search did not return relevant results on this specific inquiry.\n",
      "\n",
      "If you need this information for research purposes, I recommend checking veterinary journals or studies focused on pharmacology and toxicology involving albuterol sulfate.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Propranolol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.001992\n",
      "prediction:  I was unable to find specific studies or official data that directly report the percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets. \n",
      "\n",
      "However, pantoprazole is commonly used for the treatment of erosive esophagitis due to gastroesophageal reflux disease (GERD), and it is generally indicated for short-term treatment (up to 8 weeks) for this condition. Clinical outcomes can vary among different studies, and the effectiveness of pantoprazole might be reflected in various clinical trials, but specific healing percentages typically require access to proprietary data or clinical study results.\n",
      "\n",
      "For accurate details, I recommend checking primary literature or clinical trial registries focusing on the efficacy of pantoprazole for healing esophageal lesions linked with GERD. If you need specific study citations or publications, further searches in larger databases like PubMed may be warranted.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.293839\n",
      "prediction:  I'm sorry, but I don't have specific information about G-62. If you can provide more context or details about G-62, I may be able to help you analyze the options.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: G-62 has low solubility and slow absorption.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.039821\n",
      "prediction:  If a patient develops hypersensitivity reactions, such as anaphylaxis, while taking Ondansetron, the recommended actions are as follows:\n",
      "\n",
      "1. **Immediate Discontinuation of Ondansetron**: The first step is to stop the administration of Ondansetron immediately to prevent any further exposure to the allergen.\n",
      "\n",
      "2. **Assessment of Airway and Breathing**: Anaphylaxis can lead to severe respiratory distress, so assessing the patientâ€™s airway and breathing is crucial. If there are signs of airway swelling or difficulty breathing, prepare for airway management.\n",
      "\n",
      "3. **Administration of Epinephrine**: Administer intramuscular epinephrine (usually 0.3-0.5 mg for adults, 0.01 mg/kg in children) as the first-line treatment for anaphylaxis. Epinephrine works quickly to reverse the symptoms of anaphylaxis such as bronchospasm and hypotension.\n",
      "\n",
      "4. **Call for Emergency Help**: Activate emergency medical services (EMS) or prepare for immediate advanced medical assistance.\n",
      "\n",
      "5. **Supplemental Oxygen**: If the patient is experiencing respiratory distress, provide supplemental oxygen to maintain adequate oxygen saturation levels.\n",
      "\n",
      "6. **Positioning**: Keep the patient lying down with legs elevated if possible, which can help improve venous return and support blood pressure.\n",
      "\n",
      "7. **Fluid Resuscitation**: Administer IV fluids to combat hypotension if the patient is experiencing low blood pressure.\n",
      "\n",
      "8. **Monitoring**: Monitor the patientâ€™s vital signs continuously. Pay attention to heart rate, blood pressure, respiratory rate, and oxygen saturation.\n",
      "\n",
      "9. **Additional Medications**: After administering epinephrine, consider additional medications like antihistamines (e.g., diphenhydramine) and corticosteroids to further manage the allergic reaction.\n",
      "\n",
      "10. **Emergency Follow-Up**: Ensure that the patient is fully stabilized, and provide further medical evaluation and treatment as necessary, potentially including hospitalization for observation, especially if there are concerns about biphasic anaphylaxis.\n",
      "\n",
      "Itâ€™s important to educate the patient about the potential for future reactions and consider providing an emergency anaphylaxis kit, including epinephrine auto-injectors, for use in case of further episodes.\n",
      "\n",
      "These steps are aligned with current clinical guidelines for the management of anaphylactic reactions, emphasizing rapid intervention to prevent severe complications (Cureus, 2025).\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Discontinue Ondansetron and treat promptly per standard of care\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.014481\n",
      "prediction:  If a patient has a history of hypersensitivity to clindamycin, it is essential to avoid the use of **lincomycin**. Both clindamycin and lincomycin belong to the same class of antibiotics known as lincosamides, and there exists a potential for cross-reactivity between them due to their similar chemical structures. \n",
      "\n",
      "Cross-reactivity occurs because the immune system may recognize similar antigens present in both drugs, leading to allergic reactions. Therefore, if a patient is allergic to clindamycin, they may also react adversely to lincomycin. \n",
      "\n",
      "In clinical practice, it's advisable for healthcare providers to assess the patient's allergy history thoroughly and consider alternative classes of antibiotics that do not share the same structure. Possible alternatives could include tetracyclines or macrolides, depending on the infection being treated and the patient's specific allergy profile. \n",
      "\n",
      "The findings from literature emphasize the importance of being cautious with lincosamide antibiotics in patients with known clindamycin hypersensitivity. Thus, the safest course of action is to avoid lincomycin and consult with an infectious disease specialist or pharmacist when needing to prescribe antibiotics for such patients.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010488\n",
      "prediction:  If a patient has a history of hypersensitivity to clindamycin, it is important to avoid not only clindamycin itself but also other drugs that are structurally related or that may have cross-reactivity. The primary drug to avoid in this case is **lincomycin**, as it is chemically related to clindamycin and can elicit similar allergic reactions in susceptible individuals.\n",
      "\n",
      "Clindamycin and lincomycin are both lincosamide antibiotics, and they share a similar mechanism of action, targeting bacterial protein synthesis. Therefore, if a patient has experienced an allergic reaction to clindamycin, there is a significant risk that they may also react to lincomycin.\n",
      "\n",
      "In addition to lincomycin, it is prudent to exercise caution with other antibiotics that may have similar side effects or mechanisms, although the risk of cross-reactivity may not be as high. For example, while not directly related, some healthcare providers may choose to avoid other antibiotics that can cause similar hypersensitivity reactions, such as certain macrolides (e.g., erythromycin) or other classes of antibiotics, depending on the patient's overall allergy history.\n",
      "\n",
      "When managing a patient with a known hypersensitivity to clindamycin, it is essential to conduct a thorough medication history and consider alternative antibiotics that are not related to lincosamides. Options may include penicillins (if the patient does not have a penicillin allergy), cephalosporins (with caution, as some patients may have cross-reactivity), or other classes of antibiotics such as tetracyclines or fluoroquinolones, depending on the infection being treated and the patient's overall health status.\n",
      "\n",
      "In summary, the primary drug to avoid in a patient with a history of hypersensitivity to clindamycin is lincomycin, and careful consideration should be given to the selection of alternative antibiotics to ensure patient safety.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010304\n",
      "prediction:  If a patient has a history of hypersensitivity to clindamycin, it is important to avoid not only clindamycin itself but also other drugs that are structurally related or that may have cross-reactivity. The primary drug to avoid in this case is **lincomycin**, as it is chemically related to clindamycin and can elicit similar allergic reactions in susceptible individuals.\n",
      "\n",
      "Clindamycin and lincomycin belong to the same class of antibiotics known as lincosamides. They share a similar mechanism of action, targeting bacterial protein synthesis, and therefore, a patient with a hypersensitivity reaction to clindamycin may also react to lincomycin due to their structural similarities.\n",
      "\n",
      "In addition to lincomycin, it is prudent to exercise caution with other antibiotics that may have overlapping mechanisms or similar side effect profiles, although the risk of cross-reactivity may not be as high. For example, while not directly contraindicated, caution should be taken with other antibiotics that can cause gastrointestinal side effects or allergic reactions, such as macrolides (e.g., erythromycin) or other classes of antibiotics, depending on the patient's overall allergy history.\n",
      "\n",
      "In clinical practice, if a patient has a documented hypersensitivity to clindamycin, it is essential to thoroughly review their medical history for any other drug allergies and to consider alternative antibiotics that are not related to lincosamides. Options may include penicillins, cephalosporins (if no history of penicillin allergy), tetracyclines, or fluoroquinolones, depending on the type of infection being treated and the patient's overall health status.\n",
      "\n",
      "In summary, the primary drug to avoid in a patient with a history of hypersensitivity to clindamycin is lincomycin, and careful consideration should be given to the selection of alternative antibiotics based on the patient's allergy history and the specific clinical scenario.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.010274\n",
      "prediction:  If a patient has a history of hypersensitivity to clindamycin, the drug that should be avoided is **lincomycin**. \n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Clindamycin**: \n",
      "   - Clindamycin is an antibiotic that belongs to the lincosamide class. It is commonly used to treat various bacterial infections, particularly those caused by anaerobic bacteria and certain protozoa.\n",
      "\n",
      "2. **Hypersensitivity Reactions**: \n",
      "   - Hypersensitivity reactions can range from mild allergic reactions (such as rashes) to severe reactions (such as anaphylaxis). If a patient has a documented hypersensitivity to clindamycin, it indicates that their immune system has reacted adversely to this medication.\n",
      "\n",
      "3. **Cross-Reactivity**: \n",
      "   - Drugs that belong to the same class often have similar structures and mechanisms of action, which can lead to cross-reactivity. In the case of clindamycin, lincomycin is its parent compound and shares a similar chemical structure.\n",
      "\n",
      "4. **Clinical Implications**: \n",
      "   - Due to the structural similarities and the potential for cross-reactivity, lincomycin should be avoided in patients with a known hypersensitivity to clindamycin. Administering lincomycin could trigger a similar allergic reaction.\n",
      "\n",
      "5. **Alternative Antibiotics**: \n",
      "   - If a patient requires antibiotic therapy and has a history of hypersensitivity to clindamycin, healthcare providers should consider alternative classes of antibiotics that do not share the same lincosamide structure. Options may include:\n",
      "     - **Macrolides** (e.g., azithromycin, erythromycin) for certain infections.\n",
      "     - **Tetracyclines** (e.g., doxycycline) for specific bacterial infections.\n",
      "     - **Beta-lactams** (e.g., penicillins or cephalosporins), provided the patient does not have a history of hypersensitivity to these drugs.\n",
      "\n",
      "6. **Consultation and Testing**: \n",
      "   - In cases of uncertainty regarding drug allergies, consultation with an allergist or performing allergy testing may be beneficial to clarify the patient's sensitivities and guide appropriate antibiotic selection.\n",
      "\n",
      "### Conclusion:\n",
      "In summary, if a patient has a history of hypersensitivity to clindamycin, lincomycin should be avoided due to the risk of cross-reactivity. Alternative antibiotics from different classes should be considered to ensure safe and effective treatment.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.010494\n",
      "prediction:  If a patient has a history of hypersensitivity to clindamycin, the drug that should be avoided is **lincomycin**. \n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Clindamycin**: \n",
      "   - Clindamycin is an antibiotic that belongs to the lincosamide class. It is commonly used to treat various bacterial infections, particularly those caused by anaerobic bacteria and certain protozoa.\n",
      "\n",
      "2. **Hypersensitivity Reactions**: \n",
      "   - Hypersensitivity reactions can range from mild allergic reactions (such as rashes) to severe reactions (such as anaphylaxis). If a patient has a documented hypersensitivity to clindamycin, it indicates that their immune system has reacted adversely to this medication.\n",
      "\n",
      "3. **Cross-Reactivity**: \n",
      "   - Drugs that belong to the same class often have similar structures and mechanisms of action, which can lead to cross-reactivity. In the case of clindamycin, lincomycin is its parent compound and shares a similar chemical structure.\n",
      "\n",
      "4. **Lincomycin**: \n",
      "   - Lincomycin is also a lincosamide antibiotic and is structurally related to clindamycin. Therefore, if a patient is allergic to clindamycin, there is a significant risk that they may also react to lincomycin due to this structural similarity.\n",
      "\n",
      "5. **Clinical Recommendations**: \n",
      "   - In clinical practice, it is generally recommended to avoid prescribing lincomycin to patients with a known hypersensitivity to clindamycin. Instead, alternative antibiotics that do not belong to the lincosamide class should be considered based on the type of infection and the sensitivity of the bacteria involved.\n",
      "\n",
      "6. **Alternative Antibiotics**: \n",
      "   - Depending on the infection being treated, alternatives may include:\n",
      "     - **Macrolides** (e.g., azithromycin, erythromycin) for certain bacterial infections.\n",
      "     - **Tetracyclines** (e.g., doxycycline) for a variety of infections.\n",
      "     - **Beta-lactams** (e.g., penicillins or cephalosporins) if the patient does not have a history of allergy to these classes.\n",
      "\n",
      "### Conclusion:\n",
      "In summary, if a patient has a history of hypersensitivity to clindamycin, lincomycin should be avoided due to the risk of cross-reactivity. It is essential to assess the patient's allergy history thoroughly and consider alternative antibiotics that are safe for the patient.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.009954\n",
      "prediction:  If a patient has a history of hypersensitivity to clindamycin, the drug that should be avoided is **lincomycin**. \n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Clindamycin**: \n",
      "   - Clindamycin is an antibiotic that belongs to the lincosamide class. It is commonly used to treat various bacterial infections, particularly those caused by anaerobic bacteria and certain protozoa.\n",
      "\n",
      "2. **Hypersensitivity Reactions**: \n",
      "   - Hypersensitivity reactions can range from mild skin rashes to severe anaphylactic reactions. If a patient has previously experienced an allergic reaction to clindamycin, it indicates that their immune system has reacted adversely to this specific drug.\n",
      "\n",
      "3. **Cross-Reactivity**: \n",
      "   - Drugs that belong to the same class often have similar structures and mechanisms of action, which can lead to cross-reactivity. In the case of clindamycin, lincomycin is its parent compound and shares a similar chemical structure and mechanism of action.\n",
      "\n",
      "4. **Clinical Implications**: \n",
      "   - Due to the potential for cross-reactivity, it is generally recommended that patients with a known hypersensitivity to clindamycin should also avoid lincomycin. This is to prevent the risk of a similar or more severe allergic reaction.\n",
      "\n",
      "5. **Alternative Antibiotics**: \n",
      "   - If a patient requires antibiotic therapy and has a history of clindamycin hypersensitivity, healthcare providers should consider alternative classes of antibiotics. Options may include:\n",
      "     - **Macrolides** (e.g., azithromycin, erythromycin) for certain infections.\n",
      "     - **Tetracyclines** (e.g., doxycycline) for specific bacterial infections.\n",
      "     - **Beta-lactams** (e.g., penicillins or cephalosporins), provided the patient does not have a history of hypersensitivity to these drugs.\n",
      "\n",
      "6. **Consultation and Testing**: \n",
      "   - In cases where the choice of antibiotic is critical, and there is uncertainty about the nature of the hypersensitivity, consultation with an allergist or performing skin testing may be warranted to assess the risk of cross-reactivity.\n",
      "\n",
      "### Conclusion:\n",
      "In summary, if a patient has a history of hypersensitivity to clindamycin, lincomycin should be avoided due to the risk of cross-reactivity. Alternative antibiotics should be considered based on the specific infection and the patient's overall medical history. Always consult with a healthcare professional for personalized medical advice.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Cleocin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.058531\n",
      "prediction:  If a patient misses a dose of RoxyBond (an immediate-release form of oxycodone), they should take the following steps:\n",
      "\n",
      "1. **Skip the Missed Dose**: If it is almost time for the next scheduled dose, the patient should skip the missed dose. They should not take two doses at the same time to make up for the missed dose, as this can increase the risk of overdose and other adverse effects.\n",
      "\n",
      "2. **Timing**: If there is still a significant amount of time until the next dose, the patient can take the missed dose as soon as they remember. However, they should adhere to their prescribed dosing schedule and not exceed the recommended doses.\n",
      "\n",
      "3. **Pain Management**: Since RoxyBond is typically used for managing pain, the patient should consider how their pain level may change if they miss a dose. If pain control is insufficient after missing a dose, they should contact their healthcare provider for guidance.\n",
      "\n",
      "4. **Consult Healthcare Provider**: If the patient frequently misses doses or has questions about their pain management regimen, they should discuss this with their healthcare provider, who may need to adjust their treatment plan.\n",
      "\n",
      "For more detailed instructions, it's advisable to refer to the medication's prescribing information or consult a healthcare professional. Additionally, information from resources such as Drugs.com recommends following these steps to ensure safety and effective pain management. \n",
      "\n",
      "For further reading, patients can refer to detailed prescribing guidelines found [here](https://www.drugs.com/mtm/roxybond.html).\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Take the next dose at the usual time\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.057387\n",
      "prediction:  If a patient misses a dose of RoxyBond (an opioid medication), here are some general recommendations based on standard guidelines for missed doses of opioid medications:\n",
      "\n",
      "1. **Timing of the Missed Dose**: \n",
      "   - If the patient remembers the missed dose relatively soon and it is safe, they should take it as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their regular dosing schedule.\n",
      "\n",
      "2. **Avoid Doubling Up**: \n",
      "   - It is crucial not to take a double dose to make up for a missed one. This can lead to an increased risk of overdose, particularly with opioids like RoxyBond.\n",
      "\n",
      "3. **Monitor for Symptoms**:\n",
      "   - Patients should be aware of any withdrawal symptoms that might occur due to the missed dose. Symptoms may include increased pain, irritability, anxiety, and sleep disturbances.\n",
      "\n",
      "4. **Consult Healthcare Provider**:\n",
      "   - If a patient is unsure about what to do or if they consistently forget doses, they should contact their healthcare provider for personalized advice and to reassess their treatment plan.\n",
      "\n",
      "5. **Precautions**:\n",
      "   - It is important to adhere to the prescribed dosage and frequency due to the potential risks of addiction and side effects associated with opioid medications.\n",
      "\n",
      "6. **Keep Medication Secure**: \n",
      "   - Patients should ensure that their medication is stored securely and that they follow the prescribed instructions to maintain the effectiveness of the treatment.\n",
      "\n",
      "Always consult with a healthcare provider regarding specific medical advice tailored to individual needs.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Take the next dose at the usual time\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.067684\n",
      "prediction:  If a patient misses a dose of RoxyBond (an opioid medication), they should follow these guidelines:\n",
      "\n",
      "1. **Take it as Soon as Remembered**: If the patient remembers the missed dose within a reasonable timeframe (usually a few hours), they should take it as soon as possible. \n",
      "\n",
      "2. **Skip if Close to Next Dose**: If it is almost time for the next scheduled dose, the patient should skip the missed dose and continue with their regular dosing schedule. It's important **not to double up** on doses to make up for the missed one.\n",
      "\n",
      "3. **Consult with Healthcare Provider**: In case of uncertainty or if the patient misses multiple doses, they should contact their healthcare provider for advice on how to proceed.\n",
      "\n",
      "4. **Monitor for Side Effects**: Patients should be vigilant for any side effects or unusual symptoms, especially if they resume taking RoxyBond after a missed dose. Opioids can have potent effects, and any change in the dosing schedule may increase the risk of side effects or overdose.\n",
      "\n",
      "5. **Keep a Regular Schedule**: To minimize the chances of forgetting doses in the future, patients might consider setting reminders or using a pill organizer.\n",
      "\n",
      "These steps are crucial not only for maintaining the effectiveness of the medication but also for ensuring the patient's safety, as opioid medications carry a risk of dependency and overdose. Always adhere to the prescribed regimen and consult a healthcare professional for personalized advice.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Take the next dose at the usual time\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.035472\n",
      "prediction:  If a patient misses a dose of RoxyBond (oxycodone), it is important to follow specific steps to ensure safety and effectiveness in managing their pain. Hereâ€™s a comprehensive guide on what to do:\n",
      "\n",
      "### Step 1: Assess the Timing\n",
      "- **Determine When the Dose Was Missed**: Check how much time has passed since the scheduled dose. This will help in deciding the next steps.\n",
      "\n",
      "### Step 2: Follow the Prescribing Instructions\n",
      "- **Refer to the Prescription Label**: The label on the medication bottle often contains specific instructions regarding missed doses. Follow these instructions closely.\n",
      "\n",
      "### Step 3: Take the Missed Dose\n",
      "- **If Itâ€™s Close to the Next Dose**: If the time to the next scheduled dose is approaching (usually within 1-2 hours), it is generally advised to skip the missed dose and take the next dose at the regular time. Do not double up on doses to make up for the missed one.\n",
      "  \n",
      "- **If Thereâ€™s Enough Time**: If it is still a reasonable time to take the missed dose (not close to the next scheduled dose), take the missed dose as soon as you remember.\n",
      "\n",
      "### Step 4: Monitor for Side Effects\n",
      "- **Be Aware of Side Effects**: After taking the missed dose, monitor for any side effects or unusual symptoms, especially if the patient has taken a higher dose than usual.\n",
      "\n",
      "### Step 5: Consult Healthcare Provider\n",
      "- **Contact a Healthcare Professional**: If there is any uncertainty about what to do after missing a dose, or if the patient has missed multiple doses, it is important to contact a healthcare provider for guidance. They can provide personalized advice based on the patient's specific situation.\n",
      "\n",
      "### Step 6: Maintain a Medication Schedule\n",
      "- **Use Reminders**: To prevent missing doses in the future, consider using a pill organizer, setting alarms, or using a medication management app. Consistency is key in managing pain effectively with medications like RoxyBond.\n",
      "\n",
      "### Step 7: Understand the Risks\n",
      "- **Be Aware of Dependence and Withdrawal**: RoxyBond is an opioid medication, and missing doses can lead to withdrawal symptoms if the medication is not taken as prescribed. If the patient is experiencing withdrawal symptoms, they should seek medical advice immediately.\n",
      "\n",
      "### Conclusion\n",
      "In summary, if a patient misses a dose of RoxyBond, they should assess the timing, follow the prescribing instructions, take the missed dose if appropriate, monitor for side effects, consult a healthcare provider if needed, and implement strategies to avoid future missed doses. Always prioritize safety and communication with healthcare professionals when managing medication regimens.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Take the next dose at the usual time\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.029316\n",
      "prediction:  If a patient on Agrylin (anagrelide) develops progressive dyspnea and lung infiltrations, it is crucial to take the following steps:\n",
      "\n",
      "1. **Assess Symptoms and Medical History**: Evaluate the patientâ€™s respiratory symptoms, duration, severity, and any associated features. It is important to obtain a thorough medical history, including the timeline of Agrylin use and the onset of respiratory symptoms.\n",
      "\n",
      "2. **Conduct Diagnostic Imaging**: A chest X-ray or CT scan should be performed to assess the extent of lung infiltrations and to help identify any specific patterns that may suggest interstitial lung disease or another pulmonary condition.\n",
      "\n",
      "3. **Laboratory Tests**: Consider conducting pulmonary function tests (PFTs) to evaluate the extent of any restrictive or obstructive patterns in the patient's lung function. Blood tests may also be useful to rule out other causes of dyspnea.\n",
      "\n",
      "4. **Evaluate for Drug-Induced Lung Disease**: There have been reports of interstitial lung diseases, including allergic alveolitis and eosinophilic pneumonia, associated with Agrylin. If these conditions are suspected, it may be necessary to consult a pulmonologist for specialized care.\n",
      "\n",
      "5. **Discontinue Agrylin**: If Agrylin is strongly suspected to be the cause of the respiratory symptoms, it should be discontinued immediately. Monitoring the patient's condition after cessation is crucial to ensure any improvement in respiratory symptoms.\n",
      "\n",
      "6. **Supportive Care**: Administer supportive care for dyspnea, which may include supplemental oxygen, bronchodilators, or corticosteroids if there is an inflammatory component.\n",
      "\n",
      "7. **Referral to a Specialist**: If the lung infiltrations are significant or if there is a persistent decline in pulmonary function, referral to a pulmonary specialist is advised for comprehensive management, which may include further imaging, biopsy, or advanced therapies.\n",
      "\n",
      "8. **Long-term Monitoring**: The patient will require follow-up to monitor for any resolution of lung symptoms and to assess any long-term effects from Agrylin or other treatments initiated.\n",
      "\n",
      "It's essential for healthcare providers to be aware of the potential pulmonary side effects associated with Agrylin and to act proactively in managing such cases. For more detailed information on Agrylin and its side effects, healthcare providers can refer to the [FDA Package Insert](https://www.drugs.com/pro/agrylin.html).\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Discontinue Agrylin and evaluate the patient\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.039575\n",
      "prediction:  If a patient receiving Ogivri (trastuzumab) experiences a â‰¥16% absolute decrease in left ventricular ejection fraction (LVEF) from pre-treatment values, the recommended action typically includes the following steps based on recent clinical guidelines and evidence found in relevant studies:\n",
      "\n",
      "1. **Immediate Assessment**: Conduct a detailed cardiological evaluation, which may involve repeating echocardiography to confirm the decrease in LVEF and to assess the overall cardiac function.\n",
      "\n",
      "2. **Discontinuation Consideration**: If the LVEF is confirmed to be significantly decreased (often â‰¥10% decline and particularly â‰¥16% as noted), cessation of trastuzumab may be warranted to prevent the progression of cardiotoxicity.\n",
      "\n",
      "3. **Management of Cardiac Dysfunction**: Initiate appropriate management for heart failure or related symptoms if present. This could involve starting medications such as ACE inhibitors, beta-blockers, or diuretics depending on the severity and nature of the patient's cardiac dysfunction.\n",
      "\n",
      "4. **Monitoring and Multidisciplinary Approach**: Implement close monitoring of cardiac function if trastuzumab is resumed at a later stage, or involve a cardiologist for a multidisciplinary treatment plan. Regular follow-up echocardiograms may also be advised.\n",
      "\n",
      "5. **Patient Education**: Inform the patient about the symptoms of heart failure and the importance of promptly reporting any such symptoms during their treatment.\n",
      "\n",
      "These steps are essential to ensuring patient safety and managing the risk of left ventricular dysfunction associated with anti-HER2 therapies like Ogivri. Continuous assessment and collaboration between oncologists and cardiologists can optimize care for patients who are at risk of cardiotoxicity.\n",
      "\n",
      "For reference, information on the incidence of cardiotoxicity associated with trastuzumab and management recommendations can be found in the recent literature ([PMID: 39110914](https://pubmed.ncbi.nlm.nih.gov/39110914), [PMID: 38696070](https://pubmed.ncbi.nlm.nih.gov/38696070)).\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Withhold Ogivri treatment.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.152502\n",
      "prediction:  If a patient's platelet count drops to 50,000/mcL or less while receiving MONJUVI (tafasitamab-cxix), the following management steps should generally be taken:\n",
      "\n",
      "1. **Withhold Treatment**: Both MONJUVI and any concurrent therapy, such as lenalidomide, should be withheld. This step is crucial to prevent further complications associated with low platelet counts.\n",
      "\n",
      "2. **Monitoring**: A complete blood count (CBC) should be monitored weekly. This ongoing assessment is important to determine when the platelet count has returned to a safer level (i.e., above 50,000/mcL).\n",
      "\n",
      "3. **Resumption of MONJUVI**: Once the platelet count is back to 50,000/mcL or higher, MONJUVI may be resumed at the same dose as before. However, it's important to consider resuming lenalidomide, if applicable, at a reduced dose. \n",
      "\n",
      "4. **Consultation**: Consider involving a hematologist or the healthcare team for further evaluation and management strategies, especially if the patient has recurrent issues with platelet counts.\n",
      "\n",
      "Always follow specific guidelines and protocols established for the management of patients receiving MONJUVI, as individual clinical circumstances may vary.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Withhold MONJUVI and lenalidomide and monitor CBC weekly until platelet count is 50,000/mcL or higher.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.075472\n",
      "prediction:  If a patientâ€™s platelet count drops to 50,000/mcL or less while receiving MONJUVI (tafasitamab-cxix), the following management steps should be taken:\n",
      "\n",
      "1. **Withhold Treatment**: MONJUVI and any combinatory treatments (e.g., lenalidomide) should be withheld immediately to prevent further complications arising from low platelet counts.\n",
      "\n",
      "2. **Monitor Blood Counts**: Closely monitor the patient's complete blood count (CBC) on a weekly basis to track the recovery of platelet levels.\n",
      "\n",
      "3. **Resumption of Treatment**: Once the platelet count rises back to 50,000/mcL or higher, MONJUVI can be resumed. However, it is important to resume MONJUVI at the same dose while considering a potential dose reduction for lenalidomide, if it was being administered.\n",
      "\n",
      "4. **Clinical Assessment**: Throughout this process, the patient's clinical status should be assessed, especially for any signs of bleeding or other complications related to thrombocytopenia.\n",
      "\n",
      "5. **Consultation with Hematology**: Depending on the severity of thrombocytopenia and its complications, consultation with a hematologist may be warranted for further management.\n",
      "\n",
      "6. **Patient Education**: Inform the patient to report any signs of bleeding, bruising, or other symptoms that could indicate worsening thrombocytopenia.\n",
      "\n",
      "For specific details, medical professionals should refer to tailored guidelines provided in the treatment summary or management guidelines from relevant oncology organizations or resources.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Withhold MONJUVI and lenalidomide and monitor CBC weekly until platelet count is 50,000/mcL or higher.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.047748\n",
      "prediction:  In a carcinogenicity study of fluoxetine conducted over a 2-year period involving Fischer rats, the highest dose administered was 10.0 mg/kg body weight. This study involved dietary dosing and aimed to evaluate the carcinogenic potential of fluoxetine.\n",
      "\n",
      "To compare this rat dose to human dosages, we need to convert mg/kg to mg/mÂ². The standard conversion factor from body weight (kg) to body surface area (mÂ²) for humans is approximately 37.8 kg/mÂ² for a typical adult. The maximum recommended human dose (MRHD) for fluoxetine is typically around 80 mg/day.\n",
      "\n",
      "**Calculating the equivalent dose in humans:**\n",
      "\n",
      "1. **Rat Dose:** 10 mg/kg\n",
      "2. **Conversion to mg/mÂ² for rats:** \n",
      "   - Assuming an average rat weighs about 0.25 kg.\n",
      "   - Therefore, 10 mg/kg corresponds to:\n",
      "     \\[\n",
      "     10 \\, \\text{mg/kg} \\times 0.25 \\, \\text{kg} = 2.5 \\, \\text{mg/rat}\n",
      "     \\]\n",
      "\n",
      "3. **Human Equivalent Dose (mg/mÂ²):**\n",
      "   - For a typical human weighing about 70 kg:\n",
      "   \\[\n",
      "   10 \\, \\text{mg/kg} \\times \\frac{70 \\, \\text{kg}}{37.8 \\, \\text{kg/mÂ²}} \\approx 18.4 \\, \\text{mg/mÂ²}\n",
      "   \\]\n",
      "\n",
      "4. **Maximum Recommended Human Dose (MRHD):**\n",
      "   - The MRHD of fluoxetine is approximately 80 mg/day for adults.\n",
      "   - Dividing this by a human's average body surface area:\n",
      "   \\[\n",
      "   \\frac{80 \\, \\text{mg}}{1.73 \\, \\text{mÂ²}} \\approx 46.2 \\, \\text{mg/mÂ²}\n",
      "   \\]\n",
      "\n",
      "**Comparison:**\n",
      "- The highest dose tested in the rat study (10 mg/kg) converts to about 18.4 mg/mÂ².\n",
      "- The MRHD for humans is approximately 46.2 mg/mÂ².\n",
      "\n",
      "This comparison shows that the highest dose administered to rats in the carcinogenicity study is significantly lower than the maximum recommended human dose when adjusted for body surface area. Additionally, the study concluded that fluoxetine did not present as a carcinogen, providing further context regarding its safety profile.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.005797\n",
      "prediction:  In a clinical trial involving lamotrigine for the treatment of primary generalized tonic-clonic seizures (PGTC), studies indicated a median percent reduction in seizure frequency. Specifically, participants treated with lamotrigine experienced a median percent reduction of about 50% in seizure frequency. This finding aligns with other antiseizure medications investigated in the trials and reflects lamotrigine's efficacy as an add-on therapy for patients with treatment-resistant epilepsy. \n",
      "\n",
      "These results are derived from a comprehensive analysis of multiple clinical trials focusing on various antiseizure medications, including lamotrigine, indicating consistent efficacy across different study designs. The median percent reduction is a critical metric for assessing the drug's effectiveness in real-world clinical settings, affirming its role in managing PGTC seizures. \n",
      "\n",
      "For more in-depth details, refer to recent publications and analyses comparing the efficacy of lamotrigine with other treatments in controlled settings.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.011407\n",
      "prediction:  In a study investigating the use of pantoprazole sodium in patients with Zollinger-Ellison Syndrome, the target basal acid secretion level for those without prior gastric surgery was assessed. The study included a cohort of 11 male patients and evaluated their basal acid output. During treatment with pantoprazole, the mean dosage administered was approximately 116 mg/day, with a range from 40 to 200 mg/day.\n",
      "\n",
      "The findings indicated that the median basal acid output values during pantoprazole treatment did not significantly differ from those observed with other proton pump inhibitors previously used in the patients. The exact numerical target for basal acid secretion was not directly reported in the study; however, the research aimed to reduce gastric acid secretion effectively.\n",
      "\n",
      "Thus, while a specific target basal acid secretion value is not explicitly stated in the abstract of the study, the goal of therapy is to significantly reduce acid output to manage the symptoms and complications associated with Zollinger-Ellison Syndrome.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 10 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011872\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats has been reported to be 32 mg/kg/day. This dosage is significant as it helps researchers evaluate the potential long-term effects of ondansetron, particularly in relation to cancer development.\n",
      "\n",
      "To provide a comprehensive understanding, let's break down the context and implications of this information:\n",
      "\n",
      "1. **Background on Ondansetron**: Ondansetron is a selective serotonin 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. Its safety profile and potential side effects are critical for both clinical use and regulatory approval.\n",
      "\n",
      "2. **Carcinogenicity Studies**: These studies are designed to assess whether a substance has the potential to cause cancer in living organisms. They typically involve long-term exposure to the substance at various doses to observe any carcinogenic effects.\n",
      "\n",
      "3. **Dosing in Animal Studies**: The maximum dose of 32 mg/kg/day in rats is significant because it allows researchers to determine the threshold at which ondansetron may or may not induce carcinogenic effects. This dose is often chosen based on previous studies, pharmacokinetics, and the expected human equivalent dose.\n",
      "\n",
      "4. **Relevance of Findings**: The results from these studies can inform regulatory agencies, such as the FDA, about the safety of ondansetron for human use. If no carcinogenic effects are observed at this maximum dose, it supports the drug's safety profile. Conversely, if adverse effects are noted, it may lead to further investigation or restrictions on its use.\n",
      "\n",
      "5. **Comparative Analysis**: It's also important to compare the doses used in animal studies to those used in humans. The typical oral dose of ondansetron for humans is much lower, usually ranging from 4 mg to 16 mg, depending on the indication. This difference highlights the importance of understanding species-specific responses to drugs.\n",
      "\n",
      "6. **Regulatory and Clinical Implications**: The findings from carcinogenicity studies contribute to the overall risk assessment of ondansetron. If the studies indicate a lack of carcinogenic potential, it can bolster confidence in the drug's safety for patients requiring antiemetic therapy.\n",
      "\n",
      "In summary, the maximum oral dose of ondansetron administered to rats in carcinogenicity studies is 32 mg/kg/day. This information is crucial for understanding the drug's safety profile and its implications for human health.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011976\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats has been reported to be 32 mg/kg/day. This dosage is significant as it helps researchers evaluate the potential long-term effects of ondansetron, particularly its carcinogenic potential, when given over extended periods.\n",
      "\n",
      "To provide a comprehensive understanding, let's break down the context and implications of this dosage:\n",
      "\n",
      "1. **Background on Ondansetron**: Ondansetron is a selective serotonin 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. Its safety profile has been extensively studied, including its potential carcinogenic effects.\n",
      "\n",
      "2. **Carcinogenicity Studies**: These studies are designed to assess whether a substance can cause cancer in living organisms. In the case of ondansetron, rats are often used as a model organism due to their physiological similarities to humans and their well-documented response to various drugs.\n",
      "\n",
      "3. **Dosage Administration**: The maximum dose of 32 mg/kg/day is significant in the context of these studies. This high dose is typically chosen to ensure that any potential carcinogenic effects can be observed, as lower doses may not elicit a response. The duration of these studies often spans a significant portion of the animals' lifespan, allowing researchers to monitor for the development of tumors or other long-term health effects.\n",
      "\n",
      "4. **Findings and Implications**: The results of these studies are crucial for regulatory agencies when determining the safety of ondansetron for human use. If no significant increase in tumor incidence is observed at this maximum dose, it supports the conclusion that ondansetron is not carcinogenic at the tested levels. Conversely, if an increase in tumors is noted, it may lead to further investigation and potential regulatory action.\n",
      "\n",
      "5. **Relevance to Human Use**: While animal studies provide valuable insights, the translation of these findings to humans is complex. Factors such as differences in metabolism, dosage, and exposure duration must be considered. Regulatory agencies like the FDA evaluate these studies alongside clinical data to ensure the safety of ondansetron for patients.\n",
      "\n",
      "In summary, the maximum oral dose of ondansetron administered to rats in carcinogenicity studies is 32 mg/kg/day. This information is critical for understanding the drug's safety profile and its potential long-term effects on health.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.008016\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats has been reported to be 32 mg/kg/day. This dose is significant in the context of evaluating the long-term safety and potential carcinogenic effects of the drug.\n",
      "\n",
      "### Step-by-Step Breakdown:\n",
      "\n",
      "1. **Understanding Ondansetron**: \n",
      "   - Ondansetron is a medication primarily used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, or surgery. It is a selective serotonin 5-HT3 receptor antagonist.\n",
      "\n",
      "2. **Carcinogenicity Studies**: \n",
      "   - Carcinogenicity studies are conducted to assess whether a substance has the potential to cause cancer in living organisms. These studies typically involve long-term exposure to the substance at various doses.\n",
      "\n",
      "3. **Study Design**: \n",
      "   - In these studies, rats are often used as a model organism due to their biological similarities to humans and their well-understood genetics. The studies usually involve administering the drug over a significant portion of the animals' lifespan.\n",
      "\n",
      "4. **Dose Administration**: \n",
      "   - The maximum oral dose of 32 mg/kg/day is determined based on various factors, including the pharmacokinetics of the drug, previous toxicity studies, and the need to observe potential long-term effects without causing excessive toxicity.\n",
      "\n",
      "5. **Relevance of the Dose**: \n",
      "   - This dose is critical for understanding the safety profile of ondansetron. It helps researchers evaluate the risk of carcinogenic effects and contributes to the overall assessment of the drug's safety for human use.\n",
      "\n",
      "6. **Regulatory Considerations**: \n",
      "   - Data from these studies are submitted to regulatory agencies (like the FDA or EMA) as part of the drug approval process. The findings help inform guidelines for safe dosing in humans.\n",
      "\n",
      "7. **Conclusion**: \n",
      "   - The maximum oral dose of ondansetron administered to rats in carcinogenicity studies is 32 mg/kg/day, which is a key figure in assessing the drug's long-term safety and potential risks.\n",
      "\n",
      "### Additional Notes:\n",
      "- It is important to consider that findings from animal studies do not always directly translate to humans due to differences in metabolism, physiology, and other factors.\n",
      "- Ongoing monitoring and post-marketing surveillance are essential to ensure the continued safety of ondansetron in the human population. \n",
      "\n",
      "This comprehensive understanding of the dosing in carcinogenicity studies provides insight into the safety evaluation process for pharmaceuticals.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.022422\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats has varied depending on the specific study design and objectives. However, in general, the doses used in these studies have been quite high to assess the potential long-term effects of the drug.\n",
      "\n",
      "For example, in some studies, doses of ondansetron were administered at levels up to 80 mg/kg body weight per day. These high doses were intended to evaluate the drug's safety profile and potential carcinogenic effects over an extended period, typically spanning the lifespan of the animals involved in the study.\n",
      "\n",
      "It's important to note that the specific maximum dose can differ based on the regulatory guidelines followed, the duration of the study, and the endpoints being evaluated. The results from these studies are crucial for understanding the long-term safety of ondansetron, especially since it is widely used for the prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery.\n",
      "\n",
      "In summary, while the maximum oral dose of ondansetron administered to rats in carcinogenicity studies can reach up to 80 mg/kg/day, the exact dose may vary based on the study parameters. These studies are essential for assessing the potential risks associated with long-term use of the medication in humans.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021629\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats has varied depending on the specific study design and objectives. However, in general, the doses used in these studies have been quite high to assess the potential long-term effects of the drug.\n",
      "\n",
      "For instance, in some studies, doses of ondansetron were administered at levels up to 40 mg/kg body weight per day. These high doses were chosen to evaluate the drug's safety profile and potential carcinogenic effects over an extended period, typically spanning two years. The studies aimed to observe any tumor development or other long-term health effects resulting from chronic exposure to ondansetron.\n",
      "\n",
      "It's important to note that the specific maximum dose can differ based on the regulatory guidelines followed, the objectives of the study, and the particular strain of rats used. Additionally, the results of these studies are crucial for understanding the safety of ondansetron in humans, as they help inform the risk assessment and regulatory decisions regarding its use.\n",
      "\n",
      "In summary, while the maximum oral dose of ondansetron administered to rats in carcinogenicity studies can reach up to 40 mg/kg/day, the exact dose may vary based on the study parameters. These studies are essential for evaluating the long-term safety of ondansetron and its potential carcinogenicity.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.023511\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats has varied depending on the specific study design and objectives. However, in general, the maximum doses used in these studies have been reported to be around 40 mg/kg/day. \n",
      "\n",
      "For example, in a two-year carcinogenicity study, rats were typically given doses of ondansetron that ranged from 5 mg/kg/day to 40 mg/kg/day. These doses were selected to evaluate the long-term effects of ondansetron exposure and to assess any potential carcinogenic risks associated with its use.\n",
      "\n",
      "It's important to note that the selection of doses in such studies is based on a variety of factors, including the pharmacokinetics of the drug, the expected human therapeutic dose, and the need to observe any potential adverse effects over an extended period. The findings from these studies contribute to the overall understanding of the safety profile of ondansetron and help inform regulatory decisions regarding its use in humans.\n",
      "\n",
      "If you are looking for specific study references or more detailed information about the methodology and results of these studies, it would be advisable to consult the original research articles or regulatory documents from agencies such as the FDA or EMA.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.030361\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats typically ranged from 10 to 40 mg/kg per day, depending on the specific study design and objectives. For example, in some studies, doses of 10, 20, and 40 mg/kg per day were evaluated to assess the potential long-term effects of ondansetron on tumor development and other health outcomes in rats.\n",
      "\n",
      "It's important to note that the exact maximum dose can vary based on the specific study protocols, the duration of the study, and the regulatory guidelines followed. These studies are designed to evaluate the safety and potential carcinogenic effects of ondansetron over extended periods, often involving multiple generations of animals.\n",
      "\n",
      "If you are looking for specific data from a particular study or regulatory submission, it would be best to refer to the original research articles or the documentation provided by regulatory agencies such as the FDA or EMA, which may contain detailed information on the dosing regimens used in these studies.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.029823\n",
      "prediction:  In carcinogenicity studies involving ondansetron, the maximum oral dose administered to rats typically ranged from 10 to 40 mg/kg per day, depending on the specific study design and objectives. These studies were conducted to evaluate the long-term effects of ondansetron, particularly its potential to induce cancer or other adverse effects over extended periods.\n",
      "\n",
      "For example, in some studies, doses of 10, 20, and 40 mg/kg per day were used to assess the safety and potential carcinogenic effects of ondansetron. The highest dose, often set at 40 mg/kg per day, was chosen to evaluate the upper limits of safety and to observe any potential dose-dependent effects.\n",
      "\n",
      "It's important to note that the specific dose used can vary based on the regulatory guidelines followed, the objectives of the study, and the design of the experiment. Therefore, while 40 mg/kg per day is a common maximum dose reported in various studies, it is essential to refer to the specific study documentation for precise details regarding the dosing regimen and outcomes observed.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.028868\n",
      "prediction:  In cases of severe forms of diseases, particularly conditions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which can cause significant ocular damage, alternatives to treatments like TOXEX (if referring to a specific therapeutic agent) might include innovative approaches like a sutureless amniotic membrane dressing (AMD).\n",
      "\n",
      "1. **Amniotic Membrane Dressings**: A study showed the effectiveness of self-made sutureless AMD rings in patients with acute SJS/TEN experiencing severe ocular involvement. The amniotic membrane is known for its anti-inflammatory and regenerative properties, promoting healing, reducing scarring, and providing comfort to the patients.\n",
      "\n",
      "2. **Comprehensive Care**: It is critical to involve multidisciplinary teams for the management of severe diseases. This can include dermatologists for skin management, ophthalmologists for ocular protection, and possibly pain management specialists.\n",
      "\n",
      "3. **Standardized Protocols**: Referral to specialized burn units or ocular surface disease clinics where advanced therapies, including surgical interventions, can be applied is often necessary for severe cases.\n",
      "\n",
      "4. **Management Strategies**: The focus should be on preventing further tissue loss, managing pain effectively, and considering systemic therapies that modulate inflammatory responses when standard topical treatments prove insufficient.\n",
      "\n",
      "Ultimately, treatment plans should be tailored to the specific needs of the patient based on the severity and progression of the disease. \n",
      "\n",
      "For a more detailed understanding and specific treatment recommendations, always consult with healthcare professionals specializing in the respective disease areas.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A clinically proven therapy\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.016453\n",
      "prediction:  In clinical studies, the use of certain beta blockers has been associated with significant bronchospasm in patients with mild asthma. Atenolol, in particular, has been reported to cause bronchospasm in asthmatic patients. A case study illustrated that a young patient with a history of asthma developed serious bronchospasm while being treated with atenolol, necessitating a switch to esmolol, which did not elicit the same adverse respiratory effects.\n",
      "\n",
      "It's essential to recognize that beta blockers can have variable effects based on their selectivity. Non-selective beta blockers can antagonize Î²2-adrenergic receptors in the lungs, leading to bronchoconstriction and exacerbating asthma symptoms, whereas selective Î²1-blockers like metoprolol might have a lower risk of inducing bronchospasm but are not without risk.\n",
      "\n",
      "Given this information, it is crucial for healthcare providers to weigh the benefits and risks of beta blocker therapy in patients with a history of asthma or reactive airway disease, and choose alternatives or monitor closely if such medications are necessary.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Propranolol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.004396\n",
      "prediction:  In clinical trials assessing the efficacy of lamotrigine as adjunctive therapy for adults with partial-onset seizures, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo typically ranged around 50% to 60%. \n",
      "\n",
      "In these studies, participants receiving lamotrigine often experienced a significant reduction in seizure frequency compared to those receiving a placebo. For instance, in some trials, the median percentage reduction in seizure frequency for patients on lamotrigine at this dosage was reported to be approximately 50% or more, indicating that a substantial number of patients benefited from the treatment.\n",
      "\n",
      "It's important to note that individual responses to lamotrigine can vary, and while many patients may experience a notable reduction in seizure frequency, others may have a less pronounced response. Additionally, the overall effectiveness of lamotrigine can be influenced by factors such as the duration of treatment, the specific characteristics of the patient population, and the presence of other medications.\n",
      "\n",
      "In summary, the median seizure frequency reduction with a 400 mg/day dose of lamotrigine in adults with partial-onset seizures compared to placebo is generally reported to be around 50% to 60%, highlighting its role as an effective adjunctive therapy in managing this condition.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.004854\n",
      "prediction:  In clinical trials assessing the efficacy of lamotrigine as adjunctive therapy for adults with partial-onset seizures, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo typically ranged around 50% to 60%. \n",
      "\n",
      "In these studies, participants receiving lamotrigine often experienced a significant reduction in seizure frequency compared to those receiving a placebo. For instance, in some trials, the median percentage reduction in seizure frequency for patients on lamotrigine at this dosage was reported to be approximately 50% or more, indicating that a substantial number of patients benefited from the treatment.\n",
      "\n",
      "It's important to note that individual responses to lamotrigine can vary, and while many patients may experience a notable reduction in seizure frequency, others may have a lesser response or may not respond at all. The overall findings from these trials support the use of lamotrigine as an effective adjunctive treatment option for managing partial-onset seizures in adults. \n",
      "\n",
      "For the most accurate and specific data, it is advisable to refer to the results of the specific clinical trials or meta-analyses that evaluated lamotrigine's efficacy in this context.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.004655\n",
      "prediction:  In clinical trials assessing the efficacy of lamotrigine as an adjunctive therapy for adults with partial-onset seizures, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo typically ranges around 50% to 60%. \n",
      "\n",
      "In these studies, participants receiving lamotrigine often experienced a significant reduction in seizure frequency compared to those on placebo. For instance, in some trials, the median percentage reduction in seizure frequency for patients on lamotrigine at this dosage was reported to be approximately 50% or more, indicating that a substantial number of patients benefited from the treatment.\n",
      "\n",
      "It's important to note that individual responses to lamotrigine can vary, and while some patients may experience a greater reduction in seizure frequency, others may have a lesser response. Additionally, the overall effectiveness of lamotrigine can be influenced by factors such as the duration of treatment, the presence of other medications, and individual patient characteristics.\n",
      "\n",
      "In summary, the median seizure frequency reduction with a 400 mg/day dose of lamotrigine in adults with partial-onset seizures compared to placebo is generally around 50% to 60%, reflecting its efficacy as an adjunctive treatment option.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "default\n",
      "default\n",
      "SIM_score:  0.004644\n",
      "0.004644\n",
      "0.004644\n",
      "prediction:  In clinical trials assessing the efficacy of lamotrigine for the treatment of primary generalized tonic-clonic seizures (PGTC), the median percent reduction in seizure frequency can vary based on the specific study design, patient population, and dosage used. However, in general, lamotrigine has been shown to be effective in reducing the frequency of PGTC seizures.\n",
      "\n",
      "In several studies, patients treated with lamotrigine typically experienced a median percent reduction in seizure frequency ranging from approximately 50% to 70%. For instance, in some trials, patients on lamotrigine reported a median reduction of around 60% in the frequency of PGTC seizures compared to baseline measurements. \n",
      "\n",
      "It's important to note that individual responses to lamotrigine can vary significantly, and factors such as the duration of treatment, concomitant medications, and individual patient characteristics can influence the overall efficacy. Additionally, the specific median percent reduction may differ between studies, so it is advisable to refer to the results of specific clinical trials for precise figures.\n",
      "\n",
      "Overall, lamotrigine is recognized as an effective treatment option for patients with PGTC seizures, contributing to significant reductions in seizure frequency for many individuals.\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.008708\n",
      "prediction:  In clinical trials evaluating the efficacy of adjunctive therapy with lamotrigine for adults with partial-onset seizures, a 400 mg/day dose was associated with a significant reduction in median seizure frequency compared to placebo. The specific median reduction observed was approximately 50%, according to a meta-analysis of studies involving lamotrigine. \n",
      "\n",
      "This shows that lamotrigine is an effective addition to treatment regimens for adult patients with uncontrolled partial-onset seizures, leading to considerable reductions in seizure activity when compared to placebo. As a result, lamotrigine is often recommended as a viable option for patients seeking better seizure control.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.023433\n",
      "prediction:  In clinical trials investigating the effects of treatments on plasma glucose levels in adults and adolescents, specific groups may exhibit varying responses to medications. In particular, trials assessing glucose levels after the first dose can yield insights into which demographic or treatment group shows the least change in plasma glucose.\n",
      "\n",
      "From the analysis of relevant studies, one notable trial is the one involving amycretin, a first-in-class GLP-1 and amylin receptor agonist. In this randomized, placebo-controlled trial, participants were assessed for pharmacodynamic effects, including changes in plasma glucose one hour after dosing.\n",
      "\n",
      "While detailed results regarding the smallest mean change in plasma glucose for specific groups were not explicitly stated in the provided resources, trials like this typically measure glucose responses across different demographic groups (adults vs. adolescents, or based on treatment vs. control). Investigating this trial further in clinical data or academic publications may provide specifics on group comparisons.\n",
      "\n",
      "For real insights into which group exhibited the smallest mean change in plasma glucose after the first dose, it would typically require reviewing the full published results of these trials, as raw data comparison across treatment groups would be outlined within specific trial outcomes in peer-reviewed literature. \n",
      "\n",
      "If you're seeking precise numerical data or comparative evidence, I recommend accessing the full texts of these studies or related articles in biomedical databases like PubMed, as this will provide the most reliable and targeted information regarding plasma glucose measurements post-intervention.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.016915\n",
      "prediction:  In clinical trials involving adolescents and adults, a study focusing on the glucose-lowering effects of a novel drug called amycretin has provided insights into mean changes in plasma glucose levels 1 hour after administration. As detailed in a recent article published in *The Lancet*, this phase 1 trial was designed to investigate the pharmacodynamics of amycretin, a GLP-1 and amylin receptor agonist.\n",
      "\n",
      "### Key Findings\n",
      "- **Study Population**: Participants included adults with overweight or obesity, aged between 18 and 55 years. \n",
      "- **Trial Structure**: It was a randomized, double-blind, placebo-controlled study that examined multiple ascending doses of the medication.\n",
      "\n",
      "### Results\n",
      "- The group administered **amycretin** showed a **reduction** in plasma glucose levels, indicating its efficacy in glucose management; however, the specific results detailing which group had the smallest mean change in plasma glucose levels 1 hour after the first dose were not explicitly quantified in the provided abstracts.\n",
      "\n",
      "Full details regarding the smallest mean change observed can potentially be obtained from the complete article, but based on the information from the clinical trials and studies reviewed, the focus lies on the effects of amycretin being beneficial over placebo without definitive comparative metrics directly from the trial text regarding mean changes across groups.\n",
      "\n",
      "### Conclusion\n",
      "To determine which specific group demonstrated the smallest mean change in plasma glucose post-first dose, the complete study findings would need to be consulted. The reported trials suggest that **amycretin**, as a new therapy, is under investigation for its effectiveness in managing plasma glucose levels in adults and adolescents, yet the exact comparative metrics remain to be fully analyzed in detail. \n",
      "\n",
      "For further information, examining the trial records and published outcomes in detail, especially focusing on the metrics from the clinical trial results, would be essential.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.050682\n",
      "prediction:  In clinical trials of venlafaxine, several behaviors and side effects were commonly monitored, including its efficacy in treating depression and anxiety disorders, as well as various adverse effects like nausea, dizziness, and increased blood pressure. However, the behavior that was **not commonly observed** in these trials relates to **significantly increased rates of aggression or violent behavior**, which are often concerns with other classes of psychotropic medications but were not a primary focus associated with venlafaxine.\n",
      "\n",
      "Research has indicated that while venlafaxine can lead to some withdrawal symptoms upon discontinuation and may cause agitation in some patients, large-scale trials have not highlighted a significant incidence of aggressive behavior as a primary outcome compared to placebo or other medications in its class.\n",
      "\n",
      "Thus, the behavior **not observed** significantly in these clinical trials of venlafaxine includes **increased aggression or violent behavior**.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.037412\n",
      "prediction:  In clinical trials of venlafaxine, several behaviors are typically observed, including treatment responses and side effects. However, specific behaviors that were NOT observed include:\n",
      "\n",
      "1. **Weight Loss**: Unlike some other antidepressants that may lead to weight loss, venlafaxine trials have not consistently shown a significant reduction in weight as a prominent effect. Weight gain or neutral effects on weight have been more common.\n",
      "\n",
      "2. **Severe Sedation**: Venlafaxine, as a serotonin-norepinephrine reuptake inhibitor (SNRI), is generally associated with less sedation compared to tricyclic antidepressants. It has not shown severe sedative effects in clinical trials.\n",
      "\n",
      "3. **High Incidence of Addictive Behaviors**: Unlike certain medications for anxiety or mood disorders, venlafaxine has not been associated with high rates of dependence or abuse behaviors in the trials reviewed.\n",
      "\n",
      "4. **Euphoria**: Experiences of euphoria, which can sometimes be reported with stimulant medications, are not typically documented or observed in those taking venlafaxine as an antidepressant.\n",
      "\n",
      "These behaviors underscore the profile of venlafaxine being more neutral or less impactful in specific non-target effects compared to other antidepressant classes.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.051866\n",
      "prediction:  In fertility studies involving adult male rats, the highest dose of fluoxetine administered was **200 mg/kg** for a duration of 60 days. This study was conducted to evaluate the effects of fluoxetine on various fertility parameters, including spermatogenesis, sperm motility, and reproductive organ weights. The results indicated significant adverse effects on fertility, including decreased testosterone levels and sperm density.\n",
      "\n",
      "To compare this dose to the Maximum Recommended Human Dose (MRHD) on a mg/mÂ² basis, we need to standardize the dose based on surface area. The MRHD for fluoxetine (Prozac) is approximately **60 mg/day** for adults. \n",
      "\n",
      "Assuming an average human body surface area of **1.73 mÂ²**, we can calculate the MRHD dose in mg/mÂ²:\n",
      "- MRHD in mg/mÂ² = 60 mg / 1.73 mÂ² â‰ˆ **34.64 mg/mÂ²**\n",
      "\n",
      "For the rat dosages, considering the conversion between rats and humans based on body surface area, the equivalent dose can be calculated (using a conversion factor) but is usually simplified as follows:\n",
      "\n",
      "- Rat dose (200 mg/kg) in mg/mÂ² can be compared by converting 200 mg/kg to mg/mÂ² using a conversion factor approximately of 12.3 for rats to humans:\n",
      "   - 200 mg/kg * 12.3 = **2460 mg/mÂ²**\n",
      "\n",
      "Thus, the 200 mg/kg dose given to adult male rats is significantly higher than the MRHD when adjusted for body surface area, highlighting a marked difference in the dosing between the two species. \n",
      "\n",
      "This information can be essential in assessing the relevance of animal data for understanding the effects of fluoxetine on human fertility.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.065811\n",
      "prediction:  In fertility studies involving adult rats, the highest dose of fluoxetine administered was **20 mg/kg body weight**. This dosage, when compared to the maximum recommended human dose (MRHD) of fluoxetine, approximately translates to a risk assessment on a mg/mÂ² basis. \n",
      "\n",
      "The MRHD for fluoxetine in adults is typically noted as 60 mg per day for conditions such as major depressive disorder. To make an appropriate comparison, it's important to calculate the human equivalent dose (HED) based on body surface area.\n",
      "\n",
      "When comparing mg/kg dosing in rats to humans, the conversion factor often used is approximately 6.2 for rats to humans (the average body surface area of an adult human is roughly 70 kg). Thus, a dose of **20 mg/kg in rats** would be about **129 mg/mÂ²** when converted.\n",
      "\n",
      "This indicates the fluoxetine exposure at the highest tested dose in rats is significantly higher than the MRHD on a mg/mÂ² basis, pointing towards a higher threshold for adverse effects observed in animal studies when translated to potential human equivalent doses. \n",
      "\n",
      "In summary, the highest dose of fluoxetine used in these studies was **20 mg/kg**, substantially exceeding the MRHD when compared on a mg/mÂ² basis.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.050604\n",
      "prediction:  In fertility studies involving fluoxetine, the highest dose administered to adult rats typically ranged around 40 mg/kg/day. When comparing this dose to the Maximum Recommended Human Dose (MRHD) of fluoxetine, which is approximately 60 mg/day for adults, the conversion to a mg/mÂ² basis is necessary to make an appropriate comparison.\n",
      "\n",
      "To convert the doses from mg/kg to mg/mÂ², we can use the body surface area (BSA) normalization method. The BSA for an average adult human is often estimated to be around 1.73 mÂ². The conversion formula is as follows:\n",
      "\n",
      "1. Calculate the human equivalent dose (HED) using the formula:\n",
      "   \\[\n",
      "   HED (mg/mÂ²) = Animal Dose (mg/kg) \\times (Animal Weight (kg) / Human Weight (kg))^{0.33}\n",
      "   \\]\n",
      "\n",
      "Assuming an average weight of 250 g for a rat (0.25 kg) and an average human weight of 70 kg, the calculation would be:\n",
      "\n",
      "\\[\n",
      "HED = 40 mg/kg \\times (0.25 kg / 70 kg)^{0.33}\n",
      "\\]\n",
      "\n",
      "This calculation yields an approximate HED of around 5.7 mg/mÂ² for the 40 mg/kg dose in rats.\n",
      "\n",
      "Now, if we consider the MRHD of fluoxetine, which is about 60 mg/day for an adult, we can convert this to mg/mÂ²:\n",
      "\n",
      "\\[\n",
      "MRHD (mg/mÂ²) = 60 mg / 1.73 mÂ² \\approx 34.64 mg/mÂ²\n",
      "\\]\n",
      "\n",
      "In summary, the highest dose of fluoxetine administered to adult rats in fertility studies was approximately 40 mg/kg/day, which translates to about 5.7 mg/mÂ². In comparison, the MRHD for humans is approximately 34.64 mg/mÂ². This indicates that the dose given to rats in these studies was significantly lower than the MRHD for humans when adjusted for body surface area. This information is crucial for understanding the potential implications of fluoxetine on fertility and reproductive health in both animal models and humans.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.049718\n",
      "prediction:  In fertility studies involving fluoxetine, the highest dose administered to adult rats typically reached up to 40 mg/kg/day. When comparing this dose to the Maximum Recommended Human Dose (MRHD) of fluoxetine, which is approximately 60 mg/day for adults, the conversion to a mg/mÂ² basis is necessary to make an accurate comparison.\n",
      "\n",
      "To convert the doses from mg/kg to mg/mÂ², we can use the body surface area (BSA) normalization method. The BSA for an average adult human is often estimated to be around 1.73 mÂ². The conversion formula is as follows:\n",
      "\n",
      "1. Calculate the human equivalent dose (HED) using the formula:\n",
      "   \\[\n",
      "   HED (mg/mÂ²) = Animal Dose (mg/kg) \\times (Animal Weight (kg) / Human Weight (kg))^{0.33}\n",
      "   \\]\n",
      "\n",
      "Assuming an average weight of 0.25 kg for a rat and 70 kg for a human, the calculation would be:\n",
      "\n",
      "1. Convert the rat dose to mg/mÂ²:\n",
      "   \\[\n",
      "   HED = 40 mg/kg \\times (0.25 kg / 70 kg)^{0.33}\n",
      "   \\]\n",
      "\n",
      "2. The conversion factor for the body weight ratio (0.25/70) raised to the power of 0.33 is approximately 0.1. Therefore, the HED would be:\n",
      "   \\[\n",
      "   HED \\approx 40 mg/kg \\times 0.1 \\approx 4 mg/mÂ²\n",
      "   \\]\n",
      "\n",
      "3. The MRHD of fluoxetine, when converted to mg/mÂ², is:\n",
      "   \\[\n",
      "   MRHD = 60 mg/day / 1.73 mÂ² \\approx 34.64 mg/mÂ²\n",
      "   \\]\n",
      "\n",
      "In summary, the highest dose of fluoxetine administered to adult rats in fertility studies was 40 mg/kg/day, which translates to approximately 4 mg/mÂ². In comparison, the MRHD for humans is about 34.64 mg/mÂ², indicating that the dose given to rats was significantly lower than the MRHD for humans. This comparison highlights the importance of considering species differences in pharmacokinetics and pharmacodynamics when interpreting animal study results in the context of human health.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.051014\n",
      "prediction:  In fertility studies involving fluoxetine, the highest dose administered to adult rats typically reached up to 40 mg/kg/day. When comparing this dose to the Maximum Recommended Human Dose (MRHD) of fluoxetine, which is generally around 60 mg/day for adults, the conversion to a mg/mÂ² basis is necessary to make an appropriate comparison.\n",
      "\n",
      "To convert the doses from mg/kg to mg/mÂ², we can use the body surface area (BSA) conversion factor. The BSA for an average adult human is approximately 1.73 mÂ². The conversion formula is as follows:\n",
      "\n",
      "1. Calculate the human equivalent dose (HED) using the formula:\n",
      "   \\[\n",
      "   HED (mg/mÂ²) = Animal Dose (mg/kg) \\times (Animal Weight (kg) / Human Weight (kg))^{0.33}\n",
      "   \\]\n",
      "\n",
      "Assuming an average weight of 0.25 kg for a rat and 70 kg for a human, the calculation would be:\n",
      "\n",
      "1. Convert the rat dose to mg/mÂ²:\n",
      "   \\[\n",
      "   HED = 40 mg/kg \\times (0.25 kg / 70 kg)^{0.33}\n",
      "   \\]\n",
      "\n",
      "2. The conversion factor for the body weight ratio is approximately 0.25/70 = 0.00357. Raising this to the power of 0.33 gives a value that can be used to adjust the dose.\n",
      "\n",
      "3. After performing the calculations, the approximate human equivalent dose for 40 mg/kg in rats would be significantly lower than the MRHD when adjusted for body surface area.\n",
      "\n",
      "In summary, while the highest dose of fluoxetine administered to adult rats in fertility studies was 40 mg/kg/day, when adjusted for body surface area, this dose is considerably higher than the MRHD of fluoxetine in humans when expressed in mg/mÂ². This highlights the importance of considering species differences in pharmacokinetics and pharmacodynamics when interpreting animal study results in the context of human health.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.004731\n",
      "prediction:  In patients with Zollinger-Ellison Syndrome (ZES) who have not undergone prior gastric surgery, the target for basal acid secretion levels during treatment with pantoprazole sodium for injection is typically maintained below specific thresholds to control gastric acid hypersecretion effectively.\n",
      "\n",
      "The standard dosing for managing ZES with pantoprazole sodium involves an initial intravenous dose of 80 mg every 12 hours. This dosage can be adjusted based on the individual patientâ€™s needs, with clinicians often titrating the dose according to measurements of gastric acid secretion. Reports indicate that a total dose of 160 mg to 240 mg per day generally maintains basal acid secretion levels to below the desired target in the majority of patients. Therefore, the aim is to achieve a level of gastric acid secretion that is substantially lower than what is considered excessive or harmful, although specific numerical targets can vary based on clinical judgment and patient response.\n",
      "\n",
      "In summary, the emphasis is on individualized treatment where repeated measurements of gastric acid output help guide the necessary adjustments in dosing of pantoprazole sodium to keep acid secretion within a safe range, focusing on alleviating symptoms and preventing complications associated with excessive gastric acidity.\n",
      "\n",
      "For further reference, additional details can be found in articles discussing the rapid control of gastric acid hypersecretion in ZES and dosage recommendations. For example, the FDA package insert for pantoprazole sodium outlines the use and management protocols pertinent to this syndrome [source](https://medlibrary.org/lib/rx/meds/pantoprazole-sodium-48/page/7/).\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 10 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.011915\n",
      "prediction:  In patients with Zollinger-Ellison Syndrome (ZES) who have not undergone prior gastric surgery, treatment with pantoprazole sodium aims to achieve a target basal acid secretion level of less than 5 mEq/hour. This target is established based on the normal physiological reference, as patients with ZES typically exhibit significantly elevated basal acid outputs, often exceeding 60 mEq/hour.\n",
      "\n",
      "Studies have shown that pantoprazole effectively reduces gastric acid secretion in ZES patients. For instance, it was observed that the mean dosage of pantoprazole administered was around 116 mg/day, and during treatment, the patients' basal acid output was significantly lowered, although exact values can vary from patient to patient.\n",
      "\n",
      "The primary goal of therapy in ZES is to control acid secretion to prevent complications such as peptic ulcers and esophagitis. Therefore, monitoring and adjusting the dosage of pantoprazole is crucial to manage acid levels effectively while minimizing the risks of hypersecretion. Itâ€™s essential that clinicians closely monitor these patients and adjust their treatment plans accordingly to achieve optimal management of their condition.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 10 mEq/h\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.043716\n",
      "prediction:  In reviewing the recommended use of BRILINTA (ticagrelor) in patients with end-stage renal disease (ESRD) on dialysis, a few key points emerge based on current evidence.\n",
      "\n",
      "1. **Risk/Benefit Consideration**: Antiplatelet agents, including BRILINTA, are essential for preventing cardiovascular events. However, patients with chronic kidney disease (CKD) and ESRD may have a different risk/benefit profile due to the prevalence of occlusive atherosclerotic events being relatively lower, while the risk of bleeding complications tends to be higher. This delicate balance necessitates careful consideration of the appropriateness of BRILINTA in this patient population.\n",
      "\n",
      "2. **Clinical Studies**: Evidence from systematic reviews indicates that antiplatelet agents can be beneficial in patients with CKD, including those undergoing dialysis. However, the specific impact of BRILINTA in ESRD patients remains less clear, necessitating more targeted research.\n",
      "\n",
      "3. **Dosing Adjustments**: While BRILINTA does not require significant dose adjustments in cases of mild to moderate renal impairment, its use in severe renal impairment (such as ESRD) should be approached with caution, typically with an emphasis on close monitoring and adjusting treatment as necessary based on individual bleeding risk and overall health status.\n",
      "\n",
      "4. **Expert Recommendations**: The existing literature and expert opinions generally advocate for individualized treatment plans, especially for those with concurrent conditions or complications associated with ESRD. Physicians are encouraged to weigh the necessity of antiplatelet therapy in these patients against potential risks.\n",
      "\n",
      "In conclusion, while BRILINTA might be considered in patients with ESRD on dialysis, careful evaluation of individual risks, potential benefits, and close monitoring are essential parts of the management process. Further studies are warranted to elucidate its safety and efficacy in this specific demographic.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: BRILINTA can be used, but efficacy and safety are not established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.004751\n",
      "prediction:  In studies investigating the efficacy of lamotrigine as adjunctive therapy for adults with partial-onset seizures, a notable trial was conducted to evaluate the median seizure frequency reduction associated with a 400 mg/day dose of lamotrigine compared to placebo.\n",
      "\n",
      "The clinical trial that primarily addressed this dosage was identified as **NCT03116828**. According to data pooled from various studies, patients treated with lamotrigine showed a **significant median seizure frequency reduction** compared to those receiving a placebo. Specifically, it was observed that the median seizure frequency reduction for the 400 mg/day lamotrigine group was around **31.5%**. This contrasts with the placebo group's seizure frequency reduction, which was significantly less, illustrating the therapeutic benefit of lamotrigine in managing partial-onset seizures in conjunction with other antiepileptic medications.\n",
      "\n",
      "This reduction in median seizure frequency indicates the potential effectiveness of lamotrigine as an adjunctive treatment for individuals not fully controlled by existing therapy regimens. Overall, lamotrigine at this dosage demonstrated a promising profile for alleviating partial-onset seizures, supporting its continued use in clinical practice.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.046194\n",
      "prediction:  In the 2-year carcinogenicity study of fluoxetine conducted on rats, the highest dose administered was typically around 60 mg/kg/day. However, the exact dose can vary depending on the specific study and its design. To compare this dose to the maximum recommended human dose (MRHD) on a mg/mÂ² basis, we need to convert the rat dose to a human equivalent dose (HED).\n",
      "\n",
      "The MRHD for fluoxetine in humans is generally 60 mg/day for adults, although it can vary based on the specific condition being treated and individual patient factors. To make a proper comparison, we can use the body surface area (BSA) conversion method, which is a common approach for translating animal doses to human doses.\n",
      "\n",
      "The conversion factor from rats to humans is approximately 6.2 (based on BSA calculations). Therefore, to convert the rat dose of 60 mg/kg to a human equivalent dose, we can use the following formula:\n",
      "\n",
      "\\[ \\text{HED (mg/kg)} = \\text{Animal Dose (mg/kg)} \\times \\text{Conversion Factor} \\]\n",
      "\n",
      "Using the highest dose of 60 mg/kg for rats:\n",
      "\n",
      "\\[ \\text{HED} = 60 \\, \\text{mg/kg} \\div 6.2 \\approx 9.68 \\, \\text{mg/kg} \\]\n",
      "\n",
      "To convert this to a daily dose for a typical adult human, we can multiply by an average human weight (let's say 70 kg for calculation purposes):\n",
      "\n",
      "\\[ \\text{HED (mg/day)} = 9.68 \\, \\text{mg/kg} \\times 70 \\, \\text{kg} \\approx 678 \\, \\text{mg/day} \\]\n",
      "\n",
      "This calculated human equivalent dose of approximately 678 mg/day is significantly higher than the MRHD of 60 mg/day. \n",
      "\n",
      "In summary, the highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was around 60 mg/kg/day, which translates to a human equivalent dose of approximately 678 mg/day. This is much higher than the maximum recommended human dose of 60 mg/day, indicating that the safety margin in animal studies can be substantial when compared to human dosing guidelines.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.042739\n",
      "prediction:  In the 2-year carcinogenicity study of fluoxetine conducted on rats, the highest dose administered was typically around 60 mg/kg/day. However, the exact dose can vary depending on the specific study and its design. To compare this dose to the maximum recommended human dose (MRHD) on a mg/mÂ² basis, we need to convert the rat dose to a human equivalent dose (HED).\n",
      "\n",
      "The MRHD for fluoxetine in humans is generally 60 mg/day for adults, although it can vary based on the specific condition being treated and individual patient factors. To make a proper comparison, we can use the body surface area (BSA) conversion method, which is a common approach for translating animal doses to human doses.\n",
      "\n",
      "The conversion factor from rats to humans is approximately 6.2 (based on BSA calculations). Therefore, to convert the rat dose of 60 mg/kg to a human equivalent dose, we can use the following formula:\n",
      "\n",
      "\\[ \\text{HED (mg/kg)} = \\text{Animal Dose (mg/kg)} \\times \\text{Conversion Factor} \\]\n",
      "\n",
      "Using the highest dose of 60 mg/kg:\n",
      "\n",
      "\\[ \\text{HED} = 60 \\, \\text{mg/kg} \\div 6.2 \\approx 9.68 \\, \\text{mg/kg} \\]\n",
      "\n",
      "To convert this to a daily dose for a typical adult human, we can multiply by an average human weight (let's say 70 kg for calculation purposes):\n",
      "\n",
      "\\[ \\text{HED (mg/day)} = 9.68 \\, \\text{mg/kg} \\times 70 \\, \\text{kg} \\approx 678 \\, \\text{mg/day} \\]\n",
      "\n",
      "This calculated HED of approximately 678 mg/day is significantly higher than the MRHD of 60 mg/day for fluoxetine in humans. \n",
      "\n",
      "In summary, the highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was around 60 mg/kg/day, which translates to a human equivalent dose of approximately 678 mg/day. This is much higher than the maximum recommended human dose of 60 mg/day, indicating that the doses used in animal studies can be substantially higher than those recommended for human use. This difference is important for understanding the safety and potential risks of fluoxetine as it relates to carcinogenicity and other long-term effects.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.035309\n",
      "prediction:  In the 2-year carcinogenicity study of fluoxetine conducted on rats, the highest dose administered was typically around 60 mg/kg/day. However, the exact dose can vary depending on the specific study and its design. To compare this dose to the maximum recommended human dose (MRHD) on a mg/mÂ² basis, we need to convert the rat dose to a human equivalent dose (HED).\n",
      "\n",
      "The MRHD for fluoxetine in humans is generally 60 mg/day for adults, although it can vary based on the specific condition being treated and individual patient factors. To make a proper comparison, we can use the body surface area (BSA) conversion method, which is commonly used to estimate equivalent doses between species.\n",
      "\n",
      "The formula for converting animal doses to human equivalent doses is:\n",
      "\n",
      "\\[ \\text{HED (mg/kg)} = \\text{Animal Dose (mg/kg)} \\times \\left( \\frac{\\text{Animal Weight (kg)}}{\\text{Human Weight (kg)}} \\right)^{0.33} \\]\n",
      "\n",
      "For this calculation, we can assume an average rat weight of about 0.25 kg (250 grams) and an average human weight of about 70 kg. \n",
      "\n",
      "1. **Convert the rat dose to HED:**\n",
      "   - Using the highest dose of 60 mg/kg for rats:\n",
      "   - HED = 60 mg/kg Ã— (0.25 kg / 70 kg)^(0.33)\n",
      "\n",
      "2. **Calculate the HED:**\n",
      "   - The ratio of weights raised to the power of 0.33 is approximately 0.25^(0.33) / 70^(0.33).\n",
      "   - This results in a HED of approximately 60 mg/kg Ã— 0.1 = 6 mg/kg.\n",
      "\n",
      "3. **Convert HED to mg/mÂ²:**\n",
      "   - To convert mg/kg to mg/mÂ², we can use the average BSA for humans, which is about 1.73 mÂ² for a 70 kg person.\n",
      "   - Therefore, 6 mg/kg corresponds to approximately 6 mg/kg Ã— 70 kg / 1.73 mÂ² = 24.1 mg/mÂ².\n",
      "\n",
      "4. **Comparison with MRHD:**\n",
      "   - The MRHD of fluoxetine is 60 mg/day for adults, which translates to approximately 34.6 mg/mÂ² (60 mg / 1.73 mÂ²).\n",
      "   - Thus, the highest dose administered to rats in the carcinogenicity study (when adjusted for body surface area) is significantly lower than the MRHD for humans.\n",
      "\n",
      "In summary, the highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study was around 60 mg/kg/day, which, when adjusted for body surface area, is much lower than the maximum recommended human dose of 60 mg/day. This comparison highlights the importance of considering species differences in pharmacokinetics and toxicology when interpreting animal study results in the context of human health.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.004605\n",
      "prediction:  In the context of clinical trials involving lamotrigine for the treatment of primary generalized tonic-clonic seizures (PGTC), a comprehensive review of multiple studies suggests that the median percent reduction in seizure frequency varies across different trials. Specifically, the analysis of 11 completed trials, which included lamotrigine, indicated that the median percent reduction in seizure frequency was reported to be a pivotal efficacy measure.\n",
      "\n",
      "Although the exact median percent reduction for lamotrigine alone was not explicitly detailed in the available abstracts, similar studies generally report efficacy rates that typically demonstrate a substantial reduction in seizure frequency, often in the range of 30-50% among population groups. \n",
      "\n",
      "For a definitive percentage reduction corresponding specifically to lamotrigine, further scrutiny of the individual studies mentioned in the summarized analyses would be needed, particularly referencing specific tables or sections that provide these metrics explicitly for lamotrigine.\n",
      "\n",
      "For in-depth evidence and exact figures, one should refer to individual clinical trial reports where lamotrigine's efficacy in treating PGTC seizures is detailed. If you would like more specific references or results from those studies, please let me know!\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.001349\n",
      "prediction:  In the context of general body cleansing, there are various methods and products available, but specific brand names of drugs can vary based on the intended purpose of the detoxification process. Detoxification involves the removal of toxins from the body, primarily through the liver and kidneys. While many detox products, including supplements and cleanses, are marketed to promote body cleansing, it is important to approach these with caution and consult a healthcare professional.\n",
      "\n",
      "Some commonly recognized detox products may include herbal detox teas, colon cleanse products, or comprehensive detox supplements. Specific brand names may include:\n",
      "\n",
      "1. **Herbalife Herbal Aloe Concentrate** - often used for digestive health.\n",
      "2. **Garden of Life Raw Cleanse** - a whole food detox supplement.\n",
      "3. **Renew Life Cleanse More** - a colon cleanse product.\n",
      "4. **Detoxify Mega Clean** - marketed as a cleansing drink.\n",
      "\n",
      "It's crucial to note that while these products can be found on the market, the effectiveness and safety of detoxification supplements are subjects of debate. Many health professionals assert that the body is naturally equipped to detoxify without the need for supplements, emphasizing the importance of a balanced diet, hydration, and overall lifestyle for bodily health. \n",
      "\n",
      "For more detailed and specific information regarding detox methods and products, individuals should consider consulting with healthcare providers or looking for reliable medical sources.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021841\n",
      "prediction:  In the context of pharmaceuticals, a controlled substance is a drug that is regulated by law due to its potential for abuse or addiction. These substances are classified into schedules (I-V) based on their medical use, potential for abuse, and safety or dependence liability.\n",
      "\n",
      "One example of a drug brand name that is explicitly stated as not being a controlled substance is **Tylenol**, which is the brand name for acetaminophen. Acetaminophen is widely used as a pain reliever and fever reducer and is available over-the-counter (OTC) without the need for a prescription. It is not classified under any of the controlled substance schedules, making it accessible for general use without the restrictions that apply to controlled substances.\n",
      "\n",
      "Other examples of non-controlled substances include common medications like **ibuprofen** (Advil, Motrin), **aspirin**, and **loratadine** (Claritin), which are also available OTC and do not fall under the controlled substance regulations.\n",
      "\n",
      "It's important to note that while these medications are not controlled substances, they can still have side effects and potential risks, especially if misused or taken in excessive amounts. Always consult with a healthcare professional before starting any new medication.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020478\n",
      "prediction:  In the realm of pharmaceuticals, many drugs are classified as controlled substances due to their potential for abuse and dependence. However, there are numerous medications that are not classified as controlled substances and are available by prescription or over-the-counter. \n",
      "\n",
      "One notable example of a drug brand name that is explicitly stated as not being a controlled substance is **Tylenol**, which is the brand name for acetaminophen. Acetaminophen is widely used as a pain reliever and fever reducer. It is available in various formulations, including tablets, capsules, and liquid forms, and is commonly used for mild to moderate pain relief, such as headaches, muscle aches, arthritis, and colds.\n",
      "\n",
      "Tylenol (acetaminophen) is not classified under the Controlled Substances Act, meaning it does not have the same restrictions as drugs that are considered to have a higher potential for abuse, such as opioids or benzodiazepines. This makes it accessible for consumers without the need for stringent regulations that govern controlled substances.\n",
      "\n",
      "It's important to note that while Tylenol is not a controlled substance, it is still essential to use it responsibly and according to the recommended dosages, as excessive use can lead to serious health issues, including liver damage. Always consult with a healthcare professional if you have questions about medication use or if you are considering combining it with other treatments.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.019718\n",
      "prediction:  In the realm of pharmaceuticals, many drugs are classified as controlled substances due to their potential for abuse and dependence. However, there are numerous medications that are not classified as controlled substances and are available for prescription or over-the-counter use without the same level of regulatory restrictions.\n",
      "\n",
      "One example of a drug brand name that is explicitly stated as not being a controlled substance is **Tylenol**, which is the brand name for acetaminophen. Acetaminophen is a widely used analgesic (pain reliever) and antipyretic (fever reducer) that is commonly used to treat mild to moderate pain and to reduce fever. It is available in various formulations, including tablets, capsules, and liquid forms, and can be purchased over the counter without a prescription.\n",
      "\n",
      "Unlike opioids, benzodiazepines, and other medications that are classified as controlled substances due to their potential for misuse, Tylenol is considered safe for use when taken as directed. However, it is important to note that while it is not a controlled substance, acetaminophen can still pose risks, particularly in cases of overdose, which can lead to severe liver damage.\n",
      "\n",
      "In summary, Tylenol (acetaminophen) is an example of a drug brand name that is not classified as a controlled substance, making it accessible for general use while still requiring caution in its administration.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.029703\n",
      "prediction:  In the study of acute reflux esophagitis, patients were treated with pantoprazole sodium for injection at a dose of 20 mg once daily for a duration of 28 days during the acute phase. After this initial treatment period, patients who did not experience heartburn during the final three days transitioned to oral pantoprazole sodium delayed-release tablets for ongoing management of their condition.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.011614\n",
      "prediction:  In the study of acute reflux esophagitis, the initial treatment duration with pantoprazole sodium for injection before switching to oral pantoprazole sodium delayed-release tablets is not explicitly stated in the sourced article. However, it discusses the general treatment strategies for severe erosive esophagitis and highlights that proton pump inhibitors (PPIs), including pantoprazole, are effective in healing such conditions. The review emphasizes that PPIs are typically used for a duration sufficient to heal the mucosal lesions, after which maintenance therapy is necessary.\n",
      "\n",
      "Overall, while specific timelines for pantoprazole treatment in the case of acute reflux esophagitis are not defined in the article accessed, it is essential for practitioners to tailor the duration based on individual patient responses and the severity of esophagitis.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.028283\n",
      "prediction:  In the study of acute reflux esophagitis, the initial treatment with pantoprazole sodium for injection is recommended for a duration of 7 to 10 days. Following this, patients are typically switched to oral pantoprazole sodium delayed-release tablets to continue their treatment. This protocol aims to manage symptoms effectively during the initial phase of treatment with the injectable form, which offers rapid symptom control before transitioning to oral therapy for ongoing management.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.01317\n",
      "prediction:  In the study of acute reflux esophagitis, the initial treatment with pantoprazole sodium for injection typically lasts for a duration of 7 to 10 days. This intravenous (IV) formulation is used for patients who are unable to take oral medications due to various reasons, such as severe symptoms or complications associated with acute reflux esophagitis.\n",
      "\n",
      "After the initial treatment period with the IV formulation, patients are usually transitioned to oral pantoprazole sodium delayed-release tablets. This switch is made once the patient's condition stabilizes and they are able to tolerate oral intake. The oral formulation is then continued for a longer duration, often for several weeks, to ensure adequate healing of the esophagus and to manage symptoms effectively.\n",
      "\n",
      "The exact duration of treatment may vary based on individual patient factors, the severity of the esophagitis, and the clinical judgment of the healthcare provider. It is important to follow up with the patient to assess their response to treatment and make any necessary adjustments.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.013035\n",
      "prediction:  In the study of acute reflux esophagitis, the initial treatment with pantoprazole sodium for injection typically lasts for a duration of 7 to 10 days. This intravenous (IV) formulation is used for patients who are unable to take oral medications due to various reasons, such as severe symptoms or complications associated with esophagitis.\n",
      "\n",
      "After the initial treatment period with the IV formulation, patients are usually switched to oral pantoprazole sodium delayed-release tablets. This transition is made once the patient's condition stabilizes and they are able to tolerate oral intake. The oral formulation is then continued for a longer duration, often several weeks, to ensure adequate healing of the esophagus and to manage symptoms effectively.\n",
      "\n",
      "The exact duration of treatment may vary based on individual patient factors, the severity of the esophagitis, and the clinical judgment of the healthcare provider. It is essential to follow up with the patient to assess their response to treatment and make any necessary adjustments to their medication regimen.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010152\n",
      "prediction:  In the study of acute reflux esophagitis, the initial treatment with pantoprazole sodium for injection typically lasts for a duration of 7 to 10 days. This intravenous (IV) formulation is used for patients who are unable to take oral medications due to various reasons, such as severe symptoms or complications. After this initial treatment period, patients are usually switched to oral pantoprazole sodium delayed-release tablets for continued management of their condition.\n",
      "\n",
      "The transition from IV to oral therapy is based on the patient's clinical improvement and ability to tolerate oral medications. The oral formulation allows for ongoing acid suppression, which is crucial for healing the esophagus and managing symptoms associated with reflux esophagitis. The total duration of therapy may vary depending on the severity of the esophagitis and the patient's response to treatment, but it is common for patients to continue oral pantoprazole for several weeks to months after the initial treatment phase to ensure complete healing and prevent recurrence of symptoms.\n",
      "\n",
      "It is important to note that the specific duration and management plan should always be tailored to the individual patient's needs and guided by clinical judgment, taking into account factors such as symptom resolution, endoscopic findings, and any underlying conditions that may affect treatment.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.059497\n",
      "prediction:  It appears that I was unable to find specific studies or articles that detail the highest dose of fluoxetine administered to adult rats in fertility studies along with a comparison to the Maximum Recommended Human Dose (MRHD) on a mg/mÂ² basis. \n",
      "\n",
      "Normally, in animal studies, doses can vary significantly based on the study design, and a conversion to human equivalent doses involves considerations for body surface area. For general reference, the MRHD for fluoxetine in humans is usually around 60 mg/day, depending on the condition being treated, which would need to be adjusted to an mg/mÂ² basis when comparing to animal study doses.\n",
      "\n",
      "If you require precise data or specific study references, I recommend looking into specific pharmacological research articles or databases focused on veterinary or experimental pharmacology.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.0883\n",
      "prediction:  It appears that the search results did not directly provide detailed storage requirements for HIMARK. However, based on a general understanding of biological and medical entities like Himark Biogas, storage requirements typically involve considerations for maintaining the viability of biological materials.\n",
      "\n",
      "For HIMARK-related products, particularly in biotechnology, storage requirements often include:\n",
      "\n",
      "1. **Temperature Control**: Many biological samples or products need to be stored at specific temperatures (e.g., refrigeration at 4Â°C or storage at -20Â°C or -80Â°C for long-term storage) to maintain stability and prevent degradation.\n",
      "\n",
      "2. **Environmental Conditions**: It's crucial to store products away from light and humidity, which can influence the chemical integrity of biological materials.\n",
      "\n",
      "3. **Contamination Prevention**: Ensuring that the storage containers are sterile and properly sealed is vital to prevent contamination.\n",
      "\n",
      "In the context of materials like pre-stained proteins or similar products, they may need to be stored in a buffer solution and kept cold until use.\n",
      "\n",
      "For precise storage requirements specific to a product named HIMARK, referring to specific product datasheets or contacting the manufacturer directly would provide the most accurate information.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: HIMARK should be stored at room temperature for optimal stability.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.027846\n",
      "prediction:  It appears that there are various resources discussing drugs and their indications, but without a specific drug or medical condition provided, itâ€™s challenging to give a precise answer regarding which drug is specifically associated with the indication 'INDICATION'.\n",
      "\n",
      "Here are some key points found from the search results that might be helpful in understanding drug indications and their relevance:\n",
      "\n",
      "1. **Drug Repurposing**: Several articles mention the concept of drug repurposing, where existing drugs are used for new medical indications. For instance, sildenafil, initially developed for angina, was repurposed for erectile dysfunction.\n",
      "\n",
      "2. **Multi-Indication Drugs**: Some drugs have received approval for multiple indications, particularly in oncology, which may allow them to be used for several different types of cancer.\n",
      "\n",
      "3. **Predictive Methods**: There are computational methods available for predicting drug-disease associations, which can help find new indications for existing medications.\n",
      "\n",
      "For a specific answer regarding a particular drug associated with 'INDICATION', I would need the exact drug name or specific therapeutic area related to the query. Please provide further details.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.042553\n",
      "prediction:  It appears that there is limited direct information available in the search results regarding the abuse liability profile of venlafaxine in primate drug discrimination studies. However, I can summarize what is generally known about venlafaxine and its implications regarding abuse liability.\n",
      "\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) often used as an antidepressant. Research on its abuse potential has suggested that venlafaxine has a lower risk of abuse compared to conventional stimulants and certain opioids. This is largely due to its pharmacological profile, which does not produce euphoria commonly associated with higher addiction potential drugs.\n",
      "\n",
      "In animal studies, including primate drug discrimination studies, venlafaxine does not exhibit significant discriminative stimulus effects typical of drugs of abuse. This suggests that primates treated with venlafaxine do not show the same drug-seeking behavior or response patterns that are seen with substances known for their high abuse liability, such as cocaine or amphetamines.\n",
      "\n",
      "Additionally, while venlafaxine can lead to withdrawal symptoms and certain side effects suggestive of dependency (especially with abrupt discontinuation), these factors do not necessarily equate to a high abuse liability profile. The overall consensus in the literature is that venlafaxine possesses a comparatively low potential for abuse, making it a safer option in terms of addiction risk for the management of conditions like depression and anxiety. \n",
      "\n",
      "For more precise and scientifically robust conclusions, further empirical studies focusing specifically on venlafaxine in drug discrimination paradigms would be beneficial.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: No significant stimulant or depressant abuse liability\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.127601\n",
      "prediction:  It appears that there is limited information available regarding the storage requirements for HIMARK based on current resources. If \"HIMARK\" refers to a specific product, process, or entity in medicine, further clarification on what HIMARK specifically relates to would be helpful for providing an accurate and comprehensive answer.\n",
      "\n",
      "Typically, storage requirements in a medical context could involve considerations like temperature controls, humidity levels, and safeguards against contamination, but without more context, I cannot provide detailed storage guidelines. Please provide additional details about HIMARK, and I will be glad to assist further!\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: HIMARK should be stored at room temperature for optimal stability.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.050058\n",
      "prediction:  It is recommended not to eat or drink for 15 minutes before using or while the nicotine lozenge is in the mouth primarily due to the pharmacokinetics of nicotine absorption and the effect of food or beverages on this process.\n",
      "\n",
      "1. **Nicotine Absorption**: Nicotine lozenges are designed to release nicotine slowly as they dissolve in the mouth. The presence of food or drink can alter the pH levels in the mouth, which may affect the dissolution of the lozenge and consequently the rate at which nicotine is absorbed. For optimal absorption, it's critical that the lozenge is allowed to dissolve without interference.\n",
      "\n",
      "2. **Flavor and Flavor Masking**: Consuming food or beverages right before or during the use of the lozenge may also mask the taste of the lozenge or affect its flavor. This can lead to an unpleasant experience and potentially decrease adherence to the smoking cessation protocol.\n",
      "\n",
      "3. **Gastrointestinal Interactions**: Eating or drinking can stimulate saliva production and stomach acid secretion. These physiological changes could interfere with the absorption of nicotine through the oral mucosa, potentially reducing the lozenge's overall effectiveness.\n",
      "\n",
      "4. **Clinical Recommendations**: As noted in several studies, adherence to guidelines regarding the use of nicotine lozenges, such as not consuming food or drink during use, is vital for achieving optimal therapeutic outcomes in smoking cessation (PMID: 41509942, 41482382).\n",
      "\n",
      "In summary, the recommendation to avoid eating or drinking before or during the use of a nicotine lozenge is to ensure maximal nicotine absorption and to enhance the effectiveness of the lozenge as a smoking cessation aid.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To enhance the effectiveness of the lozenge\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.025114\n",
      "prediction:  JAIMIESS is a combination therapy that includes the antiretroviral agents dolutegravir, lamivudine, and tenofovir alafenamide, primarily used for the treatment of HIV. When considering the management strategy for JAIMIESS in the context of co-administration with enzyme inducers, it is essential to understand the implications of such interactions.\n",
      "\n",
      "### Understanding Enzyme Inducers\n",
      "\n",
      "Enzyme inducers are substances that increase the activity of enzymes that metabolize drugs, often leading to reduced plasma concentrations of co-administered medications. Common enzyme inducers include:\n",
      "\n",
      "- Rifampin\n",
      "- Phenytoin\n",
      "- Carbamazepine\n",
      "- Phenobarbital\n",
      "- St. Johnâ€™s Wort\n",
      "\n",
      "These agents can significantly affect the pharmacokinetics of JAIMIESS, particularly dolutegravir, which is primarily metabolized by the UGT1A1 enzyme and to a lesser extent by CYP3A4.\n",
      "\n",
      "### Recommended Management Strategy\n",
      "\n",
      "1. **Assessment of Drug Interactions**: Before initiating therapy with JAIMIESS, a thorough medication review should be conducted to identify any potential enzyme inducers the patient may be taking. This includes both prescription medications and over-the-counter supplements.\n",
      "\n",
      "2. **Alternative Antiretroviral Regimens**: If a patient is on a strong enzyme inducer, it may be advisable to consider alternative antiretroviral regimens that are less affected by these inducers. For example, integrase inhibitors like bictegravir or non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be more suitable options, depending on the patient's treatment history and resistance profile.\n",
      "\n",
      "3. **Monitoring Drug Levels**: If co-administration of JAIMIESS with an enzyme inducer is unavoidable, close monitoring of drug levels may be warranted. Therapeutic drug monitoring (TDM) can help ensure that drug concentrations remain within the therapeutic range, particularly for dolutegravir.\n",
      "\n",
      "4. **Dose Adjustments**: In some cases, dose adjustments may be necessary. While dolutegravir is generally well-tolerated, the presence of an enzyme inducer may necessitate an increase in the dose to achieve therapeutic levels. However, this should be done cautiously and under the guidance of a healthcare professional.\n",
      "\n",
      "5. **Patient Education**: Educating patients about the potential interactions and the importance of adherence to their antiretroviral regimen is crucial. Patients should be informed about the signs of suboptimal treatment response, such as increased viral load or new HIV-related symptoms.\n",
      "\n",
      "6. **Regular Follow-Up**: Regular follow-up appointments should be scheduled to assess the efficacy of the treatment, monitor for side effects, and make any necessary adjustments to the regimen based on the patient's response and any changes in their medication list.\n",
      "\n",
      "7. **Consultation with Specialists**: In complex cases, or when managing patients with multiple comorbidities and polypharmacy, consultation with a clinical pharmacist or an infectious disease specialist may provide additional insights and recommendations tailored to the individual patient.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "The management of JAIMIESS in patients co-administered with enzyme inducers requires a multifaceted approach that includes careful assessment of drug interactions, consideration of alternative therapies, monitoring, and patient education. By implementing these strategies, healthcare providers can optimize treatment outcomes and minimize the risk of therapeutic failure in patients with HIV.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Use a backup or alternative method of contraception\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.056616\n",
      "prediction:  JAYPIRCA (generic name: pexidartinib) is a medication primarily used for the treatment of certain types of tumors, specifically tenosynovial giant cell tumors (TGCT). It functions as a selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R). When considering its pharmacokinetic interactions, particularly with cytochrome P450 enzymes, it is important to understand how JAYPIRCA affects CYP3A substrates.\n",
      "\n",
      "CYP3A is a major enzyme in the liver responsible for the metabolism of a wide variety of drugs. Substrates of CYP3A can be affected by other medications that either inhibit or induce this enzyme. \n",
      "\n",
      "Regarding JAYPIRCA, it has been shown to be a moderate inhibitor of CYP3A. This means that when JAYPIRCA is administered alongside drugs that are metabolized by CYP3A, it can lead to increased plasma concentrations of those drugs, potentially enhancing their effects and increasing the risk of adverse reactions. \n",
      "\n",
      "Therefore, the true statement regarding JAYPIRCA's effect on CYP3A substrates is that it can increase the exposure of these substrates by inhibiting their metabolism. Clinicians should be cautious when prescribing CYP3A substrates to patients who are also receiving JAYPIRCA, and dose adjustments or increased monitoring may be necessary to avoid toxicity.\n",
      "\n",
      "In summary, JAYPIRCA is a moderate inhibitor of CYP3A, which can lead to increased levels of CYP3A substrates in the body, necessitating careful management of concomitant medications.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.047331\n",
      "prediction:  JAYPIRCA (generic name: pexidartinib) is a medication primarily used for the treatment of tenosynovial giant cell tumor (TGCT) in adults. It is a selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R) and has been studied for its effects on various metabolic pathways, including those involving cytochrome P450 enzymes.\n",
      "\n",
      "Regarding its effect on CYP3A substrates, it is important to note that JAYPIRCA is known to be a substrate of CYP3A4, which is one of the most significant enzymes in the cytochrome P450 family responsible for the metabolism of many drugs. When a drug is a substrate of CYP3A4, it means that the enzyme is involved in its breakdown and elimination from the body.\n",
      "\n",
      "In terms of drug interactions, JAYPIRCA can potentially affect the metabolism of other drugs that are substrates of CYP3A4. If JAYPIRCA is administered alongside other medications that are also metabolized by CYP3A4, it may lead to increased plasma concentrations of those drugs, resulting in enhanced effects or toxicity. Conversely, if a strong CYP3A4 inducer is used concurrently, it may decrease the effectiveness of JAYPIRCA by increasing its metabolism.\n",
      "\n",
      "Therefore, the true statement regarding JAYPIRCA's effect on CYP3A substrates is that it can influence the pharmacokinetics of other drugs metabolized by CYP3A4, necessitating careful monitoring and potential dose adjustments when used in combination with such medications. It is crucial for healthcare providers to be aware of these interactions to ensure safe and effective treatment regimens for patients receiving JAYPIRCA. \n",
      "\n",
      "In summary, JAYPIRCA can affect the metabolism of CYP3A substrates, and caution should be exercised when prescribing it alongside other drugs that are metabolized by the same enzyme.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.040351\n",
      "prediction:  JAYPIRCA (generic name: pexidartinib) is a medication primarily used for the treatment of tenosynovial giant cell tumor (TGCT). It is important to understand how JAYPIRCA interacts with the cytochrome P450 enzyme system, particularly CYP3A, as this can have significant implications for drug-drug interactions and patient management.\n",
      "\n",
      "CYP3A is a major enzyme in the liver responsible for the metabolism of a wide variety of drugs. Substrates of CYP3A are medications that are metabolized by this enzyme. When a drug like JAYPIRCA is introduced into a patient's regimen, it can either inhibit or induce the activity of CYP3A, which can affect the plasma levels of other medications that are CYP3A substrates.\n",
      "\n",
      "**True Statement Regarding JAYPIRCA's Effect on CYP3A Substrates:**\n",
      "\n",
      "JAYPIRCA is known to be a moderate inhibitor of CYP3A. This means that when JAYPIRCA is administered alongside other medications that are metabolized by CYP3A, it can lead to increased plasma concentrations of those CYP3A substrates. This increase can potentially enhance the therapeutic effects of those drugs but also raises the risk of adverse effects and toxicity.\n",
      "\n",
      "**Clinical Implications:**\n",
      "\n",
      "1. **Drug Interactions:** Clinicians should be cautious when prescribing CYP3A substrates to patients who are also taking JAYPIRCA. Dosing adjustments may be necessary for these substrates to avoid toxicity.\n",
      "\n",
      "2. **Monitoring:** Patients on JAYPIRCA who are also taking CYP3A substrates should be closely monitored for signs of increased drug effects or side effects. Therapeutic drug monitoring may be warranted for certain medications.\n",
      "\n",
      "3. **Patient Education:** Patients should be informed about the potential for increased side effects from other medications they may be taking, and they should be encouraged to report any unusual symptoms.\n",
      "\n",
      "4. **Consultation with Pharmacists:** Healthcare providers should consider consulting with pharmacists for guidance on managing potential drug interactions involving JAYPIRCA and CYP3A substrates.\n",
      "\n",
      "In summary, JAYPIRCA acts as a moderate inhibitor of CYP3A, which can lead to increased levels of co-administered CYP3A substrates, necessitating careful management to ensure patient safety and therapeutic efficacy.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.050821\n",
      "prediction:  JAYPIRCA (generic name: pirtobrutinib) is a medication used in the treatment of certain types of B-cell malignancies, particularly in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy. As with any medication, it is essential to understand its contraindications to ensure patient safety and effective treatment.\n",
      "\n",
      "**Contraindications of JAYPIRCA:**\n",
      "\n",
      "1. **Hypersensitivity Reactions**: JAYPIRCA is contraindicated in patients who have a known hypersensitivity to pirtobrutinib or any of its components. This includes any severe allergic reactions, such as anaphylaxis, angioedema, or severe skin reactions.\n",
      "\n",
      "2. **Active Infections**: Patients with active infections, particularly those that are serious or life-threatening, may be contraindicated for JAYPIRCA therapy. The immunosuppressive effects of the drug can exacerbate infections or hinder the bodyâ€™s ability to fight them.\n",
      "\n",
      "3. **Severe Liver Impairment**: JAYPIRCA is metabolized in the liver, and patients with severe hepatic impairment may not be able to process the drug effectively, leading to increased toxicity. Therefore, it is contraindicated in patients with severe liver dysfunction.\n",
      "\n",
      "4. **Pregnancy and Lactation**: JAYPIRCA is contraindicated in pregnant women due to potential harm to the fetus. It is also advised that breastfeeding should be discontinued during treatment, as the drug may be excreted in breast milk and could affect a nursing infant.\n",
      "\n",
      "5. **Concomitant Use with Certain Medications**: While not a strict contraindication, caution is advised when JAYPIRCA is used in conjunction with other medications that may interact adversely, particularly those that are strong inhibitors or inducers of CYP3A4, as they can affect the metabolism of pirtobrutinib.\n",
      "\n",
      "6. **Cardiovascular Conditions**: Patients with certain pre-existing cardiovascular conditions may need careful evaluation before starting JAYPIRCA, as the drug can have effects on heart rhythm and function.\n",
      "\n",
      "In summary, the contraindications for JAYPIRCA primarily revolve around hypersensitivity, active infections, severe liver impairment, pregnancy, and potential drug interactions. It is crucial for healthcare providers to assess these factors before initiating treatment to ensure patient safety and optimize therapeutic outcomes. Always consult the prescribing information and clinical guidelines for the most current and detailed contraindications and warnings associated with JAYPIRCA.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.046143\n",
      "prediction:  JAYPIRCA (generic name: pirtobrutinib) is a medication used in the treatment of certain types of B-cell malignancies, particularly in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy. When considering the contraindications of JAYPIRCA, it is essential to understand the specific conditions or factors that may render its use inappropriate or unsafe for certain patients.\n",
      "\n",
      "1. **Hypersensitivity Reactions**: One of the primary contraindications for JAYPIRCA is a known hypersensitivity to pirtobrutinib or any of its components. Patients with a history of severe allergic reactions to the drug should not be treated with it.\n",
      "\n",
      "2. **Active Infections**: Patients with active infections, particularly those that are severe or uncontrolled, may be contraindicated for JAYPIRCA. The drug can affect the immune system, and using it in the presence of an active infection could exacerbate the condition or lead to complications.\n",
      "\n",
      "3. **Severe Liver Impairment**: JAYPIRCA is metabolized in the liver, and patients with severe hepatic impairment may be at increased risk for adverse effects due to altered drug metabolism. Therefore, it is generally contraindicated in individuals with severe liver dysfunction.\n",
      "\n",
      "4. **Pregnancy and Lactation**: JAYPIRCA is not recommended for use during pregnancy due to potential risks to the fetus. Women who are pregnant or planning to become pregnant should avoid this medication. Additionally, breastfeeding is contraindicated while on JAYPIRCA, as it is not known whether the drug is excreted in human milk and could potentially harm a nursing infant.\n",
      "\n",
      "5. **Drug Interactions**: While not a strict contraindication, caution should be exercised when JAYPIRCA is used in conjunction with other medications that may interact with it, particularly those that are strong inhibitors or inducers of CYP3A4, the enzyme responsible for its metabolism. This could lead to increased toxicity or reduced efficacy.\n",
      "\n",
      "6. **Cardiovascular Conditions**: Patients with certain cardiovascular conditions may need to be monitored closely if prescribed JAYPIRCA, as the drug can have effects on heart rhythm and function.\n",
      "\n",
      "In summary, the contraindications for JAYPIRCA primarily include hypersensitivity to the drug, active infections, severe liver impairment, pregnancy and lactation, and potential drug interactions. It is crucial for healthcare providers to evaluate each patient's medical history and current health status before initiating treatment with JAYPIRCA to ensure safety and efficacy. Always consult the prescribing information and clinical guidelines for the most up-to-date and detailed contraindications and precautions.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.046126\n",
      "prediction:  JAYPIRCA (generic name: pirtobrutinib) is a medication used in the treatment of certain types of B-cell malignancies, particularly in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy. When considering the contraindications of JAYPIRCA, it is essential to understand the specific conditions or factors that would make its use inadvisable.\n",
      "\n",
      "1. **Hypersensitivity Reactions**: One of the primary contraindications for JAYPIRCA is a known hypersensitivity to pirtobrutinib or any of its components. Patients with a history of severe allergic reactions to the drug should not be treated with it.\n",
      "\n",
      "2. **Severe Liver Impairment**: JAYPIRCA is metabolized in the liver, and patients with severe hepatic impairment (Child-Pugh Class C) may have an increased risk of adverse effects due to altered drug metabolism. Therefore, its use in such patients is generally contraindicated.\n",
      "\n",
      "3. **Concurrent Use of Strong CYP3A Inhibitors**: JAYPIRCA is primarily metabolized by the CYP3A enzyme pathway. The concomitant use of strong CYP3A inhibitors can lead to increased plasma concentrations of pirtobrutinib, raising the risk of toxicity. Therefore, it is contraindicated to use JAYPIRCA with strong CYP3A inhibitors.\n",
      "\n",
      "4. **Pregnancy and Lactation**: JAYPIRCA is not recommended for use during pregnancy due to potential harm to the fetus. Women of childbearing potential should be advised to use effective contraception during treatment and for a period after discontinuation. Additionally, it is contraindicated in breastfeeding, as it is not known whether pirtobrutinib is excreted in human milk.\n",
      "\n",
      "5. **Severe Cardiac Conditions**: While not an absolute contraindication, caution is advised in patients with severe cardiac conditions, as JAYPIRCA can have cardiovascular effects. Close monitoring may be necessary in these patients.\n",
      "\n",
      "6. **Active Infections**: Patients with active infections, particularly those that are severe or uncontrolled, may be at increased risk for complications when taking immunomodulatory therapies like JAYPIRCA. Therefore, careful consideration is warranted before initiating treatment in such cases.\n",
      "\n",
      "In summary, the contraindications for JAYPIRCA primarily include hypersensitivity to the drug, severe liver impairment, concurrent use of strong CYP3A inhibitors, pregnancy and lactation, and caution in patients with severe cardiac conditions or active infections. It is crucial for healthcare providers to evaluate these factors before prescribing JAYPIRCA to ensure patient safety and optimal therapeutic outcomes. Always refer to the latest prescribing information and clinical guidelines for the most current recommendations.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.090622\n",
      "prediction:  JAYPIRCA (pirtobrutinib) has been found to affect substrates of the CYP3A enzyme. Based on the information available from various sources, the following statement can be made concerning its effect on CYP3A substrates:\n",
      "\n",
      "JAYPIRCA increases the plasma concentrations of sensitive CYP3A substrates. This can lead to potential increases in the effects and side effects associated with these substrates when they are used concurrently with JAYPIRCA. Therefore, caution is recommended when prescribing medications that are primarily metabolized by CYP3A in patients treated with JAYPIRCA.\n",
      "\n",
      "For more details, you can refer to the following resources:\n",
      "- [Jaypirca (Pirtobrutinib) - Side Effects, Uses, Dosage](https://www.rxlist.com/jaypirca-drug.htm)\n",
      "- [Phase 3 Results for Lilly's Jaypirca](https://investor.lilly.com/news-releases/news-release-details/phase-3-results-lillys-jaypircar-pirtobrutinib-covalent-btk)\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.093886\n",
      "prediction:  JAYPIRCA (pirtobrutinib) has notable effects on CYP3A substrates. Specifically, it has been reported that pirtobrutinib can increase the area under the curve (AUC) and maximum concentration (Cmax) of certain CYP3A substrates. For instance, it increased the AUC and Cmax of orally administered midazolam, a sensitive CYP3A substrate, by 70% and 58%, respectively. This indicates that JAYPIRCA not only affects the metabolism of CYP3A substrates but can also lead to increased systemic exposure of these drugs.\n",
      "\n",
      "On the other hand, when JAYPIRCA is used in conjunction with strong or moderate CYP3A inducers, there may be a decrease in the systemic exposure of pirtobrutinib itself, which could potentially diminish its efficacy.\n",
      "\n",
      "In summary, JAYPIRCA has the potential to increase the effects of other CYP3A substrates while its own exposure can be reduced by CYP3A inducers.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.062566\n",
      "prediction:  JAYPIRCA (pirtobrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor used primarily in the treatment of mantle cell lymphoma (MCL) and other hematological malignancies. Understanding its contraindications is crucial for ensuring patient safety and optimal therapeutic outcomes.\n",
      "\n",
      "### Contraindications for JAYPIRCA:\n",
      "\n",
      "1. **Active Central Nervous System Lymphoma**: Patients diagnosed with active central nervous system lymphoma should not use JAYPIRCA as it may exacerbate their condition.\n",
      "\n",
      "2. **Recent Hematopoietic Stem Cell Transplantation (HSCT)**: Those who have undergone allogeneic HSCT or CAR-T cell therapy within the last 60 days are also contraindicated for JAYPIRCA.\n",
      "\n",
      "3. **Severe Allergic Reactions**: As with any medication, patients with a known hypersensitivity or severe allergic reaction to pirtobrutinib or any of its components should not be prescribed JAYPIRCA.\n",
      "\n",
      "4. **Drug Interactions**: Caution is advised in patients taking strong or moderate CYP3A inhibitors, as these can lead to increased systemic exposure to the drug, creating potential toxicity risks.\n",
      "\n",
      "5. **Pregnancy and Breastfeeding**: JAYPIRCAâ€™s safety has not been established in pregnant or breastfeeding women. It is generally recommended to avoid using the medication under these circumstances unless absolutely necessary.\n",
      "\n",
      "It is crucial for healthcare providers to conduct a thorough evaluation of a patient's medical history and current medications before prescribing JAYPIRCA to avoid these contraindications. \n",
      "\n",
      "For further detailed information, please refer to the official prescribing information and resources from the FDA and EMA [here](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216059s005lbl.pdf) and [here](https://www.ema.europa.eu/en/documents/product-information/jaypirca-epar-product-information_en.pdf).\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.094033\n",
      "prediction:  JAYPIRCA, which contains the active ingredient pirtobrutinib, is indicated for the treatment of certain types of lymphomas, specifically chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Regarding its contraindications, the following points are relevant:\n",
      "\n",
      "1. **Active Central Nervous System (CNS) Lymphoma:** Patients diagnosed with active CNS lymphoma should not use JAYPIRCA.\n",
      "  \n",
      "2. **Recent Hematopoietic Stem Cell Transplantation or CAR-T Cell Therapy:** Individuals who have undergone allogeneic hematopoietic stem cell transplantation or CAR-T cell therapy in the last 60 days are excluded from being treated with JAYPIRCA.\n",
      "\n",
      "These contraindications are critical to ensure the safety and efficacy of treatment with JAYPIRCA, as the drug's interaction with these conditions could lead to adverse effects or ineffective treatment. \n",
      "\n",
      "For more detailed information, including additional contraindications and warnings, consulting the prescribing information or medical literature is recommended.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.051151\n",
      "prediction:  Junel 21 Day is a combination oral contraceptive pill (OCP) that contains estrogen and progestin. It is designed to prevent pregnancy primarily by inhibiting ovulation, thickening cervical mucus, and thinning the uterine lining. When comparing Junel 21 Day to other contraceptive methods, it is essential to consider the typical failure rates associated with each method, which reflect the percentage of women who experience an unintended pregnancy within the first year of use.\n",
      "\n",
      "### Typical Failure Rates of Junel 21 Day\n",
      "\n",
      "The typical failure rate for combination oral contraceptives like Junel 21 Day is approximately 7%. This means that out of 100 women using the pill for one year, about 7 will become pregnant if they do not use the pill consistently and correctly. However, with perfect use, the failure rate drops to about 0.3%, indicating that adherence to the prescribed regimen is crucial for maximizing effectiveness.\n",
      "\n",
      "### Comparison with Other Contraceptive Methods\n",
      "\n",
      "1. **Long-Acting Reversible Contraceptives (LARCs)**:\n",
      "   - **IUDs (Intrauterine Devices)**: Copper IUDs and hormonal IUDs have failure rates of less than 1% with typical use. They are highly effective and can last several years, making them a preferred choice for many women.\n",
      "   - **Implants**: Subdermal implants (e.g., Nexplanon) also have a failure rate of less than 1% and can provide contraception for up to 3 years.\n",
      "\n",
      "2. **Injectable Contraceptives**:\n",
      "   - **Depo-Provera**: This method has a typical failure rate of about 4% with typical use. It requires an injection every three months, which can be less convenient than daily pills.\n",
      "\n",
      "3. **Barrier Methods**:\n",
      "   - **Condoms**: Male condoms have a typical failure rate of about 13% with typical use, while female condoms have a failure rate of about 21%. These methods also provide protection against sexually transmitted infections (STIs).\n",
      "   - **Diaphragms**: With typical use, diaphragms have a failure rate of about 12%.\n",
      "\n",
      "4. **Fertility Awareness Methods**:\n",
      "   - These methods, which involve tracking the menstrual cycle and avoiding intercourse during fertile periods, have a typical failure rate of about 24%. They require significant education and commitment.\n",
      "\n",
      "5. **Sterilization**:\n",
      "   - Permanent methods such as tubal ligation for women and vasectomy for men have very low failure rates, typically around 0.5% or less.\n",
      "\n",
      "### Summary\n",
      "\n",
      "In summary, Junel 21 Day has a typical failure rate of about 7%, which is higher than that of LARCs and sterilization but lower than many barrier methods and fertility awareness methods. The effectiveness of Junel 21 Day is highly dependent on consistent and correct use. For women who prefer a non-daily method or those who may have difficulty adhering to a daily regimen, LARCs or injectables may be more suitable options. Ultimately, the choice of contraceptive method should be individualized based on personal preferences, lifestyle, health considerations, and reproductive goals. Consulting with a healthcare provider can help in making an informed decision.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.040729\n",
      "prediction:  Junel 21 Day is a combination oral contraceptive pill that contains estrogen and progestin, specifically ethinyl estradiol and norethindrone. When comparing Junel 21 Day to other contraceptive methods in terms of typical failure rates, it is essential to understand the effectiveness of various contraceptive options.\n",
      "\n",
      "### Typical Failure Rates of Contraceptive Methods\n",
      "\n",
      "1. **Junel 21 Day (Combination Oral Contraceptive Pills)**:\n",
      "   - **Typical Failure Rate**: Approximately 7% per year. This means that out of 100 women using this method for one year, about 7 will become pregnant despite using the pill.\n",
      "\n",
      "2. **Other Hormonal Methods**:\n",
      "   - **Progestin-Only Pills (Mini-Pills)**: Typical failure rate is about 9%. These pills must be taken at the same time every day, and missing a dose can increase the risk of pregnancy.\n",
      "   - **Contraceptive Injections (e.g., Depo-Provera)**: Typical failure rate is about 4%. The injection is administered every three months, and its effectiveness is higher than that of the pill when used correctly.\n",
      "   - **Contraceptive Implants (e.g., Nexplanon)**: Typical failure rate is less than 1%. Implants are placed under the skin and can provide protection for up to three years.\n",
      "\n",
      "3. **Intrauterine Devices (IUDs)**:\n",
      "   - **Copper IUD**: Typical failure rate is about 0.8%. It can remain effective for up to 10 years.\n",
      "   - **Hormonal IUD (e.g., Mirena)**: Typical failure rate is also about 0.2%. It can provide protection for up to 5 years.\n",
      "\n",
      "4. **Barrier Methods**:\n",
      "   - **Male Condoms**: Typical failure rate is about 18%. Effectiveness can be improved with proper use and additional spermicide.\n",
      "   - **Female Condoms**: Typical failure rate is about 21%.\n",
      "   - **Diaphragms**: Typical failure rate is about 12% with perfect use, but around 17% with typical use.\n",
      "\n",
      "5. **Permanent Methods**:\n",
      "   - **Tubal Ligation**: Typical failure rate is about 0.5%. This is a surgical procedure intended for women who do not wish to have children in the future.\n",
      "   - **Vasectomy**: Typical failure rate is about 0.15%. This is a surgical procedure for men.\n",
      "\n",
      "### Comparison and Considerations\n",
      "\n",
      "- **Effectiveness**: Junel 21 Day, while effective, has a higher typical failure rate compared to long-acting reversible contraceptives (LARCs) like IUDs and implants. LARCs are often recommended for their high efficacy and low maintenance.\n",
      "  \n",
      "- **User Dependency**: The effectiveness of Junel 21 Day is highly dependent on user adherence. Missing doses or not taking the pill at the same time each day can significantly increase the risk of pregnancy. In contrast, methods like IUDs and implants do not require daily attention, making them more reliable for some users.\n",
      "\n",
      "- **Side Effects and Health Considerations**: Each contraceptive method has its own side effect profile and health considerations. For example, combination pills like Junel 21 Day may increase the risk of blood clots, while hormonal IUDs may cause irregular bleeding initially.\n",
      "\n",
      "- **Personal Preference and Lifestyle**: The choice of contraceptive method often depends on individual lifestyle, health conditions, and personal preferences. Some may prefer the convenience of a daily pill, while others may opt for a long-term solution like an IUD.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, Junel 21 Day has a typical failure rate of about 7%, which is higher than that of long-acting methods like IUDs and implants but comparable to other oral contraceptives. The choice of contraceptive method should be based on a thorough discussion with a healthcare provider, considering factors such as effectiveness, side effects, personal health history, and lifestyle preferences.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.048796\n",
      "prediction:  Junel 21 Day is a combination oral contraceptive pill that contains estrogen and progestin, specifically ethinyl estradiol and norethindrone. When comparing Junel 21 Day to other contraceptive methods, it is essential to consider the typical failure rates, which reflect the percentage of women who experience an unintended pregnancy within the first year of use.\n",
      "\n",
      "### Typical Failure Rates of Junel 21 Day\n",
      "\n",
      "The typical failure rate for combination oral contraceptives like Junel 21 Day is approximately 7%. This means that out of 100 women using the pill for one year, about 7 will become pregnant if they do not use the pill consistently and correctly. The effectiveness of the pill can be significantly improved with perfect use, where the failure rate drops to about 0.3%.\n",
      "\n",
      "### Comparison with Other Contraceptive Methods\n",
      "\n",
      "1. **Contraceptive Implants (e.g., Nexplanon)**:\n",
      "   - **Typical Failure Rate**: <1%\n",
      "   - Implants are highly effective and can last for up to 3 years. They require a minor surgical procedure for insertion and removal but do not require daily attention.\n",
      "\n",
      "2. **Intrauterine Devices (IUDs)**:\n",
      "   - **Typical Failure Rate**: <1% for both hormonal (e.g., Mirena) and copper IUDs (e.g., Paragard).\n",
      "   - IUDs are long-acting reversible contraceptives (LARCs) that can last from 3 to 10 years, depending on the type. They are highly effective and require minimal maintenance once inserted.\n",
      "\n",
      "3. **Depo-Provera (Injectable Contraceptive)**:\n",
      "   - **Typical Failure Rate**: 4% with typical use.\n",
      "   - This method involves receiving an injection every three months. While it is more effective than the pill with typical use, it still has a higher failure rate than LARCs.\n",
      "\n",
      "4. **Condoms (Male and Female)**:\n",
      "   - **Typical Failure Rate**: 13% for male condoms and 21% for female condoms.\n",
      "   - Condoms are barrier methods that also provide protection against sexually transmitted infections (STIs). Their effectiveness can be influenced by improper use.\n",
      "\n",
      "5. **Diaphragm**:\n",
      "   - **Typical Failure Rate**: 12% with typical use.\n",
      "   - This barrier method requires proper fitting and use with spermicide, which can complicate its effectiveness.\n",
      "\n",
      "6. **Natural Family Planning (Fertility Awareness Methods)**:\n",
      "   - **Typical Failure Rate**: 24% with typical use.\n",
      "   - These methods rely on tracking the menstrual cycle and avoiding intercourse during fertile periods. They require significant commitment and knowledge of oneâ€™s cycle.\n",
      "\n",
      "### Summary\n",
      "\n",
      "In summary, Junel 21 Day has a typical failure rate of about 7%, which is higher than that of long-acting methods like IUDs and implants but lower than barrier methods like condoms and natural family planning. The effectiveness of any contraceptive method can be influenced by user adherence and proper use. For individuals seeking a reliable contraceptive method, LARCs are often recommended due to their high efficacy and low maintenance requirements. However, the choice of contraceptive should also consider personal preferences, health conditions, and lifestyle factors.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.052531\n",
      "prediction:  Junel 21 Day is a combined hormonal contraceptive (CHC) that consists of ethinyl estradiol and a progestin. It is taken daily for 21 days, followed by a 7-day pill-free interval. The efficacy of Junel and other contraceptive methods can be compared through their typical-use failure rates, which take into account common user errors.\n",
      "\n",
      "### **Typical Failure Rates of Junel 21 Day:**\n",
      "- **Junel 21 Day**: The typical-use failure rate for combined hormonal contraceptives like Junel is approximately **7%**. This means that 7 out of 100 women using this method will experience an unintended pregnancy within the first year of use if they do not adhere strictly to the regimen.\n",
      "\n",
      "### **Comparison with Other Contraceptive Methods:**\n",
      "1. **Long-acting reversible contraceptives (LARCs)** (e.g., IUDs, implants):\n",
      "   - **Failure Rate**: Less than **1%**. LARCs are among the most effective methods, as they do not rely on user adherence once they are placed.\n",
      "   \n",
      "2. **Birth Control Pills (similar to Junel)**:\n",
      "   - The failure rate for typical use is roughly between **7% and 9%** depending on the specific type of pill and user adherence.\n",
      "\n",
      "3. **Condoms**:\n",
      "   - **Male condoms**: Typical-use failure rate is about **18%**.\n",
      "   - **Female condoms**: Typical-use failure rate is higher at about **21%**.\n",
      "\n",
      "4. **Injectable contraceptives (e.g., Depo-Provera)**:\n",
      "   - **Failure Rate**: Approximately **6%** with typical use. Adherence can vary, and missed injections increase failure rates.\n",
      "\n",
      "5. **Emergency Contraceptive Pills**:\n",
      "   - These are intended for use after unprotected intercourse or contraceptive failure. Their failure rate depends on how soon they are taken after intercourse but can be higher in comparison to regular methods.\n",
      "\n",
      "### **Conclusion**:\n",
      "When comparing Junel 21 Day to other contraceptive methods, it is evident that while it is effective, there are options like LARCs that offer much lower failure rates. The effectiveness of Junel, similar to other birth control pills, is significantly impacted by user adherence. In contrast, LARCs provide a \"set and forget\" convenience that minimizes the possibility of user error, leading to their highest effectiveness.\n",
      "\n",
      "For detailed statistics and additional information on contraceptives, you may refer to resources such as the [Guttmacher Institute](https://www.guttmacher.org/fact-sheet/contraceptive-effectiveness-united-states) and the [American Pregnancy Association](https://americanpregnancy.org/unplanned-pregnancy/birth-control-pills-patches-and-devices/birth-control-failure/).\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.096819\n",
      "prediction:  Junel 21 Day is an oral contraceptive that falls under the category of combination hormonal contraceptives. In terms of typical failure rates, it is important to compare it with other contraceptive methods:\n",
      "\n",
      "1. **Combination Oral Contraceptives**: The typical failure rate of combination oral contraceptives like Junel 21 Day is approximately 7%. This rate reflects the effectiveness when these methods are used incorrectly or inconsistently.\n",
      "\n",
      "2. **Other Hormonal Methods**:\n",
      "   - **Implants** (e.g., Nexplanon): 0.1% typical failure rate.\n",
      "   - **Intrauterine Devices (IUDs)**: 0.2-0.8% typical failure rate for hormonal IUDs.\n",
      "   - **Depo-Provera Shot**: 6% typical failure rate.\n",
      "  \n",
      "3. **Barrier Methods**:\n",
      "   - **Condoms**: 13% typical failure rate for male condoms.\n",
      "   - **Diaphragms**: 12% typical failure rate.\n",
      "\n",
      "4. **Natural Methods**:\n",
      "   - **Fertility Awareness Methods**: 24% typical failure rate.\n",
      "\n",
      "5. **Surgical Options**:\n",
      "   - **Tubal ligation**: 0.5% typical failure rate.\n",
      "\n",
      "In summary, Junel 21 Day has a typical failure rate of about 7%, making it more effective than barrier methods but less effective compared to long-acting reversible contraceptives like IUDs or implants. When choosing a contraceptive method, it's essential to consider effectiveness in conjunction with factors like convenience, side effects, and personal health circumstances.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.031579\n",
      "prediction:  MRRV winner=A; scores={'A': 0.611111111111111, 'B': 0.5277777777777778, 'C': 0.5, 'D': 0.4444444444444444}; rankings=[['C', 'A', 'D', 'B'], ['B', 'D', 'A', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 500 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.078947\n",
      "prediction:  MRRV winner=A; scores={'A': 0.611111111111111, 'B': 0.611111111111111, 'C': 0.3611111111111111, 'D': 0.5}; rankings=[['A', 'B', 'C', 'D'], ['B', 'C', 'A', 'D'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.078947\n",
      "prediction:  MRRV winner=A; scores={'A': 0.611111111111111, 'B': 0.611111111111111, 'C': 0.3611111111111111, 'D': 0.5}; rankings=[['B', 'C', 'A', 'D'], ['D', 'A', 'B', 'C'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.099099\n",
      "prediction:  MRRV winner=A; scores={'A': 0.75, 'B': 0.5, 'C': 0.4444444444444444, 'D': 0.38888888888888884}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B'], ['B', 'D', 'C', 'A']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: They interfere with the manufacturing of apheresed cells\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.087591\n",
      "prediction:  MRRV winner=A; scores={'A': 0.75, 'B': 0.6666666666666666, 'C': 0.3333333333333333, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Hydroxym has not been tested for mutagenicity, but prednisolone and hydrocortisone showed negative results.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.142857\n",
      "prediction:  MRRV winner=A; scores={'A': 0.75, 'B': 0.6666666666666666, 'C': 0.38888888888888884, 'D': 0.27777777777777773}; rankings=[['B', 'C', 'D', 'A'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Interactions have been observed with other macrolides, so careful monitoring is advised\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.041451\n",
      "prediction:  MRRV winner=A; scores={'A': 0.7777777777777777, 'B': 0.6666666666666666, 'C': 0.38888888888888884, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['B', 'C', 'A', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 8 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.125\n",
      "prediction:  MRRV winner=A; scores={'A': 0.7777777777777778, 'B': 0.25, 'C': 0.5555555555555555, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Hydroxym for disorders other than the one prescribed.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.064865\n",
      "prediction:  MRRV winner=A; scores={'A': 0.7777777777777778, 'B': 0.5, 'C': 0.5555555555555555, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: At least every 2 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.078431\n",
      "prediction:  MRRV winner=A; scores={'A': 0.7777777777777778, 'B': 0.6666666666666666, 'C': 0.38888888888888884, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  D\n",
      "correct answer: Acetaminophen\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.031414\n",
      "0.031414\n",
      "prediction:  MRRV winner=A; scores={'A': 0.8333333333333334, 'B': 0.3055555555555555, 'C': 0.5, 'D': 0.4444444444444444}; rankings=[['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C'], ['C', 'A', 'D', 'B']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 500 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.093333\n",
      "prediction:  MRRV winner=A; scores={'A': 0.8333333333333334, 'B': 0.6666666666666666, 'C': 0.3055555555555555, 'D': 0.27777777777777773}; rankings=[['A', 'B', 'C', 'D'], ['B', 'A', 'D', 'C'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: No data supports specific dosage adjustments; close monitoring of hematologic parameters is advised.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.098246\n",
      "prediction:  MRRV winner=A; scores={'A': 0.8333333333333334, 'B': 0.6666666666666666, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['B', 'A', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: No data supports specific dosage adjustments; close monitoring of hematologic parameters is advised.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.13278\n",
      "prediction:  MRRV winner=A; scores={'A': 0.8333333333333334, 'B': 0.6666666666666666, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: It showed a negative result, indicating no mutagenicity.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.150538\n",
      "0.116402\n",
      "0.067416\n",
      "0.112994\n",
      "0.132075\n",
      "0.113990\n",
      "0.150538\n",
      "0.116402\n",
      "0.067416\n",
      "0.112994\n",
      "0.132075\n",
      "0.113990\n",
      "0.150538\n",
      "0.116402\n",
      "0.067416\n",
      "0.112994\n",
      "0.132075\n",
      "0.113990\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "correct answer: Treatment of chronic pain conditions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.060976\n",
      "0.090000\n",
      "0.116402\n",
      "0.101695\n",
      "0.161137\n",
      "0.120370\n",
      "0.060976\n",
      "0.117188\n",
      "0.090000\n",
      "0.116402\n",
      "0.101695\n",
      "0.161137\n",
      "0.120370\n",
      "0.060976\n",
      "0.117188\n",
      "0.090000\n",
      "0.116402\n",
      "0.101695\n",
      "0.161137\n",
      "0.120370\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.25, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  B\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "correct answer: Salicylic Acid\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.092593\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.27777777777777773, 'C': 0.5, 'D': 0.3055555555555555}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'D', 'B'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: G-62 has low solubility and slow absorption.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.092593\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.3055555555555555, 'C': 0.5, 'D': 0.27777777777777773}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'D', 'B']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: G-62 has low solubility and slow absorption.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.092593\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.3055555555555555, 'C': 0.5, 'D': 0.27777777777777773}; rankings=[['A', 'C', 'D', 'B'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: G-62 has low solubility and slow absorption.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.125604\n",
      "0.141304\n",
      "0.036585\n",
      "0.082353\n",
      "0.082192\n",
      "0.088670\n",
      "0.135417\n",
      "0.098901\n",
      "0.133333\n",
      "0.077348\n",
      "0.125604\n",
      "0.141304\n",
      "0.036585\n",
      "0.082353\n",
      "0.082192\n",
      "0.088670\n",
      "0.135417\n",
      "0.119266\n",
      "0.133333\n",
      "0.077348\n",
      "0.125604\n",
      "0.141304\n",
      "0.036585\n",
      "0.082353\n",
      "0.082192\n",
      "0.088670\n",
      "0.135417\n",
      "0.119266\n",
      "0.098901\n",
      "0.133333\n",
      "0.077348\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.25, 'D': 0.5}; rankings=[['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "D\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "A\n",
      "C\n",
      "D\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "correct answer: XENOVIEW has no contraindications, unlike drugs with common contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.098214\n",
      "0.112245\n",
      "0.084656\n",
      "0.109091\n",
      "0.112994\n",
      "0.087912\n",
      "0.083770\n",
      "0.159204\n",
      "0.098214\n",
      "0.084656\n",
      "0.109091\n",
      "0.112994\n",
      "0.087912\n",
      "0.083770\n",
      "0.159204\n",
      "0.098214\n",
      "0.084656\n",
      "0.109091\n",
      "0.112994\n",
      "0.087912\n",
      "0.083770\n",
      "0.159204\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.3333333333333333, 'C': 0.5, 'D': 0.25}; rankings=[['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  B\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "correct answer: Levalbuterol had a slightly higher rate of systemic beta-adrenergic adverse effects.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.111111\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.38888888888888884, 'C': 0.25, 'D': 0.4444444444444444}; rankings=[['A', 'B', 'D', 'C'], ['A', 'D', 'B', 'C'], ['A', 'D', 'B', 'C']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: The safety and efficacy have not been established.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.103774\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'C', 'B', 'D'], ['A', 'C', 'B', 'D']]\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Non-inferiority was not demonstrated.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.078652\n",
      "0.142857\n",
      "0.135135\n",
      "0.098765\n",
      "0.078652\n",
      "0.142857\n",
      "0.135135\n",
      "0.098765\n",
      "0.078652\n",
      "0.142857\n",
      "0.135135\n",
      "0.144796\n",
      "0.098765\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "B\n",
      "D\n",
      "A\n",
      "A\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  A\n",
      "B\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "A\n",
      "correct answer: Complexion Protection Moisturizer SPF\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.095238\n",
      "0.049383\n",
      "0.082474\n",
      "0.072289\n",
      "0.036585\n",
      "0.157025\n",
      "0.095238\n",
      "0.120370\n",
      "0.107527\n",
      "0.113744\n",
      "0.025316\n",
      "0.048485\n",
      "0.036585\n",
      "0.140187\n",
      "0.070588\n",
      "0.070588\n",
      "0.150943\n",
      "0.077348\n",
      "0.125000\n",
      "0.104265\n",
      "0.161538\n",
      "0.043716\n",
      "0.131980\n",
      "0.113402\n",
      "0.116959\n",
      "0.149254\n",
      "0.118227\n",
      "0.121495\n",
      "0.095238\n",
      "0.082474\n",
      "0.072289\n",
      "0.036585\n",
      "0.112245\n",
      "0.157025\n",
      "0.095238\n",
      "0.120370\n",
      "0.107527\n",
      "0.113744\n",
      "0.025316\n",
      "0.048485\n",
      "0.036585\n",
      "0.140187\n",
      "0.070588\n",
      "0.150943\n",
      "0.077348\n",
      "0.125000\n",
      "0.100559\n",
      "0.104265\n",
      "0.161538\n",
      "0.043716\n",
      "0.131980\n",
      "0.113402\n",
      "0.116959\n",
      "0.149254\n",
      "0.118227\n",
      "0.121495\n",
      "0.095238\n",
      "0.082474\n",
      "0.072289\n",
      "0.036585\n",
      "0.157025\n",
      "0.095238\n",
      "0.120370\n",
      "0.107527\n",
      "0.113744\n",
      "0.025316\n",
      "0.048485\n",
      "0.036585\n",
      "0.140187\n",
      "0.070588\n",
      "0.070588\n",
      "0.163636\n",
      "0.150943\n",
      "0.077348\n",
      "0.125000\n",
      "0.104265\n",
      "0.161538\n",
      "0.043716\n",
      "0.131980\n",
      "0.113402\n",
      "0.116959\n",
      "0.149254\n",
      "0.118227\n",
      "0.121495\n",
      "prediction:  MRRV winner=A; scores={'A': 1.0, 'B': 0.5, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D'], ['A', 'B', 'C', 'D']]\n",
      "pred_SIM:  B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "D\n",
      "D\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "D\n",
      "A\n",
      "C\n",
      "D\n",
      "C\n",
      "choice:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "correct_answer:  A\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "B\n",
      "correct answer: History of severe hypersensitivity reaction to Pemetrexed\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.158996\n",
      "0.061404\n",
      "0.025000\n",
      "0.119565\n",
      "0.158996\n",
      "0.099010\n",
      "0.061404\n",
      "0.111111\n",
      "0.025000\n",
      "0.158996\n",
      "0.061404\n",
      "0.025000\n",
      "0.137931\n",
      "prediction:  MRRV winner=B; scores={'A': 0.25, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.5}; rankings=[['B', 'D', 'C', 'A'], ['B', 'D', 'C', 'A'], ['B', 'D', 'C', 'A']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "A\n",
      "B\n",
      "correct answer: It may result in overlapping effects on CYP3A, leading to adverse drug interactions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.114833\n",
      "0.137097\n",
      "0.090452\n",
      "0.081633\n",
      "0.114833\n",
      "0.081633\n",
      "0.114833\n",
      "prediction:  MRRV winner=B; scores={'A': 0.25, 'B': 1.0, 'C': 0.5, 'D': 0.3333333333333333}; rankings=[['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  D\n",
      "B\n",
      "A\n",
      "A\n",
      "D\n",
      "A\n",
      "D\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Discontinue Levalbuterol immediately\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.076190\n",
      "0.129278\n",
      "prediction:  MRRV winner=B; scores={'A': 0.3055555555555555, 'B': 1.0, 'C': 0.5, 'D': 0.27777777777777773}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'D', 'A'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  B\n",
      "C\n",
      "correct answer: It may take 1 to 4 days for full effect.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.086207\n",
      "prediction:  MRRV winner=B; scores={'A': 0.3333333333333333, 'B': 0.8333333333333334, 'C': 0.6666666666666666, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['C', 'B', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Albuterol HFA was clinically comparable to CFC 11/12-propelled Albuterol.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.109589\n",
      "0.074468\n",
      "0.092486\n",
      "0.024845\n",
      "0.146789\n",
      "0.155340\n",
      "0.120603\n",
      "0.137097\n",
      "0.074468\n",
      "0.024845\n",
      "0.146789\n",
      "0.155340\n",
      "0.120603\n",
      "0.109589\n",
      "0.074468\n",
      "0.118919\n",
      "0.024845\n",
      "0.146789\n",
      "0.155340\n",
      "0.120603\n",
      "prediction:  MRRV winner=B; scores={'A': 0.3333333333333333, 'B': 1.0, 'C': 0.5, 'D': 0.25}; rankings=[['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "D\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "A\n",
      "D\n",
      "B\n",
      "D\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  B\n",
      "B\n",
      "D\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Reduce the dosage of Guanfacine extended-release tablets by 50%.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.078818\n",
      "prediction:  MRRV winner=B; scores={'A': 0.38888888888888884, 'B': 0.7777777777777777, 'C': 0.4166666666666667, 'D': 0.5}; rankings=[['B', 'C', 'A', 'D'], ['D', 'A', 'B', 'C'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Acetaminophen\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.100503\n",
      "prediction:  MRRV winner=B; scores={'A': 0.5, 'B': 0.7777777777777777, 'C': 0.25, 'D': 0.5555555555555555}; rankings=[['D', 'A', 'B', 'C'], ['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C']]\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Terbinafine hydrochloride USP\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.087912\n",
      "prediction:  MRRV winner=B; scores={'A': 0.5, 'B': 0.8333333333333334, 'C': 0.4166666666666667, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['B', 'C', 'D', 'A'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Hydroxym has not been tested for mutagenicity, but prednisolone and hydrocortisone showed negative results.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.087912\n",
      "prediction:  MRRV winner=B; scores={'A': 0.5, 'B': 0.8333333333333334, 'C': 0.4166666666666667, 'D': 0.3333333333333333}; rankings=[['B', 'C', 'D', 'A'], ['A', 'B', 'D', 'C'], ['B', 'C', 'D', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: Hydroxym has not been tested for mutagenicity, but prednisolone and hydrocortisone showed negative results.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.094241\n",
      "0.133333\n",
      "0.145299\n",
      "0.139037\n",
      "0.108696\n",
      "0.119565\n",
      "0.070588\n",
      "0.154589\n",
      "0.117073\n",
      "0.126214\n",
      "0.094241\n",
      "0.145299\n",
      "0.139037\n",
      "0.119565\n",
      "0.070588\n",
      "0.154589\n",
      "0.117073\n",
      "0.126214\n",
      "0.094241\n",
      "0.145299\n",
      "0.139037\n",
      "0.108696\n",
      "0.119565\n",
      "0.125000\n",
      "0.175732\n",
      "0.070588\n",
      "0.154589\n",
      "0.117073\n",
      "0.126214\n",
      "prediction:  MRRV winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "D\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "C\n",
      "A\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "C\n",
      "C\n",
      "A\n",
      "B\n",
      "A\n",
      "D\n",
      "D\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "A\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Paxlovid is not recommended for use.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.130435\n",
      "0.114286\n",
      "0.096774\n",
      "0.036145\n",
      "0.191667\n",
      "0.134715\n",
      "0.099448\n",
      "0.119403\n",
      "0.120930\n",
      "0.099448\n",
      "0.105691\n",
      "0.101523\n",
      "0.077348\n",
      "0.092486\n",
      "0.100000\n",
      "0.122066\n",
      "0.049689\n",
      "0.143498\n",
      "0.116279\n",
      "0.131455\n",
      "0.126829\n",
      "0.115108\n",
      "0.157407\n",
      "0.125561\n",
      "0.036364\n",
      "0.117073\n",
      "0.128440\n",
      "0.130435\n",
      "0.096774\n",
      "0.036145\n",
      "0.191667\n",
      "0.134715\n",
      "0.099448\n",
      "0.119403\n",
      "0.120930\n",
      "0.099448\n",
      "0.105691\n",
      "0.101523\n",
      "0.077348\n",
      "0.092486\n",
      "0.100000\n",
      "0.122066\n",
      "0.049689\n",
      "0.116279\n",
      "0.131455\n",
      "0.102564\n",
      "0.126829\n",
      "0.115108\n",
      "0.157407\n",
      "0.125561\n",
      "0.128440\n",
      "0.130435\n",
      "0.114286\n",
      "0.096774\n",
      "0.036145\n",
      "0.191667\n",
      "0.134715\n",
      "0.099448\n",
      "0.119403\n",
      "0.151659\n",
      "0.120930\n",
      "0.099448\n",
      "0.105691\n",
      "0.101523\n",
      "0.077348\n",
      "0.092486\n",
      "0.100000\n",
      "0.122066\n",
      "0.049689\n",
      "0.143498\n",
      "0.116279\n",
      "0.131455\n",
      "0.126829\n",
      "0.115108\n",
      "0.157407\n",
      "0.125561\n",
      "0.036364\n",
      "0.117073\n",
      "prediction:  MRRV winner=B; scores={'A': 0.5, 'B': 1.0, 'C': 0.3333333333333333, 'D': 0.25}; rankings=[['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D'], ['B', 'A', 'C', 'D']]\n",
      "pred_SIM:  A\n",
      "D\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "D\n",
      "C\n",
      "B\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "D\n",
      "B\n",
      "B\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "A\n",
      "B\n",
      "D\n",
      "B\n",
      "B\n",
      "D\n",
      "B\n",
      "D\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct_answer:  C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "C\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "B\n",
      "correct answer: Discontinue Ogivri permanently\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.050251\n",
      "prediction:  MRRV winner=B; scores={'A': 0.6666666666666666, 'B': 0.8333333333333334, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['A', 'B', 'D', 'C'], ['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C']]\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: LidoPro Patch\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.110236\n",
      "0.050251\n",
      "prediction:  MRRV winner=B; scores={'A': 0.6666666666666666, 'B': 0.8333333333333334, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['B', 'A', 'D', 'C'], ['A', 'B', 'D', 'C'], ['B', 'A', 'D', 'C']]\n",
      "pred_SIM:  A\n",
      "B\n",
      "choice:  B\n",
      "B\n",
      "correct_answer:  A\n",
      "A\n",
      "correct answer: Underestimating the total daily dosage of RoxyBond to avoid overdose.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.110236\n",
      "prediction:  MRRV winner=B; scores={'A': 0.6666666666666666, 'B': 0.8333333333333334, 'C': 0.25, 'D': 0.3333333333333333}; rankings=[['B', 'A', 'D', 'C'], ['B', 'A', 'D', 'C'], ['A', 'B', 'D', 'C']]\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Underestimating the total daily dosage of RoxyBond to avoid overdose.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.092308\n",
      "0.058480\n",
      "0.142180\n",
      "0.092308\n",
      "0.058480\n",
      "0.142180\n",
      "0.092308\n",
      "0.058480\n",
      "0.142180\n",
      "prediction:  MRRV winner=C; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A'], ['C', 'D', 'B', 'A']]\n",
      "pred_SIM:  D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "D\n",
      "A\n",
      "D\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct_answer:  C\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "B\n",
      "correct answer: Notify their healthcare providers\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.082902\n",
      "0.123552\n",
      "prediction:  MRRV winner=C; scores={'A': 0.25, 'B': 0.5, 'C': 1.0, 'D': 0.3333333333333333}; rankings=[['C', 'B', 'D', 'A'], ['C', 'B', 'D', 'A'], ['C', 'B', 'D', 'A']]\n",
      "pred_SIM:  B\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "C\n",
      "correct answer: Its weakly basic and acidic properties\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.130841\n",
      "prediction:  MRRV winner=C; scores={'A': 0.25, 'B': 0.6666666666666666, 'C': 0.8333333333333334, 'D': 0.3333333333333333}; rankings=[['C', 'B', 'D', 'A'], ['B', 'C', 'D', 'A'], ['C', 'B', 'D', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: It causes depolarization of XENOVIEW\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.076923\n",
      "prediction:  MRRV winner=C; scores={'A': 0.27777777777777773, 'B': 0.5, 'C': 1.0, 'D': 0.3055555555555555}; rankings=[['C', 'B', 'A', 'D'], ['C', 'B', 'D', 'A'], ['C', 'B', 'D', 'A']]\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Its weakly basic and acidic properties\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.105820\n",
      "0.123552\n",
      "0.105820\n",
      "0.133333\n",
      "prediction:  MRRV winner=C; scores={'A': 0.3333333333333333, 'B': 0.25, 'C': 1.0, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B']]\n",
      "pred_SIM:  C\n",
      "C\n",
      "C\n",
      "D\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "B\n",
      "correct answer: Consult your doctor for the dosage\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.116183\n",
      "0.137615\n",
      "0.130435\n",
      "0.123077\n",
      "0.116183\n",
      "0.137615\n",
      "0.099010\n",
      "0.116183\n",
      "0.137615\n",
      "0.130435\n",
      "0.082902\n",
      "prediction:  MRRV winner=C; scores={'A': 0.3333333333333333, 'B': 0.5, 'C': 1.0, 'D': 0.25}; rankings=[['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  C\n",
      "A\n",
      "C\n",
      "A\n",
      "C\n",
      "A\n",
      "B\n",
      "C\n",
      "A\n",
      "C\n",
      "B\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "correct_answer:  C\n",
      "C\n",
      "C\n",
      "B\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "C\n",
      "B\n",
      "correct answer: Hypersensitivity to both inactive ingredients and other products containing guanfacine\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.105263\n",
      "0.105263\n",
      "0.086207\n",
      "prediction:  MRRV winner=C; scores={'A': 0.3333333333333333, 'B': 0.6666666666666666, 'C': 0.8333333333333334, 'D': 0.25}; rankings=[['C', 'B', 'A', 'D'], ['B', 'C', 'A', 'D'], ['C', 'B', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "B\n",
      "B\n",
      "choice:  C\n",
      "C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "C\n",
      "correct answer: Breastfeeding females should avoid OCELLA and use other methods of contraception.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "SIM_score:  0.105263\n",
      "0.106667\n",
      "prediction:  MRRV winner=C; scores={'A': 0.3333333333333333, 'B': 0.6666666666666666, 'C': 0.8333333333333334, 'D': 0.25}; rankings=[['C', 'B', 'A', 'D'], ['C', 'B', 'A', 'D'], ['B', 'C', 'A', 'D']]\n",
      "pred_SIM:  B\n",
      "A\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: Breastfeeding females should avoid OCELLA and use other methods of contraception.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.125\n",
      "prediction:  MRRV winner=C; scores={'A': 0.5555555555555555, 'B': 0.25, 'C': 0.7777777777777778, 'D': 0.5}; rankings=[['C', 'D', 'A', 'B'], ['C', 'D', 'A', 'B'], ['A', 'D', 'C', 'B']]\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Use Hydroxym for disorders other than the one prescribed.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.012821\n",
      "0.012739\n",
      "0.012739\n",
      "0.012658\n",
      "0.012739\n",
      "0.012658\n",
      "prediction:  MRRV winner=D; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 0.5, 'D': 1.0}; rankings=[['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "correct_answer:  C\n",
      "A\n",
      "A\n",
      "B\n",
      "A\n",
      "B\n",
      "correct answer: 15\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.010753\n",
      "prediction:  MRRV winner=D; scores={'A': 0.25, 'B': 0.3333333333333333, 'C': 0.6666666666666666, 'D': 0.8333333333333334}; rankings=[['D', 'C', 'B', 'A'], ['C', 'D', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: 15\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.058480\n",
      "0.159204\n",
      "0.089385\n",
      "0.058480\n",
      "0.113636\n",
      "0.159204\n",
      "0.089385\n",
      "0.058480\n",
      "0.113636\n",
      "0.089552\n",
      "0.131980\n",
      "0.089385\n",
      "prediction:  MRRV winner=D; scores={'A': 0.5, 'B': 0.3333333333333333, 'C': 0.25, 'D': 1.0}; rankings=[['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  D\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "D\n",
      "A\n",
      "D\n",
      "C\n",
      "B\n",
      "C\n",
      "A\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "D\n",
      "correct_answer:  D\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "B\n",
      "D\n",
      "D\n",
      "B\n",
      "D\n",
      "A\n",
      "D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "SIM_score:  0.011494\n",
      "prediction:  MRRV winner=D; scores={'A': 0.5, 'B': 0.38888888888888884, 'C': 0.4444444444444444, 'D': 0.75}; rankings=[['A', 'B', 'C', 'D'], ['D', 'C', 'B', 'A'], ['D', 'C', 'B', 'A']]\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 20%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  mrr\n",
      "mrr\n",
      "mrr\n",
      "SIM_score:  0.087805\n",
      "0.114537\n",
      "0.114537\n",
      "prediction:  MRRV winner=D; scores={'A': 0.6666666666666666, 'B': 0.3333333333333333, 'C': 0.25, 'D': 0.8333333333333334}; rankings=[['D', 'A', 'B', 'C'], ['A', 'D', 'B', 'C'], ['D', 'A', 'B', 'C']]\n",
      "pred_SIM:  A\n",
      "C\n",
      "C\n",
      "choice:  D\n",
      "D\n",
      "D\n",
      "correct_answer:  B\n",
      "A\n",
      "A\n",
      "correct answer: Between 4Â°C and 30Â°C\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.039545\n",
      "prediction:  NUZYRA (sotagliflozin) is an antibiotic that has been studied for the treatment of Community-Acquired Bacterial Pneumonia (CABP). In clinical trials, the efficacy and safety of NUZYRA have been compared to that of moxifloxacin, a commonly used antibiotic for CABP.\n",
      "\n",
      "The observed mortality rate in patients treated with NUZYRA for CABP has been shown to be comparable to that of patients treated with moxifloxacin. In clinical studies, the mortality rates for both treatment groups were generally low, reflecting the overall effectiveness of both antibiotics in managing CABP. \n",
      "\n",
      "Specifically, in the clinical trials, the mortality rate for patients receiving NUZYRA was reported to be around 2-3%, which is similar to the mortality rate observed in patients treated with moxifloxacin, which also ranged from 2-4%. These rates indicate that both NUZYRA and moxifloxacin are effective in reducing mortality in patients with CABP.\n",
      "\n",
      "It is important to note that while mortality rates are a critical endpoint in evaluating the effectiveness of a treatment, other factors such as the time to clinical improvement, the resolution of symptoms, and the overall safety profile of the medications are also essential in determining the best treatment option for patients with CABP.\n",
      "\n",
      "In conclusion, the observed mortality rates in patients treated with NUZYRA for CABP are comparable to those treated with moxifloxacin, suggesting that both antibiotics are effective options for managing this condition. However, individual patient factors and specific clinical scenarios should always be considered when choosing an appropriate antibiotic therapy.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.035676\n",
      "prediction:  NUZYRA (sotagliflozin) is an antibiotic that has been studied for the treatment of Community-Acquired Bacterial Pneumonia (CABP). In clinical trials, the efficacy and safety of NUZYRA have been compared to that of moxifloxacin, a commonly used antibiotic for CABP.\n",
      "\n",
      "The observed mortality rate in patients treated with NUZYRA for CABP has been shown to be comparable to that of patients treated with moxifloxacin. In clinical studies, the overall mortality rates for both treatment groups were low, reflecting the effectiveness of both antibiotics in managing CABP. \n",
      "\n",
      "Specifically, in the clinical trials, the mortality rate for patients receiving NUZYRA was reported to be around 2-3%, which is similar to the mortality rate observed in patients treated with moxifloxacin, which also ranged from 2-3%. These rates indicate that both NUZYRA and moxifloxacin are effective options for treating CABP, with no significant difference in mortality outcomes.\n",
      "\n",
      "It is important to note that while mortality rates are a critical endpoint in evaluating the effectiveness of a treatment, other factors such as the rate of clinical success, adverse events, and the overall safety profile of the medications should also be considered when making treatment decisions. Additionally, the choice of antibiotic may depend on the specific bacterial pathogens involved, patient comorbidities, and local resistance patterns.\n",
      "\n",
      "In conclusion, the mortality rates for patients treated with NUZYRA for CABP are comparable to those treated with moxifloxacin, indicating that both antibiotics are effective in reducing mortality in this patient population. Further studies may continue to refine our understanding of the best treatment options for CABP, but current evidence supports the use of both NUZYRA and moxifloxacin as viable choices.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.039759\n",
      "prediction:  NUZYRA (sotagliflozin) is an antibiotic that has been studied for the treatment of Community-Acquired Bacterial Pneumonia (CABP). In clinical trials, the efficacy and safety of NUZYRA have been compared to that of moxifloxacin, a commonly used antibiotic for CABP.\n",
      "\n",
      "The observed mortality rate in patients treated with NUZYRA for CABP has been shown to be comparable to that of patients treated with moxifloxacin. In clinical studies, the overall mortality rates for both treatment groups were low, reflecting the effectiveness of both antibiotics in managing CABP. \n",
      "\n",
      "Specifically, in the clinical trials, the mortality rate for patients receiving NUZYRA was reported to be around 2-3%, which is similar to the mortality rate observed in patients treated with moxifloxacin, which also ranged from 2-3%. These rates indicate that both treatments are effective in reducing the risk of mortality associated with CABP.\n",
      "\n",
      "It is important to note that while the mortality rates are similar, the choice of antibiotic may depend on various factors, including the specific bacterial pathogens involved, patient comorbidities, and local resistance patterns. Additionally, the safety profiles of NUZYRA and moxifloxacin may differ, influencing the decision-making process for clinicians when selecting an appropriate treatment for CABP.\n",
      "\n",
      "In conclusion, the observed mortality rates in patients treated with NUZYRA for CABP are comparable to those treated with moxifloxacin, with both showing low rates of mortality. However, clinical decisions should consider individual patient factors and the broader context of antibiotic stewardship.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.040996\n",
      "prediction:  One brand name drug that is specifically indicated for the treatment of acne is **TWYNEO**. TWYNEO is a topical treatment that combines two active ingredients: tretinoin (a retinoid) and benzoyl peroxide. It is used for the treatment of acne vulgaris in both adults and pediatric patients.\n",
      "\n",
      "Additionally, **Isotretinoin**, previously marketed under the brand name **Accutane** (though this specific brand is now discontinued), is another well-known medication highly effective in treating severe cases of acne. \n",
      "\n",
      "For further details, you may refer to sources discussing acne treatments such as [MediFind](https://www.medifind.com/conditions/acne/40/drugs).\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.074854\n",
      "prediction:  One of the benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that it is specifically designed to relieve symptoms during the day without causing drowsiness. Unlike nighttime formulations that often contain sedative ingredients to help promote sleep, daytime formulas typically focus on active ingredients that alleviate symptoms such as congestion, cough, fever, and body aches while allowing the user to stay alert and functional throughout the day.\n",
      "\n",
      "This can be particularly beneficial for individuals who need to continue with their daily activities, such as work or caring for family members, while managing the discomfort associated with cold and flu symptoms. The formulation may often include non-drowsy antihistamines, decongestants, and analgesics tailored for daytime use.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.018783\n",
      "prediction:  One of the most well-known brand name drugs specifically indicated for the treatment of acne is **Accutane**, which is the brand name for isotretinoin. Isotretinoin is a powerful retinoid derived from vitamin A and is primarily used for severe cases of acne that have not responded to other treatments, such as topical medications or antibiotics.\n",
      "\n",
      "### Mechanism of Action\n",
      "Isotretinoin works by reducing the size and activity of sebaceous (oil) glands in the skin, leading to decreased oil production. It also helps to prevent the clogging of pores, reduces inflammation, and has antibacterial properties that can help combat the bacteria associated with acne.\n",
      "\n",
      "### Indications\n",
      "Accutane is typically indicated for:\n",
      "- Severe nodular acne\n",
      "- Acne that has not responded to other treatments\n",
      "- Acne that causes significant scarring or psychological distress\n",
      "\n",
      "### Dosage and Administration\n",
      "Isotretinoin is usually taken orally in capsule form, and the dosage is tailored to the individual based on their weight and the severity of the acne. Treatment courses typically last for 15 to 20 weeks, and patients may require multiple courses over time.\n",
      "\n",
      "### Side Effects\n",
      "While isotretinoin can be highly effective, it is also associated with a range of potential side effects, including:\n",
      "- Dry skin and lips\n",
      "- Nosebleeds\n",
      "- Dry eyes\n",
      "- Increased sensitivity to the sun\n",
      "- Changes in mood or depression\n",
      "- Elevated liver enzymes\n",
      "- Increased triglycerides\n",
      "\n",
      "### Pregnancy Category\n",
      "Isotretinoin is classified as a Category X medication, meaning it can cause severe birth defects if taken during pregnancy. Therefore, strict guidelines are in place to prevent pregnancy during treatment, including the iPLEDGE program in the United States, which requires patients to use two forms of contraception and undergo regular pregnancy tests.\n",
      "\n",
      "### Alternatives\n",
      "Other brand name medications for acne include:\n",
      "- **Benzaclin** (benzoyl peroxide and clindamycin)\n",
      "- **Epiduo** (adapalene and benzoyl peroxide)\n",
      "- **Differin** (adapalene)\n",
      "- **Ortho Tri-Cyclen** (a birth control pill that can help regulate hormones contributing to acne)\n",
      "\n",
      "### Conclusion\n",
      "Accutane (isotretinoin) remains a cornerstone in the treatment of severe acne, particularly for patients who have not found relief from other therapies. Due to its potency and potential side effects, it is essential for patients to be closely monitored by a healthcare provider throughout their treatment.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.017235\n",
      "prediction:  One of the most well-known brand name drugs specifically indicated for the treatment of acne is **Accutane**, which is the brand name for isotretinoin. Isotretinoin is a powerful retinoid derived from vitamin A and is primarily used for severe cases of acne that have not responded to other treatments, such as topical medications or antibiotics.\n",
      "\n",
      "### Mechanism of Action\n",
      "Isotretinoin works by reducing the size and activity of sebaceous (oil) glands in the skin, leading to decreased oil production. It also helps to prevent the clogging of pores, reduces inflammation, and has antibacterial properties that can help combat the bacteria associated with acne.\n",
      "\n",
      "### Indications\n",
      "Accutane is typically indicated for:\n",
      "- Severe nodular acne\n",
      "- Acne that has not responded to other treatments\n",
      "- Acne that causes significant scarring or psychological distress\n",
      "\n",
      "### Dosage and Administration\n",
      "Isotretinoin is usually taken orally in the form of capsules. The dosage is individualized based on the patient's weight, the severity of the acne, and their response to treatment. Treatment courses typically last for 15 to 20 weeks, and patients may require more than one course.\n",
      "\n",
      "### Side Effects\n",
      "While effective, isotretinoin can have significant side effects, including:\n",
      "- Dry skin and mucous membranes\n",
      "- Chapped lips\n",
      "- Nosebleeds\n",
      "- Increased sensitivity to the sun\n",
      "- Potential for more serious effects such as liver enzyme changes, elevated cholesterol levels, and, most critically, teratogenic effects (birth defects) if taken during pregnancy.\n",
      "\n",
      "### Monitoring\n",
      "Due to the risk of serious side effects, particularly the teratogenic risk, patients on isotretinoin are usually required to participate in a risk management program, such as the iPLEDGE program in the United States. This program mandates regular pregnancy tests for women of childbearing age and requires the use of effective contraception during treatment.\n",
      "\n",
      "### Alternatives\n",
      "Other brand name medications for acne include:\n",
      "- **Benzaclin** (a combination of benzoyl peroxide and clindamycin)\n",
      "- **Epiduo** (a combination of adapalene and benzoyl peroxide)\n",
      "- **Differin** (adapalene, a topical retinoid)\n",
      "\n",
      "These alternatives may be used for milder forms of acne or in conjunction with isotretinoin for more comprehensive treatment.\n",
      "\n",
      "### Conclusion\n",
      "Accutane (isotretinoin) remains a cornerstone in the treatment of severe acne, particularly when other therapies have failed. Its effectiveness is well-documented, but it requires careful monitoring and patient education due to its potential side effects. Always consult a healthcare provider for personalized medical advice and treatment options.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.012341\n",
      "prediction:  One of the most well-known brand name drugs specifically indicated for the treatment of acne is **Accutane**, which is the brand name for isotretinoin. Isotretinoin is a powerful retinoid that is derived from vitamin A and is primarily used for severe cases of acne, particularly nodular acne that has not responded to other treatments, such as topical medications or antibiotics.\n",
      "\n",
      "Accutane works by reducing the size and activity of sebaceous (oil) glands in the skin, leading to decreased oil production. It also helps to prevent the clogging of pores, reduces inflammation, and has antibacterial properties that can help combat the bacteria associated with acne.\n",
      "\n",
      "While Accutane can be highly effective, it is also associated with a range of potential side effects, some of which can be serious. These include:\n",
      "\n",
      "1. **Teratogenicity**: Isotretinoin can cause severe birth defects if taken during pregnancy. Therefore, strict pregnancy prevention measures are required for women of childbearing age, including participation in the iPLEDGE program in the United States, which mandates pregnancy testing and contraception.\n",
      "\n",
      "2. **Psychiatric Effects**: Some patients have reported mood changes, depression, and suicidal thoughts while on isotretinoin, although a direct causal relationship has not been definitively established.\n",
      "\n",
      "3. **Physical Side Effects**: Common side effects include dry skin, chapped lips, dry eyes, and nosebleeds. More serious side effects can include liver enzyme changes, increased cholesterol levels, and pancreatitis.\n",
      "\n",
      "Due to these potential side effects, isotretinoin is typically prescribed after careful consideration and discussion between the patient and healthcare provider. Regular monitoring through blood tests is often required during treatment to check for any adverse effects.\n",
      "\n",
      "Other brand name medications for acne include **Benzaclin** (a combination of benzoyl peroxide and clindamycin), **Differin** (adapalene), and **Epiduo** (a combination of adapalene and benzoyl peroxide), which are used for milder forms of acne and are available in topical formulations.\n",
      "\n",
      "In summary, while Accutane (isotretinoin) is a prominent brand name drug specifically indicated for the treatment of severe acne, it is essential for patients to discuss the risks and benefits with their healthcare provider to determine the most appropriate treatment for their individual situation.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.051948\n",
      "prediction:  One of the primary benefits of the daytime formulation of \"nighttime severe cold and flu\" medicines is that it is designed to provide relief from cold and flu symptoms without causing drowsiness. This is particularly important for individuals who need to maintain alertness during the day for work or daily activities.\n",
      "\n",
      "Daytime formulations typically include ingredients that address common symptoms such as nasal congestion, headaches, and body aches, while avoiding sedative agents that can lead to sleepiness. For instance, many daytime cold medications utilize non-drowsy antihistamines and pain relievers to alleviate symptoms effectively without impairing cognitive function or motor skills.\n",
      "\n",
      "This design allows individuals to manage their symptoms and go about their daily routines while experiencing relief from discomfort. In contrast, nighttime formulations often include sedatives to promote sleep, making them unsuitable for daytime use. Therefore, daytime formulations serve a vital role in managing cold and flu symptoms in a way that supports daily functioning. \n",
      "\n",
      "For more information, you can refer to sources like [Drugs.com](https://www.drugs.com/mtm/daytime-nighttime-cold-and-flu-relief.html) and [Vicks](https://vicks.com/en-us/shop-products/dayquil).\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.045802\n",
      "prediction:  One of the primary benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that it allows individuals to manage their cold and flu symptoms effectively during the day without causing drowsiness. \n",
      "\n",
      "Daytime formulations are specifically designed to alleviate symptoms such as congestion, cough, and body aches while avoiding ingredients that induce sleepiness, such as antihistamines commonly found in nighttime versions. This is particularly important for individuals who need to maintain their daily activities, such as work or school, while still addressing their illness. \n",
      "\n",
      "By using a daytime formulation, patients can experience relief from symptoms like nasal congestion, sore throat, and fever, enabling them to function normally throughout the day. This targeted approach helps to improve overall quality of life during illness, allowing individuals to remain productive and engaged in their daily responsibilities without the sedative effects that nighttime formulations typically provide. \n",
      "\n",
      "Additionally, the availability of both daytime and nighttime formulations allows for a more tailored approach to symptom management, giving patients the flexibility to choose the appropriate medication based on their specific needs at different times of the day. This can lead to better adherence to treatment regimens and improved outcomes in managing cold and flu symptoms.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.042315\n",
      "prediction:  One of the primary benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that it allows individuals to manage their cold and flu symptoms effectively during the day without causing drowsiness. \n",
      "\n",
      "Nighttime formulations typically contain ingredients such as antihistamines (like diphenhydramine or doxylamine) that are effective in alleviating symptoms like runny nose, sneezing, and cough, but they also have sedative properties that can induce sleepiness. This makes them suitable for nighttime use when rest is essential for recovery. \n",
      "\n",
      "In contrast, daytime formulations are specifically designed to provide relief from similar symptoms while minimizing the risk of drowsiness. They often contain non-sedating antihistamines or other active ingredients that help relieve symptoms such as nasal congestion, headache, and body aches without impairing alertness or cognitive function. This allows individuals to continue with their daily activities, such as work or school, while still managing their cold or flu symptoms effectively.\n",
      "\n",
      "Additionally, daytime formulations may include ingredients like decongestants (such as pseudoephedrine) that help to relieve nasal congestion and promote easier breathing, further enhancing the ability to function throughout the day. \n",
      "\n",
      "Overall, the benefit of a daytime formulation lies in its ability to provide symptom relief while allowing individuals to maintain their productivity and quality of life during the day, which is particularly important when dealing with the discomfort of a cold or flu.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.040989\n",
      "prediction:  One of the primary benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that it allows individuals to manage their cold and flu symptoms effectively during the day without causing drowsiness. \n",
      "\n",
      "Nighttime formulations typically contain ingredients that promote sleep, such as antihistamines (like diphenhydramine or doxylamine), which can help alleviate symptoms like runny nose and sneezing but also induce sedation. This is beneficial for nighttime use when rest is essential for recovery. However, during the day, individuals need to remain alert and functional, whether for work, school, or daily activities.\n",
      "\n",
      "The daytime formulation is designed to provide relief from symptoms such as congestion, cough, sore throat, and fever while avoiding sedative effects. It often contains non-drowsy antihistamines, decongestants (like pseudoephedrine), and pain relievers (like acetaminophen or ibuprofen) that help alleviate symptoms without impairing cognitive function or alertness. \n",
      "\n",
      "This distinction allows individuals to continue their daily routines while managing their illness, improving their overall quality of life during the day. Additionally, it can help prevent the cycle of fatigue that can occur when individuals are unable to rest properly due to persistent symptoms, thereby supporting a more effective recovery process. \n",
      "\n",
      "In summary, the daytime formulation of 'nighttime severe cold and flu' medications provides symptom relief without sedation, enabling individuals to maintain productivity and engagement in their daily activities while dealing with cold and flu symptoms.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.085349\n",
      "prediction:  One of the primary benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that they are specifically designed to alleviate symptoms without causing drowsiness. Daytime formulations often include active ingredients such as decongestants and pain relievers that help relieve symptoms like nasal congestion, headaches, and body aches, allowing individuals to maintain their normal daily activities while they recover from cold or flu symptoms. This contrasts with nighttime formulations which typically contain sedative components to promote sleep, making daytime versions more suitable for use during the day when alertness is necessary.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.028829\n",
      "prediction:  One of the prominent brand products indicated for preventing the recurrence of flaking and itching associated with dandruff is **Nizoral A-D** (Ketoconazole). Ketoconazole is an antifungal medication that targets the Malassezia yeast that is often associated with dandruff, helping to alleviate symptoms and prevent future flare-ups.\n",
      "\n",
      "In addition to Nizoral, **Head & Shoulders** is another well-known brand that offers various formulations specifically designed to combat dandruff and soothe the scalp. Their products typically contain active ingredients like pyrithione zinc, which helps to reduce flaking and itching.\n",
      "\n",
      "It's essential to follow the instructions for use carefully and consult with a healthcare provider for recommendations tailored to individual needs, especially if symptoms persist.\n",
      "\n",
      "For additional information and recent research on the topic, recent reviews and studies highlight several treatment strategies for dandruff and seborrheic dermatitis, focusing on antifungals and anti-inflammatory medications as effective ways to manage these conditions (Hill et al., 2025).\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014698\n",
      "prediction:  One of the symptoms that 'nighttime severe cold and flu' medications help relieve to improve sleep quality is **nasal congestion**. \n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Nasal Congestion**: Nasal congestion occurs when the nasal passages become swollen or inflamed, often due to inflammation from a cold or flu virus. This can lead to difficulty breathing through the nose, which can be particularly bothersome at night.\n",
      "\n",
      "2. **Impact on Sleep Quality**: When a person is experiencing nasal congestion, it can make it challenging to breathe comfortably while lying down. This can lead to disrupted sleep, frequent awakenings, and an overall decrease in sleep quality. \n",
      "\n",
      "3. **Role of Nighttime Cold and Flu Medications**: Nighttime cold and flu medications often contain ingredients such as antihistamines (e.g., diphenhydramine or doxylamine) and decongestants (e.g., phenylephrine or pseudoephedrine). \n",
      "   - **Antihistamines**: These help reduce the body's allergic response and can dry up nasal secretions, providing relief from congestion.\n",
      "   - **Decongestants**: These work by constricting blood vessels in the nasal passages, leading to reduced swelling and improved airflow.\n",
      "\n",
      "4. **Improvement in Sleep Quality**: By alleviating nasal congestion, these medications can help individuals breathe more easily at night. This can lead to a more restful sleep, as the person is less likely to wake up due to difficulty breathing or the need to breathe through the mouth, which can also lead to a dry throat and further discomfort.\n",
      "\n",
      "5. **Conclusion**: Therefore, one of the key symptoms that nighttime severe cold and flu medications help relieve is nasal congestion, which significantly contributes to improving sleep quality during illness.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013151\n",
      "prediction:  One of the symptoms that 'nighttime severe cold and flu' medications help relieve to improve sleep quality is **nasal congestion**. \n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Nighttime Cold and Flu Medications**: These medications are specifically formulated to address multiple symptoms associated with colds and flu, particularly those that can disrupt sleep. They often contain a combination of ingredients such as antihistamines, decongestants, pain relievers, and cough suppressants.\n",
      "\n",
      "2. **Nasal Congestion**: This symptom occurs when the nasal passages become swollen and inflamed due to infection, leading to difficulty breathing through the nose. It can be caused by the common cold, flu, or other respiratory infections.\n",
      "\n",
      "3. **Impact on Sleep Quality**: Nasal congestion can significantly hinder sleep quality. When a person is congested, they may struggle to breathe comfortably while lying down, leading to frequent awakenings, snoring, or even sleep apnea. This can result in a restless night and feelings of fatigue the next day.\n",
      "\n",
      "4. **Mechanism of Relief**: Nighttime cold and flu medications often include decongestants (like pseudoephedrine) that work by narrowing the blood vessels in the nasal passages, reducing swelling and allowing for easier airflow. Additionally, some formulations may contain antihistamines (like diphenhydramine) that can help dry up nasal secretions and promote drowsiness, further aiding in sleep.\n",
      "\n",
      "5. **Overall Benefit**: By alleviating nasal congestion, these medications help individuals breathe more easily at night, which can lead to a more restful and uninterrupted sleep. Improved sleep quality is crucial for recovery from illness, as it allows the body to heal and restore its immune function.\n",
      "\n",
      "In summary, one of the key symptoms that nighttime severe cold and flu medications help relieve is nasal congestion, which in turn improves sleep quality by allowing for easier breathing during the night.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013279\n",
      "prediction:  One of the symptoms that 'nighttime severe cold and flu' medications help relieve to improve sleep quality is **nasal congestion**. \n",
      "\n",
      "### Step-by-Step Explanation:\n",
      "\n",
      "1. **Understanding Nighttime Severe Cold and Flu Medications**: These medications are specifically formulated to address multiple symptoms associated with colds and flu, particularly those that can disrupt sleep. They often contain a combination of ingredients such as antihistamines, decongestants, pain relievers, and cough suppressants.\n",
      "\n",
      "2. **Nasal Congestion**: This symptom occurs when the nasal passages become inflamed and swollen, often due to viral infections like the common cold or flu. It can lead to difficulty breathing through the nose, which can be particularly bothersome at night when lying down.\n",
      "\n",
      "3. **Impact on Sleep Quality**: Nasal congestion can significantly hinder sleep quality. When a person is unable to breathe easily through their nose, they may resort to breathing through their mouth, which can lead to snoring, dry mouth, and discomfort. This can result in frequent awakenings and an overall restless night.\n",
      "\n",
      "4. **Relief Provided by Medications**: Nighttime cold and flu medications often include decongestants (like pseudoephedrine) that work by shrinking swollen blood vessels in the nasal passages, thereby reducing congestion. Additionally, some formulations may include antihistamines (like diphenhydramine) that can have a sedative effect, helping to promote sleep.\n",
      "\n",
      "5. **Conclusion**: By alleviating nasal congestion, nighttime severe cold and flu medications can help individuals breathe more easily while sleeping, leading to improved sleep quality. This relief allows for a more restful night, which is crucial for recovery from illness.\n",
      "\n",
      "In summary, one of the key symptoms that nighttime severe cold and flu medications help relieve to improve sleep quality is nasal congestion, facilitating better breathing and more restful sleep.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.018909\n",
      "prediction:  One of the symptoms that 'nighttime severe cold and flu' medications help relieve to improve sleep quality is **nasal congestion**. \n",
      "\n",
      "Nasal congestion can be particularly bothersome at night, making it difficult for individuals to breathe comfortably while lying down. This can lead to disrupted sleep patterns, frequent awakenings, and overall poor sleep quality. Nighttime cold and flu medications often contain ingredients such as antihistamines (like diphenhydramine or doxylamine) and decongestants (like phenylephrine or pseudoephedrine) that work together to alleviate this symptom.\n",
      "\n",
      "Antihistamines help reduce mucus production and swelling in the nasal passages, providing relief from the stuffiness that can obstruct airflow. Decongestants work by constricting blood vessels in the nasal passages, which reduces swelling and allows for easier breathing. By alleviating nasal congestion, these medications can help individuals breathe more freely during the night, leading to a more restful sleep.\n",
      "\n",
      "Additionally, many nighttime formulations also include ingredients that promote drowsiness, further aiding in the ability to fall asleep and stay asleep. Overall, by addressing nasal congestion and promoting better airflow, nighttime severe cold and flu medications can significantly enhance sleep quality for those suffering from cold or flu symptoms.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.01672\n",
      "prediction:  One of the symptoms that 'nighttime severe cold and flu' medications help relieve to improve sleep quality is **nasal congestion**. \n",
      "\n",
      "Nasal congestion occurs when the nasal passages become swollen or inflamed, often due to the common cold or flu. This can lead to difficulty breathing through the nose, which can be particularly bothersome at night when lying down. When nasal congestion is present, it can disrupt sleep by causing discomfort, leading to frequent awakenings, and making it difficult to fall asleep.\n",
      "\n",
      "Nighttime cold and flu medications typically contain a combination of ingredients designed to alleviate this symptom. For instance, they may include:\n",
      "\n",
      "1. **Decongestants**: These help reduce swelling in the nasal passages, making it easier to breathe. Common decongestants include pseudoephedrine and phenylephrine.\n",
      "\n",
      "2. **Antihistamines**: Many nighttime formulations contain first-generation antihistamines like diphenhydramine or doxylamine, which not only help relieve nasal congestion but also have sedative properties that can promote drowsiness and help users fall asleep more easily.\n",
      "\n",
      "3. **Pain relievers**: Ingredients like acetaminophen or ibuprofen can help alleviate any associated pain or discomfort, such as headaches or sore throats, which can also interfere with sleep.\n",
      "\n",
      "By addressing nasal congestion and other related symptoms, nighttime severe cold and flu medications can significantly improve sleep quality, allowing individuals to rest more comfortably and recover more effectively from their illness.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Cough\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02835\n",
      "prediction:  RETHYMIC (thymoglobulin) is an immunosuppressive agent primarily used in the treatment of acute rejection in kidney transplant patients and for the treatment of certain hematological conditions. Understanding its contraindication profile is essential for safe and effective use, especially when compared to other drugs with specific contraindications.\n",
      "\n",
      "### Contraindications of RETHYMIC\n",
      "\n",
      "1. **Hypersensitivity Reactions**: RETHYMIC is contraindicated in patients with a known hypersensitivity to rabbit proteins or any component of the formulation. This is critical as severe allergic reactions can occur.\n",
      "\n",
      "2. **Active Infections**: Due to its immunosuppressive effects, RETHYMIC is contraindicated in patients with active infections. The drug can exacerbate existing infections or increase the risk of new infections due to its impact on the immune system.\n",
      "\n",
      "3. **Severe Bone Marrow Suppression**: Patients with significant bone marrow suppression or cytopenias should not receive RETHYMIC, as it can further impair hematopoiesis and lead to serious complications.\n",
      "\n",
      "4. **Pregnancy and Lactation**: RETHYMIC is generally contraindicated in pregnant and breastfeeding women due to potential risks to the fetus or infant, as immunosuppressive therapy can affect fetal development and immune function.\n",
      "\n",
      "### Comparison with Other Drugs\n",
      "\n",
      "When comparing RETHYMIC to other drugs with specific contraindications, several factors come into play:\n",
      "\n",
      "1. **Mechanism of Action**: Many immunosuppressants, such as cyclosporine or tacrolimus, also have contraindications related to hypersensitivity and active infections. However, the specific mechanisms of action can lead to different profiles of contraindications. For instance, while RETHYMIC is a polyclonal antibody that depletes T-cells, cyclosporine works by inhibiting T-cell activation. This difference can influence the types of infections or conditions that are particularly risky with each drug.\n",
      "\n",
      "2. **Side Effect Profiles**: Drugs like corticosteroids have a different set of contraindications, including uncontrolled diabetes or peptic ulcer disease, which are not typically a concern with RETHYMIC. This highlights the importance of understanding the broader pharmacological context when assessing contraindications.\n",
      "\n",
      "3. **Patient Population**: The contraindications for RETHYMIC may be more relevant in specific populations, such as transplant patients, compared to other drugs that may be used in a wider range of conditions. For example, certain antibiotics may have contraindications related to renal function or liver disease, which are not as pertinent for RETHYMIC.\n",
      "\n",
      "4. **Drug Interactions**: RETHYMIC's immunosuppressive nature can lead to increased susceptibility to infections when used with other immunosuppressants, whereas other drugs may have contraindications based on their interactions with specific metabolic pathways (e.g., CYP450 interactions).\n",
      "\n",
      "5. **Monitoring Requirements**: The contraindications associated with RETHYMIC necessitate careful monitoring for infections and blood counts, similar to other immunosuppressants, but may differ in the frequency and type of monitoring required.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, RETHYMIC has a specific contraindication profile that is primarily focused on hypersensitivity, active infections, and bone marrow suppression. When compared to other drugs with specific contraindications, it shares some commonalities, particularly in the context of immunosuppression, but also has unique aspects that reflect its mechanism of action and intended use. Understanding these differences is crucial for healthcare providers to ensure patient safety and optimize therapeutic outcomes.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.032297\n",
      "prediction:  RETHYMIC (thymoglobulin) is an immunosuppressive agent primarily used in the treatment of acute rejection in kidney transplant patients and for the treatment of certain hematological conditions. Understanding its contraindication profile is essential for safe and effective use, especially when compared to other drugs with specific contraindications.\n",
      "\n",
      "### Contraindications of RETHYMIC\n",
      "\n",
      "1. **Hypersensitivity Reactions**: RETHYMIC is contraindicated in patients with a known hypersensitivity to rabbit proteins or any component of the formulation. This is critical as severe allergic reactions can occur.\n",
      "\n",
      "2. **Active Infections**: Due to its immunosuppressive effects, RETHYMIC is contraindicated in patients with active infections. The drug can exacerbate existing infections or increase the risk of new infections due to its impact on the immune system.\n",
      "\n",
      "3. **Severe Bone Marrow Suppression**: Patients with significant bone marrow suppression or cytopenias should not receive RETHYMIC, as it can further impair hematopoiesis and lead to serious complications.\n",
      "\n",
      "4. **Pregnancy and Lactation**: RETHYMIC is generally contraindicated in pregnant or breastfeeding women due to potential risks to the fetus or infant, as immunosuppressive therapy can affect fetal development and immune function.\n",
      "\n",
      "### Comparison with Other Drugs\n",
      "\n",
      "When comparing RETHYMIC to other drugs with specific contraindications, several factors come into play:\n",
      "\n",
      "1. **Immunosuppressants**: Other immunosuppressive agents, such as cyclosporine or tacrolimus, also have contraindications related to hypersensitivity and active infections. However, they may have additional contraindications related to specific organ dysfunction (e.g., liver or kidney impairment) that RETHYMIC does not explicitly share.\n",
      "\n",
      "2. **Antibiotics**: Many antibiotics have contraindications related to hypersensitivity, particularly penicillins and sulfonamides. However, they may also have contraindications based on renal function or interactions with other medications, which is less of a concern with RETHYMIC.\n",
      "\n",
      "3. **Chemotherapeutic Agents**: Drugs like methotrexate have contraindications related to pregnancy, active infections, and pre-existing bone marrow suppression. Similar to RETHYMIC, they can exacerbate existing conditions but may also have additional contraindications based on specific cancer types or organ function.\n",
      "\n",
      "4. **Biologics**: Other biologic therapies, such as monoclonal antibodies, often have contraindications related to active infections and hypersensitivity. However, they may also have specific contraindications based on the underlying condition being treated, which can differ from the more generalized profile of RETHYMIC.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "The contraindication profile of RETHYMIC is primarily focused on hypersensitivity, active infections, and bone marrow suppression, which is common among immunosuppressive agents. However, it is essential to consider the broader context of each drug's specific indications, patient population, and potential interactions. Understanding these nuances helps healthcare providers make informed decisions about the use of RETHYMIC and its alternatives, ensuring patient safety and optimal therapeutic outcomes.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.029404\n",
      "prediction:  RETHYMIC (thymoglobulin) is an immunosuppressive agent primarily used in the treatment of acute rejection in kidney transplant patients. Understanding its contraindication profile is essential for safe and effective use, especially when compared to other drugs with specific contraindications.\n",
      "\n",
      "### Contraindications of RETHYMIC\n",
      "\n",
      "1. **Hypersensitivity Reactions**: RETHYMIC is contraindicated in patients with a known hypersensitivity to rabbit proteins or any component of the formulation. This is critical as severe allergic reactions can occur.\n",
      "\n",
      "2. **Active Infections**: Due to its immunosuppressive effects, RETHYMIC is contraindicated in patients with active infections. The drug can exacerbate existing infections or increase the risk of new infections due to its impact on the immune system.\n",
      "\n",
      "3. **Severe Bone Marrow Suppression**: Patients with significant bone marrow suppression or cytopenias should not receive RETHYMIC, as it can further impair hematopoiesis and lead to serious complications.\n",
      "\n",
      "4. **Pregnancy and Lactation**: While not an absolute contraindication, caution is advised when considering RETHYMIC in pregnant or breastfeeding women due to potential risks to the fetus or infant.\n",
      "\n",
      "### Comparison with Other Drugs\n",
      "\n",
      "When comparing RETHYMIC to other immunosuppressive agents or drugs with specific contraindications, several factors come into play:\n",
      "\n",
      "1. **Immunosuppressants (e.g., Cyclosporine, Tacrolimus)**:\n",
      "   - **Contraindications**: Similar to RETHYMIC, these drugs are contraindicated in patients with active infections and hypersensitivity. However, they may have additional contraindications related to renal impairment or specific drug interactions that RETHYMIC does not have.\n",
      "   - **Bone Marrow Suppression**: While RETHYMIC is contraindicated in severe bone marrow suppression, some immunosuppressants may be used cautiously in patients with mild cytopenias, depending on the clinical scenario.\n",
      "\n",
      "2. **Chemotherapeutic Agents (e.g., Methotrexate)**:\n",
      "   - **Contraindications**: Chemotherapeutic agents often have a broader range of contraindications, including severe liver disease, active peptic ulcer disease, or specific infections (e.g., tuberculosis). RETHYMIC's contraindications are more focused on hypersensitivity and active infections.\n",
      "   - **Monitoring**: Chemotherapeutic agents typically require more intensive monitoring for toxicity, whereas RETHYMIC's monitoring focuses on infection risk and organ function.\n",
      "\n",
      "3. **Biologics (e.g., Rituximab)**:\n",
      "   - **Contraindications**: Like RETHYMIC, biologics may be contraindicated in patients with active infections. However, they may also have specific contraindications related to cardiovascular conditions or previous infusion reactions, which are not a primary concern with RETHYMIC.\n",
      "   - **Infusion Reactions**: RETHYMIC is associated with infusion-related reactions, which necessitates premedication in some cases, while other biologics may have different profiles of infusion reactions.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "The contraindication profile of RETHYMIC is primarily centered around hypersensitivity, active infections, and severe bone marrow suppression. Compared to other drugs, particularly immunosuppressants and biologics, RETHYMIC shares some common contraindications but is more narrowly focused on specific patient conditions. Understanding these differences is crucial for healthcare providers to make informed decisions about patient management and to mitigate risks associated with immunosuppressive therapy. Careful patient selection and monitoring are essential to optimize outcomes while minimizing adverse effects.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.033613\n",
      "prediction:  RETHYMIC, a medication used in specific medical contexts, has a contraindication profile that reflects its potential interactions and adverse effects in certain patient populations. \n",
      "\n",
      "### Contraindications of RETHYMIC\n",
      "RETHYMIC is primarily contraindicated in patients with severe hypersensitivity to any of its components or those with a history of anaphylactic reactions to similar drugs. Specific contraindications may also include:\n",
      "\n",
      "1. **Active Infections**: Patients with active infections should not receive RETHYMIC due to the drug's immunosuppressive effects, which can exacerbate infections or hinder immune responses.\n",
      "2. **Severe Liver or Renal Impairment**: The drug may be contraindicated in patients with severe liver or renal impairment due to altered drug metabolism and clearance, leading to potentially toxic levels.\n",
      "3. **Concurrent Live Vaccinations**: Because of its immunosuppressive nature, RETHYMIC is contraindicated in patients who are to receive live vaccines. This can put patients at risk for vaccine-preventable diseases.\n",
      "4. **Severe Cardiovascular Disease**: Caution or avoidance may be advised in patients with severe cardiovascular conditions due to the potential for exacerbation.\n",
      "\n",
      "### Comparison with Other Drugs with Specific Contraindications\n",
      "When comparing RETHYMIC's contraindication profile to drugs with well-defined contraindications, several key points arise:\n",
      "\n",
      "- **Immunosuppressive Drugs**: Similar to other immunosuppressive agents (e.g., corticosteroids, cyclosporine), RETHYMIC shares contraindications concerning active infections and live vaccinations. These drugs typically require careful monitoring in patients with heightened susceptibility to infections, highlighting a common contraindication across immunosuppressive therapies.\n",
      "\n",
      "- **Cardiovascular Medications**: Some cardiovascular medications also have contraindications related to severe cardiovascular disease. However, the nature of these contraindications may differ as they often focus on specific heart conditions (e.g., contraindications of beta-blockers in patients with bradycardia).\n",
      "\n",
      "- **Anticoagulants and Antiplatelets**: These drugs often carry contraindications related to bleeding disorders or active bleeding conditions. In comparison, RETHYMIC's contraindications emphasize immunological and infectious conditions rather than coagulopathy.\n",
      "\n",
      "Overall, while RETHYMIC's contraindications share similarities with those of other immunosuppressive medicines, they are distinct in their emphasis on infection risk and immunological stability. Each drug class carries its unique profile based on the underlying mechanisms of action and patient health considerations, highlighting the necessity for personalized medical evaluation and risk assessment in therapy selection.\n",
      "\n",
      "In conclusion, RETHYMIC's contraindication profile is critical in guiding its safe use in specific patient populations, requiring healthcare professionals to assess the risk of severe reactions and adverse effects when considering this treatment option.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.031543\n",
      "prediction:  Recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy with Pemetrexed for Injection presents a challenging clinical scenario. The treatment options for such patients depend on several factors, including the patient's overall health, performance status, the presence of specific genetic mutations, and prior treatment history. Here are some potential treatment options:\n",
      "\n",
      "1. **Targeted Therapy**:\n",
      "   - **EGFR Inhibitors**: If the tumor has an EGFR mutation (common in non-squamous NSCLC), targeted therapies such as Osimertinib (Tagrisso) may be appropriate. Testing for EGFR mutations is essential before initiating this treatment.\n",
      "   - **ALK Inhibitors**: For patients with ALK rearrangements, options like Alectinib, Brigatinib, or Lorlatinib can be considered.\n",
      "   - **ROS1 Inhibitors**: If the tumor is ROS1-positive, Crizotinib or Entrectinib may be effective.\n",
      "\n",
      "2. **Immunotherapy**:\n",
      "   - **Checkpoint Inhibitors**: Pembrolizumab (Keytruda) or Nivolumab (Opdivo) can be used, especially if the tumor expresses PD-L1. The combination of Nivolumab and Ipilimumab (Yervoy) is also an option for some patients.\n",
      "   - **Combination Therapy**: In some cases, combining immunotherapy with chemotherapy (e.g., Nivolumab with chemotherapy) may be beneficial, particularly if the patient has not received prior immunotherapy.\n",
      "\n",
      "3. **Chemotherapy**:\n",
      "   - If the patient has not received a full course of second-line chemotherapy, options such as Docetaxel or Gemcitabine may be considered. However, the efficacy of these agents may be limited in patients who have already been treated with Pemetrexed.\n",
      "\n",
      "4. **Clinical Trials**:\n",
      "   - Participation in clinical trials can be an excellent option for patients with recurrent metastatic NSCLC. Trials may offer access to novel therapies, including new targeted agents, immunotherapies, or combination regimens that are not yet widely available.\n",
      "\n",
      "5. **Supportive Care**:\n",
      "   - In cases where the disease is symptomatic or the patient has a poor performance status, palliative care and supportive measures should be prioritized to improve quality of life.\n",
      "\n",
      "In summary, the choice of treatment for recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed should be individualized based on molecular profiling, prior treatment history, and the patient's overall condition. A multidisciplinary approach involving oncologists, radiologists, and palliative care specialists is essential to optimize outcomes and manage symptoms effectively. Regular reassessment and monitoring are crucial to adapt the treatment plan as needed.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.033601\n",
      "prediction:  Recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy with Pemetrexed for Injection presents a challenging clinical scenario. The treatment options for such patients depend on several factors, including the patient's overall health, performance status, the presence of specific genetic mutations, and prior treatment responses. Here are some potential treatment options:\n",
      "\n",
      "1. **Targeted Therapy**:\n",
      "   - **EGFR Inhibitors**: If the tumor has an EGFR mutation (common in non-squamous NSCLC), targeted therapies such as Osimertinib (Tagrisso) may be appropriate. Testing for EGFR mutations is essential before initiating this treatment.\n",
      "   - **ALK Inhibitors**: For patients with ALK rearrangements, options like Alectinib, Brigatinib, or Lorlatinib can be considered.\n",
      "   - **ROS1 Inhibitors**: If the tumor is ROS1-positive, Crizotinib or Entrectinib may be effective.\n",
      "\n",
      "2. **Immunotherapy**:\n",
      "   - **Checkpoint Inhibitors**: Agents such as Pembrolizumab (Keytruda) or Nivolumab (Opdivo) can be used, especially if the tumor expresses PD-L1. The combination of Nivolumab and Ipilimumab (Yervoy) may also be considered in certain cases.\n",
      "   - **Combination Therapy**: For patients with high PD-L1 expression, combining chemotherapy with immunotherapy (e.g., Pembrolizumab with chemotherapy) may be an option, although this is more relevant for first-line treatment.\n",
      "\n",
      "3. **Chemotherapy**:\n",
      "   - If the patient has not received a taxane-based regimen, docetaxel or cabazitaxel may be considered as second-line chemotherapy options. However, the efficacy of chemotherapy in the setting of recurrent disease after Pemetrexed is generally limited.\n",
      "\n",
      "4. **Clinical Trials**:\n",
      "   - Participation in clinical trials can be an excellent option for patients with recurrent metastatic NSCLC. Trials may offer access to novel therapies, including new targeted agents, immunotherapies, or combination regimens that are not yet widely available.\n",
      "\n",
      "5. **Supportive Care**:\n",
      "   - In cases where the disease is symptomatic or the patient has a poor performance status, palliative care and supportive measures should be prioritized to improve quality of life.\n",
      "\n",
      "In summary, the choice of treatment for recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed should be individualized based on molecular profiling, prior treatment history, and the patient's overall condition. A multidisciplinary approach involving oncologists, radiologists, and palliative care specialists is essential to optimize outcomes and manage symptoms effectively.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.052692\n",
      "prediction:  Terbinafine is an antifungal medication commonly used to treat fungal infections, particularly onychomycosis (nail fungus). However, there are certain conditions under which terbinafine should not be prescribed:\n",
      "\n",
      "1. **Hepatic Impairment**: Terbinafine is primarily metabolized by the liver. Patients with hepatic disease or abnormalities in liver function tests should avoid using terbinafine due to the risk of severe liver damage.\n",
      "\n",
      "2. **Renal Impairment**: Although not as critical as liver function, patients with significant renal impairment may also face increased risks associated with the drug's metabolism and excretion.\n",
      "\n",
      "3. **Hypersensitivity Reactions**: Any patient with a known hypersensitivity to terbinafine or any of its components should not be prescribed this medication, as it may provoke severe allergic reactions.\n",
      "\n",
      "4. **History of Psoriasis**: Terbinafine may exacerbate psoriasis in patients with a history of this skin condition, as systemic antifungal treatments can sometimes destabilize pre-existing dermatological conditions.\n",
      "\n",
      "5. **Concurrent Use of Certain Medications**: Due to potential drug interactions with medications that affect liver enzymes (e.g., CYP450 enzyme system), care should be taken with patients already on other medications that could interact adversely with terbinafine.\n",
      "\n",
      "In summary, while terbinafine is effective against fungal infections, its prescription is contraindicated in patients with hepatic or renal impairment, history of severe hypersensitivity, concurrent medications that may interact, and those with psoriasis. It is essential to evaluate each patient's individual health status and medication history before prescribing terbinafine.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.060714\n",
      "prediction:  The American Academy of Pediatrics (AAP) plays a critical role in establishing usage guidelines for various medications, including D-109. As a prominent professional association of pediatricians, the AAP focuses on the health, safety, and well-being of children.\n",
      "\n",
      "While detailed guidelines specific to D-109 were not identified in the search, the AAP typically issues comprehensive clinical practice guidelines that address the prescribing and administration of medications in pediatric populations. These guidelines are developed based on the latest research and evidence and serve as a standard for pediatric care. \n",
      "\n",
      "The AAP's guidelines generally encompass various aspects, such as dosing recommendations, potential side effects, interaction warnings, and overall safety profiles, aiming to optimize treatment outcomes and minimize harm to children. They may also address specific conditions for which a medication like D-109 would be appropriate, ensuring that healthcare providers have the necessary information to make informed prescribing decisions.\n",
      "\n",
      "For pediatric practitioners, adherence to AAP guidelines represents best practices in clinical care, ensuring consistent and effective treatment protocols across the healthcare system. Thus, while direct references to D-109 in AAP guidelines were not located, the organization's overarching mandate to provide clinically relevant guidelines underscores its significant role in pediatric pharmacotherapy. \n",
      "\n",
      "For further details, you can explore the AAP's official publications and resources that outline their clinical practice statements and recommendations.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.045837\n",
      "prediction:  The American Academy of Pediatrics (AAP) plays a crucial role in establishing usage guidelines for various medical practices, including medications and treatments for children. The AAP is the largest professional association of pediatricians in the United States and is dedicated to the health and well-being of children through various initiatives, including the development of policy statements and clinical guidelines.\n",
      "\n",
      "### Role of the AAP in Usage Guidelines\n",
      "\n",
      "1. **Expert Consensus**: The AAP convenes expert panels to review the existing literature, clinical evidence, and expert opinions related to specific medications, including D-109. This process ensures that the guidelines are based on the most current and relevant data.\n",
      "\n",
      "2. **Policy Statements**: The AAP publishes comprehensive policy statements that outline the recommended practices for using medications like D-109. These statements serve as resources for pediatricians, helping them make informed decisions in the best interest of their patients.\n",
      "\n",
      "3. **Focus on Safety and Efficacy**: When developing guidelines, the AAP emphasizes the importance of safety and efficacy, ensuring that treatments are appropriate for children and based on sound clinical evidence.\n",
      "\n",
      "4. **Advocacy**: In addition to creating usage guidelines, the AAP advocates for policies that ensure access to quality healthcare and safe medication practices for children.\n",
      "\n",
      "5. **Educational Resources**: The AAP provides educational materials and resources for pediatricians to stay up-to-date on new guidelines, including those related to specific treatments like D-109.\n",
      "\n",
      "While specific guidelines related to D-109 were not found in the search results, the AAP's broad approach to pediatric health care suggests that any recommendations would likely align with their overarching goal of promoting children's health and preventing medication misuse.\n",
      "\n",
      "For further details about specific medications and their guidelines, it is encouraged to consult the AAP's official publications or their dedicated platforms, such as HealthyChildren.org.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.039024\n",
      "prediction:  The American Academy of Pediatrics (AAP) plays a significant role in establishing guidelines and recommendations for various medical practices, including the use of medications and treatments in pediatric populations. However, as of my last knowledge update in October 2023, there is no specific medication or treatment known as D-109 that is widely recognized in the medical community or literature. \n",
      "\n",
      "If D-109 refers to a specific drug, treatment, or intervention that has emerged after my last update, the AAP's involvement would typically include the following aspects:\n",
      "\n",
      "1. **Research and Evidence Review**: The AAP often conducts or reviews research studies to evaluate the safety, efficacy, and appropriateness of new treatments for children. This includes analyzing clinical trials, observational studies, and meta-analyses to gather evidence on the use of D-109.\n",
      "\n",
      "2. **Guideline Development**: Based on the evidence gathered, the AAP may develop clinical practice guidelines that outline the recommended usage of D-109. These guidelines would address indications, dosing, potential side effects, contraindications, and monitoring requirements.\n",
      "\n",
      "3. **Education and Training**: The AAP provides educational resources and training for pediatricians and healthcare providers regarding new treatments. This may include workshops, webinars, and published articles that help practitioners understand how to incorporate D-109 into their practice safely and effectively.\n",
      "\n",
      "4. **Advocacy**: The AAP advocates for policies that support the health and well-being of children. If D-109 is a treatment that requires specific regulatory considerations or insurance coverage, the AAP may engage in advocacy efforts to ensure that children have access to this treatment.\n",
      "\n",
      "5. **Monitoring and Updates**: The AAP continuously monitors new research and clinical outcomes related to treatments like D-109. As new data becomes available, the AAP may update its guidelines to reflect the latest evidence and best practices.\n",
      "\n",
      "6. **Collaboration with Other Organizations**: The AAP often collaborates with other medical organizations, regulatory bodies, and stakeholders to ensure a comprehensive approach to pediatric care. This collaboration can help in the development of consensus statements or joint guidelines regarding the use of D-109.\n",
      "\n",
      "In summary, while the AAP's specific role regarding D-109 would depend on the nature of the drug or treatment, their general responsibilities include research evaluation, guideline development, education, advocacy, monitoring, and collaboration to ensure that pediatric patients receive safe and effective care. If D-109 is a newly introduced treatment, it would be essential to consult the latest AAP guidelines or publications for the most accurate and up-to-date information.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.040609\n",
      "prediction:  The American Academy of Pediatrics (AAP) plays a significant role in establishing guidelines and recommendations for various medical practices, including the use of medications and treatments in pediatric populations. However, as of my last knowledge update in October 2023, there is no specific medication or treatment known as D-109 that is widely recognized in the medical community or literature. \n",
      "\n",
      "If D-109 refers to a specific drug, treatment, or intervention that has emerged after my last update, the AAP's involvement would typically include the following aspects:\n",
      "\n",
      "1. **Research and Evidence Review**: The AAP often conducts or reviews research studies to evaluate the safety, efficacy, and appropriateness of new treatments for children. This includes analyzing clinical trials, observational studies, and meta-analyses to gather evidence on the use of D-109.\n",
      "\n",
      "2. **Guideline Development**: Based on the evidence gathered, the AAP may develop clinical practice guidelines that outline the recommended usage of D-109. These guidelines would address indications, dosing, potential side effects, contraindications, and monitoring requirements.\n",
      "\n",
      "3. **Education and Training**: The AAP provides educational resources and training for pediatricians and healthcare providers regarding new treatments. This may include workshops, webinars, and published articles that help practitioners understand the appropriate use of D-109 in clinical practice.\n",
      "\n",
      "4. **Advocacy**: The AAP advocates for policies that promote the health and well-being of children. If D-109 is a treatment that requires specific access or insurance coverage considerations, the AAP may engage in advocacy efforts to ensure that children have access to necessary medications.\n",
      "\n",
      "5. **Monitoring and Updates**: The AAP continuously monitors new research and clinical outcomes related to treatments like D-109. As new data becomes available, the AAP may update its guidelines to reflect the latest evidence and best practices.\n",
      "\n",
      "6. **Collaboration with Other Organizations**: The AAP often collaborates with other medical organizations, regulatory bodies, and stakeholders to ensure that guidelines are comprehensive and reflect a consensus in the medical community.\n",
      "\n",
      "In summary, while the AAP's specific role regarding D-109 cannot be detailed without more context about what D-109 refers to, the organization generally focuses on evidence-based guidelines, education, advocacy, and ongoing research to ensure the best outcomes for pediatric patients. If D-109 is a newly introduced treatment, it would be essential to consult the latest AAP publications or official statements for the most accurate and up-to-date information.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.039759\n",
      "prediction:  The American Academy of Pediatrics (AAP) plays a significant role in establishing guidelines and recommendations for various medical practices, including the use of medications and treatments in pediatric populations. However, as of my last knowledge update in October 2023, there is no specific medication or treatment known as D-109 that is widely recognized in the medical community or literature. \n",
      "\n",
      "If D-109 refers to a specific drug, treatment, or intervention that has emerged after my last update, the AAP's involvement would typically include the following aspects:\n",
      "\n",
      "1. **Research and Evidence Review**: The AAP often conducts or reviews research studies to evaluate the safety, efficacy, and appropriateness of new treatments for children. This includes analyzing clinical trials, observational studies, and meta-analyses to gather evidence on the use of D-109.\n",
      "\n",
      "2. **Guideline Development**: Based on the evidence gathered, the AAP may develop clinical practice guidelines that outline the recommended usage of D-109. These guidelines would address indications, dosing, potential side effects, contraindications, and monitoring requirements.\n",
      "\n",
      "3. **Education and Training**: The AAP provides educational resources and training for pediatricians and healthcare providers regarding new treatments. This may include workshops, webinars, and published articles that help practitioners understand the appropriate use of D-109 in clinical practice.\n",
      "\n",
      "4. **Advocacy**: The AAP advocates for policies that promote the health and well-being of children. If D-109 is a treatment that requires specific regulatory considerations or insurance coverage, the AAP may engage in advocacy efforts to ensure that children have access to this treatment.\n",
      "\n",
      "5. **Monitoring and Updates**: The AAP continuously monitors new research and clinical outcomes related to treatments like D-109. As new data becomes available, the AAP may update its guidelines to reflect the latest evidence and best practices.\n",
      "\n",
      "6. **Collaboration with Other Organizations**: The AAP often collaborates with other medical organizations, regulatory bodies, and stakeholders to ensure a comprehensive approach to pediatric care. This collaboration can help in the formulation of guidelines that are widely accepted and implemented.\n",
      "\n",
      "In summary, while the AAP's specific role regarding D-109 cannot be detailed without more context about what D-109 refers to, the organization generally focuses on evidence-based guidelines, education, advocacy, and ongoing research to ensure the best outcomes for pediatric patients. If D-109 is a new or emerging treatment, it would be essential to consult the latest AAP publications or official statements for the most accurate and up-to-date information.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: They provide guidelines for fluoride supplementation in children.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.05708\n",
      "prediction:  The administration of Verkazia (cyclosporine A) eye drops, especially when used in conjunction with other ocular medications, requires careful timing to ensure maximum efficacy of both treatments. The correct sequence for administering Verkazia and other eye drops or ointments generally follows these guidelines:\n",
      "\n",
      "1. **Wait Between Weaving Drops**: If a patient is prescribed multiple eye drops, they should wait about 5 to 10 minutes between administering different drops. This interval allows the first medication to absorb effectively without dilution or washout by the subsequent drop.\n",
      "\n",
      "2. **Verkazia as First Option**: If Verkazia is among the medications, it is often recommended to administer it first. This is due to its specific mechanism of action and the need for optimal ocular surface exposure.\n",
      "\n",
      "3. **Ointments Last**: If an ointment is being used, it should be applied last. Ointments can create a barrier that may prevent the absorption of liquids, including eye drops, so using them last helps ensure the drops have maximal effect.\n",
      "\n",
      "4. **Compliance with Instructions**: It is crucial for patients to carefully follow the instructions provided by their healthcare provider or as indicated on the medication guide, as variations might exist based on individual medical needs.\n",
      "\n",
      "By strictly following this protocol, patients can ensure that they maximize the therapeutic effects of Verkazia while using other ocular treatments. This sequence helps maintain the efficacy of the medications being used and supports better management of ocular conditions such as dry eye associated with sjÃ¶gren's syndrome. \n",
      "\n",
      "If further specifics on an individual case are required, consultation with a healthcare professional is advised for personalized recommendations.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.016039\n",
      "prediction:  The answer to the question regarding which group showed the smallest mean change in plasma glucose one hour after the first dose in a clinical trial of adults and adolescents is not definitively available in the searched clinical trials. However, recent studies and trials related to glucose control suggest various factors influencing glucose levels in these populations, especially in the context of interventions like continuous glucose monitoring or insulin therapy.\n",
      "\n",
      "1. A notable trial titled \"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes\" emphasizes the ongoing efforts in managing glucose levels effectively in diabetic individuals. Such studies often analyze mean changes in plasma glucose post-dose, although specific group comparisons weren't directly detailed in the retrieved information.\n",
      "\n",
      "2. Another reference from the retrieved literature emphasizes dietary interventions and their impact on plasma glucose levels after meals, indicating that the mean change can significantly vary based on the type of intervention or dosage of the substance tested (e.g., ReducoseÂ®, a mulberry leaf extract).\n",
      "\n",
      "It is essential to consult specific papers or trial results directly for precise numbers and comparative data to obtain a clear answer regarding the smallest mean change in plasma glucose after the first dose among different groups in clinical trials. If you're looking for detailed numerical results or comparative analyses, accessing the full texts of the mentioned trials or their publications would be beneficial.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.015\n",
      "prediction:  The available search results did not provide specific percentage data regarding the plasma concentrations of albuterol sulfate in the brain of rats during intravenous studies. Therefore, I cannot definitively answer the question based on the information gathered. \n",
      "\n",
      "However, if I had to select based on common findings in pharmacokinetics, I would suggest the answer may be around 10%. \n",
      "\n",
      "Answer: B\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: 5%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020063\n",
      "prediction:  The brand name product commonly indicated for preventing the recurrence of flaking and itching associated with dandruff is **Head & Shoulders**. This brand offers a variety of formulations that contain active ingredients designed to combat dandruff, such as pyrithione zinc, selenium sulfide, and ketoconazole. \n",
      "\n",
      "Head & Shoulders products work by targeting the underlying causes of dandruff, which often include an overgrowth of a yeast-like fungus called Malassezia, as well as scalp dryness and irritation. The active ingredients help to reduce the fungal population on the scalp, alleviate inflammation, and restore the scalp's natural balance, thereby minimizing symptoms like flaking and itching.\n",
      "\n",
      "In addition to Head & Shoulders, other brands such as **Nizoral** (which contains ketoconazole), **Selsun Blue** (which contains selenium sulfide), and **Neutrogena T/Gel** (which contains coal tar) are also effective in treating dandruff and preventing its recurrence. Each of these products may have different active ingredients and mechanisms of action, so individuals may need to try different options to find the one that works best for their specific scalp condition.\n",
      "\n",
      "For optimal results, it is often recommended to use these products regularly as part of a hair care routine, and to follow the instructions on the label regarding frequency of use and application methods. If dandruff persists despite using over-the-counter treatments, it may be advisable to consult a healthcare professional or dermatologist for further evaluation and potential prescription options.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021477\n",
      "prediction:  The brand name product commonly indicated for preventing the recurrence of flaking and itching associated with dandruff is **Head & Shoulders**. This brand offers a variety of formulations that contain active ingredients designed to combat dandruff, such as pyrithione zinc, selenium sulfide, and ketoconazole. \n",
      "\n",
      "Head & Shoulders products work by targeting the underlying causes of dandruff, which often include an overgrowth of a yeast-like fungus called Malassezia, as well as scalp dryness and irritation. The active ingredients help to reduce the fungal population on the scalp, alleviate inflammation, and restore the scalp's natural balance.\n",
      "\n",
      "In addition to Head & Shoulders, other brands such as **Nizoral** (which contains ketoconazole), **Selsun Blue** (which contains selenium sulfide), and **Neutrogena T/Gel** (which contains coal tar) are also effective in treating dandruff and preventing its recurrence. Each of these products may have different active ingredients and mechanisms of action, so individuals may choose one based on their specific needs, scalp condition, and personal preferences.\n",
      "\n",
      "For optimal results, it is often recommended to use these products regularly as part of a hair care routine, and to follow the instructions provided on the packaging. If dandruff persists despite using over-the-counter treatments, it may be advisable to consult a healthcare professional or dermatologist for further evaluation and potential prescription options.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020766\n",
      "prediction:  The brand name product commonly indicated for preventing the recurrence of flaking and itching associated with dandruff is **Head & Shoulders**. This brand offers a variety of formulations that contain active ingredients designed to combat dandruff, such as pyrithione zinc, selenium sulfide, and ketoconazole. \n",
      "\n",
      "Head & Shoulders products work by targeting the underlying causes of dandruff, which often include an overgrowth of a yeast-like fungus called Malassezia, as well as scalp dryness and irritation. The active ingredients help to reduce the fungal population on the scalp, alleviate inflammation, and restore the scalp's natural balance.\n",
      "\n",
      "In addition to Head & Shoulders, other brands such as **Nizoral** (which contains ketoconazole), **Selsun Blue** (which contains selenium sulfide), and **Neutrogena T/Gel** (which contains coal tar) are also effective in treating dandruff and preventing its recurrence. Each of these products may have different active ingredients and mechanisms of action, so individuals may need to try different options to find the one that works best for their specific scalp condition.\n",
      "\n",
      "For optimal results, it is often recommended to use these products regularly as part of a hair care routine, and to follow the instructions on the label regarding frequency of use and application methods. If dandruff persists despite using over-the-counter treatments, it may be advisable to consult a healthcare professional or dermatologist for further evaluation and potential prescription options.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.051498\n",
      "prediction:  The co-administration of OCELLA, which is a combination oral contraceptive containing ethinyl estradiol and desogestrel, with a strong CYP3A4 inhibitor like ketoconazole can significantly affect the pharmacokinetics of OCELLA.\n",
      "\n",
      "CYP3A4 is a key enzyme involved in the metabolism of many drugs, including the components of OCELLA. Ketoconazole is known to inhibit the CYP3A4 enzyme, which can lead to increased plasma concentrations of drugs that are substrates of this enzyme. \n",
      "\n",
      "1. **Increased Hormone Levels**: With ketoconazole inhibiting CYP3A4, the metabolism of ethinyl estradiol and desogestrel may be reduced, potentially leading to elevated serum levels of these hormones. This increase can result in an enhanced contraceptive effect, but it may also raise the risk of adverse effects, such as thromboembolic events.\n",
      "\n",
      "2. **Monitoring and Dose Adjustment**: Due to the potential for increased exposure to the active ingredients of OCELLA, it is recommended that healthcare providers closely monitor patients who are on both OCELLA and ketoconazole. Depending on the patient's response and any side effects experienced, adjustments to the contraceptive method or additional contraceptive measures may be necessary.\n",
      "\n",
      "3. **Clinical Considerations**: The clinical implications of this interaction highlight the need for careful patient counseling and monitoring. Patients should be informed about the signs of potential side effects associated with higher hormone levels, and alternative medications that do not interact with CYP3A4 can be considered if prolonged use of ketoconazole is necessary.\n",
      "\n",
      "In summary, combining OCELLA with a strong CYP3A4 inhibitor like ketoconazole can lead to increased hormone levels and heightened risk of side effects, necessitating careful monitoring and consideration of alternative therapies.\n",
      "pred_SIM:  B\n",
      "choice:  E\n",
      "correct_answer:  B\n",
      "correct answer: Increases the AUC of DRSP and EE by 2.68-fold and 1.40-fold, respectively.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.054094\n",
      "prediction:  The comparison between 1.25 mg Levalbuterol and 2.5 mg racemic Albuterol sulfate in clinical studies primarily revolves around their effects as bronchodilators over a spectrum of evaluation periods, including a 6-hour timeframe. \n",
      "\n",
      "**Key Findings:**\n",
      "\n",
      "1. **Efficacy:**\n",
      "   - **Levalbuterol (LEV):** It is the (R)-enantiomer of albuterol and is thought to have similar efficacy as the racemic formulation at lower doses. For instance, in studies assessing its use in asthmatic children, low doses of Levalbuterol were compared to higher doses of racemic Albuterol, and it was concluded that the therapeutic outcomes were comparable or even favorable at lower dosages due to reduced side effects from the (S)-enantiomer present in racemic formulations. One study indicated significant bronchodilation immediately post-administration, with improvements in Forced Expiratory Volume (FEV1) observed.\n",
      "   \n",
      "2. **Safety and Side Effects:**\n",
      "   - Levalbuterol may offer an advantage in terms of safety, particularly concerning the lower incidence of side effects commonly associated with the (S)-isomer found in racemic Albuterol. Use of Levalbuterol could lead to fewer cardiovascular side effects, which is particularly critical in sensitive populations such as young children.\n",
      "\n",
      "3. **Clinical Findings from Controlled Studies:**\n",
      "   - In a randomized trial of severe asthma exacerbations where high doses of Levalbuterol and racemic Albuterol were administered, both therapies exhibited comparably effective bronchodilation over the treatment course. The findings suggested that while both drugs are effective, Levalbuterol can be administered at lower doses to achieve similar bronchodilatory benefits, thus reducing potential adverse events.\n",
      "\n",
      "4. **Study Parameters:**\n",
      "   - Many studies deployed objective measurements like FEVI, and patient-reported outcomes assessed for up to 6 hours post-administration, aligning with the evaluation needs in acute settings or routine management of asthma.\n",
      "\n",
      "In conclusion, the bronchodilator response when comparing 1.25 mg Levalbuterol to 2.5 mg racemic Albuterol sulfate is favorable for Levalbuterol concerning efficacy similar to that of a higher dose of racemic Albuterol, with a better safety profile due to the absence of the (S)-isomer. This makes Levalbuterol a potentially preferred therapeutic choice under certain clinical circumstances, particularly in pediatric patients where the risk of side effects is a significant consideration. \n",
      "\n",
      "**References:**\n",
      "- Low-dose levalbuterol vs placebo and racemic albuterol [PMID: 11742271].\n",
      "- High-dose uses and pharmacokinetics of Levalbuterol in pediatric patients [PMID: 19464028].\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Levalbuterol and racemic albuterol sulfate have clinically comparable responses.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.032891\n",
      "prediction:  The comparison of mortality rates in patients treated for Community-Acquired Bacterial Pneumonia (CABP) with NUZYRA (omadacycline) versus moxifloxacin is an important aspect of evaluating the safety and efficacy of these treatments.\n",
      "\n",
      "A systematic review and meta-analysis were conducted to evaluate various antibiotics for the treatment of CABP in adults, which included recently published data comparing NUZYRA to traditional treatment options like moxifloxacin. It appears from the available literature that the mortality rates associated with omadacycline (NUZYRA) may be comparable to those treated with moxifloxacin, but specific mortality data directly comparing the two agents in a controlled setting is scarce.\n",
      "\n",
      "The clinical trials (â€œNCT02531438,â€ â€œNCT04779242,â€ and â€œNCT06162286â€) indicate that both treatments are being actively researched for their effectiveness, safety, and included outcomes like mortality. For instance, the completed trials have shown promising results for NUZYRA regarding clinical outcomes, including potential reductions in mortality compared to older antibiotics like moxifloxacin, although exact numerical mortality rates were not specified in the abstracts available.\n",
      "\n",
      "Further details from the studies would highlight the significance of these findings. Therefore, clinicians should consider individual patient factors and local resistance patterns when making treatment choices for CABP.\n",
      "\n",
      "In conclusion, while there is a basis for optimism regarding the potential for NUZYRA to match or potentially exceed the outcomes provided by moxifloxacin, further data is essential to draw definitive conclusions regarding mortality rates in a direct comparative manner. Continuous updates from ongoing studies will provide more insights into the comparative safety and effectiveness of these antibiotics in CABP patients.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.063348\n",
      "prediction:  The contraindication profile of WL-AAB-Z-W-982 is critical to assess its safety and efficacy in clinical use. Although specific studies pertaining to WL-AAB-Z-W-982 have been limited, literature indicates that every drug carries its unique set of contraindications based on patient demographics, comorbidities, and potential drug interactions.\n",
      "\n",
      "WL-AAB-Z-W-982 is often compared to other medications in order to establish a safety framework. For instance, general research on drug contraindications has shown varying profiles depending on drug classification:\n",
      "\n",
      "1. **Narcotics** typically have contraindications in patients with respiratory issues due to the risk of respiratory depression.\n",
      "2. **Antidepressants**, such as SSRIs, may have contraindications related to specific drug interactions with other medications, particularly those that affect serotonin levels.\n",
      "3. **Antihypertensives** often have contraindications in patients with renal impairment, which could exacerbate their conditions.\n",
      "\n",
      "In a systematic review comparing the contraindications, it was found that multinational pharmaceutical companies generally provided clearer, more comprehensive Patient Information Leaflets (PILs) compared to local companies. This difference highlights the variability in how information about contraindications is conveyed to healthcare providers and patients.\n",
      "\n",
      "Additionally, emerging studies are evaluating the pharmacogenomics of drugs, offering insights into how genetic variations can affect drug metabolism and the safety profile of these substances, including WL-AAB-Z-W-982. By correlating genetic data with contraindications, personalized medicine aims to enhance treatment outcomes while minimizing adverse effects.\n",
      "\n",
      "Overall, while WL-AAB-Z-W-982's contraindications may share similarities with those of other drugs, ongoing research is vital for establishing a robust safety protocol as new clinical evidence emerges.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.028192\n",
      "prediction:  The daytime formulation of 'nighttime severe cold and flu' medications is specifically designed to provide relief from cold and flu symptoms while allowing individuals to remain alert and functional during the day. Hereâ€™s a step-by-step breakdown of the benefits:\n",
      "\n",
      "1. **Symptom Relief**: Daytime formulations typically contain active ingredients that target common cold and flu symptoms such as nasal congestion, cough, sore throat, and fever. Ingredients like acetaminophen or ibuprofen help reduce fever and alleviate pain, while decongestants like phenylephrine or pseudoephedrine relieve nasal congestion.\n",
      "\n",
      "2. **Non-Drowsy Formula**: Unlike nighttime formulations, which often include antihistamines (like diphenhydramine or doxylamine) that can cause drowsiness, daytime formulations are designed to be non-drowsy. This allows individuals to carry on with their daily activities, such as work or school, without feeling sedated or lethargic.\n",
      "\n",
      "3. **Improved Functionality**: By alleviating symptoms without inducing drowsiness, daytime formulations help individuals maintain productivity and focus. This is particularly important for those who need to perform tasks that require concentration, such as driving or operating machinery.\n",
      "\n",
      "4. **Convenience**: Daytime formulations are often available in various forms, such as tablets, capsules, or liquid, making them easy to take and convenient for individuals on the go. This accessibility encourages adherence to the medication regimen.\n",
      "\n",
      "5. **Combination of Ingredients**: Many daytime formulations combine multiple active ingredients to address a range of symptoms simultaneously. This multi-symptom approach can be more effective than taking separate medications for each symptom.\n",
      "\n",
      "6. **Targeted Use**: The availability of both daytime and nighttime formulations allows individuals to tailor their medication use based on their needs. They can take the daytime formulation during the day and switch to the nighttime version when they are ready to rest, ensuring comprehensive symptom management throughout the day and night.\n",
      "\n",
      "In summary, the primary benefit of the daytime formulation of 'nighttime severe cold and flu' medications is that it provides effective relief from cold and flu symptoms while allowing individuals to remain alert and functional, thereby supporting their daily activities and overall well-being.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.025049\n",
      "prediction:  The daytime formulation of 'nighttime severe cold and flu' medications is specifically designed to provide relief from cold and flu symptoms while allowing individuals to remain alert and functional during the day. Hereâ€™s a step-by-step breakdown of the benefits:\n",
      "\n",
      "1. **Symptom Relief**: Daytime formulations typically contain active ingredients that target common cold and flu symptoms such as nasal congestion, cough, sore throat, and fever. Ingredients like acetaminophen or ibuprofen help reduce fever and alleviate pain, while decongestants like phenylephrine or pseudoephedrine relieve nasal congestion.\n",
      "\n",
      "2. **Non-Drowsy Formula**: Unlike nighttime formulations, which often include antihistamines (like diphenhydramine or doxylamine) that can cause drowsiness, daytime formulations are designed to be non-drowsy. This allows individuals to continue their daily activities, such as work or school, without the sedative effects that nighttime medications can induce.\n",
      "\n",
      "3. **Convenience**: Having a separate daytime formulation allows individuals to manage their symptoms effectively throughout the day without the need to switch medications or worry about feeling sleepy. This convenience is particularly beneficial for those who need to maintain productivity.\n",
      "\n",
      "4. **Targeted Ingredients**: Daytime formulations may include specific ingredients that are more effective during the day. For example, they might contain a combination of a decongestant and a pain reliever, which can help clear nasal passages and reduce discomfort without causing sedation.\n",
      "\n",
      "5. **Improved Quality of Life**: By alleviating symptoms without causing drowsiness, daytime formulations can significantly improve a person's quality of life during the day. This is especially important for individuals who are managing their symptoms while trying to fulfill work or family responsibilities.\n",
      "\n",
      "6. **Flexibility in Treatment**: The availability of both daytime and nighttime formulations allows individuals to tailor their treatment based on their needs. They can take the daytime formulation during the day for symptom relief and switch to the nighttime version when they are ready to rest, ensuring comprehensive management of their cold or flu symptoms.\n",
      "\n",
      "In summary, one of the primary benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that it provides effective symptom relief while allowing individuals to remain alert and active throughout the day, thus supporting their overall well-being and productivity.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.027419\n",
      "prediction:  The daytime formulation of 'nighttime severe cold and flu' medications is specifically designed to provide relief from cold and flu symptoms while allowing individuals to remain alert and functional during the day. Hereâ€™s a step-by-step breakdown of the benefits:\n",
      "\n",
      "1. **Symptom Relief**: Daytime formulations typically contain active ingredients that target common cold and flu symptoms such as nasal congestion, cough, sore throat, and fever. Ingredients like acetaminophen or ibuprofen help reduce fever and alleviate pain, while decongestants like phenylephrine or pseudoephedrine relieve nasal congestion.\n",
      "\n",
      "2. **Non-Drowsy Formula**: Unlike nighttime formulations, which often include antihistamines like diphenhydramine that can cause drowsiness, daytime formulations are designed to be non-drowsy. This allows individuals to carry on with their daily activities, such as work or school, without feeling sleepy or lethargic.\n",
      "\n",
      "3. **Convenience**: Having a specific formulation for daytime use means that individuals can manage their symptoms effectively without the risk of sedation. This is particularly beneficial for those who need to drive, operate machinery, or engage in tasks that require full attention.\n",
      "\n",
      "4. **Improved Quality of Life**: By alleviating symptoms without causing drowsiness, daytime formulations can help individuals maintain their productivity and social interactions, which can be particularly important during times of illness. This can lead to a better overall experience while dealing with cold or flu symptoms.\n",
      "\n",
      "5. **Targeted Ingredients**: Daytime formulations may also include additional ingredients that are specifically chosen to address symptoms that are more bothersome during the day, such as cough suppressants or expectorants, which can help clear mucus and reduce coughing.\n",
      "\n",
      "6. **Flexibility in Treatment**: The availability of both daytime and nighttime formulations allows individuals to tailor their treatment based on their needs. They can take the daytime formulation during the day for symptom relief while reserving the nighttime formulation for when they are ready to rest and need help with sleep.\n",
      "\n",
      "In summary, one of the key benefits of the daytime formulation of 'nighttime severe cold and flu' medications is that it provides effective symptom relief without causing drowsiness, allowing individuals to remain alert and active throughout the day while managing their cold or flu symptoms.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Helps loosen phlegm and thin bronchial secretions\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.015167\n",
      "prediction:  The drug branded as \"70%\" typically refers to a solution of isopropyl alcohol (also known as isopropanol or rubbing alcohol) that contains 70% isopropyl alcohol by volume. This concentration is commonly used for various purposes in both medical and non-medical settings. Here are the primary uses of 70% isopropyl alcohol:\n",
      "\n",
      "1. **Antiseptic**: One of the most common uses of 70% isopropyl alcohol is as an antiseptic. It is effective in killing a wide range of bacteria, viruses, and fungi, making it suitable for disinfecting skin before injections, minor surgical procedures, or when cleaning wounds. The 70% concentration is particularly effective because it allows for a longer contact time with the microorganisms, enhancing its ability to penetrate cell walls and denature proteins.\n",
      "\n",
      "2. **Disinfectant**: In healthcare settings, 70% isopropyl alcohol is used to disinfect surfaces, medical instruments, and equipment. It is effective against many pathogens, including those that cause healthcare-associated infections. It is often used in hospitals, clinics, and laboratories to maintain a sterile environment.\n",
      "\n",
      "3. **Cleaning Agent**: Beyond its antiseptic properties, 70% isopropyl alcohol is also used as a cleaning agent for various surfaces, including electronics, glass, and metal. It evaporates quickly, leaving no residue, which makes it ideal for cleaning delicate items like computer screens and optical equipment.\n",
      "\n",
      "4. **Solvent**: Isopropyl alcohol is a versatile solvent used in various industrial and laboratory applications. It can dissolve oils, resins, and other organic compounds, making it useful in the formulation of products such as paints, coatings, and adhesives.\n",
      "\n",
      "5. **Deodorizer**: Due to its ability to kill bacteria that cause odors, 70% isopropyl alcohol can be used as a deodorizer in various settings, including homes and vehicles.\n",
      "\n",
      "6. **Hand Sanitizer**: In the absence of soap and water, 70% isopropyl alcohol can be used as a hand sanitizer. However, it is important to note that formulations specifically designed for hand sanitization may include additional ingredients to enhance skin hydration and reduce irritation.\n",
      "\n",
      "7. **Laboratory Use**: In laboratories, 70% isopropyl alcohol is often used for sterilizing equipment, cleaning glassware, and preparing samples. It is a common reagent in various chemical and biological experiments.\n",
      "\n",
      "While 70% isopropyl alcohol is widely used and effective, it is important to handle it with care. It is flammable, and proper storage and usage guidelines should be followed to ensure safety. Additionally, it should not be ingested or applied to large areas of broken skin, as it can cause irritation or systemic toxicity.\n",
      "\n",
      "In summary, the primary use of the drug branded as 70% is isopropyl alcohol, which serves as an antiseptic, disinfectant, cleaning agent, solvent, deodorizer, hand sanitizer, and is utilized in laboratory settings. Its effectiveness and versatility make it a staple in both medical and everyday applications.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.016782\n",
      "prediction:  The drug branded as \"70%\" typically refers to a solution of isopropyl alcohol (also known as isopropanol or rubbing alcohol) that contains 70% isopropyl alcohol by volume. This concentration is commonly used for various purposes in both medical and non-medical settings. Here are the primary uses of 70% isopropyl alcohol:\n",
      "\n",
      "1. **Antiseptic**: One of the most common uses of 70% isopropyl alcohol is as an antiseptic. It is effective in killing a wide range of bacteria, viruses, and fungi, making it suitable for disinfecting skin before injections, minor surgical procedures, or when cleaning wounds. The 70% concentration is particularly effective because it allows for a longer contact time with the microorganisms, enhancing its germicidal activity.\n",
      "\n",
      "2. **Disinfectant**: In healthcare settings, 70% isopropyl alcohol is used to disinfect surfaces, medical instruments, and equipment. It is effective against many pathogens, including those that cause healthcare-associated infections. It is often used in hospitals, clinics, and laboratories to maintain a sterile environment.\n",
      "\n",
      "3. **Cleaning Agent**: Isopropyl alcohol is also used as a cleaning agent for various surfaces, including electronics, glass, and metal. It evaporates quickly and leaves no residue, making it ideal for cleaning delicate items like computer screens and optical lenses.\n",
      "\n",
      "4. **Solvent**: In pharmaceutical and laboratory settings, 70% isopropyl alcohol can be used as a solvent for various substances. It can dissolve oils, resins, and other compounds, making it useful in the preparation of certain formulations.\n",
      "\n",
      "5. **Skin Preparation**: Before medical procedures, 70% isopropyl alcohol is often used to prepare the skin by removing oils and contaminants, which helps to reduce the risk of infection.\n",
      "\n",
      "6. **Deodorizer**: Due to its volatile nature and ability to kill bacteria that cause odors, isopropyl alcohol can also be used as a deodorizer in various applications.\n",
      "\n",
      "7. **First Aid**: In first aid kits, 70% isopropyl alcohol is commonly included for its antiseptic properties, allowing individuals to clean minor cuts and scrapes.\n",
      "\n",
      "It is important to note that while 70% isopropyl alcohol is effective for many uses, it should be handled with care. It is flammable, and proper ventilation is necessary when using it in enclosed spaces. Additionally, it should not be ingested or applied to large areas of broken skin, as it can cause irritation or systemic toxicity.\n",
      "\n",
      "In summary, the primary use of the drug branded as \"70%\" is as an antiseptic and disinfectant, with additional applications in cleaning, solvent use, and skin preparation. Its effectiveness and versatility make it a staple in both medical and everyday settings.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.014393\n",
      "prediction:  The drug branded as \"70%\" typically refers to a solution of isopropyl alcohol (also known as isopropanol or rubbing alcohol) that contains 70% isopropyl alcohol by volume. This concentration is widely used in various medical and healthcare settings for its antiseptic properties.\n",
      "\n",
      "### Primary Uses of 70% Isopropyl Alcohol:\n",
      "\n",
      "1. **Antiseptic for Skin Disinfection**: \n",
      "   - 70% isopropyl alcohol is commonly used to disinfect the skin before injections, minor surgical procedures, or blood draws. It effectively reduces the number of viable pathogens on the skin surface, minimizing the risk of infection.\n",
      "\n",
      "2. **Surface Disinfection**: \n",
      "   - It is used to clean and disinfect surfaces in healthcare environments, such as countertops, medical equipment, and instruments. Its efficacy against a broad spectrum of bacteria, viruses, and fungi makes it a valuable tool in infection control.\n",
      "\n",
      "3. **Hand Sanitizer**: \n",
      "   - In situations where soap and water are not available, 70% isopropyl alcohol can be used as a hand sanitizer. It is effective in killing many types of germs, although it is important to ensure that the hands are not visibly dirty or greasy for optimal effectiveness.\n",
      "\n",
      "4. **Solvent for Laboratory Use**: \n",
      "   - In laboratory settings, 70% isopropyl alcohol is often used as a solvent for various chemical reactions and processes. It can dissolve a wide range of non-polar compounds and is useful in preparing samples for analysis.\n",
      "\n",
      "5. **Cleaning Agent**: \n",
      "   - It is effective in cleaning electronic devices, such as keyboards and screens, as it evaporates quickly and leaves no residue. However, care should be taken to avoid damage to sensitive components.\n",
      "\n",
      "6. **Decontamination**: \n",
      "   - In the event of spills involving biological materials, 70% isopropyl alcohol can be used to decontaminate surfaces and equipment, helping to ensure safety in laboratory and clinical environments.\n",
      "\n",
      "### Mechanism of Action:\n",
      "The effectiveness of 70% isopropyl alcohol as an antiseptic is attributed to its ability to denature proteins and disrupt cell membranes of microorganisms. The presence of water in the solution enhances the penetration of alcohol into cells, making it more effective than higher concentrations (e.g., 90% or 99% isopropyl alcohol), which can cause rapid coagulation of proteins and create a protective barrier around the microorganisms.\n",
      "\n",
      "### Safety Considerations:\n",
      "While 70% isopropyl alcohol is generally safe for external use, it is flammable and should be kept away from open flames and heat sources. It can also cause skin irritation in some individuals, so it is advisable to perform a patch test before extensive use. Ingestion or inhalation of isopropyl alcohol can be toxic, and appropriate safety measures should be taken when handling the substance.\n",
      "\n",
      "### Conclusion:\n",
      "In summary, the primary use of the drug branded as \"70%\" refers to 70% isopropyl alcohol, which serves as a potent antiseptic for skin disinfection, surface cleaning, and various applications in healthcare and laboratory settings. Its effectiveness, rapid evaporation, and broad-spectrum antimicrobial activity make it a staple in infection control and hygiene practices.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.004691\n",
      "prediction:  The drug class typically associated with general body cleansing processes includes various detoxification agents and dietary supplements, often marketed as \"cleanses\" or \"detox drinks.\" One notable brand name is **\"Colon Cleanse.\"** This product is often used to support the body's natural detoxification processes, particularly focusing on the colon.\n",
      "\n",
      "Detoxification itself is defined as the physiological process of removing toxic substances from the body, primarily carried out by the liver. There are various methods and products available for individuals seeking these cleansing processes, including herbal supplements and commercial cleanses that claim to support liver health and toxin elimination.\n",
      "\n",
      "Furthermore, academic resources highlight that while many marketed detoxification diets and products exist, their efficacy and necessity are sometimes debated in the scientific community. For example, the body is equipped with organs such as the liver and kidneys that naturally manage detoxification without the need for specialized diets or products.\n",
      "\n",
      "In summary, while \"Colon Cleanse\" may be one of the more recognizable brand names in the marketplace for general body cleansing, several other options are available depending on the intended use and formulation.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.006144\n",
      "prediction:  The drug commonly used for general body cleansing processes is often categorized under detoxification agents. While there isn't a singular \"brand name\" for detox drugs as they can vary based on their intended use (such as detoxing from substances like alcohol or drugs), there are several popular products known for body cleansing. \n",
      "\n",
      "Some notable brand names associated with detoxification and cleansing include:\n",
      "\n",
      "1. **Colon Cleanse Products** - Various brands market colon cleansing products, which are often used for bowel purification. Examples include \"Fleet\" (for enemas) and \"Miralax\" (as a laxative).\n",
      "   \n",
      "2. **Detox Teas** - Brands like \"Yogi Cleanse\" teas or \"Brew Detox\" are marketed for whole-body detoxification.\n",
      "\n",
      "3. **Liver Detox Supplements** - Products such as \"Herbal Detox Cleanse\" or \"Milk Thistle\" extracts are often used for liver cleansing.\n",
      "\n",
      "4. **Complete Body Detox Kits** - Brands like \"GNC Herbal Plus Detox\" and \"NutraBlast Detox Cleanse\" provide comprehensive body cleansing solutions.\n",
      "\n",
      "These products often claim to flush out toxins or promote overall health, but it's important to approach detox products with caution, as their efficacy can vary and may not be scientifically supported. Always consult with a healthcare professional before starting any detox regimen.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.006873\n",
      "prediction:  The duration of treatment for athlete's foot (tinea pedis) with antifungal medications can vary depending on the specific brand-name drug used, the severity of the infection, and individual patient factors. Generally, most topical antifungal treatments are recommended for a period of 2 to 4 weeks. Hereâ€™s a more detailed breakdown:\n",
      "\n",
      "1. **Topical Antifungals**: Common over-the-counter (OTC) topical antifungal medications include clotrimazole (Lotrimin), miconazole (Monistat), terbinafine (Lamisil), and tolnaftate (Tinactin). These are typically applied once or twice daily for 2 to 4 weeks. It is crucial to continue using the medication for the full recommended duration, even if symptoms improve before the treatment is completed, to ensure that the infection is fully eradicated and to prevent recurrence.\n",
      "\n",
      "2. **Oral Antifungals**: In cases of more severe or persistent athlete's foot, or if the infection has spread to the nails (onychomycosis), a healthcare provider may prescribe oral antifungal medications such as terbinafine or itraconazole. The duration of oral treatment can range from 2 weeks to several months, depending on the specific medication and the extent of the infection.\n",
      "\n",
      "3. **Follow-Up**: After completing the antifungal treatment, it is advisable to monitor the affected area for any signs of recurrence. If symptoms persist or worsen after the treatment course, it is important to consult a healthcare professional for further evaluation and possible alternative treatments.\n",
      "\n",
      "4. **Prevention**: To prevent athlete's foot from recurring, it is essential to maintain good foot hygiene, keep feet dry, and use antifungal powders or sprays in shoes if prone to fungal infections.\n",
      "\n",
      "In summary, topical antifungal treatments for athlete's foot are typically used daily for 2 to 4 weeks, while oral treatments may require a longer duration based on the severity of the infection. Always follow the specific instructions provided with the medication and consult a healthcare provider for personalized advice.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.007338\n",
      "prediction:  The duration of treatment for athlete's foot (tinea pedis) with antifungal medications can vary depending on the specific brand-name drug used, the severity of the infection, and individual patient factors. However, here are some general guidelines for common antifungal treatments:\n",
      "\n",
      "1. **Topical Antifungals**: Many over-the-counter (OTC) antifungal creams, powders, or sprays are effective for treating athlete's foot. Common brand-name medications include clotrimazole (Lotrimin), miconazole (Lotrimin AF), terbinafine (Lamisil AT), and tolnaftate (Tinactin). \n",
      "\n",
      "   - **Duration**: These topical treatments are typically applied once or twice daily for **2 to 4 weeks**. It's important to continue using the medication for at least one week after symptoms resolve to ensure the infection is fully cleared.\n",
      "\n",
      "2. **Oral Antifungals**: In cases of severe or persistent athlete's foot, or if the infection has spread, a healthcare provider may prescribe oral antifungal medications such as terbinafine (Lamisil) or itraconazole (Sporanox).\n",
      "\n",
      "   - **Duration**: Oral treatments usually last longer, often for **2 to 6 weeks**, depending on the specific medication and the severity of the infection. The healthcare provider will determine the appropriate duration based on the individual case.\n",
      "\n",
      "3. **Follow-Up**: Regardless of the treatment chosen, it is essential to follow up with a healthcare provider if symptoms do not improve within a week or if they worsen. \n",
      "\n",
      "4. **Prevention**: To prevent recurrence, it is advisable to maintain good foot hygiene, keep feet dry, and avoid walking barefoot in communal areas such as pools or locker rooms.\n",
      "\n",
      "In summary, topical antifungals are generally used for 2 to 4 weeks, while oral antifungals may be prescribed for 2 to 6 weeks, depending on the severity of the infection. Always consult a healthcare professional for personalized advice and treatment options.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.00692\n",
      "prediction:  The duration of treatment for athlete's foot (tinea pedis) with antifungal medications can vary depending on the specific brand-name drug used, the severity of the infection, and individual patient factors. However, here are some general guidelines for common antifungal treatments:\n",
      "\n",
      "1. **Topical Antifungals**: Many over-the-counter (OTC) antifungal creams, powders, or sprays are effective for treating athlete's foot. Common brand-name medications include clotrimazole (Lotrimin), miconazole (Lotrimin AF), terbinafine (Lamisil), and tolnaftate (Tinactin). \n",
      "\n",
      "   - **Duration**: Typically, these topical treatments are applied once or twice daily for **2 to 4 weeks**. It's important to continue using the medication for at least one week after symptoms have resolved to ensure the infection is fully cleared.\n",
      "\n",
      "2. **Oral Antifungals**: In cases of severe athlete's foot or when topical treatments are ineffective, a healthcare provider may prescribe oral antifungal medications such as terbinafine (Lamisil) or itraconazole (Sporanox).\n",
      "\n",
      "   - **Duration**: Oral antifungal treatment usually lasts for **2 to 6 weeks**, depending on the specific medication and the severity of the infection. The healthcare provider will determine the appropriate duration based on the patient's response to treatment.\n",
      "\n",
      "3. **Follow-Up**: Regardless of the treatment chosen, it is essential to follow up with a healthcare provider if symptoms do not improve within a week or if they worsen. Persistent or recurrent infections may require a different treatment approach or further evaluation.\n",
      "\n",
      "4. **Prevention**: To prevent recurrence, it is advisable to maintain good foot hygiene, keep feet dry, and avoid walking barefoot in communal areas such as pools and locker rooms.\n",
      "\n",
      "In summary, topical antifungals are generally used for 2 to 4 weeks, while oral antifungals may be prescribed for 2 to 6 weeks, depending on the severity of the infection. Always consult a healthcare professional for personalized advice and treatment options.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.016484\n",
      "prediction:  The maximum number of nicotine lozenges that can be used in a single day typically depends on the specific product and its formulation but generally adheres to established guidelines.\n",
      "\n",
      "According to clinical guidelines and product labeling, the maximum recommended daily dose of nicotine lozenges is usually 24 lozenges per day. However, many health organizations recommend an initial dose that is lower in order to assess tolerance and effectiveness, especially for individuals who are just starting to use the product.\n",
      "\n",
      "For example, users might be advised to start with a specific daily dose for the first couple of weeks and then gradually adjust based on their withdrawal symptoms and cravings. Itâ€™s crucial for users to follow the instructions provided on the nicotine lozenge packaging or those given by healthcare professionals to avoid potential side effects or nicotine overdose.\n",
      "\n",
      "If youâ€™re considering using nicotine lozenges or need personalized advice, it would be best to consult with a healthcare provider for tailored recommendations based on individual health needs.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 20 lozenges\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.018137\n",
      "prediction:  The maximum number of nicotine lozenges that can be used in a single day varies based on the specific formulation of the product. Generally, nicotine lozenges are available in 2 mg and 4 mg doses, and the daily usage guidelines are as follows:\n",
      "\n",
      "1. **2 mg lozenges**: The maximum recommended dosage is usually 24 lozenges per day for individuals who smoke less than 25 cigarettes per day.\n",
      "2. **4 mg lozenges**: The maximum recommended dosage can be up to 20 lozenges per day for individuals who smoke 25 or more cigarettes per day.\n",
      "\n",
      "It is important to note that these recommendations are meant to guide usage during the behavior change process aimed at smoking cessation and are typically included in the product instructions. Long-term use beyond the recommended dosage may lead to increased dependence on nicotine and other potential health risks. It's always advisable for individuals to consult with healthcare professionals for personalized advice about nicotine replacement therapies.\n",
      "\n",
      "In summary, for nicotine lozenges:\n",
      "- **2 mg**: Up to **24 lozenges** per day.\n",
      "- **4 mg**: Up to **20 lozenges** per day. \n",
      "\n",
      "Adherence to these guidelines promotes a safer approach to nicotine replacement therapy.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 20 lozenges\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.021236\n",
      "prediction:  The maximum storage temperature for 'up and up ibuprofen,' as with most ibuprofen formulations, is generally recommended to be controlled at room temperature, typically not exceeding 25Â°C (77Â°F). Additionally, it is advisable to store ibuprofen away from excessive heat and moisture and to keep it in a tightly closed container.\n",
      "\n",
      "In various studies, it has been noted that ibuprofen can retain its stability when stored under controlled conditions. For example, ibuprofen solutions have demonstrated stability at room temperature (around 23Â°C/73Â°F) and even under refrigeration (around 4Â°C/39Â°F), but these conditions may vary depending on the specific formulation and presentation of the ibuprofen (such as tablets, suspensions, or injectable forms).\n",
      "\n",
      "To ensure the integrity of the medication, always refer to the product labeling and storage instructions specified by the manufacturer. For 'up and up ibuprofen,' you should adhere to the standard storage recommendations mentioned on the packaging or accompanying leaflet.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.036026\n",
      "prediction:  The mortality rates in patients treated for Community-Acquired Bacterial Pneumonia (CABP) using NUZYRA (suzá€”á€±á€·) compared to moxifloxacin have been evaluated in clinical studies, but specific numerical results on mortality rates are often inconsistent or insufficiently detailed across studies.\n",
      "\n",
      "1. **NUZYRA (suzromycin)**:\n",
      "   - A systematic review and Bayesian network meta-analysis involving multiple antibiotics for hospitalized adults with Community-Acquired Pneumonia indicated variability in treatment effectiveness, including mortality outcomes. However, specific data directly comparing NUZYRA with moxifloxacin in terms of mortality were not conclusively reported in the studies accessed.\n",
      "   - The findings from one study indicated that respiratory failure and mortality can occur with severe cases of pneumonia, especially involving resistant organisms; however, the specific mortality rate for NUZYRA was not detailed.\n",
      "\n",
      "2. **Moxifloxacin**:\n",
      "   - The literature has reported concerning moxifloxacin's effectiveness in treating CABP, indicating it has a mortality rate that varies based on severity, comorbidities, and the causative pathogen of pneumonia. One report highlighted that treatment efficacy can differentially impact mortality, suggesting that while it is effective, high-risk patients still face significant mortality.\n",
      "\n",
      "In conclusion, while both NUZYRA and moxifloxacin are utilized for treating CABP, and there is some evidence suggesting that antibiotics like NUZYRA could be beneficial, specific comparative mortality rates are not consistently documented in available literature, necessitating further studies for definitive statistics. Thus, the mortality rate remains heavily contingent upon patient characteristics and disease severity rather than the antibiotic alone.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02027\n",
      "prediction:  The nighttime formulation of 'nighttime severe cold and flu' medications is specifically designed to relieve symptoms that can disrupt sleep, particularly cough and nasal congestion. These formulations typically contain a combination of active ingredients that target various symptoms associated with colds and flu, but they often include a sedating antihistamine, such as diphenhydramine or doxylamine, which helps to alleviate cough and promote sleep.\n",
      "\n",
      "1. **Cough Relief**: Nighttime formulations often include cough suppressants like dextromethorphan, which can help reduce the urge to cough, allowing for a more restful sleep. Coughing can be particularly bothersome at night, making it difficult to fall asleep or stay asleep.\n",
      "\n",
      "2. **Nasal Congestion Relief**: Many nighttime cold medications also contain decongestants (though some formulations may avoid them to prevent insomnia), which help to relieve nasal congestion, making it easier to breathe through the nose while lying down.\n",
      "\n",
      "3. **Sleep Aid**: The inclusion of sedating antihistamines not only helps with allergy-related symptoms but also serves to induce drowsiness, making it easier for individuals to fall asleep despite their cold or flu symptoms.\n",
      "\n",
      "In summary, the primary symptom specifically relieved by the nighttime formulation of 'nighttime severe cold and flu' medications is the disruptive cough, along with associated nasal congestion, allowing for improved sleep quality during illness.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.018715\n",
      "prediction:  The nighttime formulation of 'nighttime severe cold and flu' medications is specifically designed to relieve symptoms that can disrupt sleep, particularly cough and nasal congestion. These formulations typically contain a combination of active ingredients, including antihistamines, decongestants, and sometimes pain relievers or fever reducers.\n",
      "\n",
      "1. **Cough Relief**: Many nighttime cold medications include an antihistamine, such as diphenhydramine or doxylamine, which can help suppress the cough reflex. This is particularly beneficial for individuals who experience a persistent cough that worsens at night, making it difficult to sleep.\n",
      "\n",
      "2. **Nasal Congestion Relief**: Decongestants, such as phenylephrine or pseudoephedrine, are often included to help reduce nasal swelling and congestion. This can make it easier to breathe through the nose, which is crucial for restful sleep.\n",
      "\n",
      "3. **Sleep Aid**: The sedative properties of the antihistamines in these formulations can also help promote sleep, making it easier for individuals to fall asleep and stay asleep despite their cold or flu symptoms.\n",
      "\n",
      "4. **Other Symptoms**: While the primary focus is on cough and nasal congestion, nighttime formulations may also help alleviate other symptoms such as minor aches and pains or fever, contributing to overall comfort during the night.\n",
      "\n",
      "In summary, the nighttime formulation of 'nighttime severe cold and flu' specifically targets symptoms like cough and nasal congestion, which can interfere with sleep, while also providing a sedative effect to help users achieve a more restful night.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.043597\n",
      "prediction:  The nighttime formulation of 'nighttime severe cold and flu' medicines, such as Theraflu Nighttime Multi-Symptom Severe Cold Medicine, is specifically designed to relieve symptoms that typically disrupt sleep. One of the primary symptoms relieved by these formulations is nighttime cough. Additionally, these products often include ingredients such as antihistamines (like diphenhydramine) that can help alleviate nasal congestion, runny nose, and sneezing, promoting better rest.\n",
      "\n",
      "For further understanding of specific relief mechanisms and ingredients, you can explore the medications on the manufacturer's website [here](https://www.theraflu.com/products/nighttime-multi-symptom-severe-cold-tea-infusions/?intcmp=).\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.023651\n",
      "prediction:  The nighttime formulation of the drug \"nighttime severe cold and flu,\" particularly exemplified by products like Vicks NyQuil, is specifically designed to relieve symptoms that disrupt sleep. The main symptomatic relief provided by these nighttime formulations includes:\n",
      "\n",
      "1. **Cough Relief:** One of the primary symptoms that is alleviated is the cough, making it easier for individuals to rest without frequent interruptions due to coughing fits.\n",
      "2. **Nasal Congestion:** These formulations typically contain ingredients that help reduce nasal congestion, allowing for easier breathing during the night.\n",
      "3. **Sore Throat and Headache Relief:** Nighttime remedies often relieve sore throats and headaches, which can be exacerbated by cold and flu infections.\n",
      "4. **Fever and Body Aches:** They provide relief from fever and minor body pains, which are common symptoms of cold and flu.\n",
      "\n",
      "In summary, the nighttime formulations are specifically aimed at alleviating cough, nasal congestion, sore throat, headaches, fever, and body aches, thereby facilitating restful sleep during times of illness. Products like NyQuil also contain a sedating antihistamine, which helps promote sleep and reduce nighttime disruptions [Source: Vicks NyQuil Official Site](https://vicks.com/en-us/shop-products/nyquil/nyquil-severe-cold-and-flu-relief-liquid).\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02852\n",
      "prediction:  The nighttime formulation of the drug 'nighttime severe cold and flu' is specifically designed to relieve symptoms that can disrupt sleep, particularly those associated with colds and flu. One of the primary symptoms that this formulation targets is **cough**. \n",
      "\n",
      "Nighttime cold and flu medications typically contain ingredients such as diphenhydramine or doxylamine, which are antihistamines that help reduce coughing and promote drowsiness, making it easier for individuals to sleep through the night. These formulations may also include other components like pain relievers (e.g., acetaminophen or ibuprofen) to alleviate headaches and body aches, as well as decongestants to relieve nasal congestion. However, the key symptom that is specifically addressed by the nighttime formulation is the **cough**, as it can be particularly bothersome at night and interfere with restful sleep.\n",
      "\n",
      "In summary, the nighttime formulation of 'nighttime severe cold and flu' primarily relieves **cough**, along with other symptoms, but its unique focus is on providing relief that allows for better sleep during illness.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.036571\n",
      "prediction:  The nighttime formulations of cold and flu medications, such as those marketed under the name \"nighttime severe cold and flu,\" are specifically designed to relieve symptoms that interfere with sleep. One primary symptom targeted by these formulations is cough. \n",
      "\n",
      "Nighttime cold and flu medications often contain ingredients like diphenhydramine or doxylamine, which are antihistamines that help to suppress coughing and promote drowsiness, making it easier for individuals to sleep despite their cold symptoms. They may also provide relief from other discomforts such as nasal congestion and body aches, but their primary advantage is helping alleviate coughing to enable a better night's rest.\n",
      "\n",
      "Overall, the main symptom specifically relieved by nighttime formulations of cold and flu drugs is a troublesome cough, allowing for improved sleep during illness.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.040486\n",
      "prediction:  The patient population at higher risk of abusing RoxyBond, which is an immediate-release formulation of oxycodone, includes several distinct groups:\n",
      "\n",
      "1. **Opioid-NaÃ¯ve Patients**: Recent studies have indicated that individuals who are opioid-naÃ¯ve and get exposed to opioids in the setting of acute care (e.g., ICU survivors) can develop persistent opioid use post-discharge. These individuals may not have a prior history of substance abuse but can still transition to opioid dependence after initial exposure (reference PMID: 41184942).\n",
      "\n",
      "2. **Patients with Pain Disorders**: Patients suffering from chronic pain conditions who are frequently prescribed opioids, including RoxyBond, are at an elevated risk of developing substance use disorders. The management of pain often leads to prolonged exposure to opioids, increasing the likelihood of misuse.\n",
      "\n",
      "3. **History of Substance Abuse**: Individuals with a prior history of substance use disorders or those who have engaged in drug-seeking behavior are also at greater risk for RoxyBond abuse. Their previous experiences with addiction can make them more susceptible to misuse of opioids.\n",
      "\n",
      "4. **Mental Health Disorders**: Patients diagnosed with mental health conditions, such as anxiety or depression, may be more vulnerable to opioid misuse. The interplay between pain and mental health can lead to increased consumption of opioids, including RoxyBond.\n",
      "\n",
      "5. **Younger Adults**: Emerging data suggests that younger populations might also show higher tendencies toward substance misuse. This demographic often includes individuals experimenting with pain medications outside of their intended medical use.\n",
      "\n",
      "6. **Social and Environmental Factors**: Those in environments with higher rates of drug abuse within their community or social circles may also exhibit higher misuse rates of opioids.\n",
      "\n",
      "In summary, the risk factors for RoxyBond abuse include opioid-naÃ¯vetÃ©, chronic pain conditions, a history of substance abuse, mental health issues, younger age, and adverse social environments. Awareness of these factors can help in devising strategies to monitor and reduce the risk of opioid misuse in susceptible populations.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.004112\n",
      "prediction:  The percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets can vary based on the specific study or clinical trial being referenced. However, in general, pantoprazole, which is a proton pump inhibitor (PPI), is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and esophagitis caused by acid reflux.\n",
      "\n",
      "In clinical studies, pantoprazole has shown significant efficacy in healing esophageal lesions. For instance, in trials involving patients with erosive esophagitis, the healing rates after 8 weeks of treatment with pantoprazole have been reported to be around 70% to 90%. \n",
      "\n",
      "For example, one study might report that approximately 80% of patients achieved endoscopic healing of their esophageal lesions after 8 weeks of treatment with pantoprazole. However, it is essential to refer to specific clinical trial data or meta-analyses for precise figures, as these can differ based on the population studied, the severity of the lesions, and the specific dosages used.\n",
      "\n",
      "In summary, while the exact percentage can vary, pantoprazole is generally effective in promoting the healing of esophageal lesions, with healing rates typically reported in the range of 70% to 90% after 8 weeks of treatment. For the most accurate and specific information, consulting the results of relevant clinical studies or guidelines would be necessary.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.004129\n",
      "prediction:  The percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets can vary based on the specific study or clinical trial being referenced. However, in general, pantoprazole, which is a proton pump inhibitor (PPI), is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and esophagitis caused by acid reflux.\n",
      "\n",
      "In clinical studies, pantoprazole has shown significant efficacy in healing esophageal lesions. For instance, in trials involving patients with erosive esophagitis, the healing rates after 8 weeks of treatment with pantoprazole have been reported to be around 70% to 90%. \n",
      "\n",
      "For example, one study might report that approximately 80% of patients achieved endoscopic healing of their esophageal lesions after 8 weeks of treatment with pantoprazole. However, it is essential to refer to specific clinical trial data or product labeling for precise statistics, as these figures can differ based on the population studied, the severity of the lesions, and other factors.\n",
      "\n",
      "In summary, while the exact percentage can vary, pantoprazole is generally effective in promoting the healing of esophageal lesions, with healing rates typically reported in the range of 70% to 90% after 8 weeks of treatment. For the most accurate and specific information, consulting the latest clinical studies or product information is recommended.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.004046\n",
      "prediction:  The percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets can vary based on the specific study or clinical trial being referenced. However, in general, pantoprazole, which is a proton pump inhibitor (PPI), is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and esophagitis caused by acid reflux.\n",
      "\n",
      "In clinical studies, pantoprazole has shown significant efficacy in healing esophageal lesions. For instance, in trials involving patients with erosive esophagitis, the healing rates after 8 weeks of treatment with pantoprazole have been reported to be around 70% to 90%. \n",
      "\n",
      "For example, one study might report that approximately 80% of patients experienced endoscopic healing of their esophageal lesions after 8 weeks of treatment with pantoprazole. However, it is essential to consult specific clinical trial data or product labeling for precise statistics, as these figures can differ based on the population studied, the severity of the lesions, and other factors.\n",
      "\n",
      "In summary, while the exact percentage can vary, pantoprazole is generally effective in promoting the healing of esophageal lesions, with healing rates typically reported in the range of 70% to 90% after 8 weeks of treatment. For the most accurate and specific information, it is advisable to refer to the results of clinical trials or meta-analyses that focus on this treatment.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.004498\n",
      "prediction:  The percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets varies based on specific studies and patient populations. However, it has been observed that pantoprazole, a proton pump inhibitor (PPI), is effective in treating conditions associated with esophageal lesions, such as gastroesophageal reflux disease (GERD) and erosive esophagitis.\n",
      "\n",
      "For example, in a clinical setting, patients treated with pantoprazole have shown significant improvements, with healing rates often reported above 70% within a short duration. In one study, patients with erosive esophagitis showed a healing rate of approximately 81% after 8 weeks of treatment with pantoprazole (PMID: 27109388). \n",
      "\n",
      "Additionally, case studies also highlight the healing efficacy of pantoprazole. For instance, after treatment for adverse effects such as esophagitis induced by other medications, follow-up endoscopies demonstrated successful healing of the lesions after similar treatment durations (PMID: 39452506).\n",
      "\n",
      "In conclusion, while exact percentages can vary, it is reasonable to assert that pantoprazole sodium delayed-release tablets are typically associated with substantial rates of healing esophageal lesions, often exceeding 70%-80% after 8 weeks of therapy.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.028642\n",
      "prediction:  The potential effect of DG Health nasal spray, which contains oxymetazoline, on the growth rate of children aged 4 to 11 years has not been specifically studied in the literature reviewed. The use of nasal sprays in this age group primarily addresses nasal congestion and related symptoms, and while there is limited direct evidence linking nasal decongestants to growth outcomes, indirect impacts may be inferred.\n",
      "\n",
      "1. **Mechanism of Action**: Oxymetazoline is a topical decongestant that works by constricting blood vessels in the nasal passages, leading to reduced swelling and congestion. While effective for symptom relief, its prolonged use can lead to rebound congestion (rhinitis medicamentosa), which complicates nasal breathing and can indirectly affect a child's quality of sleep and overall health by impacting breathing during rest.\n",
      "\n",
      "2. **Related Research**: Some related studies have examined the effects of other nasal treatments, notably intranasal corticosteroids (such as triamcinolone) in children. Research has shown that while these can effectively manage allergic rhinitis and other conditions, concerns have been raised regarding their long-term use and potential implications on growth due to systemic absorption, particularly if used inappropriately or for extended periods (Source: *The Annals of Otology, Rhinology, and Laryngology*).\n",
      "\n",
      "3. **Broader Impacts on Growth**: Growth can be influenced by many factors beyond nasal spray use, including nutrition, overall health, underlying medical conditions, and environmental factors. Chronic nasal obstruction and associated conditions, if left untreated, could potentially contribute to growth issues due to inadequate sleep or poor nutritional intake.\n",
      "\n",
      "4. **Recommendations**: Parents should consult healthcare providers for guidance about appropriate usage of nasal sprays and consider periodic evaluations of any potential side effects, including impacts on growth and development. If allergies or nasal congestion persist, alternative treatments or interventions may be explored under medical guidance.\n",
      "\n",
      "In summary, while DG Health nasal spray can relieve nasal congestion in children, its potential long-term effects on growth rates specifically have not been rigorously explored in available literature. Regular medical supervision is advised for ongoing treatments to monitor any indirect effects on growth and overall health.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02155\n",
      "prediction:  The potential effect of dg health nasal spray on the growth rate of children aged 4 to 11 years can be assessed by considering several factors, including the active ingredients in the nasal spray, its intended use, and any existing research on its effects on pediatric populations.\n",
      "\n",
      "1. **Active Ingredients**: The specific components of dg health nasal spray are crucial in determining its effects. Common ingredients in nasal sprays include saline, corticosteroids, antihistamines, and decongestants. For instance, corticosteroids, while effective for reducing inflammation and treating conditions like allergic rhinitis, have been associated with potential side effects, including growth suppression in children when used long-term or in high doses.\n",
      "\n",
      "2. **Intended Use**: If dg health nasal spray is designed for treating conditions such as allergies, sinusitis, or nasal congestion, its impact on growth would depend on the duration and frequency of use. Short-term use of saline nasal sprays is generally considered safe and unlikely to affect growth. However, prolonged use of corticosteroid nasal sprays may warrant caution, as chronic exposure can lead to systemic absorption and potential growth inhibition.\n",
      "\n",
      "3. **Research Evidence**: Studies on the effects of nasal sprays, particularly corticosteroids, on children's growth have shown mixed results. Some research indicates that while short-term use does not significantly impact growth, long-term use may lead to a reduction in growth velocity. The degree of impact can vary based on the specific medication, dosage, and individual child factors, such as overall health and nutritional status.\n",
      "\n",
      "4. **Monitoring and Guidelines**: Pediatricians often recommend monitoring growth in children who require long-term treatment with nasal sprays, especially those containing corticosteroids. Regular check-ups can help assess growth patterns and ensure that any potential side effects are addressed promptly.\n",
      "\n",
      "5. **Individual Variability**: Each child is unique, and factors such as genetics, overall health, and concurrent medications can influence how a child responds to nasal sprays. Therefore, it is essential for parents and caregivers to consult healthcare professionals regarding the use of dg health nasal spray and its potential effects on growth.\n",
      "\n",
      "6. **Conclusion**: In summary, while dg health nasal spray may be beneficial for treating nasal conditions in children aged 4 to 11 years, its potential effect on growth rate largely depends on its active ingredients, duration of use, and individual child factors. Parents should work closely with healthcare providers to monitor growth and make informed decisions about the use of nasal sprays in their children. Regular assessments and adherence to recommended guidelines can help mitigate any risks associated with long-term use.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.055402\n",
      "prediction:  The primary indication for using laxatives in women, as supported by recent literature, primarily involves the treatment of constipation. Constipation is a common issue that can stem from various factors including dietary habits, hormonal changes, and certain medical conditions. \n",
      "\n",
      "In clinical settings, laxatives serve as a symptomatic treatment option and can be particularly important for women, who may experience constipation more frequently than men due to gastrointestinal motility differences, hormonal fluctuations during menstrual cycles, and pregnancy. Laxatives can aid in alleviating discomfort, promoting regular bowel movements, and preventing complications associated with fecal retention, such as fecal impaction or bowel obstruction.\n",
      "\n",
      "For instance, a case report highlighted the complications that can arise if bowel movements are infrequent, demonstrating the potential severity of untreated constipation (PMID: 41368478). Other studies indicated that laxatives could also be beneficial in managing constipation in specific populations, including elderly women and postpartum patients, where hormonal changes may play a significant role in bowel function.\n",
      "\n",
      "In summary, the primary indication for the use of laxatives among women is to treat constipation, especially given the demographic's unique physiological factors that contribute to increased prevalence of this condition.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Relief of occasional constipation (irregularity)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.191781\n",
      "prediction:  The property of pantoprazole sodium that contributes to its solubility in water relates to its **structural formula**, which determines how effectively it interacts with water molecules.\n",
      "\n",
      "Answer: C\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Its weakly basic and acidic properties\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.063002\n",
      "prediction:  The question pertains to the genotoxic effects of Fluoxetine and its metabolite Norfluoxetine. However, the available resources did not directly provide specific assays that demonstrated their lack of genotoxic effects. Hereâ€™s a general overview based on what is known:\n",
      "\n",
      "Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and its active metabolite Norfluoxetine have been the subject of various toxicological studies. In general, fluoxetine has been evaluated for its potential genotoxic effects using several in vitro and in vivo assays.\n",
      "\n",
      "1. **Ames Test:** This is a common bacterial reverse mutation test used to assess the mutagenic potential of compounds. Some studies have shown that neither Fluoxetine nor Norfluoxetine produced significant mutagenic effects in the Ames test.\n",
      "\n",
      "2. **Micronucleus Test:** This in vivo assay evaluates the potential of a substance to induce chromosomal damage. Research has indicated that both Fluoxetine and Norfluoxetine did not induce micronuclei in rodent models.\n",
      "\n",
      "3. **Comet Assay:** This assay measures DNA strand breaks in individual cells. Studies have suggested that exposure to Fluoxetine and Norfluoxetine does not result in significant DNA damage.\n",
      "\n",
      "Overall, while specific articles detailing these findings were not retrieved in this instance, existing literature suggests that Fluoxetine and Norfluoxetine do not exhibit genotoxic properties in the commonly used assays. For detailed substantiation, further literature searches in specialized toxicology databases or journals may be needed.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.035138\n",
      "prediction:  The recommended action for individuals who become pregnant during therapy with Tybost (cobicistat) coadministered with darunavir or atazanavir involves several critical considerations. These recommendations aim to ensure the health and safety of both the mother and the fetus while maintaining effective HIV management.\n",
      "\n",
      "1. **Continue Antiretroviral Therapy (ART)**: It is generally advised that pregnant women continue their current suppressive ART regimen. This is crucial to prevent mother-to-child transmission of HIV. Studies indicate that maintaining an effective and safe regimen during pregnancy is essential for viral suppression and overall health.\n",
      "\n",
      "2. **Monitoring and Tailoring Treatment**: For individuals with a history of multiclass drug resistance (MDR), adjustments to the treatment plan may be necessary. In cases where components of the treatment pose tolerability or toxicity issues, personalized therapy might need to be employed. This could involve switching to alternative medications that maintain viral suppression without compromising safety.\n",
      "\n",
      "3. **Consultation with Healthcare Providers**: Pregnant individuals should work closely with their healthcare providers to monitor their HIV status and adjust their treatment as needed. This is particularly important for those who may face complications during pregnancy or those who have drug-resistant HIV strains.\n",
      "\n",
      "4. **Delivery Considerations**: In specific cases, such as those involving MDR or other complicating factors, the delivery method may be influenced by the treatment regimen and the health status of the mother. Ensuring that the newborn receives appropriate prophylaxis immediately after birth is also vital to prevent HIV transmission.\n",
      "\n",
      "In summary, the standard recommendation is to continue ART, closely monitor the therapy's effectiveness, and adjust as necessary, while consulting healthcare professionals for tailored care strategies during pregnancy. This collaborative approach aims to safeguard the health of both mother and child throughout the pregnancy and beyond.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Switch to an alternative regimen\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.02347\n",
      "prediction:  The recommended amount of hydrocortisone shampoo to use during application can vary based on the specific product and the guidance of healthcare providers. However, common instructions suggest the following:\n",
      "\n",
      "1. **Application**: Generally, a small amount (such as a few teaspoons, or enough to cover the affected area) is applied to the scalp, chest, back, or other areas as prescribed.\n",
      "2. **Usage Frequency**: It is typically recommended to use medicated shampoos like hydrocortisone shampoo as directed by a healthcare professional, often a few times a week.\n",
      "3. **Technique**: The shampoo should be applied directly to the affected areas of the scalp or skin and gently massaged in. After allowing it to sit for a few minutes, it should be rinsed thoroughly.\n",
      "\n",
      "For specific product details and a precise dosage, referring to the package instructions or the prescribing doctor's guidelines is essential. You can also find more detailed information about hydrocortisone shampoo [here](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51dde4fa-88d7-19cd-e054-00144ff88e88). Always consult with a healthcare provider for personalized advice based on individual health needs.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.041935\n",
      "prediction:  The recommended amount of hydrocortisone shampoo to use during application is typically a small amount sufficient to cover the affected area of the scalp. Generally, it is suggested to apply about 1-2 teaspoons of the shampoo directly onto the scalp, then massage it gently into the skin. \n",
      "\n",
      "The shampoo is usually left on for a certain duration, often around 10-15 minutes, before rinsing it out with water. It is essential to follow specific product instructions and consult a healthcare professional for personalized recommendations, especially if there are specific conditions or sensitivities involved.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A moderate amount\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.057088\n",
      "prediction:  The recommended approach for dose adjustment of Signifor LAR (pasireotide) in patients with moderately impaired hepatic function (Child-Pugh B) is as follows:\n",
      "\n",
      "1. **Acromegaly**:\n",
      "   - **Initial Dose**: 20 mg administered by intramuscular injection once every 4 weeks.\n",
      "   - **Maximum Recommended Dose**: 40 mg once every 4 weeks.\n",
      "\n",
      "2. **Cushing's Disease**:\n",
      "   - **Initial Dose**: 10 mg administered by intramuscular injection once every 4 weeks.\n",
      "   - **Maximum Recommended Dose**: 20 mg once every 4 weeks.\n",
      "\n",
      "It's important to note that in patients with severe hepatic impairment (Child-Pugh C), Signifor LAR is not recommended. Continuous monitoring of liver function is also advised during treatment. Regular assessments need to be conducted to evaluate liver enzyme levels and other parameters that may be affected by the medication. \n",
      "\n",
      "For further detailed information, please refer to the [Signifor LAR Prescribing Information](https://anovorx.com/wp-content/uploads/2023/08/SIGNIFOR-LAR-Prescribing-Information.pdf).\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Dose adjustment is required.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.053239\n",
      "prediction:  The recommended dosage for laxatives in children aged 6 to under 12 years can vary based on the specific type of laxative being used. Here are some general guidelines:\n",
      "\n",
      "1. **Bulk-Forming Laxatives**: For children aged 6 to under 12 years, the typical starting dose may be around 1/2 tablet of a product containing sennosides once daily. The maximum dosage can be increased to 1 tablet twice a day as needed, but it is important not to exceed this without consulting a healthcare provider.\n",
      "\n",
      "2. **Stimulant Laxatives**: For stimulant laxatives, dosages will also depend on the product. For example, sennosides may be dosed at 12.5â€“25 mg three times a day. \n",
      "\n",
      "3. **Osmotic Laxatives**: If using products such as magnesium citrate, the dosage may be around 195 to 300 ml with a full glass of water.\n",
      "\n",
      "Always ensure that any laxative is used as directed, and it is crucial to advise consulting a pediatrician before beginning any laxative treatment for a child, particularly for long-term use or higher dosages. Parents should monitor the childâ€™s response and adjust as necessary under medical guidance.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.040984\n",
      "prediction:  The recommended dosage for laxatives in children aged 6 to under 12 years can vary depending on the specific type of laxative being used. Here's a general overview based on available guidelines:\n",
      "\n",
      "1. **Bulk-forming laxatives**: For children aged 6 to 12 years, the typical dosage can be around 500 mg (1 caplet) taken 1 to 6 times daily. It's important to start with the lowest dose and adjust as needed based on the child's response.\n",
      "\n",
      "2. **Stimulant laxatives**: These are generally not recommended for regular use in children but may be prescribed under specific circumstances. Dosage should be determined by a healthcare provider.\n",
      "\n",
      "3. **Osmotic laxatives**: For osmotic agents like polyethylene glycol, the dosage might be dose-dependent on the child's condition and specific product recommendations, usually around 0.5 to 1 g/kg/day.\n",
      "\n",
      "Before administering any laxative to a child, especially in this age group, it is crucial to consult a healthcare professional to ensure safety and appropriateness based on the child's individual health needs. \n",
      "\n",
      "For further details and specific brands, consulting reliable sources such as children's hospitals or pediatric care websites is advisable.\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.061433\n",
      "prediction:  The recommended dosage for laxatives in children aged 6 to under 12 years varies depending on the specific drug and its formulation. Commonly used laxatives include Milk of Magnesia and MiraLAX.\n",
      "\n",
      "1. **Milk of Magnesia**: For children aged 6 to 11 years, the typical dosage is:\n",
      "   - **15 mL** up to twice daily for a maximum of 2 days.\n",
      "\n",
      "2. **MiraLAX**: The dosing can vary based on the specific treatment plan, but an example dosage for maintaining bowel regularity might be:\n",
      "   - For children aged 6 to under 12 years: Typically, 1 capful (17 grams) of MiraLAX dissolved in at least 8 oz. of liquid daily, after an initial clean-out dose.\n",
      "\n",
      "3. **Saline Laxatives**: For chewable tablet formulations, the dosage for children aged 6 to under 12 years is generally:\n",
      "   - **3 to 6 tablets**, which can be taken as a single daily dose or divided doses, accompanied by a full glass (8 ounces) of liquid.\n",
      "\n",
      "Itâ€™s important to consult with a healthcare professional to determine the most appropriate laxative and dosage based on the child's specific needs, medical history, and any existing conditions. Always follow medical advice for treatment.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.061555\n",
      "prediction:  The recommended dosage of Belladonna (also known as Atropa belladonna) for children aged 2 to 12 years varies significantly based on the specific condition being treated, as well as the child's age, weight, and individual response to the medication.\n",
      "\n",
      "1. **Homeopathic Dosages**: In homeopathic practices, Belladonna may be administered in potencies ranging from 6X to 12C. However, it is crucial that this is done under the guidance of a qualified homeopath, as these doses are tailored to individual symptoms.\n",
      "\n",
      "2. **Toxicity Concerns**: Belladonna is known to contain tropane alkaloids, including atropine, scopolamine, and hyoscyamine, which can be highly toxic. There is a general caution in using it, especially in children, due to the severity of side effects which can include delirium, hallucinations, and other serious health issues if overdosed.\n",
      "\n",
      "3. **Maximum Dosage Guidelines**: While specific dosage guidelines for children are not universally established, caution is advised:\n",
      "\n",
      "   - The American Herbal Pharmacopoeia notes the potential for Belladonna's use in pediatric populations, but stresses that proper dosing and monitoring must be maintained.\n",
      "\n",
      "4. **Consult Healthcare Professionals**: Given the potential risks associated with Belladonna, it is recommended that any use in children under 12 should only be done following explicit guidance from a medical professional familiar with the child's health history and specific needs.\n",
      "\n",
      "In conclusion, due to the associated risks and variability in dosing based on individual circumstances, parents and guardians should seek professional medical advice before administering Belladonna to children aged 2 to 12 years. It is crucial to prioritize safety and informed decision-making surrounding the use of such potent herbal remedies.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 5 drops mixed with half a cup of water, 3-4 times per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.023689\n",
      "prediction:  The recommended frequency of nicotine lozenge usage during Weeks 7 to 9 of a typical 12-week smoking cessation program can vary based on individual needs and the specific guidelines provided by healthcare professionals. However, general recommendations for nicotine replacement therapy (NRT) such as nicotine lozenges can be outlined as follows:\n",
      "\n",
      "1. **Dosage and Frequency**: During Weeks 7 to 9, users are typically advised to gradually reduce their nicotine intake. For those using a 2 mg lozenge, the general recommendation is to use 1 lozenge every 1 to 2 hours, while for the 4 mg lozenge, it may be similar, but the exact frequency can depend on the individual's level of dependence and cravings.\n",
      "\n",
      "2. **Total Daily Limit**: It is important to adhere to the maximum daily limit of lozenges. For example, the maximum recommended usage is often around 20 lozenges per day. This limit helps prevent potential side effects associated with excessive nicotine intake.\n",
      "\n",
      "3. **Gradual Reduction**: The goal during Weeks 7 to 9 is to continue tapering off nicotine. If a user has been using the lozenges frequently in the earlier weeks, they should aim to reduce the number of lozenges used as cravings decrease. This might mean moving from using a lozenge every hour to every 1.5 to 2 hours, depending on individual comfort and cravings.\n",
      "\n",
      "4. **Listening to the Body**: Users should pay attention to their cravings and use the lozenges as needed, but also be mindful of not becoming overly reliant on them. If cravings are manageable, it may be beneficial to reduce usage further.\n",
      "\n",
      "5. **Consultation with Healthcare Providers**: It is always advisable for individuals to consult with healthcare providers for personalized recommendations based on their smoking history, dependence level, and any other health considerations.\n",
      "\n",
      "6. **Behavioral Support**: Alongside the use of nicotine lozenges, incorporating behavioral support and counseling can significantly enhance the chances of successfully quitting smoking.\n",
      "\n",
      "In summary, during Weeks 7 to 9, the focus should be on gradually reducing the frequency of nicotine lozenge use while managing cravings effectively, with a typical recommendation of 1 lozenge every 1 to 2 hours, not exceeding the daily limit, and adjusting based on individual needs and guidance from healthcare professionals.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 1 lozenge every 2 to 4 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.181818\n",
      "prediction:  The recommended storage temperature range for DG Health Nasal is \"store at 20-25 Â°C (68-77 Â°F)\". \n",
      "\n",
      "The correct answer is: D\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Between 4Â°C and 30Â°C\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.012834\n",
      "prediction:  The recommended storage temperature range for sterile drugs generally falls between 36Â°F to 46Â°F (2Â°C to 8Â°C) for refrigeration, as indicated by various standards for pharmaceutical storage. This is crucial to maintain the stability and efficacy of many injectable medications and biologics. \n",
      "\n",
      "Room temperature conditions, often considered to be between 68Â°F to 77Â°F (20Â°C to 25Â°C), are also commonly acceptable for many medications when refrigeration is not required. However, adherence to specific manufacturer guidelines, as well as guidelines from organizations like the FDA and USP, is essential to prevent drug degradation.\n",
      "\n",
      "For instance, a PubMed article discusses the physicochemical and microbiological stability of drugs stored under refrigerated conditions compared to room temperature and elevated temperatures, illustrating the importance of these ranges in maintaining drug integrity and safety [PMID: 38782645].\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 59 - 86Â°F\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.007658\n",
      "prediction:  The recommended storage temperature range for sterile medications typically depends on various factors including the specific drug and its stability requirements. However, general guidelines for sterile storage as per various authoritative sources are as follows:\n",
      "\n",
      "1. **General Guidelines**: The Joint Commission and ASHRAE suggest a maximum temperature of **78Â°F (26Â°C)** for sterile medical supplies. Some resources indicate a range of **72Â°F to 78Â°F** for sterile storage, focusing on maintaining stable temperature and humidity conditions to ensure the integrity of the products.\n",
      "\n",
      "2. **USP Standards**: The United States Pharmacopeia (USP) outlines good practices for drug storage which include specific temperature requirements. For most sterile products requiring refrigeration, the temperatures should be maintained between **36Â°F to 46Â°F (2Â°C to 8Â°C)** to ensure stability and efficacy.\n",
      "\n",
      "3. **Environmental Control**: It's crucial to monitor and control environmental factors, including temperature and humidity, as stipulated by standards such as the ASHRAE 170, which sets a maximum relative humidity of **60%** and emphasizes maintaining set temperature ranges for sterile storage facilities.\n",
      "\n",
      "In summary, while the exact temperature can vary by specific medication, sterile drugs are often stored within the ranges of **72Â°F to 78Â°F** for ambient conditions, and **36Â°F to 46Â°F** for those requiring refrigeration. Always refer to the manufacturer's labeling for precise storage recommendations as these can differ based on formulation specifics.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 59 - 86Â°F\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.052336\n",
      "prediction:  The search did not yield specific information on the symptoms relieved by 'nighttime severe cold and flu' medications. However, typical symptoms that such medications aim to alleviate include cough, sore throat, nasal congestion, fever, and runny nose. \n",
      "\n",
      "To determine which symptom is NOT mentioned as being relieved, we can infer that generally, symptoms like fatigue or muscle aches might be common but not explicitly treated by such medications. \n",
      "\n",
      "Thus, an appropriate answer to your question would be:\n",
      "\n",
      "**Fatigue**.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.014388\n",
      "prediction:  The search did not yield specific information regarding the percentage of lamotrigine removed during a 4-hour hemodialysis session in renal failure patients. However, based on known pharmacological information, lamotrigine is not highly removed by hemodialysis.\n",
      "\n",
      "Common reports suggest that approximately 10% of lamotrigine is typically removed by hemodialysis. Based on this information, I will choose:\n",
      "\n",
      "Answer: A\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 20%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.032086\n",
      "prediction:  The search did not yield specific results regarding the recommended dosage of vaginal essential oil for preventing repeated cross-infection during menstruation. However, the use of essential oils in this context is generally guided by principles of aromatherapy and clinical recommendations.\n",
      "\n",
      "Essential oils used vaginally must be diluted properlyâ€”typically in a carrier oilâ€”due to their potency and potential for irritation. While specific dosages are not universally established, here are some recommendations that can be considered based on general practices with essential oils:\n",
      "\n",
      "1. **Dilution**: Essential oils should be diluted to a safe concentration before use. Common guidance suggests a dilution of 1-2% for topical applications, which translates to about 1-2 drops of essential oil per teaspoon of carrier oil.\n",
      "\n",
      "2. **Types of Essential Oils**: Some essential oils considered for their antimicrobial properties include tea tree oil, lavender oil, and thyme oil. However, itâ€™s crucial to ensure that the essential oil is safe for vaginal use.\n",
      "\n",
      "3. **Application Timing**: For menstrual care, some individuals might apply diluted essential oils to the lower abdomen to help alleviate cramps or discomfort during menstruation rather than applying directly in the vaginal area.\n",
      "\n",
      "4. **Consultation with Healthcare Providers**: Because of the sensitive nature of vaginal use, it is advisable to consult healthcare providers, especially to discuss potential allergic reactions or contraindications.\n",
      "\n",
      "5. **Safety and Hygiene**: Essential oils should not replace medical treatments for infections. If cross-infection is a concern, it is important to follow hygienic practices and consult a healthcare professional for necessary treatments.\n",
      "\n",
      "In conclusion, while thereâ€™s no standardized dosage specifically for preventing repeated cross-infection during menstruation, the general practice involves proper dilution, careful selection of essential oils, and consultation with a healthcare provider for personalized advice.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.042885\n",
      "prediction:  The search for clinical studies regarding the effects of venlafaxine on suicidality risk revealed that while it is primarily used to treat depression, there are specific age groups that may benefit differently from its use compared to placebo.\n",
      "\n",
      "Based on the meta-analysis from multiple randomized clinical trials included in the research, venlafaxine was shown to have a statistically significant impact on reducing suicidality risk in adults, particularly among individuals aged 18 to 24. This age group showed a marked reduction in suicidality compared to those receiving a placebo, indicating that younger adults may experience an improved safety profile regarding suicidal thoughts and behaviors when treated with venlafaxine.\n",
      "\n",
      "However, it's essential to note that results can vary based on other factors, including individual health conditions and concurrent treatments. Ongoing monitoring and evaluation are crucial for individuals of all age groups undergoing treatment with antidepressants.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.094787\n",
      "prediction:  The search for specific mutagenicity tests involving levalbuterol HCl did not yield any direct results in PubMed or DuckDuckGo. As such, I cannot determine the correct answer based solely on the available information.\n",
      "\n",
      "However, based on general knowledge, the Ames test (C) is a well-known test for mutagenicity. If levalbuterol HCl was tested in all mentioned methods and found to not be mutagenic in any, then D (All of the above) would be the correct choice.\n",
      "\n",
      "Since I do not have definitive evidence for one of the tests being specifically mentioned in a study, I conclude:\n",
      "\n",
      "Answer: D\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: All of the above\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.038559\n",
      "prediction:  The specific abuse liability profile of venlafaxine in primate drug discrimination studies is not extensively documented in the literature, and searches reveal limited direct studies on this topic. However, some general insights can be inferred from what is known about venlafaxine and how it is classified in pharmacological contexts.\n",
      "\n",
      "Venlafaxine is an antidepressant that functions primarily as a serotonin-norepinephrine reuptake inhibitor (SNRI). It is often prescribed for major depressive disorder and anxiety disorders. While it is not classified as a controlled substance and is generally considered to have a low potential for abuse compared to other stimulant drugs, some reports suggest that it can lead to dependence in certain individuals, particularly when taken in higher doses or when there is a history of substance use disorder.\n",
      "\n",
      "In terms of drug discrimination studies, these are designed to test whether a subject can distinguish between the effects of a drug versus a placebo or a different drug, which serves to assess the potential for abuse and the subjective effects of substances. Though specific primate studies on venlafaxine may be lacking, studies involving other SNRIs and various conditions potentially involving positive reinforcement have indicated that certain antidepressants can produce discriminative stimuli that might mimic mild stimulant qualities under specific conditions. \n",
      "\n",
      "Overall, while venlafaxine appears to possess a low abuse liability in most assessments, the presence of individual variability means that some users could develop a psychological dependence. Therefore, healthcare providers typically monitor patients for signs of misuse, especially in those with prior substance abuse histories.\n",
      "  \n",
      "For detailed and more specific findings, accessing dedicated pharmacology journal articles or comprehensive meta-analyses regarding venlafaxine would be beneficial when available.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: No significant stimulant or depressant abuse liability\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.025362\n",
      "prediction:  The specific animal model in which albuterol sulfate (also known as salbutamol) showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg is not explicitly found in the literature or readily available resources. Current research suggests that such assessments often utilize rodent models, particularly rats and mice, to evaluate the long-term safety of drugs like albuterol sulfate.\n",
      "\n",
      "To answer questions about specific studies, particularly those concerning tumorigenicity, one would typically reference formal reports, such as those from toxicology studies, which detail the findings on potential carcinogenic effects. Such studies are often published in scientific journals but may not always be easily accessible.\n",
      "\n",
      "For definitive information, it's advisable to look into dedicated toxicology databases or publications specifically focused on animal testing and drug safety evaluations. If you are interested in more detailed or specific findings, it would be useful to access scientific literature through platforms like PubMed or specific pharmaceutical safety reports.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: CD-1 mice\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.02832\n",
      "prediction:  The specific effects of DG Health nasal spray on the growth rate of children aged 4 to 11 years are not well-documented in the available literature or online resources. DG Health nasal spray contains oxymetazoline hydrochloride, which is a topical decongestant primarily used for relieving nasal congestion associated with colds, allergies, and sinusitis. \n",
      "\n",
      "**Potential Effects:**\n",
      "1. **Growth Rate Impact**: There is limited evidence directly linking the use of topical nasal sprays like oxymetazoline with growth rate modulation in children. While oxymetazoline is generally regarded as safe for short-term use in children, chronic use may carry risks. Long-term use of any medication in children can have unintended consequences, including potential hormonal effects, although specific studies on oxymetazoline and growth are lacking.\n",
      "\n",
      "2. **Age-Specific Considerations**: In children, medications that affect the mucus membranes often come with guidelines for age and dosage based on safety profiles established through clinical trials. Parents should use medications like nasal sprays judiciously, ensuring they are appropriate for their child's age and health status.\n",
      "\n",
      "3. **Adverse Effects**: Frequent or inappropriate use of nasal decongestants can lead to rebound congestion or rhinitis medicamentosa, which, while not directly affecting growth, could impact overall well-being and health status, possibly leading to other health issues that could indirectly affect growth.\n",
      "\n",
      "4. **Medical Advice**: It is always advisable for parents to consult a pediatrician before administering any new medication, including nasal sprays, to understand the potential benefits and risks specific to their child's health.\n",
      "\n",
      "In conclusion, while DG Health nasal spray is used to alleviate nasal congestion, there is insufficient evidence to determine its impact on the growth rate of children aged 4 to 11 years specifically. Parents should be cautious with its use and consult healthcare providers for personalized advice.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: It may slow down growth rate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.036934\n",
      "prediction:  The starting regimen for pantoprazole sodium for injection in patients with Zollinger-Ellison Syndrome, which is characterized by pathological gastric acid hypersecretion, typically begins with a dosage of **40 mg once daily** by intravenous injection. This dose can be given as a bolus injection over at least 2 minutes. \n",
      "\n",
      "In certain cases, the dosage may be adjusted higher depending on the patient's individual acid secretion levels, with some protocols recommending doses of up to 120 mg daily for those requiring more aggressive suppression of gastric acid secretion. Itâ€™s important to monitor the patient's response and adjust as necessary to control gastric acidity effectively.\n",
      "\n",
      "This regimen is indicated in adults for the management of conditions like Zollinger-Ellison Syndrome, where the goal is to limit gastric acid output and aid in symptom management. \n",
      "\n",
      "For detailed information regarding the safe use and administration of pantoprazole, practitioners refer to the prescribing information and clinical guidelines relevant to specific patient cases.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 80 mg every 12 hours\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.030581\n",
      "prediction:  The storage conditions for 'up and up nighttime cold and flu' medications are important for maintaining their efficacy and safety. Typically, over-the-counter medications like this one should be stored at room temperature, away from moisture and heat, and kept out of reach of children.\n",
      "\n",
      "However, the specifics can vary by formulation and brand. For instance, 'up and up daytime cold and flu' products should not be stored in excessively humid locations, such as bathrooms. Additionally, it is crucial not to freeze these medications.\n",
      "\n",
      "If you encounter storage conditions that suggest refrigeration or exposure to direct sunlight, these would likely be incorrect for this type of medication.\n",
      "\n",
      "To summarize, one of the following could be considered NOT a correct storage condition:\n",
      "- **Storing in a freezer** (which can deterioration the medication).\n",
      "\n",
      "If you have specific conditions listed in your options, please let me know to identify which one is incorrect.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.054245\n",
      "prediction:  The suggested water temperature for a sitz bath typically ranges from warm to comfortably hot, but it is essential not to exceed 100Â°F (37.8Â°C) for safety. This temperature helps to relax the pelvic muscles and can provide soothing relief, especially when combined with vaginal essential oils. \n",
      "\n",
      "Common recommendations include adding 3-5 drops of essential oil to the warm water, stirring it well before using the sitz bath for about 10-15 minutes. Care should be taken to ensure that the water isnâ€™t too hot to avoid burns, especially for sensitive areas. Always start with a comfortable temperature, which can be adjusted to personal preference within safe limits. \n",
      "\n",
      "For anyone pregnant or with specific medical conditions, it is advisable to consult a healthcare provider before using essential oils in a sitz bath.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: About 40 degrees Celsius.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.031104\n",
      "prediction:  The term \"70% drug\" does not appear to be a specific drug name or widely recognized brand in medical literature. It could refer to a concentration of a particular medication or solution, but it does not correspond to a standalone drug. \n",
      "\n",
      "In general, drug naming conventions can lead to confusion, and various substances may be labeled according to their active ingredient concentration. For example, some pharmaceutical products are represented by their concentration, such as \"70% ethanol\" for antiseptic use.\n",
      "\n",
      "However, based on the search, it's more likely that the term could refer to protocols or studies that involve medications at a certain strength or dose, rather than a specific branded drug. Clinical trials show that drugs often undergo various condition-specific trials, yet not all trials or findings relate directly to a drug branded with a numeric value like \"70%\".\n",
      "\n",
      "For detailed information on specific medications or ongoing clinical trials, referring to official databases or publications would be necessary. This would provide better insights into how, or if, a drug with such a name is utilized in clinical practice.\n",
      "\n",
      "If you are seeking specific information on a drug or concentration, please provide additional context or clarify your query!\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.038745\n",
      "prediction:  The term \"branded as 70%\" is quite ambiguous as it doesn't directly relate to a specific drug name or class in common medical terminology. It might imply a branded medication that is recognized for costing 70% less compared to other medications or possibly a concentration of an active ingredient. \n",
      "\n",
      "After conducting a search, I did not find a specific drug by the name or brand of \"70%.\" However, this might refer to various medications in the context of generic drugs, where generics often cost significantly less than their branded counterparts (about 70-90% less). This is common in the pharmaceutical industry whereby generics provide the same efficacy but at a reduced price. \n",
      "\n",
      "Additionally, there may be potential implications for drugs with specific concentrations (e.g., 70% ethanol for disinfectants), but these would require more specific context to accurately detail.\n",
      "\n",
      "If you meant a particular drug or type of medication that is recognized as \"70%\", please provide additional details or clarify your query, and I'll be happy to assist you further!\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.023145\n",
      "prediction:  The term \"drug branded as 70%\" does not appear to refer to a specific pharmaceutical product based on available information. However, the mention of \"70%\" may denote a concentration or formulation of a drug rather than a branded name. \n",
      "\n",
      "In medicine, medications are typically classified based on their therapeutic use, chemical structure, or pharmacological effects. Common drug concentrations include solutions (like antiseptics) or particular formulations used in specific treatments; for example, some alcohol solutions (70% isopropyl alcohol) are used as antiseptics.\n",
      "\n",
      "A systematic search did not yield relevant results specifically linking the phrase \"branded as 70%\" to a known medication; however, several clinical trials were noted that include various drugs and conditions. For example:\n",
      "\n",
      "1. **NCT01490450**: This study focused on a dose-ranging study for a drug aimed at treating psoriatic arthritis in patients unresponsive to NSAIDs or other treatments.\n",
      "2. **NCT04847674**: Investigated a medication for asthma relief, but the trial was terminated.\n",
      "3. **NCT01287897**: Assessed the efficacy of a drug for Crohn's disease in patients failing anti-TNF therapy.\n",
      "\n",
      "Each of these points suggests that \"70%\" could refer to either a specific treatment context or concentration, rather than a specific branded drug. For more precise identification, further clarification or details about the context in which \"70%\" is used would be beneficial.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.00311\n",
      "prediction:  The term \"general body cleansing processes\" can refer to various types of detoxification or cleansing regimens, and there are several products marketed for this purpose. However, one of the most commonly recognized brand names associated with body cleansing is **\"Colon Cleanse\"** or **\"Colon Cleanse Products.\"** These products often contain a combination of natural ingredients, such as fiber, herbs, and probiotics, aimed at promoting digestive health and regularity.\n",
      "\n",
      "Another notable brand is **\"Detoxify,\"** which offers a range of detox products, including herbal cleanses and detox drinks designed to support the body's natural detoxification processes.\n",
      "\n",
      "It's important to note that the effectiveness and necessity of such cleansing products are subjects of debate within the medical community. Many healthcare professionals emphasize that the body has its own efficient detoxification systems, primarily through the liver, kidneys, and digestive system, and that a balanced diet and healthy lifestyle are typically sufficient for maintaining overall health.\n",
      "\n",
      "If you are considering using a cleansing product, it is advisable to consult with a healthcare provider to ensure it is appropriate for your individual health needs and to discuss any potential risks or benefits.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.003084\n",
      "prediction:  The term \"general body cleansing processes\" can refer to various types of detoxification or cleansing regimens, and there are several products marketed for this purpose. However, one of the most commonly recognized brand names associated with body cleansing is **\"Colon Cleanse\"** or **\"Colon Cleanse Products.\"** These products often contain a combination of natural ingredients, such as fiber, herbs, and probiotics, aimed at promoting digestive health and regularity.\n",
      "\n",
      "Another notable brand is **\"Detoxify,\"** which offers a range of detox products, including herbal supplements designed to support the body's natural detoxification processes. Additionally, **\"Herbalife\"** and **\"Isagenix\"** are brands that provide meal replacement shakes and detox programs that are often marketed for body cleansing.\n",
      "\n",
      "It's important to note that while these products are popular, the scientific evidence supporting the efficacy of many detox or cleansing products is limited. The human body has its own highly effective detoxification systems, primarily through the liver, kidneys, and digestive system. Therefore, before starting any cleansing regimen or using such products, it is advisable to consult with a healthcare professional to ensure safety and appropriateness for individual health needs.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.003067\n",
      "prediction:  The term \"general body cleansing processes\" can refer to various types of detoxification or cleansing regimens, and there are several products marketed for this purpose. However, one of the most commonly recognized brand names associated with body cleansing is **\"Colon Cleanse\"** or **\"Colon Cleanse Products.\"** These products often contain a combination of natural ingredients, such as fiber, herbs, and probiotics, aimed at promoting digestive health and regularity.\n",
      "\n",
      "Another notable brand is **\"Detoxify,\"** which offers a range of detox products, including those designed to cleanse the body of toxins, particularly in preparation for drug testing or to support liver health.\n",
      "\n",
      "It's important to note that the effectiveness and safety of these cleansing products can vary widely, and many health professionals advise caution when using them. The body has its own natural detoxification systems, primarily through the liver, kidneys, and digestive system. Therefore, before starting any cleansing regimen, it is advisable to consult with a healthcare provider to ensure it is appropriate for individual health needs and conditions. \n",
      "\n",
      "In summary, while there are several brands associated with body cleansing, \"Colon Cleanse\" and \"Detoxify\" are among the more recognized names in this category.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.11463\n",
      "prediction:  The true statement regarding JAYPIRCA (pirtobrutinib) and its effect on CYP3A substrates is that JAYPIRCA increases the area under the curve (AUC) and maximum concentration (Cmax) of orally administered midazolam, a sensitive CYP3A substrate, by 70% and 58%, respectively. However, it does not have a clinically meaningful effect on the exposure of intravenously administered midazolam. \n",
      "\n",
      "This indicates that JAYPIRCA can significantly alter the pharmacokinetics of drugs metabolized by CYP3A, which may necessitate careful monitoring and possible dose adjustments for such substrates when co-administered with JAYPIRCA.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.050125\n",
      "prediction:  The updated label claim for a drug branded as \"sterile\" generally refers to its assurance of sterility, meaning that the product is free from viable pathogens. This claim is critical, particularly for injectable medications and other products that must be administered in a manner where contamination could introduce serious health risks. \n",
      "\n",
      "In recent years, regulatory standards around the production of sterile drugs have intensified. The U.S. FDA, as part of its oversight, focuses on ensuring that drugs labeled as sterile meet stringent manufacturing and quality control processes. The key updates often include:\n",
      "\n",
      "1. **Enhanced Sterility Assurance**: Manufacturers must provide clear evidence that their sterile processes prevent contamination. This includes rigorous testing and validation of sterilization methods.\n",
      "\n",
      "2. **Labeling Requirements**: Updated regulations also dictate that the labeling of sterile drugs must accurately reflect their sterility assurance and include necessary warnings regarding potential contamination risks, especially for compounded formulations.\n",
      "\n",
      "3. **Post-Market Surveillance**: The FDA can now enforce more stringent monitoring of sterile drugs post-market, particularly following incidents of contamination that have led to public health crises.\n",
      "\n",
      "Overall, to maintain compliance with regulatory standards, companies must continually update their label claims to reflect their adherence to these practices, ensuring that healthcare providers and patients can trust the sterility of their medications.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: It is used for preparation of the skin prior to injection.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.05\n",
      "prediction:  The updated label claim for the drug brand name 'sterile' generally reflects a focus on ensuring the product's sterility and safety standards, as dictated by relevant regulations. \n",
      "\n",
      "1. **Overview of Regulations**: The regulatory landscape for sterile drugs has evolved, especially after incidents involving poorly compounded sterile medications that caused serious health issues. Notably, the Drug Quality and Security Act (DQSA) of 2013 enhanced the FDA's authority to regulate compounded sterile drugs. This act allows for increased oversight to prevent contamination and ensure compliance with sterility standards.\n",
      "\n",
      "2. **Labeling Requirements**: Updated labeling for 'sterile' drugs typically includes comprehensive information about the preparation process, storage conditions, and the specific sterility assurance measures. Labels might now emphasize that the products must meet established sterility testing procedures, as per FDA requirements, which aim to protect patients by ensuring that sterile drugs are free from viable microorganisms.\n",
      "\n",
      "3. **Compounded Sterile Drugs**: For compounded drugs, particularly those labeled as 'sterile', the FDA encourages pharmacists and manufacturers to adhere to stringent guidelines that necessitate environmental controls and sterile techniques throughout the compounding process. The updated labels often highlight the importance of using aseptic techniques to maintain sterility and provide clear guidance on use and handling.\n",
      "\n",
      "4. **Impact on Patients**: The revised label claims not only serve as a regulatory compliance tool but also help inform patients and healthcare providers about the safety and handling of sterile products. This reflects a commitment to improving safety measures in response to past incidents related to compounded sterile medications.\n",
      "\n",
      "In summary, the updated label claims regarding 'sterile' drugs emphasize stringent adherence to safety and sterility protocols, reflecting ongoing efforts by regulatory bodies to protect public health and ensure the quality of compounded medications.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: It is used for preparation of the skin prior to injection.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020841\n",
      "prediction:  The use of essential oils for vaginal health, including the prevention of repeated cross-infection during menstruation, is a topic that requires careful consideration. However, it is important to note that there is limited scientific evidence supporting the efficacy and safety of using essential oils in the vaginal area, and specific dosage recommendations are not well-established in clinical guidelines.\n",
      "\n",
      "### General Considerations:\n",
      "\n",
      "1. **Essential Oil Selection**: If considering the use of essential oils, it is crucial to choose oils that are known for their antimicrobial properties. Commonly suggested oils include tea tree oil, lavender oil, and oregano oil. However, each oil has its own profile of benefits and potential side effects.\n",
      "\n",
      "2. **Dilution**: Essential oils are highly concentrated and should never be used undiluted. A common recommendation for topical application is to dilute essential oils in a carrier oil (such as coconut oil, almond oil, or jojoba oil) at a ratio of 1-2 drops of essential oil per teaspoon of carrier oil. This dilution helps to minimize irritation and adverse reactions.\n",
      "\n",
      "3. **Application Method**: For vaginal use, it is advisable to apply the diluted essential oil externally rather than internally. This can be done by applying the mixture to the vulva or the surrounding area. Inserting essential oils directly into the vagina is generally not recommended due to the risk of irritation and disruption of the natural vaginal flora.\n",
      "\n",
      "4. **Frequency of Use**: If using essential oils during menstruation, it may be appropriate to apply the diluted mixture once or twice a day, depending on individual sensitivity and response. Monitoring for any signs of irritation or allergic reaction is essential.\n",
      "\n",
      "5. **Consultation with Healthcare Providers**: Before using essential oils for any health-related purpose, it is crucial to consult with a healthcare provider, especially for individuals with pre-existing conditions, those who are pregnant, or those who are taking other medications. A healthcare provider can offer personalized advice and ensure that the use of essential oils is safe and appropriate.\n",
      "\n",
      "6. **Alternative Approaches**: In addition to essential oils, maintaining good hygiene practices during menstruation, such as regular changing of menstrual products, using breathable materials, and avoiding douching, can help prevent infections.\n",
      "\n",
      "### Conclusion:\n",
      "\n",
      "While essential oils may offer some benefits, their use in the vaginal area should be approached with caution. There is no standardized dosage for vaginal essential oils, and individual responses can vary significantly. Always prioritize safety and consult with a healthcare professional before starting any new treatment regimen.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.019672\n",
      "prediction:  The use of essential oils for vaginal health, including the prevention of repeated cross-infection during menstruation, is a topic that requires careful consideration. However, it is important to note that there is limited scientific evidence supporting the efficacy and safety of using essential oils in the vaginal area. Therefore, any recommendations regarding dosage should be approached with caution.\n",
      "\n",
      "### General Guidelines for Essential Oils\n",
      "\n",
      "1. **Dilution**: Essential oils are highly concentrated and should never be used undiluted. A common recommendation is to dilute essential oils in a carrier oil (such as coconut oil, almond oil, or jojoba oil) at a ratio of 1-2 drops of essential oil per teaspoon of carrier oil. This dilution helps to minimize the risk of irritation or adverse reactions.\n",
      "\n",
      "2. **Application Method**: If using essential oils for vaginal health, it is advisable to apply the diluted mixture externally rather than internally. This can be done by applying the mixture to the vulva or the surrounding area, rather than inserting it into the vagina.\n",
      "\n",
      "3. **Frequency of Use**: For general maintenance, using the diluted essential oil mixture 1-2 times a week may be sufficient. During menstruation, some individuals may choose to apply it more frequently, but this should be based on personal comfort and tolerance.\n",
      "\n",
      "### Recommended Essential Oils\n",
      "\n",
      "Some essential oils that are often cited for their potential antimicrobial and antifungal properties include:\n",
      "\n",
      "- **Tea Tree Oil**: Known for its antifungal and antibacterial properties, tea tree oil is often used in various health applications. However, it should be used with caution and always diluted.\n",
      "  \n",
      "- **Lavender Oil**: Lavender is known for its calming properties and may also have some antimicrobial effects.\n",
      "\n",
      "- **Oregano Oil**: Oregano oil has strong antimicrobial properties but should be used very cautiously due to its potency.\n",
      "\n",
      "### Precautions\n",
      "\n",
      "- **Consult a Healthcare Professional**: Before using essential oils for vaginal health, it is crucial to consult with a healthcare provider, especially for individuals with pre-existing conditions, those who are pregnant, or those who have sensitive skin.\n",
      "\n",
      "- **Allergic Reactions**: Always perform a patch test on a small area of skin to check for allergic reactions before applying any essential oil mixture to a larger area.\n",
      "\n",
      "- **Avoid Internal Use**: Essential oils should not be inserted into the vagina, as this can disrupt the natural flora and lead to irritation or infections.\n",
      "\n",
      "- **Monitor for Side Effects**: If any irritation, burning, or discomfort occurs, discontinue use immediately and consult a healthcare professional.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "While essential oils may offer some benefits for vaginal health, their use should be approached with caution. There is no standardized dosage for preventing cross-infection during menstruation, and individual responses can vary widely. Always prioritize safety and consult with a healthcare provider for personalized advice.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02268\n",
      "prediction:  The use of essential oils for vaginal health, including the prevention of repeated cross-infection during menstruation, is a topic that requires careful consideration. However, it is important to note that there is limited scientific evidence supporting the efficacy and safety of using essential oils in the vaginal area. Therefore, any recommendations should be approached with caution.\n",
      "\n",
      "### General Guidelines for Essential Oils\n",
      "\n",
      "1. **Dilution**: Essential oils are highly concentrated and should never be used undiluted. A common recommendation is to dilute essential oils in a carrier oil (such as coconut oil, almond oil, or jojoba oil) at a ratio of 1-2 drops of essential oil per teaspoon of carrier oil. This dilution helps to minimize the risk of irritation or adverse reactions.\n",
      "\n",
      "2. **Selection of Essential Oils**: Some essential oils are known for their antimicrobial properties, such as tea tree oil, lavender oil, and oregano oil. However, individual responses to these oils can vary, and some may cause irritation or allergic reactions.\n",
      "\n",
      "3. **Application Method**: If using essential oils for vaginal health, it is advisable to apply the diluted mixture externally rather than internally. This can be done by applying the mixture to the vulva or the perineal area, rather than inserting it into the vagina.\n",
      "\n",
      "4. **Frequency of Use**: The frequency of application can vary based on individual needs and responses. It is generally recommended to use essential oils sparingly, perhaps a few times a week, rather than daily, to avoid irritation.\n",
      "\n",
      "5. **Consultation with Healthcare Providers**: Before using essential oils for any health-related purpose, it is crucial to consult with a healthcare provider, especially for individuals with pre-existing conditions, those who are pregnant, or those who have a history of allergies.\n",
      "\n",
      "### Considerations for Menstrual Health\n",
      "\n",
      "- **Hygiene Practices**: Maintaining good hygiene during menstruation is essential for preventing infections. This includes regular changing of menstrual products, using breathable materials, and avoiding douching or using scented products that can disrupt the natural vaginal flora.\n",
      "\n",
      "- **Alternative Remedies**: In addition to essential oils, other natural remedies such as probiotics, dietary adjustments, and herbal supplements may also support vaginal health. However, these should also be discussed with a healthcare provider.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "While some individuals may choose to use essential oils for vaginal health, there is no standardized or universally recommended dosage for preventing repeated cross-infection during menstruation. The focus should be on safe practices, proper dilution, and consultation with healthcare professionals. It is essential to prioritize evidence-based approaches and personal health needs when considering the use of essential oils in this context.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.040153\n",
      "prediction:  There appears to be limited direct research specifically focusing on the mutagenicity of Hydrocort (Hydrocortisone) available from the gathered resources. However, I can summarize the existing knowledge and related studies on the topic.\n",
      "\n",
      "1. **General Overview of Hydrocortisone**: Hydrocortisone, also known as cortisol, is a corticosteroid hormone that is involved in various physiological processes and is frequently prescribed for its anti-inflammatory and immunosuppressive effects. Studies on hydrocortisone often focus on its pharmacological effects, metabolism, and safety profile but may not specifically address its mutagenic potential. \n",
      "\n",
      "2. **Mutagenicity Studies in Related Contexts**: Although there is no specific study retrieved that directly assesses the mutagenicity of hydrocortisone, many hormone-related drugs, including glucocorticoids, have undergone genotoxicity evaluations. For example, the paper titled \"In vitro and in vivo genotoxicity evaluation of hormonal drugs\" discusses effects related to hormonal drugs and might provide insights into the broader category of corticosteroids and their potential genetic impacts.\n",
      "\n",
      "3. **Alternative Studies on Mutagenicity**: The concept of mutagenicity is often assessed through in vitro studies using models like Salmonella typhimurium. These models help evaluate the potential mutagenic effects of various substances, providing indirect insights into similar compounds or drugs.\n",
      "\n",
      "4. **Conclusion**: To conclude, while direct studies on the mutagenicity of Hydrocortisone are sparse, related research evaluating the genotoxic effects of hormonal drugs suggests a need for careful evaluation of such compounds in terms of their mutagenic potential. Further studies, preferably including specific mutagenicity assessments for hydrocortisone, would be beneficial for understanding its safety profile regarding genetic mutations.\n",
      "\n",
      "For more detailed information, I recommend consulting specific pharmacology and toxicology literature or databases dedicated to drug safety assessments.\n",
      "pred_SIM:  D\n",
      "choice:  E\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.07987\n",
      "prediction:  There appears to be limited specific research directly addressing the genotoxic effects of Fluoxetine and its metabolite Norfluoxetine. However, searching through general resources has provided insights into their properties. \n",
      "\n",
      "Fluoxetine (commonly known as Prozac) is a selective serotonin reuptake inhibitor (SSRI) used primarily to treat depression and anxiety disorders. Its metabolite, Norfluoxetine, is considered to contribute to its therapeutic effects.\n",
      "\n",
      "From available literature, Fluoxetine and Norfluoxetine have undergone various safety assessments, including mutagenicity tests which are typically part of pharmacological evaluations. Despite the absence of specific articles detailing assays confirming the absence of genotoxic effects, the overall consensus in chemical safety evaluations suggests that both compounds have not demonstrated significant genotoxicity in standard tests.\n",
      "\n",
      "If you are looking for specific assays or studies that unequivocally demonstrate their lack of genotoxic effects, I recommend consulting primary pharmacological research or toxicology databases that may hold unpublished data or ongoing studies in this realm.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: All of the above.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.052423\n",
      "prediction:  There is currently limited scientific literature specifically detailing the recommended dosage of vaginal essential oil for preventing repeated cross-infection during menstruation. Most resources involving essential oils suggest that they should be used with caution, particularly in sensitive areas like the vagina.\n",
      "\n",
      "General guidelines for using essential oils include diluting them in a carrier oil and consulting with healthcare professionals, such as herbalists or aromatherapy practitioners, before use. For vaginal applications, essential oils are often diluted significantlyâ€”usually at a concentration of 1-2% (which translates to about 1-2 drops of essential oil in a teaspoon of carrier oil).\n",
      "\n",
      "It is important to note that essential oils may not always be appropriate for everyone due to potential allergic reactions or sensitivities. Additionally, maintaining proper menstrual hygiene is critical for preventing infections. This can include using clean menstrual products, washing hands before changing these products, and avoiding the use of overly fragrant products in the vaginal area.\n",
      "\n",
      "For personalized advice, it is best to consult a healthcare provider experienced in aromatherapy or alternative medicine.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.047131\n",
      "prediction:  There is currently no established or recommended dosage for vaginal essential oil specifically aimed at preventing repeated cross-infection during menstruation. Essential oils can vary significantly in strength and individual response, making standardized dosages difficult to define. \n",
      "\n",
      "When considering the use of essential oils vaginally, it is crucial to note the lack of clinical guidelines or standardized dosage recommendations in the scientific literature. While some essential oils are recognized for their antimicrobial properties, the usage, especially in sensitive areas such as the vagina, requires caution to avoid irritation or adverse reactions.\n",
      "\n",
      "If someone is considering the use of essential oils for health purposes, including for vaginal use during menstruation, itâ€™s advisable to consult a healthcare provider or a qualified aromatherapist. They can provide guidance tailored to individual health needs and conditions.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.073193\n",
      "prediction:  There seems to be a lack of direct studies specifically addressing the effects of pantoprazole sodium on bone development in offspring in animal models. Currently, the PubMed and broader search results did not yield relevant data regarding this specific inquiry.\n",
      "\n",
      "However, it is known that proton pump inhibitors (PPIs) like pantoprazole can impact calcium absorption in the gastrointestinal tract. Chronic use of PPIs has been associated with an increased risk of fractures, which could imply some underlying effects on bone health. In terms of developmental impacts, any potential consequences for offspring would likely stem from maternal nutrient absorption changes during pregnancy, which could theoretically influence fetal bone development.\n",
      "\n",
      "For concrete conclusions, further dedicated research focusing on animal models assessing the relationship between pantoprazole sodium administration and subsequent bone development in offspring would be necessary. Thus, the field may benefit from future studies explicitly examining this topic.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: It leads to changes in bone parameters that are partially reversible.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.055754\n",
      "prediction:  To accurately assess the use of Sumatriptan during pregnancy, we need to consider several factors, including the drug's classification, its mechanism of action, available research, and guidelines from health authorities.\n",
      "\n",
      "### Step 1: Understanding Sumatriptan\n",
      "Sumatriptan is a medication that belongs to a class of drugs known as triptans, which are commonly used to treat migraine headaches. It works by stimulating serotonin receptors in the brain, leading to vasoconstriction of cranial blood vessels and alleviating migraine symptoms.\n",
      "\n",
      "### Step 2: Pregnancy Category\n",
      "In the United States, medications are classified by the FDA into categories based on their safety during pregnancy. Sumatriptan is classified as a Category C drug. This means that:\n",
      "\n",
      "- Animal reproduction studies have shown an adverse effect on the fetus.\n",
      "- There are no adequate and well-controlled studies in pregnant women.\n",
      "- The potential benefits may warrant use of the drug in pregnant women despite potential risks.\n",
      "\n",
      "### Step 3: Research and Evidence\n",
      "Research on the use of Sumatriptan during pregnancy has yielded mixed results. Some studies suggest that the use of triptans, including Sumatriptan, may be associated with certain risks, such as:\n",
      "\n",
      "- Increased risk of congenital malformations, particularly when used in the first trimester.\n",
      "- Potential for adverse pregnancy outcomes, although the evidence is not conclusive.\n",
      "\n",
      "However, other studies indicate that untreated migraines during pregnancy can also pose risks, such as increased stress and potential complications for both the mother and the fetus.\n",
      "\n",
      "### Step 4: Clinical Guidelines\n",
      "Clinical guidelines generally recommend a cautious approach when considering the use of Sumatriptan during pregnancy. Healthcare providers often weigh the risks of medication against the potential consequences of untreated migraines. \n",
      "\n",
      "- If a pregnant woman has a history of severe migraines that significantly impact her quality of life, a healthcare provider may consider prescribing Sumatriptan after discussing the potential risks and benefits.\n",
      "- Non-pharmacological treatments and lifestyle modifications are often recommended as first-line approaches for managing migraines during pregnancy.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "In summary, the accurate statement regarding the use of Sumatriptan during pregnancy is that it is classified as a Category C medication, indicating that while there may be potential risks, the benefits of treating severe migraines may outweigh those risks in certain cases. It is essential for pregnant women to consult with their healthcare providers to make informed decisions based on their individual circumstances and health needs. \n",
      "\n",
      "### Final Answer\n",
      "The accurate statement about the use of Sumatriptan during pregnancy is that it is classified as a Category C drug, meaning that while there are potential risks, the benefits may outweigh those risks in certain cases, and it should be used under the guidance of a healthcare provider.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Animal studies have shown embryolethality and fetal abnormalities with Sumatriptan use.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.027243\n",
      "prediction:  To address the management strategy for co-administering JAIMIESS (a hypothetical medication) with enzyme inducers, we need to consider several key factors. Hereâ€™s a step-by-step breakdown of the recommended management strategy:\n",
      "\n",
      "### Step 1: Understand JAIMIESS\n",
      "- **Mechanism of Action**: Determine how JAIMIESS works in the body. Is it metabolized by the liver? Does it have a narrow therapeutic index?\n",
      "- **Pharmacokinetics**: Understand the pharmacokinetic profile of JAIMIESS, including its absorption, distribution, metabolism, and excretion (ADME).\n",
      "\n",
      "### Step 2: Identify Enzyme Inducers\n",
      "- **Common Enzyme Inducers**: Identify the specific enzyme inducers that may be co-administered with JAIMIESS. Common inducers include rifampin, phenytoin, carbamazepine, and St. Johnâ€™s Wort.\n",
      "- **Mechanism of Induction**: Understand how these inducers affect the cytochrome P450 enzyme system or other metabolic pathways relevant to JAIMIESS.\n",
      "\n",
      "### Step 3: Assess Drug-Drug Interactions\n",
      "- **Impact on JAIMIESS Levels**: Enzyme inducers can increase the metabolism of JAIMIESS, potentially leading to subtherapeutic levels. Assess the risk of reduced efficacy.\n",
      "- **Therapeutic Monitoring**: If JAIMIESS has a narrow therapeutic index, consider therapeutic drug monitoring to ensure effective dosing.\n",
      "\n",
      "### Step 4: Adjust Dosing Strategy\n",
      "- **Dose Adjustment**: If JAIMIESS is significantly affected by the enzyme inducers, consider increasing the dose of JAIMIESS to maintain therapeutic levels. This should be done cautiously and based on clinical judgment and monitoring.\n",
      "- **Alternative Dosing Regimens**: Explore alternative dosing regimens, such as more frequent dosing or higher doses, depending on the pharmacokinetics of JAIMIESS.\n",
      "\n",
      "### Step 5: Monitor Patient Response\n",
      "- **Clinical Monitoring**: Closely monitor the patient for signs of reduced efficacy or adverse effects. This includes assessing the clinical response to JAIMIESS and any side effects.\n",
      "- **Laboratory Tests**: If applicable, perform laboratory tests to measure drug levels, liver function tests, or other relevant biomarkers to ensure safety and efficacy.\n",
      "\n",
      "### Step 6: Educate the Patient\n",
      "- **Patient Counseling**: Inform the patient about the potential interactions and the importance of adherence to the adjusted dosing regimen. Discuss any signs or symptoms that may indicate reduced efficacy or toxicity.\n",
      "- **Lifestyle Considerations**: Advise the patient on lifestyle factors that may influence drug metabolism, such as diet, alcohol consumption, and the use of other medications or supplements.\n",
      "\n",
      "### Step 7: Re-evaluate Therapy\n",
      "- **Regular Review**: Schedule regular follow-up appointments to re-evaluate the need for continued co-administration of JAIMIESS and the enzyme inducers. Adjust the management strategy as necessary based on the patientâ€™s clinical status and any new evidence or guidelines.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the recommended management strategy when JAIMIESS is co-administered with enzyme inducers involves understanding the pharmacokinetics of JAIMIESS, assessing the impact of the inducers, adjusting dosing as necessary, monitoring the patient closely, educating the patient, and regularly re-evaluating the therapy. This comprehensive approach helps ensure the safe and effective use of JAIMIESS in the presence of enzyme inducers.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use a backup or alternative method of contraception\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.028005\n",
      "prediction:  To address the question of how the contraindication profile of RETHYMIC compares to drugs with specific contraindications, we need to break down the analysis into several key components. \n",
      "\n",
      "### Step 1: Understanding RETHYMIC\n",
      "\n",
      "**RETHYMIC** (also known as thymoglobulin) is a medication primarily used in the context of organ transplantation and certain autoimmune diseases. It is a polyclonal antibody that targets T-lymphocytes, leading to immunosuppression. This is crucial in preventing organ rejection in transplant patients.\n",
      "\n",
      "### Step 2: Identifying Contraindications of RETHYMIC\n",
      "\n",
      "The contraindications for RETHYMIC typically include:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients with a known hypersensitivity to rabbit proteins or any component of the formulation should not receive RETHYMIC.\n",
      "2. **Severe Infections**: Active infections, particularly those that are systemic or uncontrolled, may be exacerbated by the immunosuppressive effects of RETHYMIC.\n",
      "3. **Pregnancy and Lactation**: The safety of RETHYMIC in pregnant or breastfeeding women has not been established, and it is generally contraindicated due to potential risks to the fetus or infant.\n",
      "4. **Severe Bone Marrow Suppression**: Patients with significant bone marrow suppression or cytopenias may be at increased risk for complications.\n",
      "\n",
      "### Step 3: Comparing with Other Drugs\n",
      "\n",
      "To compare RETHYMIC's contraindication profile with other drugs, we can look at a few categories of medications that have specific contraindications:\n",
      "\n",
      "1. **Antibiotics (e.g., Penicillin)**:\n",
      "   - **Contraindications**: Known allergy to penicillin or related antibiotics.\n",
      "   - **Comparison**: RETHYMIC's contraindications are broader, focusing on immunosuppression and infection risk, while antibiotics primarily focus on allergic reactions.\n",
      "\n",
      "2. **Anticoagulants (e.g., Warfarin)**:\n",
      "   - **Contraindications**: Active bleeding, severe liver disease, and certain drug interactions.\n",
      "   - **Comparison**: Anticoagulants have specific contraindications related to bleeding risks, while RETHYMIC's contraindications are more related to immune function and infection.\n",
      "\n",
      "3. **Chemotherapy Agents (e.g., Doxorubicin)**:\n",
      "   - **Contraindications**: Pre-existing heart conditions, severe myelosuppression.\n",
      "   - **Comparison**: Both RETHYMIC and chemotherapy agents have contraindications related to bone marrow suppression, but RETHYMIC also emphasizes the risk of infections due to its immunosuppressive nature.\n",
      "\n",
      "### Step 4: Analyzing the Broader Implications\n",
      "\n",
      "The contraindication profile of RETHYMIC reflects its role as an immunosuppressant. This means that its use is particularly sensitive to the patient's immune status and the presence of infections. In contrast, many other drugs have contraindications that are more focused on specific organ systems or conditions (e.g., liver function for anticoagulants, allergies for antibiotics).\n",
      "\n",
      "### Step 5: Conclusion\n",
      "\n",
      "In summary, RETHYMIC's contraindication profile is characterized by its immunosuppressive effects, which necessitate caution in patients with infections, hypersensitivity, and certain hematological conditions. When compared to other drugs with specific contraindications, RETHYMIC's profile is broader and more focused on the implications of immune suppression. This highlights the importance of careful patient selection and monitoring when using RETHYMIC, particularly in populations at risk for infections or those with compromised immune systems. \n",
      "\n",
      "### Final Note\n",
      "\n",
      "When considering the use of RETHYMIC or any medication, it is essential for healthcare providers to conduct a thorough assessment of the patient's medical history, current health status, and potential drug interactions to ensure safe and effective treatment.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.027643\n",
      "prediction:  To address the question of how the contraindication profile of RETHYMIC compares to drugs with specific contraindications, we need to break down the analysis into several key components. \n",
      "\n",
      "### Step 1: Understanding RETHYMIC\n",
      "\n",
      "**RETHYMIC** (also known as thymoglobulin) is a medication primarily used in the context of organ transplantation, particularly for the prevention of acute rejection in kidney transplant patients. It is a polyclonal antibody that targets T-lymphocytes, leading to immunosuppression.\n",
      "\n",
      "### Step 2: Identifying Contraindications of RETHYMIC\n",
      "\n",
      "The contraindications for RETHYMIC typically include:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients with a known hypersensitivity to rabbit proteins or any component of the formulation should not receive RETHYMIC.\n",
      "2. **Severe Infections**: Patients with active infections, particularly those that are systemic or uncontrolled, may be at increased risk for complications due to immunosuppression.\n",
      "3. **Pregnancy and Lactation**: The safety of RETHYMIC in pregnant or breastfeeding women has not been established, and it is generally contraindicated due to potential risks to the fetus or infant.\n",
      "4. **Severe Bone Marrow Suppression**: Patients with significant bone marrow suppression may be at risk for exacerbated hematological issues when receiving RETHYMIC.\n",
      "\n",
      "### Step 3: Comparing with Other Drugs\n",
      "\n",
      "To compare RETHYMIC's contraindication profile with other drugs, we can look at a few classes of medications that have specific contraindications:\n",
      "\n",
      "1. **Antibiotics (e.g., Penicillin)**:\n",
      "   - **Contraindications**: Known allergy to penicillin or related antibiotics.\n",
      "   - **Comparison**: Similar to RETHYMIC, the contraindication is primarily based on hypersensitivity. However, antibiotics may have additional contraindications related to renal function or specific infections.\n",
      "\n",
      "2. **Anticoagulants (e.g., Warfarin)**:\n",
      "   - **Contraindications**: Active bleeding, severe liver disease, and certain drug interactions.\n",
      "   - **Comparison**: Anticoagulants have a broader range of contraindications related to bleeding risks and liver function, which are not as prominent in RETHYMIC's profile.\n",
      "\n",
      "3. **Chemotherapeutic Agents (e.g., Doxorubicin)**:\n",
      "   - **Contraindications**: Severe myelosuppression, active infections, and certain cardiac conditions.\n",
      "   - **Comparison**: Like RETHYMIC, chemotherapeutics have contraindications related to infections and bone marrow suppression, but they also include specific cardiac contraindications that are not applicable to RETHYMIC.\n",
      "\n",
      "### Step 4: Analyzing the Implications of Contraindications\n",
      "\n",
      "The implications of contraindications are crucial for clinical decision-making:\n",
      "\n",
      "- **Patient Safety**: Both RETHYMIC and other drugs with contraindications aim to protect patients from adverse effects. The specific contraindications of RETHYMIC focus on immunosuppression risks, while others may focus on bleeding or organ function.\n",
      "- **Monitoring Requirements**: Patients receiving RETHYMIC may require close monitoring for infections and hematological parameters, similar to patients on certain chemotherapeutics or anticoagulants.\n",
      "- **Alternative Therapies**: Understanding contraindications helps clinicians choose alternative therapies when RETHYMIC is not suitable, ensuring that patients receive effective treatment without undue risk.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "\n",
      "In summary, RETHYMIC's contraindication profile is primarily focused on hypersensitivity, active infections, and conditions that may exacerbate immunosuppression. When compared to other drug classes, RETHYMIC shares some common contraindications, particularly regarding infections and bone marrow suppression, but also has unique aspects related to its immunosuppressive nature. Understanding these differences is essential for safe and effective patient management in clinical practice.\n",
      "pred_SIM:  C\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.025176\n",
      "prediction:  To address the question of how the contraindication profile of RETHYMIC compares to drugs with specific contraindications, we need to break down the analysis into several key components. RETHYMIC (also known as thymoglobulin) is a medication primarily used in the context of organ transplantation and certain autoimmune diseases. It is important to understand its contraindications, how they relate to other drugs, and the implications for patient safety.\n",
      "\n",
      "### Step 1: Understanding RETHYMIC and Its Indications\n",
      "\n",
      "RETHYMIC is an immunosuppressive agent derived from rabbit polyclonal antibodies against human thymocytes. It is primarily used to prevent acute rejection in kidney transplant patients and to treat conditions like aplastic anemia. Its mechanism of action involves depleting T-lymphocytes, which are crucial for the immune response.\n",
      "\n",
      "### Step 2: Identifying Contraindications of RETHYMIC\n",
      "\n",
      "The contraindications for RETHYMIC include:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients with a known hypersensitivity to rabbit proteins or any component of the formulation should not receive RETHYMIC due to the risk of severe allergic reactions.\n",
      "2. **Active Infections**: Since RETHYMIC suppresses the immune system, it is contraindicated in patients with active infections, as it can exacerbate the condition and lead to severe complications.\n",
      "3. **Severe Bone Marrow Suppression**: Patients with significant bone marrow suppression or cytopenias should avoid RETHYMIC, as it can further impair hematopoiesis.\n",
      "\n",
      "### Step 3: Comparing with Other Drugs\n",
      "\n",
      "To compare RETHYMIC's contraindication profile with other drugs, we can look at a few classes of medications that also have specific contraindications:\n",
      "\n",
      "1. **Antibiotics (e.g., Penicillins)**:\n",
      "   - **Contraindications**: Known allergies to penicillin or cephalosporins.\n",
      "   - **Comparison**: While both RETHYMIC and penicillins have hypersensitivity as a contraindication, the implications differ. RETHYMIC's immunosuppressive nature poses a broader risk of infections, while antibiotics are typically used to treat infections.\n",
      "\n",
      "2. **Chemotherapy Agents (e.g., Doxorubicin)**:\n",
      "   - **Contraindications**: Severe myelosuppression, active infections, and certain cardiac conditions.\n",
      "   - **Comparison**: Both RETHYMIC and chemotherapy agents have contraindications related to bone marrow suppression and infections. However, chemotherapy agents often have additional contraindications related to specific organ toxicities.\n",
      "\n",
      "3. **Biologics (e.g., TNF inhibitors)**:\n",
      "   - **Contraindications**: Active infections, malignancies, and certain autoimmune conditions.\n",
      "   - **Comparison**: Similar to RETHYMIC, TNF inhibitors also carry risks related to infections and malignancies due to their immunosuppressive effects. However, the specific patient populations and conditions treated may differ.\n",
      "\n",
      "### Step 4: Implications for Patient Safety\n",
      "\n",
      "The contraindication profile of RETHYMIC highlights the importance of careful patient selection and monitoring. The immunosuppressive effects necessitate a thorough assessment of a patient's infection status and overall health before administration. In contrast, other drugs may have contraindications that are more focused on specific organ systems or conditions.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "\n",
      "In summary, RETHYMIC's contraindication profile shares similarities with other immunosuppressive and certain therapeutic agents, particularly concerning hypersensitivity and infection risks. However, the broader implications of its use in immunosuppression necessitate a more cautious approach in patient management. Understanding these contraindications is crucial for healthcare providers to ensure patient safety and optimize therapeutic outcomes. \n",
      "\n",
      "By comparing RETHYMIC with other drugs, we can appreciate the nuances of its contraindications and the importance of individualized patient care in the context of immunosuppressive therapy.\n",
      "pred_SIM:  D\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: RETHYMIC has no contraindications, making it unique.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.035706\n",
      "prediction:  To address the question of how the contraindication profile of Zynteglo differs from drugs with specific contraindications, we first need to understand what Zynteglo is, its mechanism of action, and its specific contraindications. Then, we can compare it to other drugs with specific contraindications.\n",
      "\n",
      "### Step 1: Understanding Zynteglo\n",
      "\n",
      "**Zynteglo (betibeglogene autotemcel)** is a gene therapy product approved for the treatment of beta-thalassemia, a genetic blood disorder characterized by reduced production of hemoglobin. Zynteglo works by using a modified version of a patient's own stem cells, which are genetically engineered to produce functional beta-globin, thereby addressing the underlying cause of the disease.\n",
      "\n",
      "### Step 2: Contraindications of Zynteglo\n",
      "\n",
      "Zynteglo has specific contraindications that are important to consider:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients with a known hypersensitivity to any component of Zynteglo should not receive the treatment.\n",
      "2. **Active Infections**: Patients with active infections should not be treated until the infection is resolved.\n",
      "3. **Pregnancy and Breastfeeding**: The safety of Zynteglo in pregnant or breastfeeding women has not been established, so it is contraindicated in these populations.\n",
      "4. **Bone Marrow Disorders**: Patients with certain bone marrow disorders or malignancies may be contraindicated due to the nature of the therapy involving stem cell manipulation.\n",
      "\n",
      "### Step 3: Comparing with Other Drugs\n",
      "\n",
      "When comparing Zynteglo's contraindication profile to other drugs, we can categorize them based on their mechanisms of action and the nature of their contraindications:\n",
      "\n",
      "1. **Traditional Pharmaceuticals**: Many traditional drugs have contraindications based on organ function (e.g., liver or kidney impairment), drug interactions, or specific patient populations (e.g., elderly, children). For example, non-steroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with active peptic ulcer disease or severe renal impairment.\n",
      "\n",
      "2. **Biologics and Gene Therapies**: Similar to Zynteglo, other biologics and gene therapies may have contraindications related to immune system status, hypersensitivity, or specific genetic conditions. For instance, CAR T-cell therapies have contraindications related to active infections and certain pre-existing conditions that could exacerbate side effects.\n",
      "\n",
      "3. **Chemotherapy Agents**: Chemotherapy drugs often have contraindications based on blood counts (e.g., neutropenia) or specific organ toxicities. For example, certain chemotherapeutic agents are contraindicated in patients with severe liver dysfunction due to the risk of increased toxicity.\n",
      "\n",
      "### Step 4: Key Differences\n",
      "\n",
      "The key differences in the contraindication profile of Zynteglo compared to other drugs can be summarized as follows:\n",
      "\n",
      "- **Mechanism of Action**: Zynteglo's gene therapy approach necessitates a unique set of contraindications related to stem cell manipulation and genetic modification, which may not apply to traditional pharmaceuticals.\n",
      "- **Patient Population**: The specific patient population for Zynteglo (those with beta-thalassemia) may have different health considerations compared to patients taking other medications, leading to tailored contraindications.\n",
      "- **Long-term Effects**: Gene therapies like Zynteglo may have long-term implications that necessitate monitoring for late-onset adverse effects, which may not be as pronounced with traditional drugs.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, Zynteglo's contraindication profile is shaped by its unique mechanism of action as a gene therapy, focusing on hypersensitivity, active infections, and specific patient populations. This contrasts with the contraindications of traditional drugs, which often focus on organ function and drug interactions. Understanding these differences is crucial for healthcare providers when considering treatment options for patients with beta-thalassemia or other conditions requiring specialized therapies.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.037602\n",
      "prediction:  To address the question of how the contraindication profile of Zynteglo differs from drugs with specific contraindications, we first need to understand what Zynteglo is, its mechanism of action, and its specific contraindications. Then, we can compare it to other drugs with specific contraindications.\n",
      "\n",
      "### Step 1: Understanding Zynteglo\n",
      "\n",
      "**Zynteglo (betibeglogene autotemcel)** is a gene therapy product approved for the treatment of beta-thalassemia, a genetic blood disorder characterized by reduced production of hemoglobin. Zynteglo works by using a modified version of the patient's own stem cells, which are genetically engineered to produce functional beta-globin, thereby addressing the underlying cause of the disease.\n",
      "\n",
      "### Step 2: Contraindications of Zynteglo\n",
      "\n",
      "Zynteglo has specific contraindications that are important to consider:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients with a known hypersensitivity to any component of Zynteglo should not receive the therapy.\n",
      "2. **Active Infections**: Patients with active infections should not be treated with Zynteglo until the infection is resolved.\n",
      "3. **Certain Hematologic Conditions**: Patients with certain hematologic malignancies or conditions that could be exacerbated by the treatment may also be contraindicated.\n",
      "\n",
      "### Step 3: Understanding Drugs with Specific Contraindications\n",
      "\n",
      "Many drugs have specific contraindications based on their pharmacological properties, mechanisms of action, and potential adverse effects. For example:\n",
      "\n",
      "- **Anticoagulants (e.g., Warfarin)**: Contraindicated in patients with active bleeding disorders or severe liver disease.\n",
      "- **ACE Inhibitors (e.g., Lisinopril)**: Contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy.\n",
      "- **Certain Chemotherapeutics (e.g., Doxorubicin)**: Contraindicated in patients with severe cardiac dysfunction.\n",
      "\n",
      "### Step 4: Comparing Contraindication Profiles\n",
      "\n",
      "1. **Nature of Contraindications**:\n",
      "   - **Zynteglo**: Contraindications are primarily related to the patient's immune status and the presence of active infections, as the therapy involves manipulating the immune system and hematopoietic stem cells.\n",
      "   - **Other Drugs**: Contraindications often relate to the drug's mechanism of action and potential for exacerbating existing conditions (e.g., bleeding risk with anticoagulants).\n",
      "\n",
      "2. **Patient Population**:\n",
      "   - **Zynteglo**: Specifically targets patients with beta-thalassemia, a genetic disorder, and thus contraindications are tailored to this unique patient population.\n",
      "   - **Other Drugs**: Contraindications may apply to broader populations and are often based on common comorbidities or drug interactions.\n",
      "\n",
      "3. **Risk Assessment**:\n",
      "   - **Zynteglo**: The risks are associated with gene therapy, including potential immune reactions and the need for careful monitoring of infections.\n",
      "   - **Other Drugs**: Risks may include organ toxicity, bleeding, or other adverse effects that are more common in the general population.\n",
      "\n",
      "4. **Management of Contraindications**:\n",
      "   - **Zynteglo**: Requires a multidisciplinary approach, including hematologists and genetic counselors, to assess the appropriateness of therapy.\n",
      "   - **Other Drugs**: Often managed by primary care providers or specialists who may adjust dosages or choose alternative therapies based on contraindications.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the contraindication profile of Zynteglo is distinct from that of many other drugs due to its specific application in gene therapy for beta-thalassemia, focusing on immune status and infection risk. In contrast, other drugs may have contraindications based on broader pharmacological effects and patient comorbidities. Understanding these differences is crucial for healthcare providers when considering treatment options for patients with complex medical histories.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.034601\n",
      "prediction:  To address the question of how the contraindication profile of Zynteglo differs from drugs with specific contraindications, we first need to understand what Zynteglo is, its mechanism of action, and its specific contraindications. Then, we can compare it to other drugs with specific contraindications.\n",
      "\n",
      "### Step 1: Understanding Zynteglo\n",
      "\n",
      "**Zynteglo (betibeglogene autotemcel)** is a gene therapy product approved for the treatment of beta-thalassemia, a genetic blood disorder characterized by reduced production of hemoglobin. Zynteglo works by using a modified version of the patient's own stem cells, which are genetically engineered to produce functional beta-globin, thereby addressing the underlying cause of the disease.\n",
      "\n",
      "### Step 2: Contraindications of Zynteglo\n",
      "\n",
      "Zynteglo has specific contraindications that are important to consider:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients with a known hypersensitivity to any component of Zynteglo should not receive the treatment.\n",
      "2. **Active Infections**: Patients with active infections should not be treated until the infection is resolved.\n",
      "3. **Pregnancy and Breastfeeding**: The safety of Zynteglo in pregnant or breastfeeding women has not been established, so it is contraindicated in these populations.\n",
      "4. **Severe Comorbidities**: Patients with severe comorbidities that could complicate the treatment or recovery process may also be contraindicated.\n",
      "\n",
      "### Step 3: Comparing with Other Drugs\n",
      "\n",
      "When comparing Zynteglo's contraindication profile to other drugs, we can categorize them based on their mechanisms of action and therapeutic areas. Here are a few examples:\n",
      "\n",
      "1. **Chemotherapy Agents (e.g., Doxorubicin)**:\n",
      "   - **Contraindications**: Doxorubicin is contraindicated in patients with severe myocardial insufficiency, recent myocardial infarction, or severe liver impairment.\n",
      "   - **Comparison**: While Zynteglo's contraindications focus on hypersensitivity and active infections, chemotherapy agents often have contraindications related to organ function and specific health conditions due to their systemic toxicity.\n",
      "\n",
      "2. **Antibiotics (e.g., Penicillin)**:\n",
      "   - **Contraindications**: Penicillin is contraindicated in patients with a history of severe allergic reactions to penicillin or related antibiotics.\n",
      "   - **Comparison**: Similar to Zynteglo, the contraindications for antibiotics often focus on hypersensitivity. However, antibiotics may also have contraindications based on specific infections or conditions that could exacerbate side effects.\n",
      "\n",
      "3. **Biologics (e.g., Adalimumab)**:\n",
      "   - **Contraindications**: Adalimumab is contraindicated in patients with active infections, including tuberculosis, and those with a history of hypersensitivity to the drug.\n",
      "   - **Comparison**: Both Zynteglo and biologics share contraindications related to active infections and hypersensitivity. However, biologics may also have additional contraindications related to malignancies or specific autoimmune conditions.\n",
      "\n",
      "### Step 4: Summary of Differences\n",
      "\n",
      "- **Nature of Contraindications**: Zynteglo's contraindications are primarily focused on hypersensitivity, active infections, and specific patient populations (e.g., pregnant women). In contrast, other drugs may have contraindications that are more related to organ function, specific health conditions, or potential drug interactions.\n",
      "- **Therapeutic Context**: Zynteglo is a gene therapy targeting a genetic disorder, which may lead to a unique set of contraindications compared to traditional pharmacological agents that may have broader systemic effects.\n",
      "- **Patient Population**: The patient population for Zynteglo is more specific (e.g., those with beta-thalassemia), which may influence the contraindications compared to more general medications used across various conditions.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, Zynteglo's contraindication profile is distinct due to its specific therapeutic context as a gene therapy for beta-thalassemia, focusing on hypersensitivity and active infections, while other drugs may have contraindications that are more related to organ function, systemic toxicity, or broader patient health considerations. Understanding these differences is crucial for healthcare providers when considering treatment options for patients with complex medical histories.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.032799\n",
      "prediction:  To address the question of which formulation of Diclofenac is not necessarily bioequivalent to Diclofenac Potassium tablets, we need to understand the concept of bioequivalence and the different formulations of Diclofenac available.\n",
      "\n",
      "### Step 1: Understanding Bioequivalence\n",
      "Bioequivalence refers to the relationship between two formulations of a drug that have similar bioavailability and produce similar concentrations of the drug in the bloodstream over time. For two formulations to be considered bioequivalent, they must have comparable pharmacokinetic profiles, which include parameters such as peak plasma concentration (Cmax), time to reach peak concentration (Tmax), and the area under the concentration-time curve (AUC).\n",
      "\n",
      "### Step 2: Different Formulations of Diclofenac\n",
      "Diclofenac is available in various formulations, including:\n",
      "\n",
      "1. **Diclofenac Potassium**: This formulation is a fast-acting salt form of Diclofenac, which is often used for acute pain relief due to its rapid absorption and onset of action.\n",
      "\n",
      "2. **Diclofenac Sodium**: This is another salt form of Diclofenac, which may have different pharmacokinetic properties compared to Diclofenac Potassium. It is often used in extended-release formulations.\n",
      "\n",
      "3. **Topical Formulations**: These include gels, creams, and patches that deliver Diclofenac through the skin. The systemic absorption and bioavailability can differ significantly from oral formulations.\n",
      "\n",
      "4. **Extended-Release Formulations**: These formulations are designed to release the drug over an extended period, which can alter the pharmacokinetic profile compared to immediate-release formulations.\n",
      "\n",
      "### Step 3: Identifying Non-Bioequivalent Formulations\n",
      "Given the above formulations, the one that is not necessarily bioequivalent to Diclofenac Potassium tablets, even if the milligram strength is the same, is:\n",
      "\n",
      "- **Diclofenac Sodium Extended-Release Tablets**: While both Diclofenac Potassium and Diclofenac Sodium may contain the same milligram strength, the pharmacokinetics can differ significantly due to the different salt forms and the release characteristics of the extended-release formulation. The extended-release formulation is designed to release the drug slowly over time, leading to different Cmax, Tmax, and AUC values compared to the immediate-release Diclofenac Potassium tablets.\n",
      "\n",
      "### Conclusion\n",
      "In summary, while Diclofenac Potassium and Diclofenac Sodium may have the same milligram strength, the extended-release formulation of Diclofenac Sodium is not necessarily bioequivalent to Diclofenac Potassium tablets due to differences in their pharmacokinetic profiles. Therefore, it is crucial to consider the specific formulation and its release characteristics when evaluating bioequivalence.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Both A and B\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.029132\n",
      "prediction:  To address the question of which formulation of Diclofenac is not necessarily bioequivalent to Diclofenac Potassium tablets, we need to understand the different formulations of Diclofenac and the concept of bioequivalence.\n",
      "\n",
      "### Step 1: Understanding Bioequivalence\n",
      "Bioequivalence refers to the relationship between two formulations of a drug that have similar bioavailability, meaning they release the active ingredient into the bloodstream at a similar rate and extent. For two formulations to be considered bioequivalent, they must have comparable pharmacokinetic profiles, which include parameters such as peak plasma concentration (Cmax), time to reach peak concentration (Tmax), and the area under the concentration-time curve (AUC).\n",
      "\n",
      "### Step 2: Different Formulations of Diclofenac\n",
      "Diclofenac is available in various formulations, including:\n",
      "\n",
      "1. **Diclofenac Potassium**: This formulation is a fast-acting salt form of Diclofenac, which is often used for acute pain relief due to its rapid absorption and onset of action.\n",
      "\n",
      "2. **Diclofenac Sodium**: This is another salt form of Diclofenac, which may have different pharmacokinetic properties compared to Diclofenac Potassium. It is often used in extended-release formulations.\n",
      "\n",
      "3. **Diclofenac Extended-Release (ER) Tablets**: These formulations are designed to release the drug slowly over time, providing prolonged therapeutic effects. \n",
      "\n",
      "4. **Topical Formulations**: These include gels, creams, and patches that deliver Diclofenac through the skin, which can have different absorption characteristics compared to oral formulations.\n",
      "\n",
      "5. **Injectable Formulations**: These are used for immediate pain relief and can have different pharmacokinetics compared to oral forms.\n",
      "\n",
      "### Step 3: Identifying Non-Bioequivalent Formulations\n",
      "Among the formulations listed, **Diclofenac Extended-Release (ER) tablets** are not necessarily bioequivalent to Diclofenac Potassium tablets, even if they contain the same milligram strength of Diclofenac. This is due to the following reasons:\n",
      "\n",
      "- **Release Mechanism**: The extended-release formulation is designed to release the drug over an extended period, leading to different absorption rates and times compared to the immediate-release Diclofenac Potassium.\n",
      "\n",
      "- **Pharmacokinetics**: The pharmacokinetic profiles of the two formulations will differ significantly. The Cmax and Tmax will be different, which can affect the overall therapeutic effect and onset of action.\n",
      "\n",
      "- **Clinical Implications**: The differences in absorption and release can lead to variations in efficacy and safety profiles, making it crucial to consider these factors when switching between formulations.\n",
      "\n",
      "### Conclusion\n",
      "In summary, while Diclofenac Potassium and Diclofenac Sodium may have the same milligram strength, Diclofenac Extended-Release tablets are not necessarily bioequivalent to Diclofenac Potassium tablets due to differences in their release mechanisms and pharmacokinetic profiles. Therefore, healthcare providers must be cautious when substituting one formulation for another, even if the dosage appears to be the same.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Both A and B\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013536\n",
      "prediction:  To address the question regarding a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff, we can break down the answer into several steps:\n",
      "\n",
      "### Step 1: Understanding Dandruff\n",
      "Dandruff is a common scalp condition characterized by flaking and itching. It can be caused by various factors, including dry skin, seborrheic dermatitis, fungal infections (such as Malassezia), and sensitivity to hair care products.\n",
      "\n",
      "### Step 2: Treatment Options\n",
      "There are several treatment options available for dandruff, including:\n",
      "- **Medicated shampoos**: These often contain active ingredients that target the underlying causes of dandruff.\n",
      "- **Lifestyle changes**: Such as improving scalp hygiene and managing stress.\n",
      "- **Home remedies**: Including natural oils and exfoliation.\n",
      "\n",
      "### Step 3: Active Ingredients in Dandruff Shampoos\n",
      "Common active ingredients found in dandruff shampoos include:\n",
      "- **Zinc pyrithione**: Antifungal and antibacterial properties.\n",
      "- **Ketoconazole**: An antifungal agent effective against Malassezia.\n",
      "- **Selenium sulfide**: Reduces fungus and slows down skin cell turnover.\n",
      "- **Coal tar**: Slows down skin cell turnover and reduces inflammation.\n",
      "- **Salicylic acid**: Helps remove scales and flakes.\n",
      "\n",
      "### Step 4: Identifying Brand Name Products\n",
      "Several brand name products are well-known for treating dandruff. Some of the most recognized include:\n",
      "- **Head & Shoulders**: Contains zinc pyrithione and is widely used for dandruff prevention.\n",
      "- **Nizoral**: Contains ketoconazole and is effective for severe dandruff and seborrheic dermatitis.\n",
      "- **Selsun Blue**: Contains selenium sulfide and is effective in reducing flaking and itching.\n",
      "- **Neutrogena T/Gel**: Contains coal tar and is effective for chronic scalp conditions.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "Among these options, **Head & Shoulders** is one of the most popular and widely recognized brand name products specifically indicated for preventing the recurrence of flaking and itching associated with dandruff. It is available in various formulations, including those for sensitive skin and extra strength, making it a versatile choice for many individuals dealing with dandruff.\n",
      "\n",
      "### Final Answer\n",
      "**Head & Shoulders** is a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013734\n",
      "prediction:  To address the question regarding a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff, we can break down the answer into several steps:\n",
      "\n",
      "### Step 1: Understanding Dandruff\n",
      "Dandruff is a common scalp condition characterized by the shedding of dead skin cells, which can lead to flaking and itching. It can be caused by various factors, including dry skin, seborrheic dermatitis, fungal infections (such as Malassezia), and sensitivity to hair care products.\n",
      "\n",
      "### Step 2: Treatment Options\n",
      "There are several treatment options available for dandruff, including:\n",
      "- **Medicated shampoos**: These often contain active ingredients that target the underlying causes of dandruff.\n",
      "- **Lifestyle changes**: Such as improving scalp hygiene and managing stress.\n",
      "- **Home remedies**: Including natural oils and exfoliation.\n",
      "\n",
      "### Step 3: Active Ingredients in Dandruff Shampoos\n",
      "Common active ingredients found in dandruff shampoos include:\n",
      "- **Zinc pyrithione**: An antifungal and antibacterial agent.\n",
      "- **Ketoconazole**: An antifungal that helps reduce the fungus associated with dandruff.\n",
      "- **Selenium sulfide**: Reduces flaking and itching by slowing down skin cell turnover.\n",
      "- **Coal tar**: Slows down the production of skin cells and has anti-inflammatory properties.\n",
      "- **Salicylic acid**: Helps remove scales and flakes.\n",
      "\n",
      "### Step 4: Identifying Brand Name Products\n",
      "Several brand name products are well-known for treating dandruff. One of the most recognized is **Head & Shoulders**, which contains zinc pyrithione as its active ingredient. Other notable products include:\n",
      "- **Nizoral**: Contains ketoconazole and is effective against fungal dandruff.\n",
      "- **Selsun Blue**: Contains selenium sulfide.\n",
      "- **Neutrogena T/Gel**: Contains coal tar and is effective for severe dandruff and scalp psoriasis.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "Based on the information above, a specific brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff is **Head & Shoulders**. This product is widely available and has a variety of formulations tailored to different hair types and preferences. \n",
      "\n",
      "### Final Answer\n",
      "**Head & Shoulders** is a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014753\n",
      "prediction:  To address the question regarding a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff, we can break down the answer into several steps:\n",
      "\n",
      "### Step 1: Understanding Dandruff\n",
      "Dandruff is a common scalp condition characterized by the shedding of dead skin cells, which can lead to flaking and itching. It can be caused by various factors, including dry skin, seborrheic dermatitis, fungal infections (such as Malassezia), and sensitivity to hair care products.\n",
      "\n",
      "### Step 2: Treatment Options\n",
      "There are several treatment options available for dandruff, including:\n",
      "- **Medicated shampoos**: These often contain active ingredients that target the underlying causes of dandruff.\n",
      "- **Lifestyle changes**: Such as improving scalp hygiene and managing stress.\n",
      "- **Home remedies**: Including natural oils and exfoliation.\n",
      "\n",
      "### Step 3: Active Ingredients in Dandruff Shampoos\n",
      "Common active ingredients found in dandruff shampoos include:\n",
      "- **Zinc pyrithione**: Antifungal and antibacterial properties.\n",
      "- **Ketoconazole**: An antifungal agent effective against Malassezia.\n",
      "- **Selenium sulfide**: Reduces fungus and slows down skin cell turnover.\n",
      "- **Coal tar**: Slows down skin cell turnover and reduces inflammation.\n",
      "- **Salicylic acid**: Helps remove scales and flakes.\n",
      "\n",
      "### Step 4: Identifying Brand Name Products\n",
      "Several brand name products are specifically formulated to prevent the recurrence of dandruff. One of the most well-known products is:\n",
      "\n",
      "**Head & Shoulders**: This brand offers a range of shampoos that contain zinc pyrithione, which is effective in treating and preventing dandruff. Head & Shoulders is widely recognized and recommended for its efficacy in reducing flaking and itching associated with dandruff.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "In summary, a brand name product indicated for preventing the recurrence of flaking and itching associated with dandruff is **Head & Shoulders**. It is important to follow the instructions on the product label and consult a healthcare professional if dandruff persists or worsens, as it may indicate an underlying condition that requires further evaluation.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: EUZ-Clean\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.016601\n",
      "prediction:  To address the question regarding the age group that showed a reduction in suicidality risk with venlafaxine tablets compared to placebo, we can break down the answer into several key components:\n",
      "\n",
      "### Step 1: Understanding Venlafaxine\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, anxiety disorders, and certain other mood disorders. It works by increasing the levels of serotonin and norepinephrine in the brain, which can help improve mood and reduce anxiety.\n",
      "\n",
      "### Step 2: Suicidality and Antidepressants\n",
      "The relationship between antidepressants and suicidality is complex. Some studies have indicated that certain antidepressants may increase the risk of suicidal thoughts and behaviors, particularly in younger populations. This has led to the establishment of black box warnings for many antidepressants, including venlafaxine, regarding the potential for increased suicidality in children, adolescents, and young adults.\n",
      "\n",
      "### Step 3: Age Groups and Clinical Studies\n",
      "Clinical trials and meta-analyses have been conducted to evaluate the efficacy and safety of venlafaxine across different age groups. Research has shown that:\n",
      "\n",
      "- **Children and Adolescents (under 18 years)**: This age group has been associated with an increased risk of suicidality when treated with venlafaxine. Therefore, it is generally recommended that venlafaxine be used with caution in this population, and close monitoring is advised.\n",
      "\n",
      "- **Young Adults (18-24 years)**: Some studies have indicated that while there may still be a risk of increased suicidality in this age group, the overall benefits of treatment with venlafaxine may outweigh the risks for certain individuals. However, the evidence is mixed, and careful monitoring is still essential.\n",
      "\n",
      "- **Adults (25 years and older)**: Research has shown that adults aged 25 and older may experience a reduction in suicidality risk when treated with venlafaxine compared to placebo. This age group generally shows a more favorable response to treatment, with a lower incidence of suicidal thoughts and behaviors.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "Based on the available evidence, the age group that showed a reduction in suicidality risk with venlafaxine tablets compared to placebo is primarily **adults aged 25 years and older**. In this population, venlafaxine has been found to be effective in reducing depressive symptoms and associated suicidality, making it a viable treatment option.\n",
      "\n",
      "### Final Note\n",
      "It is important to remember that individual responses to medication can vary, and treatment should always be tailored to the individual. Close monitoring by healthcare professionals is crucial, especially in populations at risk for suicidality.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017289\n",
      "prediction:  To address the question regarding the age group that showed a reduction in suicidality risk with venlafaxine tablets compared to placebo, we can break down the answer into several key components:\n",
      "\n",
      "### Step 1: Understanding Venlafaxine\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, anxiety disorders, and certain other mood disorders. It works by increasing the levels of serotonin and norepinephrine in the brain, which can help improve mood and reduce anxiety.\n",
      "\n",
      "### Step 2: Suicidality and Antidepressants\n",
      "The relationship between antidepressants and suicidality is complex. Some studies have indicated that certain antidepressants may increase the risk of suicidal thoughts and behaviors, particularly in younger populations. This has led to the implementation of black box warnings on many antidepressants, including venlafaxine.\n",
      "\n",
      "### Step 3: Age Groups and Clinical Studies\n",
      "Clinical trials and meta-analyses have been conducted to evaluate the efficacy and safety of venlafaxine across different age groups. Research has shown that:\n",
      "\n",
      "- **Children and Adolescents (under 18 years)**: This age group has been associated with an increased risk of suicidality when treated with venlafaxine. The FDA has issued warnings regarding the use of antidepressants in this population due to the potential for increased suicidal thoughts and behaviors.\n",
      "\n",
      "- **Adults (18 years and older)**: In contrast, studies have indicated that adults may experience a reduction in suicidality risk when treated with venlafaxine. The evidence suggests that adults generally benefit from the antidepressant effects of venlafaxine without the same level of increased risk seen in younger patients.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "Based on the available evidence, the age group that showed a reduction in suicidality risk with venlafaxine tablets compared to placebo is primarily **adults (18 years and older)**. In this population, venlafaxine has been found to be effective in reducing depressive symptoms and associated suicidality, while the younger population (children and adolescents) may not experience the same benefits and could be at a higher risk for adverse effects.\n",
      "\n",
      "### Summary\n",
      "In summary, while venlafaxine can be beneficial for adults in reducing suicidality risk, caution is advised when prescribing it to younger individuals due to the potential for increased suicidality. Always consult healthcare professionals for personalized medical advice and treatment options.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017364\n",
      "prediction:  To address the question regarding the age group that showed a reduction in suicidality risk with venlafaxine tablets compared to placebo, we can break down the answer into several key components:\n",
      "\n",
      "### Step 1: Understanding Venlafaxine\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, anxiety disorders, and certain other mood disorders. It works by increasing the levels of serotonin and norepinephrine in the brain, which can help improve mood and reduce anxiety.\n",
      "\n",
      "### Step 2: Suicidality and Antidepressants\n",
      "The relationship between antidepressants and suicidality is complex. Some studies have indicated that certain antidepressants may increase the risk of suicidal thoughts and behaviors, particularly in younger populations. This has led to the implementation of black box warnings on many antidepressants, including venlafaxine.\n",
      "\n",
      "### Step 3: Age Groups and Clinical Studies\n",
      "Clinical trials and meta-analyses have been conducted to evaluate the efficacy and safety of venlafaxine across different age groups. Research has shown that:\n",
      "\n",
      "- **Children and Adolescents (under 18 years)**: This age group has been associated with an increased risk of suicidality when treated with venlafaxine. The FDA has issued warnings regarding the use of antidepressants in this population due to the potential for increased suicidal thoughts and behaviors.\n",
      "\n",
      "- **Adults (18 years and older)**: In contrast, studies have indicated that adults may experience a reduction in suicidality risk when treated with venlafaxine. The evidence suggests that adults generally benefit from venlafaxine, with a decrease in depressive symptoms and associated suicidality.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "Based on the available evidence, the age group that showed a reduction in suicidality risk with venlafaxine tablets compared to placebo is primarily **adults (18 years and older)**. In this population, venlafaxine has been found to be effective in reducing depressive symptoms and associated suicidality, while the younger population (children and adolescents) may be at a higher risk for adverse effects, including increased suicidality.\n",
      "\n",
      "### Summary\n",
      "In summary, while venlafaxine can be beneficial for adults in reducing suicidality risk, caution is advised when prescribing it to younger individuals due to the potential for increased risk of suicidal thoughts and behaviors. Always consult healthcare professionals for personalized medical advice and treatment options.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.03062\n",
      "prediction:  To address the question regarding the contraindication profile of WL-AAB-Z-W-982 in comparison to other drugs with known contraindications, we will follow a structured approach. This will involve defining contraindications, discussing the specific contraindications of WL-AAB-Z-W-982, and then comparing these with those of other drugs.\n",
      "\n",
      "### Step 1: Understanding Contraindications\n",
      "\n",
      "**Definition of Contraindications:**\n",
      "Contraindications are specific situations or conditions under which a drug should not be used because it may be harmful to the patient. These can be absolute (where the drug should never be used) or relative (where caution is advised, and the drug may be used under certain circumstances).\n",
      "\n",
      "### Step 2: Contraindications of WL-AAB-Z-W-982\n",
      "\n",
      "**Hypothetical Profile of WL-AAB-Z-W-982:**\n",
      "Since WL-AAB-Z-W-982 is a fictional drug, we will create a hypothetical profile for it. Letâ€™s assume WL-AAB-Z-W-982 is an immunosuppressant used in the treatment of autoimmune diseases. \n",
      "\n",
      "**Potential Contraindications:**\n",
      "1. **Active Infections:** Use in patients with active infections may exacerbate the condition.\n",
      "2. **Severe Liver Dysfunction:** The drug may be metabolized in the liver, and impaired function could lead to toxicity.\n",
      "3. **Pregnancy and Lactation:** Potential teratogenic effects or risks to the fetus.\n",
      "4. **History of Malignancy:** Increased risk of developing certain cancers due to immunosuppression.\n",
      "5. **Hypersensitivity Reactions:** Patients with known allergies to components of the drug should avoid it.\n",
      "\n",
      "### Step 3: Comparison with Other Drugs\n",
      "\n",
      "**Comparison with Other Immunosuppressants:**\n",
      "To provide a meaningful comparison, we can look at other immunosuppressants, such as Azathioprine, Methotrexate, and Cyclosporine.\n",
      "\n",
      "1. **Azathioprine:**\n",
      "   - **Contraindications:** Active infections, pregnancy, and hypersensitivity.\n",
      "   - **Comparison:** Similar to WL-AAB-Z-W-982, it is contraindicated in active infections and pregnancy. However, it has additional concerns regarding its use in patients with certain genetic deficiencies (e.g., TPMT deficiency).\n",
      "\n",
      "2. **Methotrexate:**\n",
      "   - **Contraindications:** Pregnancy, liver disease, and blood disorders.\n",
      "   - **Comparison:** Methotrexate shares contraindications related to pregnancy and liver dysfunction, similar to WL-AAB-Z-W-982. However, it has a broader range of contraindications related to hematological conditions.\n",
      "\n",
      "3. **Cyclosporine:**\n",
      "   - **Contraindications:** Active infections, uncontrolled hypertension, and hypersensitivity.\n",
      "   - **Comparison:** Cyclosporine also has contraindications for active infections and hypersensitivity, aligning with WL-AAB-Z-W-982. However, it has specific contraindications related to renal impairment and hypertension.\n",
      "\n",
      "### Step 4: Summary of Findings\n",
      "\n",
      "**Overall Comparison:**\n",
      "- **Common Contraindications:** WL-AAB-Z-W-982 shares several contraindications with other immunosuppressants, particularly concerning active infections and pregnancy.\n",
      "- **Unique Aspects:** The specific contraindications may vary based on the drug's mechanism of action, metabolism, and patient population. For instance, WL-AAB-Z-W-982 may have unique contraindications based on its pharmacokinetics or specific patient demographics that are not present in other drugs.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In conclusion, the contraindication profile of WL-AAB-Z-W-982, while hypothetical, can be compared to other known immunosuppressants. It shares common contraindications, particularly regarding active infections and pregnancy, but may also have unique contraindications based on its specific pharmacological properties. Understanding these profiles is crucial for safe prescribing practices and patient management. Further research and clinical data would be necessary to establish a comprehensive contraindication profile for WL-AAB-Z-W-982 in real-world scenarios.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004582\n",
      "prediction:  To address the question regarding the duration of initial treatment with pantoprazole sodium for injection before switching to oral pantoprazole sodium delayed-release tablets in the context of acute reflux esophagitis, we can break down the answer into several key components:\n",
      "\n",
      "### Step 1: Understanding Acute Reflux Esophagitis\n",
      "Acute reflux esophagitis is an inflammation of the esophagus caused by the backflow of stomach acid into the esophagus. It can lead to symptoms such as heartburn, difficulty swallowing, and chest pain. Treatment typically involves the use of proton pump inhibitors (PPIs) to reduce gastric acid production.\n",
      "\n",
      "### Step 2: Role of Pantoprazole\n",
      "Pantoprazole is a PPI that is commonly used to treat conditions related to excessive stomach acid, including gastroesophageal reflux disease (GERD) and esophagitis. It is available in both intravenous (IV) and oral formulations.\n",
      "\n",
      "### Step 3: Initial Treatment Protocol\n",
      "In clinical practice, the initial treatment for acute reflux esophagitis often starts with intravenous pantoprazole, especially in cases where patients are unable to take oral medications due to severe symptoms or complications. The IV formulation allows for rapid absorption and immediate effect in reducing gastric acid secretion.\n",
      "\n",
      "### Step 4: Duration of IV Treatment\n",
      "The duration of initial treatment with IV pantoprazole can vary based on clinical guidelines and individual patient needs. However, a common practice is to administer IV pantoprazole for a period of 3 to 7 days. This duration allows for adequate control of symptoms and healing of the esophagus before transitioning to oral therapy.\n",
      "\n",
      "### Step 5: Transition to Oral Therapy\n",
      "After the initial treatment period with IV pantoprazole, patients are typically switched to oral pantoprazole delayed-release tablets. This transition is usually made when the patientâ€™s condition has stabilized, and they are able to tolerate oral medications. The switch is often made after 3 to 7 days of IV treatment, depending on the patient's clinical response and ability to take oral medications.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the duration of initial treatment with pantoprazole sodium for injection in the management of acute reflux esophagitis is generally around 3 to 7 days before switching to oral pantoprazole sodium delayed-release tablets. This approach allows for effective management of symptoms and promotes healing of the esophagus while ensuring that the patient can safely transition to oral therapy. Always consult specific clinical guidelines or studies for the most accurate and tailored treatment protocols.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004345\n",
      "prediction:  To address the question regarding the duration of initial treatment with pantoprazole sodium for injection before switching to oral pantoprazole sodium delayed-release tablets in the context of acute reflux esophagitis, we can break down the answer into several key components:\n",
      "\n",
      "### Step 1: Understanding Acute Reflux Esophagitis\n",
      "Acute reflux esophagitis is an inflammation of the esophagus caused by the backflow of stomach acid into the esophagus. It can lead to symptoms such as heartburn, difficulty swallowing, and chest pain. Treatment typically involves the use of proton pump inhibitors (PPIs) to reduce gastric acid production.\n",
      "\n",
      "### Step 2: Role of Pantoprazole\n",
      "Pantoprazole is a PPI that is commonly used to treat conditions related to excessive stomach acid, including gastroesophageal reflux disease (GERD) and esophagitis. It is available in both intravenous (IV) and oral formulations.\n",
      "\n",
      "### Step 3: Initial Treatment Protocol\n",
      "In clinical practice, the initial treatment for acute reflux esophagitis often starts with intravenous pantoprazole, especially in cases where patients are unable to take oral medications due to severe symptoms or complications. The intravenous formulation allows for rapid absorption and immediate effect in reducing gastric acid secretion.\n",
      "\n",
      "### Step 4: Duration of IV Treatment\n",
      "The duration of initial treatment with intravenous pantoprazole can vary based on the severity of the condition and the clinical guidelines followed. However, a common practice is to administer IV pantoprazole for a period of 3 to 7 days. This duration allows for adequate control of symptoms and healing of the esophagus before transitioning to oral therapy.\n",
      "\n",
      "### Step 5: Transition to Oral Therapy\n",
      "Once the patient's condition stabilizes and they are able to tolerate oral medications, the treatment is typically switched to oral pantoprazole delayed-release tablets. This transition is usually made after the initial IV treatment period, which is often around 3 to 7 days, depending on the patient's clinical response and ability to ingest oral medications.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the duration of initial treatment with pantoprazole sodium for injection in the management of acute reflux esophagitis is generally around **3 to 7 days** before switching to oral pantoprazole sodium delayed-release tablets. This approach allows for effective management of symptoms and promotes healing of the esophagus while ensuring that the patient can safely transition to oral therapy. \n",
      "\n",
      "It is important to note that individual treatment plans may vary based on specific patient needs, clinical guidelines, and physician discretion. Always refer to the latest clinical guidelines and studies for the most accurate and up-to-date information.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004789\n",
      "prediction:  To address the question regarding the duration of initial treatment with pantoprazole sodium for injection before switching to oral pantoprazole sodium delayed-release tablets in the context of acute reflux esophagitis, we can break down the answer into several key components:\n",
      "\n",
      "### Step 1: Understanding Acute Reflux Esophagitis\n",
      "Acute reflux esophagitis is an inflammation of the esophagus caused by the backflow of stomach acid into the esophagus. It can lead to symptoms such as heartburn, difficulty swallowing, and chest pain. Treatment typically involves the use of proton pump inhibitors (PPIs) to reduce gastric acid production.\n",
      "\n",
      "### Step 2: Role of Pantoprazole\n",
      "Pantoprazole is a PPI that is commonly used to treat conditions related to excessive stomach acid, including gastroesophageal reflux disease (GERD) and esophagitis. It is available in both intravenous (IV) and oral formulations.\n",
      "\n",
      "### Step 3: Initial Treatment Protocol\n",
      "In clinical practice, the initial treatment for acute reflux esophagitis often starts with intravenous pantoprazole, especially in cases where patients are unable to take oral medications due to severe symptoms or complications. The intravenous formulation allows for rapid absorption and immediate effect in reducing gastric acid secretion.\n",
      "\n",
      "### Step 4: Duration of IV Treatment\n",
      "The duration of initial treatment with intravenous pantoprazole can vary based on the severity of the condition and the clinical judgment of the healthcare provider. However, a common practice is to administer IV pantoprazole for a period of 3 to 7 days. This duration allows for adequate control of symptoms and healing of the esophagus before transitioning to oral therapy.\n",
      "\n",
      "### Step 5: Transition to Oral Therapy\n",
      "Once the patient's condition stabilizes and they are able to tolerate oral medications, the treatment is typically switched to oral pantoprazole sodium delayed-release tablets. This transition is crucial for ongoing management and prevention of recurrence of reflux esophagitis.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the duration of initial treatment with pantoprazole sodium for injection in the management of acute reflux esophagitis is generally around 3 to 7 days before switching to oral pantoprazole sodium delayed-release tablets. This approach ensures effective management of the condition while facilitating a smooth transition to long-term oral therapy. Always consult specific clinical guidelines or studies for the most accurate and tailored treatment protocols.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 5 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017002\n",
      "prediction:  To address the question regarding the recommended intervention if a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (an immediate-release formulation of oxycodone), we need to consider several factors related to pharmacology, patient safety, and clinical management. Hereâ€™s a step-by-step breakdown:\n",
      "\n",
      "### Step 1: Understand the Role of CYP3A4\n",
      "CYP3A4 is an important enzyme in the liver that metabolizes many drugs, including opioids like oxycodone. When a CYP3A4 inhibitor is present, it can increase the plasma concentration of drugs that are metabolized by this enzyme, potentially leading to increased effects and side effects.\n",
      "\n",
      "### Step 2: Effects of Discontinuing a CYP3A4 Inhibitor\n",
      "When a CYP3A4 inhibitor is discontinued, the metabolism of drugs like RoxyBond may return to normal levels. This can lead to a decrease in the plasma concentration of oxycodone, which may result in reduced analgesic efficacy and potential withdrawal symptoms in patients who have been on a stable dose of the medication.\n",
      "\n",
      "### Step 3: Assess the Patient's Clinical Status\n",
      "Before making any changes to the medication regimen, it is essential to assess the patient's current clinical status, including:\n",
      "- Pain management needs\n",
      "- Current dosage of RoxyBond\n",
      "- Duration of therapy\n",
      "- Any signs of withdrawal or inadequate pain control\n",
      "- Other medications the patient is taking\n",
      "\n",
      "### Step 4: Recommended Intervention\n",
      "1. **Monitor the Patient**: After the CYP3A4 inhibitor is discontinued, closely monitor the patient for changes in pain control and any signs of withdrawal symptoms. This monitoring should include regular assessments of pain levels and functional status.\n",
      "\n",
      "2. **Adjust the Dose of RoxyBond**: If the patient experiences inadequate pain control after the discontinuation of the CYP3A4 inhibitor, consider adjusting the dose of RoxyBond. This may involve:\n",
      "   - **Increasing the Dose**: If the patient is experiencing increased pain, a dose adjustment may be necessary to achieve adequate analgesia.\n",
      "   - **Reassessing the Dosing Schedule**: Depending on the patient's pain levels, it may be appropriate to adjust the frequency of dosing.\n",
      "\n",
      "3. **Consider Alternative Pain Management Strategies**: If the patient continues to have inadequate pain control despite dose adjustments, consider alternative pain management strategies. This may include:\n",
      "   - Switching to a different opioid that is not primarily metabolized by CYP3A4.\n",
      "   - Adding adjuvant medications (e.g., NSAIDs, gabapentinoids) to enhance pain control.\n",
      "\n",
      "4. **Educate the Patient**: Inform the patient about the potential changes in their pain management regimen and the importance of reporting any changes in pain levels or side effects.\n",
      "\n",
      "5. **Follow-Up**: Schedule follow-up appointments to reassess the patient's pain management and make further adjustments as necessary.\n",
      "\n",
      "### Step 5: Document Changes\n",
      "Ensure that all changes to the medication regimen, patient assessments, and follow-up plans are well-documented in the patient's medical record for continuity of care.\n",
      "\n",
      "### Conclusion\n",
      "In summary, if a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond, the recommended intervention involves monitoring the patient closely, adjusting the dose of RoxyBond as needed, considering alternative pain management strategies, educating the patient, and ensuring proper follow-up. This comprehensive approach helps to maintain effective pain control while minimizing the risk of withdrawal symptoms or inadequate analgesia.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017592\n",
      "prediction:  To address the question regarding the recommended intervention if a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (oxycodone), we need to consider several factors related to pharmacology, the metabolism of oxycodone, and patient safety.\n",
      "\n",
      "### Step 1: Understanding RoxyBond and CYP3A4\n",
      "\n",
      "**RoxyBond (Oxycodone)**: RoxyBond is an immediate-release formulation of oxycodone, an opioid analgesic used for the management of pain. Oxycodone is primarily metabolized in the liver, with CYP3A4 and CYP2D6 being the key enzymes involved in its metabolism.\n",
      "\n",
      "**CYP3A4 Inhibitors**: These are substances that can decrease the activity of the CYP3A4 enzyme, leading to increased plasma concentrations of drugs metabolized by this pathway, such as oxycodone. Common CYP3A4 inhibitors include certain antifungals (e.g., ketoconazole), antibiotics (e.g., erythromycin), and some HIV protease inhibitors.\n",
      "\n",
      "### Step 2: Effects of Discontinuing a CYP3A4 Inhibitor\n",
      "\n",
      "When a CYP3A4 inhibitor is discontinued, the metabolism of oxycodone may increase, leading to lower plasma levels of the drug. This can result in reduced analgesic efficacy and may necessitate adjustments in the patient's pain management regimen.\n",
      "\n",
      "### Step 3: Recommended Intervention\n",
      "\n",
      "1. **Monitor the Patient**: After discontinuation of the CYP3A4 inhibitor, it is crucial to closely monitor the patient for changes in pain control and any signs of withdrawal or inadequate analgesia. This monitoring should include assessing pain levels, functional status, and any side effects.\n",
      "\n",
      "2. **Assess Pain Management Needs**: Evaluate the patient's current pain management plan. If the patient was stable on a certain dose of RoxyBond while on the CYP3A4 inhibitor, it may be necessary to reassess their pain control needs after the inhibitor is stopped.\n",
      "\n",
      "3. **Consider Dose Adjustment**: If the patient experiences inadequate pain control after the CYP3A4 inhibitor is discontinued, a dose adjustment of RoxyBond may be warranted. This should be done cautiously, considering the patient's overall opioid tolerance and pain management needs.\n",
      "\n",
      "4. **Educate the Patient**: Inform the patient about the potential changes in their pain management due to the discontinuation of the CYP3A4 inhibitor. Encourage them to report any changes in pain levels or side effects promptly.\n",
      "\n",
      "5. **Consult with a Pharmacist or Specialist**: If there are uncertainties regarding the appropriate dose adjustment or management strategy, consulting with a clinical pharmacist or pain management specialist can provide additional insights and recommendations.\n",
      "\n",
      "### Step 4: Follow-Up\n",
      "\n",
      "Schedule a follow-up appointment to reassess the patient's pain management and make any necessary adjustments based on their response to the changes in their medication regimen.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, if a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond, the recommended intervention includes close monitoring of the patient, reassessing their pain management needs, considering dose adjustments of RoxyBond, educating the patient about potential changes, and ensuring appropriate follow-up. This comprehensive approach helps ensure effective pain management while minimizing the risk of inadequate analgesia or withdrawal symptoms.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.018305\n",
      "prediction:  To address the question regarding the recommended intervention if a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (oxycodone), we need to consider several factors related to pharmacology, the metabolism of oxycodone, and patient safety.\n",
      "\n",
      "### Step 1: Understanding RoxyBond and CYP3A4\n",
      "\n",
      "**RoxyBond (Oxycodone)**: RoxyBond is an immediate-release formulation of oxycodone, an opioid analgesic used for the management of pain. Oxycodone is primarily metabolized in the liver, with significant involvement of the cytochrome P450 enzyme system, particularly CYP3A4 and CYP2D6.\n",
      "\n",
      "**CYP3A4 Inhibitors**: These are substances that can decrease the activity of the CYP3A4 enzyme, leading to increased plasma concentrations of drugs metabolized by this pathway, such as oxycodone. Common CYP3A4 inhibitors include certain antifungals (e.g., ketoconazole), antibiotics (e.g., erythromycin), and some protease inhibitors.\n",
      "\n",
      "### Step 2: Effects of Discontinuing a CYP3A4 Inhibitor\n",
      "\n",
      "When a CYP3A4 inhibitor is discontinued, the metabolism of oxycodone may increase, leading to lower plasma levels of the drug. This can result in reduced analgesic efficacy and may necessitate adjustments in the patient's pain management regimen.\n",
      "\n",
      "### Step 3: Recommended Intervention\n",
      "\n",
      "1. **Monitor the Patient**: After the discontinuation of the CYP3A4 inhibitor, it is crucial to closely monitor the patient for changes in pain control and any signs of withdrawal or inadequate analgesia.\n",
      "\n",
      "2. **Assess Pain Control**: Evaluate the patient's current pain levels and overall response to RoxyBond. This assessment should include both subjective reports from the patient and objective measures of pain relief.\n",
      "\n",
      "3. **Adjust Oxycodone Dosage**: If the patient experiences inadequate pain control after the CYP3A4 inhibitor is stopped, consider adjusting the dosage of RoxyBond. This may involve increasing the dose or frequency of administration, depending on the patient's pain levels and previous dosing regimen.\n",
      "\n",
      "4. **Consider Alternative Pain Management Strategies**: If adjusting the oxycodone dosage is insufficient or if the patient has concerns about opioid use, explore alternative pain management strategies. This could include non-opioid analgesics (e.g., acetaminophen, NSAIDs), adjuvant medications (e.g., gabapentin, pregabalin), or non-pharmacological interventions (e.g., physical therapy, cognitive-behavioral therapy).\n",
      "\n",
      "5. **Educate the Patient**: Inform the patient about the potential changes in their medication regimen and the importance of reporting any changes in pain levels or side effects. Encourage them to communicate openly about their pain management needs.\n",
      "\n",
      "6. **Follow-Up**: Schedule a follow-up appointment to reassess the patient's pain management plan and make further adjustments as necessary. Continuous evaluation is key to ensuring effective pain control.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, if a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond, the recommended intervention involves monitoring the patient closely, assessing pain control, adjusting the oxycodone dosage if needed, considering alternative pain management strategies, educating the patient, and ensuring follow-up care. This comprehensive approach helps to maintain effective pain management while minimizing the risk of inadequate analgesia or withdrawal symptoms.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004479\n",
      "prediction:  To answer the question about the brand name of a drug used for general body cleansing processes, we need to clarify what is meant by \"general body cleansing.\" This term can refer to various contexts, including detoxification, bowel preparation, or cleansing for specific medical procedures. \n",
      "\n",
      "1. **Understanding the Context**: \n",
      "   - If we are discussing bowel cleansing, particularly before medical procedures like colonoscopy, there are specific medications designed for this purpose.\n",
      "   - If the context is more about detoxification or general health, it could refer to supplements or herbal products.\n",
      "\n",
      "2. **Common Drugs for Bowel Cleansing**:\n",
      "   - **Polyethylene Glycol (PEG)**: A common brand name for this type of bowel cleansing agent is **GoLYTELY** or **MoviPrep**. These are often used to prepare patients for colonoscopy by inducing a clear liquid bowel movement.\n",
      "   - **Sodium Phosphate**: Another option is **Fleet Phospho-soda**, which is also used for bowel cleansing.\n",
      "\n",
      "3. **Detoxification Products**:\n",
      "   - If the question pertains to detoxification, there are various herbal supplements and products marketed for this purpose, but they are not typically classified as drugs. Examples include products like **Detox Tea** or **Herbal Clean**.\n",
      "\n",
      "4. **Conclusion**:\n",
      "   - For the specific context of bowel cleansing, the brand names **GoLYTELY** and **MoviPrep** are widely recognized. If the question is about general detoxification, there are numerous products available, but they may not have a single brand name associated with them.\n",
      "\n",
      "**Final Answer**: The brand name of the drug commonly used for bowel cleansing processes is **GoLYTELY** or **MoviPrep**. For general detoxification, there are various products available, but they do not have a singular brand name.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004067\n",
      "prediction:  To answer the question about the brand name of a drug used for general body cleansing processes, we need to clarify what is meant by \"general body cleansing.\" This term can refer to various contexts, including detoxification, preparation for medical procedures, or general health and wellness.\n",
      "\n",
      "1. **Understanding General Body Cleansing**: \n",
      "   - General body cleansing can involve the removal of toxins, waste products, or impurities from the body. This can be achieved through various means, including dietary changes, supplements, or medications.\n",
      "\n",
      "2. **Types of Products**:\n",
      "   - There are several types of products that may be used for body cleansing, including:\n",
      "     - **Laxatives**: Used to cleanse the intestines.\n",
      "     - **Detox Supplements**: Often marketed for detoxification.\n",
      "     - **Enemas**: Used for bowel cleansing.\n",
      "     - **Hydration Solutions**: Used for cleansing before medical procedures.\n",
      "\n",
      "3. **Common Brand Names**:\n",
      "   - **Laxatives**: \n",
      "     - **Miralax** (Polyethylene Glycol 3350) is a common over-the-counter laxative used for bowel cleansing.\n",
      "     - **Dulcolax** (Bisacodyl) is another well-known brand for bowel preparation.\n",
      "   - **Detox Supplements**: \n",
      "     - **Herbalife** offers various detox products, though their efficacy can vary.\n",
      "     - **Detox teas** and other herbal supplements often have brand names like **Yogi Detox Tea**.\n",
      "   - **Enemas**: \n",
      "     - **Fleet Enema** is a popular brand for saline enemas used for bowel cleansing.\n",
      "   - **Hydration Solutions**: \n",
      "     - **GoLYTELY** is a brand used for bowel preparation before colonoscopy.\n",
      "\n",
      "4. **Specific Contexts**:\n",
      "   - If the question pertains to a specific medical procedure, such as colonoscopy preparation, the brand name **GoLYTELY** or **MoviPrep** would be appropriate.\n",
      "   - For general detoxification, products like **Detoxify** or **Cleanse** may be referenced, but these are often less scientifically validated.\n",
      "\n",
      "5. **Conclusion**:\n",
      "   - The answer to the question can vary based on the specific type of cleansing being referred to. However, a commonly recognized brand for general body cleansing, particularly in the context of bowel preparation, is **GoLYTELY**. For general detoxification, **Miralax** is a widely used product.\n",
      "\n",
      "In summary, the brand name of the drug used for general body cleansing processes can vary, but **GoLYTELY** is a prominent example in the context of bowel cleansing, while **Miralax** is a well-known laxative for general use.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.005485\n",
      "prediction:  To answer the question about the brand name of a drug used for general body cleansing processes, we need to clarify what is meant by \"general body cleansing.\" This term can refer to various contexts, including detoxification, preparation for medical procedures, or general health and wellness.\n",
      "\n",
      "1. **Understanding the Context**: \n",
      "   - If the question pertains to detoxification or cleansing diets, there are numerous supplements and herbal products marketed for these purposes, but they may not be scientifically validated.\n",
      "   - If it refers to medical procedures, such as colon cleansing before a colonoscopy, specific medications are used.\n",
      "\n",
      "2. **Common Uses**:\n",
      "   - **Colon Cleansing**: For medical procedures, drugs like **GoLYTELY** (polyethylene glycol) or **Miralax** (polyethylene glycol 3350) are commonly used to cleanse the bowel.\n",
      "   - **Detoxification**: Products like **Herbalife** or various detox teas are marketed for general body cleansing, but their efficacy and safety can vary widely.\n",
      "\n",
      "3. **Brand Names**:\n",
      "   - For bowel preparation, **GoLYTELY** is a well-known brand that is often prescribed for patients needing a clean colon for procedures.\n",
      "   - Another example is **Fleet Phospho-soda**, which is also used for bowel cleansing.\n",
      "\n",
      "4. **Conclusion**: \n",
      "   - If the focus is on medical cleansing, **GoLYTELY** is a prominent brand name associated with general body cleansing processes, particularly for bowel preparation. \n",
      "   - If the context is broader and includes detox products, there are many brands, but they may not have the same level of scientific backing.\n",
      "\n",
      "In summary, the brand name of a drug used for general body cleansing processes, particularly in a medical context, is **GoLYTELY**. For other contexts, the answer may vary based on the specific type of cleansing being referred to.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: TOXEX\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017836\n",
      "prediction:  To answer the question about which brand name drug is specifically indicated for the treatment of acne, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Understanding Acne\n",
      "Acne is a common skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It can manifest as pimples, blackheads, and cysts, primarily affecting the face, back, and shoulders. Treatment options vary based on the severity of the condition.\n",
      "\n",
      "### Step 2: Types of Acne Treatments\n",
      "Acne treatments can be categorized into topical medications, oral medications, and procedural interventions. Topical treatments include retinoids, antibiotics, and benzoyl peroxide, while oral treatments may involve antibiotics, hormonal therapies, or isotretinoin.\n",
      "\n",
      "### Step 3: Identifying Brand Name Drugs\n",
      "Several brand name drugs are specifically indicated for the treatment of acne. Here are a few notable examples:\n",
      "\n",
      "1. **Accutane (Isotretinoin)**: This is a powerful oral retinoid used for severe acne that has not responded to other treatments. It works by reducing oil production, preventing clogged pores, and has anti-inflammatory properties.\n",
      "\n",
      "2. **Differin (Adapalene)**: This is a topical retinoid that helps to prevent acne by promoting cell turnover and preventing clogged pores. It is available over-the-counter and is effective for mild to moderate acne.\n",
      "\n",
      "3. **Benzac (Benzoyl Peroxide)**: This topical medication is an antibacterial agent that helps to reduce acne-causing bacteria and is often used in combination with other treatments.\n",
      "\n",
      "4. **Clindagel (Clindamycin)**: This is a topical antibiotic that helps to reduce inflammation and bacterial growth on the skin, making it effective for treating acne.\n",
      "\n",
      "5. **Epiduo (Adapalene and Benzoyl Peroxide)**: This combination topical treatment combines a retinoid and benzoyl peroxide, targeting multiple pathways involved in acne development.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "Among the various brand name drugs indicated for the treatment of acne, **Accutane (Isotretinoin)** is particularly notable for its effectiveness in severe cases. However, for milder forms of acne, **Differin (Adapalene)** and **Benzac (Benzoyl Peroxide)** are commonly recommended. The choice of treatment depends on the severity of the acne, patient history, and potential side effects.\n",
      "\n",
      "### Final Answer\n",
      "**Accutane (Isotretinoin)** is a brand name drug specifically indicated for the treatment of severe acne. Other effective brand name options include **Differin (Adapalene)** and **Benzac (Benzoyl Peroxide)** for milder cases.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017927\n",
      "prediction:  To answer the question about which brand name drug is specifically indicated for the treatment of acne, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Understanding Acne\n",
      "Acne is a common skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It can manifest as pimples, blackheads, and cysts, primarily affecting the face, back, and shoulders. Treatment options vary based on the severity of the condition.\n",
      "\n",
      "### Step 2: Types of Acne Treatments\n",
      "Acne treatments can be categorized into topical medications, oral medications, and procedural interventions. Topical treatments include retinoids, antibiotics, and benzoyl peroxide, while oral treatments may involve antibiotics, hormonal therapies, or isotretinoin.\n",
      "\n",
      "### Step 3: Identifying Brand Name Drugs\n",
      "Several brand name drugs are specifically indicated for the treatment of acne. Here are a few notable examples:\n",
      "\n",
      "1. **Accutane (Isotretinoin)**: This is a powerful oral retinoid used for severe acne that has not responded to other treatments. It works by reducing oil production, preventing clogged pores, and has anti-inflammatory properties.\n",
      "\n",
      "2. **Differin (Adapalene)**: This is a topical retinoid that helps to prevent acne by promoting cell turnover and preventing clogged pores. It is available over-the-counter and is effective for mild to moderate acne.\n",
      "\n",
      "3. **Benzac (Benzoyl Peroxide)**: This topical medication is an antibacterial agent that helps to reduce acne-causing bacteria and is often used in combination with other treatments.\n",
      "\n",
      "4. **Clindagel (Clindamycin)**: This is a topical antibiotic that helps to reduce inflammation and bacterial growth on the skin, making it effective for treating acne.\n",
      "\n",
      "5. **Epiduo (Adapalene and Benzoyl Peroxide)**: This combination topical treatment combines a retinoid and benzoyl peroxide, targeting multiple pathways involved in acne development.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "Among the various brand name drugs indicated for the treatment of acne, **Accutane (Isotretinoin)** is particularly notable for its effectiveness in severe cases. However, for milder forms of acne, **Differin (Adapalene)** and **Benzac (Benzoyl Peroxide)** are commonly recommended. The choice of treatment depends on the severity of the acne, patient history, and potential side effects.\n",
      "\n",
      "### Final Answer\n",
      "**Accutane (Isotretinoin)** is a brand name drug specifically indicated for the treatment of severe acne. Other notable options include **Differin (Adapalene)** and **Benzac (Benzoyl Peroxide)** for milder cases.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017537\n",
      "prediction:  To answer the question about which brand name drug is specifically indicated for the treatment of acne, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Understanding Acne\n",
      "Acne is a common skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It can manifest as pimples, blackheads, and cysts, primarily affecting the face, back, and shoulders. Treatment options vary based on the severity of the condition.\n",
      "\n",
      "### Step 2: Types of Acne Treatments\n",
      "Acne treatments can be categorized into topical medications, oral medications, and procedures. Topical treatments include retinoids, antibiotics, and benzoyl peroxide, while oral medications may include antibiotics and hormonal treatments.\n",
      "\n",
      "### Step 3: Identifying Brand Name Drugs\n",
      "Several brand name drugs are specifically indicated for the treatment of acne. Here are a few notable examples:\n",
      "\n",
      "1. **Accutane (Isotretinoin)**: This is a powerful oral retinoid used for severe acne that has not responded to other treatments. It works by reducing oil production, preventing clogged pores, and has anti-inflammatory properties.\n",
      "\n",
      "2. **Differin (Adapalene)**: This is a topical retinoid that helps to prevent acne by promoting cell turnover and preventing clogged pores. It is available over-the-counter and is effective for mild to moderate acne.\n",
      "\n",
      "3. **Benzac (Benzoyl Peroxide)**: This topical medication is effective in killing acne-causing bacteria and reducing inflammation. It is available in various formulations and concentrations.\n",
      "\n",
      "4. **Clindagel (Clindamycin)**: This is a topical antibiotic that helps reduce acne by decreasing the number of bacteria on the skin and reducing inflammation.\n",
      "\n",
      "5. **Ortho Tri-Cyclen**: While primarily a birth control pill, it is also indicated for the treatment of acne in women due to its hormonal regulation effects.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "Among the various options, **Accutane (Isotretinoin)** is often highlighted as a specific brand name drug indicated for the treatment of severe acne. However, the choice of treatment can depend on the severity of the acne, patient history, and other individual factors. It is essential for patients to consult with a healthcare provider to determine the most appropriate treatment for their specific condition.\n",
      "\n",
      "### Final Answer\n",
      "**Accutane (Isotretinoin)** is a brand name drug specifically indicated for the treatment of severe acne. Other notable options include **Differin (Adapalene)** and **Benzac (Benzoyl Peroxide)** for milder cases. Always consult a healthcare professional for personalized treatment recommendations.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: MD-Acne Body Acne Treatment\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014493\n",
      "prediction:  To answer the question about which symptom is specifically relieved by the nighttime formulation of the drug 'nighttime severe cold and flu,' we need to consider the common ingredients and intended effects of such formulations.\n",
      "\n",
      "1. **Understanding Nighttime Formulations**: Nighttime cold and flu medications are designed to help alleviate symptoms that can interfere with sleep. These formulations typically contain a combination of ingredients that target various symptoms associated with colds and flu, such as cough, congestion, fever, and body aches.\n",
      "\n",
      "2. **Common Ingredients**: Nighttime cold and flu medications often include:\n",
      "   - **Antihistamines** (e.g., diphenhydramine or doxylamine): These help relieve symptoms like runny nose and sneezing, and they also have sedative properties that can help induce sleep.\n",
      "   - **Cough Suppressants** (e.g., dextromethorphan): These help reduce the urge to cough, which can be particularly bothersome at night.\n",
      "   - **Decongestants** (e.g., phenylephrine or pseudoephedrine): These help relieve nasal congestion but are often avoided in nighttime formulations due to their stimulating effects.\n",
      "   - **Pain Relievers/Fever Reducers** (e.g., acetaminophen or ibuprofen): These help alleviate body aches and reduce fever.\n",
      "\n",
      "3. **Specific Symptom Relief**: The primary symptom that is specifically targeted and relieved by nighttime formulations is **cough**. The inclusion of cough suppressants in these formulations is crucial because coughing can disrupt sleep, making it difficult for individuals to rest and recover from their illness.\n",
      "\n",
      "4. **Sedative Effects**: Additionally, the sedative effects of antihistamines in nighttime formulations help users fall asleep more easily, which is another symptom that is particularly addressed by these medications.\n",
      "\n",
      "5. **Conclusion**: In summary, the symptom specifically relieved by the nighttime formulation of 'nighttime severe cold and flu' is **cough**, along with the added benefit of promoting sleep through the sedative effects of antihistamines. This combination allows individuals to manage their cold or flu symptoms effectively while also ensuring they can get the rest they need to recover.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013704\n",
      "prediction:  To answer the question about which symptom is specifically relieved by the nighttime formulation of the drug 'nighttime severe cold and flu,' we need to consider the common ingredients and intended effects of such formulations.\n",
      "\n",
      "1. **Understanding Nighttime Formulations**: Nighttime cold and flu medications are designed to help alleviate symptoms that can interfere with sleep. These formulations typically contain a combination of ingredients that target various symptoms associated with colds and flu, such as cough, congestion, fever, and body aches.\n",
      "\n",
      "2. **Common Ingredients**: Nighttime cold and flu medications often include:\n",
      "   - **Antihistamines** (e.g., diphenhydramine or doxylamine): These help relieve symptoms like runny nose and sneezing, and they also have sedative properties that can help induce sleep.\n",
      "   - **Cough Suppressants** (e.g., dextromethorphan): These help reduce the urge to cough, which can be particularly bothersome at night.\n",
      "   - **Pain Relievers/Fever Reducers** (e.g., acetaminophen or ibuprofen): These help alleviate body aches and reduce fever.\n",
      "   - **Decongestants** (e.g., phenylephrine or pseudoephedrine): These help relieve nasal congestion, although they are less commonly included in nighttime formulations due to their stimulating effects.\n",
      "\n",
      "3. **Specific Symptom Relief**: The primary symptom that is specifically targeted and relieved by nighttime formulations is **cough**. Coughing can be particularly disruptive during the night, making it difficult for individuals to fall asleep or stay asleep. The inclusion of cough suppressants in these formulations is aimed at providing relief from this symptom, allowing for a more restful night.\n",
      "\n",
      "4. **Additional Considerations**: While nighttime formulations also address other symptoms like nasal congestion and body aches, the sedative effect of antihistamines and the cough suppressant action are particularly important for promoting sleep. Therefore, while multiple symptoms may be alleviated, the relief of cough is a key focus of nighttime cold and flu medications.\n",
      "\n",
      "In summary, the symptom specifically relieved by the nighttime formulation of the drug 'nighttime severe cold and flu' is **cough**, which is addressed through the inclusion of cough suppressants and sedative antihistamines to facilitate better sleep.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014078\n",
      "prediction:  To answer the question about which symptom is specifically relieved by the nighttime formulation of the drug 'nighttime severe cold and flu,' we need to consider the common ingredients and intended effects of such formulations.\n",
      "\n",
      "1. **Understanding Nighttime Formulations**: Nighttime cold and flu medications are designed to help alleviate symptoms that can interfere with sleep. These formulations typically contain a combination of ingredients that target various symptoms associated with colds and flu, such as cough, congestion, fever, and body aches.\n",
      "\n",
      "2. **Common Ingredients**: Nighttime cold and flu medications often include:\n",
      "   - **Antihistamines** (e.g., diphenhydramine or doxylamine): These help relieve symptoms like runny nose and sneezing, and they also have sedative properties that can help promote sleep.\n",
      "   - **Cough Suppressants** (e.g., dextromethorphan): These help reduce the urge to cough, which can be particularly bothersome at night.\n",
      "   - **Decongestants** (e.g., phenylephrine or pseudoephedrine): These help relieve nasal congestion but are often avoided in nighttime formulations due to their stimulating effects.\n",
      "   - **Pain Relievers/Fever Reducers** (e.g., acetaminophen or ibuprofen): These help alleviate body aches and reduce fever.\n",
      "\n",
      "3. **Specific Symptom Relief**: The primary symptom that is specifically targeted and relieved by nighttime formulations is **cough**. Coughing can be particularly disruptive during the night, making it difficult for individuals to fall asleep or stay asleep. The inclusion of cough suppressants in these formulations is aimed at providing relief from this symptom, allowing for a more restful night.\n",
      "\n",
      "4. **Additional Considerations**: While nighttime formulations also help with other symptoms like nasal congestion and body aches, the sedative effect of antihistamines and the cough suppressant action are particularly important for promoting sleep. Therefore, the relief of cough is a key focus of these medications.\n",
      "\n",
      "In summary, the symptom specifically relieved by the nighttime formulation of the drug 'nighttime severe cold and flu' is **cough**, which is addressed through the inclusion of cough suppressants and sedative antihistamines to facilitate better sleep during illness.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Runny nose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.034824\n",
      "prediction:  To answer the question regarding JAYPIRCA's effect on CYP3A substrates, we need to break down the components involved:\n",
      "\n",
      "1. **Understanding JAYPIRCA**: JAYPIRCA (generic name: pexidartinib) is a medication primarily used for the treatment of certain types of cancer, specifically tenosynovial giant cell tumor (TGCT). It is a kinase inhibitor that targets the CSF1R (colony-stimulating factor 1 receptor).\n",
      "\n",
      "2. **CYP3A Enzyme**: CYP3A is a major enzyme in the cytochrome P450 family that is responsible for the metabolism of a wide variety of drugs. It plays a crucial role in the biotransformation of many medications, including those used in oncology, and is involved in the metabolism of approximately 50% of all drugs on the market.\n",
      "\n",
      "3. **Drug Interactions**: When considering the effect of JAYPIRCA on CYP3A substrates, it is important to determine whether JAYPIRCA acts as an inhibitor, inducer, or has no significant effect on the CYP3A enzyme. \n",
      "\n",
      "4. **Clinical Data**: According to clinical studies and pharmacokinetic data, JAYPIRCA has been shown to inhibit CYP3A activity. This means that when JAYPIRCA is administered, it can potentially increase the plasma concentrations of drugs that are metabolized by CYP3A, leading to an increased risk of adverse effects or toxicity from those drugs.\n",
      "\n",
      "5. **Implications for Co-Administration**: If a patient is taking other medications that are substrates of CYP3A while on JAYPIRCA, healthcare providers need to be cautious. Dose adjustments of the CYP3A substrates may be necessary to avoid toxicity. \n",
      "\n",
      "6. **Conclusion**: Based on the above information, the true statement regarding JAYPIRCA's effect on CYP3A substrates is that JAYPIRCA is an inhibitor of CYP3A. This inhibition can lead to increased levels of co-administered drugs that are metabolized by this enzyme, necessitating careful monitoring and potential dose adjustments.\n",
      "\n",
      "In summary, the true statement regarding JAYPIRCA's effect on CYP3A substrates is that JAYPIRCA inhibits CYP3A, which can affect the metabolism of other drugs that are substrates of this enzyme.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.032671\n",
      "prediction:  To answer the question regarding JAYPIRCA's effect on CYP3A substrates, we need to break down the components involved:\n",
      "\n",
      "1. **Understanding JAYPIRCA**: JAYPIRCA (generic name: pirtobrutinib) is a medication primarily used in the treatment of certain types of blood cancers, particularly those that are resistant to other therapies. It is a Brutonâ€™s tyrosine kinase (BTK) inhibitor.\n",
      "\n",
      "2. **CYP3A Enzyme**: CYP3A is a major enzyme in the cytochrome P450 family, responsible for the metabolism of a wide variety of drugs. It plays a crucial role in the pharmacokinetics of many medications, influencing their efficacy and safety profiles.\n",
      "\n",
      "3. **Interaction with CYP3A Substrates**: When discussing a drug's effect on CYP3A substrates, we are interested in whether the drug inhibits or induces the activity of the CYP3A enzyme. \n",
      "   - **Inhibition**: If a drug inhibits CYP3A, it can lead to increased plasma concentrations of drugs that are metabolized by this enzyme, potentially causing toxicity or adverse effects.\n",
      "   - **Induction**: Conversely, if a drug induces CYP3A, it can decrease the plasma concentrations of CYP3A substrates, potentially leading to reduced efficacy of those medications.\n",
      "\n",
      "4. **JAYPIRCA's Effect on CYP3A**: According to available clinical data and pharmacokinetic studies, JAYPIRCA is not a significant inhibitor or inducer of CYP3A. This means that it does not substantially affect the metabolism of drugs that are substrates of the CYP3A enzyme.\n",
      "\n",
      "5. **Clinical Implications**: The lack of significant interaction with CYP3A substrates is clinically relevant. It suggests that JAYPIRCA can be used in conjunction with other medications that are metabolized by CYP3A without the need for dose adjustments or increased monitoring for drug interactions.\n",
      "\n",
      "### Conclusion:\n",
      "In summary, the true statement regarding JAYPIRCA's effect on CYP3A substrates is that JAYPIRCA does not significantly inhibit or induce CYP3A activity. Therefore, it is unlikely to cause clinically relevant interactions with other drugs that are metabolized by this enzyme. This characteristic can be beneficial in managing patients who are on multiple medications, particularly in oncology settings where polypharmacy is common.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.043626\n",
      "prediction:  To answer the question regarding JAYPIRCA's effect on CYP3A substrates, we need to break down the components involved:\n",
      "\n",
      "1. **Understanding JAYPIRCA**: JAYPIRCA (generic name: pirtobrutinib) is a medication primarily used in the treatment of certain types of blood cancers, particularly those that are resistant to other therapies. It is a selective Bruton's tyrosine kinase (BTK) inhibitor.\n",
      "\n",
      "2. **CYP3A Enzyme**: CYP3A is a major enzyme in the cytochrome P450 family that is responsible for the metabolism of a wide variety of drugs. It plays a crucial role in the biotransformation of many medications, including those used in oncology, cardiovascular diseases, and more.\n",
      "\n",
      "3. **Interaction with CYP3A Substrates**: When discussing the effect of a drug like JAYPIRCA on CYP3A substrates, we are interested in whether JAYPIRCA inhibits or induces the activity of the CYP3A enzyme. \n",
      "\n",
      "4. **Clinical Data**: According to clinical studies and pharmacokinetic data, JAYPIRCA has been shown to have a minimal effect on CYP3A substrates. It is not a strong inhibitor or inducer of CYP3A, which means that it does not significantly alter the metabolism of drugs that are processed by this enzyme.\n",
      "\n",
      "5. **Implications for Drug Interactions**: Because JAYPIRCA does not significantly inhibit or induce CYP3A, it is generally considered safe to use in conjunction with other medications that are metabolized by this pathway. However, as with any medication, it is essential for healthcare providers to review a patientâ€™s complete medication list to avoid potential interactions.\n",
      "\n",
      "6. **Conclusion**: In summary, the true statement regarding JAYPIRCA's effect on CYP3A substrates is that it does not significantly inhibit or induce CYP3A activity. This characteristic is important for clinicians when considering drug interactions and managing patient therapy.\n",
      "\n",
      "In conclusion, the answer to the question is that JAYPIRCA has a minimal effect on CYP3A substrates, meaning it does not significantly inhibit or induce the CYP3A enzyme.\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA weakly inhibits CYP3A substrates.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.022736\n",
      "prediction:  To answer the question regarding the behaviors that were NOT observed in clinical trials of venlafaxine, we first need to understand what venlafaxine is and the common behaviors or side effects that have been documented in clinical trials.\n",
      "\n",
      "### Step 1: Understanding Venlafaxine\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters associated with mood regulation.\n",
      "\n",
      "### Step 2: Commonly Observed Behaviors and Side Effects\n",
      "In clinical trials and post-marketing studies, venlafaxine has been associated with several behaviors and side effects, including:\n",
      "\n",
      "1. **Nausea**: A common side effect, especially during the initial stages of treatment.\n",
      "2. **Dizziness**: Patients often report dizziness, particularly when standing up quickly.\n",
      "3. **Increased Blood Pressure**: Venlafaxine can lead to dose-dependent increases in blood pressure.\n",
      "4. **Sexual Dysfunction**: This includes decreased libido, delayed ejaculation, and anorgasmia.\n",
      "5. **Withdrawal Symptoms**: Discontinuation syndrome can occur, characterized by flu-like symptoms, irritability, and insomnia.\n",
      "6. **Anxiety or Agitation**: Some patients may experience increased anxiety or agitation, particularly at the start of treatment.\n",
      "\n",
      "### Step 3: Identifying Behaviors NOT Observed\n",
      "To determine what behaviors were NOT observed in clinical trials, we can consider the following:\n",
      "\n",
      "- **Severe Weight Gain**: While some antidepressants are associated with significant weight gain, venlafaxine is generally not known for this side effect. In fact, some patients may experience weight loss.\n",
      "- **Severe Sedation**: Unlike some other antidepressants, venlafaxine is not typically associated with significant sedation or drowsiness.\n",
      "- **Mania or Hypomania**: While some antidepressants can trigger manic episodes in susceptible individuals, this is not a commonly reported behavior with venlafaxine.\n",
      "- **Severe Allergic Reactions**: While allergic reactions can occur with any medication, severe reactions like anaphylaxis are not commonly reported with venlafaxine.\n",
      "\n",
      "### Conclusion\n",
      "In summary, a behavior that was NOT observed in clinical trials of venlafaxine includes **severe weight gain** or **severe sedation**. These behaviors are not characteristic of venlafaxine's side effect profile based on the data from clinical trials. It is important to note that individual responses to medication can vary, and patients should always discuss potential side effects with their healthcare provider.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.024252\n",
      "prediction:  To answer the question regarding the behaviors that were NOT observed in clinical trials of venlafaxine, we first need to understand what venlafaxine is and the context of its clinical trials.\n",
      "\n",
      "### Step 1: Understanding Venlafaxine\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters associated with mood regulation.\n",
      "\n",
      "### Step 2: Reviewing Clinical Trials\n",
      "Clinical trials for venlafaxine have been conducted to evaluate its efficacy and safety. These trials typically assess various outcomes, including:\n",
      "\n",
      "- **Efficacy in reducing depressive symptoms**\n",
      "- **Side effects and adverse reactions**\n",
      "- **Impact on anxiety levels**\n",
      "- **Withdrawal symptoms upon discontinuation**\n",
      "\n",
      "### Step 3: Commonly Observed Behaviors\n",
      "In clinical trials, several behaviors and side effects have been commonly observed with venlafaxine, including:\n",
      "\n",
      "- **Nausea and gastrointestinal disturbances**\n",
      "- **Increased blood pressure**\n",
      "- **Dizziness and sedation**\n",
      "- **Sexual dysfunction**\n",
      "- **Withdrawal symptoms upon abrupt discontinuation**\n",
      "\n",
      "### Step 4: Identifying Behaviors NOT Observed\n",
      "To answer the question, we need to identify behaviors that were not typically reported in clinical trials. Some behaviors that are generally NOT associated with venlafaxine include:\n",
      "\n",
      "- **Severe cognitive impairment**: While some patients may experience mild cognitive effects, severe cognitive impairment is not a commonly reported side effect.\n",
      "- **Significant weight gain**: Unlike some other antidepressants, venlafaxine is not typically associated with significant weight gain; in fact, some patients may experience weight loss.\n",
      "- **Hallucinations or delusions**: These are not common side effects of venlafaxine and are more associated with other classes of medications or underlying psychiatric conditions.\n",
      "- **Severe allergic reactions**: While any medication can cause allergic reactions, severe reactions like anaphylaxis are not commonly reported with venlafaxine.\n",
      "\n",
      "### Conclusion\n",
      "In summary, while venlafaxine has a range of observed behaviors and side effects in clinical trials, behaviors such as severe cognitive impairment, significant weight gain, hallucinations or delusions, and severe allergic reactions were NOT typically observed. It is important for healthcare providers to monitor patients for any side effects and to consider individual patient responses to the medication.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.022222\n",
      "prediction:  To answer the question regarding the behaviors that were NOT observed in clinical trials of venlafaxine, we first need to understand what venlafaxine is and the context of its clinical trials.\n",
      "\n",
      "### Step 1: Understanding Venlafaxine\n",
      "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters associated with mood regulation.\n",
      "\n",
      "### Step 2: Reviewing Clinical Trials\n",
      "Clinical trials for venlafaxine have been conducted to evaluate its efficacy and safety. These trials typically assess various outcomes, including:\n",
      "\n",
      "- **Efficacy in reducing depressive symptoms**\n",
      "- **Side effects and adverse reactions**\n",
      "- **Impact on anxiety levels**\n",
      "- **Withdrawal symptoms upon discontinuation**\n",
      "\n",
      "### Step 3: Commonly Observed Behaviors\n",
      "In clinical trials, several behaviors and side effects have been commonly observed with venlafaxine, including:\n",
      "\n",
      "- **Nausea and gastrointestinal disturbances**\n",
      "- **Increased blood pressure**\n",
      "- **Dizziness and sedation**\n",
      "- **Sexual dysfunction**\n",
      "- **Withdrawal symptoms upon abrupt discontinuation**\n",
      "\n",
      "### Step 4: Identifying Behaviors NOT Observed\n",
      "To answer the question, we need to identify behaviors that were not typically reported in clinical trials. Some behaviors that are generally NOT associated with venlafaxine include:\n",
      "\n",
      "1. **Severe Cognitive Impairment**: While some patients may experience mild cognitive effects, severe cognitive impairment is not a commonly reported side effect.\n",
      "  \n",
      "2. **Significant Weight Gain**: Unlike some other antidepressants, venlafaxine is not typically associated with significant weight gain; in fact, some patients may experience weight loss.\n",
      "\n",
      "3. **Hallucinations or Delusions**: These severe psychiatric symptoms are not commonly reported in clinical trials for venlafaxine.\n",
      "\n",
      "4. **Severe Allergic Reactions**: While allergic reactions can occur with any medication, severe reactions like anaphylaxis are not commonly observed in venlafaxine trials.\n",
      "\n",
      "5. **Manic Episodes**: Venlafaxine is not typically associated with inducing manic episodes in patients with bipolar disorder, especially when used appropriately.\n",
      "\n",
      "### Conclusion\n",
      "In summary, while venlafaxine has a range of observed behaviors and side effects in clinical trials, behaviors such as severe cognitive impairment, significant weight gain, hallucinations, severe allergic reactions, and manic episodes are generally NOT observed. It is important for healthcare providers to monitor patients for any unusual symptoms and to consider individual patient histories when prescribing venlafaxine.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004938\n",
      "prediction:  To answer the question regarding the highest dietary dose of albuterol sulfate tested in Golden hamsters that showed no evidence of tumorigenicity, we need to consider several aspects of the research and testing protocols typically used in toxicology and pharmacology.\n",
      "\n",
      "1. **Understanding Albuterol Sulfate**: Albuterol sulfate is a bronchodilator commonly used to treat asthma and other conditions involving bronchospasm. It works by relaxing the muscles in the airways and increasing airflow to the lungs. \n",
      "\n",
      "2. **Tumorigenicity Testing**: Tumorigenicity studies are conducted to assess the potential of a substance to cause cancer. These studies often involve long-term exposure to the substance in question, typically through dietary or other routes of administration, in animal models such as rodents.\n",
      "\n",
      "3. **Golden Hamsters as a Model**: Golden hamsters (Mesocricetus auratus) are often used in research due to their unique physiological and metabolic characteristics. They can be particularly useful for studying the effects of various substances, including pharmaceuticals.\n",
      "\n",
      "4. **Study Design**: In studies assessing the tumorigenic potential of a substance like albuterol sulfate, researchers would typically administer varying doses of the compound to groups of hamsters over an extended period, often their entire lifespan. The doses would be carefully calculated based on body weight and expected human exposure levels.\n",
      "\n",
      "5. **Determining the No-Observed-Adverse-Effect Level (NOAEL)**: The highest dietary dose that shows no evidence of tumorigenicity would be identified as the NOAEL. This is the maximum dose at which no significant adverse effects, including tumor formation, are observed in the test subjects.\n",
      "\n",
      "6. **Review of Literature**: To find the specific dose tested in Golden hamsters, one would need to review scientific literature, including toxicology reports, peer-reviewed studies, and regulatory assessments from agencies such as the FDA or EPA. These documents would provide detailed findings on the doses used and the outcomes observed.\n",
      "\n",
      "7. **Conclusion**: While I cannot provide a specific numerical value for the highest dietary dose of albuterol sulfate tested in Golden hamsters without access to specific studies, it is essential to consult relevant toxicological studies or databases for precise information. Typically, such studies would report the NOAEL in terms of mg/kg body weight per day, and this value would be critical for understanding the safety profile of albuterol sulfate in long-term dietary exposure scenarios.\n",
      "\n",
      "In summary, to find the exact highest dietary dose of albuterol sulfate tested in Golden hamsters that showed no evidence of tumorigenicity, one would need to refer to specific toxicological studies or regulatory documents that detail the findings of such research.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.003681\n",
      "prediction:  To answer the question regarding the highest dietary dose of albuterol sulfate tested in golden hamsters that showed no evidence of tumorigenicity, we need to consider several aspects of the research and testing protocols typically used in toxicology and pharmacology studies.\n",
      "\n",
      "1. **Understanding Albuterol Sulfate**: Albuterol sulfate is a bronchodilator commonly used to treat asthma and other conditions that cause breathing difficulties. It works by relaxing the muscles in the airways, making it easier to breathe.\n",
      "\n",
      "2. **Tumorigenicity Testing**: Tumorigenicity studies are conducted to assess whether a substance has the potential to cause cancer. These studies often involve long-term exposure to the substance in question, typically through dietary or other routes of administration, in animal models.\n",
      "\n",
      "3. **Use of Golden Hamsters**: Golden hamsters (Mesocricetus auratus) are often used in research due to their well-characterized biology and susceptibility to certain types of tumors. They serve as a model organism for studying the effects of various compounds, including pharmaceuticals.\n",
      "\n",
      "4. **Study Design**: In studies assessing the tumorigenic potential of a substance like albuterol sulfate, researchers would typically administer varying doses of the compound to groups of golden hamsters over an extended period. The doses would be carefully calculated based on factors such as body weight and expected human exposure levels.\n",
      "\n",
      "5. **Determining the No-Observed-Adverse-Effect Level (NOAEL)**: The highest dietary dose that shows no evidence of tumorigenicity would be identified as the NOAEL. This is the maximum dose at which no adverse effects, including tumor formation, are observed in the test subjects.\n",
      "\n",
      "6. **Review of Literature**: To provide a specific answer to the question, one would need to review scientific literature or regulatory documents that detail the findings of studies involving albuterol sulfate in golden hamsters. These studies would typically be published in peer-reviewed journals or included in safety assessment reports by regulatory agencies.\n",
      "\n",
      "7. **Conclusion**: Without access to specific studies or data, I cannot provide the exact highest dietary dose of albuterol sulfate tested in golden hamsters that showed no evidence of tumorigenicity. However, such information would typically be found in toxicological studies or safety assessments conducted by organizations such as the U.S. Environmental Protection Agency (EPA) or the Food and Drug Administration (FDA).\n",
      "\n",
      "In summary, to find the precise dose, one would need to consult specific toxicological studies or regulatory documents that report the results of albuterol sulfate testing in golden hamsters.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.005299\n",
      "prediction:  To answer the question regarding the highest dietary dose of albuterol sulfate tested in golden hamsters that showed no evidence of tumorigenicity, we need to consider several aspects of the research and testing protocols typically used in toxicology and pharmacology.\n",
      "\n",
      "1. **Understanding Albuterol Sulfate**: Albuterol sulfate is a bronchodilator commonly used to treat asthma and other conditions that cause breathing difficulties. It works by relaxing the muscles in the airways, making it easier to breathe.\n",
      "\n",
      "2. **Tumorigenicity Testing**: Tumorigenicity studies are conducted to assess whether a substance has the potential to cause cancer. These studies often involve long-term exposure to the substance in question, typically in animal models, to observe any potential carcinogenic effects.\n",
      "\n",
      "3. **Use of Golden Hamsters**: Golden hamsters (Mesocricetus auratus) are often used in laboratory studies due to their well-characterized biology and susceptibility to certain types of tumors. They serve as a model organism for studying the effects of various substances, including pharmaceuticals.\n",
      "\n",
      "4. **Dietary Dose Studies**: In dietary dose studies, animals are fed varying amounts of a substance over a prolonged period. The doses are typically expressed in terms of milligrams per kilogram of body weight (mg/kg) per day. Researchers monitor the animals for any signs of adverse effects, including tumor development.\n",
      "\n",
      "5. **Findings from Research**: While specific studies may vary, it is essential to refer to published research or regulatory documents that detail the findings of such studies. For albuterol sulfate, the highest dietary dose tested in golden hamsters that showed no evidence of tumorigenicity would be documented in toxicological assessments or safety evaluations conducted by organizations such as the FDA or EPA.\n",
      "\n",
      "6. **Conclusion**: To provide a precise answer to the question, one would need to reference specific studies or reports that detail the results of albuterol sulfate testing in golden hamsters. If such data is available, it would indicate the highest dose at which no tumors were observed, typically expressed in mg/kg/day.\n",
      "\n",
      "In summary, while I cannot provide a specific numerical answer without access to the latest research data, the process of determining the highest dietary dose of albuterol sulfate that showed no evidence of tumorigenicity in golden hamsters involves reviewing scientific literature and regulatory assessments that detail the outcomes of long-term exposure studies. For accurate information, consulting peer-reviewed journals or toxicological databases would be necessary.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.026698\n",
      "prediction:  To answer the question regarding the highest dose of fluoxetine administered to adult rats in fertility studies and its comparison to the Maximum Recommended Human Dose (MRHD) on a mg/mÂ² basis, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Understanding Fluoxetine\n",
      "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression, anxiety disorders, and other mental health conditions. In animal studies, including fertility studies, researchers often assess the effects of various doses of the drug on reproductive health.\n",
      "\n",
      "### Step 2: Identifying the Highest Dose in Fertility Studies\n",
      "In fertility studies involving adult rats, the highest dose of fluoxetine that has been reported varies across different studies. However, a common high dose used in such studies is often around 20 mg/kg/day. Some studies may use doses as high as 40 mg/kg/day, but 20 mg/kg/day is frequently cited in the literature.\n",
      "\n",
      "### Step 3: Converting Rat Doses to Human Equivalent Doses\n",
      "To compare the doses administered to rats with the MRHD for humans, we need to convert the rat dose to a human equivalent dose (HED). The conversion is typically done using the following formula:\n",
      "\n",
      "\\[\n",
      "\\text{HED (mg/kg)} = \\text{Animal Dose (mg/kg)} \\times \\left( \\frac{\\text{Animal Weight (kg)}}{\\text{Human Weight (kg)}} \\right)^{0.33}\n",
      "\\]\n",
      "\n",
      "For this calculation, we can use the following assumptions:\n",
      "- Average weight of a rat: approximately 0.25 kg (250 g)\n",
      "- Average weight of a human: approximately 70 kg\n",
      "\n",
      "Using the conversion factor for rats to humans, we can calculate the HED for a dose of 20 mg/kg:\n",
      "\n",
      "\\[\n",
      "\\text{HED} = 20 \\, \\text{mg/kg} \\times \\left( \\frac{0.25}{70} \\right)^{0.33}\n",
      "\\]\n",
      "\n",
      "Calculating this gives us an approximate HED.\n",
      "\n",
      "### Step 4: Calculating the MRHD\n",
      "The Maximum Recommended Human Dose (MRHD) for fluoxetine is typically around 60 mg/day for adults. To compare this to the calculated HED from the rat studies, we need to convert the MRHD to a mg/mÂ² basis.\n",
      "\n",
      "The average human body surface area (BSA) can be estimated using the formula:\n",
      "\n",
      "\\[\n",
      "\\text{BSA (mÂ²)} = \\sqrt{\\frac{\\text{height (cm)} \\times \\text{weight (kg)}}{3600}}\n",
      "\\]\n",
      "\n",
      "For an average adult (175 cm tall and 70 kg), the BSA is approximately 1.9 mÂ². Therefore, the MRHD in mg/mÂ² can be calculated as follows:\n",
      "\n",
      "\\[\n",
      "\\text{MRHD (mg/mÂ²)} = \\frac{60 \\, \\text{mg}}{1.9 \\, \\text{mÂ²}} \\approx 31.58 \\, \\text{mg/mÂ²}\n",
      "\\]\n",
      "\n",
      "### Step 5: Comparison\n",
      "Now, we can compare the calculated HED from the rat studies to the MRHD in mg/mÂ². If we assume the HED from the rat studies is approximately 2.5 mg/mÂ² (this is a hypothetical value for illustration; actual values may vary based on specific studies), we can see how it compares to the MRHD of approximately 31.58 mg/mÂ².\n",
      "\n",
      "### Conclusion\n",
      "In summary, the highest dose of fluoxetine administered to adult rats in fertility studies is often around 20 mg/kg/day, which can be converted to a human equivalent dose. The MRHD for fluoxetine in humans is approximately 60 mg/day, which translates to about 31.58 mg/mÂ². The comparison of these values helps researchers understand the potential implications of fluoxetine on fertility and reproductive health across species. \n",
      "\n",
      "For precise values and specific studies, it is essential to refer to the original research articles and regulatory documents that detail these findings.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.027726\n",
      "prediction:  To answer the question regarding the highest dose of fluoxetine administered to adult rats in fertility studies and its comparison to the Maximum Recommended Human Dose (MRHD) on a mg/mÂ² basis, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Understanding Fluoxetine\n",
      "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression, anxiety disorders, and other mental health conditions. In animal studies, including fertility studies, researchers often assess the effects of various doses on reproductive health.\n",
      "\n",
      "### Step 2: Identifying the Highest Dose in Fertility Studies\n",
      "In fertility studies involving adult rats, the highest doses of fluoxetine administered can vary based on the specific study design and objectives. However, a common high dose used in many studies is around 20 mg/kg body weight per day. Some studies may use even higher doses, such as 40 mg/kg/day, to assess the effects on fertility and reproductive outcomes.\n",
      "\n",
      "### Step 3: Converting Rat Doses to Human Equivalent Doses\n",
      "To compare the doses administered to rats with the MRHD for humans, we need to convert the rat doses to a human equivalent dose (HED) using a standard conversion factor. The conversion from animal doses to human doses typically uses the following formula:\n",
      "\n",
      "\\[\n",
      "\\text{HED (mg/kg)} = \\text{Animal Dose (mg/kg)} \\times \\left( \\frac{\\text{Animal Weight (kg)}}{\\text{Human Weight (kg)}} \\right)^{0.33}\n",
      "\\]\n",
      "\n",
      "For this calculation, we often use a standard human weight of approximately 60 kg.\n",
      "\n",
      "### Step 4: Calculating the Human Equivalent Dose\n",
      "Assuming a high dose of 40 mg/kg for rats, we can calculate the HED:\n",
      "\n",
      "1. **Rat Dose**: 40 mg/kg\n",
      "2. **Rat Weight**: Assume an average rat weight of 0.25 kg (250 g).\n",
      "3. **Human Weight**: 60 kg\n",
      "\n",
      "Using the formula:\n",
      "\n",
      "\\[\n",
      "\\text{HED} = 40 \\, \\text{mg/kg} \\times \\left( \\frac{0.25}{60} \\right)^{0.33}\n",
      "\\]\n",
      "\n",
      "Calculating the ratio:\n",
      "\n",
      "\\[\n",
      "\\frac{0.25}{60} \\approx 0.00417\n",
      "\\]\n",
      "\n",
      "Now, raising this to the power of 0.33:\n",
      "\n",
      "\\[\n",
      "0.00417^{0.33} \\approx 0.215\n",
      "\\]\n",
      "\n",
      "Now, multiplying by the rat dose:\n",
      "\n",
      "\\[\n",
      "\\text{HED} \\approx 40 \\times 0.215 \\approx 8.6 \\, \\text{mg/kg}\n",
      "\\]\n",
      "\n",
      "### Step 5: Comparing to MRHD\n",
      "The MRHD for fluoxetine in humans is typically around 60 mg/day for adults, which can be converted to mg/mÂ² based on an average human body surface area (BSA). The BSA can be estimated using the formula:\n",
      "\n",
      "\\[\n",
      "\\text{BSA (mÂ²)} = \\sqrt{\\frac{\\text{height (cm)} \\times \\text{weight (kg)}}{3600}}\n",
      "\\]\n",
      "\n",
      "For an average adult (e.g., 170 cm tall and 70 kg), the BSA is approximately 1.8 mÂ². Thus, the MRHD in mg/mÂ² would be:\n",
      "\n",
      "\\[\n",
      "\\text{MRHD (mg/mÂ²)} = \\frac{60 \\, \\text{mg}}{1.8 \\, \\text{mÂ²}} \\approx 33.33 \\, \\text{mg/mÂ²}\n",
      "\\]\n",
      "\n",
      "### Step 6: Conclusion\n",
      "In summary, the highest dose of fluoxetine administered to adult rats in fertility studies is often around 40 mg/kg. When converted to a human equivalent dose, this is approximately 8.6 mg/kg, which translates to about 15.5 mg/mÂ². In comparison, the MRHD for humans is approximately 33.33 mg/mÂ². This indicates that the doses used in rat studies can be significantly lower than the MRHD for humans, highlighting the importance of careful dose selection in preclinical studies to ensure safety and relevance to human health.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.027174\n",
      "prediction:  To answer the question regarding the highest dose of fluoxetine administered to adult rats in fertility studies and its comparison to the Maximum Recommended Human Dose (MRHD) on a mg/mÂ² basis, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Understanding Fluoxetine\n",
      "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression, anxiety disorders, and other mental health conditions. In animal studies, including fertility studies, researchers often assess the effects of various doses on reproductive health.\n",
      "\n",
      "### Step 2: Identifying the Highest Dose in Fertility Studies\n",
      "In fertility studies involving adult rats, the highest doses of fluoxetine can vary based on the specific study design and objectives. However, a common high dose used in many studies is around 20 mg/kg body weight per day. Some studies may use even higher doses, such as 40 mg/kg/day, to assess the effects on fertility and reproductive outcomes.\n",
      "\n",
      "### Step 3: Converting Rat Doses to Human Equivalent Doses\n",
      "To compare the doses administered to rats with the MRHD for humans, we need to convert the rat dose to a human equivalent dose (HED). The conversion is typically done using the following formula:\n",
      "\n",
      "\\[\n",
      "\\text{HED (mg/kg)} = \\text{Animal Dose (mg/kg)} \\times \\left( \\frac{\\text{Animal Weight (kg)}}{\\text{Human Weight (kg)}} \\right)^{0.33}\n",
      "\\]\n",
      "\n",
      "For this calculation, we can use the following assumptions:\n",
      "- Average weight of a rat: approximately 0.25 kg (250 g)\n",
      "- Average weight of a human: approximately 70 kg\n",
      "\n",
      "Using the highest dose of 40 mg/kg for the rat:\n",
      "\n",
      "\\[\n",
      "\\text{HED} = 40 \\, \\text{mg/kg} \\times \\left( \\frac{0.25}{70} \\right)^{0.33}\n",
      "\\]\n",
      "\n",
      "Calculating the ratio:\n",
      "\n",
      "\\[\n",
      "\\left( \\frac{0.25}{70} \\right)^{0.33} \\approx 0.017\n",
      "\\]\n",
      "\n",
      "Thus, the HED would be:\n",
      "\n",
      "\\[\n",
      "\\text{HED} \\approx 40 \\times 0.017 \\approx 0.68 \\, \\text{mg/kg}\n",
      "\\]\n",
      "\n",
      "### Step 4: Calculating the MRHD\n",
      "The Maximum Recommended Human Dose (MRHD) for fluoxetine is typically around 60 mg/day for adults. To convert this to a mg/mÂ² basis, we can use the average body surface area (BSA) for humans, which is approximately 1.73 mÂ².\n",
      "\n",
      "To find the dose in mg/mÂ²:\n",
      "\n",
      "\\[\n",
      "\\text{MRHD (mg/mÂ²)} = \\frac{\\text{MRHD (mg/day)}}{\\text{BSA (mÂ²)}}\n",
      "\\]\n",
      "\n",
      "Calculating this:\n",
      "\n",
      "\\[\n",
      "\\text{MRHD (mg/mÂ²)} = \\frac{60 \\, \\text{mg}}{1.73 \\, \\text{mÂ²}} \\approx 34.64 \\, \\text{mg/mÂ²}\n",
      "\\]\n",
      "\n",
      "### Step 5: Comparison of Rat Dose to MRHD\n",
      "Now, we can compare the highest dose administered to rats (40 mg/kg) converted to mg/mÂ² with the MRHD. \n",
      "\n",
      "1. Convert the rat dose to mg/mÂ²:\n",
      "   - For a rat weighing 0.25 kg, the dose in mg/mÂ² would be:\n",
      "   \\[\n",
      "   \\text{Rat Dose (mg/mÂ²)} = 40 \\, \\text{mg/kg} \\times 0.25 \\, \\text{kg} \\times \\frac{1}{0.25} \\approx 160 \\, \\text{mg/mÂ²}\n",
      "   \\]\n",
      "\n",
      "2. Now, we can compare:\n",
      "   - Rat Dose: 160 mg/mÂ²\n",
      "   - MRHD: 34.64 mg/mÂ²\n",
      "\n",
      "### Conclusion\n",
      "In summary, the highest dose of fluoxetine administered to adult rats in fertility studies is often around 40 mg/kg, which translates to approximately 160 mg/mÂ² when considering the body surface area of the rat. In comparison, the MRHD for humans is approximately 34.64 mg/mÂ². This indicates that the doses used in rat studies are significantly higher than the MRHD for humans, which is a common practice in preclinical studies to assess safety and efficacy before human trials.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 12.5 mg/kg/day, approximately 1.5 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.028502\n",
      "prediction:  To answer the question regarding the highest dose of fluoxetine administered to rats in a 2-year carcinogenicity study and its comparison to the maximum recommended human dose (MRHD) on a mg/mÂ² basis, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Identify the Highest Dose Administered to Rats\n",
      "\n",
      "In carcinogenicity studies, various doses of a drug are administered to laboratory animals to assess potential long-term effects, including cancer risk. For fluoxetine, the highest dose used in a 2-year carcinogenicity study in rats is typically reported in scientific literature or regulatory documents. \n",
      "\n",
      "For fluoxetine, the highest dose administered to rats in such studies is often around **60 mg/kg/day**. However, it is essential to verify this figure from specific studies or regulatory filings, as it may vary slightly depending on the study design.\n",
      "\n",
      "### Step 2: Determine the Maximum Recommended Human Dose (MRHD)\n",
      "\n",
      "The MRHD for fluoxetine in humans is generally around **60 mg/day** for the treatment of major depressive disorder and other conditions. This dose can vary based on the specific condition being treated and individual patient factors, but 60 mg/day is a common upper limit.\n",
      "\n",
      "### Step 3: Convert Human Dose to mg/mÂ²\n",
      "\n",
      "To compare doses between species, it is common to convert the human dose to a body surface area (BSA) basis, typically expressed in mg/mÂ². The conversion factor used for humans is approximately **37 mÂ²** for an average adult.\n",
      "\n",
      "To convert the MRHD of fluoxetine (60 mg/day) to mg/mÂ²:\n",
      "\n",
      "\\[\n",
      "\\text{Dose in mg/mÂ²} = \\frac{\\text{Human Dose (mg/day)}}{\\text{Average BSA (mÂ²)}}\n",
      "\\]\n",
      "\n",
      "\\[\n",
      "\\text{Dose in mg/mÂ²} = \\frac{60 \\text{ mg}}{1.73 \\text{ mÂ²}} \\approx 34.64 \\text{ mg/mÂ²}\n",
      "\\]\n",
      "\n",
      "### Step 4: Convert Rat Dose to mg/mÂ²\n",
      "\n",
      "Next, we need to convert the rat dose (60 mg/kg/day) to mg/mÂ². The average body weight of a rat is approximately **0.25 kg** (250 grams). The BSA for a rat can be estimated using the formula:\n",
      "\n",
      "\\[\n",
      "\\text{BSA (mÂ²)} = \\text{Weight (kg)}^{0.67} \\times 0.1\n",
      "\\]\n",
      "\n",
      "For a rat weighing 0.25 kg:\n",
      "\n",
      "\\[\n",
      "\\text{BSA} \\approx 0.25^{0.67} \\times 0.1 \\approx 0.025 \\text{ mÂ²}\n",
      "\\]\n",
      "\n",
      "Now, we can convert the rat dose to mg/mÂ²:\n",
      "\n",
      "\\[\n",
      "\\text{Dose in mg/mÂ²} = \\frac{60 \\text{ mg/kg} \\times 0.25 \\text{ kg}}{0.025 \\text{ mÂ²}} = 600 \\text{ mg/mÂ²}\n",
      "\\]\n",
      "\n",
      "### Step 5: Compare the Doses\n",
      "\n",
      "Now we can compare the doses:\n",
      "\n",
      "- **Rat Dose**: 600 mg/mÂ²\n",
      "- **Human Dose**: 34.64 mg/mÂ²\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study is approximately **600 mg/mÂ²**, which is significantly higher than the maximum recommended human dose of approximately **34.64 mg/mÂ²**. This comparison highlights the differences in dosing between species and underscores the importance of considering these factors when interpreting the results of animal studies in relation to human health.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.029706\n",
      "prediction:  To answer the question regarding the highest dose of fluoxetine administered to rats in a 2-year carcinogenicity study and its comparison to the maximum recommended human dose (MRHD) on a mg/mÂ² basis, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Identify the Highest Dose Administered to Rats\n",
      "\n",
      "In the 2-year carcinogenicity studies for fluoxetine, the highest dose administered to rats is typically reported in scientific literature and regulatory documents. For fluoxetine, the highest dose used in these studies is often around 60 mg/kg/day. However, it is essential to refer to specific studies or regulatory filings (such as those from the FDA or EMA) for precise figures, as they may vary slightly based on the study design.\n",
      "\n",
      "### Step 2: Convert the Dose to mg/mÂ²\n",
      "\n",
      "To compare the dose administered to rats with the maximum recommended human dose, we need to convert the rat dose from mg/kg to mg/mÂ². The conversion factor from kg to mÂ² for rats is approximately 6.2 (based on the body surface area normalization). \n",
      "\n",
      "Using the highest dose of 60 mg/kg/day:\n",
      "- **Dose in mg/mÂ²** = Dose in mg/kg Ã— Body Surface Area Conversion Factor\n",
      "- **Dose in mg/mÂ²** = 60 mg/kg Ã— 6.2 mÂ²/kg = 372 mg/mÂ²/day\n",
      "\n",
      "### Step 3: Identify the Maximum Recommended Human Dose (MRHD)\n",
      "\n",
      "The maximum recommended human dose (MRHD) for fluoxetine varies based on the indication. For example, the MRHD for major depressive disorder is typically around 80 mg/day for adults. To convert this to mg/mÂ², we need to consider the average weight of an adult human. \n",
      "\n",
      "Assuming an average adult weight of 70 kg:\n",
      "- **Body Surface Area (BSA)** can be estimated using the Du Bois formula: \n",
      "  \\[ BSA (mÂ²) = 0.007184 Ã— (weight (kg)^{0.425}) Ã— (height (cm)^{0.725}) \\]\n",
      "  For a 70 kg person, the BSA is approximately 1.73 mÂ².\n",
      "\n",
      "Now, we can calculate the MRHD in mg/mÂ²:\n",
      "- **MRHD in mg/mÂ²** = 80 mg/day Ã· 1.73 mÂ² â‰ˆ 46.24 mg/mÂ²/day\n",
      "\n",
      "### Step 4: Compare the Rat Dose to the Human Dose\n",
      "\n",
      "Now that we have both doses in mg/mÂ²:\n",
      "- **Rat Dose**: 372 mg/mÂ²/day\n",
      "- **Human MRHD**: 46.24 mg/mÂ²/day\n",
      "\n",
      "### Step 5: Conclusion\n",
      "\n",
      "The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study (372 mg/mÂ²/day) is significantly higher than the maximum recommended human dose (46.24 mg/mÂ²/day). This comparison highlights the differences in dosing between animal studies and human clinical recommendations, which is a common consideration in pharmacology and toxicology. \n",
      "\n",
      "### Summary\n",
      "\n",
      "- Highest dose in rats: 60 mg/kg/day (equivalent to 372 mg/mÂ²/day)\n",
      "- MRHD for humans: approximately 80 mg/day (equivalent to 46.24 mg/mÂ²/day)\n",
      "- The rat dose is approximately 8 times higher than the human MRHD on a mg/mÂ² basis. \n",
      "\n",
      "This information is crucial for understanding the safety and potential risks associated with fluoxetine, especially in the context of long-term exposure and carcinogenicity.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.028289\n",
      "prediction:  To answer the question regarding the highest dose of fluoxetine administered to rats in a 2-year carcinogenicity study and its comparison to the maximum recommended human dose (MRHD) on a mg/mÂ² basis, we can break it down into several steps:\n",
      "\n",
      "### Step 1: Identify the Highest Dose Administered to Rats\n",
      "\n",
      "In the 2-year carcinogenicity studies for fluoxetine, the highest dose administered to rats is typically reported in scientific literature and regulatory documents. For fluoxetine, the highest dose used in these studies is often around 60 mg/kg/day. However, it is essential to refer to specific studies or regulatory filings (such as those from the FDA or EMA) for precise figures, as they may vary slightly based on the study design.\n",
      "\n",
      "### Step 2: Determine the Maximum Recommended Human Dose (MRHD)\n",
      "\n",
      "The MRHD for fluoxetine in adults is generally 60 mg per day. This is the maximum dose recommended for treating conditions such as major depressive disorder, obsessive-compulsive disorder, and other psychiatric conditions.\n",
      "\n",
      "### Step 3: Convert the MRHD to mg/mÂ²\n",
      "\n",
      "To compare the doses on a mg/mÂ² basis, we need to convert the human dose to a body surface area (BSA) equivalent. The BSA can be estimated using the Mosteller formula:\n",
      "\n",
      "\\[\n",
      "BSA (mÂ²) = \\sqrt{\\frac{(height \\, in \\, cm) \\times (weight \\, in \\, kg)}{3600}}\n",
      "\\]\n",
      "\n",
      "For an average adult, we can use a height of 170 cm and a weight of 70 kg as an example:\n",
      "\n",
      "\\[\n",
      "BSA = \\sqrt{\\frac{(170) \\times (70)}{3600}} \\approx 1.85 \\, mÂ²\n",
      "\\]\n",
      "\n",
      "Now, we can calculate the dose in mg/mÂ²:\n",
      "\n",
      "\\[\n",
      "\\text{Dose (mg/mÂ²)} = \\frac{MRHD (mg)}{BSA (mÂ²)} = \\frac{60 \\, mg}{1.85 \\, mÂ²} \\approx 32.43 \\, mg/mÂ²\n",
      "\\]\n",
      "\n",
      "### Step 4: Compare the Rat Dose to the Human Dose\n",
      "\n",
      "Now, we need to convert the rat dose of 60 mg/kg to mg/mÂ². The conversion factor from kg to mÂ² can be approximated using the average weight of a rat, which is about 0.25 kg (250 grams). \n",
      "\n",
      "Using the same BSA formula for a rat, we can estimate the BSA for a rat weighing 0.25 kg:\n",
      "\n",
      "\\[\n",
      "BSA_{rat} \\approx 0.25^{0.67} \\times 0.1^{0.33} \\approx 0.025 \\, mÂ²\n",
      "\\]\n",
      "\n",
      "Now, we can calculate the dose in mg/mÂ² for the rat:\n",
      "\n",
      "\\[\n",
      "\\text{Dose (mg/mÂ²)} = \\frac{60 \\, mg/kg \\times 0.25 \\, kg}{0.025 \\, mÂ²} = \\frac{15 \\, mg}{0.025 \\, mÂ²} = 600 \\, mg/mÂ²\n",
      "\\]\n",
      "\n",
      "### Step 5: Final Comparison\n",
      "\n",
      "Now we can compare the two doses:\n",
      "\n",
      "- **Rat Dose**: 600 mg/mÂ²\n",
      "- **Human Dose**: 32.43 mg/mÂ²\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "The highest dose of fluoxetine administered to rats in the 2-year carcinogenicity study (600 mg/mÂ²) is significantly higher than the maximum recommended human dose (32.43 mg/mÂ²). This indicates that the safety margins and potential risks associated with fluoxetine in long-term studies in rats may not directly translate to human dosing, highlighting the importance of species differences in pharmacokinetics and toxicology.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg/day, approximately 1.2 times the MRHD\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002754\n",
      "prediction:  To answer the question regarding the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo in a trial for adjunctive therapy in adults with partial-onset seizures, we can follow these steps:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Lamotrigine is an anticonvulsant medication commonly used to treat epilepsy, including partial-onset seizures. In clinical trials, researchers often compare the efficacy of a drug against a placebo to determine its effectiveness.\n",
      "\n",
      "### Step 2: Review Clinical Trial Data\n",
      "In clinical trials assessing the efficacy of lamotrigine for partial-onset seizures, participants are typically divided into groups receiving either the active drug (in this case, lamotrigine at a dose of 400 mg/day) or a placebo. The primary outcome measure is often the reduction in seizure frequency over a specified period.\n",
      "\n",
      "### Step 3: Identify Key Findings\n",
      "In many studies, the results are reported as a percentage reduction in seizure frequency from baseline to the end of the treatment period. For lamotrigine, studies have shown that patients receiving the drug often experience a significant reduction in seizure frequency compared to those receiving placebo.\n",
      "\n",
      "### Step 4: Specific Data on Lamotrigine\n",
      "While the exact median seizure frequency reduction can vary between studies, a common finding in clinical trials is that patients taking lamotrigine at a dose of 400 mg/day may experience a median reduction in seizure frequency of approximately 50% or more compared to placebo. \n",
      "\n",
      "### Step 5: Conclusion\n",
      "Based on the data from various clinical trials, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo is typically around 50% to 60%. However, for precise figures, one would need to refer to specific trial results or meta-analyses that summarize these findings.\n",
      "\n",
      "### Final Answer\n",
      "In trials for adjunctive therapy in adults with partial-onset seizures, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo is generally reported to be around 50% to 60%. For exact figures, specific trial data should be consulted.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.00258\n",
      "prediction:  To answer the question regarding the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo in a trial for adjunctive therapy in adults with partial-onset seizures, we can follow these steps:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Lamotrigine is an anticonvulsant medication commonly used to treat epilepsy, including partial-onset seizures. In clinical trials, researchers often compare the efficacy of a drug against a placebo to determine its effectiveness.\n",
      "\n",
      "### Step 2: Review Clinical Trial Data\n",
      "In clinical trials assessing the efficacy of lamotrigine for partial-onset seizures, participants are typically divided into groups receiving either the active drug (in this case, lamotrigine at a dose of 400 mg/day) or a placebo. The primary outcome measure is often the reduction in seizure frequency over a specified period.\n",
      "\n",
      "### Step 3: Identify Key Findings\n",
      "In many studies, the results are reported in terms of median seizure frequency reduction. For lamotrigine, studies have shown that patients receiving 400 mg/day often experience a significant reduction in seizure frequency compared to those receiving placebo.\n",
      "\n",
      "### Step 4: Provide Specific Data\n",
      "While the exact median seizure frequency reduction can vary between studies, a common finding in clinical trials is that patients on lamotrigine at a dose of 400 mg/day may experience a median reduction in seizure frequency of approximately 50% or more compared to placebo. \n",
      "\n",
      "For example, in a pivotal trial, the median reduction in seizure frequency for patients taking lamotrigine 400 mg/day was reported to be around 50% compared to a much lower reduction in the placebo group, which might be around 10-20%.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "In summary, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo in trials for adjunctive therapy in adults with partial-onset seizures is typically around 50%. This indicates that lamotrigine is an effective adjunctive treatment for reducing seizure frequency in this patient population.\n",
      "\n",
      "### Note\n",
      "For precise figures and specific study references, it is advisable to consult the original clinical trial publications or meta-analyses that summarize the findings related to lamotrigine's efficacy in treating partial-onset seizures.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002636\n",
      "prediction:  To answer the question regarding the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo in a trial for adjunctive therapy in adults with partial-onset seizures, we can follow these steps:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Lamotrigine is an anticonvulsant medication commonly used to treat epilepsy, including partial-onset seizures. In clinical trials, researchers often compare the efficacy of a drug against a placebo to determine its effectiveness.\n",
      "\n",
      "### Step 2: Review Clinical Trial Data\n",
      "In clinical trials assessing the efficacy of lamotrigine for partial-onset seizures, participants are typically divided into groups receiving either the active drug (in this case, lamotrigine at a dose of 400 mg/day) or a placebo. The primary outcome measure is often the reduction in seizure frequency over a specified period.\n",
      "\n",
      "### Step 3: Identify Key Findings\n",
      "In many studies, the results are reported in terms of median seizure frequency reduction. For lamotrigine, studies have shown that patients receiving the drug often experience a significant reduction in seizure frequency compared to those receiving placebo.\n",
      "\n",
      "### Step 4: Provide Specific Data\n",
      "While the exact median seizure frequency reduction can vary between studies, a common finding in clinical trials is that patients taking lamotrigine at a dose of 400 mg/day may experience a median reduction in seizure frequency of approximately 50% or more compared to placebo. \n",
      "\n",
      "For example, in some trials, the median reduction in seizure frequency for patients on lamotrigine was reported to be around 50% to 60%, while the placebo group typically showed a much lower reduction, often around 20% or less.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "In conclusion, the median seizure frequency reduction observed with a 400 mg/day dose of lamotrigine compared to placebo in trials for adjunctive therapy in adults with partial-onset seizures is generally reported to be around 50% to 60%. This indicates that lamotrigine is effective in reducing seizure frequency in this patient population.\n",
      "\n",
      "### Note\n",
      "For precise figures, it is essential to refer to specific clinical trial publications or meta-analyses that detail the outcomes of studies involving lamotrigine for partial-onset seizures.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 25%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.021526\n",
      "prediction:  To answer the question regarding the observed mortality rate in patients treated with NUZYRA (sotagliflozin) for Community-Acquired Bacterial Pneumonia (CABP) compared to those treated with moxifloxacin, we need to follow a systematic approach. \n",
      "\n",
      "### Step 1: Understanding the Medications\n",
      "- **NUZYRA (sotagliflozin)**: This is an antibiotic that is used to treat CABP and is known for its activity against a range of bacteria, including resistant strains. It is a newer agent in the class of antibiotics.\n",
      "- **Moxifloxacin**: This is a fluoroquinolone antibiotic that has been widely used for treating CABP and is known for its efficacy against various bacterial pathogens.\n",
      "\n",
      "### Step 2: Reviewing Clinical Trials\n",
      "To compare the mortality rates, we need to look at clinical trial data that specifically evaluates the efficacy and safety of NUZYRA versus moxifloxacin in treating CABP. \n",
      "\n",
      "1. **Clinical Trials**: Review the results from Phase III clinical trials that have been conducted to assess the effectiveness of NUZYRA in comparison to moxifloxacin. These trials typically report on various outcomes, including mortality rates, clinical cure rates, and adverse events.\n",
      "\n",
      "2. **Endpoints**: The primary endpoint of interest in these trials would be all-cause mortality at a specified time point (e.g., 30 days post-treatment) and possibly other secondary endpoints related to clinical outcomes.\n",
      "\n",
      "### Step 3: Analyzing Mortality Rates\n",
      "- **Data Extraction**: Extract the specific mortality rates from the clinical trial results. For example, if the trial reports that the mortality rate in the NUZYRA group was 5% and in the moxifloxacin group was 7%, this would indicate that NUZYRA may have a lower mortality rate in this patient population.\n",
      "\n",
      "- **Statistical Significance**: It is also important to determine if the difference in mortality rates is statistically significant. This is typically assessed using p-values or confidence intervals.\n",
      "\n",
      "### Step 4: Interpreting Results\n",
      "- **Clinical Implications**: If NUZYRA shows a lower mortality rate compared to moxifloxacin, this could suggest that NUZYRA is a more effective treatment option for CABP, particularly in populations at higher risk for mortality.\n",
      "\n",
      "- **Considerations**: It is also essential to consider other factors such as the patient population, the severity of pneumonia, comorbidities, and resistance patterns, as these can influence outcomes.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "In conclusion, to provide a comprehensive answer to the question, one would need to refer to specific clinical trial data comparing NUZYRA and moxifloxacin in the treatment of CABP. The observed mortality rates, along with their statistical significance, would be critical in determining the relative efficacy of these two antibiotics. \n",
      "\n",
      "If you have access to specific clinical trial results or publications, you can provide those details for a more precise comparison. Otherwise, the general approach outlined above can guide you in evaluating the mortality rates associated with these treatments.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.021059\n",
      "prediction:  To answer the question regarding the observed mortality rate in patients treated with NUZYRA (sotagliflozin) for Community-Acquired Bacterial Pneumonia (CABP) compared to those treated with moxifloxacin, we need to follow a systematic approach. \n",
      "\n",
      "### Step 1: Understanding the Medications\n",
      "- **NUZYRA (sotagliflozin)**: This is an antibiotic that is used to treat CABP and is known for its broad-spectrum activity against various bacteria, including resistant strains.\n",
      "- **Moxifloxacin**: This is a fluoroquinolone antibiotic that is also used to treat CABP and is effective against a range of bacterial pathogens.\n",
      "\n",
      "### Step 2: Reviewing Clinical Trials\n",
      "To compare the mortality rates, we need to look at clinical trial data that specifically evaluates the efficacy and safety of NUZYRA versus moxifloxacin in treating CABP. \n",
      "\n",
      "1. **Clinical Trials**: Review the results from Phase III clinical trials that have been conducted to assess the effectiveness of NUZYRA in comparison to moxifloxacin. These trials typically report on various outcomes, including mortality rates, clinical cure rates, and adverse events.\n",
      "\n",
      "2. **Endpoints**: The primary endpoint of interest in these trials would be all-cause mortality at a specified time point (e.g., 30 days post-treatment) and possibly other secondary endpoints related to clinical outcomes.\n",
      "\n",
      "### Step 3: Analyzing Mortality Rates\n",
      "- **Data Extraction**: Extract the relevant data from the clinical trials, focusing on the number of patients treated with NUZYRA and moxifloxacin, the number of deaths in each group, and the total number of patients in each treatment arm.\n",
      "  \n",
      "- **Calculating Mortality Rates**: The mortality rate can be calculated using the formula:\n",
      "  \\[\n",
      "  \\text{Mortality Rate} = \\left( \\frac{\\text{Number of Deaths}}{\\text{Total Number of Patients}} \\right) \\times 100\n",
      "  \\]\n",
      "\n",
      "### Step 4: Comparing Results\n",
      "- **Statistical Analysis**: Once the mortality rates are calculated for both treatment groups, a statistical analysis (such as a chi-square test) can be performed to determine if there is a significant difference between the two groups.\n",
      "\n",
      "- **Interpreting Results**: If the mortality rate for NUZYRA is lower than that for moxifloxacin, it may suggest that NUZYRA is more effective in reducing mortality in CABP patients. Conversely, if the mortality rate is higher or similar, it may indicate that moxifloxacin is equally effective or superior.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "- **Summarizing Findings**: Based on the data from clinical trials, summarize the findings regarding the mortality rates. For example, if NUZYRA showed a mortality rate of 5% compared to 7% for moxifloxacin, you would conclude that NUZYRA has a lower observed mortality rate in patients with CABP.\n",
      "\n",
      "- **Clinical Implications**: Discuss the implications of these findings for clinical practice, including considerations for antibiotic selection in treating CABP, especially in populations at risk for severe disease.\n",
      "\n",
      "### Final Note\n",
      "It is essential to refer to the most recent clinical trial data and published literature to provide accurate and up-to-date information regarding the mortality rates associated with NUZYRA and moxifloxacin in the treatment of CABP. Always consult peer-reviewed sources and clinical guidelines for the most reliable data.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.020237\n",
      "prediction:  To answer the question regarding the observed mortality rate in patients treated with NUZYRA (sotagliflozin) for Community-Acquired Bacterial Pneumonia (CABP) compared to those treated with moxifloxacin, we need to follow a systematic approach. \n",
      "\n",
      "### Step 1: Understanding the Medications\n",
      "- **NUZYRA (sotagliflozin)**: This is an antibiotic that is used to treat CABP and is known for its broad-spectrum activity against various bacteria, including resistant strains.\n",
      "- **Moxifloxacin**: This is a fluoroquinolone antibiotic that is also used to treat CABP and is effective against a range of bacterial pathogens.\n",
      "\n",
      "### Step 2: Reviewing Clinical Trials\n",
      "To compare the mortality rates, we need to look at clinical trial data that specifically evaluates the efficacy and safety of NUZYRA versus moxifloxacin in treating CABP. \n",
      "\n",
      "1. **Clinical Trials**: Review the results from pivotal clinical trials that have been conducted. These trials typically include a control group (often receiving moxifloxacin) and a treatment group (receiving NUZYRA).\n",
      "2. **Endpoints**: The primary endpoint of interest in these trials would be all-cause mortality, which is often measured at specific time points (e.g., 14 days, 28 days post-treatment).\n",
      "\n",
      "### Step 3: Analyzing Mortality Rates\n",
      "- **Data Extraction**: Extract the mortality rates from the clinical trial results. This data is usually presented in the form of percentages or rates per 100 patients.\n",
      "- **Comparison**: Compare the mortality rates between the two groups. For example, if the trial shows that 5% of patients treated with NUZYRA died compared to 7% of those treated with moxifloxacin, we can conclude that NUZYRA has a lower mortality rate in this context.\n",
      "\n",
      "### Step 4: Interpreting Results\n",
      "- **Statistical Significance**: It is important to determine if the difference in mortality rates is statistically significant. This is typically assessed using p-values or confidence intervals.\n",
      "- **Clinical Relevance**: Beyond statistical significance, consider the clinical relevance of the findings. A small difference in mortality rates may not be clinically meaningful, while a larger difference could have significant implications for treatment choices.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "Based on the data from clinical trials, we can summarize the findings:\n",
      "\n",
      "- **Observed Mortality Rate**: If the trials indicate that the mortality rate for NUZYRA is lower than that for moxifloxacin, we would state the specific rates and the statistical significance of the findings.\n",
      "- **Clinical Implications**: Discuss the implications of these findings for clinical practice, including considerations for prescribing NUZYRA over moxifloxacin in patients with CABP, especially in populations at higher risk for mortality.\n",
      "\n",
      "### Example Conclusion\n",
      "In a hypothetical scenario, if the clinical trial data indicated that the mortality rate for patients treated with NUZYRA was 5% compared to 7% for those treated with moxifloxacin, we would conclude that NUZYRA demonstrates a statistically significant lower mortality rate in patients with CABP. This could suggest that NUZYRA may be a preferable option in certain patient populations, particularly those at higher risk for complications.\n",
      "\n",
      "### Note\n",
      "For the most accurate and up-to-date information, it is essential to refer to the latest clinical trial data, peer-reviewed studies, and official prescribing information for both NUZYRA and moxifloxacin.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: 2% for NUZYRA and 1% for moxifloxacin\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.008249\n",
      "prediction:  To answer the question regarding the oral dose of albuterol sulfate that demonstrated no evidence of impaired fertility in rats, we can follow a systematic approach:\n",
      "\n",
      "### Step 1: Understanding Albuterol Sulfate\n",
      "Albuterol sulfate is a bronchodilator commonly used to treat asthma and other conditions involving bronchospasm. It works by relaxing the muscles in the airways, making it easier to breathe. As with many medications, it is important to assess its safety profile, including potential effects on fertility.\n",
      "\n",
      "### Step 2: Reviewing Toxicology Studies\n",
      "To determine the effects of albuterol sulfate on fertility, researchers typically conduct reproductive toxicity studies in animal models, such as rats. These studies assess various endpoints, including mating performance, fertility rates, and any potential teratogenic effects.\n",
      "\n",
      "### Step 3: Identifying Relevant Studies\n",
      "In the case of albuterol sulfate, studies have been conducted to evaluate its effects on reproductive health. The findings from these studies are usually published in scientific literature or regulatory documents, such as those from the FDA or other health authorities.\n",
      "\n",
      "### Step 4: Finding the No-Observed-Adverse-Effect Level (NOAEL)\n",
      "The key metric to look for in these studies is the No-Observed-Adverse-Effect Level (NOAEL) for fertility. This is the highest dose at which no adverse effects on reproductive performance are observed.\n",
      "\n",
      "### Step 5: Reporting the Findings\n",
      "According to available data from reproductive toxicity studies, the NOAEL for albuterol sulfate in rats regarding fertility is typically reported at doses around **100 mg/kg/day**. At this dose, no significant impairment of fertility was observed in male or female rats.\n",
      "\n",
      "### Conclusion\n",
      "In summary, albuterol sulfate demonstrated no evidence of impaired fertility in rats at an oral dose of **100 mg/kg/day**. This information is crucial for understanding the safety profile of the drug, especially for populations that may be concerned about reproductive health, such as pregnant women or those planning to conceive. Always consult specific studies or regulatory documents for the most accurate and detailed information.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.008646\n",
      "prediction:  To answer the question regarding the oral dose of albuterol sulfate that demonstrated no evidence of impaired fertility in rats, we can follow a systematic approach:\n",
      "\n",
      "### Step 1: Understanding Albuterol Sulfate\n",
      "Albuterol sulfate is a bronchodilator commonly used to treat asthma and other conditions that cause bronchospasm. It works by relaxing the muscles in the airways and increasing airflow to the lungs. \n",
      "\n",
      "### Step 2: Reviewing Toxicology Studies\n",
      "To assess the effects of albuterol sulfate on fertility, researchers typically conduct reproductive toxicity studies in animal models, such as rats. These studies evaluate the impact of the drug on various reproductive parameters, including mating behavior, fertility rates, gestation, and offspring development.\n",
      "\n",
      "### Step 3: Identifying Relevant Studies\n",
      "In the context of albuterol sulfate, studies have been conducted to determine its safety profile, including its effects on fertility. The findings from these studies are usually published in scientific literature or regulatory documents.\n",
      "\n",
      "### Step 4: Finding the No-Observed-Adverse-Effect Level (NOAEL)\n",
      "The key metric in these studies is the NOAEL, which is the highest dose at which no adverse effects are observed. For albuterol sulfate, the NOAEL for fertility impairment in rats is typically reported in the context of specific studies.\n",
      "\n",
      "### Step 5: Reporting the Findings\n",
      "According to available data from reproductive toxicity studies, the NOAEL for albuterol sulfate regarding fertility impairment in rats is often cited at doses around **100 mg/kg/day**. At this dose, no significant adverse effects on fertility were observed in the treated groups compared to control groups.\n",
      "\n",
      "### Conclusion\n",
      "In summary, albuterol sulfate demonstrated no evidence of impaired fertility in rats at an oral dose of **100 mg/kg/day**. This information is crucial for understanding the safety profile of albuterol sulfate, especially in the context of reproductive health. Always refer to specific studies or regulatory documents for the most accurate and detailed information.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002622\n",
      "prediction:  To answer the question regarding the percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets, we need to follow a systematic approach:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Pantoprazole is a proton pump inhibitor (PPI) commonly used to treat conditions like gastroesophageal reflux disease (GERD) and esophagitis caused by acid reflux. The healing of esophageal lesions, particularly erosive esophagitis, is a key outcome measure in clinical studies evaluating the efficacy of PPIs.\n",
      "\n",
      "### Step 2: Identify Relevant Studies\n",
      "To find the specific percentage of patients who experienced healing after 8 weeks of treatment, we would typically look for clinical trials or studies that have investigated the efficacy of pantoprazole in treating esophageal lesions. \n",
      "\n",
      "### Step 3: Review Clinical Trial Data\n",
      "In clinical trials, the results are often reported in terms of the percentage of patients who achieved healing of esophageal lesions as determined by endoscopy. For example, a study might report that a certain percentage of patients showed complete healing of erosive esophagitis after 8 weeks of treatment with pantoprazole.\n",
      "\n",
      "### Step 4: Analyze the Results\n",
      "While I do not have access to specific clinical trial data or results beyond my training cut-off in October 2023, studies have generally shown that pantoprazole is effective in healing esophageal lesions. For instance, in some clinical trials, the percentage of patients achieving endoscopic healing after 8 weeks of treatment with pantoprazole has been reported to be around 70-80%.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "Based on the typical findings from clinical studies, one might conclude that approximately **70-80%** of patients with endoscopically proven esophageal lesions achieve healing after 8 weeks of treatment with pantoprazole sodium delayed-release tablets. However, for precise figures, one would need to refer to specific clinical trial results or meta-analyses that provide exact percentages.\n",
      "\n",
      "### Final Note\n",
      "For the most accurate and up-to-date information, it is advisable to consult recent clinical studies, medical literature, or clinical guidelines that focus on the use of pantoprazole for treating esophageal lesions.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002505\n",
      "prediction:  To answer the question regarding the percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets, we need to follow a systematic approach:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Pantoprazole is a proton pump inhibitor (PPI) commonly used to treat conditions like gastroesophageal reflux disease (GERD) and esophagitis caused by acid reflux. The healing of esophageal lesions, particularly erosive esophagitis, is a key outcome measure in clinical studies evaluating the efficacy of PPIs.\n",
      "\n",
      "### Step 2: Review Clinical Study Data\n",
      "To find the specific percentage of patients who experienced healing after 8 weeks of treatment, we would typically refer to clinical trial data or published studies. These studies often report outcomes such as the percentage of patients with complete healing of esophageal lesions as determined by endoscopy.\n",
      "\n",
      "### Step 3: Identify Relevant Studies\n",
      "In clinical trials involving pantoprazole, researchers often assess the healing rates of esophageal lesions at various time points, including 8 weeks. For example, a common reference point is the study published in the \"American Journal of Gastroenterology\" or similar gastroenterology journals, which may provide data on healing rates.\n",
      "\n",
      "### Step 4: Analyze the Data\n",
      "Assuming we have access to a specific study, we would look for the results section, which typically includes:\n",
      "- The total number of patients treated.\n",
      "- The number of patients who achieved endoscopic healing after 8 weeks.\n",
      "- The calculation of the percentage based on these figures.\n",
      "\n",
      "### Step 5: Provide the Answer\n",
      "While I do not have access to specific study data or percentages beyond my training cut-off in October 2023, a common finding in clinical studies is that the percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole can range from approximately 70% to 90%, depending on the severity of the lesions and the specific study design.\n",
      "\n",
      "### Conclusion\n",
      "To provide an accurate percentage, one would need to refer to a specific clinical trial or meta-analysis that reports on the healing rates of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets. If you have access to a particular study or dataset, I can help interpret that data further.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002526\n",
      "prediction:  To answer the question regarding the percentage of patients with endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets, we need to follow a systematic approach:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Pantoprazole is a proton pump inhibitor (PPI) commonly used to treat conditions like gastroesophageal reflux disease (GERD) and esophagitis caused by acid reflux. The healing of esophageal lesions, particularly erosive esophagitis, is a key outcome measure in clinical studies evaluating the efficacy of PPIs.\n",
      "\n",
      "### Step 2: Review Clinical Study Data\n",
      "To find the specific percentage of patients who experienced healing after 8 weeks of treatment, we would typically refer to clinical trial data or published studies. These studies often report outcomes such as the percentage of patients with complete healing of esophageal lesions as determined by endoscopy.\n",
      "\n",
      "### Step 3: Identify Relevant Studies\n",
      "In clinical trials involving pantoprazole, researchers usually assess the healing of esophageal lesions at various time points, including 8 weeks. For example, a study might report that a certain percentage of patients showed complete healing of erosive esophagitis after 8 weeks of treatment.\n",
      "\n",
      "### Step 4: Analyze Results\n",
      "While I do not have access to specific study results or databases, it is common for studies to report healing rates in the range of 70% to 90% for patients treated with PPIs like pantoprazole after 8 weeks. The exact percentage can vary based on the study design, patient population, and severity of the lesions at baseline.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "To provide a precise answer, one would need to reference a specific clinical trial or meta-analysis that reports the healing rates for esophageal lesions after 8 weeks of pantoprazole treatment. If you have access to a particular study or data source, you can look up the results there. \n",
      "\n",
      "In summary, while I cannot provide an exact percentage without specific study data, it is reasonable to expect that a significant proportion of patients (often reported between 70% and 90%) may achieve endoscopically proven healing of esophageal lesions after 8 weeks of treatment with pantoprazole sodium delayed-release tablets. For the most accurate information, consulting the relevant clinical literature or trial results is recommended.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: 86%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.014967\n",
      "prediction:  To answer the question regarding which group showed the smallest mean change in plasma glucose 1 hour after the first dose in a clinical trial for adults and adolescents, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "Clinical trials often involve multiple groups, typically including a treatment group (receiving the drug or intervention) and a control group (receiving a placebo or standard treatment). The goal is to assess the efficacy and safety of the treatment.\n",
      "\n",
      "### Step 2: Identify the Groups\n",
      "In a typical clinical trial, groups may be categorized based on various factors such as:\n",
      "- Treatment type (e.g., different dosages of a drug)\n",
      "- Age (adults vs. adolescents)\n",
      "- Health status (e.g., diabetic vs. non-diabetic)\n",
      "- Other demographic factors (e.g., gender, ethnicity)\n",
      "\n",
      "### Step 3: Define the Measurement\n",
      "The primary measurement in this context is the \"mean change in plasma glucose\" after 1 hour. This means we are looking at the average difference in plasma glucose levels from baseline (before the first dose) to 1 hour post-dose.\n",
      "\n",
      "### Step 4: Analyze the Data\n",
      "To determine which group showed the smallest mean change, we would typically look at the results section of the clinical trial report. This section would provide statistical data, including:\n",
      "- Mean plasma glucose levels before and after the intervention for each group\n",
      "- Standard deviations or confidence intervals to understand variability\n",
      "- Statistical significance of the changes observed\n",
      "\n",
      "### Step 5: Compare the Results\n",
      "Once we have the data:\n",
      "- Calculate the mean change for each group by subtracting the baseline glucose level from the post-dose level.\n",
      "- Compare these mean changes across all groups.\n",
      "\n",
      "### Step 6: Identify the Group with the Smallest Change\n",
      "After performing the calculations and comparisons, we would identify the group with the smallest mean change in plasma glucose. This group would be the one that experienced the least fluctuation in glucose levels after the first dose.\n",
      "\n",
      "### Conclusion\n",
      "Without specific data from the clinical trial, we cannot definitively state which group showed the smallest mean change in plasma glucose. However, by following the steps outlined above, one would be able to analyze the trial results effectively to arrive at the answer. \n",
      "\n",
      "If you have access to the specific data or results from the clinical trial, please provide that information, and I can help you interpret it to find the answer to your question.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.012428\n",
      "prediction:  To answer the question regarding which symptom is NOT mentioned as being relieved by 'nighttime severe cold and flu' medications, we first need to identify the common symptoms associated with colds and flu, as well as the typical ingredients found in nighttime cold and flu medications.\n",
      "\n",
      "### Step 1: Identify Common Symptoms of Cold and Flu\n",
      "Common symptoms of cold and flu include:\n",
      "- Cough\n",
      "- Nasal congestion\n",
      "- Sore throat\n",
      "- Fever\n",
      "- Body aches\n",
      "- Headache\n",
      "- Fatigue\n",
      "- Chills\n",
      "- Sneezing\n",
      "\n",
      "### Step 2: Understand Nighttime Cold and Flu Medications\n",
      "Nighttime cold and flu medications are designed to alleviate symptoms that can disrupt sleep. They often contain a combination of the following ingredients:\n",
      "- Antihistamines (e.g., diphenhydramine) to relieve sneezing and runny nose\n",
      "- Decongestants (e.g., phenylephrine) to relieve nasal congestion\n",
      "- Pain relievers (e.g., acetaminophen or ibuprofen) to reduce fever and body aches\n",
      "- Cough suppressants (e.g., dextromethorphan) to reduce coughing\n",
      "- Expectorants (e.g., guaifenesin) to help clear mucus\n",
      "\n",
      "### Step 3: Identify Symptoms Typically Relieved\n",
      "Nighttime cold and flu medications typically relieve:\n",
      "- Cough (especially at night)\n",
      "- Nasal congestion\n",
      "- Sore throat\n",
      "- Fever and body aches\n",
      "- General discomfort that interferes with sleep\n",
      "\n",
      "### Step 4: Identify Symptoms NOT Typically Relieved\n",
      "While nighttime cold and flu medications are effective for many symptoms, there are some symptoms that they may not specifically target or relieve. For example:\n",
      "- **Chills**: While chills can be associated with fever, they are not directly relieved by medications. Instead, they are a symptom of the bodyâ€™s response to infection.\n",
      "- **Fatigue**: This is a common symptom of both cold and flu, but it is not something that can be directly relieved by medication. Fatigue often requires rest and recovery time.\n",
      "\n",
      "### Conclusion\n",
      "Based on the analysis, a symptom that is NOT typically mentioned as being relieved by 'nighttime severe cold and flu' medications is **fatigue**. While medications may help alleviate other symptoms, fatigue is a result of the body fighting off the infection and cannot be directly treated with over-the-counter medications. \n",
      "\n",
      "Thus, the answer to the question is:\n",
      "**Fatigue**.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: Nausea\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.057143\n",
      "prediction:  To clean the spray nozzle of a DG Health nasal spray properly, you can follow these steps:\n",
      "\n",
      "1. **Remove the Nozzle:** Gently pull the spray nozzle off the bottle. Be careful not to apply too much force as this may damage the nozzle or the bottle.\n",
      "\n",
      "2. **Wash with Soapy Water:** Rinse the nozzle under warm running water. Use mild soap or dishwashing detergent to clean the nozzle thoroughly. Ensure that you scrub all parts of the nozzle to remove any medication residue or buildup.\n",
      "\n",
      "3. **Rinse Again:** After cleaning, rinse the nozzle well under warm water to remove all soap residue. Soap can irritate nasal tissues if left on the nozzle.\n",
      "\n",
      "4. **Dry Thoroughly:** Allow the nozzle to air dry completely on a clean towel or paper towel. Make sure it is completely dry before reattaching it to the bottle, as moisture can promote bacterial growth.\n",
      "\n",
      "5. **Reattach:** Once the nozzle is dry, firmly but gently reattach it to the nasal spray bottle.\n",
      "\n",
      "6. **Regular Cleaning:** It is advisable to clean the nasal spray nozzle regularly (at least once a week) to maintain hygiene and prevent contamination, especially if the spray is used frequently.\n",
      "\n",
      "For further detailed information, you can refer to resources such as [Cleanestor](https://cleanestor.com/how-to-clean-nasal-spray-nozzle/) or [Biology Insights](https://biologyinsights.com/how-to-properly-clean-a-nasal-spray-nozzle/).\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Follow the Quick Start Guide for cleaning instructions.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.042527\n",
      "prediction:  To compare Junel 21 Day, a combination oral contraceptive pill, to other contraceptive methods in terms of typical failure rates, we need to first understand what typical failure rates mean. The typical failure rate refers to the percentage of women who will experience an unintended pregnancy within the first year of using a particular contraceptive method, assuming typical use (which accounts for human error).\n",
      "\n",
      "### Step 1: Understanding Junel 21 Day\n",
      "\n",
      "Junel 21 Day is a combination oral contraceptive that contains two hormones: estrogen (ethinyl estradiol) and progestin (levonorgestrel). It is taken daily for 21 days, followed by a 7-day break during which menstruation occurs. When taken correctly, it is highly effective at preventing pregnancy.\n",
      "\n",
      "### Step 2: Typical Failure Rate of Junel 21 Day\n",
      "\n",
      "The typical failure rate for combination oral contraceptives like Junel 21 Day is approximately **7%**. This means that about 7 out of 100 women using this method for one year will become pregnant if they do not use it perfectly. However, with perfect use, the failure rate drops to about **0.3%**.\n",
      "\n",
      "### Step 3: Comparing with Other Contraceptive Methods\n",
      "\n",
      "Now, letâ€™s compare Junel 21 Day with other common contraceptive methods based on their typical failure rates:\n",
      "\n",
      "1. **Contraceptive Implants (e.g., Nexplanon)**: \n",
      "   - Typical failure rate: **0.1%**\n",
      "   - Implants are highly effective and can last for several years.\n",
      "\n",
      "2. **Intrauterine Devices (IUDs)**:\n",
      "   - Hormonal IUDs (e.g., Mirena): Typical failure rate: **0.1%**\n",
      "   - Copper IUDs: Typical failure rate: **0.8%**\n",
      "   - IUDs are long-term methods that can be effective for 3-10 years depending on the type.\n",
      "\n",
      "3. **Injectable Contraceptives (e.g., Depo-Provera)**:\n",
      "   - Typical failure rate: **4%**\n",
      "   - Requires an injection every three months.\n",
      "\n",
      "4. **Condoms (male)**:\n",
      "   - Typical failure rate: **13%**\n",
      "   - Effectiveness can be improved with proper use and consistent application.\n",
      "\n",
      "5. **Diaphragms**:\n",
      "   - Typical failure rate: **12%**\n",
      "   - Requires proper fitting and use with spermicide.\n",
      "\n",
      "6. **Withdrawal Method**:\n",
      "   - Typical failure rate: **22%**\n",
      "   - Highly dependent on the male partner's ability to withdraw before ejaculation.\n",
      "\n",
      "7. **Natural Family Planning (Fertility Awareness)**:\n",
      "   - Typical failure rate: **24%**\n",
      "   - Involves tracking menstrual cycles and fertility signs.\n",
      "\n",
      "### Step 4: Summary of Comparison\n",
      "\n",
      "- **Junel 21 Day (7%)** is more effective than condoms, diaphragms, withdrawal, and natural family planning but less effective than long-acting reversible contraceptives like IUDs and implants.\n",
      "- The effectiveness of Junel 21 Day can be significantly improved with perfect use, but it requires daily adherence, which can be a challenge for some users.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "\n",
      "In conclusion, while Junel 21 Day is a reliable contraceptive method with a typical failure rate of 7%, it is important for users to consider their lifestyle, ability to adhere to a daily regimen, and personal preferences when choosing a contraceptive method. For those seeking higher efficacy with less daily management, long-acting methods like IUDs or implants may be more suitable options.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.038366\n",
      "prediction:  To compare Junel 21 Day, a combination oral contraceptive pill, to other contraceptive methods in terms of typical failure rates, we need to first understand what typical failure rates mean. The typical failure rate refers to the percentage of women who will experience an unintended pregnancy within the first year of using a particular contraceptive method, assuming typical use (which includes inconsistent or incorrect use).\n",
      "\n",
      "### Step 1: Understanding Junel 21 Day\n",
      "\n",
      "Junel 21 Day is a combination oral contraceptive pill that contains two hormones: estrogen (ethinyl estradiol) and progestin (levonorgestrel). It is taken daily for 21 days, followed by a 7-day break during which menstruation occurs. When taken correctly, combination pills like Junel are highly effective at preventing pregnancy.\n",
      "\n",
      "### Step 2: Typical Failure Rate of Junel 21 Day\n",
      "\n",
      "The typical failure rate for combination oral contraceptives, including Junel 21 Day, is approximately **7%**. This means that about 7 out of 100 women using this method for one year will experience an unintended pregnancy due to factors such as missed pills, incorrect timing, or other inconsistencies in use.\n",
      "\n",
      "### Step 3: Comparison with Other Contraceptive Methods\n",
      "\n",
      "Now, let's compare Junel 21 Day to other common contraceptive methods based on their typical failure rates:\n",
      "\n",
      "1. **Contraceptive Implants (e.g., Nexplanon)**: \n",
      "   - Typical failure rate: **<1%**\n",
      "   - Implants are highly effective and can last for several years.\n",
      "\n",
      "2. **Intrauterine Devices (IUDs)**:\n",
      "   - Hormonal IUDs (e.g., Mirena): Typical failure rate: **<1%**\n",
      "   - Copper IUDs: Typical failure rate: **<1%**\n",
      "   - IUDs are long-term methods that can provide protection for 3 to 10 years, depending on the type.\n",
      "\n",
      "3. **Injectable Contraceptives (e.g., Depo-Provera)**:\n",
      "   - Typical failure rate: **4%**\n",
      "   - Injectables are administered every three months and can be effective if the schedule is followed.\n",
      "\n",
      "4. **Condoms (male and female)**:\n",
      "   - Typical failure rate: **13% for male condoms** and **21% for female condoms**.\n",
      "   - Condoms also provide protection against sexually transmitted infections (STIs).\n",
      "\n",
      "5. **Diaphragms**:\n",
      "   - Typical failure rate: **12%**\n",
      "   - Diaphragms require proper fitting and use with spermicide.\n",
      "\n",
      "6. **Fertility Awareness Methods**:\n",
      "   - Typical failure rate: **24%**\n",
      "   - These methods require careful tracking of the menstrual cycle and ovulation.\n",
      "\n",
      "7. **Withdrawal Method**:\n",
      "   - Typical failure rate: **22%**\n",
      "   - This method relies on the male partner withdrawing before ejaculation.\n",
      "\n",
      "### Step 4: Summary of Comparison\n",
      "\n",
      "In summary, Junel 21 Day has a typical failure rate of about **7%**, which is higher than long-acting reversible contraceptives (LARCs) like IUDs and implants, which have failure rates of less than 1%. It is also more effective than methods like condoms and fertility awareness methods. However, it is less effective than injectables, which have a failure rate of about 4%. \n",
      "\n",
      "### Step 5: Considerations for Choice of Contraceptive Method\n",
      "\n",
      "When choosing a contraceptive method, individuals should consider several factors beyond just failure rates, including:\n",
      "\n",
      "- **Convenience**: Daily pills require consistent use, while IUDs and implants are more \"set and forget.\"\n",
      "- **Side Effects**: Different methods have varying side effects, and personal tolerance can vary.\n",
      "- **Health Conditions**: Certain medical conditions may contraindicate the use of hormonal contraceptives.\n",
      "- **Desire for Future Fertility**: Some may prefer methods that allow for quick return to fertility after discontinuation.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "Junel 21 Day is a moderately effective contraceptive method compared to other options. While it is effective for many, individuals should weigh the pros and cons of all available methods to find the one that best suits their lifestyle and reproductive goals. Consulting with a healthcare provider can help in making an informed decision.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.044538\n",
      "prediction:  To compare Junel 21 Day, a combined oral contraceptive pill (COC), to other contraceptive methods in terms of typical failure rates, we need to first understand what typical failure rates mean. The typical failure rate refers to the percentage of women who will experience an unintended pregnancy within the first year of using a particular contraceptive method, assuming typical use (which accounts for human error).\n",
      "\n",
      "### Step 1: Understanding Junel 21 Day\n",
      "\n",
      "Junel 21 Day is a combination oral contraceptive that contains two hormones: estrogen (ethinyl estradiol) and progestin (levonorgestrel). It is taken daily for 21 days, followed by a 7-day break during which withdrawal bleeding occurs. When taken correctly, COCs like Junel 21 Day are highly effective.\n",
      "\n",
      "### Step 2: Typical Failure Rate of Junel 21 Day\n",
      "\n",
      "The typical failure rate for combined oral contraceptives, including Junel 21 Day, is approximately **7%**. This means that about 7 out of 100 women using this method for one year will experience an unintended pregnancy due to factors such as missed pills, incorrect timing, or other user errors.\n",
      "\n",
      "### Step 3: Comparison with Other Contraceptive Methods\n",
      "\n",
      "Now, letâ€™s compare Junel 21 Day to other common contraceptive methods based on their typical failure rates:\n",
      "\n",
      "1. **Contraceptive Implants (e.g., Nexplanon)**: \n",
      "   - Typical failure rate: **<1%**\n",
      "   - Implants are highly effective and can last for up to 3 years.\n",
      "\n",
      "2. **Intrauterine Devices (IUDs)**:\n",
      "   - Hormonal IUDs (e.g., Mirena): Typical failure rate: **<1%**\n",
      "   - Copper IUDs: Typical failure rate: **<1%**\n",
      "   - IUDs are long-term methods that can last from 3 to 10 years, depending on the type.\n",
      "\n",
      "3. **Injectable Contraceptives (e.g., Depo-Provera)**:\n",
      "   - Typical failure rate: **4%**\n",
      "   - This method requires an injection every three months.\n",
      "\n",
      "4. **Condoms (male and female)**:\n",
      "   - Male condoms: Typical failure rate: **13%**\n",
      "   - Female condoms: Typical failure rate: **21%**\n",
      "   - Condoms also provide protection against sexually transmitted infections (STIs).\n",
      "\n",
      "5. **Diaphragms**:\n",
      "   - Typical failure rate: **12%**\n",
      "   - Effectiveness can be improved with spermicide.\n",
      "\n",
      "6. **Spermicides**:\n",
      "   - Typical failure rate: **28%**\n",
      "   - Often used in conjunction with other methods for increased effectiveness.\n",
      "\n",
      "7. **Natural Family Planning (Fertility Awareness Methods)**:\n",
      "   - Typical failure rate: **24%**\n",
      "   - Relies on tracking menstrual cycles and fertility signs.\n",
      "\n",
      "### Step 4: Summary of Comparison\n",
      "\n",
      "In summary, Junel 21 Day has a typical failure rate of about **7%**, which is more effective than barrier methods like condoms and diaphragms but less effective than long-acting reversible contraceptives (LARCs) such as IUDs and implants. The choice of contraceptive method should consider not only effectiveness but also individual preferences, health conditions, lifestyle, and the desire for future fertility.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "\n",
      "When choosing a contraceptive method, it is essential to discuss options with a healthcare provider to find the most suitable method based on personal health, lifestyle, and reproductive goals. While Junel 21 Day is a reliable option for many, other methods may offer higher efficacy or align better with individual needs.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day has a typical failure rate of 3%, which is lower than condoms.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004825\n",
      "prediction:  To determine how much sumatriptan is equivalent to 8.4 mg of sumatriptan succinate in each 0.5 mL of Sumatriptan injection, we need to understand the relationship between sumatriptan and sumatriptan succinate.\n",
      "\n",
      "### Step 1: Understand the Chemical Forms\n",
      "Sumatriptan is the active drug, while sumatriptan succinate is its salt form. When medications are formulated as salts, the molecular weight of the salt is different from that of the active drug. \n",
      "\n",
      "### Step 2: Determine the Molecular Weights\n",
      "- The molecular weight of sumatriptan (C14H21N3O2S) is approximately 295.4 g/mol.\n",
      "- The molecular weight of sumatriptan succinate (C14H21N3O2SÂ·C4H6O4) is approximately 414.5 g/mol.\n",
      "\n",
      "### Step 3: Calculate the Equivalent Amount of Sumatriptan\n",
      "To find out how much sumatriptan corresponds to 8.4 mg of sumatriptan succinate, we can use the following formula:\n",
      "\n",
      "\\[\n",
      "\\text{Amount of Sumatriptan} = \\text{Amount of Sumatriptan Succinate} \\times \\left( \\frac{\\text{Molecular Weight of Sumatriptan}}{\\text{Molecular Weight of Sumatriptan Succinate}} \\right)\n",
      "\\]\n",
      "\n",
      "Substituting the values:\n",
      "\n",
      "\\[\n",
      "\\text{Amount of Sumatriptan} = 8.4 \\, \\text{mg} \\times \\left( \\frac{295.4 \\, \\text{g/mol}}{414.5 \\, \\text{g/mol}} \\right)\n",
      "\\]\n",
      "\n",
      "### Step 4: Perform the Calculation\n",
      "First, calculate the ratio of the molecular weights:\n",
      "\n",
      "\\[\n",
      "\\frac{295.4}{414.5} \\approx 0.712\n",
      "\\]\n",
      "\n",
      "Now, multiply this ratio by the amount of sumatriptan succinate:\n",
      "\n",
      "\\[\n",
      "\\text{Amount of Sumatriptan} = 8.4 \\, \\text{mg} \\times 0.712 \\approx 5.98 \\, \\text{mg}\n",
      "\\]\n",
      "\n",
      "### Conclusion\n",
      "Therefore, 8.4 mg of sumatriptan succinate is approximately equivalent to **5.98 mg of sumatriptan** in each 0.5 mL of Sumatriptan injection, USP.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 6 mg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.044795\n",
      "prediction:  To determine the appropriate treatment option for recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy with Pemetrexed, we need to consider several factors, including the patient's overall health, the specific characteristics of the cancer, and available treatment options. Hereâ€™s a step-by-step approach to answering this question:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "- **Non-Small Cell Lung Cancer (NSCLC)**: This is a type of lung cancer that is not squamous cell carcinoma. It is the most common type of lung cancer.\n",
      "- **Recurrent Metastatic NSCLC**: This indicates that the cancer has returned after treatment and has spread to other parts of the body.\n",
      "- **Prior Chemotherapy with Pemetrexed**: Pemetrexed is a chemotherapy drug commonly used for non-squamous NSCLC, often in combination with other agents.\n",
      "\n",
      "### Step 2: Assess Previous Treatments\n",
      "- Since the patient has already received Pemetrexed, it is important to consider the treatment history and response to this drug. If the patient had a good response to Pemetrexed, it may be beneficial to explore other treatment options rather than reintroducing the same agent.\n",
      "\n",
      "### Step 3: Evaluate Current Treatment Guidelines\n",
      "- Current treatment guidelines for recurrent metastatic non-squamous NSCLC recommend several options based on the patient's previous treatments and the presence of specific biomarkers (e.g., PD-L1 expression, EGFR mutations, ALK rearrangements).\n",
      "\n",
      "### Step 4: Consider Targeted Therapies and Immunotherapy\n",
      "1. **Targeted Therapy**: If the tumor has specific mutations (e.g., EGFR, ALK, ROS1), targeted therapies such as:\n",
      "   - **EGFR inhibitors** (e.g., Osimertinib) for EGFR-mutated NSCLC.\n",
      "   - **ALK inhibitors** (e.g., Alectinib, Crizotinib) for ALK-positive NSCLC.\n",
      "   - **ROS1 inhibitors** (e.g., Crizotinib) for ROS1-positive NSCLC.\n",
      "   \n",
      "2. **Immunotherapy**: If the tumor expresses PD-L1, immune checkpoint inhibitors such as:\n",
      "   - **Pembrolizumab** or **Nivolumab** (anti-PD-1 antibodies) can be considered, especially if the patient has not received prior immunotherapy.\n",
      "\n",
      "### Step 5: Consider Clinical Trials\n",
      "- If standard treatment options are exhausted or not suitable, enrolling the patient in a clinical trial may provide access to novel therapies that could be beneficial.\n",
      "\n",
      "### Step 6: Multidisciplinary Approach\n",
      "- It is essential to involve a multidisciplinary team, including oncologists, radiologists, and pathologists, to evaluate the best treatment plan tailored to the patient's specific situation.\n",
      "\n",
      "### Conclusion\n",
      "In summary, for a patient with recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed, the appropriate treatment options may include:\n",
      "- **Targeted therapies** if specific mutations are present (e.g., EGFR, ALK).\n",
      "- **Immunotherapy** with PD-1/PD-L1 inhibitors if the tumor expresses PD-L1.\n",
      "- **Clinical trials** for access to new therapies.\n",
      "\n",
      "The final decision should be made based on a thorough evaluation of the patient's health status, tumor characteristics, and preferences, in consultation with their healthcare team.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.028906\n",
      "prediction:  To determine the appropriate treatment option for recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy with Pemetrexed, we need to consider several factors, including the patient's overall health, the specific characteristics of the cancer, and available treatment options. Hereâ€™s a step-by-step approach to arrive at a comprehensive answer:\n",
      "\n",
      "### Step 1: Understand the Disease Context\n",
      "Non-squamous NSCLC is a subtype of lung cancer that does not have squamous cell characteristics. It is often treated with chemotherapy, targeted therapy, and immunotherapy. Pemetrexed is a chemotherapy agent commonly used for non-squamous NSCLC, particularly in combination with platinum-based chemotherapy.\n",
      "\n",
      "### Step 2: Assess Previous Treatment\n",
      "Since the patient has already received Pemetrexed, it is important to note that re-treatment with the same agent is generally not recommended due to the potential for resistance and limited efficacy. Therefore, alternative treatment options must be considered.\n",
      "\n",
      "### Step 3: Evaluate Molecular Characteristics\n",
      "Before deciding on the next line of treatment, it is crucial to evaluate the molecular characteristics of the tumor. Testing for specific mutations (e.g., EGFR, ALK, ROS1, BRAF) and PD-L1 expression can guide treatment decisions. \n",
      "\n",
      "- **EGFR Mutations**: If the tumor has an EGFR mutation, targeted therapies such as osimertinib (a third-generation EGFR inhibitor) may be appropriate.\n",
      "- **ALK Rearrangements**: If ALK is positive, crizotinib or other ALK inhibitors (e.g., alectinib, brigatinib) would be suitable.\n",
      "- **ROS1 Rearrangements**: If ROS1 is positive, crizotinib can also be used.\n",
      "- **BRAF Mutations**: If BRAF V600E mutation is present, targeted therapy with a combination of BRAF and MEK inhibitors (e.g., dabrafenib and trametinib) may be indicated.\n",
      "- **PD-L1 Expression**: If PD-L1 expression is high (â‰¥50%), immunotherapy with pembrolizumab may be considered.\n",
      "\n",
      "### Step 4: Consider Immunotherapy\n",
      "If the tumor does not have actionable mutations, or if the patient is not a candidate for targeted therapy, immunotherapy may be a viable option. Immune checkpoint inhibitors, such as nivolumab or atezolizumab, can be used in patients with recurrent metastatic NSCLC, especially if they have not been previously treated with immunotherapy.\n",
      "\n",
      "### Step 5: Evaluate Clinical Trials\n",
      "For patients with recurrent disease, participation in clinical trials may also be an option. New therapies and combinations are continually being tested, and clinical trials may provide access to cutting-edge treatments that are not yet widely available.\n",
      "\n",
      "### Step 6: Multidisciplinary Approach\n",
      "It is essential to involve a multidisciplinary team, including oncologists, radiologists, and pathologists, to discuss the best treatment strategy tailored to the individual patientâ€™s needs and preferences.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the appropriate treatment option for recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed may include:\n",
      "\n",
      "1. **Targeted Therapy**: If specific mutations (EGFR, ALK, ROS1, BRAF) are present.\n",
      "2. **Immunotherapy**: If no actionable mutations are found, especially if PD-L1 expression is high.\n",
      "3. **Clinical Trials**: Consideration of participation in ongoing clinical trials for novel therapies.\n",
      "\n",
      "Ultimately, the choice of treatment should be personalized based on the patient's specific clinical scenario, molecular profile, and overall health status. Regular follow-up and reassessment are crucial to monitor treatment response and adjust the management plan as needed.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.036926\n",
      "prediction:  To determine the appropriate treatment option for recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy with Pemetrexed, we need to consider several factors, including the patient's overall health, the specific characteristics of the cancer, and the available treatment options. Hereâ€™s a step-by-step approach to answering this question:\n",
      "\n",
      "### Step 1: Understand the Context\n",
      "- **Non-Small Cell Lung Cancer (NSCLC)**: This is a type of lung cancer that is not squamous cell carcinoma. It is the most common type of lung cancer.\n",
      "- **Recurrent Metastatic NSCLC**: This indicates that the cancer has returned after initial treatment and has spread to other parts of the body.\n",
      "- **Prior Chemotherapy with Pemetrexed**: Pemetrexed is a chemotherapy drug commonly used for non-squamous NSCLC, often in combination with other agents.\n",
      "\n",
      "### Step 2: Assess Treatment Options\n",
      "After the failure of first-line chemotherapy, several treatment options may be considered for recurrent metastatic non-squamous NSCLC:\n",
      "\n",
      "1. **Targeted Therapy**: \n",
      "   - If the tumor has specific genetic mutations (e.g., EGFR, ALK, ROS1, BRAF), targeted therapies may be appropriate. For example:\n",
      "     - **EGFR Inhibitors**: Osimertinib for EGFR mutations.\n",
      "     - **ALK Inhibitors**: Alectinib or crizotinib for ALK rearrangements.\n",
      "     - **ROS1 Inhibitors**: Crizotinib for ROS1 rearrangements.\n",
      "     - **BRAF Inhibitors**: Dabrafenib and trametinib for BRAF V600E mutations.\n",
      "\n",
      "2. **Immunotherapy**:\n",
      "   - Immune checkpoint inhibitors such as pembrolizumab, nivolumab, or atezolizumab may be considered, especially if the tumor expresses PD-L1. These agents can be used as monotherapy or in combination with chemotherapy.\n",
      "\n",
      "3. **Second-Line Chemotherapy**:\n",
      "   - If the patient has not received certain agents, second-line chemotherapy options may include docetaxel or gemcitabine. However, the efficacy of these agents may be limited after prior treatment with Pemetrexed.\n",
      "\n",
      "4. **Clinical Trials**:\n",
      "   - Participation in clinical trials may provide access to novel therapies that are not yet widely available. This can be an important consideration for patients with recurrent disease.\n",
      "\n",
      "### Step 3: Consider Patient Factors\n",
      "- **Performance Status**: The patient's overall health and performance status (e.g., ECOG score) will influence treatment decisions.\n",
      "- **Previous Response**: The response to prior treatments and the duration of response can guide the choice of subsequent therapies.\n",
      "- **Comorbidities**: Other health conditions may affect the choice of treatment.\n",
      "\n",
      "### Step 4: Make a Recommendation\n",
      "Based on the above considerations, the appropriate treatment option for recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed may include:\n",
      "\n",
      "- **If the tumor has actionable mutations**: Consider targeted therapy based on the specific mutation.\n",
      "- **If PD-L1 expression is high**: Consider immunotherapy with a checkpoint inhibitor.\n",
      "- **If no specific mutations are identified and the patient is not a candidate for immunotherapy**: Consider second-line chemotherapy with docetaxel or gemcitabine.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the treatment for recurrent metastatic non-squamous NSCLC after prior chemotherapy with Pemetrexed should be individualized based on the tumor's molecular characteristics, the patient's health status, and previous treatment responses. Targeted therapy and immunotherapy are often preferred options, while second-line chemotherapy may be considered if other options are not viable. Consulting with an oncologist is essential for personalized treatment planning.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Pemetrexed as a single agent.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.016268\n",
      "prediction:  To determine the maximum oral dose of ondansetron administered to rats in carcinogenicity studies, we need to refer to the specific studies and data available in the scientific literature or regulatory documents. Carcinogenicity studies are typically conducted to assess the potential cancer-causing effects of a substance over a prolonged period.\n",
      "\n",
      "1. **Understanding Carcinogenicity Studies**: These studies are designed to evaluate the long-term effects of a substance, often involving multiple doses over an extended period. The doses are usually expressed in mg/kg per day, which allows for comparison across different studies and species.\n",
      "\n",
      "2. **Finding Relevant Data**: The maximum dose used in these studies can often be found in the study reports or summaries provided by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These documents may include detailed information about the methodology, including the dosing regimen.\n",
      "\n",
      "3. **Typical Dosing Ranges**: In many carcinogenicity studies, doses can vary widely depending on the substance being tested. For ondansetron, a commonly used antiemetic, the doses in studies may range from low to high, often with a maximum dose that is significantly higher than the therapeutic dose used in humans.\n",
      "\n",
      "4. **Example Data**: For ondansetron, studies have reported maximum doses in the range of 10 to 100 mg/kg per day in rats, depending on the specific study design and objectives. \n",
      "\n",
      "5. **Conclusion**: To provide a specific answer, one would need to reference the exact study or regulatory document. However, based on available literature, the maximum oral dose of ondansetron administered to rats in carcinogenicity studies is often reported to be around **100 mg/kg per day**. \n",
      "\n",
      "For precise figures, it is advisable to consult the original research articles or regulatory submissions that detail the carcinogenicity studies for ondansetron.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011834\n",
      "prediction:  To determine the maximum oral dose of ondansetron administered to rats in carcinogenicity studies, we need to refer to the specific studies and data available in the scientific literature or regulatory documents. Hereâ€™s a step-by-step approach to find this information:\n",
      "\n",
      "1. **Understanding Carcinogenicity Studies**: Carcinogenicity studies are conducted to evaluate the potential of a substance to cause cancer in animals. These studies typically involve administering various doses of a compound to test subjects over an extended period.\n",
      "\n",
      "2. **Identifying Relevant Studies**: Look for published studies or regulatory submissions (such as those to the FDA or EMA) that detail the carcinogenicity testing of ondansetron. These documents often include information on the doses used, the duration of the study, and the species tested.\n",
      "\n",
      "3. **Finding the Maximum Dose**: In the identified studies, locate the section that describes the dosing regimen. The maximum dose will typically be listed in the methods section, where the researchers outline how the study was conducted.\n",
      "\n",
      "4. **Converting to mg/kg per day**: If the dose is provided in a different format (e.g., total daily dose or per animal), convert it to mg/kg per day. This involves knowing the weight of the rats used in the study. For example, if the maximum dose was 100 mg per day for a rat weighing 250 grams, the calculation would be:\n",
      "   \\[\n",
      "   \\text{Dose in mg/kg} = \\frac{\\text{Total dose in mg}}{\\text{Weight in kg}} = \\frac{100 \\text{ mg}}{0.25 \\text{ kg}} = 400 \\text{ mg/kg per day}\n",
      "   \\]\n",
      "\n",
      "5. **Reviewing the Findings**: After calculating the dose, review the findings of the study to understand the implications of the dose on the health and safety of the rats, as well as any observed carcinogenic effects.\n",
      "\n",
      "6. **Consulting Regulatory Guidelines**: Regulatory agencies may have specific guidelines on the acceptable doses for carcinogenicity studies. This can provide context for the maximum dose used in the studies.\n",
      "\n",
      "7. **Final Answer**: After gathering all the necessary information, compile it into a comprehensive answer. \n",
      "\n",
      "As of my last knowledge update in October 2023, the maximum oral dose of ondansetron administered to rats in carcinogenicity studies was typically reported to be around 40 mg/kg per day, but this can vary based on the specific study design and objectives. Always refer to the most recent and relevant studies for the most accurate information. \n",
      "\n",
      "In conclusion, the maximum oral dose of ondansetron administered to rats in carcinogenicity studies is approximately **40 mg/kg per day**, but it is essential to verify this with the latest research and regulatory documents for precise figures.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013451\n",
      "prediction:  To determine the maximum oral dose of ondansetron administered to rats in carcinogenicity studies, we need to refer to the specific studies and data available in the scientific literature or regulatory documents. Hereâ€™s a step-by-step approach to find this information:\n",
      "\n",
      "1. **Understanding Ondansetron**: Ondansetron is a medication primarily used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, or surgery. It is a selective serotonin 5-HT3 receptor antagonist.\n",
      "\n",
      "2. **Carcinogenicity Studies**: Carcinogenicity studies are conducted to evaluate the potential of a substance to cause cancer in animals, which can then be extrapolated to humans. These studies typically involve long-term exposure to the substance at various doses.\n",
      "\n",
      "3. **Reviewing Available Literature**: To find the maximum oral dose of ondansetron administered to rats, we would typically look at:\n",
      "   - Published scientific articles in journals.\n",
      "   - Regulatory submissions to agencies like the FDA or EMA.\n",
      "   - Toxicology databases or reports from pharmaceutical companies.\n",
      "\n",
      "4. **Finding Specific Data**: In the case of ondansetron, the maximum doses used in carcinogenicity studies are often reported in the context of the study design. For example, studies may report doses in mg/kg/day based on the body weight of the rats.\n",
      "\n",
      "5. **Typical Doses in Studies**: In many carcinogenicity studies, doses can vary widely. For ondansetron, doses reported in studies can range from low (e.g., 1 mg/kg/day) to high (e.g., 100 mg/kg/day or more), depending on the study design and objectives.\n",
      "\n",
      "6. **Consulting Regulatory Documents**: The maximum dose is often specified in the results section of the studies or in the summary of findings. For ondansetron, the maximum dose reported in some studies is around 100 mg/kg/day.\n",
      "\n",
      "7. **Conclusion**: Based on available data from carcinogenicity studies, the maximum oral dose of ondansetron administered to rats is typically reported to be **100 mg/kg per day**. However, it is essential to consult specific studies or regulatory documents for precise figures, as they may vary based on the study design and objectives.\n",
      "\n",
      "In summary, the maximum oral dose of ondansetron administered to rats in carcinogenicity studies is generally around **100 mg/kg per day**, but it is advisable to refer to specific studies for confirmation.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 10 mg/kg per day\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.01012\n",
      "prediction:  To determine the maximum temperature that 'up and up ibuprofen' should be exposed to during storage, we can follow these steps:\n",
      "\n",
      "### Step 1: Understand the Product\n",
      "'Up and Up' is a brand of over-the-counter medications sold by Target, which includes ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relieve pain, reduce inflammation, and lower fever.\n",
      "\n",
      "### Step 2: Check the Packaging\n",
      "The storage instructions for ibuprofen, including the 'up and up' brand, are typically found on the product packaging or in the accompanying patient information leaflet. These instructions are based on stability studies conducted by the manufacturer.\n",
      "\n",
      "### Step 3: General Storage Guidelines for Ibuprofen\n",
      "Most ibuprofen products, including generic brands, generally have similar storage requirements. The typical recommendations include:\n",
      "- Store at room temperature, away from excess heat and moisture.\n",
      "- The ideal temperature range is usually between 20Â°C to 25Â°C (68Â°F to 77Â°F).\n",
      "- Some products may allow for storage between 15Â°C to 30Â°C (59Â°F to 86Â°F).\n",
      "\n",
      "### Step 4: Identify Maximum Temperature\n",
      "While the specific maximum temperature for 'up and up ibuprofen' may not be explicitly stated, it is generally advised not to expose ibuprofen to temperatures above 30Â°C (86Â°F). Exceeding this temperature can lead to degradation of the medication, potentially reducing its effectiveness and safety.\n",
      "\n",
      "### Step 5: Consider Environmental Factors\n",
      "In addition to temperature, it is important to consider other environmental factors such as humidity and light exposure. Ibuprofen should be stored in a cool, dry place, away from direct sunlight and moisture.\n",
      "\n",
      "### Step 6: Conclusion\n",
      "In summary, the maximum temperature that 'up and up ibuprofen' should be exposed to during storage is generally around 30Â°C (86Â°F). For optimal storage, it is best to keep it at room temperature, ideally between 20Â°C to 25Â°C (68Â°F to 77Â°F), and to follow any specific instructions provided on the product packaging.\n",
      "\n",
      "### Additional Note\n",
      "For the most accurate and specific information, always refer to the product label or consult a pharmacist or healthcare provider.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011179\n",
      "prediction:  To determine the maximum temperature that 'up and up ibuprofen' should be exposed to during storage, we can follow these steps:\n",
      "\n",
      "### Step 1: Understand the Product\n",
      "'Up and Up' is a brand of over-the-counter medications, including ibuprofen, which is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce inflammation, and lower fever. Proper storage is crucial to maintain the efficacy and safety of the medication.\n",
      "\n",
      "### Step 2: Check the Packaging\n",
      "The packaging of ibuprofen typically includes storage instructions. These instructions are based on stability studies conducted by the manufacturer. It is essential to refer to the specific product packaging for the most accurate information.\n",
      "\n",
      "### Step 3: General Storage Guidelines for Ibuprofen\n",
      "In general, most ibuprofen products, including those from various brands, are recommended to be stored at room temperature. The typical storage temperature range is:\n",
      "\n",
      "- **Room Temperature**: 20Â°C to 25Â°C (68Â°F to 77Â°F)\n",
      "- **Maximum Temperature**: Often, the maximum temperature for storage is around 30Â°C (86Â°F).\n",
      "\n",
      "### Step 4: Consider Environmental Factors\n",
      "Ibuprofen should be kept away from excessive heat, moisture, and direct sunlight. High temperatures can degrade the medication, leading to reduced effectiveness and potential safety concerns.\n",
      "\n",
      "### Step 5: Manufacturer's Recommendations\n",
      "For the most accurate information, it is best to consult the specific product insert or the manufacturer's website. For 'up and up ibuprofen', the storage instructions should be clearly stated, and it is advisable to adhere to those guidelines.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the maximum temperature that 'up and up ibuprofen' should be exposed to during storage is generally around 30Â°C (86Â°F). However, it is always best to refer to the specific product packaging for the most accurate and detailed storage instructions. Proper storage helps ensure the medication remains effective and safe for use.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011429\n",
      "prediction:  To determine the maximum temperature that 'up and up ibuprofen' should be exposed to during storage, we can follow these steps:\n",
      "\n",
      "### Step 1: Understand the Product\n",
      "'Up and up ibuprofen' is a brand of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce inflammation, and lower fever. Like many medications, it has specific storage requirements to maintain its efficacy and safety.\n",
      "\n",
      "### Step 2: Check the Packaging\n",
      "The packaging of over-the-counter medications, including 'up and up ibuprofen', typically includes storage instructions. These instructions are based on stability studies conducted by the manufacturer.\n",
      "\n",
      "### Step 3: General Storage Guidelines for Ibuprofen\n",
      "Most ibuprofen products, including generic brands, generally have similar storage requirements. The common recommendations are:\n",
      "- Store at room temperature, typically between 20Â°C to 25Â°C (68Â°F to 77Â°F).\n",
      "- Avoid exposure to excessive heat, moisture, and direct sunlight.\n",
      "\n",
      "### Step 4: Identify Maximum Temperature\n",
      "While specific maximum temperature limits can vary slightly by manufacturer, a common guideline is:\n",
      "- Do not store above 30Â°C (86Â°F). \n",
      "\n",
      "Exceeding this temperature can lead to degradation of the active ingredient, potentially reducing the medication's effectiveness and safety.\n",
      "\n",
      "### Step 5: Consider Environmental Factors\n",
      "In addition to temperature, it is important to consider humidity and light exposure, as these factors can also affect the stability of ibuprofen. It is best to store the medication in a cool, dry place, away from direct sunlight.\n",
      "\n",
      "### Conclusion\n",
      "In summary, 'up and up ibuprofen' should ideally be stored at room temperature, with a maximum exposure temperature of 30Â°C (86Â°F). Always refer to the specific product packaging for the most accurate storage instructions, and consult a pharmacist or healthcare provider if there are any uncertainties regarding medication storage.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 40Â°C (104Â°F)\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.001972\n",
      "prediction:  To determine the median percent reduction in primary generalized tonic-clonic seizures (PGTC) observed in patients treated with lamotrigine during a clinical trial, we would typically follow these steps:\n",
      "\n",
      "1. **Identify the Clinical Trial**: First, we need to identify the specific clinical trial or studies that investigated the efficacy of lamotrigine in treating PGTC seizures. This information can usually be found in published research articles, clinical trial registries, or meta-analyses.\n",
      "\n",
      "2. **Review Study Design**: Examine the study design, including the number of participants, the duration of the trial, and the dosage of lamotrigine administered. This information is crucial for understanding the context of the results.\n",
      "\n",
      "3. **Collect Data on Seizure Frequency**: Look for data on the frequency of PGTC seizures before and after treatment with lamotrigine. This data is often presented in terms of the number of seizures per month or per week.\n",
      "\n",
      "4. **Calculate Percent Reduction**: For each participant, calculate the percent reduction in seizure frequency using the formula:\n",
      "   \\[\n",
      "   \\text{Percent Reduction} = \\left( \\frac{\\text{Baseline Seizure Frequency} - \\text{Post-Treatment Seizure Frequency}}{\\text{Baseline Seizure Frequency}} \\right) \\times 100\n",
      "   \\]\n",
      "\n",
      "5. **Determine the Median**: Once you have the percent reduction for all participants, sort these values and find the median. The median is the middle value when the data is arranged in ascending order. If there is an even number of observations, the median is the average of the two middle numbers.\n",
      "\n",
      "6. **Report Findings**: Finally, summarize the findings, including the median percent reduction in PGTC seizures, and provide context regarding the clinical significance of this reduction.\n",
      "\n",
      "### Example of Findings (Hypothetical Data)\n",
      "\n",
      "For illustrative purposes, letâ€™s assume a clinical trial involving 100 patients treated with lamotrigine reported the following median percent reduction in PGTC seizures:\n",
      "\n",
      "- **Baseline Seizure Frequency**: 10 seizures per month\n",
      "- **Post-Treatment Seizure Frequency**: 3 seizures per month\n",
      "- **Percent Reduction Calculation**: \n",
      "   \\[\n",
      "   \\text{Percent Reduction} = \\left( \\frac{10 - 3}{10} \\right) \\times 100 = 70\\%\n",
      "   \\]\n",
      "\n",
      "If the median percent reduction across all participants was calculated to be 65%, this would be reported as:\n",
      "\n",
      "**Answer**: In a clinical trial evaluating the efficacy of lamotrigine for the treatment of primary generalized tonic-clonic seizures (PGTC), the median percent reduction in seizure frequency observed in patients was 65%. This indicates a significant reduction in seizure activity, suggesting that lamotrigine may be an effective treatment option for individuals experiencing PGTC seizures. \n",
      "\n",
      "### Conclusion\n",
      "\n",
      "To provide an accurate answer, one would need to reference specific clinical trial data. The steps outlined above serve as a guide for how to approach the question methodically. If you have access to specific trial data or results, please provide that information for a more precise answer.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002035\n",
      "prediction:  To determine the median percent reduction in primary generalized tonic-clonic seizures (PGTC) observed in patients treated with lamotrigine during a clinical trial, we would typically follow these steps:\n",
      "\n",
      "1. **Identify the Clinical Trial**: First, we need to identify the specific clinical trial or studies that investigated the efficacy of lamotrigine in treating PGTC seizures. This information can usually be found in published research articles, clinical trial registries, or meta-analyses.\n",
      "\n",
      "2. **Review Study Design**: Examine the study design, including the number of participants, the duration of the trial, and the dosage of lamotrigine administered. This information is crucial for understanding the context of the results.\n",
      "\n",
      "3. **Collect Data on Seizure Frequency**: Look for data on the frequency of PGTC seizures before and after treatment with lamotrigine. This data is often presented in terms of the number of seizures per month or per week.\n",
      "\n",
      "4. **Calculate Percent Reduction**: For each participant, calculate the percent reduction in seizure frequency using the formula:\n",
      "   \\[\n",
      "   \\text{Percent Reduction} = \\left( \\frac{\\text{Baseline Seizure Frequency} - \\text{Post-Treatment Seizure Frequency}}{\\text{Baseline Seizure Frequency}} \\right) \\times 100\n",
      "   \\]\n",
      "   This calculation will yield the percent reduction for each patient.\n",
      "\n",
      "5. **Determine the Median**: Once you have the percent reductions for all participants, sort these values and find the median. The median is the middle value when the data is arranged in ascending order. If there is an even number of observations, the median is the average of the two middle numbers.\n",
      "\n",
      "6. **Report Findings**: Finally, summarize the findings, including the median percent reduction in PGTC seizures, and provide context regarding the significance of this reduction in terms of clinical outcomes and patient quality of life.\n",
      "\n",
      "### Example of Findings (Hypothetical)\n",
      "\n",
      "For illustrative purposes, letâ€™s say a clinical trial involving 100 patients treated with lamotrigine reported the following median percent reduction in PGTC seizures:\n",
      "\n",
      "- **Baseline Seizure Frequency**: 10 seizures per month\n",
      "- **Post-Treatment Seizure Frequency**: 3 seizures per month\n",
      "- **Percent Reduction Calculation**: \n",
      "   \\[\n",
      "   \\text{Percent Reduction} = \\left( \\frac{10 - 3}{10} \\right) \\times 100 = 70\\%\n",
      "   \\]\n",
      "\n",
      "If the median of all calculated percent reductions from the trial data was found to be 65%, we would report:\n",
      "\n",
      "**Answer**: The median percent reduction in primary generalized tonic-clonic seizures (PGTC) observed in patients treated with lamotrigine during the clinical trial was 65%. \n",
      "\n",
      "### Conclusion\n",
      "\n",
      "This step-by-step approach allows for a thorough understanding of the efficacy of lamotrigine in reducing PGTC seizures, providing valuable insights for clinicians and patients alike. For precise data, one would need to refer to specific clinical trial results or published literature on the subject.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.002317\n",
      "prediction:  To determine the median percent reduction in primary generalized tonic-clonic seizures (PGTC) observed in patients treated with lamotrigine during a clinical trial, we would typically follow these steps:\n",
      "\n",
      "1. **Identify the Clinical Trial**: First, we need to identify the specific clinical trial or studies that investigated the efficacy of lamotrigine in treating PGTC seizures. This information can usually be found in published research articles, clinical trial registries, or meta-analyses.\n",
      "\n",
      "2. **Review Study Design**: Examine the study design, including the number of participants, the duration of the trial, and the dosage of lamotrigine administered. This information is crucial for understanding the context of the results.\n",
      "\n",
      "3. **Data Collection**: Look for the data on seizure frequency before and after treatment with lamotrigine. This data is often presented in terms of the number of seizures per month or per week.\n",
      "\n",
      "4. **Calculate Percent Reduction**: For each participant, calculate the percent reduction in seizure frequency using the formula:\n",
      "   \\[\n",
      "   \\text{Percent Reduction} = \\left( \\frac{\\text{Baseline Seizures} - \\text{Post-Treatment Seizures}}{\\text{Baseline Seizures}} \\right) \\times 100\n",
      "   \\]\n",
      "   This calculation needs to be done for all participants in the study.\n",
      "\n",
      "5. **Determine the Median**: Once you have the percent reduction values for all participants, sort these values in ascending order and find the median. The median is the middle value in a sorted list. If there is an even number of observations, the median is the average of the two middle numbers.\n",
      "\n",
      "6. **Report Findings**: Finally, report the median percent reduction along with any relevant statistical measures (e.g., confidence intervals, p-values) that indicate the significance of the findings.\n",
      "\n",
      "### Example of Findings\n",
      "While I cannot provide specific data from a clinical trial without access to the latest studies, previous research has shown that lamotrigine can lead to significant reductions in seizure frequency for patients with generalized epilepsy, including PGTC seizures. In some studies, median reductions have been reported in the range of 50% to 70%, but these figures can vary based on the population studied, the duration of treatment, and other factors.\n",
      "\n",
      "### Conclusion\n",
      "To provide an accurate answer to the question regarding the median percent reduction in PGTC seizures with lamotrigine, one would need to refer to specific clinical trial data. If you have access to a particular study or dataset, I can help you interpret that data to find the median percent reduction.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  C\n",
      "correct answer: 66%\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.031212\n",
      "prediction:  To determine the mutagenicity of Hydrocort (hydrocortisone), various studies have been conducted, primarily focusing on the assessment of its potential to induce genetic mutations in vitro (laboratory settings) and in vivo (living organisms). Although specific studies directly linking hydrocortisone to mutagenicity were not found in PubMed, several pertinent pieces of literature discuss related methodologies and findings in the field of mutagenicity and genotoxicity.\n",
      "\n",
      "1. **In Vitro Testing**: Studies typically utilize cell cultures to assess whether hydrocortisone can cause mutations. This is often done using assays such as the Ames test, which examines whether a compound can induce mutations in bacterial DNA.\n",
      "\n",
      "2. **In Vivo Testing**: Animal studies are also conducted to observe the effects of hydrocortisone on living organisms, particularly focusing on any chromosomal damage or mutations. These studies can include assessing micronucleus formation in blood samples from treated animals to evaluate genotoxic effects.\n",
      "\n",
      "3. **Comparison with Other Compounds**: In some cases, hydrocortisone may be evaluated alongside other drugs to determine relative risks of mutagenicity. For example, studies have explored the genotoxic impacts of various hormonal drugs, which may include hydrocortisone derivatives.\n",
      "\n",
      "4. **Regulatory Framework**: Mutagenicity testing is governed by guidelines from organizations such as the OECD (Organization for Economic Co-operation and Development) and involves standardized in vivo and in vitro tests to ensure comprehensive safety assessments.\n",
      "\n",
      "Overall, while specific studies on hydrocortisone's mutagenicity may be limited, the existing research framework provides foundational approaches to assess its potential effects, with considerations detailed in safety evaluations of hormonal drugs and the biology of the corticosteroids.\n",
      "\n",
      "For further reading, the following references can provide additional insights:\n",
      "\n",
      "- \"Mutagenicity and Genotoxicity - ChemSafetyPro.COM\" discusses the guidelines and methodologies used for risk assessment related to mutagenicity studies.\n",
      "- \"In vitro and in vivo genotoxicity evaluation of hormonal drugs\" may delve deeper into testing methods relevant to hydrocortisone's mutagenic potential.\n",
      "\n",
      "(References: [ChemSafetyPro](https://chemsafetypro.com/Topics/CRA/Mutagenicity_and_Genotoxicity.html), [Wiley Online Library](https://onlinelibrary.wiley.com/doi/pdf/10.1002/em.2850160406))\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.029157\n",
      "prediction:  To determine the mutagenicity of Hydrocortisone (often referred to as Hydrocort), various categories of studies can be conducted. Hereâ€™s a step-by-step breakdown of the types of studies typically involved in assessing mutagenicity:\n",
      "\n",
      "### 1. **In Vitro Studies**\n",
      "   - **Ames Test**: This is one of the most common initial tests for mutagenicity. It uses strains of bacteria (usually *Salmonella typhimurium*) that are sensitive to mutations. The test assesses whether Hydrocort can cause mutations in the bacterial DNA when exposed to the compound.\n",
      "   - **Mammalian Cell Tests**: These tests involve exposing cultured mammalian cells (like Chinese hamster ovary cells) to Hydrocort to observe any changes in the genetic material. Common assays include the micronucleus test and the chromosomal aberration test.\n",
      "\n",
      "### 2. **In Vivo Studies**\n",
      "   - **Animal Studies**: These studies involve administering Hydrocort to laboratory animals (such as mice or rats) and then examining their tissues for mutations. This can include bone marrow analysis for chromosomal damage or other genetic changes.\n",
      "   - **Transgenic Mouse Models**: Some studies use genetically modified mice that carry reporter genes to detect mutations. These models can provide more sensitive and specific data regarding the mutagenic potential of Hydrocort.\n",
      "\n",
      "### 3. **Mechanistic Studies**\n",
      "   - **DNA Repair Studies**: These studies investigate whether Hydrocort induces DNA damage that triggers repair mechanisms. They can help elucidate the pathways involved in any mutagenic effects.\n",
      "   - **Biochemical Pathway Analysis**: Understanding how Hydrocort interacts with cellular components can provide insights into its potential mutagenicity. This may involve studying its effects on enzymes involved in DNA replication and repair.\n",
      "\n",
      "### 4. **Epidemiological Studies**\n",
      "   - While not directly assessing mutagenicity, epidemiological studies can provide data on the long-term effects of Hydrocort exposure in humans. These studies can help identify any correlations between Hydrocort use and increased mutation rates or cancer incidence in populations.\n",
      "\n",
      "### 5. **Regulatory and Review Studies**\n",
      "   - Regulatory agencies (like the FDA or EMA) often review existing data on the mutagenicity of drugs. They may require specific studies to be conducted or may rely on previously published research to assess the safety of Hydrocort.\n",
      "\n",
      "### Conclusion\n",
      "The determination of mutagenicity for Hydrocort involves a combination of in vitro and in vivo studies, mechanistic investigations, and epidemiological data. Each category of study contributes to a comprehensive understanding of the potential genetic risks associated with Hydrocort use. The results from these studies help inform regulatory decisions and clinical guidelines regarding the safe use of Hydrocort in medical practice.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.033097\n",
      "prediction:  To determine the mutagenicity of Hydrocortisone (often referred to as Hydrocort), various categories of studies can be conducted. Hereâ€™s a step-by-step breakdown of the types of studies typically involved in assessing mutagenicity:\n",
      "\n",
      "### 1. **In Vitro Studies**\n",
      "   - **Ames Test**: This is one of the most common initial tests for mutagenicity. It uses strains of bacteria (usually *Salmonella typhimurium*) that are sensitive to mutations. The test assesses whether Hydrocort can cause mutations in the bacterial DNA when exposed to the compound.\n",
      "   - **Mammalian Cell Tests**: These tests involve exposing cultured mammalian cells to Hydrocort to observe any changes in the genetic material. Common assays include the Mouse Lymphoma Assay and the Chinese Hamster Ovary (CHO) cell assay.\n",
      "\n",
      "### 2. **In Vivo Studies**\n",
      "   - **Micronucleus Test**: This test involves administering Hydrocort to animals (often rodents) and then examining their bone marrow for the presence of micronuclei, which are indicative of chromosomal damage.\n",
      "   - **Comet Assay**: This assay measures DNA strand breaks in individual cells. It can be performed on various tissues from animals exposed to Hydrocort to assess potential genotoxic effects.\n",
      "\n",
      "### 3. **Long-term Carcinogenicity Studies**\n",
      "   - While primarily focused on cancer risk, these studies can provide insights into mutagenicity as well. Animals are exposed to Hydrocort over an extended period, and researchers monitor for tumor development and any associated genetic changes.\n",
      "\n",
      "### 4. **Epidemiological Studies**\n",
      "   - Although not a direct measure of mutagenicity, epidemiological studies can provide data on the long-term effects of Hydrocort exposure in humans, including any associations with cancer or genetic disorders.\n",
      "\n",
      "### 5. **Mechanistic Studies**\n",
      "   - These studies aim to understand the biological mechanisms by which Hydrocort may cause mutations. This can include examining the interaction of Hydrocort with DNA, its metabolic pathways, and the cellular responses to DNA damage.\n",
      "\n",
      "### Conclusion\n",
      "The assessment of mutagenicity for Hydrocort involves a combination of in vitro and in vivo studies, each providing different insights into its potential genetic effects. Regulatory agencies often require a battery of these tests to comprehensively evaluate the mutagenic potential of pharmaceutical compounds. The results from these studies help inform safety profiles and regulatory decisions regarding the use of Hydrocort in clinical settings.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.02627\n",
      "prediction:  To determine the mutagenicity of Hydrocortisone (often referred to as Hydrocort), various categories of studies can be conducted. Hereâ€™s a step-by-step breakdown of the types of studies typically involved in assessing mutagenicity:\n",
      "\n",
      "### 1. **In Vitro Studies**\n",
      "   - **Ames Test**: This is one of the most common initial tests for mutagenicity. It uses strains of bacteria (usually Salmonella typhimurium) that are sensitive to mutations. The test assesses whether Hydrocort can cause mutations in the bacterial DNA when exposed to the compound.\n",
      "   - **Mammalian Cell Tests**: These tests involve exposing cultured mammalian cells (like Chinese hamster ovary cells) to Hydrocort to observe any changes in the genetic material, such as chromosomal aberrations or gene mutations.\n",
      "\n",
      "### 2. **In Vivo Studies**\n",
      "   - **Animal Models**: Studies in animals (such as mice or rats) can be conducted to evaluate the mutagenic potential of Hydrocort. This may involve administering the drug and then analyzing tissues for mutations or chromosomal damage.\n",
      "   - **Micronucleus Test**: This test involves treating animals with Hydrocort and then examining their bone marrow for the presence of micronuclei, which are indicative of chromosomal damage.\n",
      "\n",
      "### 3. **Genotoxicity Studies**\n",
      "   - **Comet Assay**: This assay can be used to detect DNA strand breaks in cells exposed to Hydrocort. It provides information on the genotoxic potential of the compound.\n",
      "   - **Sister Chromatid Exchange (SCE)**: This test measures the exchange of genetic material between sister chromatids and can indicate mutagenic activity.\n",
      "\n",
      "### 4. **Long-term Carcinogenicity Studies**\n",
      "   - While not exclusively focused on mutagenicity, long-term studies in animals can provide insights into whether Hydrocort has the potential to cause cancer, which is often linked to mutagenic effects.\n",
      "\n",
      "### 5. **Epidemiological Studies**\n",
      "   - Although not a direct measure of mutagenicity, epidemiological studies can provide data on the long-term effects of Hydrocort exposure in humans, including any associations with cancer or genetic disorders.\n",
      "\n",
      "### Conclusion\n",
      "The determination of mutagenicity for Hydrocort involves a combination of in vitro and in vivo studies, including bacterial assays, mammalian cell tests, and animal studies. Regulatory agencies often require a comprehensive assessment of mutagenicity before a drug can be approved for clinical use. The results from these studies help to ensure the safety of Hydrocort for patients and guide its therapeutic applications. \n",
      "\n",
      "It is important to note that the specific studies conducted may vary based on regulatory requirements, the intended use of the drug, and the results of preliminary tests. Always refer to the latest scientific literature and regulatory guidelines for the most current information on the mutagenicity of Hydrocort.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Studies with prednisolone and hydrocortisone\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.007513\n",
      "prediction:  To determine the oral dose of albuterol sulfate that demonstrated no evidence of impaired fertility in rats, we can refer to studies and data from preclinical trials that assess the reproductive toxicity of the drug.\n",
      "\n",
      "1. **Background on Albuterol Sulfate**: Albuterol sulfate is a bronchodilator commonly used to treat asthma and other conditions involving bronchospasm. It is a beta-2 adrenergic agonist that relaxes muscles in the airways and increases airflow to the lungs.\n",
      "\n",
      "2. **Reproductive Toxicity Studies**: Before a drug is approved for human use, it undergoes various preclinical studies, including reproductive toxicity assessments in animal models, such as rats. These studies typically evaluate the effects of the drug on fertility, gestation, and offspring development.\n",
      "\n",
      "3. **Finding the Relevant Studies**: In the case of albuterol sulfate, studies have been conducted to assess its effects on fertility in rats. These studies usually involve administering different doses of the drug to male and female rats before mating and observing any effects on reproductive performance, including mating success, pregnancy rates, and offspring viability.\n",
      "\n",
      "4. **Dose Levels**: In the reproductive toxicity studies for albuterol sulfate, various doses are tested, often ranging from low to high levels. The specific dose at which no adverse effects on fertility are observed is referred to as the no-observed-adverse-effect level (NOAEL).\n",
      "\n",
      "5. **Reported NOAEL for Albuterol**: According to available data, the NOAEL for albuterol sulfate in terms of fertility impairment in rats is typically reported to be around 100 mg/kg/day. At this dose, studies have shown no significant effects on mating performance, fertility rates, or reproductive outcomes.\n",
      "\n",
      "6. **Conclusion**: Therefore, the oral dose of albuterol sulfate that demonstrated no evidence of impaired fertility in rats is approximately **100 mg/kg/day**. This information is crucial for understanding the safety profile of albuterol sulfate, especially in the context of its use in pregnant women or those planning to conceive.\n",
      "\n",
      "It is important to note that while animal studies provide valuable insights, the results may not always directly translate to humans due to differences in physiology and metabolism. Therefore, further studies and clinical data are essential for comprehensive risk assessment in human populations.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: 50 mg/kg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.016793\n",
      "prediction:  To determine which condition is NOT treated by antifungal drugs, we first need to understand what antifungal medications are and the types of conditions they are designed to treat.\n",
      "\n",
      "### Step 1: Understanding Antifungal Drugs\n",
      "Antifungal drugs are medications specifically used to treat infections caused by fungi. These infections can affect various parts of the body, including the skin, nails, and internal organs. Common types of antifungal medications include:\n",
      "\n",
      "- **Azoles** (e.g., fluconazole, itraconazole)\n",
      "- **Echinocandins** (e.g., caspofungin, micafungin)\n",
      "- **Polyene antifungals** (e.g., amphotericin B, nystatin)\n",
      "- **Allylamines** (e.g., terbinafine)\n",
      "\n",
      "### Step 2: Conditions Treated by Antifungal Drugs\n",
      "Antifungal medications are used to treat a variety of fungal infections, including but not limited to:\n",
      "\n",
      "- **Candidiasis**: Infections caused by Candida species, such as oral thrush or vaginal yeast infections.\n",
      "- **Aspergillosis**: Infections caused by Aspergillus species, often affecting the lungs.\n",
      "- **Dermatophyte infections**: Such as athlete's foot, ringworm, and nail fungus (onychomycosis).\n",
      "- **Cryptococcal meningitis**: A serious infection of the brain caused by Cryptococcus neoformans, often seen in immunocompromised patients.\n",
      "- **Histoplasmosis**: A lung infection caused by the fungus Histoplasma capsulatum.\n",
      "\n",
      "### Step 3: Conditions NOT Treated by Antifungal Drugs\n",
      "To identify a condition that is NOT treated by antifungal drugs, we can consider various types of infections and diseases that are caused by other pathogens, such as bacteria, viruses, or parasites. Here are some examples:\n",
      "\n",
      "- **Bacterial Infections**: Conditions like strep throat, bacterial pneumonia, or urinary tract infections are caused by bacteria and are treated with antibiotics, not antifungals.\n",
      "- **Viral Infections**: Conditions such as influenza, COVID-19, or herpes are caused by viruses and require antiviral medications for treatment.\n",
      "- **Parasitic Infections**: Diseases like malaria, giardiasis, or toxoplasmosis are caused by parasites and are treated with antiparasitic drugs.\n",
      "\n",
      "### Conclusion\n",
      "Based on the information above, a condition that is NOT treated by antifungal drugs would be:\n",
      "\n",
      "**Bacterial infections (e.g., strep throat, bacterial pneumonia)**.\n",
      "\n",
      "These conditions require antibiotics for treatment, as they are caused by bacteria, not fungi.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.0151\n",
      "prediction:  To determine which condition is NOT treated by antifungal drugs, we first need to understand what antifungal medications are and the types of conditions they are designed to treat.\n",
      "\n",
      "### Step 1: Understanding Antifungal Drugs\n",
      "Antifungal drugs are medications specifically used to treat infections caused by fungi. These infections can affect various parts of the body, including the skin, nails, and internal organs. Common types of antifungal medications include:\n",
      "\n",
      "- **Azoles** (e.g., fluconazole, itraconazole)\n",
      "- **Echinocandins** (e.g., caspofungin, micafungin)\n",
      "- **Polyene antifungals** (e.g., amphotericin B, nystatin)\n",
      "- **Allylamines** (e.g., terbinafine)\n",
      "\n",
      "### Step 2: Conditions Treated by Antifungal Drugs\n",
      "Antifungal medications are used to treat a variety of fungal infections, including but not limited to:\n",
      "\n",
      "- **Candidiasis**: Infections caused by Candida species, such as oral thrush or vaginal yeast infections.\n",
      "- **Aspergillosis**: Infections caused by Aspergillus species, often affecting the lungs.\n",
      "- **Dermatophyte infections**: Such as athlete's foot, ringworm, and nail fungus (onychomycosis).\n",
      "- **Cryptococcosis**: A serious infection caused by Cryptococcus neoformans, often affecting immunocompromised individuals.\n",
      "- **Histoplasmosis**: A fungal infection caused by Histoplasma capsulatum, typically affecting the lungs.\n",
      "\n",
      "### Step 3: Conditions NOT Treated by Antifungal Drugs\n",
      "To identify a condition that is NOT treated by antifungal drugs, we can consider various types of infections and diseases. Here are some examples of conditions that are NOT treated with antifungals:\n",
      "\n",
      "- **Bacterial Infections**: Conditions such as strep throat, bacterial pneumonia, or urinary tract infections caused by bacteria are treated with antibiotics, not antifungals.\n",
      "- **Viral Infections**: Conditions like the flu, COVID-19, or herpes are caused by viruses and are treated with antiviral medications, not antifungals.\n",
      "- **Parasitic Infections**: Diseases such as malaria or giardiasis are caused by parasites and require antiparasitic medications.\n",
      "- **Autoimmune Diseases**: Conditions like rheumatoid arthritis or lupus are treated with immunosuppressants or anti-inflammatory drugs, not antifungals.\n",
      "\n",
      "### Conclusion\n",
      "Based on the information above, a condition that is NOT treated by antifungal drugs would be **bacterial infections** (e.g., strep throat). Antifungal medications are ineffective against bacteria, viruses, or parasites, which require different classes of medications for treatment. \n",
      "\n",
      "Thus, the answer to the question is:\n",
      "\n",
      "**Bacterial infections (e.g., strep throat) are NOT treated by antifungal drugs.**\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015917\n",
      "prediction:  To determine which condition is NOT treated by antifungal drugs, we first need to understand what antifungal medications are and the types of conditions they are designed to treat.\n",
      "\n",
      "### Step 1: Understanding Antifungal Drugs\n",
      "Antifungal drugs are medications specifically used to treat infections caused by fungi. These infections can affect various parts of the body, including the skin, nails, and internal organs. Common types of antifungal medications include:\n",
      "\n",
      "- **Azoles** (e.g., fluconazole, itraconazole)\n",
      "- **Echinocandins** (e.g., caspofungin, micafungin)\n",
      "- **Polyene antifungals** (e.g., amphotericin B, nystatin)\n",
      "- **Allylamines** (e.g., terbinafine)\n",
      "\n",
      "### Step 2: Conditions Treated by Antifungal Drugs\n",
      "Antifungal medications are used to treat a variety of fungal infections, including:\n",
      "\n",
      "- **Candidiasis**: Infections caused by Candida species, which can affect the mouth (oral thrush), vagina (vaginal yeast infections), and bloodstream (invasive candidiasis).\n",
      "- **Aspergillosis**: A serious infection caused by Aspergillus species, often affecting the lungs.\n",
      "- **Dermatophyte infections**: Such as athlete's foot, ringworm, and nail fungus (onychomycosis).\n",
      "- **Cryptococcosis**: A severe infection caused by Cryptococcus neoformans, often affecting immunocompromised individuals.\n",
      "\n",
      "### Step 3: Conditions NOT Treated by Antifungal Drugs\n",
      "To identify a condition that is NOT treated by antifungal drugs, we can consider various types of infections and diseases:\n",
      "\n",
      "1. **Bacterial Infections**: Conditions such as strep throat, bacterial pneumonia, and urinary tract infections are caused by bacteria and are treated with antibiotics, not antifungals.\n",
      "  \n",
      "2. **Viral Infections**: Conditions like influenza, HIV/AIDS, and COVID-19 are caused by viruses and require antiviral medications, not antifungals.\n",
      "\n",
      "3. **Parasitic Infections**: Diseases such as malaria, giardiasis, and toxoplasmosis are caused by parasites and are treated with antiparasitic drugs.\n",
      "\n",
      "4. **Non-infectious Conditions**: Conditions like diabetes, hypertension, and cancer are not infections and therefore are not treated with antifungal medications.\n",
      "\n",
      "### Conclusion\n",
      "Based on the above analysis, a condition that is NOT treated by antifungal drugs would be **bacterial infections**. For example, **strep throat**, which is caused by the bacterium Streptococcus pyogenes, is treated with antibiotics, not antifungals. \n",
      "\n",
      "### Final Answer\n",
      "**Bacterial infections (e.g., strep throat) are NOT treated by antifungal drugs.**\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Eczema\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015755\n",
      "prediction:  To determine which drug brand name is explicitly stated as not being a controlled substance, we need to understand the classification of drugs and the criteria that define controlled substances.\n",
      "\n",
      "### Step 1: Understanding Controlled Substances\n",
      "Controlled substances are drugs that are regulated by law due to their potential for abuse, addiction, and dependence. In the United States, the Drug Enforcement Administration (DEA) categorizes these substances into five schedules (I-V) based on their medical use, potential for abuse, and safety or dependence liability. \n",
      "\n",
      "- **Schedule I**: High potential for abuse, no accepted medical use (e.g., heroin, LSD).\n",
      "- **Schedule II**: High potential for abuse, accepted medical use with severe restrictions (e.g., oxycodone, morphine).\n",
      "- **Schedule III**: Moderate to low potential for physical and psychological dependence (e.g., anabolic steroids, certain barbiturates).\n",
      "- **Schedule IV**: Lower potential for abuse relative to Schedule III (e.g., alprazolam, diazepam).\n",
      "- **Schedule V**: Lower potential for abuse relative to Schedule IV (e.g., cough preparations with less than 200 mg of codeine).\n",
      "\n",
      "### Step 2: Identifying Non-Controlled Substances\n",
      "Drugs that are not classified as controlled substances typically fall outside these schedules. They may include over-the-counter medications, certain prescription medications that do not have a high potential for abuse, and other therapeutic agents.\n",
      "\n",
      "### Step 3: Examples of Non-Controlled Substances\n",
      "Some common examples of drug brand names that are not controlled substances include:\n",
      "\n",
      "- **Tylenol** (acetaminophen): A widely used pain reliever and fever reducer.\n",
      "- **Ibuprofen** (Advil, Motrin): An anti-inflammatory medication used for pain relief.\n",
      "- **Loratadine** (Claritin): An antihistamine used to relieve allergy symptoms.\n",
      "- **Amoxicillin** (Amoxil): An antibiotic used to treat bacterial infections.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "To answer the question, we can state that a specific drug brand name that is explicitly not a controlled substance is **Tylenol** (acetaminophen). This medication is commonly used for pain relief and fever reduction and is available over the counter without any restrictions associated with controlled substances.\n",
      "\n",
      "### Final Answer\n",
      "**Tylenol (acetaminophen)** is an example of a drug brand name that is explicitly stated as not being a controlled substance.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015101\n",
      "prediction:  To determine which drug brand name is explicitly stated as not being a controlled substance, we need to understand the classification of drugs and the criteria that define controlled substances.\n",
      "\n",
      "### Step 1: Understanding Controlled Substances\n",
      "Controlled substances are drugs that are regulated by law due to their potential for abuse, addiction, and dependence. In the United States, the Drug Enforcement Administration (DEA) categorizes these substances into five schedules (I-V) based on their medical use, potential for abuse, and safety or dependence liability. \n",
      "\n",
      "- **Schedule I**: No accepted medical use (e.g., heroin, LSD).\n",
      "- **Schedule II**: High potential for abuse but accepted medical use (e.g., oxycodone, morphine).\n",
      "- **Schedule III**: Moderate to low potential for physical and psychological dependence (e.g., anabolic steroids, certain barbiturates).\n",
      "- **Schedule IV**: Lower potential for abuse relative to Schedule III (e.g., alprazolam, diazepam).\n",
      "- **Schedule V**: Lower potential for abuse relative to Schedule IV (e.g., cough preparations with less than 200 mg of codeine per 100 mL).\n",
      "\n",
      "### Step 2: Identifying Non-Controlled Substances\n",
      "Drugs that are not classified as controlled substances typically include over-the-counter medications, certain prescription medications that do not have a high potential for abuse, and many common therapeutic agents. Examples include:\n",
      "\n",
      "- **Acetaminophen (Tylenol)**: A widely used pain reliever and fever reducer.\n",
      "- **Ibuprofen (Advil, Motrin)**: A nonsteroidal anti-inflammatory drug (NSAID) used for pain relief.\n",
      "- **Amoxicillin (Amoxil)**: An antibiotic used to treat bacterial infections.\n",
      "- **Lisinopril (Prinivil, Zestril)**: An antihypertensive medication used to treat high blood pressure.\n",
      "\n",
      "### Step 3: Conclusion\n",
      "To answer the question, we can provide examples of drug brand names that are explicitly stated as not being controlled substances. \n",
      "\n",
      "**Answer**: One example of a drug brand name that is explicitly stated as not being a controlled substance is **Tylenol** (acetaminophen). This medication is commonly used for pain relief and fever reduction and is available over-the-counter without any restrictions associated with controlled substances. \n",
      "\n",
      "Other examples include **Advil** (ibuprofen) and **Amoxil** (amoxicillin), both of which are also not classified as controlled substances.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.01875\n",
      "prediction:  To determine which drug brand name is explicitly stated as not being a controlled substance, we need to understand the classification of drugs and what constitutes a controlled substance.\n",
      "\n",
      "1. **Understanding Controlled Substances**: Controlled substances are drugs that are regulated by law due to their potential for abuse, addiction, and dependence. In the United States, the Drug Enforcement Administration (DEA) categorizes these substances into schedules (I-V) based on their medical use, potential for abuse, and safety or dependence liability.\n",
      "\n",
      "2. **Identifying Non-Controlled Substances**: Non-controlled substances are medications that do not fall under the DEA's scheduling system. These drugs can be prescription medications or over-the-counter (OTC) medications that are considered safe for use without the same level of regulation as controlled substances.\n",
      "\n",
      "3. **Examples of Non-Controlled Substances**: Common examples of non-controlled substances include:\n",
      "   - **Acetaminophen (Tylenol)**: A widely used pain reliever and fever reducer.\n",
      "   - **Ibuprofen (Advil, Motrin)**: An anti-inflammatory medication used for pain relief.\n",
      "   - **Amoxicillin (Amoxil)**: An antibiotic used to treat various infections.\n",
      "   - **Lisinopril (Prinivil, Zestril)**: A medication used to treat high blood pressure and heart failure.\n",
      "\n",
      "4. **Brand Name Identification**: To answer the question, we need to identify a specific brand name that is known to be a non-controlled substance. \n",
      "\n",
      "5. **Conclusion**: One clear example of a drug brand name that is explicitly stated as not being a controlled substance is **Tylenol** (acetaminophen). It is widely recognized as a safe and effective pain reliever and is available over the counter without any restrictions associated with controlled substances.\n",
      "\n",
      "In summary, **Tylenol** is a brand name that is explicitly stated as not being a controlled substance.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Bupropion Hydrochloride SR\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.022901\n",
      "prediction:  To determine which storage condition is NOT correct for \"Up and Up Nighttime Cold and Flu\" medication, one typically needs to refer to specific storage guidelines for cold and flu medications.\n",
      "\n",
      "Generally, over-the-counter medications, including cold and flu products, should be stored as follows:\n",
      "\n",
      "1. **Room Temperature**: Most liquid medications should be stored at room temperature, away from excessive heat, moisture, and direct sunlight.\n",
      "2. **Childproof Areas**: Medications should be kept out of reach of children, often in high cabinets or locked areas.\n",
      "3. **Avoid Refrigeration**: While some medications may require refrigeration, most cold and flu medications do not and should not be stored in a refrigerator unless specifically indicated.\n",
      "\n",
      "If any of the options provided suggest storing the medication in the refrigerator, or exposing it to direct sunlight, or conditions contrary to general guidelines, it would likely be the incorrect storage condition.\n",
      "\n",
      "Since specific information about the \"Up and Up Nighttime Cold and Flu\" storage was not found in the searches, it is best practice to refer to the product packaging or the manufacturer's recommendations for the most accurate storage conditions.\n",
      "\n",
      "**Answer:** Avoid refrigerating the medication (if that option is presented).\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.01564\n",
      "prediction:  To determine which storage condition is NOT correct for 'up and up nighttime cold and flu' (a common over-the-counter medication), it is essential to consider the general storage guidelines for medications, particularly those containing active ingredients like acetaminophen, diphenhydramine, or dextromethorphan, which are often found in cold and flu remedies.\n",
      "\n",
      "Typically, the correct storage conditions for such medications include:\n",
      "\n",
      "1. **Temperature**: Most medications should be stored at room temperature, generally between 20Â°C to 25Â°C (68Â°F to 77Â°F). Some may have specific temperature requirements, but extreme heat or cold should be avoided.\n",
      "\n",
      "2. **Humidity**: Medications should be kept in a dry place. High humidity can affect the stability and efficacy of the medication.\n",
      "\n",
      "3. **Light**: Many medications should be stored away from direct sunlight to prevent degradation of the active ingredients.\n",
      "\n",
      "4. **Child Safety**: Medications should be stored out of reach of children, often in a locked cabinet or high shelf.\n",
      "\n",
      "5. **Original Container**: It is advisable to keep medications in their original container to ensure that the labeling and expiration date are easily accessible.\n",
      "\n",
      "Given these guidelines, a storage condition that would NOT be correct for 'up and up nighttime cold and flu' might include:\n",
      "\n",
      "- **Storing in a bathroom cabinet**: Bathrooms often have high humidity levels due to showers and baths, which can compromise the integrity of the medication.\n",
      "\n",
      "- **Exposing to extreme temperatures**: For example, storing the medication in a car during hot summer months or in a freezer would be incorrect.\n",
      "\n",
      "- **Leaving it in direct sunlight**: Placing the medication on a windowsill where it can be exposed to sunlight would also be incorrect.\n",
      "\n",
      "In summary, any storage condition that involves high humidity, extreme temperatures, or exposure to light would be considered incorrect for 'up and up nighttime cold and flu'. Always refer to the specific product packaging for the most accurate storage instructions.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.013823\n",
      "prediction:  To determine which storage condition is NOT correct for 'up and up nighttime cold and flu' (a common over-the-counter medication), it is essential to consider the general storage guidelines for medications, particularly those containing active ingredients like acetaminophen, diphenhydramine, or dextromethorphan, which are often found in cold and flu remedies.\n",
      "\n",
      "Typically, the correct storage conditions for such medications include:\n",
      "\n",
      "1. **Temperature**: Most over-the-counter medications should be stored at room temperature, generally between 20Â°C to 25Â°C (68Â°F to 77Â°F). Extreme temperatures, both hot and cold, can affect the efficacy of the medication.\n",
      "\n",
      "2. **Humidity**: Medications should be kept in a dry place. High humidity can lead to degradation of the active ingredients.\n",
      "\n",
      "3. **Light**: Some medications are sensitive to light and should be stored in a dark place or in their original packaging to protect them from light exposure.\n",
      "\n",
      "4. **Child Safety**: Medications should be stored out of reach of children, preferably in a locked cabinet.\n",
      "\n",
      "5. **Original Container**: It is advisable to keep medications in their original container to ensure that the labeling and instructions are readily available.\n",
      "\n",
      "Given these guidelines, a storage condition that would be considered incorrect might include:\n",
      "\n",
      "- **Storing in a bathroom cabinet**: This is often a common mistake, as bathrooms can have high humidity levels due to showers and baths, which can compromise the medication's integrity.\n",
      "\n",
      "- **Storing in a freezer**: Freezing medications can alter their chemical composition and effectiveness.\n",
      "\n",
      "- **Exposing to direct sunlight**: Leaving the medication in a place where it is exposed to direct sunlight can degrade the active ingredients.\n",
      "\n",
      "- **Storing at extreme temperatures**: For example, storing the medication in a car during hot weather or in a place that experiences freezing temperatures.\n",
      "\n",
      "In conclusion, any of the above conditions could be considered incorrect for storing 'up and up nighttime cold and flu.' Therefore, if the question provided specific options, the one that suggests a condition contrary to the general guidelines (like storing in a bathroom, freezer, or direct sunlight) would be the correct answer to the question of which storage condition is NOT correct.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.014808\n",
      "prediction:  To determine which storage condition is NOT correct for 'up and up nighttime cold and flu' (a common over-the-counter medication), it is essential to consider the general storage guidelines for medications, particularly those that contain active ingredients like acetaminophen, diphenhydramine, or dextromethorphan, which are often found in cold and flu remedies.\n",
      "\n",
      "Typically, the correct storage conditions for such medications include:\n",
      "\n",
      "1. **Temperature**: Most over-the-counter medications should be stored at room temperature, generally between 20Â°C to 25Â°C (68Â°F to 77Â°F). Extreme temperatures, both hot and cold, can affect the efficacy of the medication.\n",
      "\n",
      "2. **Humidity**: Medications should be kept in a dry place. High humidity can lead to degradation of the active ingredients, so it is advisable to avoid storing them in bathrooms or other areas prone to moisture.\n",
      "\n",
      "3. **Light**: Many medications should be stored away from direct sunlight. Exposure to light can also degrade certain compounds, reducing the medication's effectiveness.\n",
      "\n",
      "4. **Child Safety**: Medications should be stored out of reach of children, preferably in a locked cabinet, to prevent accidental ingestion.\n",
      "\n",
      "5. **Original Container**: It is recommended to keep medications in their original container, which is designed to protect them from environmental factors and provides important information such as expiration dates and dosage instructions.\n",
      "\n",
      "Given these guidelines, a storage condition that would be considered incorrect for 'up and up nighttime cold and flu' might include:\n",
      "\n",
      "- **Storing in a bathroom cabinet** (due to high humidity).\n",
      "- **Keeping it in a hot car** (exposing it to extreme heat).\n",
      "- **Leaving it in direct sunlight** (which can degrade the medication).\n",
      "- **Storing it in a freezer** (which is too cold and can alter the formulation).\n",
      "\n",
      "In summary, any condition that deviates from the recommended storage practicesâ€”such as exposure to excessive heat, moisture, or lightâ€”would be considered incorrect. Therefore, if you were presented with specific options, you would identify the one that contradicts these established storage guidelines.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.033684\n",
      "prediction:  To determine which storage condition is NOT correct for 'up and up nighttime cold and flu,' we first need to identify the generally recommended storage conditions for pharmaceutical products. \n",
      "\n",
      "Pharmaceutical products are typically stored in a cool, dry place, away from direct sunlight and moisture. Common specific conditions may include:\n",
      "- Room temperature (generally between 20-25Â°C or 68-77Â°F)\n",
      "- Avoiding storage in high humidity (e.g., bathrooms)\n",
      "- Keeping out of reach of children\n",
      "\n",
      "While the specific storage conditions for 'up and up nighttime cold and flu' were not explicitly found in the searches, based on general pharmaceutical storage guidelines, any condition that involves exposure to moisture, heat, or direct sunlight would generally be considered incorrect.\n",
      "\n",
      "Thus, if you have options in your original question regarding storage conditions, the answer would be the one that contradicts these general principles.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.01446\n",
      "prediction:  To determine which storage condition is NOT correct for 'up and up nighttime cold and flu,' we need to consider the general guidelines for storing over-the-counter medications, particularly liquid formulations like cold and flu remedies. Hereâ€™s a step-by-step breakdown:\n",
      "\n",
      "1. **Check the Label**: The first step is to refer to the product label or packaging for specific storage instructions. Most medications will have clear guidelines on how to store them properly.\n",
      "\n",
      "2. **Common Storage Conditions**:\n",
      "   - **Temperature**: Most liquid medications should be stored at room temperature, typically between 20Â°C to 25Â°C (68Â°F to 77Â°F). Some may require refrigeration, but this is less common for cold and flu medications.\n",
      "   - **Humidity**: Medications should be kept in a dry place, away from high humidity, as moisture can affect the stability and efficacy of the product.\n",
      "   - **Light**: Many medications should be stored away from direct sunlight to prevent degradation of active ingredients.\n",
      "   - **Child Safety**: Medications should be kept out of reach of children, often in a locked cabinet or high shelf.\n",
      "\n",
      "3. **Identify Incorrect Conditions**: Now, we need to identify which of the following conditions might be incorrect. Here are some examples of incorrect storage conditions:\n",
      "   - Storing the medication in the bathroom, where humidity levels can be high.\n",
      "   - Keeping the medication in a place exposed to direct sunlight.\n",
      "   - Refrigerating the medication if the label does not specify that refrigeration is required.\n",
      "   - Storing the medication in a place accessible to children.\n",
      "\n",
      "4. **Conclusion**: Without specific options provided in the question, we can conclude that any condition that contradicts the general guidelines mentioned above would be considered incorrect. For example, if one of the options states that the medication should be stored in a bathroom or exposed to sunlight, that would be the correct answer to the question.\n",
      "\n",
      "In summary, to answer the question accurately, one would need to compare the provided storage conditions against the standard guidelines for storing 'up and up nighttime cold and flu' and identify any that do not align with those guidelines.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Storing above 25 Â°C.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.00979\n",
      "prediction:  To effectively treat athlete's foot (tinea pedis) with antifungal medications, it is generally recommended to use the drug daily for a duration of 2 to 4 weeks, depending on the specific antifungal agent and the severity of the infection.\n",
      "\n",
      "1. **Common Antifungal Options**: Over-the-counter treatments such as terbinafine (Lamisil) and clotrimazole are frequently prescribed. Terbinafine cream, for instance, is often recommended to be applied once daily for a week, while clotrimazole might require application twice daily for 4 weeks. \n",
      "\n",
      "2. **Monitoring and Adjustment**: If symptoms persist beyond the initial treatment duration (typically 2 weeks), it is advisable to consult a healthcare provider to evaluate the effectiveness of the treatment and consider alternative therapies, as persistent infection may indicate a resistance to the antifungal agent being used or an incorrect diagnosis (e.g., it could be a different type of dermatitis).\n",
      "\n",
      "3. **Recurrence and Preventive Measures**: Following the initial treatment, it is important to adhere to good hygiene and preventive measures, such as keeping the feet dry and not sharing personal items, to reduce the risk of recurrence.\n",
      "\n",
      "In summary, daily application of antifungal agents for a duration of 2 to 4 weeks is commonly recommended for treating athlete's foot, with ongoing assessment and preventive care being crucial for successful management of the condition.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.00523\n",
      "prediction:  To effectively treat athlete's foot (tinea pedis) with antifungal medications, the duration of treatment can vary based on several factors, including the specific antifungal agent used, the severity of the infection, and individual patient factors. Hereâ€™s a step-by-step breakdown of the treatment duration for common antifungal brand-name drugs used for athlete's foot:\n",
      "\n",
      "### Step 1: Identify Common Antifungal Agents\n",
      "Several antifungal medications are commonly used to treat athlete's foot. Some of the brand-name drugs include:\n",
      "- **Clotrimazole (Lotrimin)**\n",
      "- **Miconazole (Monistat Derm)**\n",
      "- **Terbinafine (Lamisil)**\n",
      "- **Tolnaftate (Tinactin)**\n",
      "- **Ketoconazole (Nizoral)**\n",
      "\n",
      "### Step 2: Recommended Duration of Treatment\n",
      "The recommended duration of treatment can differ based on the specific medication:\n",
      "\n",
      "1. **Clotrimazole (Lotrimin)**\n",
      "   - **Duration**: Typically applied twice daily for 2 to 4 weeks.\n",
      "   \n",
      "2. **Miconazole (Monistat Derm)**\n",
      "   - **Duration**: Usually applied twice daily for 2 to 4 weeks.\n",
      "\n",
      "3. **Terbinafine (Lamisil)**\n",
      "   - **Duration**: Often applied once daily for 1 week for the cream formulation, or for 2 weeks for the spray formulation.\n",
      "\n",
      "4. **Tolnaftate (Tinactin)**\n",
      "   - **Duration**: Generally applied twice daily for 2 to 4 weeks.\n",
      "\n",
      "5. **Ketoconazole (Nizoral)**\n",
      "   - **Duration**: Typically applied once daily for 2 to 4 weeks.\n",
      "\n",
      "### Step 3: Consider Severity and Location\n",
      "- **Mild Cases**: For mild cases of athlete's foot, a shorter duration (1-2 weeks) may be sufficient with some topical treatments.\n",
      "- **Severe Cases**: More severe or extensive infections may require longer treatment durations, possibly up to 4 weeks or more.\n",
      "\n",
      "### Step 4: Follow-Up and Prevention\n",
      "- **Follow-Up**: After completing the treatment, if symptoms persist or worsen, it is important to consult a healthcare provider for further evaluation and possible alternative treatments.\n",
      "- **Prevention**: To prevent recurrence, it is advisable to maintain good foot hygiene, keep feet dry, and use antifungal powders or sprays in shoes.\n",
      "\n",
      "### Step 5: Individual Considerations\n",
      "- **Patient Factors**: Individual factors such as age, immune status, and presence of other skin conditions may influence treatment duration. Always consult a healthcare provider for personalized recommendations.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the duration of daily use of antifungal medications for treating athlete's foot typically ranges from 1 to 4 weeks, depending on the specific medication and the severity of the infection. It is crucial to follow the instructions provided with the medication and consult a healthcare professional if there are any concerns or if symptoms do not improve.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004459\n",
      "prediction:  To effectively treat athlete's foot (tinea pedis) with antifungal medications, the duration of treatment can vary based on several factors, including the specific antifungal agent used, the severity of the infection, and individual patient factors. Hereâ€™s a step-by-step breakdown of the treatment duration for common antifungal brand-name drugs used for athlete's foot:\n",
      "\n",
      "### Step 1: Identify Common Antifungal Agents\n",
      "Several antifungal medications are commonly used to treat athlete's foot. Some of the brand-name drugs include:\n",
      "- **Terbinafine** (Lamisil)\n",
      "- **Clotrimazole** (Lotrimin)\n",
      "- **Miconazole** (Monistat)\n",
      "- **Tolnaftate** (Tinactin)\n",
      "- **Ketoconazole** (Nizoral)\n",
      "\n",
      "### Step 2: Recommended Treatment Duration\n",
      "The recommended duration of treatment can differ based on the specific medication:\n",
      "\n",
      "1. **Terbinafine (Lamisil)**\n",
      "   - **Duration**: Typically used for 1 week (once daily) for the treatment of athlete's foot.\n",
      "   - **Form**: Available in both topical and oral forms, but topical is more common for localized infections.\n",
      "\n",
      "2. **Clotrimazole (Lotrimin)**\n",
      "   - **Duration**: Usually applied twice daily for 2 to 4 weeks.\n",
      "   - **Form**: Topical cream or solution.\n",
      "\n",
      "3. **Miconazole (Monistat)**\n",
      "   - **Duration**: Generally applied twice daily for 2 to 4 weeks.\n",
      "   - **Form**: Available as a cream or powder.\n",
      "\n",
      "4. **Tolnaftate (Tinactin)**\n",
      "   - **Duration**: Typically used twice daily for 2 to 4 weeks.\n",
      "   - **Form**: Available as a cream, powder, or spray.\n",
      "\n",
      "5. **Ketoconazole (Nizoral)**\n",
      "   - **Duration**: Usually applied once daily for 2 to 4 weeks.\n",
      "   - **Form**: Available as a cream.\n",
      "\n",
      "### Step 3: Factors Influencing Duration\n",
      "- **Severity of Infection**: More severe or extensive infections may require longer treatment durations.\n",
      "- **Response to Treatment**: If symptoms do not improve after the recommended duration, a healthcare provider may suggest extending treatment or switching to a different antifungal.\n",
      "- **Underlying Conditions**: Patients with compromised immune systems or diabetes may require more aggressive treatment.\n",
      "\n",
      "### Step 4: Importance of Adherence\n",
      "- **Complete the Full Course**: It is crucial to complete the full course of treatment even if symptoms improve before the treatment period ends. This helps prevent recurrence and resistance.\n",
      "- **Follow Instructions**: Always follow the specific instructions provided by a healthcare provider or those included with the medication.\n",
      "\n",
      "### Step 5: Additional Recommendations\n",
      "- **Hygiene Practices**: In addition to medication, maintaining good foot hygiene, keeping feet dry, and using antifungal powders can help prevent recurrence.\n",
      "- **Consult a Healthcare Provider**: If symptoms persist or worsen, it is important to consult a healthcare provider for further evaluation and possible alternative treatments.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the duration of antifungal treatment for athlete's foot typically ranges from 1 to 4 weeks, depending on the specific medication used and the severity of the infection. Adhering to the treatment regimen and following up with a healthcare provider if necessary are key to successful management of athlete's foot.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.004824\n",
      "prediction:  To effectively treat athlete's foot (tinea pedis) with antifungal medications, the duration of treatment can vary based on several factors, including the specific antifungal agent used, the severity of the infection, and individual patient factors. Hereâ€™s a step-by-step breakdown of the treatment duration for common antifungal brand-name drugs used to treat athlete's foot:\n",
      "\n",
      "### Step 1: Identify Common Antifungal Agents\n",
      "Several antifungal medications are commonly used to treat athlete's foot. Some of the brand-name drugs include:\n",
      "- **Lotrimin (clotrimazole)**\n",
      "- **Lamisil (terbinafine)**\n",
      "- **Tinactin (tolnaftate)**\n",
      "- **Micatin (miconazole)**\n",
      "\n",
      "### Step 2: Recommended Duration of Treatment\n",
      "The recommended duration of treatment can differ based on the specific medication:\n",
      "\n",
      "1. **Clotrimazole (Lotrimin)**\n",
      "   - **Duration**: Typically used for 2 to 4 weeks.\n",
      "   - **Application**: Apply twice daily for 4 weeks for best results.\n",
      "\n",
      "2. **Terbinafine (Lamisil)**\n",
      "   - **Duration**: Generally recommended for 1 to 2 weeks.\n",
      "   - **Application**: Apply once daily for 1 week or twice daily for 2 weeks, depending on the formulation.\n",
      "\n",
      "3. **Tolnaftate (Tinactin)**\n",
      "   - **Duration**: Usually recommended for 2 to 4 weeks.\n",
      "   - **Application**: Apply twice daily for 2 to 4 weeks.\n",
      "\n",
      "4. **Miconazole (Micatin)**\n",
      "   - **Duration**: Typically used for 2 to 4 weeks.\n",
      "   - **Application**: Apply twice daily for 4 weeks.\n",
      "\n",
      "### Step 3: Consider Severity and Location\n",
      "- **Mild Cases**: For mild cases of athlete's foot, a shorter duration (1-2 weeks) with a topical antifungal may be sufficient.\n",
      "- **Severe Cases**: More severe or extensive infections may require longer treatment (up to 4 weeks) and possibly oral antifungal medications, especially if there is no improvement with topical treatments.\n",
      "\n",
      "### Step 4: Follow-Up and Monitoring\n",
      "- **Symptom Improvement**: Patients should monitor their symptoms. If there is no improvement after the recommended duration, or if symptoms worsen, they should consult a healthcare provider.\n",
      "- **Preventive Measures**: After treatment, it is advisable to continue using antifungal powder or spray in shoes and on feet to prevent recurrence.\n",
      "\n",
      "### Step 5: Special Considerations\n",
      "- **Underlying Conditions**: Individuals with diabetes or compromised immune systems may require a different approach and should consult a healthcare provider for tailored treatment.\n",
      "- **Pregnancy and Lactation**: Pregnant or breastfeeding women should consult their healthcare provider before using antifungal medications.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the duration of daily use of antifungal medications for treating athlete's foot typically ranges from 1 to 4 weeks, depending on the specific drug and the severity of the infection. It is essential to follow the instructions on the product label and consult a healthcare professional for personalized advice and to ensure effective treatment.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.014103\n",
      "prediction:  To find a relevant drug brand name for a specific indication, you can utilize several online resources that provide comprehensive information about medications categorized by their therapeutic indications. Here are some valuable sources to consult:\n",
      "\n",
      "1. **RxList**: This online database offers detailed information about various medications, including common brand names, side effects, and indications. You can access it [here](https://www.rxlist.com/).\n",
      "\n",
      "2. **Drugs.com**: This site provides a wide range of drug information including brand names, warnings, and indications. Check their A to Z drug database [here](https://www.drugs.com/drug_information.html).\n",
      "\n",
      "3. **WebMD**: Their comprehensive drug database lists medications according to various indications, facilitating the search for brand names related to specific conditions. Visit WebMD's drug database [here](https://www.webmd.com/drugs/2/index).\n",
      "\n",
      "4. **RxReasoner**: This platform presents an index organized by pharmaceutical treatment indications, allowing for quick access to recommended drugs for different medical conditions. Explore their indications index [here](https://www.rxreasoner.com/indications).\n",
      "\n",
      "5. **ClinCalc**: They provide a list of top drugs organized by therapeutic category, which includes brand names associated with specific treatments. You can view their drug list [here](https://clincalc.com/Downloads/Top250Drugs-DrugList.pdf).\n",
      "\n",
      "By utilizing these resources, you can find the appropriate drug brand name relevant to the specific indication you are interested in.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.03004\n",
      "prediction:  To provide a comprehensive answer regarding the contraindication profile of WL-AAB-Z-W-982 in comparison to other drugs with known contraindications, we first need to understand what contraindications are and how they are determined for specific medications.\n",
      "\n",
      "**Understanding Contraindications:**\n",
      "Contraindications are specific situations or conditions in which a drug should not be used because it may be harmful to the patient. These can be absolute (where the drug should never be used) or relative (where caution is advised). Contraindications can arise from various factors, including:\n",
      "\n",
      "1. **Patient Characteristics:** Age, sex, genetic factors, and pre-existing health conditions (e.g., liver or kidney disease).\n",
      "2. **Drug Interactions:** Certain medications may interact negatively with others, leading to adverse effects.\n",
      "3. **Pregnancy and Lactation:** Some drugs are contraindicated in pregnant or breastfeeding women due to potential harm to the fetus or infant.\n",
      "4. **Allergies:** Known allergies to a drug or its components can lead to severe reactions.\n",
      "\n",
      "**WL-AAB-Z-W-982 Contraindications:**\n",
      "Assuming WL-AAB-Z-W-982 is a hypothetical drug, its contraindications would be determined based on clinical trials, pharmacological properties, and post-marketing surveillance. The contraindication profile would typically include:\n",
      "\n",
      "- **Specific Health Conditions:** For example, if WL-AAB-Z-W-982 is a medication that affects the cardiovascular system, it may be contraindicated in patients with a history of heart disease or arrhythmias.\n",
      "- **Drug Interactions:** If WL-AAB-Z-W-982 interacts with other medications (e.g., anticoagulants, antidepressants), it may be contraindicated in patients taking those drugs.\n",
      "- **Demographics:** Certain populations, such as the elderly or those with renal impairment, may have contraindications due to altered drug metabolism or increased risk of side effects.\n",
      "\n",
      "**Comparison with Other Drugs:**\n",
      "When comparing WL-AAB-Z-W-982 to other drugs, we can look at several well-known medications with established contraindications:\n",
      "\n",
      "1. **Warfarin:** This anticoagulant has numerous contraindications, including active bleeding disorders, severe liver disease, and pregnancy. It also has significant drug interactions with many medications, necessitating careful monitoring.\n",
      "\n",
      "2. **Metformin:** Commonly used for type 2 diabetes, metformin is contraindicated in patients with severe renal impairment, acute or chronic metabolic acidosis, and certain conditions that may predispose to lactic acidosis.\n",
      "\n",
      "3. **ACE Inhibitors (e.g., Lisinopril):** These are contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy, pregnancy, and renal artery stenosis.\n",
      "\n",
      "4. **NSAIDs (e.g., Ibuprofen):** These are contraindicated in patients with active peptic ulcer disease, severe heart failure, and certain renal conditions.\n",
      "\n",
      "**Key Considerations in Comparison:**\n",
      "- **Scope of Contraindications:** The breadth of contraindications for WL-AAB-Z-W-982 should be assessed against the number and severity of contraindications for other drugs. A drug with a narrow contraindication profile may be more versatile in clinical use.\n",
      "- **Severity of Consequences:** The potential consequences of ignoring contraindications for WL-AAB-Z-W-982 should be compared to those of other drugs. For instance, contraindications leading to life-threatening conditions would be more critical than those leading to mild side effects.\n",
      "- **Patient Population:** The specific populations affected by contraindications (e.g., elderly, pregnant women) can influence the drug's overall utility in clinical practice.\n",
      "\n",
      "**Conclusion:**\n",
      "In summary, the contraindication profile of WL-AAB-Z-W-982 can be compared to other drugs by examining the nature and severity of its contraindications, the patient populations affected, and the potential consequences of its use in contraindicated situations. A comprehensive understanding of these factors is essential for healthcare providers to make informed decisions about prescribing WL-AAB-Z-W-982 and ensuring patient safety. Further research and clinical data would be necessary to provide a detailed and specific comparison.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.031299\n",
      "prediction:  To provide a comprehensive answer regarding the contraindication profile of WL-AAB-Z-W-982 in comparison to other drugs with known contraindications, we first need to understand what contraindications are and how they are determined for specific medications.\n",
      "\n",
      "**Understanding Contraindications:**\n",
      "Contraindications are specific situations or conditions in which a drug should not be used because it may be harmful to the patient. These can be absolute (where the drug should never be used) or relative (where caution is advised). Contraindications can arise from various factors, including:\n",
      "\n",
      "1. **Patient Characteristics:** Age, sex, genetic factors, and pre-existing health conditions (e.g., liver or kidney disease).\n",
      "2. **Drug Interactions:** Certain medications may interact negatively with others, leading to adverse effects.\n",
      "3. **Pregnancy and Lactation:** Some drugs are contraindicated in pregnant or breastfeeding women due to potential harm to the fetus or infant.\n",
      "4. **Allergies:** Known allergies to a drug or its components can lead to severe reactions.\n",
      "\n",
      "**WL-AAB-Z-W-982:**\n",
      "Assuming WL-AAB-Z-W-982 is a hypothetical drug, we would need to analyze its specific contraindications based on its pharmacological profile, mechanism of action, and the patient population it is intended for. \n",
      "\n",
      "1. **Mechanism of Action:** Understanding how WL-AAB-Z-W-982 works can help identify potential contraindications. For example, if it is an immunosuppressant, it may be contraindicated in patients with active infections or certain malignancies.\n",
      "\n",
      "2. **Common Contraindications:** If WL-AAB-Z-W-982 is similar to other drugs in its class (e.g., biologics, antibiotics, or antihypertensives), we can draw parallels with known contraindications. For instance:\n",
      "   - **Biologics:** Often contraindicated in patients with active infections or those with a history of malignancy.\n",
      "   - **Antibiotics:** Certain antibiotics may be contraindicated in patients with a history of severe allergic reactions (e.g., penicillin allergy).\n",
      "   - **Antihypertensives:** Some may be contraindicated in patients with specific heart conditions or renal impairment.\n",
      "\n",
      "3. **Comparative Analysis:** To compare WL-AAB-Z-W-982 with other drugs, we would look at:\n",
      "   - **Scope of Contraindications:** Does WL-AAB-Z-W-982 have a broader or narrower range of contraindications compared to similar drugs?\n",
      "   - **Severity of Contraindications:** Are the contraindications associated with WL-AAB-Z-W-982 more severe or life-threatening than those of other drugs?\n",
      "   - **Patient Population:** Is WL-AAB-Z-W-982 intended for a specific patient population that may have unique contraindications (e.g., elderly patients, those with comorbidities)?\n",
      "\n",
      "4. **Clinical Studies and Guidelines:** Reviewing clinical trial data and treatment guidelines can provide insights into the contraindication profile of WL-AAB-Z-W-982. This information is often published in drug monographs, clinical guidelines, and peer-reviewed studies.\n",
      "\n",
      "5. **Post-Marketing Surveillance:** After a drug is approved, ongoing monitoring for adverse effects and contraindications can reveal new information that may not have been evident during clinical trials.\n",
      "\n",
      "**Conclusion:**\n",
      "In summary, the contraindication profile of WL-AAB-Z-W-982 can be compared to other drugs by examining its specific contraindications, the severity and scope of these contraindications, and the patient populations affected. A thorough review of clinical data, drug interactions, and patient characteristics is essential for understanding how WL-AAB-Z-W-982 fits within the broader context of pharmacotherapy. Ultimately, healthcare providers must weigh the benefits and risks of WL-AAB-Z-W-982 in the context of individual patient needs and existing contraindications.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02919\n",
      "prediction:  To provide a comprehensive answer regarding the contraindication profile of WL-AAB-Z-W-982 in comparison to other drugs with known contraindications, we first need to understand what contraindications are and how they are determined for specific medications.\n",
      "\n",
      "**Understanding Contraindications:**\n",
      "Contraindications are specific situations or conditions in which a drug should not be used because it may be harmful to the patient. These can be absolute (where the drug should never be used) or relative (where caution is advised, and the drug may be used under certain circumstances). Contraindications can arise from various factors, including:\n",
      "\n",
      "1. **Patient Characteristics:** Age, sex, genetic factors, and pre-existing health conditions (e.g., liver or kidney disease).\n",
      "2. **Drug Interactions:** Certain medications may interact negatively with others, leading to adverse effects.\n",
      "3. **Pregnancy and Lactation:** Some drugs are contraindicated in pregnant or breastfeeding women due to potential harm to the fetus or infant.\n",
      "4. **Allergies:** Known allergies to a drug or its components can lead to severe reactions.\n",
      "\n",
      "**WL-AAB-Z-W-982 Contraindication Profile:**\n",
      "Assuming WL-AAB-Z-W-982 is a hypothetical drug, its contraindication profile would be established based on clinical trials, post-marketing surveillance, and expert consensus. The profile would typically include:\n",
      "\n",
      "- **Absolute Contraindications:** Conditions or factors that completely rule out the use of WL-AAB-Z-W-982, such as severe allergic reactions to the drug, certain life-threatening conditions, or specific organ failures.\n",
      "- **Relative Contraindications:** Situations where the drug may be used with caution, such as in patients with mild to moderate renal impairment or those taking other medications that could interact with WL-AAB-Z-W-982.\n",
      "\n",
      "**Comparison with Other Drugs:**\n",
      "When comparing WL-AAB-Z-W-982 to other drugs, we can look at several well-known medications with established contraindications:\n",
      "\n",
      "1. **Warfarin:** This anticoagulant has numerous contraindications, including active bleeding disorders, severe liver disease, and pregnancy. It also has significant drug interactions that require careful monitoring.\n",
      "   \n",
      "2. **Metformin:** Commonly used for type 2 diabetes, metformin is contraindicated in patients with severe renal impairment, acute or chronic metabolic acidosis, and certain conditions that may predispose to lactic acidosis.\n",
      "\n",
      "3. **Ibuprofen:** This nonsteroidal anti-inflammatory drug (NSAID) is contraindicated in patients with active peptic ulcer disease, severe heart failure, and certain renal conditions.\n",
      "\n",
      "**Key Considerations in Comparison:**\n",
      "- **Scope of Contraindications:** The breadth of contraindications for WL-AAB-Z-W-982 should be assessed against those of other drugs. A drug with a narrow contraindication profile may be more versatile in clinical use.\n",
      "- **Severity of Contraindications:** The potential severity of adverse effects associated with contraindications can vary. For instance, contraindications leading to life-threatening conditions (like those seen with warfarin) may necessitate more stringent monitoring compared to those associated with WL-AAB-Z-W-982.\n",
      "- **Patient Population:** The demographics and health status of the patient population for which WL-AAB-Z-W-982 is intended can influence its contraindication profile. For example, if it is primarily used in elderly patients, contraindications related to age-related conditions would be particularly relevant.\n",
      "\n",
      "**Conclusion:**\n",
      "In summary, the contraindication profile of WL-AAB-Z-W-982 would need to be carefully evaluated in the context of its intended use, patient population, and the specific health conditions it addresses. A thorough comparison with other drugs would involve analyzing the nature and severity of contraindications, the potential for drug interactions, and the overall safety profile. Ultimately, this information is crucial for healthcare providers to make informed decisions about prescribing WL-AAB-Z-W-982 and ensuring patient safety.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.036539\n",
      "prediction:  To provide a comprehensive answer regarding the contraindications of JAYPIRCA (also known as pirtobrutinib), we need to first understand what JAYPIRCA is and its clinical use.\n",
      "\n",
      "### Step 1: Understanding JAYPIRCA\n",
      "JAYPIRCA is a medication that is primarily used in the treatment of certain types of B-cell malignancies, particularly in patients with relapsed or refractory mantle cell lymphoma (MCL). It is a selective Brutonâ€™s tyrosine kinase (BTK) inhibitor, which means it works by blocking a specific enzyme that is involved in the growth and survival of B-cells.\n",
      "\n",
      "### Step 2: Identifying Contraindications\n",
      "Contraindications are specific situations or conditions in which a drug should not be used because it may be harmful to the patient. For JAYPIRCA, the contraindications typically include:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients who have a known hypersensitivity to pirtobrutinib or any of its components should not use this medication. This includes any history of severe allergic reactions, such as anaphylaxis.\n",
      "\n",
      "2. **Active Infections**: Patients with active infections, particularly those that are serious or life-threatening, may be contraindicated for JAYPIRCA. This is due to the immunosuppressive effects of the drug, which could exacerbate the infection.\n",
      "\n",
      "3. **Severe Liver Impairment**: JAYPIRCA is metabolized in the liver, and patients with severe hepatic impairment may not be able to process the drug effectively, leading to increased toxicity.\n",
      "\n",
      "4. **Pregnancy and Breastfeeding**: JAYPIRCA is contraindicated in pregnant women due to potential harm to the fetus. It is also advised that breastfeeding should be avoided during treatment, as the drug may be excreted in breast milk.\n",
      "\n",
      "### Step 3: Additional Considerations\n",
      "While the above are primary contraindications, it is also important to consider other factors that may warrant caution or close monitoring when using JAYPIRCA:\n",
      "\n",
      "- **Cardiovascular Conditions**: Patients with a history of arrhythmias or other significant cardiovascular issues may require careful monitoring due to potential cardiac side effects associated with BTK inhibitors.\n",
      "\n",
      "- **Drug Interactions**: JAYPIRCA may interact with other medications, particularly those that affect liver enzymes. It is crucial to review a patientâ€™s medication list for potential interactions.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the true statements regarding the contraindications of JAYPIRCA include the following:\n",
      "\n",
      "- It should not be used in patients with known hypersensitivity to the drug.\n",
      "- It is contraindicated in patients with active infections.\n",
      "- Patients with severe liver impairment should avoid this medication.\n",
      "- It is contraindicated in pregnant and breastfeeding women.\n",
      "\n",
      "Always consult the prescribing information and a healthcare professional for the most accurate and personalized medical advice.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.037802\n",
      "prediction:  To provide a comprehensive answer regarding the contraindications of JAYPIRCA (also known as pirtobrutinib), we need to first understand what JAYPIRCA is and its clinical use.\n",
      "\n",
      "### Step 1: Understanding JAYPIRCA\n",
      "JAYPIRCA is a medication that is primarily used in the treatment of certain types of B-cell malignancies, particularly in patients with relapsed or refractory mantle cell lymphoma (MCL). It is a selective Brutonâ€™s tyrosine kinase (BTK) inhibitor, which means it works by blocking a specific enzyme that is involved in the growth and survival of B-cells.\n",
      "\n",
      "### Step 2: Identifying Contraindications\n",
      "Contraindications are specific situations or conditions where a drug should not be used because it may be harmful to the patient. For JAYPIRCA, the contraindications typically include:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients who have a known hypersensitivity to pirtobrutinib or any of its components should not use this medication. This includes any history of severe allergic reactions, such as anaphylaxis.\n",
      "\n",
      "2. **Active Infections**: Patients with active infections, particularly those that are serious or life-threatening, may be contraindicated for JAYPIRCA. This is due to the immunosuppressive effects of the drug, which could exacerbate infections.\n",
      "\n",
      "3. **Severe Liver Impairment**: JAYPIRCA is metabolized in the liver, and patients with severe hepatic impairment may not be able to process the drug effectively, leading to increased toxicity.\n",
      "\n",
      "4. **Pregnancy and Breastfeeding**: JAYPIRCA is contraindicated in pregnant women due to potential harm to the fetus. It is also advised that breastfeeding should be avoided during treatment, as the drug may be excreted in breast milk.\n",
      "\n",
      "### Step 3: Additional Considerations\n",
      "While the above are primary contraindications, it is also important to consider other factors that may influence the decision to use JAYPIRCA:\n",
      "\n",
      "- **Drug Interactions**: Certain medications may interact with JAYPIRCA, leading to increased side effects or reduced efficacy. Therefore, a thorough medication review is essential before starting treatment.\n",
      "\n",
      "- **Cardiovascular Conditions**: Patients with a history of certain cardiovascular conditions may require careful monitoring, as BTK inhibitors can have effects on heart rhythm.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the true statements regarding the contraindications of JAYPIRCA include the following:\n",
      "\n",
      "- It should not be used in patients with known hypersensitivity to the drug.\n",
      "- It is contraindicated in patients with active infections.\n",
      "- Patients with severe liver impairment should avoid this medication.\n",
      "- It is not recommended for use during pregnancy or breastfeeding.\n",
      "\n",
      "Always consult the prescribing information and a healthcare professional for the most accurate and personalized medical advice.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.038278\n",
      "prediction:  To provide a comprehensive answer regarding the contraindications of JAYPIRCA (also known as pirtobrutinib), we need to first understand what JAYPIRCA is and its clinical use.\n",
      "\n",
      "### Step 1: Understanding JAYPIRCA\n",
      "JAYPIRCA is a medication that is primarily used in the treatment of certain types of B-cell malignancies, particularly in patients with relapsed or refractory mantle cell lymphoma (MCL). It is a selective Brutonâ€™s tyrosine kinase (BTK) inhibitor, which means it works by blocking a specific enzyme that is involved in the growth and survival of B-cells.\n",
      "\n",
      "### Step 2: Identifying Contraindications\n",
      "Contraindications are specific situations or conditions where a drug should not be used because it may be harmful to the patient. For JAYPIRCA, the contraindications typically include:\n",
      "\n",
      "1. **Hypersensitivity Reactions**: Patients who have a known hypersensitivity to pirtobrutinib or any of its components should not use this medication. This includes any history of severe allergic reactions, such as anaphylaxis.\n",
      "\n",
      "2. **Active Infections**: Patients with active infections, particularly those that are serious or life-threatening, may be contraindicated for JAYPIRCA. This is due to the immunosuppressive effects of the drug, which could exacerbate the infection.\n",
      "\n",
      "3. **Severe Liver Impairment**: JAYPIRCA is metabolized in the liver, and patients with severe hepatic impairment may not be able to process the drug effectively, leading to increased toxicity.\n",
      "\n",
      "4. **Pregnancy and Breastfeeding**: JAYPIRCA is contraindicated in pregnant women due to potential harm to the fetus. It is also advised that breastfeeding should be avoided during treatment, as the drug may be excreted in breast milk.\n",
      "\n",
      "### Step 3: Summary of True Statements\n",
      "To determine which statements regarding the contraindications of JAYPIRCA are true, one would need to compare the provided statements against the known contraindications listed above. \n",
      "\n",
      "### Conclusion\n",
      "In summary, the true statements regarding the contraindications of JAYPIRCA would include those related to hypersensitivity, active infections, severe liver impairment, and considerations for pregnancy and breastfeeding. It is essential for healthcare providers to evaluate these factors before prescribing JAYPIRCA to ensure patient safety and efficacy of treatment. Always refer to the latest prescribing information or clinical guidelines for the most accurate and detailed contraindications.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  C\n",
      "correct answer: JAYPIRCA has no listed contraindications.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010324\n",
      "prediction:  To provide a comprehensive answer to the question regarding the clinical trial for adults and adolescents and the mean change in plasma glucose 1 hour after the first dose, we need to consider several factors typically involved in such trials.\n",
      "\n",
      "1. **Study Design**: Clinical trials often involve multiple groups, including a treatment group receiving the investigational drug and one or more control groups (placebo or standard treatment). The design may also include stratification by age, sex, or baseline health status.\n",
      "\n",
      "2. **Intervention**: The specific medication or intervention being tested is crucial. Different drugs can have varying effects on plasma glucose levels, and the mechanism of action can influence the results. For instance, medications like insulin, GLP-1 agonists, or SGLT2 inhibitors may have different impacts on glucose levels.\n",
      "\n",
      "3. **Population Characteristics**: The demographics of the participants, including age, sex, baseline glucose levels, and comorbidities, can affect the outcomes. For example, adolescents may respond differently to a medication compared to adults due to physiological differences.\n",
      "\n",
      "4. **Measurement of Plasma Glucose**: The method of measuring plasma glucose (e.g., fasting vs. postprandial) and the timing of the measurement (1 hour after the first dose) are critical. The timing can capture the peak effect of the medication, which may vary between groups.\n",
      "\n",
      "5. **Results Interpretation**: The mean change in plasma glucose is typically reported as the difference from baseline levels. The group with the smallest mean change would indicate the least response to the treatment or the most stable glucose levels post-intervention.\n",
      "\n",
      "6. **Statistical Analysis**: The results would be analyzed statistically to determine significance. Factors such as p-values, confidence intervals, and effect sizes would help in understanding the clinical relevance of the findings.\n",
      "\n",
      "7. **Conclusion**: In the context of the question, if the trial data indicated that a specific group (e.g., adolescents on a particular medication) showed the smallest mean change in plasma glucose 1 hour after the first dose, it would suggest that this group had a lesser response to the treatment compared to others. This could be due to various factors, including pharmacodynamics, adherence to the treatment, or inherent differences in glucose metabolism.\n",
      "\n",
      "In summary, to accurately answer which group showed the smallest mean change in plasma glucose 1 hour after the first dose, one would need to refer to the specific results of the clinical trial, including the characteristics of the groups involved, the intervention used, and the statistical analysis performed.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010456\n",
      "prediction:  To provide a comprehensive answer to the question regarding the clinical trial for adults and adolescents and the mean change in plasma glucose 1 hour after the first dose, we need to consider several key aspects:\n",
      "\n",
      "1. **Study Design**: Clinical trials typically involve multiple groups, often including a treatment group receiving the investigational drug and a control group receiving a placebo or standard treatment. The design may also include different dosages or formulations of the drug.\n",
      "\n",
      "2. **Population Characteristics**: The trial likely included a diverse population of adults and adolescents, which can affect the results. Factors such as age, sex, baseline glucose levels, body mass index (BMI), and the presence of comorbidities (like diabetes) can influence plasma glucose responses.\n",
      "\n",
      "3. **Intervention**: The specific intervention being tested (e.g., a new medication, dietary intervention, or lifestyle modification) is crucial. Different interventions can have varying effects on plasma glucose levels.\n",
      "\n",
      "4. **Measurement of Plasma Glucose**: Plasma glucose levels are typically measured using standardized methods, and the timing of the measurement (1 hour post-dose) is critical for assessing the immediate impact of the intervention.\n",
      "\n",
      "5. **Results Interpretation**: The mean change in plasma glucose is calculated by taking the difference between the baseline glucose levels and the levels measured 1 hour after the first dose. The group with the smallest mean change would indicate the least impact of the intervention on plasma glucose levels.\n",
      "\n",
      "6. **Statistical Analysis**: The results would be analyzed statistically to determine significance. This includes comparing the mean changes across different groups and assessing whether the differences observed are statistically significant.\n",
      "\n",
      "7. **Clinical Implications**: Understanding which group showed the smallest mean change in plasma glucose can have important implications for treatment strategies, particularly in managing conditions like diabetes. It may suggest that the intervention is less effective in that specific group or that the group has a different physiological response to the treatment.\n",
      "\n",
      "In summary, to accurately answer the question about which group showed the smallest mean change in plasma glucose 1 hour after the first dose, one would need to refer to the specific results of the clinical trial, including the characteristics of the groups involved, the nature of the intervention, and the statistical analysis performed. If this information is available, it would allow for a precise identification of the group with the smallest mean change in plasma glucose.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010219\n",
      "prediction:  To provide a comprehensive answer to the question regarding the clinical trial for adults and adolescents and the mean change in plasma glucose 1 hour after the first dose, we need to consider several key aspects:\n",
      "\n",
      "1. **Study Design**: Clinical trials typically involve multiple groups, often including a treatment group receiving the investigational drug and a control group receiving a placebo or standard treatment. The design may also include different dosages or formulations of the drug.\n",
      "\n",
      "2. **Population Characteristics**: The trial likely included a diverse population of adults and adolescents, with varying baseline characteristics such as age, sex, body mass index (BMI), and pre-existing conditions (e.g., type 1 or type 2 diabetes).\n",
      "\n",
      "3. **Intervention**: The specific medication or intervention being tested would be crucial to understanding the results. Different medications can have varying effects on plasma glucose levels, and the mechanism of action can influence the outcomes.\n",
      "\n",
      "4. **Measurement of Plasma Glucose**: Plasma glucose levels are typically measured using standardized methods, and the timing of the measurement (1 hour post-dose) is critical for assessing the immediate effects of the intervention.\n",
      "\n",
      "5. **Results Interpretation**: The mean change in plasma glucose is calculated by taking the difference between the baseline glucose levels and the levels measured 1 hour after dosing. The group with the smallest mean change would indicate the least impact of the intervention on plasma glucose levels.\n",
      "\n",
      "6. **Statistical Analysis**: The results would be analyzed statistically to determine significance. This would involve comparing the mean changes across different groups and assessing whether the differences observed are statistically significant.\n",
      "\n",
      "7. **Clinical Implications**: Understanding which group showed the smallest mean change in plasma glucose can have important implications for treatment strategies, particularly in managing conditions like diabetes. It may suggest that a particular treatment is less effective or has a different profile in terms of glucose control.\n",
      "\n",
      "8. **Conclusion**: Without specific data from the trial, it is impossible to definitively state which group showed the smallest mean change in plasma glucose. However, the answer would typically be found in the results section of the clinical trial report, where the authors would present the data in tables or figures, along with statistical analyses to support their findings.\n",
      "\n",
      "In summary, to answer the question accurately, one would need to refer to the specific clinical trial data, including the groups involved, the intervention tested, and the reported outcomes regarding plasma glucose levels.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  D\n",
      "correct answer: Placebo\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.032585\n",
      "prediction:  To provide a comprehensive answer to the question regarding the contraindication profile of WL-AAB-Z-W-982 in comparison to other drugs with known contraindications, we will follow a structured approach. \n",
      "\n",
      "### Step 1: Understanding WL-AAB-Z-W-982\n",
      "First, we need to gather information about WL-AAB-Z-W-982. This includes its pharmacological class, mechanism of action, therapeutic uses, and known contraindications. \n",
      "\n",
      "- **Pharmacological Class**: WL-AAB-Z-W-982 is a hypothetical drug, so we will assume it belongs to a specific class (e.g., antihypertensive, antibiotic, etc.) for the sake of this analysis.\n",
      "- **Mechanism of Action**: Understanding how the drug works can help identify potential contraindications based on its effects on the body.\n",
      "- **Therapeutic Uses**: Knowing what conditions WL-AAB-Z-W-982 is used to treat will help in understanding its contraindications.\n",
      "\n",
      "### Step 2: Identifying Known Contraindications\n",
      "Next, we will identify the known contraindications for WL-AAB-Z-W-982. Contraindications can be classified into:\n",
      "\n",
      "- **Absolute Contraindications**: Conditions under which the drug should never be used (e.g., known allergy to the drug, severe renal impairment).\n",
      "- **Relative Contraindications**: Conditions where the drug may be used with caution, but risks must be weighed against benefits (e.g., pregnancy, liver disease).\n",
      "\n",
      "### Step 3: Comparing with Other Drugs\n",
      "To compare WL-AAB-Z-W-982's contraindication profile with other drugs, we will select a few representative drugs from the same pharmacological class or with similar therapeutic uses. \n",
      "\n",
      "1. **Select Comparison Drugs**: Choose a few drugs that are well-studied and have established contraindications.\n",
      "2. **Analyze Contraindications**: For each selected drug, list their contraindications and categorize them as absolute or relative.\n",
      "\n",
      "### Step 4: Comparative Analysis\n",
      "Now, we will analyze the contraindications of WL-AAB-Z-W-982 in relation to the selected drugs:\n",
      "\n",
      "- **Common Contraindications**: Identify any contraindications that WL-AAB-Z-W-982 shares with the comparison drugs.\n",
      "- **Unique Contraindications**: Note any contraindications that are unique to WL-AAB-Z-W-982.\n",
      "- **Severity and Risk**: Discuss the severity of the contraindications and the potential risks associated with using WL-AAB-Z-W-982 compared to the other drugs.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "Finally, we will summarize the findings:\n",
      "\n",
      "- **Overall Profile**: Provide an overall assessment of how WL-AAB-Z-W-982's contraindication profile compares to the other drugs.\n",
      "- **Clinical Implications**: Discuss the clinical implications of these findings for healthcare providers when prescribing WL-AAB-Z-W-982.\n",
      "\n",
      "### Example Answer\n",
      "**WL-AAB-Z-W-982 is an antihypertensive medication that works by inhibiting the angiotensin II receptor. Its known contraindications include severe renal impairment and hypersensitivity to the drug. When compared to other antihypertensives like lisinopril and amlodipine, WL-AAB-Z-W-982 shares the contraindication of renal impairment but is unique in its contraindication for hypersensitivity. Lisinopril, for instance, has additional contraindications such as a history of angioedema and pregnancy, while amlodipine is contraindicated in patients with severe hypotension. Overall, WL-AAB-Z-W-982 has a more focused contraindication profile, which may simplify decision-making for clinicians, but the presence of hypersensitivity as a contraindication necessitates careful patient history assessment.** \n",
      "\n",
      "This structured approach allows for a thorough understanding of WL-AAB-Z-W-982's contraindication profile in the context of other medications, providing valuable insights for clinical practice.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.030554\n",
      "prediction:  To provide a comprehensive answer to the question regarding the contraindication profile of WL-AAB-Z-W-982 in comparison to other drugs with known contraindications, we will follow a structured approach. \n",
      "\n",
      "### Step 1: Understanding WL-AAB-Z-W-982\n",
      "First, we need to gather information about WL-AAB-Z-W-982. This includes its pharmacological class, mechanism of action, therapeutic uses, and known contraindications. \n",
      "\n",
      "- **Pharmacological Class**: WL-AAB-Z-W-982 is a hypothetical drug, so we will assume it belongs to a specific class (e.g., antihypertensive, antibiotic, etc.) for the sake of this analysis.\n",
      "- **Mechanism of Action**: Understanding how the drug works can help identify potential contraindications based on its effects on the body.\n",
      "- **Therapeutic Uses**: Knowing what conditions WL-AAB-Z-W-982 is used to treat will help in understanding the patient populations that may be affected by its contraindications.\n",
      "- **Known Contraindications**: This includes any conditions, diseases, or other medications that should not be used in conjunction with WL-AAB-Z-W-982 due to the risk of adverse effects.\n",
      "\n",
      "### Step 2: Identifying Common Contraindications\n",
      "Next, we will identify common contraindications associated with other drugs in the same class as WL-AAB-Z-W-982. This will provide a baseline for comparison.\n",
      "\n",
      "- **Cardiovascular Drugs**: Common contraindications may include severe hypotension, bradycardia, or certain arrhythmias.\n",
      "- **Antibiotics**: Contraindications might include known allergies to the drug class, renal impairment, or interactions with other medications that could lead to toxicity.\n",
      "- **Antidepressants**: Contraindications could include a history of serotonin syndrome, concurrent use of MAO inhibitors, or specific medical conditions like bipolar disorder.\n",
      "\n",
      "### Step 3: Comparative Analysis\n",
      "Now, we will compare the contraindication profile of WL-AAB-Z-W-982 with those of other drugs in its class.\n",
      "\n",
      "1. **Scope of Contraindications**: \n",
      "   - If WL-AAB-Z-W-982 has a broader range of contraindications (e.g., affecting multiple organ systems), it may be less favorable compared to other drugs with more targeted contraindications.\n",
      "   - Conversely, if it has fewer contraindications, it may be more versatile in clinical use.\n",
      "\n",
      "2. **Severity of Contraindications**: \n",
      "   - Assess whether the contraindications of WL-AAB-Z-W-982 involve life-threatening conditions or are more manageable compared to other drugs.\n",
      "   - For example, if WL-AAB-Z-W-982 is contraindicated in patients with severe liver disease, while other drugs in its class are only contraindicated in mild cases, this could limit its use.\n",
      "\n",
      "3. **Patient Population Impact**: \n",
      "   - Evaluate how the contraindications affect different patient populations. If WL-AAB-Z-W-982 is contraindicated in a significant portion of the population (e.g., elderly patients, those with comorbidities), it may be less useful than alternatives.\n",
      "\n",
      "4. **Drug Interactions**: \n",
      "   - Compare the potential for drug-drug interactions. If WL-AAB-Z-W-982 has a high potential for interactions that lead to contraindications, it may be less favorable than drugs with fewer interactions.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "In conclusion, the contraindication profile of WL-AAB-Z-W-982 can be assessed by comparing its specific contraindications to those of other drugs in its class. Factors such as the scope, severity, impact on patient populations, and potential for drug interactions are critical in determining its overall safety and usability. \n",
      "\n",
      "Ultimately, a comprehensive understanding of WL-AAB-Z-W-982's contraindications in relation to other drugs will guide clinicians in making informed decisions about its use in various patient populations. Further research and clinical data would be necessary to provide a definitive comparison.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015895\n",
      "prediction:  To provide a comprehensive answer to the question regarding the drug branded as \"70%,\" we first need to clarify what \"70%\" refers to, as it is not a specific drug name but rather a concentration that is commonly associated with certain substances. \n",
      "\n",
      "### Step 1: Identify the Substance\n",
      "The term \"70%\" is often associated with isopropyl alcohol (also known as isopropanol or rubbing alcohol), which is commonly sold in a 70% concentration. This concentration is widely used in various applications, particularly in the medical and healthcare fields.\n",
      "\n",
      "### Step 2: Primary Uses of 70% Isopropyl Alcohol\n",
      "1. **Antiseptic**: The primary use of 70% isopropyl alcohol is as an antiseptic. It is effective in killing bacteria, viruses, and fungi on the skin and surfaces. The 70% concentration is optimal because it allows for a longer contact time with the microorganisms, enhancing its efficacy compared to higher concentrations (like 90% or 99%).\n",
      "\n",
      "2. **Disinfectant**: In healthcare settings, 70% isopropyl alcohol is used to disinfect surfaces, medical instruments, and equipment. It is effective against a wide range of pathogens, making it a staple in infection control protocols.\n",
      "\n",
      "3. **Skin Preparation**: Before medical procedures, such as injections or minor surgeries, 70% isopropyl alcohol is often used to clean the skin to reduce the risk of infection.\n",
      "\n",
      "4. **Cleaning Agent**: Beyond medical uses, 70% isopropyl alcohol is also used as a cleaning agent for electronics, glass, and other surfaces due to its ability to evaporate quickly without leaving residue.\n",
      "\n",
      "5. **Solvent**: In laboratories and industrial settings, 70% isopropyl alcohol can be used as a solvent for various substances, aiding in the dissolution of compounds.\n",
      "\n",
      "### Step 3: Mechanism of Action\n",
      "The effectiveness of 70% isopropyl alcohol as an antiseptic is attributed to its ability to denature proteins and disrupt cell membranes of microorganisms. The presence of water in the solution is crucial, as it helps to slow down the evaporation rate, allowing the alcohol to penetrate the cell walls of pathogens more effectively.\n",
      "\n",
      "### Step 4: Safety and Precautions\n",
      "While 70% isopropyl alcohol is generally safe for use on skin and surfaces, it is important to follow safety guidelines:\n",
      "- Avoid contact with eyes and mucous membranes.\n",
      "- Use in well-ventilated areas to prevent inhalation of fumes.\n",
      "- Keep away from open flames, as isopropyl alcohol is flammable.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the primary use of the drug branded as \"70%\" typically refers to 70% isopropyl alcohol, which serves as an antiseptic, disinfectant, skin preparation agent, cleaning agent, and solvent. Its effectiveness in killing a wide range of pathogens makes it a valuable tool in both medical and non-medical settings. Always adhere to safety guidelines when using this substance to ensure safe and effective application.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015416\n",
      "prediction:  To provide a comprehensive answer to the question regarding the drug branded as \"70%,\" we first need to clarify what \"70%\" refers to, as it is not a specific drug name but rather a concentration that is commonly associated with certain substances. \n",
      "\n",
      "### Step 1: Identify the Substance\n",
      "The term \"70%\" is often associated with isopropyl alcohol (also known as isopropanol or rubbing alcohol), which is commonly sold in a 70% concentration. This concentration is widely used in various applications, particularly in the medical and healthcare fields.\n",
      "\n",
      "### Step 2: Primary Uses of 70% Isopropyl Alcohol\n",
      "1. **Antiseptic**: The primary use of 70% isopropyl alcohol is as an antiseptic. It is effective in killing bacteria, viruses, and fungi on the skin and surfaces. The 70% concentration is optimal because it allows for a longer contact time with the microorganisms, enhancing its efficacy compared to higher concentrations.\n",
      "\n",
      "2. **Disinfectant**: In healthcare settings, 70% isopropyl alcohol is used to disinfect surfaces, medical instruments, and equipment. It is effective against a wide range of pathogens, making it a staple in infection control protocols.\n",
      "\n",
      "3. **Skin Preparation**: Before medical procedures such as injections or minor surgeries, 70% isopropyl alcohol is often used to clean the skin to reduce the risk of infection.\n",
      "\n",
      "4. **Cleaning Agent**: Beyond medical uses, 70% isopropyl alcohol is also used as a cleaning agent for electronics, glass, and other surfaces due to its ability to evaporate quickly without leaving residue.\n",
      "\n",
      "5. **Solvent**: In laboratories and industrial settings, 70% isopropyl alcohol can be used as a solvent for various substances, aiding in the dissolution of compounds.\n",
      "\n",
      "### Step 3: Mechanism of Action\n",
      "The effectiveness of 70% isopropyl alcohol as an antiseptic is attributed to its ability to denature proteins and disrupt cell membranes of microorganisms. The presence of water in the solution is crucial, as it helps to penetrate the cell walls more effectively than pure alcohol, which can cause the outer membrane to harden and create a barrier.\n",
      "\n",
      "### Step 4: Safety and Precautions\n",
      "While 70% isopropyl alcohol is generally safe for use, it is important to follow safety guidelines:\n",
      "- **Flammability**: Isopropyl alcohol is flammable, so it should be kept away from open flames and heat sources.\n",
      "- **Skin Irritation**: Prolonged contact with skin can cause irritation or dryness, so it should be used with caution.\n",
      "- **Inhalation Risks**: Inhalation of vapors in poorly ventilated areas can lead to respiratory irritation, so adequate ventilation is recommended.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the primary use of the drug branded as \"70%\" typically refers to 70% isopropyl alcohol, which serves as an effective antiseptic, disinfectant, and cleaning agent in both medical and non-medical settings. Its ability to kill a wide range of pathogens makes it an essential tool in infection control and hygiene practices.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.013695\n",
      "prediction:  To provide a comprehensive answer to the question regarding the drug branded as \"70%,\" we first need to clarify what \"70%\" refers to, as it is not a specific drug name but rather a concentration that is commonly associated with certain substances. The most common interpretation of \"70%\" in a medical context is related to isopropyl alcohol (also known as isopropanol or rubbing alcohol), which is often sold in a 70% concentration.\n",
      "\n",
      "### Step 1: Identify the Substance\n",
      "- **Isopropyl Alcohol (IPA)**: The term \"70%\" typically refers to a solution that contains 70% isopropyl alcohol and 30% water. This concentration is widely used in various settings, including healthcare, laboratories, and households.\n",
      "\n",
      "### Step 2: Primary Uses of 70% Isopropyl Alcohol\n",
      "1. **Antiseptic**: \n",
      "   - **Skin Disinfection**: 70% isopropyl alcohol is commonly used as a topical antiseptic to clean the skin before injections or minor surgical procedures. It helps to reduce the number of microorganisms on the skin, thereby minimizing the risk of infection.\n",
      "   - **Wound Cleaning**: It can be used to clean minor cuts and abrasions, although it may cause irritation and is not always recommended for open wounds.\n",
      "\n",
      "2. **Surface Disinfection**:\n",
      "   - **Medical Equipment**: In healthcare settings, 70% isopropyl alcohol is used to disinfect surfaces and medical instruments. It is effective against a wide range of bacteria, viruses, and fungi.\n",
      "   - **Household Cleaning**: Many people use it to clean and disinfect surfaces in their homes, such as countertops, doorknobs, and electronic devices.\n",
      "\n",
      "3. **Solvent**:\n",
      "   - **Laboratory Use**: In laboratories, 70% isopropyl alcohol is often used as a solvent for various chemical reactions and processes. It can dissolve a wide range of non-polar compounds.\n",
      "\n",
      "4. **Personal Care Products**:\n",
      "   - **Cosmetics**: It is sometimes included in personal care products, such as hand sanitizers and skin cleansers, due to its antimicrobial properties.\n",
      "\n",
      "### Step 3: Mechanism of Action\n",
      "- **Microbial Activity**: The effectiveness of 70% isopropyl alcohol as an antiseptic is attributed to its ability to denature proteins and disrupt cell membranes of microorganisms. The presence of water in the solution enhances its penetration into cells, making it more effective than higher concentrations (e.g., 90% isopropyl alcohol), which can cause rapid coagulation of proteins and create a protective barrier for bacteria.\n",
      "\n",
      "### Step 4: Safety and Precautions\n",
      "- **Flammability**: Isopropyl alcohol is highly flammable, and care should be taken to keep it away from open flames and heat sources.\n",
      "- **Skin Irritation**: Prolonged use can lead to skin irritation or dryness. It is advisable to use it in moderation and follow up with a moisturizer if used frequently on the skin.\n",
      "- **Ingestion Hazard**: Isopropyl alcohol is toxic if ingested and can cause serious health issues, including poisoning.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the primary use of the drug branded as \"70%\" is most likely referring to 70% isopropyl alcohol, which serves as an effective antiseptic for skin disinfection, surface cleaning, and as a solvent in various applications. Its antimicrobial properties make it a valuable tool in both medical and household settings, but it should be used with caution due to its flammability and potential for skin irritation.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: To prevent sunburn\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017558\n",
      "prediction:  To provide a comprehensive answer to the question regarding the recommended dosage of a laxative for children aged 6 to under 12 years, it is important to clarify a few key points:\n",
      "\n",
      "1. **Type of Laxative**: There are various types of laxatives, including osmotic laxatives (like polyethylene glycol), stimulant laxatives (like bisacodyl), bulk-forming laxatives (like psyllium), and stool softeners (like docusate sodium). Each type has different dosing guidelines and indications.\n",
      "\n",
      "2. **Consultation with a Healthcare Provider**: Before administering any laxative to children, it is crucial to consult a healthcare provider. They can provide personalized recommendations based on the child's specific health needs, medical history, and the reason for laxative use.\n",
      "\n",
      "3. **General Dosage Guidelines**: While specific dosages can vary by product and formulation, here are some general guidelines for common laxatives used in children:\n",
      "\n",
      "   - **Polyethylene Glycol (MiraLAX)**: For children aged 6 to under 12 years, the typical dosage is 0.5 to 1 gram per kilogram of body weight per day, not exceeding 17 grams per day. This is usually mixed with water or another beverage.\n",
      "   \n",
      "   - **Docusate Sodium (Colace)**: The recommended dosage for children aged 6 to under 12 years is typically 50 to 150 mg per day, divided into one or two doses.\n",
      "   \n",
      "   - **Bisacodyl (Dulcolax)**: For children aged 6 to under 12 years, the usual oral dosage is 5 to 10 mg once daily. For rectal use, a 10 mg suppository can be used as needed.\n",
      "   \n",
      "   - **Psyllium (Metamucil)**: For children aged 6 to under 12 years, the dosage is usually 1 teaspoon (about 5 grams) mixed with water, taken 1 to 3 times daily.\n",
      "\n",
      "4. **Monitoring and Safety**: When using laxatives in children, it is important to monitor for effectiveness and any potential side effects, such as abdominal pain, diarrhea, or electrolyte imbalances. Long-term use of laxatives should be avoided unless directed by a healthcare provider.\n",
      "\n",
      "5. **Non-Pharmacological Approaches**: In addition to laxatives, consider non-pharmacological approaches to manage constipation in children, such as increasing dietary fiber intake, ensuring adequate hydration, and encouraging regular physical activity.\n",
      "\n",
      "In summary, the recommended dosage of a laxative for children aged 6 to under 12 years varies depending on the specific type of laxative used. Always consult a healthcare provider for tailored advice and to ensure safe and effective treatment.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015559\n",
      "prediction:  To provide a comprehensive answer to the question regarding the recommended dosage of a laxative for children aged 6 to under 12 years, it is important to clarify a few key points:\n",
      "\n",
      "1. **Type of Laxative**: There are various types of laxatives, including osmotic laxatives (like polyethylene glycol), stimulant laxatives (like bisacodyl), bulk-forming laxatives (like psyllium), and stool softeners (like docusate sodium). Each type has different dosing guidelines and safety profiles, especially for children.\n",
      "\n",
      "2. **Consultation with a Healthcare Provider**: Before administering any laxative to children, it is crucial to consult with a healthcare provider. They can provide personalized recommendations based on the child's specific health needs, age, weight, and the underlying cause of constipation.\n",
      "\n",
      "3. **General Dosage Guidelines**: While specific dosages can vary by product and formulation, here are some general guidelines for common laxatives used in children aged 6 to under 12 years:\n",
      "\n",
      "   - **Polyethylene Glycol (MiraLAX)**: The typical dosage for children aged 6 to 11 years is usually around 17 grams (1 capful) dissolved in 4 to 8 ounces of water once daily. However, it is essential to follow the specific product instructions or a doctor's advice.\n",
      "   \n",
      "   - **Docusate Sodium (Colace)**: The recommended dosage for children aged 6 to 12 years is typically 50 to 150 mg per day, divided into one or two doses. Again, it is important to follow the specific product instructions.\n",
      "   \n",
      "   - **Bisacodyl (Dulcolax)**: For children aged 6 to 12 years, the oral dosage is usually 5 to 10 mg once daily. Rectal suppositories may also be used, but the dosage and frequency should be determined by a healthcare provider.\n",
      "\n",
      "   - **Psyllium (Metamucil)**: For children aged 6 to 12 years, the dosage is generally 1 teaspoon (about 5 grams) mixed with water, taken 1 to 3 times daily, but this should be confirmed with a healthcare provider.\n",
      "\n",
      "4. **Monitoring and Safety**: When using laxatives in children, it is important to monitor for any side effects, such as abdominal pain, diarrhea, or dehydration. Long-term use of laxatives should be avoided unless directed by a healthcare provider, as it can lead to dependency or worsen constipation.\n",
      "\n",
      "5. **Non-Pharmacological Approaches**: In addition to laxatives, consider non-pharmacological approaches to manage constipation in children, such as increasing dietary fiber intake, ensuring adequate hydration, and encouraging regular physical activity.\n",
      "\n",
      "In summary, the recommended dosage of laxatives for children aged 6 to under 12 years varies depending on the type of laxative used. It is essential to consult a healthcare provider for specific recommendations tailored to the child's needs and to follow the instructions on the product label.\n",
      "pred_SIM:  A\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.021772\n",
      "prediction:  To provide a comprehensive answer to the question regarding the recommended dosage of a laxative for children aged 6 to under 12 years, it is important to clarify a few key points:\n",
      "\n",
      "1. **Type of Laxative**: There are various types of laxatives, including osmotic laxatives (like polyethylene glycol), stimulant laxatives (like bisacodyl), bulk-forming laxatives (like psyllium), and stool softeners (like docusate sodium). Each type has different dosing guidelines. Therefore, it is crucial to specify which laxative is being referred to.\n",
      "\n",
      "2. **Age and Weight Considerations**: Dosages for children are often based on weight and age. For children aged 6 to under 12 years, the dosage may vary significantly depending on the specific laxative and the child's weight.\n",
      "\n",
      "3. **Consultation with a Healthcare Provider**: It is always recommended to consult a healthcare provider before administering any medication, including laxatives, to children. A healthcare provider can provide personalized recommendations based on the child's health status, medical history, and specific needs.\n",
      "\n",
      "4. **General Guidelines**: While I cannot provide specific dosages without knowing the exact laxative, here are some general guidelines for common types of laxatives:\n",
      "\n",
      "   - **Osmotic Laxatives (e.g., Polyethylene Glycol)**: For children aged 6 to under 12 years, the typical dosage might range from 17 grams (1 packet) once daily, but this can vary based on the specific product and the child's needs.\n",
      "   \n",
      "   - **Stimulant Laxatives (e.g., Bisacodyl)**: The usual dosage for children in this age group is often 5 to 10 mg orally once daily, but again, this can vary.\n",
      "   \n",
      "   - **Bulk-Forming Laxatives (e.g., Psyllium)**: The dosage for children can vary widely, but it is often recommended to start with a lower dose and increase as needed, ensuring adequate fluid intake.\n",
      "   \n",
      "   - **Stool Softeners (e.g., Docusate Sodium)**: The typical dosage for children aged 6 to under 12 years is usually around 50 to 150 mg per day, divided into one or two doses.\n",
      "\n",
      "5. **Monitoring and Safety**: When giving laxatives to children, it is important to monitor for effectiveness and any potential side effects, such as abdominal pain, diarrhea, or dehydration. If the child experiences any adverse effects or if constipation persists, it is essential to seek medical advice.\n",
      "\n",
      "In summary, the recommended dosage for a laxative for children aged 6 to under 12 years depends on the specific type of laxative being used, the child's weight, and individual health considerations. Always consult a healthcare provider for the most accurate and safe recommendations.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.007473\n",
      "prediction:  To provide a comprehensive answer to the question regarding the relevant drug brand name for a specific indication, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Define the Indication\n",
      "First, we need to clarify what the term \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. It is essential to specify the medical condition or disease for which we are seeking a drug.\n",
      "\n",
      "### Step 2: Identify Common Indications\n",
      "Common indications include:\n",
      "- Hypertension\n",
      "- Diabetes\n",
      "- Asthma\n",
      "- Depression\n",
      "- Infection\n",
      "- Pain management\n",
      "- Allergies\n",
      "\n",
      "### Step 3: Research Relevant Drug Classes\n",
      "For each indication, there are typically several classes of drugs that are used. For example:\n",
      "- **Hypertension**: ACE inhibitors, beta-blockers, diuretics\n",
      "- **Diabetes**: Insulin, metformin, GLP-1 agonists\n",
      "- **Asthma**: Inhaled corticosteroids, bronchodilators\n",
      "- **Depression**: SSRIs, SNRIs, atypical antidepressants\n",
      "- **Infection**: Antibiotics, antivirals\n",
      "- **Pain management**: NSAIDs, opioids\n",
      "- **Allergies**: Antihistamines, corticosteroids\n",
      "\n",
      "### Step 4: Identify Specific Drug Brand Names\n",
      "Once we have identified the drug classes, we can then look for specific brand names associated with those classes. Here are some examples:\n",
      "\n",
      "- **Hypertension**:\n",
      "  - **ACE Inhibitors**: Lisinopril (Prinivil, Zestril)\n",
      "  - **Beta-blockers**: Metoprolol (Lopressor, Toprol-XL)\n",
      "  - **Diuretics**: Hydrochlorothiazide (Microzide)\n",
      "\n",
      "- **Diabetes**:\n",
      "  - **Insulin**: Humalog (insulin lispro), Lantus (insulin glargine)\n",
      "  - **Metformin**: Glucophage\n",
      "  - **GLP-1 Agonists**: Trulicity (dulaglutide)\n",
      "\n",
      "- **Asthma**:\n",
      "  - **Inhaled Corticosteroids**: Flovent (fluticasone)\n",
      "  - **Bronchodilators**: Albuterol (ProAir, Ventolin)\n",
      "\n",
      "- **Depression**:\n",
      "  - **SSRIs**: Sertraline (Zoloft), Fluoxetine (Prozac)\n",
      "  - **SNRIs**: Venlafaxine (Effexor XR)\n",
      "\n",
      "- **Infection**:\n",
      "  - **Antibiotics**: Amoxicillin (Amoxil), Ciprofloxacin (Cipro)\n",
      "\n",
      "- **Pain Management**:\n",
      "  - **NSAIDs**: Ibuprofen (Advil, Motrin)\n",
      "  - **Opioids**: Oxycodone (OxyContin)\n",
      "\n",
      "- **Allergies**:\n",
      "  - **Antihistamines**: Cetirizine (Zyrtec), Loratadine (Claritin)\n",
      "\n",
      "### Step 5: Provide the Final Answer\n",
      "Now, based on the specific indication provided, we can select the relevant drug brand name. For example:\n",
      "\n",
      "- If the indication is **Hypertension**, a relevant drug brand name could be **Lisinopril (Prinivil, Zestril)**.\n",
      "- If the indication is **Diabetes**, a relevant drug brand name could be **Metformin (Glucophage)**.\n",
      "- If the indication is **Asthma**, a relevant drug brand name could be **Flovent (fluticasone)**.\n",
      "\n",
      "### Conclusion\n",
      "To answer the original question, we need to specify the indication. Once the indication is provided, we can identify the relevant drug brand name accordingly. If you provide a specific indication, I can give you the most relevant drug brand name for that condition.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.008103\n",
      "prediction:  To provide a comprehensive answer to the question regarding the relevant drug brand name for a specific indication, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Define the Indication\n",
      "First, we need to clarify what the term \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. It is essential to specify the medical condition or disease for which we are seeking a drug.\n",
      "\n",
      "### Step 2: Identify Common Indications\n",
      "Common indications include:\n",
      "- Hypertension\n",
      "- Diabetes\n",
      "- Asthma\n",
      "- Depression\n",
      "- Infection (bacterial, viral, fungal)\n",
      "- Pain management\n",
      "- Allergies\n",
      "\n",
      "### Step 3: Research Relevant Drug Classes\n",
      "Once the indication is defined, we can identify the classes of drugs that are typically used to treat that condition. For example:\n",
      "- **Hypertension**: ACE inhibitors, beta-blockers, diuretics\n",
      "- **Diabetes**: Insulin, metformin, GLP-1 agonists\n",
      "- **Asthma**: Inhaled corticosteroids, bronchodilators\n",
      "- **Depression**: SSRIs, SNRIs, atypical antidepressants\n",
      "- **Infection**: Antibiotics, antivirals, antifungals\n",
      "- **Pain management**: NSAIDs, opioids, acetaminophen\n",
      "- **Allergies**: Antihistamines, corticosteroids\n",
      "\n",
      "### Step 4: Identify Specific Drug Brand Names\n",
      "For each class of drugs, there are specific brand names that are commonly prescribed. Here are examples for each indication:\n",
      "\n",
      "- **Hypertension**: \n",
      "  - **Lisinopril** (Brand name: Zestril)\n",
      "  - **Amlodipine** (Brand name: Norvasc)\n",
      "  \n",
      "- **Diabetes**: \n",
      "  - **Metformin** (Brand name: Glucophage)\n",
      "  - **Insulin glargine** (Brand name: Lantus)\n",
      "  \n",
      "- **Asthma**: \n",
      "  - **Fluticasone** (Brand name: Flovent)\n",
      "  - **Albuterol** (Brand name: Ventolin)\n",
      "  \n",
      "- **Depression**: \n",
      "  - **Sertraline** (Brand name: Zoloft)\n",
      "  - **Escitalopram** (Brand name: Lexapro)\n",
      "  \n",
      "- **Infection**: \n",
      "  - **Amoxicillin** (Brand name: Amoxil)\n",
      "  - **Oseltamivir** (Brand name: Tamiflu)\n",
      "  \n",
      "- **Pain management**: \n",
      "  - **Ibuprofen** (Brand name: Advil)\n",
      "  - **Oxycodone** (Brand name: OxyContin)\n",
      "  \n",
      "- **Allergies**: \n",
      "  - **Loratadine** (Brand name: Claritin)\n",
      "  - **Fluticasone nasal spray** (Brand name: Flonase)\n",
      "\n",
      "### Step 5: Conclusion\n",
      "To answer the original question, we need to specify the indication. For example, if the indication is \"hypertension,\" the relevant drug brand names could include \"Zestril\" (lisinopril) or \"Norvasc\" (amlodipine). \n",
      "\n",
      "### Final Answer\n",
      "For the indication 'INDICATION', the relevant drug brand name is [insert specific brand name based on the defined indication]. \n",
      "\n",
      "This structured approach allows for a clear and comprehensive understanding of how to identify relevant drug brand names based on specific medical indications.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.008178\n",
      "prediction:  To provide a comprehensive answer to the question regarding the relevant drug brand name for a specific indication, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Identify the Indication\n",
      "First, we need to clarify what the term \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. It is essential to specify the medical condition or disease for which we are seeking a drug.\n",
      "\n",
      "### Step 2: Research Relevant Drug Classes\n",
      "Once the indication is identified, we can research the classes of drugs that are typically used to treat that condition. For example, if the indication is hypertension, we would look into antihypertensive medications.\n",
      "\n",
      "### Step 3: Identify Specific Drugs\n",
      "Within each drug class, there are specific medications that are commonly prescribed. For instance, if we are looking at antihypertensives, we might consider:\n",
      "- ACE inhibitors (e.g., Lisinopril)\n",
      "- Beta-blockers (e.g., Metoprolol)\n",
      "- Calcium channel blockers (e.g., Amlodipine)\n",
      "\n",
      "### Step 4: Determine Brand Names\n",
      "Each medication often has one or more brand names under which it is marketed. Continuing with the example of Lisinopril, its brand names include:\n",
      "- Prinivil\n",
      "- Zestril\n",
      "\n",
      "### Step 5: Provide a Comprehensive Answer\n",
      "Now, we can compile the information into a comprehensive answer. Hereâ€™s how it would look:\n",
      "\n",
      "---\n",
      "\n",
      "**Answer:**\n",
      "\n",
      "To determine the relevant drug brand name for the indication 'INDICATION', we first need to specify the medical condition. For example, if the indication is hypertension, several classes of medications are used to manage this condition.\n",
      "\n",
      "1. **Antihypertensives**: This class includes various types of medications:\n",
      "   - **ACE Inhibitors**: One common drug is Lisinopril, which is marketed under the brand names **Prinivil** and **Zestril**.\n",
      "   - **Beta-Blockers**: An example is Metoprolol, available as **Lopressor** and **Toprol-XL**.\n",
      "   - **Calcium Channel Blockers**: A widely used drug is Amlodipine, known by the brand name **Norvasc**.\n",
      "\n",
      "2. **Other Classes**: Depending on the specific needs of the patient, other classes such as diuretics (e.g., Hydrochlorothiazide, brand name **Microzide**) or angiotensin receptor blockers (ARBs) like Losartan (brand name **Cozaar**) may also be relevant.\n",
      "\n",
      "In conclusion, the relevant drug brand name for the indication 'INDICATION' will depend on the specific medical condition being treated. If you provide the specific indication, I can give a more targeted response with the appropriate drug brand names.\n",
      "\n",
      "--- \n",
      "\n",
      "This structured approach ensures clarity and comprehensiveness in answering the question.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011786\n",
      "prediction:  To provide a comprehensive answer to the question regarding which drug is specifically associated with a particular indication, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Define the Indication\n",
      "First, we need to clarify what the term \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. It is essential to specify the condition or disease for which we are seeking a drug. For example, common indications include hypertension, diabetes, depression, or infections.\n",
      "\n",
      "### Step 2: Identify Relevant Drug Classes\n",
      "Once we have a clear indication, we can identify the classes of drugs that are typically used to treat that condition. For instance:\n",
      "- **Hypertension**: Antihypertensives (e.g., ACE inhibitors, beta-blockers, diuretics)\n",
      "- **Diabetes**: Antidiabetic agents (e.g., metformin, insulin)\n",
      "- **Depression**: Antidepressants (e.g., SSRIs, SNRIs)\n",
      "- **Infections**: Antibiotics (e.g., penicillins, cephalosporins)\n",
      "\n",
      "### Step 3: List Specific Drugs\n",
      "Next, we can list specific drugs within those classes that are commonly prescribed for the indication. For example:\n",
      "- **Hypertension**: \n",
      "  - Lisinopril (ACE inhibitor)\n",
      "  - Amlodipine (Calcium channel blocker)\n",
      "- **Diabetes**: \n",
      "  - Metformin (Biguanide)\n",
      "  - Glipizide (Sulfonylurea)\n",
      "- **Depression**: \n",
      "  - Fluoxetine (SSRI)\n",
      "  - Venlafaxine (SNRI)\n",
      "- **Infections**: \n",
      "  - Amoxicillin (Penicillin)\n",
      "  - Ciprofloxacin (Fluoroquinolone)\n",
      "\n",
      "### Step 4: Match Drug to Indication\n",
      "Now, we can match the specific drugs to the indication. For example:\n",
      "- If the indication is **hypertension**, we might say that **Lisinopril** is specifically associated with this indication.\n",
      "- If the indication is **type 2 diabetes**, we could say that **Metformin** is specifically associated with this indication.\n",
      "\n",
      "### Step 5: Provide Context and Considerations\n",
      "Itâ€™s also important to provide context about the drug, such as:\n",
      "- **Mechanism of Action**: How the drug works in the body.\n",
      "- **Side Effects**: Common side effects associated with the drug.\n",
      "- **Contraindications**: Situations where the drug should not be used.\n",
      "- **Clinical Guidelines**: Reference to clinical guidelines that support the use of the drug for the indication.\n",
      "\n",
      "### Conclusion\n",
      "In conclusion, to answer the question about which drug is specifically associated with a given indication, we must first define the indication, identify relevant drug classes, list specific drugs, and then match them to the indication while providing additional context. \n",
      "\n",
      "If you provide a specific indication, I can give you a more tailored answer regarding the drug associated with that indication.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.010386\n",
      "prediction:  To provide a comprehensive answer to the question regarding which drug is specifically associated with a particular indication, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Define the Indication\n",
      "First, we need to clarify what the term \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. It is essential to specify the condition or disease for which we are seeking a drug. For example, common indications include hypertension, diabetes, depression, or infections.\n",
      "\n",
      "### Step 2: Identify Relevant Drug Classes\n",
      "Once we have a specific indication, we can identify the classes of drugs that are typically used to treat that condition. For instance:\n",
      "- **Hypertension**: Antihypertensives (e.g., ACE inhibitors, beta-blockers, diuretics)\n",
      "- **Diabetes**: Antidiabetic agents (e.g., metformin, insulin)\n",
      "- **Depression**: Antidepressants (e.g., SSRIs, SNRIs)\n",
      "- **Infections**: Antibiotics (e.g., penicillins, cephalosporins)\n",
      "\n",
      "### Step 3: List Specific Drugs\n",
      "After identifying the relevant drug classes, we can list specific drugs within those classes that are commonly prescribed for the indication. For example:\n",
      "- **Hypertension**: \n",
      "  - Lisinopril (ACE inhibitor)\n",
      "  - Amlodipine (Calcium channel blocker)\n",
      "- **Diabetes**: \n",
      "  - Metformin (Biguanide)\n",
      "  - Glipizide (Sulfonylurea)\n",
      "- **Depression**: \n",
      "  - Fluoxetine (SSRI)\n",
      "  - Venlafaxine (SNRI)\n",
      "- **Infections**: \n",
      "  - Amoxicillin (Penicillin)\n",
      "  - Ciprofloxacin (Fluoroquinolone)\n",
      "\n",
      "### Step 4: Match Drug to Indication\n",
      "Now, we can match specific drugs to the indication. For example:\n",
      "- If the indication is **hypertension**, we might say that **Lisinopril** is specifically associated with this indication.\n",
      "- If the indication is **type 2 diabetes**, we could say that **Metformin** is specifically associated with this indication.\n",
      "\n",
      "### Step 5: Provide Context and Considerations\n",
      "Itâ€™s also important to provide context regarding the drug's mechanism of action, common side effects, and any contraindications. For instance:\n",
      "- **Lisinopril**: An ACE inhibitor that works by relaxing blood vessels to lower blood pressure. Common side effects include cough and elevated potassium levels. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment.\n",
      "- **Metformin**: A biguanide that decreases hepatic glucose production and increases insulin sensitivity. Common side effects include gastrointestinal upset, and it is contraindicated in patients with severe renal impairment.\n",
      "\n",
      "### Conclusion\n",
      "To summarize, the answer to the question of which drug is specifically associated with the indication 'INDICATION' requires us to:\n",
      "1. Define the specific indication.\n",
      "2. Identify relevant drug classes.\n",
      "3. List specific drugs within those classes.\n",
      "4. Match the drug to the indication.\n",
      "5. Provide context regarding the drug's use, mechanism, and side effects.\n",
      "\n",
      "If you provide a specific indication, I can give a more tailored response regarding the associated drug.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.011582\n",
      "prediction:  To provide a comprehensive answer to the question regarding which drug is specifically associated with a particular indication, we need to follow a systematic approach. Hereâ€™s how we can break it down step-by-step:\n",
      "\n",
      "### Step 1: Define the Indication\n",
      "First, we need to clarify what the term \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. It is essential to specify the condition or disease for which we are seeking a drug. For example, common indications include hypertension, diabetes, depression, or infections.\n",
      "\n",
      "### Step 2: Identify Relevant Drug Classes\n",
      "Once we have a specific indication, we can identify the classes of drugs that are typically used to treat that condition. For instance:\n",
      "- **Hypertension**: Antihypertensives (e.g., ACE inhibitors, beta-blockers, diuretics)\n",
      "- **Diabetes**: Antidiabetic agents (e.g., metformin, insulin)\n",
      "- **Depression**: Antidepressants (e.g., SSRIs, SNRIs)\n",
      "- **Infections**: Antibiotics (e.g., penicillins, cephalosporins)\n",
      "\n",
      "### Step 3: List Specific Drugs\n",
      "Next, we can list specific drugs within those classes that are commonly prescribed for the indication. For example:\n",
      "- **Hypertension**: \n",
      "  - Lisinopril (ACE inhibitor)\n",
      "  - Amlodipine (Calcium channel blocker)\n",
      "- **Diabetes**: \n",
      "  - Metformin (Biguanide)\n",
      "  - Glipizide (Sulfonylurea)\n",
      "- **Depression**: \n",
      "  - Fluoxetine (SSRI)\n",
      "  - Venlafaxine (SNRI)\n",
      "- **Infections**: \n",
      "  - Amoxicillin (Penicillin)\n",
      "  - Ciprofloxacin (Fluoroquinolone)\n",
      "\n",
      "### Step 4: Match Drug to Indication\n",
      "Now, we can match the specific drugs to the indication. For example:\n",
      "- If the indication is **hypertension**, we might say that **Lisinopril** is specifically associated with this condition.\n",
      "- If the indication is **type 2 diabetes**, we could identify **Metformin** as a first-line treatment.\n",
      "\n",
      "### Step 5: Provide Context and Considerations\n",
      "Itâ€™s also important to provide context about the drug's mechanism of action, common side effects, and any contraindications. For example:\n",
      "- **Lisinopril**: An ACE inhibitor that works by relaxing blood vessels to lower blood pressure. Common side effects include cough and elevated potassium levels. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment.\n",
      "\n",
      "### Conclusion\n",
      "To summarize, the answer to the question about which drug is specifically associated with the indication 'INDICATION' requires:\n",
      "1. A clear definition of the indication.\n",
      "2. Identification of relevant drug classes.\n",
      "3. Listing specific drugs within those classes.\n",
      "4. Matching the drug to the indication with context about its use.\n",
      "\n",
      "If you provide a specific indication, I can give a more tailored response regarding the associated drug.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020677\n",
      "prediction:  To provide a comprehensive answer to your question regarding a drug specifically associated with a certain indication, it is essential to first clarify what \"INDICATION\" refers to. In medicine, an indication is a valid reason to use a certain treatment or medication, typically based on clinical evidence and guidelines.\n",
      "\n",
      "For example, if the indication in question is \"hypertension,\" then a drug specifically associated with this indication would be **lisinopril**, which is an angiotensin-converting enzyme (ACE) inhibitor commonly prescribed to manage high blood pressure.\n",
      "\n",
      "If the indication is \"depression,\" then **sertraline**, a selective serotonin reuptake inhibitor (SSRI), would be a relevant drug.\n",
      "\n",
      "If the indication is \"type 2 diabetes,\" then **metformin** is a first-line medication used to improve glycemic control in adults with this condition.\n",
      "\n",
      "To provide a more tailored response, please specify the particular indication you are interested in, and I can identify the drug or drugs that are specifically associated with that indication.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.030651\n",
      "prediction:  To provide a comprehensive answer to your question regarding a drug specifically associated with a particular indication, it is essential to first clarify what \"INDICATION\" refers to. In the context of medicine, an indication is a valid reason to use a certain treatment or medication, typically based on clinical evidence and guidelines.\n",
      "\n",
      "For example, if the indication in question is \"hypertension,\" then a drug specifically associated with this indication would be a medication like lisinopril, which is an ACE inhibitor commonly prescribed to manage high blood pressure.\n",
      "\n",
      "If the indication were \"type 2 diabetes,\" a drug like metformin would be relevant, as it is one of the first-line treatments for this condition.\n",
      "\n",
      "To provide a more tailored response, please specify the indication you are interested in. This will allow me to identify the drug that is specifically associated with that indication and provide additional context, such as mechanism of action, common side effects, and any relevant clinical guidelines.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.011997\n",
      "prediction:  To provide a comprehensive answer to your question regarding a drug specifically associated with a particular indication, it is essential to first clarify what the term \"indication\" refers to in the context of medicine. An indication is a valid reason to use a certain treatment or medication, typically based on clinical evidence and guidelines. \n",
      "\n",
      "Since the specific indication is not provided in your question, I will outline a general approach to identifying a drug associated with a specific indication, along with examples of common indications and their corresponding medications.\n",
      "\n",
      "1. **Cardiovascular Indications**:\n",
      "   - **Hypertension**: A common drug used is **Lisinopril**, an ACE inhibitor that helps lower blood pressure.\n",
      "   - **Heart Failure**: **Carvedilol**, a beta-blocker, is often prescribed to manage heart failure symptoms.\n",
      "\n",
      "2. **Diabetes**:\n",
      "   - **Type 2 Diabetes Mellitus**: **Metformin** is the first-line medication used to improve glycemic control in patients with type 2 diabetes.\n",
      "\n",
      "3. **Infectious Diseases**:\n",
      "   - **Bacterial Infections**: **Amoxicillin** is a widely used antibiotic for treating various bacterial infections.\n",
      "   - **HIV/AIDS**: **Tenofovir** is an antiretroviral medication used as part of the treatment regimen for HIV.\n",
      "\n",
      "4. **Mental Health**:\n",
      "   - **Depression**: **Sertraline**, a selective serotonin reuptake inhibitor (SSRI), is commonly prescribed for major depressive disorder.\n",
      "   - **Anxiety Disorders**: **Buspirone** is often used to treat generalized anxiety disorder.\n",
      "\n",
      "5. **Pain Management**:\n",
      "   - **Chronic Pain**: **Gabapentin** is frequently used for neuropathic pain management.\n",
      "   - **Acute Pain**: **Ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID), is commonly used for pain relief.\n",
      "\n",
      "6. **Respiratory Conditions**:\n",
      "   - **Asthma**: **Albuterol** is a bronchodilator used for quick relief of asthma symptoms.\n",
      "   - **Chronic Obstructive Pulmonary Disease (COPD)**: **Tiotropium** is a long-acting anticholinergic used for maintenance treatment.\n",
      "\n",
      "7. **Oncology**:\n",
      "   - **Breast Cancer**: **Tamoxifen** is often used as a hormonal therapy for estrogen receptor-positive breast cancer.\n",
      "   - **Non-Small Cell Lung Cancer**: **Erlotinib** is a targeted therapy used for specific mutations in lung cancer.\n",
      "\n",
      "8. **Gastrointestinal Disorders**:\n",
      "   - **Gastroesophageal Reflux Disease (GERD)**: **Omeprazole**, a proton pump inhibitor, is commonly prescribed to reduce stomach acid.\n",
      "\n",
      "To accurately identify a drug associated with a specific indication, one would typically refer to clinical guidelines, pharmacology resources, or databases such as the FDA's drug database, which lists approved indications for each medication.\n",
      "\n",
      "If you provide a specific indication, I can give a more targeted response regarding the drug associated with that indication.\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.016543\n",
      "prediction:  To provide a comprehensive answer to your question regarding the relevant drug brand name for a specific indication, it is essential to first identify the indication you are referring to. In medicine, an indication refers to a valid reason to use a certain test, medication, procedure, or surgery. Different conditions or diseases have specific treatments associated with them, often represented by various drug brand names.\n",
      "\n",
      "For example, if the indication is \"hypertension,\" relevant drug brand names might include:\n",
      "\n",
      "1. **Lisinopril** (brand name: Zestril)\n",
      "2. **Amlodipine** (brand name: Norvasc)\n",
      "3. **Losartan** (brand name: Cozaar)\n",
      "\n",
      "If the indication is \"diabetes,\" relevant drug brand names could include:\n",
      "\n",
      "1. **Metformin** (brand name: Glucophage)\n",
      "2. **Insulin glargine** (brand name: Lantus)\n",
      "3. **Sitagliptin** (brand name: Januvia)\n",
      "\n",
      "If the indication is \"depression,\" relevant drug brand names might include:\n",
      "\n",
      "1. **Fluoxetine** (brand name: Prozac)\n",
      "2. **Sertraline** (brand name: Zoloft)\n",
      "3. **Escitalopram** (brand name: Lexapro)\n",
      "\n",
      "To provide a specific answer, please specify the indication you are interested in, and I can list the relevant drug brand names associated with that condition.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.024184\n",
      "prediction:  To provide a comprehensive answer to your question, I would need to know the specific medical indication you are referring to, as different drug brand names are associated with various indications. \n",
      "\n",
      "For example:\n",
      "\n",
      "1. **Hypertension**: The brand name **Lisinopril** (Prinivil, Zestril) is commonly used for treating high blood pressure.\n",
      "2. **Diabetes**: **Metformin** (Glucophage) is a well-known medication for managing type 2 diabetes.\n",
      "3. **Asthma**: **Albuterol** (Ventolin, ProAir) is frequently prescribed for asthma relief.\n",
      "4. **Depression**: **Fluoxetine** (Prozac) is a widely recognized antidepressant.\n",
      "5. **Cholesterol**: **Atorvastatin** (Lipitor) is often used to lower cholesterol levels.\n",
      "\n",
      "If you provide a specific indication, I can give you the relevant drug brand name associated with that condition.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020961\n",
      "prediction:  To provide a comprehensive answer, I would need to know the specific indication you are referring to, as different medical conditions or symptoms are treated with various medications, each associated with specific brand names. \n",
      "\n",
      "For example:\n",
      "\n",
      "1. **Hypertension (High Blood Pressure)**: A relevant drug brand name could be **Lisinopril**, which is marketed under the brand name **Prinivil** or **Zestril**.\n",
      "\n",
      "2. **Diabetes**: For managing type 2 diabetes, a relevant drug brand name could be **Metformin**, commonly known as **Glucophage**.\n",
      "\n",
      "3. **Asthma**: For asthma management, a relevant drug brand name could be **Albuterol**, which is often sold under the brand name **Ventolin** or **Proventil**.\n",
      "\n",
      "4. **Depression**: For treating major depressive disorder, a relevant drug brand name could be **Sertraline**, marketed as **Zoloft**.\n",
      "\n",
      "5. **Cholesterol Management**: For lowering cholesterol levels, a relevant drug brand name could be **Atorvastatin**, known as **Lipitor**.\n",
      "\n",
      "If you provide a specific medical indication, I can give you a more tailored response with the relevant drug brand names associated with that condition.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.022416\n",
      "prediction:  To provide an accurate answer regarding the relevant drug brand name for the indication 'INDICATION', I found some resources that discuss drug branding and naming practices. However, the search did not yield specific brand names related to a particular indication. \n",
      "\n",
      "In general, the brand name associated with a drug can vary significantly depending on its therapeutic use or indication. Some drugs are marketed under different brand names for different indications. For precise information, itâ€™s advisable to refer to drug databases or official medical resources that align specific brand names with their respective indications.\n",
      "\n",
      "If you have a specific indication in mind, I could further refine the search to find the most relevant drug brand name associated with that particular condition.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.098901\n",
      "prediction:  To provide an accurate answer, I would need the specific indication you're referring to and the list of drugs to evaluate. Could you please provide those details?\n",
      "pred_SIM:  C\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.014049\n",
      "prediction:  To provide relevant brand names of drugs for specific indications, various online resources are available that categorize medications by their uses, names, and therapeutic classifications. Here are some available options to explore:\n",
      "\n",
      "1. **Drugs.com** offers a comprehensive overview of drug information, including lists of brand names and their respective indications. More details can be found at their [website](https://www.drugs.com/drug_information.html).\n",
      "\n",
      "2. **RxList** is another resource that provides detailed information about medications, side effects, and usage for both consumers and healthcare professionals. Their site can be accessed [here](https://www.rxlist.com/).\n",
      "\n",
      "3. **Top 200 Drugs Study Guide** outlines drugs, their brand and generic names, therapeutic classes, and primary indications, which can be beneficial for understanding which drugs relate to specific conditions. Further information is available [here](https://pharmacytechscholar.com/top-200-drugs/).\n",
      "\n",
      "4. **Overview of Top 100 Drugs** also categorizes medications by their names and indications, which can be particularly useful for healthcare students and professionals seeking a quick reference. You can find more details [here](https://www.studocu.com/en-us/document/binghamton-university/pharmaceutics/top-100-drugs-classifications-and-indications-overview/124081797).\n",
      "\n",
      "Using these resources will allow you to identify the specific brand name of a drug relevant to the given indication. If you need a specific indication, please provide that, and I can assist further!\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Arnica gel\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.009321\n",
      "prediction:  To treat athlete's foot (tinea pedis), the duration of antifungal treatment can vary based on the specific antifungal medication used, the severity of the infection, and individual patient factors.\n",
      "\n",
      "1. **Topical Antifungals**: Common topical options include terbinafine (Lamisil), clotrimazole, and miconazole. \n",
      "   - Terbinafine cream is often recommended for 1-2 weeks of daily application. A clinical study supports its efficacy with a regimen of applying the cream once daily for one week as a potent option, although some may benefit from prolonged treatment up to two weeks based on persistent symptoms.\n",
      "   - Other topical antifungals like clotrimazole and miconazole generally require application twice daily for 2-4 weeks, depending on the guidance provided by healthcare professionals and the specific formulation.\n",
      "\n",
      "2. **Oral Antifungals**: For more severe or resistant cases of athlete's foot, oral antifungals such as terbinafine or itraconazole may be prescribed for 2-6 weeks based on clinical evaluation.\n",
      "\n",
      "3. **Follow-Up**: If symptoms of athlete's foot do not improve after two weeks of topical treatment or if there are recurrences, it is advisable to consult a healthcare professional. They may consider oral antifungal treatment or investigate other potential underlying conditions.\n",
      "\n",
      "In summary, topical antifungals are typically used for 1-2 weeks (once or twice daily), while oral treatments can extend from 2-6 weeks based on individual circumstances and response to therapy.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: 4 weeks\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.055359\n",
      "prediction:  Using short-acting sympathomimetic aerosol bronchodilators concomitantly with Albuterol can pose several risks. Here are the key reasons:\n",
      "\n",
      "1. **Increased Side Effects**: Both Albuterol and other short-acting sympathomimetics (such as levalbuterol) activate beta-adrenergic receptors in the lungs, leading to bronchodilation. However, when used together, they can increase the likelihood of adverse effects such as tremors, increased heart rate (tachycardia), and nervousness, due to excessive stimulation of the sympathetic nervous system.\n",
      "\n",
      "2. **Risk of Overmedication**: The simultaneous use of multiple bronchodilators can lead to overmedication, where the cumulative effect of the medications may surpass therapeutic levels, potentially resulting in increased side effects without additional benefit in symptom control.\n",
      "\n",
      "3. **No Added Benefit**: Clinical guidelines typically suggest that using multiple short-acting agents does not provide additional therapeutic benefit for asthma or COPD management. This redundancy can lead to complications without improving outcomes, thereby complicating treatment regimens.\n",
      "\n",
      "4. **Potential for Diminished Control**: The use of different short-acting agents can create confusion in dosing schedules, which may lead to poor adherence and potentially result in diminished control of asthma or COPD symptoms.\n",
      "\n",
      "Therefore, it is recommended to use Albuterol alone or in combination with long-acting bronchodilators as needed, rather than with other short-acting sympathomimetics. This approach maximizes efficacy while minimizing the risk of adverse effects and complications associated with polypharmacy.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: They may lead to deleterious cardiovascular effects.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.046787\n",
      "prediction:  Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, anxiety disorders, and certain other mood disorders. Understanding how venlafaxine interacts with drugs that are highly bound to plasma proteins is important for clinicians when considering polypharmacy and potential drug interactions.\n",
      "\n",
      "### Step 1: Understanding Plasma Protein Binding\n",
      "\n",
      "1. **Plasma Protein Binding**: Many drugs bind to plasma proteins, primarily albumin and alpha-1 acid glycoprotein. This binding affects the drug's distribution, metabolism, and elimination. Only the unbound (free) fraction of a drug is pharmacologically active and can exert therapeutic effects or cause side effects.\n",
      "\n",
      "2. **High Protein Binding**: Drugs that are highly bound to plasma proteins (typically >90% bound) can have significant interactions with other medications that also bind to these proteins. This is because the total concentration of the drug in the plasma may not reflect the active concentration.\n",
      "\n",
      "### Step 2: Venlafaxine's Protein Binding Characteristics\n",
      "\n",
      "1. **Protein Binding of Venlafaxine**: Venlafaxine is approximately 27% bound to plasma proteins. This relatively low binding means that venlafaxine has a higher proportion of free drug compared to highly protein-bound drugs.\n",
      "\n",
      "2. **Implications of Low Binding**: Because venlafaxine is not highly bound, it is less likely to displace other drugs from their protein binding sites. However, it can still be affected by the presence of other drugs that are highly protein-bound.\n",
      "\n",
      "### Step 3: Potential Drug Interactions\n",
      "\n",
      "1. **Displacement Interactions**: In cases where a highly protein-bound drug is administered alongside venlafaxine, the potential for displacement is lower due to venlafaxine's lower binding affinity. However, if a highly protein-bound drug is introduced, it may displace venlafaxine from its binding sites, leading to an increase in the free concentration of venlafaxine.\n",
      "\n",
      "2. **Increased Effects and Side Effects**: An increase in the free concentration of venlafaxine could enhance its therapeutic effects but also increase the risk of side effects, such as hypertension, nausea, or serotonin syndrome, especially if the other drug also affects serotonin levels.\n",
      "\n",
      "3. **Clinical Considerations**: When prescribing venlafaxine with other medications, especially those that are highly protein-bound (e.g., warfarin, phenytoin), clinicians should monitor for increased effects or side effects. Adjustments in dosing may be necessary based on the clinical response and side effect profile.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "\n",
      "In summary, venlafaxine's interaction with drugs that are highly bound to plasma proteins is characterized by its relatively low protein binding. While it is less likely to displace other drugs, the introduction of a highly protein-bound drug can lead to increased free concentrations of venlafaxine, potentially enhancing its effects and side effects. Clinicians should be vigilant in monitoring patients for any adverse reactions when these medications are used concurrently and consider dose adjustments as needed.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.061193\n",
      "prediction:  Venlafaxine is an antidepressant that primarily acts by inhibiting the reuptake of serotonin and norepinephrine. Its pharmacokinetics and interaction patterns are significantly influenced by its binding to plasma proteins, particularly albumin.\n",
      "\n",
      "### Mechanism of Interaction with Plasma Proteins\n",
      "\n",
      "1. **Protein Binding Characteristics**:\n",
      "   - Venlafaxine is known to have a relatively high protein binding capacity, with approximately 27% to 30% of the drug being bound to plasma proteins, primarily albumin. This binding is important as it affects the drug's distribution, efficacy, and clearance.\n",
      "\n",
      "2. **Effect on Drug Interactions**:\n",
      "   - When venlafaxine is administered alongside other drugs that are also highly bound to plasma proteins, competition for binding sites may occur. This can potentially lead to significant changes in the plasma concentrations of either or both drugs. For example, the release of unbound venlafaxine into the systemic circulation can lead to increased pharmacological effects and toxicity.\n",
      "\n",
      "3. **Impact of Binding Dynamics**:\n",
      "   - Studies have shown that venlafaxine interacts with serum albumin primarily through hydrogen bonding and van der Waals forces. The proximity and binding site can influence how other drugs may displace venlafaxine from albumin, leading to altered effects for both venlafaxine and the competing drug.\n",
      "\n",
      "### Clinical Implications\n",
      "\n",
      "- **Increased Risk of Adverse Effects**:\n",
      "   - If a patient is prescribed multiple medications that are known to be highly protein-bound (such as warfarin or some antiepileptic drugs), the risk of side effects from both venlafaxine and the other drug may increase. Clinicians should monitor patients closely for adverse effects if such combinations are necessary.\n",
      "\n",
      "- **Dose Adjustments and Monitoring**:\n",
      "   - In cases where drug interactions are suspected or observed due to the displacement from protein binding, dose adjustments may be required. Therapeutic drug monitoring could be considered to maintain efficacy while minimizing toxicity.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, venlafaxineâ€™s interaction with drugs that are highly bound to plasma proteins is a critical consideration in pharmacotherapy. Competition for binding sites can affect drug efficacy, lead to increased side effects, and necessitate careful monitoring and possible dose adjustment in patients receiving multiple therapies. Understanding these interactions can help in optimizing treatment strategies for patients requiring venlafaxine.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.029358\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has been evaluated in numerous clinical trials across various contexts, particularly for major depressive disorder and other anxiety-related conditions. \n",
      "\n",
      "In reviewing the clinical trials of venlafaxine, certain behaviors or adverse reactions that were **not** observed help to delineate its safety profile:\n",
      "\n",
      "1. **Liver Toxicity:** Unlike some other antidepressants and medications, significant liver toxicity has not been a common finding in trials of venlafaxine. While it is essential to monitor liver function in all patients, especially those with pre-existing liver conditions, venlafaxine has not been prominently associated with hepatic failure in the literature.\n",
      "\n",
      "2. **Sedation:** Venlafaxine is not typically known for causing sedation in the way that some other antidepressants (like tricyclic antidepressants or certain SSRIs) do. Many trials indicate that it can, in fact, have a stimulating effect, which could help in alleviating symptoms of fatigue associated with depression.\n",
      "\n",
      "3. **Weight Gain:** In most clinical trials, venlafaxine has not been associated with substantial weight gain, a common side effect seen with several other antidepressants. Some studies even suggest that it may be weight-neutral or associated with mild weight loss in some patients.\n",
      "\n",
      "4. **Addiction:** Venlafaxine has not shown signs of being addictive or leading to substance dependence, distinguishing it from some other classes of medications, such as benzodiazepines or certain opioids.\n",
      "\n",
      "5. **Cognitive Impairment:** Clinical trials have typically not found venlafaxine to significantly impair cognitive function, and in some contexts, it may even improve concentration and decision-making abilities in patients with depression.\n",
      "\n",
      "Thus, while venlafaxine is effective in the treatment of depression and anxiety, behaviors such as significant liver toxicity, sedation, substantial weight gain, addiction potential, and cognitive impairment were generally **not** observed in clinical trials. Always consult healthcare providers for personalized medical advice and treatment options.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.029976\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has been studied for its efficacy in treating major depressive disorder and anxiety disorders. Research indicates that venlafaxine can be effective in reducing symptoms of depression, which may include suicidality.\n",
      "\n",
      "In clinical studies, particularly those involving adolescents and young adults, there has been a focus on the impact of venlafaxine on suicidality risk. The age group that has shown a notable reduction in suicidality risk with venlafaxine compared to placebo is primarily adults, particularly those aged 18 to 24. \n",
      "\n",
      "However, it is important to note that while venlafaxine may reduce depressive symptoms and associated suicidality in adults, the findings in younger populations (such as adolescents) have been more mixed. Some studies have indicated that while venlafaxine can be effective in treating depression, there is also a potential risk of increased suicidal thoughts and behaviors in younger patients, particularly when compared to placebo. \n",
      "\n",
      "The FDA has issued warnings regarding the use of antidepressants, including venlafaxine, in children and adolescents due to the risk of increased suicidality. Therefore, while adults (especially those aged 18-24) may experience a reduction in suicidality risk with venlafaxine, caution is advised when prescribing this medication to younger populations.\n",
      "\n",
      "In summary, the age group that has shown a reduction in suicidality risk with venlafaxine compared to placebo is primarily adults, particularly those aged 18 to 24, while the effects in younger populations require careful consideration and monitoring.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.036284\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has been studied for its efficacy in treating major depressive disorder and anxiety disorders. Research indicates that venlafaxine can be effective in reducing symptoms of depression, which may include suicidality.\n",
      "\n",
      "In clinical studies, particularly those involving adolescents and young adults, there has been a focus on the impact of venlafaxine on suicidality risk. The age group that has shown a reduction in suicidality risk with venlafaxine compared to placebo is primarily adults, particularly those aged 18 to 24. \n",
      "\n",
      "However, it is important to note that while venlafaxine may reduce depressive symptoms and associated suicidality in adults, the findings in younger populations, especially those under 18, have been more complex. The FDA has issued warnings regarding the use of antidepressants, including venlafaxine, in children and adolescents due to an increased risk of suicidal thoughts and behaviors in this age group. \n",
      "\n",
      "In summary, while venlafaxine has been associated with a reduction in suicidality risk in adults, particularly those aged 18 to 24, caution is advised when considering its use in younger populations, as the risk-benefit profile may differ significantly. Always consult healthcare professionals for personalized medical advice and treatment options.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.032432\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has been studied for its efficacy in treating major depressive disorder and anxiety disorders. Research indicates that venlafaxine can be effective in reducing symptoms of depression, which may subsequently lower the risk of suicidality in certain populations.\n",
      "\n",
      "In clinical studies, particularly those involving adolescents and young adults, there has been a focus on the impact of venlafaxine on suicidality. The age group that has shown a notable reduction in suicidality risk with venlafaxine compared to placebo is primarily the adult population, particularly those aged 18 to 24 years. \n",
      "\n",
      "While some studies have indicated that venlafaxine can be effective in reducing depressive symptoms in this age group, it is important to note that the use of antidepressants, including venlafaxine, in younger populations (children and adolescents) has been associated with an increased risk of suicidality in some cases. Therefore, careful monitoring is essential when prescribing these medications to younger patients.\n",
      "\n",
      "In summary, while venlafaxine has shown efficacy in reducing suicidality risk in adults, particularly those aged 18 to 24, the results can vary based on individual circumstances, and the potential risks must be weighed against the benefits, especially in younger populations. Always consult healthcare professionals for personalized medical advice and treatment options.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.065421\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is primarily used to treat major depressive disorder, anxiety disorders, and certain other psychiatric conditions. It is significantly bound to plasma proteins, particularly to albumin and alpha-1 acid glycoprotein, which affects its pharmacokinetics and potential interactions with other drugs that are also highly protein-bound.\n",
      "\n",
      "**Key Interactions and Implications:**\n",
      "\n",
      "1. **Competitive Binding**: Drugs that are highly bound to plasma proteins can compete with venlafaxine for binding sites. When two drugs compete for the same protein binding sites, the free (unbound) concentration of one or both drugs increases in circulation, which may lead to enhanced effects or toxicity.\n",
      "\n",
      "2. **Altered Drug Concentration**: Increased levels of unbound venlafaxine could heighten its therapeutic effects or side effects, such as increased blood pressure or cardiovascular effects (as venlafaxine is known to have dose-dependent effects on blood pressure).\n",
      "\n",
      "3. **Impact on Therapeutic Monitoring**: Clinicians must be cautious when prescribing venlafaxine alongside other medications known to have high plasma protein binding. This interaction could necessitate closer monitoring of drug levels, especially in drugs with a narrow therapeutic window.\n",
      "\n",
      "4. **Clinical Significance**: Several studies have evaluated how venlafaxine interacts with drugs such as bupropion, indicating notable changes when both medications are in use. In therapeutic settings, particularly in managing conditions like depression and anxiety, it is crucial to consider these interactions to optimize patient safety and drug efficacy.\n",
      "\n",
      "5. **Populations at Risk**: Certain populations may be more vulnerable, including patients with liver impairment where protein synthesis is affected, potentially altering the dynamics of drug binding and interactions.\n",
      "\n",
      "In summary, the interaction of venlafaxine with highly protein-bound drugs can lead to significant clinical implications, necessitating careful consideration in prescribing practices to prevent adverse effects and ensure effective treatment outcomes. For healthcare professionals, awareness of these interactions is crucial in providing safe and effective medication management.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  C\n",
      "correct answer: Venlafaxine does not cause increased free concentrations of highly protein-bound drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.026282\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is primarily used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Clinical trials for venlafaxine have evaluated its efficacy, safety, and side effects. \n",
      "\n",
      "While various behaviors and side effects have been documented in clinical trials, one behavior that was NOT typically observed is the development of significant psychotic symptoms, such as hallucinations or delusions. \n",
      "\n",
      "### Explanation:\n",
      "\n",
      "1. **Commonly Observed Behaviors and Side Effects**:\n",
      "   - **Nausea and Gastrointestinal Issues**: Many patients reported nausea, vomiting, and other gastrointestinal disturbances.\n",
      "   - **Increased Blood Pressure**: Venlafaxine has been associated with dose-dependent increases in blood pressure, particularly at higher doses.\n",
      "   - **Withdrawal Symptoms**: Discontinuation of venlafaxine can lead to withdrawal symptoms, including dizziness, irritability, and flu-like symptoms.\n",
      "   - **Sexual Dysfunction**: Some patients experienced sexual side effects, including decreased libido and difficulties with orgasm.\n",
      "   - **Anxiety and Agitation**: Some individuals reported increased anxiety or agitation, particularly at the initiation of treatment or with dose increases.\n",
      "\n",
      "2. **Lack of Psychotic Symptoms**:\n",
      "   - While some antidepressants can induce manic or psychotic episodes, especially in individuals with a predisposition to bipolar disorder, venlafaxine has not been commonly associated with the emergence of psychotic symptoms in clinical trials. \n",
      "   - The absence of significant psychotic symptoms is an important consideration, as it suggests that venlafaxine may be a safer option for patients without a history of such disorders.\n",
      "\n",
      "3. **Conclusion**:\n",
      "   - In summary, while venlafaxine has a range of side effects and behaviors associated with its use, the development of significant psychotic symptoms is not a behavior that has been observed in clinical trials. This characteristic can help guide clinicians in prescribing venlafaxine, particularly for patients with a history of mood disorders. \n",
      "\n",
      "It is essential for healthcare providers to monitor patients for any emerging side effects and to consider individual patient histories when prescribing venlafaxine or any other antidepressant.\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.022206\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is primarily used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Clinical trials for venlafaxine have provided a wealth of data regarding its efficacy and safety profile. \n",
      "\n",
      "When considering behaviors or effects that were NOT observed in clinical trials of venlafaxine, it is important to note that while the drug has been associated with a range of side effects and behaviors, certain specific behaviors or outcomes were not typically reported or observed. \n",
      "\n",
      "1. **Severe Cognitive Impairment**: While some patients may experience mild cognitive effects such as difficulty concentrating or memory issues, severe cognitive impairment was not a common finding in clinical trials. Most cognitive side effects reported were mild and transient.\n",
      "\n",
      "2. **Significant Weight Gain**: Unlike some other antidepressants, venlafaxine is not typically associated with significant weight gain. In fact, some studies suggest that it may be weight-neutral or even associated with slight weight loss in some patients.\n",
      "\n",
      "3. **Severe Sedation**: Venlafaxine is not known for causing significant sedation or drowsiness compared to other classes of antidepressants, such as tricyclic antidepressants (TCAs) or certain atypical antipsychotics. While some patients may experience fatigue, severe sedation was not a prominent side effect in clinical trials.\n",
      "\n",
      "4. **Mania or Hypomania**: In patients without a history of bipolar disorder, venlafaxine has not been commonly associated with the induction of manic or hypomanic episodes. However, it is always important to monitor mood changes in patients with a history of mood disorders.\n",
      "\n",
      "5. **Severe Allergic Reactions**: While allergic reactions can occur with any medication, severe allergic reactions (such as anaphylaxis) were not commonly reported in clinical trials of venlafaxine.\n",
      "\n",
      "6. **Withdrawal Symptoms**: Although discontinuation syndrome can occur with venlafaxine, particularly at higher doses or with abrupt cessation, the trials did not typically report severe withdrawal symptoms as a common outcome. However, it is important to note that patients may experience withdrawal effects, which should be managed with a gradual tapering of the medication.\n",
      "\n",
      "In summary, while venlafaxine has a range of potential side effects, behaviors such as severe cognitive impairment, significant weight gain, severe sedation, induction of mania, severe allergic reactions, and severe withdrawal symptoms were not commonly observed in clinical trials. It is essential for healthcare providers to monitor patients closely for any adverse effects and to provide appropriate guidance on the use of venlafaxine.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.02066\n",
      "prediction:  Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is primarily used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Clinical trials for venlafaxine have provided a wealth of data regarding its efficacy and safety profile. \n",
      "\n",
      "When discussing behaviors or effects that were NOT observed in clinical trials of venlafaxine, it is important to clarify that while the drug has been associated with a range of side effects and behaviors, certain adverse effects or behaviors may not have been prominently reported or observed in the clinical trial data. \n",
      "\n",
      "1. **Severe Sedation or Drowsiness**: Unlike some other antidepressants, particularly certain tricyclic antidepressants (TCAs) or benzodiazepines, venlafaxine is not typically associated with significant sedation or drowsiness. In fact, some patients may experience increased energy or activation, especially at lower doses.\n",
      "\n",
      "2. **Weight Gain**: While weight changes can occur with many antidepressants, venlafaxine is generally not associated with significant weight gain. In clinical trials, it was often noted that venlafaxine had a more neutral effect on weight compared to other classes of antidepressants, such as certain SSRIs or TCAs, which can lead to weight gain.\n",
      "\n",
      "3. **Mania or Hypomania**: Venlafaxine has not been commonly associated with the induction of manic or hypomanic episodes in patients without a prior history of bipolar disorder. While any antidepressant can potentially trigger mania in susceptible individuals, this behavior was not a prominent finding in venlafaxine trials.\n",
      "\n",
      "4. **Severe Withdrawal Symptoms**: Although venlafaxine can lead to withdrawal symptoms upon discontinuation, the severity of withdrawal symptoms observed in clinical trials was generally not as pronounced as those seen with some other antidepressants, particularly those with a shorter half-life.\n",
      "\n",
      "5. **Significant Cognitive Impairment**: Cognitive side effects, such as significant memory impairment or confusion, were not commonly reported in clinical trials of venlafaxine. While some patients may experience mild cognitive effects, these were not a major focus of the clinical findings.\n",
      "\n",
      "6. **Addictive Behavior**: Venlafaxine is not classified as a controlled substance and does not typically lead to addictive behaviors. In clinical trials, there was no evidence to suggest that venlafaxine has a potential for abuse or dependence, which can be a concern with certain other medications.\n",
      "\n",
      "In summary, while venlafaxine has a range of potential side effects, behaviors such as severe sedation, significant weight gain, induction of mania, severe withdrawal symptoms, significant cognitive impairment, and addictive behavior were not prominently observed in clinical trials. It is important for healthcare providers to monitor patients for any side effects and to consider individual patient histories when prescribing venlafaxine.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: Drug-seeking behavior\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.033684\n",
      "prediction:  Venlafaxine, an antidepressant often used in the treatment of major depressive disorder, has demonstrated varying effects on different age groups regarding the risk of suicidality compared to placebo. A systematic review encompassing multiple randomized clinical trials concluded that venlafaxine reduces suicidality risk significantly in adults. However, findings regarding its efficacy in younger populations, specifically those below 18 years of age, show that while SSRIs (selective serotonin reuptake inhibitors) are generally well tolerated, evidence regarding venlafaxineâ€™s impacts is less conclusive.\n",
      "\n",
      "In patients aged 18 and older, venlafaxine has been associated with a statistically significant reduction in depressive symptoms and associated suicidality risks. The data showed that adults receiving venlafaxine had lower rates of suicide attempts and suicidal thoughts compared to those on placebo. In contrast, the use of venlafaxine in younger patients requires cautious consideration due to the variability in response and potential side effects observed with SSRIs in this cohort.\n",
      "\n",
      "To summarize, adults exhibit a clear benefit from venlafaxine related to a decrease in suicidality risk, while younger individuals (specifically those under 18 years) need more comprehensive studies to determine the safety and efficacy of venlafaxine for reducing suicidality risk in this age group.\n",
      "pred_SIM:  B\n",
      "choice:  B\n",
      "correct_answer:  D\n",
      "correct answer: Adults aged 65 and older\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.03962\n",
      "prediction:  Verkazia (cyclosporine A) is an ophthalmic emulsion used primarily for the treatment of dry eye disease. When administering Verkazia in conjunction with other eye drops or ointments, it is important to follow a specific sequence to ensure optimal efficacy and minimize potential interactions. Here is the recommended sequence for administering Verkazia with other eye medications:\n",
      "\n",
      "1. **Wash Hands**: Before administering any eye drops or ointments, thoroughly wash your hands with soap and water to prevent contamination.\n",
      "\n",
      "2. **Administer Other Eye Drops**: If you are using other eye drops, they should be administered first. This is because the other drops may contain preservatives or active ingredients that could interfere with the action of Verkazia if applied afterward. \n",
      "\n",
      "   - **Wait Between Drops**: If you are using multiple types of eye drops, it is advisable to wait at least 5 to 10 minutes between administering different drops. This allows the first drop to be absorbed and reduces the risk of washing it out with the subsequent drop.\n",
      "\n",
      "3. **Administer Verkazia**: After the other eye drops have been applied and the waiting period has elapsed, you can then administer Verkazia. \n",
      "\n",
      "   - **Dosage**: Typically, the recommended dosage for Verkazia is one drop in each affected eye twice daily, approximately 12 hours apart.\n",
      "\n",
      "4. **Wait Before Applying Ointments**: If you are using an eye ointment, it should be applied last. After administering Verkazia, wait at least 15 minutes before applying any ointment. This waiting period helps ensure that the Verkazia has adequate time to be absorbed and exert its therapeutic effect without being diluted or washed away by the ointment.\n",
      "\n",
      "5. **Close the Eye**: After applying Verkazia, gently close your eyes for a minute or two to help the medication spread evenly across the surface of the eye.\n",
      "\n",
      "6. **Avoid Touching the Dropper**: When administering any eye drops, avoid touching the dropper tip to your eye or any other surface to prevent contamination.\n",
      "\n",
      "7. **Follow Up**: If you experience any discomfort, redness, or changes in vision after using Verkazia or any other eye medication, consult your healthcare provider for further guidance.\n",
      "\n",
      "By following this sequence, you can maximize the effectiveness of Verkazia and ensure that your treatment for dry eye disease is as effective as possible. Always consult your healthcare provider or pharmacist if you have specific questions about your medication regimen.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.042355\n",
      "prediction:  Verkazia (cyclosporine A) is an ophthalmic emulsion used primarily for the treatment of dry eye disease. When administering Verkazia in conjunction with other eye drops or ointments, it is important to follow a specific sequence to ensure optimal efficacy and minimize potential interactions. Here is the recommended sequence for administering Verkazia with other ocular medications:\n",
      "\n",
      "1. **Wait Between Medications**: If you are using multiple eye drops or ointments, it is generally advised to wait at least 5 to 10 minutes between administering different medications. This allows the first medication to be absorbed and reduces the risk of dilution or washout of the subsequent drops.\n",
      "\n",
      "2. **Administer Other Eye Drops First**: If you are using other eye drops, they should be administered before Verkazia. This is because Verkazia is a preservative-free emulsion, and administering it after other drops can wash away the active ingredients of the other medications.\n",
      "\n",
      "3. **Use Ointments Last**: If you are using an ointment, it should be applied after all eye drops, including Verkazia. Ointments tend to create a barrier that can prevent the absorption of drops applied afterward, so they should be the last step in the sequence.\n",
      "\n",
      "4. **Follow the Prescribing Instructions**: Always adhere to the specific instructions provided by your healthcare provider or the product labeling. This includes the recommended dosage and frequency of administration for Verkazia and any other medications.\n",
      "\n",
      "5. **Wash Hands Before and After**: To prevent contamination, wash your hands thoroughly before and after administering any eye drops or ointments.\n",
      "\n",
      "6. **Avoid Touching the Dropper Tip**: When administering eye drops, avoid touching the dropper tip to your eye or any other surface to maintain sterility.\n",
      "\n",
      "7. **Close Your Eyes After Administration**: After applying Verkazia or any other eye drops, gently close your eyes for a minute or two to allow for better absorption and to minimize drainage.\n",
      "\n",
      "By following this sequence, you can help ensure that each medication is effective and that you are getting the maximum benefit from your treatment regimen. If you have any questions or concerns about the administration of Verkazia or other eye medications, consult your healthcare provider for personalized guidance.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.038986\n",
      "prediction:  Verkazia (cyclosporine A) is an ophthalmic emulsion used primarily for the treatment of dry eye disease. When administering Verkazia in conjunction with other eye drops or ointments, it is important to follow a specific sequence to ensure optimal efficacy and minimize potential interactions. Here is the recommended sequence for administering Verkazia with other ocular medications:\n",
      "\n",
      "1. **Wash Hands**: Before administering any eye drops or ointments, thoroughly wash your hands with soap and water to prevent contamination.\n",
      "\n",
      "2. **Administer Other Eye Drops**: If you are using other eye drops, they should be administered first. This is because the active ingredients in other drops may wash out or dilute the effects of Verkazia if it is applied first. \n",
      "\n",
      "   - **Wait Between Drops**: If you are using multiple types of eye drops, it is generally recommended to wait at least 5 to 10 minutes between administering different drops. This allows the first drop to be absorbed and reduces the risk of washing it out with the subsequent drop.\n",
      "\n",
      "3. **Administer Verkazia**: After the waiting period, you can then administer Verkazia. Follow the specific instructions provided with the medication regarding the number of drops and the technique for application.\n",
      "\n",
      "4. **Wait Before Applying Ointments**: If you are using an eye ointment, it should be applied last. Ointments can create a barrier that may prevent the absorption of drops applied afterward. \n",
      "\n",
      "   - **Timing**: It is advisable to wait at least 10 to 15 minutes after applying Verkazia before applying any ointment. This ensures that Verkazia has had sufficient time to be absorbed by the eye.\n",
      "\n",
      "5. **Close Eyes and Avoid Rubbing**: After applying Verkazia, gently close your eyes for a minute or two to allow the medication to spread evenly across the surface of the eye. Avoid rubbing your eyes, as this can lead to irritation or displacement of the medication.\n",
      "\n",
      "6. **Follow Up with Additional Doses**: If you have been prescribed multiple doses of Verkazia throughout the day, ensure that you maintain the same sequence of administration with other eye drops or ointments.\n",
      "\n",
      "7. **Consult Healthcare Provider**: If you have any questions or concerns about the timing or sequence of administering Verkazia with other medications, consult your healthcare provider or pharmacist for personalized advice.\n",
      "\n",
      "By following this sequence, you can help ensure that each medication is effective and that you are getting the maximum benefit from your treatment regimen.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.0369\n",
      "prediction:  Verkazia (cyclosporine A) is an ophthalmic emulsion used to treat dry eye disease. When administering Verkazia in conjunction with other eye drops or ointments, it is important to follow a specific sequence to ensure optimal efficacy and minimize potential interactions. Hereâ€™s a step-by-step guide on how to properly administer Verkazia along with other ocular medications:\n",
      "\n",
      "### Step 1: Wash Your Hands\n",
      "Before handling any eye drops or ointments, thoroughly wash your hands with soap and water to prevent contamination.\n",
      "\n",
      "### Step 2: Administer Other Eye Drops\n",
      "1. **Wait Between Drops**: If you are using multiple types of eye drops, it is generally recommended to administer the other eye drops first. \n",
      "2. **Timing**: After instilling the first eye drop, wait at least 5 to 10 minutes before administering the next drop. This waiting period allows the first drop to be absorbed and reduces the risk of washing it out with the subsequent drop.\n",
      "\n",
      "### Step 3: Administer Verkazia\n",
      "1. **Instillation**: After the waiting period, instill Verkazia as directed. Typically, this involves placing one drop in the affected eye(s).\n",
      "2. **Avoid Touching the Eye**: Ensure that the dropper tip does not touch the eye or any other surface to maintain sterility.\n",
      "\n",
      "### Step 4: Wait Before Applying Ointments\n",
      "1. **Ointments Last**: If you are using an eye ointment, it should be applied after all eye drops, including Verkazia, have been administered.\n",
      "2. **Timing**: Similar to the drops, wait at least 10 to 15 minutes after applying Verkazia before applying the ointment. This allows the drops to be absorbed effectively.\n",
      "\n",
      "### Step 5: Close Your Eyes\n",
      "After administering Verkazia, gently close your eyes for a minute or two to help the medication spread evenly across the surface of the eye.\n",
      "\n",
      "### Step 6: Avoid Rubbing Your Eyes\n",
      "Do not rub your eyes after administration, as this can cause irritation or displace the medication.\n",
      "\n",
      "### Step 7: Follow Up\n",
      "If you have any questions or experience any side effects, consult your healthcare provider for further guidance.\n",
      "\n",
      "### Summary\n",
      "In summary, the correct sequence for administering Verkazia when using other eye drops or ointments is:\n",
      "1. Wash hands.\n",
      "2. Administer other eye drops (wait 5-10 minutes between each).\n",
      "3. Administer Verkazia (wait 10-15 minutes before the next medication).\n",
      "4. Apply eye ointment last (if applicable).\n",
      "5. Close eyes gently and avoid rubbing.\n",
      "\n",
      "By following these steps, you can ensure that each medication is effective and that your eye health is managed properly. Always refer to the specific instructions provided by your healthcare provider or the medication packaging for any additional guidance.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.035499\n",
      "prediction:  Verkazia (cyclosporine A) is an ophthalmic emulsion used to treat dry eye disease. When administering Verkazia in conjunction with other eye drops or ointments, it is important to follow a specific sequence to ensure optimal efficacy and minimize potential interactions. Hereâ€™s a step-by-step guide on how to properly administer Verkazia alongside other ocular medications:\n",
      "\n",
      "### Step 1: Wash Your Hands\n",
      "Before handling any eye drops or ointments, thoroughly wash your hands with soap and water to prevent contamination.\n",
      "\n",
      "### Step 2: Administer Other Eye Drops\n",
      "1. **Wait Between Medications**: If you are using other eye drops, administer them first. It is generally recommended to wait at least 5 to 10 minutes between different eye drops. This allows the first drop to be absorbed and reduces the risk of washing it out with the subsequent drop.\n",
      "2. **Order of Administration**: If you have multiple eye drops, administer them in the following order:\n",
      "   - **Beta-blockers** (if applicable)\n",
      "   - **Prostaglandin analogs**\n",
      "   - **Carbonic anhydrase inhibitors**\n",
      "   - **Alpha agonists**\n",
      "   - **Antihistamines**\n",
      "   - **Steroids**\n",
      "   - **Verkazia (cyclosporine A)**\n",
      "\n",
      "### Step 3: Administer Ointments\n",
      "If you are using an ointment, it should be applied last. Ointments can create a barrier that may prevent the absorption of drops applied afterward. \n",
      "\n",
      "### Step 4: Administer Verkazia\n",
      "1. **Shake the Bottle**: Before using Verkazia, gently shake the bottle to ensure the emulsion is well mixed.\n",
      "2. **Instillation**: Tilt your head back slightly, pull down the lower eyelid to create a small pocket, and instill one drop of Verkazia into the pocket. Avoid touching the dropper tip to your eye or any surface to prevent contamination.\n",
      "3. **Close Your Eyes**: After instilling the drop, close your eyes gently for a minute or two to allow the medication to spread evenly across the surface of the eye.\n",
      "\n",
      "### Step 5: Wait Before Applying Additional Drops\n",
      "If you need to apply additional eye drops after Verkazia, wait at least 15 minutes to allow the Verkazia to be absorbed properly.\n",
      "\n",
      "### Step 6: Clean Up\n",
      "After administering the drops, wash your hands again to remove any residual medication.\n",
      "\n",
      "### Additional Considerations\n",
      "- **Consult Your Healthcare Provider**: Always consult with your healthcare provider or pharmacist for specific instructions tailored to your treatment plan, especially if you are using multiple medications.\n",
      "- **Follow Prescribing Information**: Adhere to the prescribing information for Verkazia and any other medications you are using, as there may be specific recommendations or contraindications.\n",
      "\n",
      "By following this sequence, you can help ensure that each medication is effective and that you minimize the risk of interactions or reduced efficacy.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.033036\n",
      "prediction:  Verkazia (cyclosporine A) is an ophthalmic emulsion used to treat dry eye disease. When administering Verkazia in conjunction with other eye drops or ointments, it is important to follow a specific sequence to ensure optimal efficacy and minimize potential interactions. Hereâ€™s a step-by-step guide on the correct sequence for administering Verkazia with other eye medications:\n",
      "\n",
      "### Step 1: Wash Your Hands\n",
      "Before administering any eye drops or ointments, thoroughly wash your hands with soap and water to prevent contamination.\n",
      "\n",
      "### Step 2: Administer Other Eye Drops\n",
      "1. **Wait Between Different Medications**: If you are using other eye drops, administer them first. It is generally recommended to wait at least 5 to 10 minutes between different eye drops. This allows the first medication to be absorbed and reduces the risk of dilution or washout of the subsequent drops.\n",
      "   \n",
      "2. **Order of Administration**: If you have multiple types of eye drops (e.g., anti-inflammatory, antibiotic, or artificial tears), the general recommendation is to administer the drops in the following order:\n",
      "   - **Preservative-free drops** (if applicable)\n",
      "   - **Medications for specific conditions** (like antibiotics or anti-inflammatories)\n",
      "   - **Artificial tears or lubricants** (if needed)\n",
      "\n",
      "### Step 3: Administer Verkazia\n",
      "1. **Shake the Bottle**: Before using Verkazia, gently shake the bottle to ensure the emulsion is well mixed.\n",
      "   \n",
      "2. **Instillation**: Tilt your head back slightly, pull down the lower eyelid to create a small pocket, and instill one drop of Verkazia into the affected eye(s). Avoid touching the dropper tip to any surface, including your eye or eyelid, to prevent contamination.\n",
      "\n",
      "3. **Close Your Eyes**: After instilling the drop, close your eyes gently for a minute or two. This helps the medication to stay in contact with the eye surface.\n",
      "\n",
      "### Step 4: Wait Before Applying Ointments\n",
      "If you are using an eye ointment, it should be applied after the drops. Wait at least 10 to 15 minutes after administering Verkazia before applying any ointment. This allows the drops to be absorbed properly without interference from the ointment.\n",
      "\n",
      "### Step 5: Follow Up\n",
      "- **Monitor for Side Effects**: After administration, be aware of any potential side effects or reactions. Common side effects of Verkazia may include burning, stinging, or discomfort upon instillation.\n",
      "- **Consult Your Healthcare Provider**: If you have any questions or concerns about the sequence of administration or the use of multiple eye medications, consult your healthcare provider or pharmacist for personalized advice.\n",
      "\n",
      "### Summary\n",
      "In summary, the correct sequence for administering Verkazia when using other eye drops or ointments is to first administer the other eye drops, wait 5 to 10 minutes, then instill Verkazia, and finally wait another 10 to 15 minutes before applying any ointments. Always ensure proper hygiene and consult with a healthcare professional if unsure about the process.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.037553\n",
      "prediction:  WL-AAB-Z-W-982 is a novel therapeutic agent, and a detailed understanding of its contraindication profile is essential when considering its clinical use, especially in comparison to other medications with known contraindications. As of the latest research, contraindications often relate to patient's pre-existing conditions, other concurrent medications, or specific physiological statuses that may amplify risks or diminish therapeutic efficacy.\n",
      "\n",
      "### Contraindications of WL-AAB-Z-W-982\n",
      "1. **Renal Compromise**: Similar to other drugs like ACE inhibitors and certain diuretics, WL-AAB-Z-W-982 shows heightened risks in patients with reduced kidney function. Renal impairment can alter drug metabolism and excretion, necessitating caution.\n",
      "  \n",
      "2. **Cardiac Conditions**: Contraindications may include various cardiac conditions, akin to drugs like beta-blockers, which necessitate caution in patients with hypotension or bradycardia.\n",
      "\n",
      "3. **Pregnancy and Lactation**: Many drugs have explicit contraindications during pregnancy due to teratogenic effects; WL-AAB-Z-W-982 falls into this category, mirroring the profiles of drugs such as ACE inhibitors, which can affect fetal development.\n",
      "\n",
      "4. **Drug Interactions**: WL-AAB-Z-W-982 may have contraindications regarding certain drug interactions that can lead to adverse effects. This is comparable to anticoagulants like warfarin, which have numerous contraindicated medications due to the risk of enhanced bleeding.\n",
      "\n",
      "### Comparison with Other Drugs\n",
      "- **Adverse Effects**: While many medications have contraindications surrounding renal function (e.g., NSAIDs, certain antibiotics), WL-AAB-Z-W-982's renal compromise contraindication is particularly linked to its unique pharmacodynamics.\n",
      "  \n",
      "- **Therapeutic Class Overlap**: Compared with other agents within its therapeutic category, WL-AAB-Z-W-982 may present a more extensive contraindication profile. For instance, biologics often have limited contraindications but are also associated with immunosuppression, which WL-AAB-Z-W-982 may share depending on its mechanism.\n",
      "\n",
      "- **Efficacy vs. Risk**: The balance of efficacy compared to risks associated with contraindications can heavily weigh on patient-specific factors, similar to the use of immunosuppressants in transplant patients. The contraindication profile of WL-AAB-Z-W-982 must be analyzed not just against categorical classifications of medications, but also in relation to patient outcomes in specific demographic groups found in recent literature [1][2][3][4][5].\n",
      "\n",
      "### Conclusion\n",
      "The contraindication profile of WL-AAB-Z-W-982 illustrates a need for careful patient assessment and management, analogous yet distinct from the profiles of other commonly used drugs. Continued research will further clarify its safety profile and guide clinical decision-making.\n",
      "\n",
      "**References**:\n",
      "1. Kidney Medicine, \"Repeat Transplantation Rate of Patients Receiving Dialysis After Allograft Nephrectomy,\" PMID: 41503185.\n",
      "2. Study trends in drug contraindications and outcomes, PMID: 41503179.\n",
      "3. Comparative analysis of biologics and novel agents, PMID: 41502394.\n",
      "4. Evaluation of renal drug metabolism, PMID: 41491117.\n",
      "5. Safety profiles in pharmacotherapy and clinical practice, PMID: 41490710.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: WL-AAB-Z-W-982 has no contraindications, unlike many other drugs.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.061135\n",
      "prediction:  When JAYPIRCA (pirtobrutinib) is co-administered with strong CYP3A inhibitors, the recommended dosage adjustment is as follows:\n",
      "\n",
      "1. **Discontinue JAYPIRCA**: If a strong CYP3A inhibitor is initiated during treatment, JAYPIRCA should be interrupted for the duration of the strong CYP3A inhibitor's use.\n",
      "  \n",
      "2. **Resume JAYPIRCA after discontinuation**: After stopping the strong CYP3A inhibitor, JAYPIRCA can be resumed after 5 half-lives of the CYP3A inhibitor have passed, at the same dose that was being taken prior to starting the strong CYP3A inhibitor.\n",
      "\n",
      "This approach helps to mitigate the risk of increased plasma concentrations of JAYPIRCA that may result from the strong CYP3A inhibitor, thereby reducing the potential for adverse reactions. \n",
      "\n",
      "Sources for this information include detailed dosage guidelines and package inserts from FDA and European Medicines Agency resources.\n",
      "pred_SIM:  D\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Reduce the dose by 50 mg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.0625\n",
      "prediction:  When Ondansetron and Tramadol are administered together, a significant potential drug interaction is noted. Research indicates that the combination of these two medications frequently results in major pharmacological interactions. Specifically, the interaction between Ondansetron and Tramadol is classified as a major potential drug interaction, meaning that it could result in clinically significant adverse effects.\n",
      "\n",
      "In particular, the co-administration of Ondansetron, an antiemetic, with Tramadol, a pain reliever, can lead to increased serotonin levels in the body. Both drugs have been associated with serotonin syndrome, a potentially life-threatening condition characterized by symptoms such as confusion, rapid heart rate, shivering, sweating, and muscle spasms.\n",
      "\n",
      "Additionally, the combination has been observed in clinical settings involving oncology patients, where polypharmacy is common. The use of these medications requires careful monitoring due to the risk of significant side effects related to their interaction.\n",
      "\n",
      "In summary, while Ondansetron is often used to control nausea and vomiting, and Tramadol for pain relief, their concurrent use should be managed with caution due to the risk of major drug interactions that could lead to serotonin syndrome or other adverse events. Regular monitoring and possible dosage adjustments may be necessary in such cases to ensure patient safety.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.05777\n",
      "prediction:  When Ondansetron is administered alongside Tramadol, there are potential drug interactions that can occur, notably categorized as major pharmacokinetic interactions. Research indicates that this combination can lead to an increase in the risk of certain adverse effects.\n",
      "\n",
      "1. **Increased Risk of Adverse Effects**: One significant finding is that the combination of Ondansetron and Tramadol has been identified as a common source of major drug interactions in cancer patients. Specifically, it was noted that this combination could enhance the central nervous system (CNS) effects, such as sedation and dizziness. These effects may increase the risk of falls, particularly in elderly patients or those with compromised health (PMID: 35404138).\n",
      "\n",
      "2. **Serotonergic Effects**: Tramadol has serotonergic properties, and when combined with other serotonergic agents like Ondansetron, there is a possibility of developing serotonin syndrome, although it is relatively rare. Symptoms of serotonin syndrome can include confusion, rapid heart rate, and elevated blood pressure, among others. Careful monitoring is advised when these drugs are used together (PMID: 41362953).\n",
      "\n",
      "3. **Overall Polypharmacy Concerns**: The concurrent use of multiple drugs, including antiemetics like Ondansetron and opioids like Tramadol, raises concerns about polypharmacy, which is commonly linked to increased risks of adverse drug reactions, particularly in inpatient settings (PMID: 34798832).\n",
      "\n",
      "In summary, the combination of Ondansetron and Tramadol can lead to significant interactions that necessitate careful consideration and monitoring to mitigate risks of adverse effects and enhance patient safety.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.053783\n",
      "prediction:  When Ondansetron is administered with Tramadol, there are potential interactions and effects that healthcare providers should be aware of:\n",
      "\n",
      "1. **Pharmacological Profile**: Ondansetron is an antiemetic commonly used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. Tramadol, on the other hand, is a pain reliever that is used to treat moderate to moderately severe pain. The combination of these two drugs is frequently encountered, especially in oncologic and postoperative settings.\n",
      "\n",
      "2. **Potential Drug Interactions**: Research indicates a notable rate of major drug interactions when Ondansetron and Tramadol are used together. A study found that the co-administration of these drugs resulted in a prevalent potential drug interaction (PDI) rate of 22.05% among patients. Such major interactions can lead to adverse effects, including increased side effects from either medication (e.g., sedation from Tramadol).\n",
      "\n",
      "3. **Side Effects**: The common side effects from Tramadol may be exacerbated when combined with Ondansetron. These include dizziness, nausea, and sedation. The central nervous system effects of Tramadol could be intensified, potentially leading to increased risks of respiratory depression, especially in vulnerable populations.\n",
      "\n",
      "4. **Clinical Recommendations**: Healthcare providers should monitor patients closely when these two medications are prescribed together, especially regarding their cardiovascular status and central nervous system functioning. Additionally, dosage adjustments and close monitoring for side effects may be prudent in such scenarios.\n",
      "\n",
      "5. **Conclusion**: While Ondansetron is effective as an antiemetic and Tramadol serves as a useful analgesic in clinical contexts, their concurrent administration necessitates careful consideration of potential interactions and side effects. Ongoing assessment and potential medication review are recommended to optimize patient outcomes.\n",
      "\n",
      "In summary, administering Ondansetron with Tramadol could lead to increased side effects and drug interactions, thus warranting cautious co-prescription and monitoring.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.045305\n",
      "prediction:  When Ondansetron, a 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting, is administered with Tramadol, an opioid analgesic used for pain relief, there are several potential effects and interactions to consider.\n",
      "\n",
      "1. **Serotonin Syndrome Risk**: One of the primary concerns when combining Ondansetron and Tramadol is the potential for serotonin syndrome. Tramadol has a dual mechanism of action; it not only acts as an opioid but also inhibits the reuptake of serotonin and norepinephrine. When combined with Ondansetron, which also influences serotonin pathways, there is a theoretical risk of increased serotonin levels in the central nervous system. Serotonin syndrome is a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, seizures or coma.\n",
      "\n",
      "2. **Enhanced Analgesic Effect**: On the other hand, the combination of Ondansetron and Tramadol may provide enhanced analgesic effects in certain patients. Ondansetron's ability to reduce nausea and vomiting can improve the overall tolerability of Tramadol, allowing patients to take it more effectively without the side effects of nausea that can accompany opioid use. This can be particularly beneficial in postoperative settings or in patients receiving chemotherapy.\n",
      "\n",
      "3. **Side Effects**: Both medications have their own side effect profiles. Ondansetron can cause headaches, constipation, and dizziness, while Tramadol can lead to nausea, dizziness, sedation, and potential dependence. When used together, the side effects may be additive, leading to increased sedation or gastrointestinal issues.\n",
      "\n",
      "4. **Individual Variability**: The effects of this combination can vary significantly among individuals based on factors such as genetic predisposition, existing medical conditions, and concurrent medications. Some patients may tolerate the combination well, while others may experience adverse effects.\n",
      "\n",
      "5. **Clinical Monitoring**: If Ondansetron and Tramadol are to be used together, it is essential for healthcare providers to monitor patients closely for any signs of serotonin syndrome, increased sedation, or other adverse effects. Adjustments to dosages or alternative therapies may be necessary based on the patient's response.\n",
      "\n",
      "In summary, while the combination of Ondansetron and Tramadol can be beneficial in managing pain and preventing nausea, it is crucial to be aware of the potential risks, particularly the risk of serotonin syndrome, and to monitor patients accordingly. Always consult with a healthcare professional before making any changes to medication regimens.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.041653\n",
      "prediction:  When Ondansetron, a 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting, is administered with Tramadol, an opioid analgesic used for pain relief, there are several potential effects and interactions to consider.\n",
      "\n",
      "1. **Serotonin Syndrome Risk**: One of the primary concerns when combining Ondansetron and Tramadol is the potential for serotonin syndrome. Tramadol has a dual mechanism of action; it not only acts as an opioid but also inhibits the reuptake of serotonin and norepinephrine. When combined with Ondansetron, which also influences serotonin pathways, there is a theoretical risk of increased serotonin levels in the central nervous system. Serotonin syndrome is a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, seizures or coma.\n",
      "\n",
      "2. **Enhanced Analgesic Effect**: On the other hand, the combination of Ondansetron and Tramadol may provide enhanced analgesic effects in certain patients. Ondansetron's ability to reduce nausea and vomiting can improve the tolerability of Tramadol, allowing patients to take it more effectively without the side effects of nausea that can accompany opioid use. This can be particularly beneficial in postoperative settings or in patients undergoing chemotherapy.\n",
      "\n",
      "3. **Side Effects**: Both medications have their own side effect profiles. Ondansetron can cause headaches, constipation, and dizziness, while Tramadol can lead to nausea, dizziness, sedation, and potential dependence. When used together, the side effects may be additive, leading to increased sedation or gastrointestinal issues.\n",
      "\n",
      "4. **Dosing Considerations**: When prescribing these medications together, healthcare providers should consider the dosing of each drug carefully. Tramadol should be used at the lowest effective dose, especially in patients who may be more susceptible to side effects, such as the elderly or those with renal impairment. Ondansetron is generally well-tolerated, but its use should be monitored in patients with a history of cardiac issues, as it can cause QT prolongation.\n",
      "\n",
      "5. **Clinical Monitoring**: If Ondansetron and Tramadol are prescribed together, it is essential for healthcare providers to monitor patients closely for any signs of serotonin syndrome, especially if the patient is on other serotonergic medications. Additionally, monitoring for the effectiveness of pain relief and any adverse effects is crucial to ensure patient safety and comfort.\n",
      "\n",
      "In summary, while the combination of Ondansetron and Tramadol can be beneficial in managing nausea and pain, it is important to be aware of the potential risks, particularly the risk of serotonin syndrome, and to monitor patients accordingly. Careful consideration of dosing and patient history is essential to minimize adverse effects and maximize therapeutic outcomes.\n",
      "pred_SIM:  D\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.041712\n",
      "prediction:  When Ondansetron, a 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting, is administered with Tramadol, an opioid analgesic used for pain relief, there are several potential effects and interactions to consider. Let's break this down step-by-step:\n",
      "\n",
      "### Step 1: Understanding the Mechanisms of Action\n",
      "\n",
      "- **Ondansetron**: It works by blocking serotonin receptors in the gastrointestinal tract and the central nervous system, which helps to reduce nausea and vomiting.\n",
      "  \n",
      "- **Tramadol**: It has a dual mechanism of action; it binds to the mu-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, which contributes to its analgesic effects.\n",
      "\n",
      "### Step 2: Potential Interactions\n",
      "\n",
      "1. **Serotonin Syndrome**: \n",
      "   - Tramadol increases serotonin levels due to its reuptake inhibition. When combined with Ondansetron, which also affects serotonin pathways, there is a theoretical risk of serotonin syndrome, a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, seizures.\n",
      "\n",
      "2. **Enhanced Analgesic Effect**:\n",
      "   - Ondansetron may help reduce nausea associated with Tramadol, potentially allowing for better tolerance and adherence to Tramadol therapy. This can be particularly beneficial in patients who experience nausea as a side effect of opioid medications.\n",
      "\n",
      "3. **Reduced Side Effects**:\n",
      "   - By managing nausea effectively with Ondansetron, patients may experience fewer side effects from Tramadol, leading to improved quality of life and better pain management.\n",
      "\n",
      "### Step 3: Clinical Considerations\n",
      "\n",
      "- **Patient Monitoring**: When these medications are used together, it is essential to monitor patients for signs of serotonin syndrome, especially if they are on other serotonergic medications.\n",
      "  \n",
      "- **Dosage Adjustments**: Depending on the patient's response, healthcare providers may need to adjust the dosages of either medication to optimize therapeutic effects while minimizing adverse effects.\n",
      "\n",
      "- **Patient Education**: Patients should be informed about the potential side effects of both medications and advised to report any unusual symptoms, particularly those indicative of serotonin syndrome.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "\n",
      "In summary, the co-administration of Ondansetron and Tramadol can lead to both beneficial effects, such as improved pain management and reduced nausea, as well as potential risks, particularly concerning serotonin syndrome. Careful monitoring and patient education are crucial to ensure safe and effective use of these medications together. Always consult with a healthcare professional before making any changes to medication regimens.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.039795\n",
      "prediction:  When Ondansetron, a 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting, is administered with Tramadol, an opioid analgesic used for pain relief, there are several potential effects and interactions to consider. Let's break this down step-by-step:\n",
      "\n",
      "### Step 1: Understanding the Medications\n",
      "\n",
      "1. **Ondansetron**:\n",
      "   - Mechanism of Action: Ondansetron works by blocking serotonin receptors in the gastrointestinal tract and the central nervous system, which helps to prevent nausea and vomiting.\n",
      "   - Common Uses: It is often used in patients undergoing chemotherapy, radiation therapy, or surgery.\n",
      "\n",
      "2. **Tramadol**:\n",
      "   - Mechanism of Action: Tramadol is a centrally acting analgesic that works by binding to mu-opioid receptors and inhibiting the reuptake of norepinephrine and serotonin, which contributes to its pain-relieving effects.\n",
      "   - Common Uses: It is used to treat moderate to moderately severe pain.\n",
      "\n",
      "### Step 2: Potential Interactions\n",
      "\n",
      "1. **Serotonin Syndrome**:\n",
      "   - Both Ondansetron and Tramadol can influence serotonin levels in the body. Tramadol, in particular, increases serotonin levels by inhibiting its reuptake. When combined with Ondansetron, which also affects serotonin pathways, there is a theoretical risk of serotonin syndrome, a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, seizures or coma.\n",
      "\n",
      "2. **Enhanced Analgesic Effect**:\n",
      "   - The combination of Ondansetron and Tramadol may provide enhanced pain relief for patients who experience nausea as a side effect of pain or pain medications. By controlling nausea with Ondansetron, patients may tolerate Tramadol better, leading to improved pain management.\n",
      "\n",
      "3. **Side Effects**:\n",
      "   - Both medications have their own side effect profiles. Ondansetron can cause headaches, constipation, and dizziness, while Tramadol can lead to nausea, dizziness, and sedation. When used together, the side effects may be additive, leading to increased sedation or gastrointestinal disturbances.\n",
      "\n",
      "### Step 3: Clinical Considerations\n",
      "\n",
      "1. **Patient Monitoring**:\n",
      "   - When these medications are used together, it is important for healthcare providers to monitor patients closely for signs of serotonin syndrome, especially if the patient is on other serotonergic medications.\n",
      "\n",
      "2. **Dosage Adjustments**:\n",
      "   - Depending on the patient's overall health, other medications, and the severity of their symptoms, healthcare providers may need to adjust dosages or consider alternative therapies.\n",
      "\n",
      "3. **Patient Education**:\n",
      "   - Patients should be informed about the potential risks and symptoms of serotonin syndrome, as well as the importance of reporting any unusual symptoms or side effects.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the administration of Ondansetron with Tramadol can lead to potential interactions, particularly concerning serotonin levels, which may increase the risk of serotonin syndrome. However, the combination may also provide benefits in managing pain and nausea. Careful monitoring, patient education, and appropriate clinical judgment are essential when using these medications together to ensure patient safety and efficacy of treatment.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.038957\n",
      "prediction:  When Ondansetron, a 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting, is administered with Tramadol, an opioid analgesic used for pain relief, there are several potential effects and interactions to consider. Let's break this down step-by-step:\n",
      "\n",
      "### Step 1: Understanding the Medications\n",
      "\n",
      "1. **Ondansetron**:\n",
      "   - Mechanism of Action: Ondansetron works by blocking serotonin receptors in the gastrointestinal tract and the central nervous system, which helps to prevent nausea and vomiting.\n",
      "   - Common Uses: It is often used in patients undergoing chemotherapy, radiation therapy, or surgery.\n",
      "\n",
      "2. **Tramadol**:\n",
      "   - Mechanism of Action: Tramadol is a centrally acting analgesic that works by binding to mu-opioid receptors and inhibiting the reuptake of norepinephrine and serotonin, which contributes to its pain-relieving effects.\n",
      "   - Common Uses: It is used to treat moderate to moderately severe pain.\n",
      "\n",
      "### Step 2: Potential Interactions\n",
      "\n",
      "1. **Serotonin Syndrome**:\n",
      "   - Both Ondansetron and Tramadol can influence serotonin levels in the body. Tramadol, in particular, increases serotonin levels by inhibiting its reuptake. When combined with Ondansetron, which also affects serotonin pathways, there is a theoretical risk of serotonin syndrome, a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, seizures or coma.\n",
      "\n",
      "2. **Enhanced Analgesic Effect**:\n",
      "   - The combination of Ondansetron and Tramadol may provide enhanced relief from nausea and pain, respectively. Ondansetron can help manage nausea that may be induced by Tramadol, allowing for better tolerance of pain management.\n",
      "\n",
      "3. **Side Effects**:\n",
      "   - The combination may also lead to an increased risk of side effects associated with both medications. For instance, Tramadol can cause dizziness, sedation, and gastrointestinal disturbances, while Ondansetron can lead to headaches, constipation, and dizziness. The combination may exacerbate these effects in some patients.\n",
      "\n",
      "### Step 3: Clinical Considerations\n",
      "\n",
      "1. **Patient Monitoring**:\n",
      "   - When these medications are used together, it is important for healthcare providers to monitor patients closely for signs of serotonin syndrome, especially if the patient is on other serotonergic medications.\n",
      "\n",
      "2. **Dosage Adjustments**:\n",
      "   - Depending on the patient's overall health, other medications, and specific circumstances, healthcare providers may need to adjust dosages or consider alternative therapies to minimize risks.\n",
      "\n",
      "3. **Patient Education**:\n",
      "   - Patients should be informed about the potential side effects and symptoms of serotonin syndrome, as well as the importance of reporting any unusual symptoms to their healthcare provider.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the administration of Ondansetron with Tramadol may lead to enhanced therapeutic effects in managing nausea and pain, but it also carries the risk of serotonin syndrome and increased side effects. Careful monitoring, patient education, and potential dosage adjustments are essential to ensure safe and effective use of these medications together. Always consult with a healthcare professional before making any changes to medication regimens.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.043113\n",
      "prediction:  When Ondansetron, a 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting, is administered with Tramadol, an opioid analgesic, there are several potential effects and interactions to consider.\n",
      "\n",
      "1. **Serotonin Syndrome Risk**: One of the primary concerns when combining Ondansetron and Tramadol is the potential for serotonin syndrome. Tramadol has a dual mechanism of action; it not only acts as an opioid but also inhibits the reuptake of serotonin and norepinephrine. Ondansetron, while primarily a serotonin antagonist, can influence serotonin levels as well. If both medications are used together, especially in higher doses or in patients with other risk factors (such as concurrent use of other serotonergic drugs), there is a risk of serotonin syndrome, a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, dilated pupils, muscle rigidity, and in severe cases, seizures or coma.\n",
      "\n",
      "2. **Enhanced Analgesic Effect**: On the other hand, the combination of Ondansetron and Tramadol may provide enhanced analgesic effects in some patients. Ondansetron can help manage nausea and vomiting that may occur as side effects of Tramadol, allowing for better tolerance of the opioid and potentially improving pain management outcomes.\n",
      "\n",
      "3. **Side Effects Management**: Ondansetron may help mitigate some of the gastrointestinal side effects associated with Tramadol, such as nausea and vomiting. This can be particularly beneficial in patients who are sensitive to these side effects or in those who are receiving Tramadol for postoperative pain management.\n",
      "\n",
      "4. **Individual Variability**: The effects of combining these medications can vary significantly between individuals based on factors such as genetic differences in drug metabolism, existing medical conditions, and concurrent medications. Some patients may tolerate the combination well, while others may experience adverse effects.\n",
      "\n",
      "5. **Monitoring and Caution**: When prescribing this combination, healthcare providers should monitor patients closely for any signs of serotonin syndrome, especially during the initiation of therapy or when doses are adjusted. It is also important to assess the patient's overall medication regimen to avoid polypharmacy and potential drug interactions.\n",
      "\n",
      "In summary, while the combination of Ondansetron and Tramadol can be beneficial in managing pain and associated nausea, it is essential to be aware of the potential risks, particularly the risk of serotonin syndrome, and to monitor patients accordingly. Always consult with a healthcare professional before making any changes to medication regimens.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Ondansetron increases patient-controlled administration of Tramadol\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.029777\n",
      "prediction:  When a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (an oxycodone formulation), it is essential to monitor the patient closely for changes in pain control and potential side effects. Since RoxyBond, like other oxycodone medications, is metabolized by the CYP3A4 enzyme, stopping a CYP3A4 inhibitor can lead to increased oxycodone levels in the body, which may enhance its effects and potential for opioid-related side effects, particularly respiratory depression.\n",
      "\n",
      "1. **Monitor Oxycodone Dosage**: After the discontinuation of the CYP3A4 inhibitor, the dosage of RoxyBond may need to be adjusted. If the patient has been stabilized on a particular dose while the inhibitor was in effect, this should be reassessed. Due to the possibility of increased opioid effects, clinicians may consider reducing the dose or closely monitoring for signs of toxicity.\n",
      "\n",
      "2. **Assess for Side Effects**: There should be vigilant monitoring for any adverse side effects, especially signs of sedation or respiratory depression as these may become more pronounced.\n",
      "\n",
      "3. **Re-evaluate Pain Management Strategy**: Depending on the patientâ€™s pain control and any side effects experienced, it may be necessary to consider alternatives in pain management. This could include switching to a different opioid or non-opioid analgesics if tolerance or adverse effects become problematic.\n",
      "\n",
      "4. **Patient Education**: Inform the patient about the signs of increased opioid effects and encourage them to report any unusual symptoms immediately.\n",
      "\n",
      "5. **Follow-up**: Regular follow-up appointments should be scheduled to evaluate the patient's response to the change and make further adjustments to the pain management plan as needed.\n",
      "\n",
      "In summary, the recommended intervention includes close monitoring of the patient's response to the discontinuation of the CYP3A4 inhibitor and adjusting the RoxyBond dosage as necessary to ensure effective pain management while minimizing the risk of adverse effects.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020812\n",
      "prediction:  When a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (oxycodone), it is important to consider the implications for the patient's medication management and overall safety. RoxyBond is an immediate-release formulation of oxycodone, an opioid analgesic that is primarily metabolized by the CYP3A4 enzyme, among others.\n",
      "\n",
      "### Recommended Intervention Steps:\n",
      "\n",
      "1. **Assess the Patient's Current Condition**: Evaluate the patient's pain management needs and overall clinical status. Determine if the discontinuation of the CYP3A4 inhibitor has led to any changes in the patient's pain levels or side effects.\n",
      "\n",
      "2. **Monitor for Increased Oxycodone Levels**: With the cessation of the CYP3A4 inhibitor, the metabolism of oxycodone may increase, potentially leading to higher plasma levels of the drug. This can increase the risk of opioid-related side effects, including sedation, respiratory depression, and overdose. Close monitoring of the patient for signs of increased sedation or respiratory depression is essential.\n",
      "\n",
      "3. **Adjust Oxycodone Dosage**: Depending on the patient's response and the clinical judgment of the healthcare provider, it may be necessary to adjust the dosage of RoxyBond. If the patient was previously stabilized on a certain dose while on the CYP3A4 inhibitor, the dose may need to be reduced to avoid toxicity after the inhibitor is stopped.\n",
      "\n",
      "4. **Consider Alternative Pain Management Strategies**: If the patient experiences inadequate pain control or adverse effects after the discontinuation of the CYP3A4 inhibitor, consider alternative pain management strategies. This may include using non-opioid analgesics, adjuvant medications, or other opioid formulations that may have a different metabolic profile.\n",
      "\n",
      "5. **Educate the Patient**: Inform the patient about the potential changes in their medication regimen and the importance of reporting any new or worsening symptoms. Educate them on the signs of opioid overdose and the importance of adhering to prescribed dosages.\n",
      "\n",
      "6. **Follow-Up**: Schedule regular follow-up appointments to reassess the patient's pain management and adjust the treatment plan as necessary. Continuous evaluation is crucial to ensure the patient remains safe and effective pain control is achieved.\n",
      "\n",
      "7. **Consult with a Pharmacist or Specialist**: If there are uncertainties regarding the management of the patient's pain or the appropriate adjustments to the oxycodone regimen, consider consulting with a clinical pharmacist or a pain management specialist for further guidance.\n",
      "\n",
      "### Conclusion:\n",
      "\n",
      "Discontinuing a CYP3A4 inhibitor in a patient taking RoxyBond necessitates careful monitoring and potential dosage adjustments to ensure patient safety and effective pain management. A collaborative approach involving the patient, healthcare providers, and possibly specialists is essential to navigate the complexities of opioid therapy in the context of changing drug interactions.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021124\n",
      "prediction:  When a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (oxycodone), it is important to consider the pharmacokinetics and potential effects on the metabolism of oxycodone. RoxyBond is an immediate-release formulation of oxycodone, which is primarily metabolized by the liver enzyme CYP3A4, among others.\n",
      "\n",
      "### Recommended Intervention Steps:\n",
      "\n",
      "1. **Assess the Patient's Current Condition**: Evaluate the patient's pain management needs and overall clinical status. Determine if the discontinuation of the CYP3A4 inhibitor has led to any changes in the patient's pain control or if they are experiencing any withdrawal symptoms.\n",
      "\n",
      "2. **Monitor for Increased Oxycodone Levels**: With the cessation of a CYP3A4 inhibitor, the metabolism of oxycodone may increase, potentially leading to higher plasma levels of the drug. This can increase the risk of opioid-related side effects, including respiratory depression, sedation, and overdose.\n",
      "\n",
      "3. **Adjust Oxycodone Dosage**: If the patient was stabilized on a certain dose of RoxyBond while on the CYP3A4 inhibitor, it may be necessary to reassess and potentially reduce the oxycodone dosage after the inhibitor is stopped. This is particularly important if the patient has been on a high dose or has other risk factors for opioid sensitivity.\n",
      "\n",
      "4. **Implement Close Monitoring**: After discontinuation of the CYP3A4 inhibitor, closely monitor the patient for signs of opioid toxicity or inadequate pain control. This includes assessing vital signs, level of sedation, and pain levels.\n",
      "\n",
      "5. **Consider Alternative Pain Management Strategies**: If the patient experiences inadequate pain control or adverse effects from oxycodone after the CYP3A4 inhibitor is stopped, consider alternative analgesics or adjunctive therapies. Non-opioid analgesics, adjuvant medications (like gabapentin or pregabalin), or non-pharmacological interventions may be appropriate.\n",
      "\n",
      "6. **Educate the Patient**: Inform the patient about the potential changes in their medication regimen and the importance of reporting any new or worsening symptoms. They should be aware of the signs of opioid overdose and the need to seek immediate medical attention if they experience severe drowsiness, difficulty breathing, or confusion.\n",
      "\n",
      "7. **Consult with a Pharmacist or Specialist**: If there is uncertainty about the appropriate dosage adjustment or alternative therapies, consider consulting with a clinical pharmacist or pain management specialist for tailored recommendations.\n",
      "\n",
      "### Conclusion:\n",
      "\n",
      "Discontinuing a CYP3A4 inhibitor in a patient taking RoxyBond necessitates careful monitoring and potential dosage adjustments to ensure safe and effective pain management. The goal is to maintain adequate pain control while minimizing the risk of adverse effects associated with increased oxycodone levels. Regular follow-up and patient education are crucial components of this process.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021269\n",
      "prediction:  When a CYP3A4 inhibitor is discontinued in a patient taking RoxyBond (oxycodone), it is important to consider the pharmacokinetics of oxycodone and the potential for increased drug metabolism. RoxyBond is an immediate-release formulation of oxycodone, an opioid analgesic that is primarily metabolized by the liver enzyme CYP3A4, among others.\n",
      "\n",
      "### Recommended Intervention Steps:\n",
      "\n",
      "1. **Assess the Patient's Pain Management Needs**: Evaluate the patient's current pain level and overall clinical status. This assessment will help determine if the current dose of RoxyBond is still appropriate or if adjustments are needed.\n",
      "\n",
      "2. **Monitor for Changes in Efficacy**: After the discontinuation of the CYP3A4 inhibitor, the metabolism of oxycodone may increase, potentially leading to reduced plasma levels of the drug. This could result in decreased analgesic efficacy. Close monitoring for signs of inadequate pain control is essential.\n",
      "\n",
      "3. **Consider Dose Adjustment**: If the patient experiences inadequate pain relief after the CYP3A4 inhibitor is stopped, it may be necessary to adjust the dose of RoxyBond. This adjustment should be done cautiously, taking into account the patient's previous response to the medication and any other medications they may be taking.\n",
      "\n",
      "4. **Educate the Patient**: Inform the patient about the potential changes in their pain management regimen. They should be advised to report any changes in pain levels or side effects promptly.\n",
      "\n",
      "5. **Consult with a Pharmacist or Specialist**: If there are concerns about managing the patient's pain or if the patient is on multiple medications, consulting with a clinical pharmacist or pain management specialist can provide additional insights and recommendations.\n",
      "\n",
      "6. **Consider Alternative Pain Management Strategies**: If adjusting the dose of RoxyBond is not effective or appropriate, consider alternative pain management strategies. This may include non-opioid analgesics, adjuvant medications, or non-pharmacological interventions.\n",
      "\n",
      "7. **Follow-Up**: Schedule a follow-up appointment to reassess the patient's pain control and overall treatment plan. Continuous evaluation is crucial to ensure effective pain management and to make any necessary adjustments.\n",
      "\n",
      "### Conclusion:\n",
      "\n",
      "Discontinuing a CYP3A4 inhibitor in a patient taking RoxyBond requires careful monitoring and potential dose adjustments to maintain effective pain control. The healthcare provider should take a comprehensive approach, considering the patient's individual needs and response to treatment, while also ensuring safety and efficacy in pain management.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021719\n",
      "prediction:  When a patient is taking NURTEC ODT (rimegepant), a medication primarily used for the acute treatment of migraine, and their blood pressure remains inadequately controlled, several factors should be considered to address the situation effectively. Here are the key considerations:\n",
      "\n",
      "### 1. **Medication Review:**\n",
      "   - **Assess NURTEC ODT's Side Effects:** While NURTEC ODT is not commonly associated with hypertension, it is essential to review the patient's overall medication regimen. Some medications can cause elevated blood pressure as a side effect.\n",
      "   - **Evaluate Other Medications:** Look for other medications the patient may be taking that could contribute to hypertension, such as NSAIDs, certain antidepressants, or stimulants.\n",
      "\n",
      "### 2. **Patient History:**\n",
      "   - **Medical History:** Review the patient's history of hypertension and any previous treatments. Consider whether the patient has a history of secondary hypertension due to conditions like renal disease, endocrine disorders, or sleep apnea.\n",
      "   - **Lifestyle Factors:** Assess lifestyle factors that may contribute to hypertension, including diet (high sodium intake), physical activity level, alcohol consumption, and smoking.\n",
      "\n",
      "### 3. **Blood Pressure Monitoring:**\n",
      "   - **Regular Monitoring:** Ensure that blood pressure is being monitored regularly to identify patterns and determine if the readings are consistently high or if there are specific triggers.\n",
      "   - **Home Monitoring:** Encourage the patient to monitor their blood pressure at home to provide more data on their blood pressure control.\n",
      "\n",
      "### 4. **Lifestyle Modifications:**\n",
      "   - **Dietary Changes:** Recommend a heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) diet, which emphasizes fruits, vegetables, whole grains, and low-fat dairy while reducing sodium intake.\n",
      "   - **Physical Activity:** Encourage regular physical activity, which can help lower blood pressure and improve overall cardiovascular health.\n",
      "   - **Weight Management:** If the patient is overweight or obese, discuss strategies for weight loss, as this can significantly impact blood pressure control.\n",
      "\n",
      "### 5. **Assessment of Comorbid Conditions:**\n",
      "   - **Evaluate for Comorbidities:** Conditions such as diabetes, hyperlipidemia, or chronic kidney disease can complicate blood pressure management. Addressing these conditions may help improve blood pressure control.\n",
      "   - **Mental Health Considerations:** Stress and anxiety can contribute to elevated blood pressure. Consider referring the patient for counseling or stress management techniques if applicable.\n",
      "\n",
      "### 6. **Pharmacological Adjustments:**\n",
      "   - **Antihypertensive Therapy:** If blood pressure remains uncontrolled, it may be necessary to adjust the antihypertensive regimen. This could involve increasing the dose of current medications or adding new agents, such as diuretics, ACE inhibitors, ARBs, calcium channel blockers, or beta-blockers.\n",
      "   - **Consultation with a Specialist:** If blood pressure remains difficult to control, consider referring the patient to a cardiologist or a hypertension specialist for further evaluation and management.\n",
      "\n",
      "### 7. **Patient Education:**\n",
      "   - **Educate on Hypertension:** Ensure the patient understands the importance of blood pressure control and the potential risks associated with uncontrolled hypertension, such as cardiovascular disease and stroke.\n",
      "   - **Medication Adherence:** Discuss the importance of adhering to prescribed medications and lifestyle changes, and address any barriers the patient may face in following their treatment plan.\n",
      "\n",
      "### 8. **Follow-Up:**\n",
      "   - **Regular Follow-Up Appointments:** Schedule regular follow-up appointments to monitor blood pressure and assess the effectiveness of any changes made to the treatment plan.\n",
      "   - **Adjustments as Needed:** Be prepared to make further adjustments based on the patient's response to treatment and any new developments in their health status.\n",
      "\n",
      "In summary, managing a patient with inadequately controlled blood pressure while on NURTEC ODT requires a comprehensive approach that includes medication review, lifestyle modifications, assessment of comorbid conditions, potential pharmacological adjustments, patient education, and regular follow-up. Each patient's situation is unique, and a tailored approach is essential for effective management.\n",
      "pred_SIM:  B\n",
      "choice:  D\n",
      "correct_answer:  B\n",
      "correct answer: Discontinuing NURTEC ODT if no alternative etiology is found\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.062376\n",
      "prediction:  When administering Dopamine to a patient who has been treated with MAO (Monoamine Oxidase) inhibitors within the past two to three weeks, it is crucial to adjust the dosage carefully due to the potential for hypertensive crises. MAO inhibitors can lead to an accumulation of catecholamines, such as dopamine, norepinephrine, and epinephrine, because these enzymes are responsible for their metabolism. \n",
      "\n",
      "**Dosage Adjustment Considerations:**\n",
      "1. **Starting Doses**: In patients with a history of MAO inhibitor use, it is generally recommended to start with a lower dose of Dopamine than would typically be used in patients not on these medications. This helps to mitigate the risk of excessive catecholamine effects.\n",
      "   \n",
      "2. **Monitoring**: Close monitoring of blood pressure and heart rate is essential. In patients with previous MAO inhibitor use, even lower doses of Dopamine may lead to significant elevations in blood pressure.\n",
      "\n",
      "3. **Incremental Dosing**: If the response is insufficient, the dosage of Dopamine can be gradually increased, but this should be done cautiously and while monitoring the patient for adverse effects.\n",
      "\n",
      "4. **Consultation with Specialists**: In complex cases, involvement of a cardiologist or clinical pharmacologist may be beneficial to optimize therapy.\n",
      "\n",
      "It remains crucial to consult updated clinical guidelines or literature specific to individual patient scenarios, as recommendations may evolve with new research findings.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Reduce the dosage to no greater than one-tenth of the recommended dose.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.06892\n",
      "prediction:  When administering Verkazia (cyclosporine ophthalmic emulsion), it is important to follow the correct sequence if using other eye drops or ointments to ensure the effectiveness of both treatments. The recommended protocol is as follows:\n",
      "\n",
      "1. **Administer Other Eye Drops First**: If you are using multiple eye drops, you should first apply non-preserved topical eye drops. This helps avoid contamination and potential interactions.\n",
      "\n",
      "2. **Wait a Specific Time**: After applying the first eye drop, wait approximately 5-10 minutes before proceeding to the next eye drop. This allows sufficient time for the first medication to be absorbed into the eye before the next drop is applied.\n",
      "\n",
      "3. **Administer Verkazia**: Once the appropriate time has elapsed, you can then administer Verkazia. This step is crucial as Verkazia may require its own absorption time to be effective.\n",
      "\n",
      "4. **Ointments Last**: If you are also using an ophthalmic ointment, it should be the last to be applied. Ointments can create a barrier that prevents the proper absorption of preceding drops, so they should be applied after all other drops have been used.\n",
      "\n",
      "5. **Final Pause**: After applying Verkazia, itâ€™s advisable to avoid other eye medications for several minutes to maximize absorption and effectiveness.\n",
      "\n",
      "Ensuring this sequence is followed will help maintain the integrity and desired therapeutic effects of both Verkazia and any other ophthalmic medications being used.\n",
      "pred_SIM:  C\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Use Verkazia 10 minutes before other eye drops or ointments\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010119\n",
      "prediction:  When children and adolescents are prescribed venlafaxine, an antidepressant belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class, several important factors should be monitored closely due to the potential risks and side effects associated with its use. Here are the key aspects to consider:\n",
      "\n",
      "1. **Mental Health Symptoms**: Regular assessment of the child's or adolescent's mental health status is crucial. This includes monitoring for any worsening of depression, emergence of suicidal thoughts or behaviors, and any changes in mood or behavior. The FDA has issued warnings about the increased risk of suicidal ideation and behavior in children and adolescents taking antidepressants, including venlafaxine.\n",
      "\n",
      "2. **Side Effects**: Common side effects of venlafaxine include nausea, headache, dizziness, dry mouth, and increased sweating. Monitoring for these side effects is important, especially during the initial weeks of treatment or when doses are adjusted. Parents and caregivers should be educated about these potential side effects and encouraged to report any that are severe or persistent.\n",
      "\n",
      "3. **Blood Pressure**: Venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Regular monitoring of blood pressure is recommended, especially in adolescents who may already have risk factors for hypertension or those taking higher doses of the medication.\n",
      "\n",
      "4. **Weight and Growth**: Monitoring weight and growth is important, particularly in younger children and adolescents, as changes in appetite and weight can occur with venlafaxine use. Any significant weight gain or loss should be addressed with the healthcare provider.\n",
      "\n",
      "5. **Withdrawal Symptoms**: Venlafaxine has a relatively short half-life, and abrupt discontinuation can lead to withdrawal symptoms such as dizziness, irritability, and flu-like symptoms. It is important to monitor for these symptoms if the medication is being tapered or discontinued.\n",
      "\n",
      "6. **Drug Interactions**: Monitoring for potential drug interactions is essential, especially if the child or adolescent is taking other medications. Venlafaxine can interact with other antidepressants, certain pain medications, and medications that affect liver enzymes.\n",
      "\n",
      "7. **Adherence to Treatment**: Ensuring that the child or adolescent is adhering to the prescribed treatment regimen is important for the effectiveness of the medication. Regular follow-up appointments can help assess adherence and make any necessary adjustments to the treatment plan.\n",
      "\n",
      "8. **Family History and Personal History**: It is important to consider the family and personal history of mental health disorders, as this can influence the treatment approach and monitoring strategies. \n",
      "\n",
      "9. **Therapeutic Response**: Regular follow-up appointments should include assessments of the therapeutic response to venlafaxine. This includes evaluating improvements in mood, functioning, and overall quality of life.\n",
      "\n",
      "In summary, monitoring children and adolescents on venlafaxine involves a comprehensive approach that includes assessing mental health symptoms, side effects, blood pressure, weight and growth, adherence to treatment, and overall therapeutic response. Close communication between healthcare providers, patients, and families is essential to ensure safe and effective treatment.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.010589\n",
      "prediction:  When children and adolescents are prescribed venlafaxine, an antidepressant belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class, several important factors should be monitored closely due to the potential risks and side effects associated with its use. Here are the key aspects to consider:\n",
      "\n",
      "1. **Mental Health Symptoms**: Regular assessment of the child's or adolescent's mental health status is crucial. This includes monitoring for any worsening of depression, emergence of suicidal thoughts, or behaviors. The FDA has issued a black box warning regarding the increased risk of suicidal ideation and behavior in children and adolescents taking antidepressants, including venlafaxine.\n",
      "\n",
      "2. **Side Effects**: Common side effects of venlafaxine can include nausea, dizziness, dry mouth, insomnia, and increased blood pressure. Parents and caregivers should be vigilant for these side effects and report any significant changes to the healthcare provider.\n",
      "\n",
      "3. **Blood Pressure Monitoring**: Venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Regular monitoring of blood pressure is recommended, especially in children and adolescents with pre-existing hypertension or those on other medications that may affect blood pressure.\n",
      "\n",
      "4. **Weight and Growth**: Monitoring weight and growth is important, as changes in appetite and weight can occur with venlafaxine use. This is particularly relevant in children and adolescents, as they are still in critical stages of physical development.\n",
      "\n",
      "5. **Withdrawal Symptoms**: If discontinuation of venlafaxine is necessary, it should be done gradually to minimize withdrawal symptoms, which can include irritability, nausea, dizziness, and flu-like symptoms. Monitoring for these symptoms during tapering is essential.\n",
      "\n",
      "6. **Drug Interactions**: It is important to monitor for potential drug interactions, especially if the child or adolescent is taking other medications. Venlafaxine can interact with other antidepressants, certain pain medications, and medications that affect serotonin levels, increasing the risk of serotonin syndrome.\n",
      "\n",
      "7. **Behavioral Changes**: Parents and caregivers should be alert for any unusual changes in behavior, such as increased agitation, aggression, or mood swings, which may indicate a need for reevaluation of the treatment plan.\n",
      "\n",
      "8. **Adherence to Treatment**: Monitoring adherence to the prescribed treatment regimen is important to ensure the effectiveness of the medication. This includes checking if the child is taking the medication as directed and discussing any barriers to adherence.\n",
      "\n",
      "9. **Follow-Up Appointments**: Regular follow-up appointments with the prescribing healthcare provider are essential to assess the effectiveness of the treatment, make necessary adjustments, and provide support to the patient and their family.\n",
      "\n",
      "In summary, careful monitoring of mental health symptoms, side effects, blood pressure, weight, growth, and overall behavior is essential for children and adolescents taking venlafaxine. Open communication between healthcare providers, patients, and their families is crucial to ensure safe and effective treatment.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.00981\n",
      "prediction:  When children and adolescents are prescribed venlafaxine, an antidepressant belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class, several important factors should be monitored closely due to the potential risks and side effects associated with its use. Here are the key aspects to consider:\n",
      "\n",
      "1. **Mental Health Symptoms**: Regular assessment of the child's or adolescent's mental health status is crucial. This includes monitoring for any worsening of depression, emergence of suicidal thoughts, or behaviors. The FDA has issued a black box warning regarding the increased risk of suicidal ideation and behavior in children and adolescents taking antidepressants, including venlafaxine.\n",
      "\n",
      "2. **Side Effects**: Common side effects of venlafaxine can include nausea, headache, dizziness, insomnia, dry mouth, and increased sweating. Monitoring for these side effects is important, especially during the initial weeks of treatment or when doses are adjusted.\n",
      "\n",
      "3. **Blood Pressure**: Venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Regular monitoring of blood pressure is recommended, especially in children and adolescents with pre-existing hypertension or those at risk for cardiovascular issues.\n",
      "\n",
      "4. **Weight and Growth**: Monitoring weight and growth is important, as some children and adolescents may experience changes in appetite or weight gain/loss while on venlafaxine. This is particularly relevant during periods of growth and development.\n",
      "\n",
      "5. **Withdrawal Symptoms**: If discontinuation of venlafaxine is necessary, it should be done gradually to minimize withdrawal symptoms, which can include irritability, nausea, dizziness, and flu-like symptoms. Monitoring for these symptoms during tapering is essential.\n",
      "\n",
      "6. **Drug Interactions**: It is important to monitor for potential drug interactions, especially if the child or adolescent is taking other medications. Venlafaxine can interact with other antidepressants, certain pain medications, and medications that affect liver enzymes.\n",
      "\n",
      "7. **Behavioral Changes**: Parents and caregivers should be vigilant for any changes in behavior, including increased agitation, irritability, or unusual mood swings. These changes may indicate a need for reevaluation of the treatment plan.\n",
      "\n",
      "8. **Compliance with Treatment**: Monitoring adherence to the prescribed treatment regimen is important to ensure the effectiveness of the medication. This includes checking if the patient is taking the medication as directed and attending follow-up appointments.\n",
      "\n",
      "9. **Therapeutic Response**: Regular follow-up appointments should be scheduled to assess the therapeutic response to venlafaxine. This includes evaluating improvements in mood, anxiety levels, and overall functioning.\n",
      "\n",
      "10. **Family History and Personal History**: Consideration of any family history of mood disorders or suicidality, as well as the individualâ€™s personal history, can guide monitoring and intervention strategies.\n",
      "\n",
      "In summary, careful monitoring of mental health symptoms, side effects, blood pressure, weight, and overall behavior is essential for children and adolescents taking venlafaxine. Regular follow-up with healthcare providers is crucial to ensure the safety and effectiveness of the treatment. Parents and caregivers should be educated about the signs of potential side effects and the importance of open communication with healthcare professionals.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.012943\n",
      "prediction:  When children and adolescents are prescribed venlafaxine, several key monitoring parameters should be closely observed due to the potential side effects and risks associated with its use, particularly in this age group. Here are the main considerations:\n",
      "\n",
      "1. **Suicidal Thoughts and Behaviors**: It is crucial to monitor for any emergence or worsening of suicidal thoughts or behaviors, especially during the initial treatment phase, after dosage adjustments, or following an increase in symptoms of depression or anxiety. The risk of suicide is particularly noted in children and adolescents taking antidepressants.\n",
      "\n",
      "2. **Side Effects**: Common side effects of venlafaxine include nausea, headache, dry mouth, dizziness, and increased sweating. Monitoring for these side effects is essential to determine if the medication is tolerated. Additionally, children may experience more unique or pronounced side effects than adults, necessitating careful observation.\n",
      "\n",
      "3. **Blood Pressure**: Venlafaxine is known to potentially cause dose-dependent increases in blood pressure. Regular monitoring should be conducted, particularly at higher doses.\n",
      "\n",
      "4. **Weight and Growth**: As with any psychotropic medication, itâ€™s important to monitor the child's overall health, including weight changes and growth patterns, as medications can impact metabolism and appetite.\n",
      "\n",
      "5. **Mood and Behavior Changes**: Regular assessments should be conducted to evaluate the effectiveness of the therapy, observe for any changes in mood that may suggest a need for therapy adjustment, and to evaluate for any emerging manic symptoms in those with a history of mood disorders.\n",
      "\n",
      "6. **Withdrawal Symptoms**: If venlafaxine needs to be discontinued, it should be done gradually due to the potential for withdrawal symptoms such as dizziness, irritability, or rebound depression.\n",
      "\n",
      "7. **Neurodevelopmental Side Effects**: Awareness of potential neurological side effects is necessary, including increased alertness and activation, which can lead to anxiety or other behavioral changes.\n",
      "\n",
      "Research and clinical trials have highlighted these considerations, indicating the importance of comprehensive monitoring strategies for young patients on venlafaxine. Continuous communication between healthcare providers, the patient, and caregivers is essential to ensure the safety and efficacy of treatment. \n",
      "\n",
      "For further information, studies such as [NCT00238719](https://clinicaltrials.gov/ct2/show/NCT00238719) explore venlafaxine's effects in pediatric populations, offering insights into the monitoring and management of therapy in these patients.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.0832\n",
      "prediction:  When co-administered with strong CYP3A inhibitors, the recommended dosage adjustment for JAYPIRCA (pirtobrutinib) involves interrupting treatment for the duration of the strong CYP3A inhibitor use. This means that if a patient is currently taking JAYPIRCA at the common dosage of 50 mg once daily, they should not take it while using a strong CYP3A inhibitor. \n",
      "\n",
      "For additional details on JAYPIRCA, you can visit various resources such as the [FDA approval announcement](https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jaypircaTM-pirtobrutinib-first-and-only-non).\n",
      "pred_SIM:  D\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  B\n",
      "correct answer: Reduce the dose by 50 mg\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.025609\n",
      "prediction:  When considering the management of women with uncontrolled dyslipidemia who are prescribed Tri Femynor (a combination oral contraceptive containing ethinyl estradiol and norethindrone), several factors must be taken into account. Hereâ€™s a step-by-step breakdown:\n",
      "\n",
      "### 1. **Understanding Dyslipidemia**\n",
      "   - **Definition**: Dyslipidemia refers to abnormal levels of lipids in the blood, which can include high levels of LDL cholesterol, low levels of HDL cholesterol, and elevated triglycerides.\n",
      "   - **Risks**: Uncontrolled dyslipidemia increases the risk of cardiovascular diseases, including heart attack and stroke.\n",
      "\n",
      "### 2. **Assessing the Patient's Health Status**\n",
      "   - **Medical History**: Review the patient's complete medical history, including any history of cardiovascular disease, hypertension, diabetes, or metabolic syndrome.\n",
      "   - **Current Medications**: Evaluate all medications the patient is currently taking, including any lipid-lowering agents (e.g., statins, fibrates) and other medications that may interact with Tri Femynor.\n",
      "\n",
      "### 3. **Evaluating the Impact of Hormonal Contraceptives**\n",
      "   - **Estrogen and Lipid Levels**: Estrogen-containing contraceptives can affect lipid metabolism. They may increase triglyceride levels and potentially impact HDL and LDL cholesterol levels.\n",
      "   - **Risk of Thrombosis**: Women with dyslipidemia may have an increased risk of thromboembolic events when using estrogen-containing contraceptives.\n",
      "\n",
      "### 4. **Monitoring Lipid Levels**\n",
      "   - **Baseline Assessment**: Obtain baseline lipid profiles before starting Tri Femynor to understand the patient's lipid status.\n",
      "   - **Regular Follow-Up**: Schedule regular follow-up appointments to monitor lipid levels after initiating the contraceptive. This is crucial to assess any changes in lipid profiles and adjust treatment as necessary.\n",
      "\n",
      "### 5. **Counseling on Lifestyle Modifications**\n",
      "   - **Diet and Exercise**: Encourage the patient to adopt a heart-healthy diet (e.g., low in saturated fats, trans fats, and cholesterol) and to engage in regular physical activity, which can help manage dyslipidemia.\n",
      "   - **Weight Management**: Discuss the importance of maintaining a healthy weight, as obesity can exacerbate dyslipidemia.\n",
      "\n",
      "### 6. **Considering Alternative Contraceptive Options**\n",
      "   - **Non-Estrogen Options**: If the risks associated with Tri Femynor are deemed too high, consider non-estrogen contraceptive options, such as progestin-only pills, intrauterine devices (IUDs), or barrier methods.\n",
      "   - **Individualized Approach**: Tailor contraceptive choices based on the patient's overall health, preferences, and the severity of dyslipidemia.\n",
      "\n",
      "### 7. **Collaboration with Healthcare Providers**\n",
      "   - **Multidisciplinary Approach**: Collaborate with other healthcare providers, such as cardiologists or endocrinologists, to manage the patient's dyslipidemia effectively while considering contraceptive needs.\n",
      "   - **Patient Education**: Educate the patient about the importance of managing both dyslipidemia and reproductive health, and ensure they understand the potential risks and benefits of the prescribed contraceptive.\n",
      "\n",
      "### 8. **Follow-Up and Reassessment**\n",
      "   - **Regular Check-Ups**: Schedule regular follow-up visits to reassess the patient's lipid levels, overall health, and the effectiveness of the contraceptive method.\n",
      "   - **Adjustments as Needed**: Be prepared to make adjustments to the contraceptive method or dyslipidemia management plan based on the patient's response and any side effects experienced.\n",
      "\n",
      "### Conclusion\n",
      "In summary, when prescribing Tri Femynor to women with uncontrolled dyslipidemia, it is essential to conduct a thorough assessment of their health status, monitor lipid levels closely, consider lifestyle modifications, and evaluate alternative contraceptive options if necessary. A collaborative and individualized approach will help ensure the safety and well-being of the patient while effectively managing both dyslipidemia and reproductive health.\n",
      "pred_SIM:  D\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Switch to an alternative contraceptive method.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.005885\n",
      "prediction:  When considering the transition from venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), to a monoamine oxidase inhibitor (MAOI), it is crucial to account for the potential risk of serotonin syndrome, a potentially life-threatening condition that can occur when serotonergic medications are combined.\n",
      "\n",
      "### Step 1: Understanding Venlafaxine's Half-Life\n",
      "Venlafaxine has a relatively short half-life, typically ranging from 5 to 11 hours for the immediate-release formulation and about 11 hours for the extended-release formulation. However, its active metabolite, O-desmethylvenlafaxine (desvenlafaxine), has a longer half-life of approximately 9 hours.\n",
      "\n",
      "### Step 2: Determining the Washout Period\n",
      "To minimize the risk of serotonin syndrome, it is generally recommended to allow a sufficient washout period after discontinuing venlafaxine before starting an MAOI. The washout period is the time required for the drug and its metabolites to be eliminated from the body.\n",
      "\n",
      "### Step 3: Recommended Washout Period\n",
      "The consensus among clinical guidelines and pharmacological references suggests that a washout period of **at least 14 days** should elapse after stopping venlafaxine before initiating treatment with an MAOI. This duration allows for the clearance of venlafaxine and its active metabolites, reducing the risk of adverse interactions.\n",
      "\n",
      "### Step 4: Clinical Considerations\n",
      "- **Patient-Specific Factors**: Individual patient factors, such as renal function, overall health, and the specific formulation of venlafaxine used, may influence the exact duration needed for a safe transition.\n",
      "- **Monitoring**: During the washout period, patients should be monitored for withdrawal symptoms from venlafaxine, which can include dizziness, irritability, and flu-like symptoms. If these symptoms are significant, they may need to be managed before transitioning to an MAOI.\n",
      "- **Consultation with Specialists**: It is advisable for healthcare providers to consult with a psychiatrist or a clinical pharmacologist when making such transitions, especially in complex cases.\n",
      "\n",
      "### Conclusion\n",
      "In summary, a minimum of **14 days** should elapse after stopping venlafaxine before starting an MAOI to ensure safety and minimize the risk of serotonin syndrome. Always consider individual patient circumstances and consult with healthcare professionals for tailored advice.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.070601\n",
      "prediction:  When considering the use of Junel 21 Day oral contraceptives, a breastfeeding mother should take into account several important factors:\n",
      "\n",
      "1. **Hormonal Composition**: Junel 21 is a combined oral contraceptive that contains both estrogen and progestin. Estrogen can potentially affect milk production, especially in the early months postpartum when breastfeeding is being established.\n",
      "\n",
      "2. **Timing**: Itâ€™s usually recommended to wait until breastfeeding is well established (often around six weeks postpartum) before starting hormonal contraceptives that contain estrogen. This timing helps to minimize any potential negative impact on milk supply.\n",
      "\n",
      "3. **Milk Supply**: Some studies suggest that estrogen-containing contraceptives may decrease milk supply in some women. Mothers should monitor their milk production and consult with a healthcare provider if they notice a decrease.\n",
      "\n",
      "4. **Alternatives**: There are progestin-only pills (POPs) available, which are often recommended for breastfeeding mothers as they tend to have a lesser effect on milk supply compared to combined oral contraceptives like Junel.\n",
      "\n",
      "5. **Consult Healthcare Providers**: It is crucial for breastfeeding mothers to discuss all contraceptive options with healthcare providers who can take individual health circumstances into account and recommend what is safest and most effective based on personal health history.\n",
      "\n",
      "6. **Potential Side Effects**: Like all medications, Junel 21 may have side effects. Mothers should educate themselves on these side effects and discuss them with their healthcare provider, especially in relation to breastfeeding.\n",
      "\n",
      "By considering these factors, breastfeeding mothers can make informed decisions about their contraceptive options while ensuring they are caring for their own health and their babyâ€™s nutritional needs.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Junel 21 Day oral contraceptives may decrease milk quantity and quality.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015453\n",
      "prediction:  When determining the appropriate dosage of nicotine lozenges for a smoker who smokes their first cigarette within 30 minutes of waking up, several factors need to be considered. Hereâ€™s a step-by-step breakdown:\n",
      "\n",
      "### Step 1: Understanding Nicotine Dependence\n",
      "Smokers who smoke their first cigarette within 30 minutes of waking are typically classified as having a higher level of nicotine dependence. This is an important factor in determining the appropriate dosage of nicotine replacement therapy (NRT), such as nicotine lozenges.\n",
      "\n",
      "### Step 2: Dosage Options for Nicotine Lozenges\n",
      "Nicotine lozenges are available in different strengths, commonly 2 mg and 4 mg. The choice between these dosages is influenced by the smoker's level of dependence:\n",
      "\n",
      "- **2 mg lozenge**: Generally recommended for smokers who smoke their first cigarette more than 30 minutes after waking.\n",
      "- **4 mg lozenge**: Recommended for smokers who smoke their first cigarette within 30 minutes of waking, as they are likely to have a higher nicotine dependence.\n",
      "\n",
      "### Step 3: Recommended Dosage for High Dependence\n",
      "Given that the individual in question smokes their first cigarette within 30 minutes of waking, the recommendation would be to use the **4 mg nicotine lozenge**. This higher dosage is intended to better match the nicotine cravings and withdrawal symptoms experienced by someone with a higher level of dependence.\n",
      "\n",
      "### Step 4: Usage Guidelines\n",
      "- **Frequency**: The lozenge should be used as needed to manage cravings, but it is important not to exceed the maximum recommended daily dosage. For most brands, this is typically around 20 lozenges per day.\n",
      "- **Administration**: The lozenge should be placed in the mouth and allowed to dissolve slowly, which can take about 20-30 minutes. It should not be chewed or swallowed.\n",
      "- **Duration of Use**: Nicotine lozenges are usually recommended for a period of 12 weeks, with a gradual tapering off of use as the individual reduces their dependence on nicotine.\n",
      "\n",
      "### Step 5: Additional Considerations\n",
      "- **Consultation with Healthcare Provider**: It is advisable for the individual to consult with a healthcare provider for personalized advice, especially if they have any underlying health conditions or are taking other medications.\n",
      "- **Behavioral Support**: Combining nicotine replacement therapy with behavioral support can significantly increase the chances of successfully quitting smoking.\n",
      "\n",
      "### Conclusion\n",
      "For a smoker who smokes their first cigarette within 30 minutes of waking up, the appropriate dosage of nicotine lozenges would be **4 mg**. This dosage is designed to help manage cravings effectively and support the individual in their efforts to quit smoking.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  C\n",
      "correct answer: 4 mg Nicotine lozenge\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.020588\n",
      "prediction:  When discussing the recommended dosage of laxatives for children aged 6 to under 12 years, it is important to clarify that laxatives are not typically categorized by gender, and the term \"laxative for women\" may refer to a specific product that is marketed towards women but can also be used by children under certain circumstances. \n",
      "\n",
      "However, the appropriate dosage of any laxative for children should be determined based on the specific type of laxative being used, the child's weight, age, and overall health condition. Here are some general guidelines for common types of laxatives:\n",
      "\n",
      "1. **Osmotic Laxatives (e.g., polyethylene glycol, lactulose)**:\n",
      "   - For children aged 6 to under 12 years, the typical dosage of polyethylene glycol (e.g., MiraLAX) is usually around 17 grams (about one capful) mixed in 4 to 8 ounces of liquid once daily. \n",
      "   - Lactulose may be dosed at 15 to 30 mL once daily, but it is essential to follow the specific product instructions or a healthcare provider's recommendations.\n",
      "\n",
      "2. **Stimulant Laxatives (e.g., bisacodyl, senna)**:\n",
      "   - Bisacodyl (Dulcolax) is generally not recommended for children under 6 years without medical advice. For children aged 6 to under 12 years, the typical dosage is 5 to 10 mg orally once daily.\n",
      "   - Senna (e.g., Senokot) can be given at a dose of 8.6 to 17.2 mg (1 to 2 tablets) once daily for children in this age group.\n",
      "\n",
      "3. **Bulk-forming Laxatives (e.g., psyllium, methylcellulose)**:\n",
      "   - For children aged 6 to under 12 years, the dosage of psyllium (e.g., Metamucil) is usually around 1 teaspoon mixed with at least 8 ounces of water, taken 1 to 3 times daily.\n",
      "\n",
      "### Important Considerations:\n",
      "- **Consult a Healthcare Provider**: Before administering any laxative to a child, it is crucial to consult a pediatrician or healthcare provider. They can provide personalized recommendations based on the child's specific health needs and circumstances.\n",
      "- **Hydration**: Ensure that the child is adequately hydrated, as laxatives can lead to dehydration if not taken with sufficient fluids.\n",
      "- **Underlying Conditions**: If a child is experiencing chronic constipation or other gastrointestinal issues, it is essential to investigate the underlying cause rather than relying solely on laxatives.\n",
      "- **Dietary Changes**: Often, dietary modifications (increased fiber intake, hydration) can help alleviate constipation without the need for laxatives.\n",
      "\n",
      "In summary, while there are general guidelines for laxative dosages for children aged 6 to under 12 years, it is essential to consult a healthcare professional for specific recommendations tailored to the child's health status and the type of laxative being considered.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021922\n",
      "prediction:  When discussing the recommended dosage of laxatives for children aged 6 to under 12 years, it is important to clarify that laxatives are not typically categorized by gender, and the term \"laxative for women\" may refer to specific formulations that are marketed towards women but can also be used by children under medical guidance. \n",
      "\n",
      "For children, the choice of laxative and its dosage should be based on the specific type of laxative being used, the child's weight, age, and the underlying cause of constipation. Here are some general guidelines for common types of laxatives:\n",
      "\n",
      "1. **Osmotic Laxatives (e.g., polyethylene glycol, lactulose)**:\n",
      "   - **Polyethylene Glycol (MiraLAX)**: The typical dosage for children aged 6 to under 12 years is usually around 0.5 to 1 gram per kilogram of body weight per day, not exceeding 17 grams per day. This can be mixed with water or juice.\n",
      "   - **Lactulose**: The usual dosage is 1 to 3 mL per kilogram of body weight per day, divided into one or two doses.\n",
      "\n",
      "2. **Stimulant Laxatives (e.g., senna, bisacodyl)**:\n",
      "   - **Senna**: For children aged 6 to under 12 years, the recommended dosage is typically 8.6 to 17.2 mg (usually 1 to 2 tablets) taken once daily at bedtime.\n",
      "   - **Bisacodyl**: The recommended dosage for children aged 6 to under 12 years is usually 5 to 10 mg taken orally once daily.\n",
      "\n",
      "3. **Bulk-forming Laxatives (e.g., psyllium, methylcellulose)**:\n",
      "   - The dosage for children can vary, but a common recommendation is to start with 1 teaspoon of psyllium husk mixed in water once or twice daily, gradually increasing as needed.\n",
      "\n",
      "4. **Saline Laxatives (e.g., magnesium hydroxide)**:\n",
      "   - For children aged 6 to under 12 years, the dosage is typically around 1 to 2 mL per kilogram of body weight, not exceeding 30 mL per day.\n",
      "\n",
      "### Important Considerations:\n",
      "- **Consult a Healthcare Provider**: Before administering any laxative to a child, it is crucial to consult a pediatrician or healthcare provider. They can provide personalized recommendations based on the child's health status and specific needs.\n",
      "- **Hydration**: Ensure that the child is adequately hydrated, as laxatives can lead to dehydration if not taken with sufficient fluids.\n",
      "- **Dietary Changes**: Often, dietary modifications (increased fiber intake, more fluids) can help alleviate constipation without the need for laxatives.\n",
      "- **Monitoring**: Monitor the child for any adverse effects or changes in bowel habits, and report these to a healthcare provider.\n",
      "\n",
      "In summary, while there are general guidelines for laxative dosages in children, it is essential to tailor the approach to the individual child and seek professional medical advice for safe and effective treatment.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.021262\n",
      "prediction:  When discussing the recommended dosage of laxatives for children aged 6 to under 12 years, it is important to clarify that laxatives are not typically categorized by gender, and the term \"laxative for women\" may refer to specific formulations that are marketed towards women but can also be used by children under medical guidance. \n",
      "\n",
      "For children, the choice of laxative and its dosage should be based on the specific type of laxative being used, the child's weight, age, and the underlying reason for constipation. Here are some general guidelines for common types of laxatives:\n",
      "\n",
      "1. **Osmotic Laxatives (e.g., polyethylene glycol, lactulose)**:\n",
      "   - **Polyethylene Glycol (MiraLAX)**: The typical dosage for children aged 6 to under 12 years is usually around 0.5 to 1 gram per kilogram of body weight per day, not exceeding 17 grams per day. This can be mixed with water or juice.\n",
      "   - **Lactulose**: The recommended dosage is typically 1 to 3 mL per kilogram of body weight per day, divided into one or two doses.\n",
      "\n",
      "2. **Stimulant Laxatives (e.g., senna, bisacodyl)**:\n",
      "   - **Senna**: For children aged 6 to under 12 years, the usual dosage is 8.6 to 17.2 mg (usually one to two tablets) taken once daily at bedtime.\n",
      "   - **Bisacodyl**: The recommended dosage for children aged 6 to under 12 years is typically 5 to 10 mg taken once daily.\n",
      "\n",
      "3. **Bulk-forming Laxatives (e.g., psyllium, methylcellulose)**:\n",
      "   - The dosage for bulk-forming laxatives can vary, but a common recommendation is to start with a lower dose, such as 1 teaspoon of psyllium mixed with water, and gradually increase as needed, ensuring adequate fluid intake.\n",
      "\n",
      "4. **Saline Laxatives (e.g., magnesium hydroxide)**:\n",
      "   - For children aged 6 to under 12 years, the dosage is usually around 1 to 2 mL per kilogram of body weight, not exceeding 15 mL per day.\n",
      "\n",
      "### Important Considerations:\n",
      "- **Consult a Healthcare Provider**: Before administering any laxative to a child, it is crucial to consult a pediatrician or healthcare provider. They can provide personalized recommendations based on the child's health status and specific needs.\n",
      "- **Hydration**: Ensure that the child is adequately hydrated, as laxatives can lead to dehydration if not taken with sufficient fluids.\n",
      "- **Dietary Changes**: Often, dietary modifications (increased fiber intake, more fruits and vegetables, and adequate hydration) can help alleviate constipation without the need for laxatives.\n",
      "- **Monitoring**: Monitor the child for any adverse effects or changes in bowel habits, and report these to a healthcare provider.\n",
      "\n",
      "In summary, while there are general guidelines for laxative dosages in children, it is essential to tailor the approach to the individual child and seek professional medical advice for safe and effective treatment.\n",
      "pred_SIM:  C\n",
      "choice:  D\n",
      "correct_answer:  A\n",
      "correct answer: 1 tablet in a single daily dose\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.015481\n",
      "prediction:  When discussing the use of essential oils for health purposes, particularly in the context of vaginal health and menstruation, it is important to approach the topic with caution. Essential oils are highly concentrated plant extracts and can have potent effects on the body. Hereâ€™s a step-by-step breakdown of the considerations regarding the use of vaginal essential oils for preventing repeated cross-infection during menstruation:\n",
      "\n",
      "### Step 1: Understanding Essential Oils\n",
      "Essential oils are derived from various parts of plants, including leaves, flowers, and roots. They are often used in aromatherapy, topical applications, and sometimes in personal care products. However, their use in the vaginal area requires careful consideration due to the sensitivity of the mucous membranes.\n",
      "\n",
      "### Step 2: Safety and Dilution\n",
      "1. **Dilution**: Essential oils should never be used undiluted, especially in sensitive areas like the vagina. A common recommendation is to dilute essential oils in a carrier oil (such as coconut oil, almond oil, or jojoba oil) at a ratio of 1-2 drops of essential oil per teaspoon of carrier oil.\n",
      "   \n",
      "2. **Skin Sensitivity**: Before using any essential oil, it is advisable to perform a patch test on a small area of skin to check for any allergic reactions or sensitivities.\n",
      "\n",
      "### Step 3: Choosing the Right Essential Oils\n",
      "Certain essential oils are known for their antimicrobial properties and may be considered for use in preventing infections. Some commonly mentioned oils include:\n",
      "- **Tea Tree Oil**: Known for its antifungal and antibacterial properties.\n",
      "- **Lavender Oil**: Has soothing properties and may help with inflammation.\n",
      "- **Oregano Oil**: Known for its strong antimicrobial effects.\n",
      "\n",
      "### Step 4: Recommended Dosage\n",
      "While there is no standardized dosage for vaginal use of essential oils, a general guideline for topical application is:\n",
      "- **1-2 drops of diluted essential oil** (in a carrier oil) applied externally around the vaginal area, not directly inside the vagina. \n",
      "\n",
      "### Step 5: Application Method\n",
      "- **External Use**: Apply the diluted mixture to the external vaginal area (vulva) rather than inserting it into the vagina. This minimizes the risk of irritation and allows for the antimicrobial properties to work effectively.\n",
      "- **Frequency**: This can be done once daily during menstruation or as needed, but it is essential to monitor for any adverse reactions.\n",
      "\n",
      "### Step 6: Consultation with Healthcare Professionals\n",
      "Before using essential oils for any health-related purpose, especially in sensitive areas, it is crucial to consult with a healthcare professional. They can provide personalized advice based on individual health needs and conditions.\n",
      "\n",
      "### Step 7: Monitoring and Adjusting\n",
      "If you choose to use essential oils, monitor your bodyâ€™s response. If you experience any irritation, discomfort, or adverse reactions, discontinue use immediately and consult a healthcare provider.\n",
      "\n",
      "### Conclusion\n",
      "While essential oils may offer some benefits, their use in the vaginal area should be approached with caution. There is no universally recommended dosage for preventing cross-infection during menstruation, and individual responses can vary. Always prioritize safety, proper dilution, and professional guidance when considering the use of essential oils for health purposes.\n",
      "pred_SIM:  B\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.01943\n",
      "prediction:  When discussing the use of essential oils for health purposes, particularly in the context of vaginal health and menstruation, it is important to approach the topic with caution. Essential oils are highly concentrated plant extracts that can have potent effects on the body, and their use should be guided by evidence-based practices and professional advice.\n",
      "\n",
      "### Step 1: Understanding Essential Oils\n",
      "\n",
      "Essential oils are derived from various parts of plants, including leaves, flowers, stems, and roots. They are often used in aromatherapy, topical applications, and sometimes in personal care products. Some essential oils are believed to have antimicrobial properties, which may be relevant in the context of preventing infections.\n",
      "\n",
      "### Step 2: Safety and Dilution\n",
      "\n",
      "Essential oils should never be used undiluted, especially in sensitive areas such as the vagina. They can cause irritation, allergic reactions, or other adverse effects. When using essential oils, it is crucial to dilute them properly. A common recommendation for topical application is to dilute essential oils in a carrier oil (such as coconut oil, almond oil, or jojoba oil) at a concentration of 1-5%, depending on the oil and the intended use.\n",
      "\n",
      "### Step 3: Recommended Dosage\n",
      "\n",
      "While there is no standardized dosage for vaginal essential oils specifically for preventing cross-infection during menstruation, general guidelines for topical application can be followed:\n",
      "\n",
      "- **Dilution**: For vaginal use, a dilution of 1% is often recommended. This means adding about 1 drop of essential oil to 1 teaspoon (5 mL) of carrier oil.\n",
      "- **Application**: The diluted mixture can be applied externally to the vulva or used in a sitz bath. It is not advisable to insert essential oils directly into the vagina without professional guidance.\n",
      "\n",
      "### Step 4: Choosing the Right Essential Oils\n",
      "\n",
      "Some essential oils that are commonly considered for their antimicrobial properties include:\n",
      "\n",
      "- **Tea Tree Oil**: Known for its antifungal and antibacterial properties.\n",
      "- **Lavender Oil**: Has calming effects and may also have antimicrobial properties.\n",
      "- **Oregano Oil**: Known for its strong antimicrobial effects.\n",
      "\n",
      "However, it is essential to consult with a healthcare professional before using any essential oil, especially for vaginal health, as some oils may not be suitable for everyone.\n",
      "\n",
      "### Step 5: Consulting Healthcare Professionals\n",
      "\n",
      "Before using essential oils for any health-related purpose, including preventing infections during menstruation, it is crucial to consult with a healthcare provider. They can provide personalized advice based on individual health needs, potential allergies, and any underlying conditions.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, while essential oils may have potential benefits, their use for preventing repeated cross-infection during menstruation should be approached with caution. There is no established recommended dosage for vaginal essential oils, and it is essential to dilute them properly and consult with a healthcare professional for safe and effective use.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.017555\n",
      "prediction:  When discussing the use of essential oils for health purposes, particularly in the context of vaginal health and menstruation, it is important to approach the topic with caution. Essential oils are highly concentrated plant extracts that can have potent effects on the body, and their use should be guided by evidence-based practices and professional advice.\n",
      "\n",
      "### Step 1: Understanding Essential Oils\n",
      "\n",
      "Essential oils are derived from various parts of plants, including leaves, flowers, stems, and roots. They are often used in aromatherapy, topical applications, and sometimes in personal care products. Some essential oils, such as tea tree oil, lavender oil, and oregano oil, are known for their antimicrobial properties.\n",
      "\n",
      "### Step 2: Safety and Dilution\n",
      "\n",
      "Essential oils should never be used undiluted, especially in sensitive areas such as the vagina. They can cause irritation, allergic reactions, or other adverse effects. When using essential oils for vaginal health, it is crucial to dilute them properly. A common recommendation is to dilute essential oils in a carrier oil (such as coconut oil, almond oil, or jojoba oil) at a ratio of 1-2 drops of essential oil per teaspoon of carrier oil.\n",
      "\n",
      "### Step 3: Recommended Dosage\n",
      "\n",
      "There is no standardized dosage for vaginal essential oils, as their use for preventing cross-infection during menstruation is not widely supported by clinical research. However, if one chooses to use essential oils for this purpose, a general guideline might be:\n",
      "\n",
      "- **Topical Application**: After proper dilution, a small amount (1-2 drops of diluted oil) can be applied externally to the vaginal area. It is advisable to do this once daily during menstruation, but this should be adjusted based on individual tolerance and response.\n",
      "\n",
      "### Step 4: Choosing the Right Essential Oils\n",
      "\n",
      "If considering essential oils for vaginal health, some options that are often mentioned for their antimicrobial properties include:\n",
      "\n",
      "- **Tea Tree Oil**: Known for its antifungal and antibacterial properties.\n",
      "- **Lavender Oil**: Has calming effects and may help with discomfort.\n",
      "- **Oregano Oil**: Known for its strong antimicrobial properties.\n",
      "\n",
      "### Step 5: Consulting Healthcare Professionals\n",
      "\n",
      "Before using essential oils for any health-related purpose, especially in sensitive areas, it is essential to consult with a healthcare professional. They can provide personalized advice based on individual health needs, potential allergies, and interactions with other medications.\n",
      "\n",
      "### Step 6: Monitoring for Adverse Reactions\n",
      "\n",
      "If essential oils are used, it is important to monitor for any signs of irritation, allergic reactions, or other adverse effects. If any discomfort occurs, discontinue use immediately and consult a healthcare provider.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "While essential oils may offer some benefits, their use for preventing cross-infection during menstruation is not well-established in scientific literature. The recommended approach is to use them cautiously, with proper dilution, and under the guidance of a healthcare professional. Always prioritize safety and individual health needs when considering alternative therapies.\n",
      "pred_SIM:  A\n",
      "choice:  NOTAVALUE\n",
      "correct_answer:  A\n",
      "correct answer: 5-8 drops applied to sanitary napkins\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.008504\n",
      "prediction:  When increasing the dose of venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly used to treat major depressive disorder, generalized anxiety disorder, and other conditions, it is important to follow a careful and systematic approach to dosing increments. \n",
      "\n",
      "**General Guidelines for Dose Increments:**\n",
      "\n",
      "1. **Initial Dosing**: Venlafaxine is typically started at a low dose to minimize side effects. The usual starting dose for adults is 75 mg/day, which can be given as either an extended-release (ER) formulation or immediate-release (IR) formulation.\n",
      "\n",
      "2. **Incremental Increases**: Dose increments should generally be made in small steps. The recommended practice is to increase the dose by 75 mg per week for the extended-release formulation. For the immediate-release formulation, increments can be made more frequently, but it is still advisable to wait at least 4 to 7 days between increases to assess tolerance and response.\n",
      "\n",
      "3. **Maximum Dose**: The maximum recommended dose of venlafaxine is typically 375 mg/day for the extended-release formulation and 375 mg/day for the immediate-release formulation, although some patients may require higher doses under close supervision. \n",
      "\n",
      "4. **Monitoring**: After each dose increase, it is crucial to monitor the patient for efficacy and side effects. This includes assessing for any adverse reactions, such as increased blood pressure, gastrointestinal disturbances, or changes in mood or anxiety levels.\n",
      "\n",
      "5. **Individualization**: The rate of dose increments may need to be adjusted based on individual patient factors, including their response to the medication, the presence of side effects, and any coexisting medical conditions. Some patients may require slower titration, especially if they are sensitive to medications or have a history of side effects.\n",
      "\n",
      "6. **Special Populations**: In elderly patients or those with renal impairment, dose increments may need to be made more cautiously, and lower maximum doses may be appropriate.\n",
      "\n",
      "7. **Patient Education**: It is important to educate patients about the potential side effects of venlafaxine and the importance of adhering to the prescribed dosing schedule. Patients should be encouraged to report any adverse effects or concerns promptly.\n",
      "\n",
      "In summary, dose increments of venlafaxine should typically be made in increments of 75 mg per week for the extended-release formulation, with careful monitoring and consideration of individual patient factors. Adjustments may be necessary based on the patient's response and tolerance to the medication.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Every 4 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.011918\n",
      "prediction:  When increasing the dose of venlafaxine, it is generally recommended to make incremental adjustments slowly to minimize side effects and allow for the patient's tolerance to the medication to be assessed effectively. \n",
      "\n",
      "1. **Initial Guidelines**: The initial starting dose of venlafaxine typically begins at 75 mg per day, which can be divided into two or three doses. After initiating treatment at this dose, increments should generally not exceed 75 mg per week, especially when considering the lower dose range. \n",
      "\n",
      "2. **Increment Rate**: More specifically, the guidelines suggest waiting at least 4 to 7 days between dose increases. This gives adequate time to assess the efficacy and side effects of the current dose before proceeding.\n",
      "\n",
      "3. **Maximum Dose**: The maximum recommended daily dose for venlafaxine in treating major depressive disorder is up to 375 mg. However, for certain conditions, higher doses might be considered under strict medical supervision.\n",
      "\n",
      "4. **Patient Monitoring**: Clinicians need to monitor patients for tolerance and any potential side effects following each increment. Adjustments may also depend on tolerability and specific patient responses, including any adverse effects experienced.\n",
      "\n",
      "5. **Pharmacogenetics Considerations**: It has been noted in some studies that certain patient populations may require dose adjustments based on genetic factors affecting drug metabolism. For instance, approximately 10% of venlafaxine patients may need dose adjustments due to atypical metabolism. \n",
      "\n",
      "In summary, the general rule is to increase venlafaxine doses incrementally by no more than 75 mg per week and to monitor the patient's response closely over a period of 4 to 7 days before making further adjustments. This cautious approach helps to optimize treatment while minimizing the risk of adverse effects.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Every 4 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.035421\n",
      "prediction:  When managing a patient taking RoxyBond (which contains the active ingredient oxycodone) if a CYP3A4 inhibitor is discontinued, it is important to consider the potential for increased metabolism of oxycodone. CYP3A4 plays a significant role in the metabolism of oxycodone, and an inhibitor may effectively increase its plasma concentration while it is being taken. Upon discontinuation of the inhibitor, there could be a risk of reduced plasma levels of oxycodone, which might result in decreased drug efficacy and pain control.\n",
      "\n",
      "Recommended interventions include:\n",
      "\n",
      "1. **Monitoring**: After discontinuing the CYP3A4 inhibitor, closely monitor the patient's pain levels and signs of withdrawal or reduced analgesic effect.\n",
      "   \n",
      "2. **Dosing Adjustment**: Consider adjusting the dose of RoxyBond if necessary. Depending on the patient's pain response, an increase in the oxycodone dose may be required to maintain effective pain control.\n",
      "\n",
      "3. **Alternative Analgesics**: If the patient does not respond adequately to adjusted doses of RoxyBond, consider the initiation of alternative analgesics that are not significantly metabolized by CYP3A4.\n",
      "\n",
      "4. **Patient Education**: Educate the patient about the signs of reduced analgesia and potential side effects from the altered pharmacotherapy. This includes advising on the importance of reporting any changes in pain levels.\n",
      "\n",
      "By implementing these strategies, potential issues arising from the discontinuation of the CYP3A4 inhibitor can be effectively managed to ensure continued patient safety and comfort.\n",
      "pred_SIM:  A\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Increase the dosage of RoxyBond\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.012436\n",
      "prediction:  When monitoring children and adolescents taking venlafaxine tablets, it is important to consider several key aspects related to both their physical and mental health due to the potential effects of this medication. Based on recent literature and clinical practices, here's a comprehensive overview of what should be monitored:\n",
      "\n",
      "1. **Psychiatric Symptoms**: Regular assessments should be made to monitor for improvement or worsening of psychiatric symptoms, including depression, anxiety, or signs of suicidality. It is crucial to address any emerging suicidal thoughts or behaviors, especially during the initial stages of treatment or when doses are adjusted.\n",
      "\n",
      "2. **Mood Changes**: Watch for any unusual mood changes, irritability, restlessness, or signs of mania. Such changes can be particularly relevant in pediatric populations, and any notable shift should prompt an immediate re-evaluation of treatment.\n",
      "\n",
      "3. **Physical Health Assessments**: \n",
      "   - **Weight and Growth**: Regular monitoring of weight and growth is essential, as venlafaxine can influence appetite and weight in children and adolescents.\n",
      "   - **Blood Pressure and Heart Rate**: Assessments of blood pressure and heart rate are important, given that venlafaxine can lead to increased blood pressure or tachycardia, particularly at higher doses.\n",
      "\n",
      "4. **Side Effects**: Monitor for common side effects such as nausea, headaches, fatigue, or insomnia. More serious adverse events, though less common, should also be closely observed.\n",
      "\n",
      "5. **Laboratory Tests**: While routine laboratory tests may not be necessary for all patients, specific cases may require monitoring of liver function tests and electrolyte levels, especially in patients with pre-existing conditions or those exhibiting concerning symptoms.\n",
      "\n",
      "6. **Family and School Feedback**: Gathering feedback from family members and teachers can provide valuable insights into the child's behavior and functioning in different settings. The impact of treatment on daily functioning and relationships should be assessed regularly.\n",
      "\n",
      "7. **Dosing and Compliance**: Ensure regular follow-ups to verify medication adherence, as inconsistent use can affect treatment outcomes. Adjustments to the dosage may be needed based on therapeutic response and side effects.\n",
      "\n",
      "8. **Long-term Monitoring**: As with any psychotropic medication, long-term follow-up is essential to evaluate efficacy and manage any potential long-term side effects or health changes.\n",
      "\n",
      "In summary, comprehensive monitoring involves regular psychiatric evaluations, physical health assessments, and engagement with family and school environments to ensure the safety and effectiveness of venlafaxine therapy in children and adolescents.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.009695\n",
      "prediction:  When monitoring children and adolescents taking venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly prescribed for depression and anxiety disorders, several key factors should be considered to ensure safety and efficacy. Hereâ€™s a step-by-step breakdown of what should be monitored:\n",
      "\n",
      "### 1. **Mental Health Symptoms**\n",
      "   - **Depression and Anxiety Levels**: Regularly assess the severity of depressive and anxiety symptoms using standardized scales (e.g., the Children's Depression Inventory or the Generalized Anxiety Disorder 7-item scale).\n",
      "   - **Suicidal Ideation**: Monitor for any signs of increased suicidal thoughts or behaviors, especially during the initial treatment phase or when doses are adjusted. The FDA has issued warnings about the increased risk of suicidality in children and adolescents taking antidepressants.\n",
      "\n",
      "### 2. **Side Effects**\n",
      "   - **Common Side Effects**: Monitor for common side effects of venlafaxine, which may include nausea, headache, dizziness, dry mouth, and increased sweating. \n",
      "   - **Serious Side Effects**: Be vigilant for more serious side effects such as elevated blood pressure, serotonin syndrome (symptoms may include confusion, rapid heart rate, and severe muscle rigidity), and withdrawal symptoms if the medication is discontinued abruptly.\n",
      "\n",
      "### 3. **Physical Health Monitoring**\n",
      "   - **Blood Pressure**: Venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Regular monitoring of blood pressure is essential, especially in children and adolescents who may already have risk factors for hypertension.\n",
      "   - **Weight and Growth**: Monitor weight and growth patterns, as changes in appetite and weight can occur with venlafaxine use. This is particularly important in children and adolescents who are still growing.\n",
      "\n",
      "### 4. **Medication Adherence**\n",
      "   - **Compliance with Treatment**: Assess adherence to the medication regimen, as non-compliance can lead to worsening symptoms or withdrawal effects. Engaging with the patient and their family about the importance of consistent medication use is crucial.\n",
      "\n",
      "### 5. **Psychosocial Factors**\n",
      "   - **Family and Social Environment**: Evaluate the childâ€™s family dynamics, school performance, and social interactions. Changes in these areas can provide insight into the effectiveness of the treatment and the childâ€™s overall well-being.\n",
      "   - **Therapeutic Support**: Encourage ongoing therapy or counseling, as combining medication with psychotherapy can enhance treatment outcomes.\n",
      "\n",
      "### 6. **Regular Follow-Up Appointments**\n",
      "   - Schedule regular follow-up appointments to reassess the childâ€™s mental health status, medication effectiveness, and any side effects. This allows for timely adjustments to the treatment plan if necessary.\n",
      "\n",
      "### 7. **Education and Communication**\n",
      "   - **Educate Patients and Families**: Provide education about the medication, including potential side effects and the importance of reporting any concerning symptoms. Open lines of communication between healthcare providers, patients, and families are essential for effective monitoring.\n",
      "\n",
      "### Conclusion\n",
      "Monitoring children and adolescents on venlafaxine requires a comprehensive approach that includes assessing mental health symptoms, side effects, physical health parameters, medication adherence, and psychosocial factors. Regular follow-up and open communication with the patient and their family are critical to ensuring safe and effective treatment.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.009944\n",
      "prediction:  When monitoring children and adolescents taking venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly prescribed for depression and anxiety disorders, several key factors should be considered to ensure safety and efficacy. Hereâ€™s a step-by-step breakdown of what should be monitored:\n",
      "\n",
      "### 1. **Mental Health Symptoms**\n",
      "   - **Depression and Anxiety Levels**: Regularly assess the severity of depressive and anxiety symptoms using standardized scales (e.g., the Children's Depression Inventory or the Generalized Anxiety Disorder 7-item scale).\n",
      "   - **Suicidal Ideation**: Monitor for any signs of increased suicidal thoughts or behaviors, especially during the initial treatment phase or when doses are adjusted. The FDA has issued warnings about the increased risk of suicidality in children and adolescents taking antidepressants.\n",
      "\n",
      "### 2. **Side Effects**\n",
      "   - **Common Side Effects**: Monitor for common side effects of venlafaxine, which may include nausea, headache, dizziness, dry mouth, and increased sweating. \n",
      "   - **Serious Side Effects**: Be vigilant for more serious side effects such as elevated blood pressure, serotonin syndrome (symptoms may include confusion, rapid heart rate, and severe muscle rigidity), and withdrawal symptoms if the medication is discontinued abruptly.\n",
      "\n",
      "### 3. **Physical Health**\n",
      "   - **Blood Pressure**: Venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Regular monitoring of blood pressure is essential, especially in children and adolescents who may already have risk factors for hypertension.\n",
      "   - **Weight and Growth**: Monitor weight and growth patterns, as changes in appetite and weight can occur with venlafaxine use. This is particularly important in children and adolescents who are still growing.\n",
      "\n",
      "### 4. **Medication Adherence**\n",
      "   - **Compliance with Treatment**: Assess adherence to the medication regimen, as non-compliance can lead to worsening symptoms or withdrawal effects. Engage with the patient and their caregivers to discuss the importance of consistent medication use.\n",
      "\n",
      "### 5. **Psychosocial Factors**\n",
      "   - **Family and Social Environment**: Evaluate the childâ€™s family dynamics, school performance, and social interactions. Changes in these areas can provide insight into the effectiveness of treatment and the childâ€™s overall well-being.\n",
      "   - **Therapeutic Support**: Encourage ongoing therapy or counseling, as medication is often most effective when combined with psychotherapy.\n",
      "\n",
      "### 6. **Regular Follow-Up Appointments**\n",
      "   - Schedule regular follow-up appointments to reassess the childâ€™s mental health status, medication effectiveness, and any side effects. This allows for timely adjustments to the treatment plan as needed.\n",
      "\n",
      "### 7. **Education and Communication**\n",
      "   - **Educate Patients and Caregivers**: Provide information about the medication, including potential side effects and the importance of reporting any concerning symptoms. Encourage open communication about any changes in mood or behavior.\n",
      "\n",
      "### Conclusion\n",
      "Monitoring children and adolescents on venlafaxine requires a comprehensive approach that includes assessing mental health symptoms, side effects, physical health parameters, and psychosocial factors. Regular follow-up and open communication with both the patient and their caregivers are essential to ensure safe and effective treatment.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.009745\n",
      "prediction:  When monitoring children and adolescents taking venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly prescribed for depression and anxiety disorders, several key factors should be considered to ensure safety and efficacy. Hereâ€™s a step-by-step breakdown of what should be monitored:\n",
      "\n",
      "### 1. **Mental Health Symptoms**\n",
      "   - **Depression and Anxiety Levels**: Regularly assess the severity of depressive and anxiety symptoms using standardized scales (e.g., the Children's Depression Inventory or the Generalized Anxiety Disorder 7-item scale).\n",
      "   - **Suicidal Thoughts and Behaviors**: Monitor for any emergence or worsening of suicidal ideation or behavior, especially during the initial treatment phase or when doses are adjusted. The FDA has issued warnings about the increased risk of suicidality in children and adolescents taking antidepressants.\n",
      "\n",
      "### 2. **Side Effects**\n",
      "   - **Common Side Effects**: Monitor for common side effects of venlafaxine, which may include nausea, headache, dizziness, dry mouth, and increased sweating.\n",
      "   - **Serious Side Effects**: Be vigilant for more serious side effects such as increased blood pressure, serotonin syndrome (symptoms may include confusion, rapid heart rate, and severe muscle rigidity), and withdrawal symptoms upon discontinuation.\n",
      "\n",
      "### 3. **Physical Health Monitoring**\n",
      "   - **Blood Pressure**: Venlafaxine can cause dose-dependent increases in blood pressure, particularly at higher doses. Regular monitoring of blood pressure is essential, especially in children and adolescents who may already have risk factors for hypertension.\n",
      "   - **Weight and Growth**: Monitor weight and growth patterns, as changes in appetite and weight can occur with venlafaxine use. This is particularly important in children and adolescents who are still growing.\n",
      "\n",
      "### 4. **Medication Adherence**\n",
      "   - **Compliance with Treatment**: Assess adherence to the medication regimen, as non-compliance can lead to worsening symptoms or withdrawal effects. Engaging with the patient and their family about the importance of consistent medication use is crucial.\n",
      "\n",
      "### 5. **Psychosocial Factors**\n",
      "   - **Family and Social Environment**: Evaluate the childâ€™s family dynamics, social interactions, and school performance. Changes in these areas can provide insight into the effectiveness of treatment and the childâ€™s overall well-being.\n",
      "   - **Therapeutic Support**: Encourage ongoing therapy or counseling, as medication is often most effective when combined with psychotherapy.\n",
      "\n",
      "### 6. **Regular Follow-Up Appointments**\n",
      "   - Schedule regular follow-up appointments to reassess the childâ€™s mental health status, medication effectiveness, and any side effects. This allows for timely adjustments to the treatment plan as needed.\n",
      "\n",
      "### 7. **Education and Communication**\n",
      "   - **Educate Patients and Families**: Provide education about the medication, including potential side effects and the importance of reporting any concerning symptoms. Open lines of communication between healthcare providers, patients, and families are essential for effective monitoring.\n",
      "\n",
      "### Conclusion\n",
      "Monitoring children and adolescents on venlafaxine requires a comprehensive approach that includes assessing mental health symptoms, side effects, physical health parameters, and psychosocial factors. Regular follow-ups and open communication with the patient and their family are critical to ensure the safe and effective use of this medication.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.053551\n",
      "prediction:  When prescribing Fluoxetine to patients with a history of drug abuse, a critical consideration for physicians is the potential for abuse and the risk of substance dependence. Patients with a history of substance abuse may exhibit a higher likelihood of seeking prescriptions improperly, which can lead to misuse or non-compliance with treatment protocols.\n",
      "\n",
      "1. **Assessment of History**: Physicians should conduct a thorough assessment of the patientâ€™s drug abuse history. Understanding the type of substances abused, the duration, and any previous treatments for substance use disorders provides essential context for prescribing Fluoxetine.\n",
      "\n",
      "2. **Monitoring for Persistance**: According to a study which evaluated the persistence of patients on SSRIs like Fluoxetine, the absence of an abuse history is associated with better treatment adherence. In clinical practice, particularly for patients with a history of substance abuse, increased monitoring might be necessary to ensure they are taking the medication as directed and to mitigate any potential for relapse into substance abuse.\n",
      "\n",
      "3. **Discontinuation Syndromes**: It is important to educate patients about the possible discontinuation symptoms associated with Fluoxetine and other SSRIs, especially since these may lead to non-compliance if not managed properly. Physicians should advise on the importance of continuity in medication and provide a tapering plan if discontinuation is necessary, as sudden cessation can cause withdrawal symptoms, affecting compliance and potentially leading back to substance use as a coping mechanism (PubMed ID: 11347722).\n",
      "\n",
      "4. **Collaborative Care**: Physicians should consider involving mental health professionals or substance abuse specialists in the patient's care plan. This collaborative approach can provide additional support and monitoring to help manage both mental health and any issues related to substance abuse.\n",
      "\n",
      "5. **Patient Education**: Educating the patient on the effects of Fluoxetine, proper usage, and the potential for misuse is crucial. This education can empower patients to manage their own treatment effectively.\n",
      "\n",
      "In summary, careful consideration of a patient's history of drug abuse, persistent monitoring, thorough education about the medication, and potentially involving a multidisciplinary team are essential steps for physicians when prescribing Fluoxetine. These considerations help mitigate risks and enhance treatment outcomes for vulnerable populations.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Observing for signs of misuse or abuse, such as dose incrementation or drug-seeking behavior.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.012928\n",
      "prediction:  When prescribing venlafaxine tablets to children and adolescents, several important monitoring aspects must be taken into account to ensure safety and effectiveness:\n",
      "\n",
      "1. **Mental Health Symptoms**: Continuous assessment of the mental health status is crucial. Monitoring for any worsening of depression, emergence of suicidal thoughts or behavior, and signs of mood swings is essential, particularly during the initial treatment phase or dosage adjustments. Due to the risk of increased suicidal ideation associated with antidepressant use in younger populations, frequent and thorough evaluations should be conducted.\n",
      "\n",
      "2. **Cardiovascular Monitoring**: Venlafaxine has been associated with dose-dependent increases in blood pressure, as well as potential cardiac side effects. Blood pressure should be measured regularly, especially in patients with pre-existing hypertension or cardiovascular issues. Additionally, monitoring for symptoms of cardiac toxicity is important. These symptoms may include palpitations, arrhythmias, or unusual fatigue during treatment.\n",
      "\n",
      "3. **Adverse Reactions**: Side effects commonly brought on by venlafaxine can include gastrointestinal disturbances, sedation, and increased perspiration. It's important to monitor for any new or worsening side effects that could impact the child's or adolescent's daily functioning.\n",
      "\n",
      "4. **Growth and Development**: In pediatric populations, itâ€™s important to monitor the growth patterns and overall development of the child or adolescent. This includes height and weight measurements at regular intervals to ensure there are no significant developmental concerns.\n",
      "\n",
      "5. **Parental/Guardian Involvement**: Regular check-ins with parents or guardians about the patient's mood, behavior changes, and any side effects are valuable. This collaboration can help in identifying any issues early on and adjusting treatment as necessary.\n",
      "\n",
      "6. **Discontinuation Symptoms**: If discontinuing venlafaxine, monitoring for withdrawal symptoms is important, as the medication can cause discontinuation syndrome. Symptoms may include irritability, dizziness, nausea, and sensory disturbances.\n",
      "\n",
      "7. **Neuroimaging**: Emerging studies suggest potential monitoring through neuroimaging to assess the neural effects of psychotropic medications, including venlafaxine, which can provide insights into treatment effects and neuronal health (e.g., functional MRI studies) (Source: PubMed articles).\n",
      "\n",
      "By keeping these monitoring points in mind, healthcare providers can better ensure the safety and therapeutic efficacy of venlafaxine treatment in children and adolescents.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: Height and weight\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.009569\n",
      "prediction:  When transitioning from venlafaxine, an antidepressant that primarily acts as a serotonin-norepinephrine reuptake inhibitor (SNRI), to a monoamine oxidase inhibitor (MAOI), it is crucial to allow sufficient time for the venlafaxine to clear from the body to minimize the risk of serotonin syndrome, a potentially life-threatening condition that can occur when combining these medications.\n",
      "\n",
      "The general recommendation is to wait at least **14 days** after discontinuing venlafaxine before starting an MAOI. This timeframe is based on the pharmacokinetics of venlafaxine and its active metabolite, O-desmethylvenlafaxine (desvenlafaxine), which can have a prolonged half-life. The 14-day interval allows for the drug and its metabolites to be sufficiently eliminated from the system.\n",
      "\n",
      "However, it is essential to consider individual patient factors, such as the dosage of venlafaxine, duration of treatment, and the patient's overall health status. In some cases, healthcare providers may recommend a longer washout period, especially if the patient was on a high dose or has other complicating factors.\n",
      "\n",
      "Before making any changes to medication regimens, it is crucial for patients to consult with their healthcare provider to ensure a safe and effective transition between these medications. The provider will take into account the patient's specific circumstances and may monitor for any potential side effects or interactions during the transition period.\n",
      "pred_SIM:  C\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "default\n",
      "SIM_score:  0.010271\n",
      "0.010271\n",
      "prediction:  When transitioning from venlafaxine, an antidepressant that primarily acts as a serotonin-norepinephrine reuptake inhibitor (SNRI), to a monoamine oxidase inhibitor (MAOI), it is crucial to allow sufficient time for the venlafaxine to clear from the body to minimize the risk of serotonin syndrome, a potentially life-threatening condition that can occur when combining these types of medications.\n",
      "\n",
      "The general recommendation is to wait at least **14 days** after discontinuing venlafaxine before starting an MAOI. This timeframe is based on the pharmacokinetics of venlafaxine and its active metabolite, O-desmethylvenlafaxine (desvenlafaxine), which can have a prolonged half-life. The 14-day waiting period helps ensure that the drug and its metabolites are sufficiently eliminated from the system, reducing the risk of adverse interactions.\n",
      "\n",
      "However, it is essential to consider individual patient factors, such as the dosage of venlafaxine, duration of treatment, and the patient's overall health status. In some cases, healthcare providers may recommend a longer washout period, especially if the patient was on a high dose or has other complicating factors.\n",
      "\n",
      "Before making any changes to medication regimens, it is always advisable for patients to consult with their healthcare provider to ensure a safe and effective transition between medications.\n",
      "pred_SIM:  C\n",
      "C\n",
      "choice:  C\n",
      "C\n",
      "correct_answer:  B\n",
      "B\n",
      "correct answer: 7 days\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.02393\n",
      "prediction:  When using a nicotine lozenge, users might experience a variety of sensations and side effects due to the pharmacological effects of nicotine and its interaction with the oral mucosa.\n",
      "\n",
      "1. **Initial Sensation**: Upon dissolving the lozenge, users often report an initial burning or tingling sensation in the mouth. This is commonly attributed to the presence of nicotine and its irritative properties on the oral mucosa.\n",
      "\n",
      "2. **Oral Irritation**: Many users experience localized irritation or soreness in the gums and oral cavity. This discomfort can manifest as a burning sensation, which is one of the most frequently reported side effects associated with nicotine replacement therapy (NRT) products, including lozenges. A study found that irritation in the mouth and throat is a common reason for discontinuing the use of nicotine products (35199839).\n",
      "\n",
      "3. **Gastrointestinal Effects**: The use of nicotine lozenges can also lead to gastrointestinal disturbances, including nausea and hiccups. These effects are likely connected to the nicotine's systemic absorption and its action on the gastrointestinal tract (35199839).\n",
      "\n",
      "4. **Transient Receptor Potential (TRP) Channels**: Research indicates that sensory nerves in the oral cavity and throat might activate specific receptors known as TRP channels when exposed to nicotine. This activation can result in sensations such as pain or irritation, which can contribute to the discomfort experienced by users (35199839).\n",
      "\n",
      "5. **Psychological Effects**: Beyond physical sensations, users may also experience psychological effects. These can include an increased sense of alertness or a reduction in cravings for tobacco, stemming from the stimulant properties of nicotine. However, for some, the physical discomfort may overshadow these potential benefits, leading to a reluctance to continue using the product.\n",
      "\n",
      "In summary, while nicotine lozenges can aid in smoking cessation, the sensations experienced can range from burning and irritation to gastrointestinal discomfort. Understanding these effects can help users manage their expectations and improve adherence to nicotine replacement therapy.\n",
      "pred_SIM:  B\n",
      "choice:  A\n",
      "correct_answer:  B\n",
      "correct answer: A warm or tingling sensation\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.037989\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy designed for the treatment of beta-thalassemia, specifically for patients who require regular red blood cell transfusions. When considering Zynteglo treatment for patients with hepatic impairment, several factors must be taken into account to ensure safety and efficacy. Hereâ€™s a step-by-step breakdown of the recommendations:\n",
      "\n",
      "### Step 1: Assess the Degree of Hepatic Impairment\n",
      "- **Mild Impairment**: Patients with mild hepatic impairment (Child-Pugh Class A) may be eligible for treatment, but careful monitoring is necessary.\n",
      "- **Moderate to Severe Impairment**: Patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment may face increased risks and complications. Generally, these patients are not recommended for Zynteglo treatment due to potential adverse effects and altered pharmacokinetics.\n",
      "\n",
      "### Step 2: Evaluate Liver Function Tests\n",
      "- Before initiating treatment, it is crucial to conduct liver function tests (LFTs) to evaluate the patient's baseline liver function. This includes assessing levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and alkaline phosphatase.\n",
      "- If LFTs indicate significant liver dysfunction, further evaluation and potential contraindications for Zynteglo treatment should be considered.\n",
      "\n",
      "### Step 3: Consider the Risks and Benefits\n",
      "- The decision to proceed with Zynteglo treatment in patients with hepatic impairment should involve a thorough discussion of the potential risks versus benefits. \n",
      "- Risks may include increased likelihood of adverse reactions, altered metabolism of the gene therapy, and complications related to the underlying liver condition.\n",
      "\n",
      "### Step 4: Multidisciplinary Team Involvement\n",
      "- Involve a multidisciplinary team, including hematologists, hepatologists, and genetic counselors, to assess the patient's overall health status and suitability for Zynteglo treatment.\n",
      "- This team can help in making a more informed decision regarding the treatment plan and necessary precautions.\n",
      "\n",
      "### Step 5: Monitor Post-Treatment\n",
      "- If a patient with mild hepatic impairment is treated with Zynteglo, close monitoring post-treatment is essential. This includes regular follow-up appointments to assess liver function and watch for any adverse effects.\n",
      "- Monitoring should also include checking for signs of hemolysis or other complications that may arise due to the therapy.\n",
      "\n",
      "### Step 6: Patient Education\n",
      "- Educate the patient and their family about the potential risks associated with Zynteglo treatment in the context of hepatic impairment. \n",
      "- Discuss the importance of adhering to follow-up appointments and reporting any new symptoms or changes in health status promptly.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the recommendation for patients with hepatic impairment being considered for Zynteglo treatment is to conduct a thorough assessment of liver function, evaluate the degree of impairment, involve a multidisciplinary team, and ensure close monitoring if treatment is initiated. Patients with moderate to severe hepatic impairment are generally not recommended for this therapy due to the associated risks. Each case should be evaluated individually, taking into account the patient's overall health and the potential benefits of the treatment.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Hepatic function should be assessed to ensure hematopoietic stem cell transplantation is appropriate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.04001\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy designed for the treatment of beta-thalassemia, specifically for patients who require regular red blood cell transfusions. When considering treatment with Zynteglo for patients with hepatic impairment, several factors must be taken into account. Hereâ€™s a step-by-step breakdown of the recommendations:\n",
      "\n",
      "### Step 1: Understanding Hepatic Impairment\n",
      "Hepatic impairment refers to the reduced ability of the liver to perform its normal functions, which can affect drug metabolism, clearance, and overall safety. The severity of hepatic impairment is typically classified into three categories:\n",
      "- **Mild (Child-Pugh Class A)**\n",
      "- **Moderate (Child-Pugh Class B)**\n",
      "- **Severe (Child-Pugh Class C)**\n",
      "\n",
      "### Step 2: Assessing the Patient's Condition\n",
      "Before considering Zynteglo treatment, a thorough assessment of the patient's hepatic function is essential. This includes:\n",
      "- **Liver Function Tests (LFTs):** Evaluating levels of liver enzymes (ALT, AST), bilirubin, and albumin.\n",
      "- **Clinical History:** Understanding the cause of hepatic impairment (e.g., viral hepatitis, alcohol-related liver disease, non-alcoholic fatty liver disease).\n",
      "- **Child-Pugh Score:** Determining the severity of liver disease using the Child-Pugh scoring system.\n",
      "\n",
      "### Step 3: Reviewing Zynteglo's Safety Profile\n",
      "Zynteglo has a specific safety profile that must be considered in the context of hepatic impairment. The therapy involves the use of a lentiviral vector to deliver a functional copy of the beta-globin gene into the patient's hematopoietic stem cells. Potential concerns include:\n",
      "- **Risk of Hepatotoxicity:** Gene therapies can sometimes lead to liver-related adverse effects.\n",
      "- **Immunogenicity:** The immune response to the vector may be altered in patients with liver dysfunction.\n",
      "\n",
      "### Step 4: Recommendations for Patients with Hepatic Impairment\n",
      "1. **Mild Hepatic Impairment (Child-Pugh Class A):**\n",
      "   - Patients with mild hepatic impairment may be considered for Zynteglo treatment, but close monitoring is recommended. Adjustments in pre-treatment evaluations and post-treatment follow-ups may be necessary.\n",
      "\n",
      "2. **Moderate Hepatic Impairment (Child-Pugh Class B):**\n",
      "   - Caution is advised. A multidisciplinary team should evaluate the risks and benefits of proceeding with treatment. It may be necessary to conduct additional assessments to ensure the patient can tolerate the therapy.\n",
      "\n",
      "3. **Severe Hepatic Impairment (Child-Pugh Class C):**\n",
      "   - Zynteglo is generally not recommended for patients with severe hepatic impairment due to the increased risk of adverse effects and complications. Alternative treatment options should be explored.\n",
      "\n",
      "### Step 5: Multidisciplinary Approach\n",
      "- **Consultation with Specialists:** Involve hepatologists, hematologists, and genetic counselors in the decision-making process to ensure a comprehensive evaluation of the patient's condition.\n",
      "- **Informed Consent:** Ensure that patients and their families are fully informed about the potential risks and benefits of Zynteglo treatment, especially in the context of hepatic impairment.\n",
      "\n",
      "### Step 6: Monitoring and Follow-Up\n",
      "- **Post-Treatment Monitoring:** Patients who receive Zynteglo should be monitored closely for liver function and any signs of hepatotoxicity or other complications.\n",
      "- **Long-Term Follow-Up:** Regular follow-up appointments should be scheduled to assess the long-term effects of the therapy and manage any emerging issues related to hepatic function.\n",
      "\n",
      "### Conclusion\n",
      "In summary, the recommendation for patients with hepatic impairment being considered for Zynteglo treatment varies based on the severity of the impairment. Mild impairment may allow for treatment with careful monitoring, while moderate impairment requires a cautious approach, and severe impairment generally contraindicates the use of Zynteglo. A multidisciplinary team should guide the decision-making process, ensuring that patients receive the most appropriate and safe care.\n",
      "pred_SIM:  A\n",
      "choice:  B\n",
      "correct_answer:  A\n",
      "correct answer: Hepatic function should be assessed to ensure hematopoietic stem cell transplantation is appropriate.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.074074\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy developed by Bluebird Bio for the treatment of beta-thalassemia. It is an autologous hematopoietic stem cell-based therapy that has shown promise in clinical studies, achieving transfusion independence in a significant percentage of patients.\n",
      "\n",
      "However, as of now, there appears to be a lack of specific scientific literature directly addressing the genotoxicity of Zynteglo in PubMed databases and clinical trial registries. The available information mostly pertains to its application, efficacy, and safety profile, but genotoxicity specifically has not been highlighted in the studies or documents retrieved.\n",
      "\n",
      "For more comprehensive and regulatory oversight information, the U.S. FDA and European Medicines Agency (EMA) have provided documentation such as risk management plans and package inserts that include safety profiles which may cover generalized cytotoxic effects but do not specify genotoxicity in detail. \n",
      "\n",
      "For further details on the therapeutic application and associated risks, you can refer to the following resources:\n",
      "- [Wikipedia entry on Betibeglogene autotemcel](https://en.wikipedia.org/wiki/Betibeglogene_autotemcel)\n",
      "- [FDA Package Insert for Zynteglo](https://www.fda.gov/media/160991/download)\n",
      "- [EMA Risk Management Plan summary for Zynteglo](https://www.ema.europa.eu/en/documents/rmp-summary/zynteglo-epar-risk-management-plan-summary_en.pdf)\n",
      "\n",
      "If specific studies examining genotoxicity do become available, keeping an eye on updated resources and scientific literature through platforms like PubMed will be essential.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: No evidence of genotoxicity was observed in a mouse model of Î²-thalassemia.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  agent\n",
      "SIM_score:  0.044323\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy primarily indicated for treating transfusion-dependent beta-thalassemia in patients without the Î²0/Î²0 genotype. The contraindication profile of Zynteglo differs from drugs with specific contraindications primarily due to its unique therapeutic mechanism and the nature of gene therapy itself. Here are some key aspects:\n",
      "\n",
      "1. **Definition and Mechanism**: Unlike conventional drugs that may have contraindications based on their active ingredients or effects on the body's systems, Zynteglo involves the introduction of genetically modified cells to treat a disease. This fundamentally alters how contraindications are considered.\n",
      "\n",
      "2. **Specific Contraindications**: Zynteglo has specific contraindications including:\n",
      "   - **Hypersensitivity**: Contraindications exist for individuals with hypersensitivity to the active substance or any of the excipients in the formulation.\n",
      "   - **Previous Gene Therapy**: Patients who have previously undergone hematopoietic stem cell gene therapy are generally contraindicated for Zynteglo.\n",
      "   - **Mobilization Agents**: There are contraindications related to the use of mobilization agents and myeloablative conditioning prior to infusion.\n",
      "\n",
      "3. **Comparison with Other Drugs**: Many conventional pharmacological agents might contraindicate use based on factors like:\n",
      "   - **Patient's Existing Conditions**: Such as hepatic impairment, renal failure, or cardiovascular diseases.\n",
      "   - **Drug Interactions**: Certain medications cannot be taken together due to adverse interactions that can compromise safety or effectiveness.\n",
      "   - **Pregnancy and Lactation**: Numerous drugs have strict contraindications in pregnant or breastfeeding women, whereas Zynteglo has a nuanced approach where its use may still be considered under strict clinical circumstances.\n",
      "\n",
      "4. **Clinical Monitoring**: Zynteglo's administration requires rigorous monitoring due to potential long-term effects and the complexity of gene therapy. Other drugs may require monitoring as well but do not often involve the intensive oversight needed for gene therapies that modify a patientâ€™s genetic material.\n",
      "\n",
      "5. **Regulatory Designations**: Zynteglo received breakthrough therapy designation from the FDA, reflecting the need for a careful assessment of both its efficacy and safety, which influences its contraindication considerations differently than many standard pharmacological treatments.\n",
      "\n",
      "In summary, Zyntegloâ€™s contraindication profile is shaped significantly by its gene therapy nature, focusing more on hypersensitivity and prior treatment factors rather than the broader spectrum of medical conditions or interactions commonly seen with conventional medications. Understanding these differences is crucial for healthcare providers in ensuring safe and effective treatment options for patients. \n",
      "\n",
      "For more detailed information, you can refer to the following sources:\n",
      "- [Wikipedia on Zynteglo](https://en.wikipedia.org/wiki/Betibeglogene_autotemcel)\n",
      "- [Medscape Drug Information](https://reference.medscape.com/drug/zynteglo-betibeglogene-autotemcel-4000275)\n",
      "- [European Medicines Agency (EMA)](https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo)\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.036448\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy product developed for the treatment of beta-thalassemia, a genetic blood disorder characterized by reduced production of hemoglobin. Understanding its contraindication profile requires a comparison with traditional medications that have specific contraindications.\n",
      "\n",
      "### Contraindication Profile of Zynteglo\n",
      "\n",
      "1. **General Contraindications**:\n",
      "   - Zynteglo is contraindicated in patients with active or uncontrolled infections, as the therapy involves modifying the patient's own stem cells and may compromise the immune system.\n",
      "   - It is also contraindicated in patients with hypersensitivity to any of the components of the product, which is a common contraindication for many medications.\n",
      "\n",
      "2. **Specific Considerations**:\n",
      "   - Zynteglo is specifically contraindicated in patients with certain genetic conditions that may interfere with the therapy's efficacy or safety. For instance, patients with certain types of severe anemia or those who have had prior gene therapy may not be suitable candidates.\n",
      "   - The therapy is not recommended for patients with a history of malignancy, as the introduction of genetically modified cells could potentially exacerbate underlying cancer risks.\n",
      "\n",
      "3. **Age and Developmental Considerations**:\n",
      "   - Zynteglo is typically indicated for patients aged 12 years and older, which may limit its use in younger populations. This age-related contraindication is less common in traditional medications, which may have broader age indications.\n",
      "\n",
      "### Comparison with Traditional Medications\n",
      "\n",
      "1. **Specificity of Contraindications**:\n",
      "   - Traditional medications often have specific contraindications based on their pharmacological action. For example, non-steroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with peptic ulcer disease due to the risk of gastrointestinal bleeding. In contrast, Zynteglo's contraindications are more related to the patient's genetic background and overall health status rather than a direct pharmacological interaction.\n",
      "\n",
      "2. **Mechanism of Action**:\n",
      "   - Many traditional drugs have contraindications based on their mechanism of action, such as anticoagulants being contraindicated in patients with active bleeding. Zynteglo, being a gene therapy, has a unique profile where contraindications are more focused on the patient's genetic makeup and the potential for adverse effects from the therapy itself.\n",
      "\n",
      "3. **Long-term Considerations**:\n",
      "   - The long-term implications of gene therapy like Zynteglo are still being studied, and contraindications may evolve as more data becomes available. Traditional medications often have well-established contraindications based on extensive clinical use and research.\n",
      "\n",
      "4. **Monitoring and Follow-up**:\n",
      "   - Zynteglo requires careful monitoring post-administration for potential complications such as insertional mutagenesis or other long-term effects, which is a consideration not typically associated with most traditional medications. This necessitates a different approach to contraindications, focusing on ongoing patient assessment rather than just pre-treatment screening.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the contraindication profile of Zynteglo is distinct from that of traditional medications due to its nature as a gene therapy, focusing on genetic and immunological factors rather than solely pharmacological interactions. While both types of therapies share some common contraindications, such as hypersensitivity and active infections, Zynteglo's profile is more nuanced, reflecting the complexities of genetic interventions and the need for careful patient selection and monitoring. As gene therapies continue to evolve, understanding these differences will be crucial for healthcare providers in making informed treatment decisions.\n",
      "pred_SIM:  A\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.04513\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy product developed for the treatment of beta-thalassemia, a genetic blood disorder characterized by reduced production of hemoglobin. Understanding its contraindication profile requires a comparison with traditional medications that have specific contraindications.\n",
      "\n",
      "### Contraindication Profile of Zynteglo\n",
      "\n",
      "1. **General Contraindications**:\n",
      "   - Zynteglo is contraindicated in patients with active or uncontrolled infections, as the therapy involves modifying the patientâ€™s own stem cells and may compromise the immune system.\n",
      "   - It is also contraindicated in patients with hypersensitivity to any of the components of the product, which is a common contraindication for many medications.\n",
      "\n",
      "2. **Specific Considerations**:\n",
      "   - Zynteglo is specifically contraindicated in patients with certain genetic conditions that may interfere with the therapy's efficacy or safety. For instance, patients with certain types of severe anemia or those who have had prior gene therapy may not be suitable candidates.\n",
      "   - The therapy is not recommended for patients with a history of malignancy, as the introduction of genetically modified cells could potentially exacerbate underlying cancer risks.\n",
      "\n",
      "3. **Age and Developmental Considerations**:\n",
      "   - Zynteglo is typically indicated for patients aged 12 years and older, which is a specific age-related contraindication. This is in contrast to many traditional medications that may have broader age indications or specific contraindications based on age-related pharmacokinetics.\n",
      "\n",
      "### Comparison with Traditional Medications\n",
      "\n",
      "1. **Specificity of Contraindications**:\n",
      "   - Traditional medications often have a list of contraindications based on organ function (e.g., renal or hepatic impairment), pregnancy, or interactions with other drugs. For example, non-steroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with peptic ulcer disease or severe renal impairment.\n",
      "   - Zyntegloâ€™s contraindications are more focused on the genetic and immunological aspects of the patient, reflecting its nature as a gene therapy rather than a conventional pharmacological agent.\n",
      "\n",
      "2. **Long-term Considerations**:\n",
      "   - Many traditional drugs have contraindications that are based on short-term effects or acute conditions. In contrast, Zyntegloâ€™s contraindications may also consider long-term implications of gene therapy, such as the potential for insertional mutagenesis or long-term immune responses to the modified cells.\n",
      "\n",
      "3. **Monitoring and Follow-up**:\n",
      "   - The contraindication profile of Zynteglo necessitates a more rigorous monitoring framework post-administration, as the long-term effects of gene therapy are still being studied. This contrasts with many traditional medications, where monitoring may be more routine and based on established pharmacological profiles.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "In summary, the contraindication profile of Zynteglo is distinct from that of traditional medications due to its nature as a gene therapy. It emphasizes genetic, immunological, and long-term safety considerations, while traditional drugs often focus on organ function, drug interactions, and acute conditions. Understanding these differences is crucial for healthcare providers when determining the appropriateness of Zynteglo for individual patients, ensuring that the benefits outweigh the risks associated with its use.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: Zynteglo has no contraindications, but safety should still be assessed individually.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.058067\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy treatment approved for patients with beta-thalassemia who require regular blood transfusions. It involves the modification of a patient's own hematopoietic stem cells to produce functional hemoglobin. When considering Zynteglo treatment for patients who are seropositive for HIV, several important factors and recommendations must be taken into account:\n",
      "\n",
      "1. **HIV Control and Management**: Before considering Zynteglo treatment, it is crucial that the patient's HIV is well-controlled. This typically means that the patient should be on antiretroviral therapy (ART) and have an undetectable viral load. Well-managed HIV reduces the risk of complications and improves overall health outcomes.\n",
      "\n",
      "2. **Immunocompromised Status**: Patients with HIV, especially those with a low CD4 count or those who are not on effective ART, may be immunocompromised. This can increase the risk of infections and complications during and after the gene therapy procedure. Therefore, a thorough assessment of the patient's immune status is essential.\n",
      "\n",
      "3. **Consultation with Specialists**: It is recommended that patients with HIV seeking Zynteglo treatment consult with both a hematologist (for beta-thalassemia management) and an infectious disease specialist (for HIV management). This multidisciplinary approach ensures that all aspects of the patient's health are considered.\n",
      "\n",
      "4. **Potential Risks and Benefits**: The risks associated with Zynteglo treatment in HIV-positive patients should be carefully weighed against the potential benefits. This includes considering the patient's overall health, the severity of their beta-thalassemia, and the potential for improved quality of life post-treatment.\n",
      "\n",
      "5. **Monitoring and Follow-Up**: If a patient with HIV is deemed a candidate for Zynteglo, close monitoring during the treatment process is essential. This includes regular follow-up appointments to monitor for any adverse effects, changes in HIV status, and overall health.\n",
      "\n",
      "6. **Regulatory and Clinical Guidelines**: As of now, there may not be specific guidelines exclusively addressing the use of Zynteglo in HIV-positive patients. Therefore, healthcare providers should refer to the latest clinical guidelines, research studies, and expert opinions when making treatment decisions.\n",
      "\n",
      "7. **Informed Consent**: Patients should be fully informed about the potential risks and benefits of Zynteglo treatment, especially in the context of their HIV status. Informed consent is a critical component of the treatment process.\n",
      "\n",
      "In summary, while Zynteglo may be a potential treatment option for patients with beta-thalassemia who are also seropositive for HIV, careful consideration of the patient's HIV management, immune status, and overall health is essential. A collaborative approach involving multiple healthcare specialists is recommended to ensure the best possible outcomes.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: They are not eligible for Zynteglo treatment as apheresis material from HIV-positive patients is not accepted.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.04453\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy treatment approved for patients with beta-thalassemia who require regular blood transfusions. It involves the modification of a patient's own hematopoietic stem cells to produce functional hemoglobin. When considering the treatment of patients who are seropositive for HIV, several factors must be taken into account.\n",
      "\n",
      "### Step 1: Understanding HIV and its Implications\n",
      "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, specifically CD4 T cells. Patients who are seropositive for HIV may have compromised immune systems, which can complicate treatment options. The management of HIV typically involves antiretroviral therapy (ART) to maintain viral suppression and immune function.\n",
      "\n",
      "### Step 2: Assessing the Patient's Health Status\n",
      "Before considering Zynteglo treatment, it is crucial to evaluate the overall health of the patient, including:\n",
      "- **Viral Load**: The level of HIV in the blood should be undetectable or well-controlled with ART.\n",
      "- **CD4 Count**: A higher CD4 count indicates a stronger immune system, which is favorable for undergoing any medical procedure, including gene therapy.\n",
      "- **Comorbidities**: Any other health issues should be assessed, as they may impact the safety and efficacy of the treatment.\n",
      "\n",
      "### Step 3: Consultation with Specialists\n",
      "Patients who are HIV-positive should be managed by a multidisciplinary team, including:\n",
      "- **Hematologists**: To evaluate the suitability of Zynteglo for beta-thalassemia.\n",
      "- **Infectious Disease Specialists**: To ensure optimal management of HIV and to assess any potential interactions between ART and the gene therapy.\n",
      "- **Genetic Counselors**: To discuss the implications of gene therapy and any genetic considerations.\n",
      "\n",
      "### Step 4: Evaluating the Risks and Benefits\n",
      "The potential benefits of Zynteglo for a patient with beta-thalassemia must be weighed against the risks, particularly in the context of HIV:\n",
      "- **Immune Response**: The gene therapy may elicit an immune response, which could be problematic for patients with HIV.\n",
      "- **Infection Risk**: The procedure involves myeloablation (destruction of bone marrow), which can increase the risk of infections, particularly in immunocompromised patients.\n",
      "\n",
      "### Step 5: Recommendations\n",
      "Based on the above considerations, the following recommendations can be made for patients who are seropositive for HIV regarding Zynteglo treatment:\n",
      "1. **Ensure Viral Suppression**: Patients should be on effective ART with an undetectable viral load before considering Zynteglo.\n",
      "2. **Comprehensive Evaluation**: A thorough assessment by a multidisciplinary team is essential to determine the appropriateness of Zynteglo.\n",
      "3. **Monitor Immune Function**: Regular monitoring of CD4 counts and overall immune function should be conducted throughout the treatment process.\n",
      "4. **Informed Consent**: Patients should be fully informed about the risks and benefits of the treatment, including the potential impact on their HIV management.\n",
      "5. **Post-Treatment Care**: Close follow-up is necessary after Zynteglo treatment to monitor for complications and to manage both beta-thalassemia and HIV effectively.\n",
      "\n",
      "### Conclusion\n",
      "In summary, while Zynteglo may offer a potential treatment option for patients with beta-thalassemia who are also HIV-positive, careful consideration of their HIV status, immune function, and overall health is critical. A collaborative approach involving various specialists will help ensure the best outcomes for these patients.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: They are not eligible for Zynteglo treatment as apheresis material from HIV-positive patients is not accepted.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.054239\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy treatment approved for patients with beta-thalassemia who require regular blood transfusions. It involves the modification of a patient's own hematopoietic stem cells to produce functional hemoglobin. When considering the treatment of patients who are seropositive for HIV, several factors must be taken into account.\n",
      "\n",
      "### Step 1: Understanding the Patient's Condition\n",
      "- **HIV Status**: Patients who are seropositive for HIV may have varying degrees of immune function depending on their viral load and CD4 count. Effective antiretroviral therapy (ART) can lead to viral suppression and improved immune function.\n",
      "- **Beta-Thalassemia**: The underlying condition for which Zynteglo is indicated. Patients with beta-thalassemia often require regular blood transfusions and may have complications related to iron overload and other organ dysfunctions.\n",
      "\n",
      "### Step 2: Assessing Eligibility for Zynteglo\n",
      "- **Viral Load and Immune Status**: Before considering Zynteglo, it is crucial to assess the patient's HIV viral load and CD4 count. Patients with well-controlled HIV (undetectable viral load and adequate CD4 count) may be better candidates for gene therapy.\n",
      "- **ART Compliance**: Patients must be adherent to their ART regimen to maintain viral suppression. Non-adherence could lead to complications and increased risk during the treatment process.\n",
      "\n",
      "### Step 3: Evaluating Risks and Benefits\n",
      "- **Risks of Gene Therapy**: The process of harvesting and modifying stem cells carries inherent risks, including infection, bleeding, and potential complications from the conditioning regimen (which may involve chemotherapy).\n",
      "- **Benefits of Zynteglo**: For patients with beta-thalassemia, successful treatment can lead to transfusion independence and improved quality of life.\n",
      "\n",
      "### Step 4: Recommendations\n",
      "1. **Consultation with Specialists**: Patients should be evaluated by a multidisciplinary team, including a hematologist, an infectious disease specialist, and a genetic counselor, to assess the risks and benefits of Zynteglo in the context of their HIV status.\n",
      "2. **Viral Suppression**: Ensure that the patientâ€™s HIV is well-controlled prior to proceeding with Zynteglo. This may involve optimizing their ART regimen.\n",
      "3. **Monitoring**: Close monitoring of the patientâ€™s immune status and viral load during the treatment process is essential. This includes pre-treatment assessments and ongoing follow-up.\n",
      "4. **Informed Consent**: Patients should be fully informed about the potential risks and benefits of Zynteglo, especially in the context of their HIV status, and should provide informed consent before proceeding with treatment.\n",
      "\n",
      "### Step 5: Conclusion\n",
      "In summary, while Zynteglo may be a viable treatment option for patients with beta-thalassemia who are also seropositive for HIV, careful consideration of their HIV management, overall health status, and the potential risks associated with the treatment is essential. A collaborative approach involving multiple healthcare providers will help ensure the best outcomes for these patients.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: They are not eligible for Zynteglo treatment as apheresis material from HIV-positive patients is not accepted.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  cot2\n",
      "SIM_score:  0.056131\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy treatment approved for patients with beta-thalassemia who require regular blood transfusions. It involves the modification of a patient's own hematopoietic stem cells to produce functional hemoglobin. When considering the treatment of patients who are seropositive for HIV, several factors must be taken into account.\n",
      "\n",
      "### Step 1: Understanding the Patient's Condition\n",
      "- **HIV Status**: Patients who are seropositive for HIV may have varying degrees of immune function depending on their viral load and CD4 count. Effective antiretroviral therapy (ART) can lead to viral suppression and improved immune status.\n",
      "- **Beta-Thalassemia**: The severity of beta-thalassemia can influence treatment decisions. Patients with severe forms of the disease are more likely to require interventions like Zynteglo.\n",
      "\n",
      "### Step 2: Assessing Eligibility for Zynteglo\n",
      "- **Immune Status**: Before considering Zynteglo, it is crucial to assess the patient's immune status. Patients should ideally be on effective ART with an undetectable viral load to minimize the risk of complications.\n",
      "- **Informed Consent**: Patients must be fully informed about the risks and benefits of Zynteglo, including the implications of their HIV status on treatment outcomes.\n",
      "\n",
      "### Step 3: Recommendations for Treatment\n",
      "1. **Consultation with Specialists**: Patients should be evaluated by a multidisciplinary team, including a hematologist and an infectious disease specialist, to assess the risks and benefits of Zynteglo in the context of their HIV status.\n",
      "  \n",
      "2. **Viral Suppression**: It is recommended that patients be on stable ART with an undetectable viral load for at least six months prior to undergoing Zynteglo treatment. This helps ensure that the risk of HIV-related complications is minimized.\n",
      "\n",
      "3. **Monitoring**: Close monitoring of the patient's immune status and HIV viral load should continue throughout the Zynteglo treatment process. This includes regular follow-ups to ensure that the patient remains virally suppressed.\n",
      "\n",
      "4. **Potential Risks**: Patients should be made aware of potential risks associated with gene therapy, including the possibility of adverse effects related to both the therapy itself and the underlying HIV infection.\n",
      "\n",
      "5. **Post-Treatment Care**: After Zynteglo treatment, ongoing care and monitoring for both beta-thalassemia and HIV are essential. This includes regular assessments of hemoglobin levels, immune function, and adherence to ART.\n",
      "\n",
      "### Step 4: Conclusion\n",
      "In summary, while Zynteglo may be a viable treatment option for patients with beta-thalassemia who are also seropositive for HIV, careful consideration of their HIV management, immune status, and overall health is crucial. A collaborative approach involving multiple healthcare providers is recommended to ensure the best possible outcomes for these patients.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: They are not eligible for Zynteglo treatment as apheresis material from HIV-positive patients is not accepted.\n",
      "\n",
      "-------------------------\n",
      "\n",
      "method:  default\n",
      "SIM_score:  0.055784\n",
      "prediction:  Zynteglo (betibeglogene autotemcel) is a gene therapy treatment approved for patients with beta-thalassemia who require regular blood transfusions. It involves the modification of a patient's own hematopoietic stem cells to produce functional hemoglobin. When considering the treatment of patients who are seropositive for HIV, several important factors must be taken into account.\n",
      "\n",
      "1. **HIV Status and Control**: The primary recommendation for patients with HIV considering Zynteglo treatment is that their HIV must be well-controlled. This typically means that the patient should be on antiretroviral therapy (ART) and have an undetectable viral load. Well-controlled HIV minimizes the risk of opportunistic infections and other complications during and after the gene therapy process.\n",
      "\n",
      "2. **Immunocompromised Status**: Patients with HIV, especially those with a low CD4 count or those who are not on effective ART, may be considered immunocompromised. This status can increase the risk of complications from the gene therapy procedure, including infections and poor recovery of hematopoietic function. Therefore, it is crucial to ensure that the patient's immune system is stable before proceeding with Zynteglo.\n",
      "\n",
      "3. **Multidisciplinary Approach**: The management of patients with HIV who are candidates for Zynteglo should involve a multidisciplinary team, including hematologists, infectious disease specialists, and possibly other healthcare providers. This team can help assess the risks and benefits of the treatment, monitor the patient's HIV status, and ensure that appropriate precautions are taken.\n",
      "\n",
      "4. **Informed Consent and Education**: Patients should be fully informed about the potential risks and benefits of Zynteglo, especially in the context of their HIV status. They should understand the importance of maintaining their ART regimen and the need for close monitoring during the treatment process.\n",
      "\n",
      "5. **Post-Treatment Monitoring**: After receiving Zynteglo, patients will require careful follow-up to monitor for any adverse effects, including those related to their HIV status. Regular assessments of viral load, CD4 counts, and overall health will be essential to ensure that the patient remains stable and to address any complications that may arise.\n",
      "\n",
      "6. **Clinical Trials and Research**: As Zynteglo is a relatively new treatment, ongoing research and clinical trials may provide additional insights into its safety and efficacy in patients with HIV. Healthcare providers should stay informed about the latest findings and consider enrolling patients in clinical trials if appropriate.\n",
      "\n",
      "In summary, the recommendation for patients seropositive for HIV regarding Zynteglo treatment is that they should only proceed if their HIV is well-controlled, with a focus on a multidisciplinary approach to care, informed consent, and rigorous post-treatment monitoring. Each case should be evaluated individually, taking into account the patient's overall health, HIV management, and potential risks associated with the treatment.\n",
      "pred_SIM:  B\n",
      "choice:  C\n",
      "correct_answer:  B\n",
      "correct answer: They are not eligible for Zynteglo treatment as apheresis material from HIV-positive patients is not accepted.\n",
      "\n",
      "-------------------------\n",
      "\n"
     ]
    }
   ],
   "execution_count": 39
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T08:59:46.933734Z",
     "start_time": "2026-01-19T08:59:46.930969Z"
    }
   },
   "cell_type": "code",
   "source": [
    "\n",
    "\n"
   ],
   "id": "a02785513fd92a7",
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1764"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 41
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2026-01-19T11:10:11.567420Z",
     "start_time": "2026-01-19T11:10:11.560821Z"
    }
   },
   "cell_type": "code",
   "source": [
    "ACC_f_old=ACC_f\n",
    "ACC_old = ACC\n",
    "DET_old=DET"
   ],
   "id": "bdb209e630c8e8da",
   "outputs": [],
   "execution_count": 79
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": "",
   "id": "66152a605a23d2a3"
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
